Clustering O 0 6.0078349633840844e-05
of O 0 6.397579909389606e-06
missense O 0 2.281506749568507e-05
mutations O 0 3.4495974432502408e-06
in O 0 3.755086254386697e-06
the O 0 2.0559171389322728e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999953508377075
telangiectasia I-Disease 1 1.0
gene O 0 1.551173409097828e-05
in O 0 1.6013869981179596e-06
a O 0 3.3384405924152816e-06
sporadic B-Disease 0 0.3136335611343384
T I-Disease 1 0.9999885559082031
- I-Disease 0 0.06478624045848846
cell I-Disease 1 0.7196428179740906
leukaemia I-Disease 1 0.998883068561554
. O 0 5.0321154958510306e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999891519546509
telangiectasia I-Disease 1 1.0
( O 0 0.022978702560067177
A B-Disease 1 1.0
- I-Disease 1 0.999996542930603
T I-Disease 1 1.0
) O 0 1.3897165729304106e-07
is O 0 3.124762315565022e-08
a O 0 5.216798015794666e-08
recessive B-Disease 0 6.532156930916244e-07
multi I-Disease 0 8.092031930573285e-05
- I-Disease 0 0.0002051414194284007
system I-Disease 0 2.361693759667105e-06
disorder I-Disease 0 9.082022734219208e-05
caused O 0 5.647896159644006e-06
by O 0 5.535001079692847e-08
mutations O 0 2.052312275679924e-08
in O 0 1.0392209759402249e-07
the O 0 2.644249548211519e-07
ATM O 0 7.098191872501047e-06
gene O 0 5.112906364956871e-07
at O 0 1.0853582352865487e-05
11q22 O 0 2.3546148440800607e-05
- O 0 5.273067017697031e-06
q23 O 0 1.5682697267038748e-05
( O 0 1.5530756058979023e-07
ref O 0 5.08390166942263e-06
. O 0 3.762259126460776e-08
3 O 0 5.068044970357732e-07
) O 0 3.609616783251113e-07
. O 0 1.7638669760344783e-06

The O 0 2.6512985641602427e-05
risk O 0 1.706847979221493e-05
of O 0 1.0208992534899153e-05
cancer B-Disease 0 0.10057299584150314
, O 0 9.589401770426775e-07
especially O 0 4.308476491132751e-07
lymphoid B-Disease 0 0.0035975794307887554
neoplasias I-Disease 0 0.0020222256425768137
, O 0 1.93738074472094e-07
is O 0 7.597840578910109e-08
substantially O 0 2.8837638410550426e-07
elevated O 0 1.3464111361827236e-05
in O 0 3.279911595654994e-07
A B-Disease 1 0.9999986886978149
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 3.694645442919864e-07
and O 0 1.191000151834487e-07
has O 0 1.8938193591111485e-07
long O 0 1.1262362420438876e-07
been O 0 1.4392148273145722e-07
associated O 0 1.890715424224254e-07
with O 0 2.492238593276852e-07
chromosomal O 1 1.0
instability O 1 1.0
. O 0 2.246605436084792e-05

By O 0 2.5175408154609613e-05
analysing O 0 7.007755630183965e-05
tumour B-Disease 1 1.0
DNA O 0 8.650681593280751e-06
from O 0 1.2801169759768527e-06
patients O 0 1.1171265867915281e-07
with O 0 5.4773128255192205e-08
sporadic B-Disease 0 0.0003650134603958577
T I-Disease 1 0.9487404823303223
- I-Disease 0 9.598720498615876e-05
cell I-Disease 0 0.0016312281368300319
prolymphocytic I-Disease 0 0.000252185040153563
leukaemia I-Disease 1 0.8657508492469788
( O 0 1.7449159486204735e-06
T B-Disease 0 7.546011329395697e-05
- I-Disease 0 6.104365638748277e-06
PLL I-Disease 0 3.1913776183500886e-05
) O 0 2.9703054238439108e-08
, O 0 1.0519520365903645e-08
a O 0 3.839742390709944e-08
rare O 0 1.4381103596861067e-07
clonal B-Disease 0 1.4393192941497546e-05
malignancy I-Disease 0 2.2117017579148524e-05
with O 0 4.818265963990598e-08
similarities O 0 3.468895783953485e-07
to O 0 1.500213357985558e-07
a O 0 2.7330515877110884e-06
mature B-Disease 0 6.095849130360875e-06
T I-Disease 0 0.0001497643970651552
- I-Disease 0 5.930813586019212e-06
cell I-Disease 0 1.02770391094964e-05
leukaemia I-Disease 0 0.00019523433002177626
seen O 0 6.533901455441082e-07
in O 0 1.6238757893916045e-07
A B-Disease 0 0.06882385909557343
- I-Disease 0 2.4699056666577235e-05
T I-Disease 0 0.014984474517405033
, O 0 1.8740912821613165e-08
we O 0 2.3796016268562425e-09
demonstrate O 0 1.3712348589933754e-08
a O 0 6.783952244404645e-08
high O 0 2.1327758759071003e-07
frequency O 0 6.60979893041258e-08
of O 0 1.7823580833464803e-07
ATM O 0 8.516242814948782e-06
mutations O 0 6.205566478456603e-07
in O 0 4.332499884185381e-06
T B-Disease 0 0.01310871634632349
- I-Disease 0 9.738656808622181e-05
PLL I-Disease 0 0.0008571595535613596
. O 0 3.211447619833052e-06

In O 0 1.140197036875179e-05
marked O 0 1.3877785022486933e-05
contrast O 0 6.409455863831681e-07
to O 0 1.3707359869385982e-07
the O 0 2.6715844114733045e-07
ATM O 0 1.0810772437253036e-05
mutation O 0 2.0156929281256453e-07
pattern O 0 2.797890374495182e-06
in O 0 1.4447088005908881e-06
A B-Disease 1 0.9999943971633911
- I-Disease 1 0.9947998523712158
T I-Disease 1 0.9999979734420776
, O 0 8.980439503147863e-08
the O 0 3.913197588190087e-08
most O 0 7.0718799705105084e-09
frequent O 0 2.440344282206297e-08
nucleotide O 0 2.4848102953001217e-07
changes O 0 1.8749494401504307e-08
in O 0 7.21964852345991e-08
this O 0 1.1414817890909035e-07
leukaemia B-Disease 0 6.75789633532986e-05
were O 0 8.470450438835542e-07
missense O 0 1.4319481124402955e-05
mutations O 0 6.847144049970666e-06
. O 0 5.812032213725615e-06

These O 0 5.226187113294145e-06
clustered O 0 1.2569203136081342e-05
in O 0 9.639877589506796e-07
the O 0 6.86822772877349e-07
region O 0 3.283078626736824e-07
corresponding O 0 6.6748225435731e-07
to O 0 1.3756363159700413e-07
the O 0 8.685780699124734e-07
kinase O 0 2.646565462782746e-06
domain O 0 8.90706814971054e-07
, O 0 6.295191923300081e-08
which O 0 3.3902285423437206e-08
is O 0 3.4459233688721724e-08
highly O 0 7.42941423936827e-08
conserved O 0 1.6207566488901648e-07
in O 0 1.5918264750780509e-07
ATM O 0 2.670176763786003e-05
- O 0 1.0956548521789955e-06
related O 0 2.441592812374438e-07
proteins O 0 8.766421188965978e-08
in O 0 1.8913124222308397e-07
mouse O 0 7.370346111201798e-07
, O 0 8.869638179476169e-08
yeast O 0 9.969052143787849e-07
and O 0 1.195847744384082e-06
Drosophila O 0 5.017620060243644e-05
. O 0 4.7087264647416305e-06

The O 0 6.337993545457721e-05
resulting O 0 4.073320815223269e-05
amino O 0 1.2921301276946906e-05
- O 0 9.078743460122496e-06
acid O 0 6.440429274334747e-07
substitutions O 0 2.2576647040750686e-07
are O 0 2.7925638690362575e-08
predicted O 0 3.5220043059780437e-07
to O 0 2.859185599390912e-08
interfere O 0 4.850400046052528e-07
with O 0 4.119820289361087e-07
ATP O 1 0.6635102033615112
binding O 0 1.4908572438798728e-06
or O 0 5.089336241326237e-07
substrate O 0 8.647234608361032e-06
recognition O 0 3.686258878587978e-06
. O 0 5.068661721452372e-06

Two O 0 8.404304935538676e-06
of O 0 7.527774414484156e-06
seventeen O 0 2.3973731003934518e-05
mutated O 0 4.972425813321024e-05
T B-Disease 0 0.0005847674910910428
- I-Disease 0 1.3796260645904113e-05
PLL I-Disease 0 4.1134142520604655e-05
samples O 0 1.0497956282051746e-07
had O 0 1.6557159199237503e-07
a O 0 1.5163898581249668e-07
previously O 0 6.3301570207841e-07
reported O 0 7.4497297646303196e-06
A B-Disease 1 0.9998868703842163
- I-Disease 1 0.9969011545181274
T I-Disease 1 0.9999978542327881
allele O 0 2.12626709981123e-05
. O 0 4.3081827243440785e-06

In O 0 1.599859751877375e-05
contrast O 0 2.009262743740692e-06
, O 0 1.88398189493455e-07
no O 0 5.401597746867992e-08
mutations O 0 4.334184211529646e-08
were O 0 1.6425411786258337e-07
detected O 0 3.3474486826889915e-07
in O 0 8.329902101422704e-08
the O 0 2.5890798838190676e-07
p53 O 0 1.9373635495867347e-06
gene O 0 2.6369164629613806e-07
, O 0 1.0447180898154329e-07
suggesting O 0 2.798387015445769e-07
that O 0 5.211596842968902e-08
this O 0 4.3051005604866077e-07
tumour B-Disease 1 1.0
suppressor O 1 0.9999973773956299
is O 0 1.1732825555554882e-07
not O 0 1.6531922497620144e-08
frequently O 0 3.325772013340611e-08
altered O 0 1.6504016286944534e-07
in O 0 2.5816731863415043e-07
this O 0 6.599865400858107e-07
leukaemia B-Disease 1 0.9796437621116638
. O 0 6.8620738602476195e-06

Occasional O 0 6.685822881991044e-05
missense O 0 4.06621111324057e-05
mutations O 0 3.3134492696262896e-06
in O 0 2.0911661522404756e-06
ATM O 0 5.176720878807828e-05
were O 0 9.905546676236554e-07
also O 0 1.7608036273486505e-07
found O 0 2.1664573068846948e-07
in O 0 8.09221660347248e-07
tumour B-Disease 1 1.0
DNA O 0 2.620391114760423e-06
from O 0 1.2392586086207302e-06
patients O 0 2.532792109377624e-07
with O 0 1.748344260477097e-07
B B-Disease 0 0.03771144151687622
- I-Disease 0 0.0002100044075632468
cell I-Disease 1 0.9105368852615356
non I-Disease 0 0.07584791630506516
- I-Disease 0 0.000859290303196758
Hodgkins I-Disease 1 0.9999997615814209
lymphomas I-Disease 0 0.01520932000130415
( O 0 5.108446430313052e-07
B B-Disease 0 3.3957928735617315e-06
- I-Disease 0 4.4598240833693126e-07
NHL I-Disease 0 4.947028173774015e-07
) O 0 1.678067285126872e-08
and O 0 2.9708152382568187e-08
a O 0 6.79716947615816e-07
B B-Disease 0 1.1460042514954694e-05
- I-Disease 0 6.98386838848819e-06
NHL I-Disease 0 1.5166202501859516e-05
cell O 0 4.1975097701651976e-05
line O 0 1.9118779164273292e-05
. O 0 2.1929806734988233e-06

The O 0 1.1224336049053818e-05
evidence O 0 2.015738346017315e-06
of O 0 1.515228973403282e-06
a O 0 5.62629907108203e-07
significant O 0 2.0002202916202805e-07
proportion O 0 7.221314035632531e-07
of O 0 2.512863829906564e-06
loss O 0 3.574824586394243e-05
- O 0 4.122722657484701e-06
of O 0 2.0084044081158936e-06
- O 0 6.902438371980679e-07
function O 0 6.620624759534621e-08
mutations O 0 1.3301749923755324e-08
and O 0 2.2899829588141074e-08
a O 0 7.985845940083891e-08
complete O 0 2.88345859189576e-07
absence O 0 1.6442337482658331e-06
of O 0 1.0475649787622388e-06
the O 0 7.360996505667572e-07
normal O 0 5.813611778648919e-07
copy O 0 2.398189167251985e-07
of O 0 2.9087360076118784e-07
ATM O 0 7.832632036297582e-06
in O 0 1.1303401947770908e-07
the O 0 1.3355548844629084e-07
majority O 0 3.7436905131471576e-08
of O 0 1.0731470183600322e-06
mutated O 0 1.1066676051996183e-05
tumours B-Disease 1 0.9999997615814209
establishes O 0 3.467814849500428e-06
somatic O 0 9.09579739527544e-06
inactivation O 0 0.00018659526540432125
of O 0 5.123146706864645e-07
this O 0 3.2056924226253614e-08
gene O 0 2.3510947855243103e-08
in O 0 4.2517722675938785e-08
the O 0 2.424441163384472e-07
pathogenesis O 0 1.1782755791500676e-05
of O 0 1.0489984560990706e-06
sporadic B-Disease 0 0.00018887920305132866
T I-Disease 1 0.7896050214767456
- I-Disease 0 4.829468161915429e-05
PLL I-Disease 0 0.00010604623093968257
and O 0 2.8283610120638514e-08
suggests O 0 2.745815486093761e-08
that O 0 1.544964689514927e-08
ATM O 0 2.7403357307775877e-06
acts O 0 3.7746079328826454e-07
as O 0 7.566111435153289e-07
a O 0 9.04829994397005e-06
tumour B-Disease 1 1.0
suppressor O 1 0.9999408721923828
. O 0 7.489092695323052e-06

As O 0 9.02055671758717e-06
constitutional O 0 4.810314749192912e-06
DNA O 0 2.1483342607098166e-06
was O 0 5.204740318731638e-06
not O 0 7.64033316613677e-08
available O 0 4.429542244110962e-08
, O 0 1.0001755867961037e-07
a O 0 8.233827202275279e-07
putative O 0 3.459282743278891e-05
hereditary O 1 0.9813827872276306
predisposition O 1 0.6756399273872375
to O 0 7.025726063147886e-06
T B-Disease 1 0.7872109413146973
- I-Disease 0 2.4527755158487707e-05
PLL I-Disease 0 6.914939149282873e-05
will O 0 2.664850917710737e-08
require O 0 2.0175944470679497e-08
further O 0 2.0726213278976502e-07
investigation O 0 1.998228981392458e-06
. O 0 4.404953415360069e-07
. O 0 2.2445829017669894e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00017939346435014158
kinase O 0 5.166167102288455e-05
is O 0 2.0686344726073003e-07
involved O 0 4.4971692148010334e-08
in O 0 4.850742740813985e-08
the O 0 2.984906899428097e-08
modulation O 0 1.3414982902304473e-07
of O 0 1.1916215214569092e-07
the O 0 2.786227923934348e-07
Ca2 O 0 4.33962486567907e-06
+ O 0 1.8959566432386055e-06
homeostasis O 0 1.025230267259758e-05
in O 0 1.3127431657267152e-06
skeletal O 1 0.9837692379951477
muscle O 0 7.593234477099031e-05
cells O 0 2.864523048629053e-05
. O 0 4.498234375205357e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0012914789840579033
DM B-Disease 1 1.0
) O 0 3.085237040068023e-06
, O 0 1.358009313889852e-07
the O 0 1.8202646856479987e-07
most O 0 1.0320860610590898e-07
prevalent O 0 1.0338821994082537e-05
muscular B-Disease 1 0.9997817873954773
disorder I-Disease 0 0.4889402985572815
in O 0 1.0073124485643348e-06
adults O 0 1.306165415826399e-07
, O 0 1.149930994870374e-07
is O 0 1.1213000306042886e-07
caused O 0 3.047368181796628e-06
by O 0 3.689012260110758e-07
( O 0 2.3296684048546012e-07
CTG O 0 1.4046912838239223e-05
) O 0 1.0807671912971273e-07
n O 0 4.129504702632403e-07
- O 0 3.230250342767249e-07
repeat O 0 1.363906960705208e-07
expansion O 0 2.7667610424941813e-07
in O 0 4.573290013354381e-08
a O 0 1.075256719218487e-07
gene O 0 5.297808769455514e-08
encoding O 0 1.0309763354143797e-07
a O 0 5.507446303454344e-07
protein O 0 2.0710558601422235e-06
kinase O 0 1.075336604117183e-05
( O 0 1.2766180361722945e-06
DM B-Disease 1 0.999923825263977
protein O 0 3.442328079472645e-06
kinase O 0 4.134148639423074e-06
; O 0 1.0157652496900482e-07
DMPK O 0 8.820324183034245e-06
) O 0 3.771829426568729e-08
and O 0 1.4524206726207467e-08
involves O 0 2.7640806976592103e-08
changes O 0 2.7079261499807217e-08
in O 0 1.0006526451888931e-07
cytoarchitecture O 0 7.233373708004365e-06
and O 0 4.3776697111752583e-07
ion O 0 8.570272621000186e-05
homeostasis O 0 0.0002518457476980984
. O 0 5.9893350226047914e-06

To O 0 4.435935352375964e-06
obtain O 0 3.2693485536583466e-06
clues O 0 5.7214560911234e-06
to O 0 4.6384693064283056e-07
the O 0 8.266928830380493e-07
normal O 0 1.8266080132889329e-06
biological O 0 5.783931555924937e-06
role O 0 3.281912313468638e-06
of O 0 7.394195108645363e-06
DMPK O 0 0.00016916071763262153
in O 0 1.3940746157459216e-06
cellular O 0 1.3108905477565713e-05
ion O 0 1.4039627785678022e-05
homeostasis O 0 1.2160137885075528e-05
, O 0 1.977465728941752e-07
we O 0 2.6003554864928446e-08
have O 0 2.9862793127222176e-08
compared O 0 1.7659142770298786e-07
the O 0 1.6599672392203502e-07
resting O 0 8.729527394280012e-07
[ O 0 1.5890205418145342e-07
Ca2 O 0 3.7761344628961524e-07
+ O 0 2.9617413588312047e-07
] O 0 2.4233131057371793e-07
i O 0 8.884165225708784e-08
, O 0 3.1113337684018916e-08
the O 0 5.386854340372338e-08
amplitude O 0 8.416099035457592e-07
and O 0 1.7982173972086457e-07
shape O 0 4.736251923986856e-07
of O 0 2.152300339730573e-06
depolarization O 0 3.134428698103875e-05
- O 0 4.168802661297377e-06
induced O 0 1.3744297575613018e-05
Ca2 O 0 3.877467406709911e-06
+ O 0 1.080090783034393e-06
transients O 0 1.7550343045513728e-06
, O 0 5.5891053563073e-08
and O 0 3.626219324814883e-08
the O 0 1.362560055895301e-07
content O 0 9.172894266384901e-08
of O 0 1.1594722764129983e-06
ATP O 0 0.0003945624630432576
- O 0 1.9996512037323555e-06
driven O 0 3.767145699384855e-06
ion O 0 1.887221969809616e-06
pumps O 0 2.4784158085822128e-06
in O 0 8.103978075268969e-07
cultured O 0 5.0758673751261085e-05
skeletal O 0 0.4013713002204895
muscle O 0 3.1117604066821514e-06
cells O 0 7.21101912404265e-07
of O 0 5.18153512985009e-07
wild O 0 3.1391357424581656e-07
- O 0 3.326895523514395e-07
type O 0 2.0666034572514036e-07
and O 0 1.3792515574095887e-07
DMPK O 0 5.7405271945754066e-05
[ O 0 1.4370248209161218e-06
- O 0 2.954287083412055e-06
/ O 0 1.4365039533004165e-05
- O 0 7.811088835296687e-06
] O 0 3.5663226753968047e-06
knockout O 0 5.685502401320264e-05
mice O 0 1.3924700397183187e-05
. O 0 3.2687873954273527e-06

In O 0 8.195346163120121e-05
vitro O 0 0.00017165843746624887
- O 0 3.550894689396955e-05
differentiated O 0 1.5322058970923536e-05
DMPK O 0 0.0002577996056061238
[ O 0 3.8127805055410136e-06
- O 0 3.6319622722658096e-06
/ O 0 6.288559234235436e-06
- O 0 1.9055568145631696e-06
] O 0 3.526020577737654e-07
myotubes O 0 7.114526283658051e-07
exhibit O 0 2.8726171308335324e-07
a O 0 1.840304406641735e-07
higher O 0 3.115806066489313e-07
resting O 0 3.603329616908013e-07
[ O 0 4.7269651304304716e-08
Ca2 O 0 2.050513074891569e-07
+ O 0 1.864598857537203e-07
] O 0 2.1337238820251514e-07
i O 0 8.022822584052847e-08
than O 0 1.23693748577125e-08
do O 0 1.025175588864613e-08
wild O 0 9.726203842319592e-08
- O 0 4.2791083387783146e-07
type O 0 3.34691236503204e-07
myotubes O 0 4.17601677327184e-06
because O 0 5.2898318614325035e-08
of O 0 2.0624904095711827e-07
an O 0 1.0359535451698321e-07
altered O 0 1.5246131113144656e-07
open O 0 2.7780134814747726e-07
probability O 0 1.4232806222480576e-07
of O 0 7.851035093153769e-07
voltage O 0 3.1087445677258074e-05
- O 0 5.958492010904592e-07
dependent O 0 2.6846407763514435e-07
l O 0 4.372879516267858e-07
- O 0 4.5835598427856894e-08
type O 0 2.790343600622691e-08
Ca2 O 0 2.1288518325945915e-07
+ O 0 7.223945885925787e-08
and O 0 4.596604696871509e-08
Na O 0 2.380793375778012e-06
+ O 0 6.084739538891881e-07
channels O 0 5.760244903285638e-07
. O 0 8.152581472131715e-07

The O 0 2.3598886400577612e-05
mutant O 0 2.8811471565859392e-05
myotubes O 0 3.8851259887451306e-05
exhibit O 0 2.0970755940652452e-06
smaller O 0 2.3145521765854937e-07
and O 0 1.2624644796233042e-07
slower O 0 1.0721946637204383e-06
Ca2 O 0 1.0312963922842755e-06
+ O 0 1.352048144553919e-07
responses O 0 2.6065675839959113e-08
upon O 0 1.1025712609580296e-07
triggering O 0 6.059202632968663e-07
by O 0 4.711672119128707e-08
acetylcholine O 0 9.994878382713068e-07
or O 0 7.871339136045208e-08
high O 0 2.50814719038317e-06
external O 0 5.551236426981632e-06
K O 0 3.137051680823788e-05
+ O 0 5.5290674936259165e-06
. O 0 1.9129383872495964e-06

In O 0 6.79916092849453e-06
addition O 0 8.188658853214292e-07
, O 0 2.044561284719748e-07
we O 0 2.063451809419803e-08
observed O 0 5.778115763632741e-08
that O 0 9.532586275895483e-09
these O 0 1.2547807237694997e-08
Ca2 O 0 1.276330749533372e-06
+ O 0 6.620321073569357e-07
transients O 0 7.159584924920637e-07
partially O 0 3.9162594589470245e-07
result O 0 8.130812290119138e-08
from O 0 4.8075623482191077e-08
an O 0 3.2103123714932735e-08
influx O 0 5.632586308479404e-08
of O 0 1.2988613207198796e-07
extracellular O 0 1.3419069091469282e-06
Ca2 O 0 9.134760148299392e-07
+ O 0 2.286470106582783e-07
through O 0 6.557710463539479e-08
the O 0 3.060311541958072e-07
l O 0 1.4130561112324358e-06
- O 0 3.8760600773457554e-07
type O 0 5.91121477100387e-07
Ca2 O 0 2.7465077891974943e-06
+ O 0 1.525850962025288e-06
channel O 0 4.38588631368475e-06
. O 0 1.6588642210990656e-06

Neither O 0 2.3078100639395416e-05
the O 0 3.2208417906076647e-06
content O 0 4.739758310279285e-07
nor O 0 3.9353835745714605e-07
the O 0 1.6017796156120312e-07
activity O 0 3.8312643368954014e-07
of O 0 3.3680740330055414e-07
Na O 0 2.932191591753508e-06
+ O 0 7.403583026643901e-07
/ O 0 1.0713124538597185e-06
K O 0 2.4842704533512006e-06
+ O 0 5.923787966821692e-07
ATPase O 0 4.837077995034633e-06
and O 0 4.465999836611445e-07
sarcoplasmic O 0 1.599342613189947e-05
reticulum O 0 1.2663917914323974e-05
Ca2 O 0 5.353225333237788e-06
+ O 0 2.5290291887358762e-06
- O 0 1.5138019762162003e-06
ATPase O 0 6.723660590068903e-06
are O 0 1.2546276018099434e-08
affected O 0 4.045964629995069e-08
by O 0 2.602266420126398e-07
DMPK O 0 0.00013202107220422477
absence O 0 9.643625162425451e-06
. O 0 3.341437604831299e-06

In O 0 1.993578734982293e-05
conclusion O 0 7.034368991298834e-06
, O 0 4.5049392838336644e-07
our O 0 2.1156112950393435e-07
data O 0 4.06507552952462e-07
suggest O 0 1.5709107969996694e-07
that O 0 1.07344327204828e-07
DMPK O 0 2.151316039089579e-05
is O 0 6.200857427529627e-08
involved O 0 2.1294198404575582e-08
in O 0 3.801528336566662e-08
modulating O 0 1.2649666132347193e-06
the O 0 7.009171554273053e-08
initial O 0 1.0954504148230626e-07
events O 0 4.0529005929101913e-08
of O 0 7.26271196072048e-07
excitation O 0 9.233497257810086e-05
- O 0 0.00015074237307999283
contraction O 0 0.0022706047166138887
coupling O 0 3.358529966135393e-06
in O 0 9.72642396845913e-07
skeletal O 0 0.04414980113506317
muscle O 0 1.6183414118131623e-05
. O 0 5.707792638531828e-07
. O 0 1.3337427162696258e-06

Constitutional O 0 0.0010369305964559317
RB1 O 1 0.8320550918579102
- O 0 4.6295248466776684e-05
gene O 0 6.444269615712983e-07
mutations O 0 3.7303013300515886e-07
in O 0 2.59128825064181e-07
patients O 0 1.8965087633660005e-07
with O 0 9.725147265271517e-08
isolated O 0 1.1063225429097656e-05
unilateral B-Disease 0 0.0018376023508608341
retinoblastoma I-Disease 1 0.9999666213989258
. O 0 3.054927583434619e-05

In O 0 1.9775950931943953e-05
most O 0 9.201902457789402e-07
patients O 0 3.1939384825818706e-07
with O 0 4.5831924921913014e-08
isolated O 0 2.064835598503123e-06
unilateral B-Disease 0 9.178857726510614e-05
retinoblastoma I-Disease 1 0.990562379360199
, O 0 7.579413932035095e-07
tumor B-Disease 0 0.021608779206871986
development O 0 2.33029069818258e-07
is O 0 1.8119402867000645e-08
initiated O 0 9.537991729757778e-08
by O 0 2.4155873745712597e-08
somatic O 0 5.141299652677844e-07
inactivation O 0 1.4869418009766378e-05
of O 0 6.26623716470931e-07
both O 0 1.0642834524787759e-07
alleles O 0 1.7218610537383938e-07
of O 0 8.949641028266342e-07
the O 0 8.61904482007958e-06
RB1 O 0 0.0010698487749323249
gene O 0 5.216009867581306e-06
. O 0 6.855996616650373e-06

However O 0 5.966759090370033e-06
, O 0 3.711887188728724e-07
some O 0 1.5640532424754383e-08
of O 0 9.652208632360271e-08
these O 0 3.9423472486532773e-08
patients O 0 3.2583500342298066e-07
can O 0 5.858795404378725e-08
transmit O 0 3.8099160519777797e-06
retinoblastoma B-Disease 1 0.971210777759552
predisposition O 0 0.0033677679020911455
to O 0 4.6089303396001924e-07
their O 0 7.637096928192477e-07
offspring O 0 1.8223336155642755e-05
. O 0 3.148368705296889e-06

To O 0 1.6212852642638609e-06
determine O 0 2.2568337953998707e-07
the O 0 3.3601591553633625e-07
frequency O 0 7.96248173173808e-07
and O 0 5.095746757888264e-08
nature O 0 1.1545231615173179e-07
of O 0 8.81146206666017e-07
constitutional O 0 1.9296674508950673e-05
RB1 O 0 0.007530219852924347
- O 0 1.8883957864090917e-06
gene O 0 1.0101198455458871e-07
mutations O 0 5.60059838505822e-08
in O 0 7.760250753108267e-08
patients O 0 3.433687112419648e-08
with O 0 2.005761245982285e-08
isolated O 0 4.979527830073494e-07
unilateral B-Disease 0 6.929209575901041e-06
retinoblastoma I-Disease 0 0.0036864897701889277
, O 0 1.1517781928205295e-07
we O 0 1.3512535090853817e-08
analyzed O 0 4.2691706170217e-08
DNA O 0 1.3959382272332732e-07
from O 0 6.421570333259297e-07
peripheral O 0 0.0001276610273635015
blood O 0 6.1159266806498636e-06
and O 0 2.1021855900471564e-06
from O 0 4.6537195885321125e-05
tumor B-Disease 1 0.9999998807907104
tissue O 1 0.9980465173721313
. O 0 1.3068226508039515e-05

The O 0 2.972332549688872e-05
analysis O 0 4.135272320127115e-06
of O 0 1.422662171535194e-05
tumors B-Disease 1 0.9999995231628418
from O 0 4.1908465391315985e-06
54 O 0 2.928893536591204e-06
( O 0 5.144066150819526e-08
71 O 0 5.405245246947743e-07
% O 0 3.500108292087134e-08
) O 0 1.5958567800566925e-08
of O 0 1.5731414748643147e-07
76 O 0 3.8039258924982278e-06
informative O 0 4.923575147586234e-07
patients O 0 9.913648568726785e-08
showed O 0 4.5705868956247286e-07
loss O 0 9.31462466269295e-07
of O 0 1.5614367612215574e-06
constitutional O 0 1.1907623957085889e-05
heterozygosity O 0 0.00010173329792451113
( O 0 2.2359047306963475e-06
LOH O 0 0.1822739839553833
) O 0 4.96196889798739e-07
at O 0 1.0759141332528088e-05
intragenic O 0 7.29495077393949e-05
loci O 0 1.6071999198175035e-05
. O 0 4.25987536800676e-06

Three O 0 1.7793716324376874e-05
of O 0 9.656066140451003e-06
13 O 0 3.636922701844014e-05
uninformative O 0 0.0008738254546187818
patients O 0 3.2993041259032907e-06
had O 0 6.636138550675241e-06
constitutional O 0 3.20609615300782e-05
deletions O 0 9.493272955296561e-05
. O 0 1.6209085515583865e-05

For O 0 1.4380076208908577e-05
39 O 0 1.2098324077669531e-05
randomly O 0 2.8979698072362226e-06
selected O 0 1.1723608622560278e-05
tumors B-Disease 1 0.9999996423721313
, O 0 5.60128819415695e-06
SSCP O 0 0.0008255859138444066
, O 0 1.1345059647283051e-06
hetero O 0 1.233872626471566e-05
- O 0 1.4850124898657668e-06
duplex O 0 8.647959475638345e-06
analysis O 0 6.735975688343387e-08
, O 0 2.061760007165958e-08
sequencing O 0 1.8660770706446783e-07
, O 0 1.804184357467875e-08
and O 0 1.5327486835303716e-08
Southern O 0 7.593320816567939e-08
blot O 0 1.1337143632772495e-06
analysis O 0 1.1281863265821812e-07
were O 0 8.424154884778545e-08
used O 0 5.4397180093701536e-08
to O 0 6.311386613333525e-08
identify O 0 3.6688979321297666e-07
mutations O 0 1.0447461136209313e-05
. O 0 1.6146756024681963e-05

Mutations O 0 1.7509904864709824e-05
were O 0 3.7825680010428187e-06
detected O 0 2.320808334843605e-06
in O 0 3.9390255324178725e-07
21 O 0 1.3408936183623155e-06
( O 0 3.234546852581843e-08
91 O 0 4.80944265746075e-07
% O 0 6.660420126536337e-08
) O 0 4.739152714705597e-08
of O 0 1.0057718782263692e-06
23 O 0 0.01200957503169775
tumors B-Disease 1 1.0
with O 0 0.0002290832344442606
LOH O 1 1.0
. O 0 4.343362161307596e-05

In O 0 2.1246109099593014e-05
6 O 0 1.2493483154685237e-05
( O 0 4.287903436761553e-07
38 O 0 1.1549574310265598e-06
% O 0 8.936834205997002e-08
) O 0 3.525414626892598e-08
of O 0 5.179766162655142e-07
16 O 0 2.16255102714058e-05
tumors B-Disease 1 1.0
without O 0 4.60252704215236e-06
LOH O 1 0.995984673500061
, O 0 9.510434040294058e-08
one O 0 1.8206634422313073e-08
mutation O 0 1.8177486182935354e-08
was O 0 7.119576252989646e-07
detected O 0 1.927561470438377e-07
, O 0 2.1870890876130034e-08
and O 0 2.514037333867236e-08
in O 0 7.646907818070758e-08
9 O 0 6.220628279152152e-07
( O 0 5.7169128098166766e-08
56 O 0 4.27927972168618e-07
% O 0 6.166547450447979e-08
) O 0 4.465680092380353e-08
of O 0 1.1043155154766282e-06
the O 0 4.5909331674920395e-05
tumors B-Disease 1 1.0
without O 0 4.215995431877673e-05
LOH O 1 0.9999974966049194
, O 0 6.634934379690094e-08
both O 0 1.4766695421997156e-08
mutations O 0 1.0281426909841684e-07
were O 0 3.7476775105460547e-07
found O 0 9.028405543176632e-07
. O 0 2.2545482352143154e-06

Thus O 0 1.2249598512426019e-05
, O 0 6.588275596186577e-07
a O 0 3.024836985332513e-07
total O 0 1.9987426469469938e-07
of O 0 3.2981293429656944e-07
45 O 0 2.3511043423241063e-07
mutations O 0 9.429064107280283e-08
were O 0 3.625880822255567e-07
identified O 0 3.7088017279529595e-07
in O 0 7.983437058101117e-07
tumors B-Disease 1 1.0
of O 0 9.326182771474123e-05
36 O 0 8.631704986328259e-05
patients O 0 5.746227543568239e-06
. O 0 7.411817477986915e-06

Thirty O 0 0.00019138914649374783
- O 0 2.9970015020808205e-05
nine O 0 4.315386831876822e-06
of O 0 1.2834786957682809e-06
the O 0 4.6698542632839235e-07
mutations O 0 2.1937931649063103e-07
- O 0 6.17977036654338e-07
including O 0 1.2921280756472697e-07
34 O 0 2.761694304354023e-07
small O 0 1.820948192232663e-08
mutations O 0 4.638102168996738e-08
, O 0 7.338798724276785e-08
2 O 0 1.5264593855590647e-07
large O 0 1.2906575364013406e-07
structural O 0 5.083116320747649e-06
alterations O 0 3.3640433230175404e-06
, O 0 1.316072228974008e-07
and O 0 4.682492615870615e-08
hypermethylation O 0 6.8562258093152195e-06
in O 0 2.278051312032403e-07
3 O 0 3.368647185197915e-06
tumors O 1 0.9999998807907104
- O 0 2.2865538085170556e-06
were O 0 1.865055878624844e-07
not O 0 9.698358560683573e-09
detected O 0 1.789494206150266e-07
in O 0 4.95697385360927e-08
the O 0 1.8374267085619067e-07
corresponding O 0 1.4043145029063453e-06
peripheral O 0 0.00038600197876803577
blood O 0 1.3825342648488004e-05
DNA O 0 1.5494168110308237e-05
. O 0 5.276075171423145e-06

In O 0 2.7413359930505976e-05
6 O 0 1.524674371466972e-05
( O 0 6.110191748120997e-07
17 O 0 1.4070117231312906e-06
% O 0 7.898952247842317e-08
) O 0 1.936371596400477e-08
of O 0 1.5176021861407207e-07
the O 0 2.569183834566502e-07
36 O 0 8.425373607678921e-07
patients O 0 7.669314783242953e-08
, O 0 5.3089863172317564e-08
a O 0 1.0639262626455093e-07
mutation O 0 6.654185824572778e-08
was O 0 1.7484137515566545e-06
detected O 0 2.0745297035773547e-07
in O 0 4.726487645712041e-08
constitutional O 0 2.1100862568346201e-07
DNA O 0 5.062518226850443e-08
, O 0 2.5911417012025595e-08
and O 0 1.917418579466812e-08
1 O 0 1.2572380114761472e-07
of O 0 8.137452311984816e-08
these O 0 6.589680801027953e-09
mutations O 0 7.025862203136057e-08
is O 0 6.132192709173978e-08
known O 0 6.652726369793527e-08
to O 0 1.7488920533992314e-08
be O 0 6.182882117400368e-08
associated O 0 1.0132787053862558e-07
with O 0 7.104600996399313e-08
reduced O 0 6.665467026323313e-06
expressivity O 0 0.00015259800420608371
. O 0 3.958920842705993e-06

The O 0 1.224416701006703e-05
presence O 0 1.82019675776246e-06
of O 0 7.042551715130685e-07
a O 0 2.606101077162748e-07
constitutional O 0 6.190824706209241e-07
mutation O 0 1.997164815747965e-07
was O 0 2.3514007807534654e-06
not O 0 1.65965001741597e-08
associated O 0 4.957995258791925e-08
with O 0 1.4764049538484869e-08
an O 0 1.44846254102049e-07
early O 0 1.2886323474958772e-06
age O 0 1.946037400557543e-06
at O 0 2.0133091311436146e-05
treatment O 0 2.0136394596192986e-05
. O 0 3.96473160435562e-06

In O 0 8.044448804866988e-06
1 O 0 6.544705229316605e-06
patient O 0 3.5288060189486714e-06
, O 0 2.765536919469014e-07
somatic O 0 6.141549420135561e-06
mosaicism O 0 0.00016943964874371886
was O 0 3.219478458049707e-06
demonstrated O 0 1.9994517685972824e-07
by O 0 1.441390118372965e-08
molecular O 0 1.3433802337203815e-07
analysis O 0 1.715949160541186e-08
of O 0 7.866687212754186e-08
DNA O 0 1.8928624001546268e-07
and O 0 4.459577667148551e-07
RNA O 0 1.757199970597867e-05
from O 0 3.3932258247659774e-06
peripheral O 0 0.013625133782625198
blood O 0 9.308927837992087e-05
. O 0 5.002106263418682e-06

In O 0 2.0603409211616963e-05
2 O 0 7.715598258073442e-06
patients O 0 3.83448082175164e-07
without O 0 5.016400095314566e-08
a O 0 2.2938040444842045e-07
detectable O 0 2.142601260857191e-06
mutation O 0 2.890887458306679e-07
in O 0 3.829532886356901e-07
peripheral O 0 4.401109254104085e-05
blood O 0 2.5138801902357955e-06
, O 0 2.529147309360269e-07
mosaicism O 0 4.097378041478805e-05
was O 0 3.5526422834664118e-06
suggested O 0 1.310040147473046e-07
because O 0 1.3607870386067589e-08
1 O 0 7.892536757481139e-08
of O 0 6.534474294994652e-08
the O 0 5.134322691446869e-07
patients O 0 6.470441462624876e-07
showed O 0 0.0004219840047881007
multifocal O 1 0.9999998807907104
tumors B-Disease 1 1.0
and O 0 1.2134651115047745e-06
the O 0 4.1981280674008303e-07
other O 0 2.3531404380605636e-08
later O 0 5.458310852191062e-07
developed O 0 1.3057173191555194e-06
bilateral B-Disease 0 0.00014829506108071655
retinoblastoma I-Disease 1 0.9984875917434692
. O 0 3.1169853173196316e-05

In O 0 1.1126307072117925e-05
conclusion O 0 3.6871729207632598e-06
, O 0 2.2251656162097788e-07
our O 0 9.652300292373184e-08
results O 0 1.0676401984710537e-07
emphasize O 0 1.221953738195225e-07
that O 0 4.562608424407699e-08
the O 0 2.904430971284455e-07
manifestation O 0 5.319752744981088e-06
and O 0 1.7649965400323708e-07
transmissibility O 0 6.8774497776757926e-06
of O 0 1.1743341019609943e-06
retinoblastoma B-Disease 0 1.554419577587396e-05
depend O 0 1.9588911470691528e-07
on O 0 7.215985533548519e-07
the O 0 1.325681040498239e-07
nature O 0 1.0993960586347384e-07
of O 0 2.507295562281797e-07
the O 0 1.7513548300485127e-07
first O 0 1.39059281423215e-07
mutation O 0 4.126236419210727e-08
, O 0 6.99709588047881e-08
its O 0 5.1510372856000686e-08
time O 0 2.851979807871885e-08
in O 0 3.264987213924542e-08
development O 0 1.1785263609453978e-07
, O 0 1.21405463460178e-08
and O 0 1.3435078827228608e-08
the O 0 3.9487588310294086e-08
number O 0 2.671242427254583e-08
and O 0 2.1484186873976796e-08
types O 0 6.292382437322885e-08
of O 0 1.2598223975146539e-06
cells O 0 9.558987130731111e-07
that O 0 4.903177597270769e-08
are O 0 2.804750387497279e-08
affected O 0 1.976687116211906e-07
. O 0 1.4841826612155273e-07
. O 0 9.190132459480083e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
of I-Disease 0 8.660891762701795e-05
the I-Disease 0 1.1255356184847187e-05
fifth I-Disease 0 4.604977948474698e-05
component I-Disease 0 2.3007235085970024e-06
of I-Disease 0 6.332379030027369e-07
complement I-Disease 0 4.5743117880192585e-06
in O 0 8.338313818967436e-06
man O 0 0.00018550730601418763
. O 0 7.3100582085317e-06

I O 0 0.0038930471055209637
. O 0 0.00016255045193247497

Clinical O 0 0.017437098547816277
, O 0 1.687332769506611e-05
immunochemical O 0 0.000405350758228451
, O 0 1.5999200968508376e-06
and O 0 9.137391430158459e-07
family O 0 1.2956204500369495e-06
studies O 0 7.648528480785899e-06
. O 0 8.787529623077717e-06

The O 0 1.0510841093491763e-05
first O 0 3.259591721871402e-06
recognized O 0 8.553599286642566e-07
human O 0 3.351075292812311e-06
kindred O 0 8.239260205300525e-05
with O 0 1.4386894235940417e-06
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9990014433860779
the I-Disease 0 0.0007461377535946667
fifth I-Disease 0 0.006867838557809591
component I-Disease 0 2.9293796615093015e-06
of I-Disease 0 1.4954638345443527e-06
complement I-Disease 0 3.1826320991967805e-06
( O 0 1.876418195934093e-06
C5 O 1 0.9224546551704407
) O 0 6.692446845590894e-07
is O 0 4.2553830326141906e-07
described O 0 3.5793316328636138e-06
. O 0 1.5447546957148006e-06

The O 0 6.737872172379866e-05
proband O 0 0.00021155508875381202
, O 0 1.5640613355571986e-06
a O 0 1.982281673917896e-06
20 O 0 2.935325028374791e-06
- O 0 3.920290509995539e-06
year O 0 1.5145442375796847e-06
- O 0 4.657837052945979e-06
old O 0 3.966509211750235e-06
black O 0 9.318551406067854e-07
female O 0 1.423179014636844e-06
with O 0 7.198951607279014e-06
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.14267726242542267
age O 0 4.666471795644611e-06
11 O 0 3.219475274818251e-06
, O 0 2.3797031190042617e-07
lacked O 0 4.829601493838709e-06
serum O 0 0.00012372848868835717
hemolytic O 1 0.9938415288925171
complement O 0 2.5016352083184756e-06
activity O 0 3.6524340885080164e-06
, O 0 9.714839421803845e-08
even O 0 4.427430155828915e-08
during O 0 2.5096737772400957e-06
remission O 0 3.807470420724712e-05
. O 0 2.016118969550007e-06

C5 O 1 0.997412383556366
was O 0 0.00045723767834715545
undetectable O 0 0.00018231129797641188
in O 0 6.366227580656414e-07
her O 0 5.559737701332779e-07
serum O 0 8.891808647604194e-06
by O 0 1.6893159227038268e-07
both O 0 1.4787870838972594e-07
immunodiffusion O 0 7.214115612441674e-05
and O 0 2.8182751066196943e-06
hemolytic O 1 0.9999997615814209
assays O 0 0.00014993344666436315
. O 0 1.1319079021632206e-05

Other O 0 2.6635834728949703e-06
complement O 0 4.283087037038058e-06
components O 0 3.151384589727968e-06
were O 0 7.023517127890955e-07
normal O 0 9.987760449803318e-07
during O 0 1.7862033701021574e-06
remission O 0 7.440797617164208e-06
of O 0 2.166020294680493e-06
lupus O 0 0.0019241634290665388
, O 0 5.196876031732245e-07
but O 0 2.664551459474751e-07
C1 O 0 3.519451274769381e-05
, O 0 3.0727525768270425e-07
C4 O 0 0.00013665648293681443
, O 0 1.057887516253686e-06
C2 O 0 1.3907448192185257e-05
, O 0 1.098718911407559e-07
and O 0 4.5614686428052664e-07
C3 O 1 0.8607112169265747
levels O 0 1.761985731718596e-05
fell O 0 0.057212501764297485
during O 0 1.641520248085726e-05
exacerbations O 0 0.021112948656082153
. O 0 9.339342796010897e-06

A O 0 0.0002754545130301267
younger O 0 8.072252057900187e-06
half O 0 1.7610028635317576e-06
- O 0 3.2990053568937583e-06
sister O 0 1.941508571690065e-06
, O 0 7.590091399833909e-08
who O 0 5.576401562734645e-08
had O 0 6.417058671104314e-07
no O 0 1.859413259808207e-06
underlying O 1 0.9967650175094604
disease O 1 0.7470460534095764
, O 0 1.6136651481701847e-07
was O 0 5.311292170517845e-06
also O 0 6.800625840241992e-08
found O 0 3.36836549763575e-08
to O 0 3.269392934157622e-08
lack O 0 9.62398189585656e-06
immunochemically O 0 0.10813070088624954
detectable O 1 0.9715226888656616
C5 O 1 0.9999393224716187
. O 0 1.2178126780781895e-05

By O 0 0.00016162868996616453
hemolytic O 1 0.9999228715896606
assay O 0 0.00038910150760784745
, O 0 2.084440438920865e-06
she O 0 7.008368925198738e-07
exhibited O 0 4.30096588388551e-06
1 O 0 8.347348057213821e-07
- O 0 2.419950533294468e-07
2 O 0 1.1614738326670704e-07
% O 0 1.7154549780684647e-08
of O 0 7.552112890607532e-08
the O 0 2.640645959672838e-07
normal O 0 1.188047690448002e-06
serum O 0 5.4594634093518835e-06
C5 O 0 4.836823791265488e-05
level O 0 2.00426654828334e-07
and O 0 1.781917191578941e-08
normal O 0 8.250729877090635e-08
concentrations O 0 1.3661096431860642e-07
of O 0 1.4350442256727547e-07
other O 0 1.7924639550415122e-08
complement O 0 9.401263127983839e-07
components O 0 6.157466486911289e-06
. O 0 2.211862693002331e-06

C5 O 0 0.09073781967163086
levels O 0 2.754204615484923e-05
of O 0 3.0525397960445844e-06
other O 0 1.0640641789905203e-07
family O 0 1.115865870815469e-07
members O 0 5.072280018225683e-08
were O 0 1.9678637386277842e-07
either O 0 1.315321753736498e-07
normal O 0 5.244383487479354e-07
or O 0 8.801605133612611e-08
approximately O 0 2.142636787993979e-07
half O 0 3.286261573975935e-07
- O 0 8.068658985393995e-07
normal O 0 2.3697904794062197e-07
, O 0 2.004537513755622e-08
consistent O 0 9.628689667806611e-08
with O 0 2.259551123984238e-08
autosomal O 0 2.04494290301227e-06
codominant O 0 6.4861983446462546e-06
inheritance O 0 2.6342522119193745e-07
of O 0 3.723750694462069e-07
the O 0 8.487391482958628e-07
gene O 0 5.215930741542252e-06
determining O 0 9.1265254013706e-05
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.6837708244565874e-05

Normal O 0 0.0038811182603240013
hemolytic O 1 0.9995792508125305
titers O 0 0.0017042752588167787
were O 0 8.90395949681988e-06
restored O 0 6.821145689173136e-06
to O 0 1.7036454380559007e-07
both O 0 3.737690406069305e-07
homozygous O 0 2.2070875274948776e-05
C5 B-Disease 1 0.9999998807907104
- I-Disease 1 0.9279286861419678
deficient I-Disease 1 0.9999983310699463
( O 0 1.7920420987138641e-06
C5D B-Disease 1 0.9999984502792358
) O 0 6.942855890201827e-08
sera O 0 1.6352810234820936e-06
by O 0 7.700987403325144e-09
addition O 0 1.210177469346263e-08
of O 0 2.1680196482520842e-07
highly O 0 1.5390728549391497e-06
purified O 0 5.191474429011578e-06
human O 0 7.417898359562969e-06
C5 O 0 0.0713050588965416
. O 0 3.9834471863287035e-06

In O 0 3.787400419241749e-05
specific O 0 8.538100701116491e-06
C5 O 0 0.002309647621586919
titrations O 0 7.550128793809563e-05
, O 0 4.0205981122198864e-07
however O 0 1.02217306618968e-07
, O 0 3.306896800836512e-08
it O 0 1.35333770856505e-08
was O 0 7.635794077032187e-07
noted O 0 1.1043496783713636e-07
that O 0 1.695343065932775e-08
when O 0 2.299322687804306e-08
limited O 0 2.519605857287388e-08
amounts O 0 3.417105531866582e-08
of O 0 1.292580691369949e-06
C5 O 0 0.00012270864681340754
were O 0 8.140236218423524e-07
assayed O 0 3.220442749807262e-06
in O 0 9.188723737452165e-08
the O 0 1.1644429065427175e-07
presence O 0 8.760120095985258e-08
of O 0 5.072730573374429e-07
low O 0 3.890791504090885e-06
dilutions O 0 1.2010907084913924e-05
of O 0 2.4620480871817563e-06
either O 0 4.5697161112912e-06
C5D B-Disease 1 0.9999991655349731
serum O 0 2.5431359972571954e-05
, O 0 2.690743770017434e-07
curving O 0 1.7272288914682576e-06
rather O 0 1.8110211996713588e-08
than O 0 4.09795974931626e-09
linear O 0 7.357397180385306e-08
dose O 0 3.0036309794923e-07
- O 0 1.3872933379843744e-07
response O 0 4.1458953603523696e-08
plots O 0 1.2819039341138705e-07
were O 0 3.466874076707427e-08
consistently O 0 5.156698890118605e-08
obtained O 0 5.3986521919568986e-08
, O 0 2.111305441587774e-08
suggesting O 0 8.25283876793037e-08
some O 0 1.3083865546548168e-08
inhibitory O 0 7.152560556278331e-06
effect O 0 4.424182407092303e-06
. O 0 1.2461371170502389e-06

Further O 0 9.874734132608864e-06
studies O 0 4.961002105119405e-06
suggested O 0 2.315873416591785e-06
that O 0 2.2955023837312183e-07
low O 0 8.170739420165773e-06
dilutions O 0 3.3969408832490444e-05
of O 0 9.933757610269822e-06
C5D B-Disease 1 0.9999924898147583
serum O 0 1.0432149792904966e-05
contain O 0 3.7848741385460016e-07
a O 0 6.186115228956623e-07
factor O 0 3.8261157442320837e-07
( O 0 4.165664080346687e-08
or O 0 3.533681436351799e-08
factors O 0 8.454126287915642e-08
) O 0 3.233671108660019e-08
interfering O 0 2.5373805101480684e-07
at O 0 1.0609641094561084e-06
some O 0 1.5364953753760346e-08
step O 0 1.423299664793376e-07
in O 0 9.33144974624156e-08
the O 0 7.968483259901404e-07
hemolytic O 0 0.4553035497665405
assay O 0 8.550633538106922e-06
of O 0 5.7391184782318305e-06
C5 O 0 0.25822144746780396
, O 0 4.478679827002452e-08
rather O 0 7.91066412375585e-09
than O 0 6.574088384780907e-09
a O 0 1.0484009038691511e-07
true O 0 5.862065108885872e-07
C5 O 0 0.002470897976309061
inhibitor O 0 5.193601464270614e-05
or O 0 9.254706014871772e-07
inactivator O 0 5.509111360879615e-05
. O 0 3.2604402804281563e-06

Of O 0 2.3499849703512155e-05
clinical O 0 4.392730988911353e-05
interest O 0 3.8069779293437023e-06
are O 0 9.994147376346518e-08
( O 0 6.96351847295773e-08
a O 0 9.739867579128259e-08
) O 0 2.362179252202168e-08
the O 0 6.791682238826979e-08
documentation O 0 8.609471251475043e-07
of O 0 1.307702677877387e-05
membranous O 1 0.9999994039535522
glomerulonephritis B-Disease 1 1.0
, O 0 0.11195459216833115
vasculitis B-Disease 1 1.0
, O 0 4.5652359403902665e-05
and O 0 0.0005153334350325167
arthritis B-Disease 1 1.0
in O 0 3.620839834184153e-06
an O 0 6.846045721431437e-07
individual O 0 1.1199789895499634e-07
lacking O 0 9.766069524630439e-06
C5 O 1 0.9243468046188354
( O 0 1.940141203249368e-07
and O 0 4.351296922777692e-08
its O 0 1.1613886385930527e-07
biologic O 0 2.370241236349102e-05
functions O 0 2.4676984367033583e-07
) O 0 2.7180790951319977e-08
, O 0 1.8075771990311296e-08
and O 0 2.7395380186590046e-08
( O 0 7.62987752978006e-08
b O 0 3.4542748039712023e-07
) O 0 1.3063792714262945e-08
a O 0 9.094672748233279e-08
remarkable O 0 4.3839239083354187e-07
propensity O 0 2.7946957743552048e-06
to O 0 4.854231860917935e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 2.1268681393848965e-06
the O 0 1.0187508223680197e-06
proband O 0 5.979974957881495e-06
, O 0 4.74300492214752e-08
even O 0 1.0661949545465177e-08
during O 0 6.956522469181436e-08
periods O 0 1.1821001777434503e-07
of O 0 2.2385664522062143e-07
low O 0 4.695430561696412e-06
- O 0 1.50521054820274e-06
dose O 0 7.840246212253987e-07
or O 0 1.697404883316267e-07
alternate O 0 6.340997060760856e-07
- O 0 4.11765404351172e-06
day O 0 2.9272657684487058e-06
corticosteroid O 0 0.00053271499928087
therapy O 0 1.9676061128848232e-05
. O 0 2.642066874614102e-06

Other O 0 4.137114501645556e-06
observations O 0 1.092733145924285e-05
indicate O 0 6.103911800892092e-06
that O 0 3.428485229051148e-07
the O 0 1.9097046788374428e-06
C5D B-Disease 1 0.9999011754989624
state O 0 1.3799093778743554e-07
is O 0 7.796941758897447e-08
compatible O 0 1.335244093070287e-07
with O 0 2.5147089743882134e-08
normal O 0 8.453092732452205e-07
coagulation O 0 4.005525624961592e-06
function O 0 2.132183993808212e-07
and O 0 3.678360371850431e-08
the O 0 6.954891063060131e-08
capacity O 0 2.0784368359727523e-07
to O 0 5.2810410267056795e-08
mount O 0 1.8819482647813857e-05
a O 0 3.0283836167654954e-06
neutrophilic O 0 0.001044748118147254
leukocytosis O 0 0.0012363530695438385
during O 0 3.8816036976641044e-05
pyogenic B-Disease 0 0.004977379459887743
infection I-Disease 0 0.00013967443373985589
. O 0 9.126505347012426e-07
. O 0 1.9038674281546264e-06

Susceptibility O 1 0.9978775978088379
to O 0 0.0006484983023256063
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.0004944083630107343
twins O 0 0.0001464067172491923
: O 0 1.3812100974064379e-07
the O 0 7.0836819077158e-08
role O 0 1.5725251500953163e-07
of O 0 2.661620612798288e-07
genes O 0 1.7250923178835365e-07
, O 0 3.8615192465840664e-07
HLA O 0 0.0011997317196801305
, O 0 1.2306171015552536e-07
and O 0 1.5707354350524838e-07
the O 0 1.791252770999563e-06
environment O 0 5.567990228882991e-06
. O 0 2.9870536764065037e-06

OBJECTIVE O 0 4.8202058678725734e-05
To O 0 7.09039966295677e-07
determine O 0 2.8185391443003027e-07
the O 0 3.5853744861924497e-07
relative O 0 8.845291290526802e-07
effects O 0 8.383711360693269e-07
of O 0 1.2693361384208401e-07
genetic O 0 1.9746730117731204e-07
and O 0 9.059233718744508e-08
environmental O 0 4.905216997030948e-07
factors O 0 4.355731064720203e-08
in O 0 1.056974383573106e-07
susceptibility O 0 0.010925794020295143
to O 0 6.560650945175439e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0007041358039714396
AS B-Disease 1 0.9999994039535522
) O 0 6.052029561942618e-07
. O 0 1.2163884548499482e-06

METHODS O 0 0.00022814703697804362
Twins O 0 0.00014707048831041902
with O 0 1.314825567533262e-06
AS B-Disease 0 0.057102758437395096
were O 0 4.068445775828877e-07
identified O 0 1.272332070811899e-07
from O 0 9.675968470901353e-08
the O 0 1.1947861366934376e-07
Royal O 0 3.7296089431038126e-05
National O 0 6.417103577405214e-05
Hospital O 1 0.9989144802093506
for O 0 2.5236027795472182e-05
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 0.0001989908196264878
. O 0 9.500019586994313e-06

Clinical O 0 0.00040089746471494436
and O 0 1.9296228401799453e-06
radiographic O 0 4.433570211404003e-05
examinations O 0 1.0232913155050483e-05
were O 0 4.1447577814324177e-07
performed O 0 2.291018859068572e-07
to O 0 2.5721053731331267e-08
establish O 0 2.3646995828130457e-07
diagnoses O 0 0.00100995774846524
, O 0 2.75216592626748e-07
and O 0 5.21280469456542e-07
disease O 1 0.9926160573959351
severity O 0 0.004163684789091349
was O 0 2.2905673176865093e-05
assessed O 0 1.9989769839412475e-07
using O 0 1.8199585838374333e-08
a O 0 6.351576331553588e-08
combination O 0 5.7808499320799456e-08
of O 0 3.8375611666197074e-07
validated O 0 2.998184299940476e-06
scoring O 0 1.8315830629944685e-06
systems O 0 7.1670365286991e-06
. O 0 2.798835112116649e-06

HLA O 0 0.42320993542671204
typing O 0 0.0002526006137486547
for O 0 1.1955949958064593e-05
HLA O 0 0.0024804873391985893
- O 0 4.4008025724906474e-05
B27 O 0 0.00014332670252770185
, O 0 1.3104415756970411e-06
HLA O 0 7.311617082450539e-05
- O 0 4.892779543297365e-06
B60 O 0 1.3939647942606825e-05
, O 0 1.7320357414973842e-07
and O 0 2.1065415012344602e-07
HLA O 0 0.00010759407450677827
- O 0 5.654055712511763e-06
DR1 O 0 0.001751444418914616
was O 0 4.672661361837527e-06
performed O 0 3.6052202290193236e-07
by O 0 1.3725477288062393e-07
polymerase O 0 7.649571671208832e-06
chain O 0 2.106460215145489e-06
reaction O 0 3.071064895721065e-07
with O 0 3.6976555151113644e-08
sequence O 0 1.771183093524087e-07
- O 0 2.896591695389361e-07
specific O 0 1.4846960105785456e-08
primers O 0 7.781281397001294e-07
, O 0 4.685172783069902e-08
and O 0 7.91134624478218e-08
zygosity O 0 4.3896188799408264e-06
was O 0 1.8007674498221604e-06
assessed O 0 3.0868449130139197e-07
using O 0 2.0146819679212058e-07
microsatellite O 0 1.3428769307211041e-05
markers O 0 1.7359234334435314e-05
. O 0 4.405421350384131e-06

Genetic O 0 2.8143160307081416e-05
and O 0 1.0729146424637293e-06
environmental O 0 1.4470584801529185e-06
variance O 0 1.0759538326965412e-06
components O 0 7.491654514524271e-07
were O 0 2.4260739905912487e-07
assessed O 0 2.0456946003832854e-07
with O 0 1.0082003676359363e-08
the O 0 1.3309673363437469e-07
program O 0 2.93973556608762e-07
Mx O 0 4.9303926061838865e-06
, O 0 4.554695820502275e-08
using O 0 2.7890239451267007e-08
data O 0 5.3015490664165554e-08
from O 0 6.537852925703191e-08
this O 0 1.7183070966098057e-08
and O 0 1.842546559771563e-08
previous O 0 7.36875875873011e-08
studies O 0 1.3435007417683664e-07
of O 0 1.0664775800250936e-06
twins O 0 2.2095220629125834e-05
with O 0 2.100860911014024e-06
AS B-Disease 1 0.9999988079071045
. O 0 8.231305400840938e-06

RESULTS O 0 0.0001603674318175763
Six O 0 6.349750492518069e-06
of O 0 6.20948912910535e-06
8 O 0 2.9788221581839025e-05
monozygotic O 0 5.334761954145506e-05
( O 0 2.2164322217577137e-06
MZ O 0 0.02173883467912674
) O 0 5.36737729817105e-07
twin O 0 5.962708655715687e-06
pairs O 0 3.245714879085426e-07
were O 0 1.0121542572960607e-06
disease O 0 1.2952997167303693e-05
concordant O 0 8.72794771566987e-06
, O 0 6.596398094416145e-08
compared O 0 1.0539486083871452e-07
with O 0 1.385790504571105e-08
4 O 0 5.042502948526817e-07
of O 0 1.0597616437735269e-06
15 O 0 2.0397403659444535e-06
B27 O 0 1.5037878256407566e-05
- O 0 1.5980124317138689e-06
positive O 0 2.660481186467223e-07
dizygotic O 0 3.992756774096051e-06
( O 0 2.370760086023438e-07
DZ O 0 9.37252480071038e-05
) O 0 1.0443434916851402e-07
twin O 0 1.4569204722647555e-06
pairs O 0 1.0854029142137733e-07
( O 0 2.9142269042381486e-08
27 O 0 2.690174198960449e-07
% O 0 1.3733026271722792e-08
) O 0 7.93776422369774e-09
and O 0 2.714980418261348e-08
4 O 0 5.035745971326833e-07
of O 0 2.4006151306821266e-06
32 O 0 1.5695175534347072e-05
DZ O 1 0.917861819267273
twin O 0 2.9969329261803068e-05
pairs O 0 1.4344175269798143e-07
overall O 0 7.013155709501007e-07
( O 0 1.5961916233209195e-08
12 O 0 6.174255418045504e-08
. O 0 7.4489920898201945e-09
5 O 0 1.1830837109982895e-07
% O 0 1.2678977157065674e-07
) O 0 1.992342362200361e-07
. O 0 1.053182586474577e-06

Nonsignificant O 0 0.0013520882930606604
increases O 0 7.647601705684792e-06
in O 0 3.126879164483398e-07
similarity O 0 2.504769440747623e-07
with O 0 4.0965787206914683e-08
regard O 0 1.79114863385621e-07
to O 0 4.375966256020547e-08
age O 0 2.3366201276076026e-06
at O 0 0.0011198683641850948
disease O 0 0.022238338366150856
onset O 0 0.47569921612739563
and O 0 1.0489890200915397e-07
all O 0 1.7721623279953747e-08
of O 0 5.02136401792086e-07
the O 0 2.8628801373997703e-06
disease O 0 9.217399201588705e-05
severity O 0 4.414513568917755e-06
scores O 0 3.227842171327211e-07
assessed O 0 2.6294154054085084e-07
were O 0 1.8886861141709232e-07
noted O 0 5.592543175225728e-07
in O 0 1.0257984968120581e-06
disease O 0 0.34382471442222595
- O 0 0.00014568967162631452
concordant O 0 0.0017688550287857652
MZ O 1 0.9998891353607178
twins O 0 2.6709305529948324e-05
compared O 0 1.2332270671322476e-06
with O 0 3.83100143608317e-07
concordant O 0 0.0006797340465709567
DZ O 1 0.9999957084655762
twins O 0 0.0006149617256596684
. O 0 1.1075459951825906e-05

HLA O 1 0.9940997362136841
- O 0 0.0008765461388975382
B27 O 0 0.0006452899542637169
and O 0 2.0191150724713225e-06
B60 O 0 5.297950701788068e-05
were O 0 1.0862619319595979e-06
associated O 0 2.2955045153594256e-07
with O 0 3.991405961301098e-08
the O 0 1.6380968190787826e-06
disease O 0 0.0004102849343325943
in O 0 3.939731811897218e-07
probands O 0 4.766518759424798e-05
, O 0 5.92640994057092e-08
and O 0 2.4807038201402065e-08
the O 0 1.0161799224306378e-07
rate O 0 9.46249940625421e-07
of O 0 2.731519543885952e-07
disease O 0 9.599104487278964e-06
concordance O 0 7.757786988804583e-06
was O 0 3.7798454286530614e-06
significantly O 0 2.7965728577328264e-07
increased O 0 7.911480111033597e-07
among O 0 2.3368291124370444e-07
DZ O 0 0.0017767568351700902
twin O 0 1.0932021723419894e-05
pairs O 0 1.868081938027899e-07
in O 0 1.4963839589654526e-07
which O 0 4.8114515038832906e-08
the O 0 2.3492171408179274e-07
co O 0 3.39215489475464e-06
- O 0 1.8754700477074948e-06
twin O 0 8.934854122344404e-06
was O 0 2.7018286345992237e-06
positive O 0 6.838033783651554e-08
for O 0 6.077362257883578e-08
both O 0 3.908420467269025e-07
B27 O 0 8.087542664725333e-05
and O 0 7.260576239787042e-06
DR1 O 1 0.7457651495933533
. O 0 1.1715360415109899e-05

Additive O 0 0.00013704379671253264
genetic O 0 6.4126006691367365e-06
effects O 0 9.300953024649061e-06
were O 0 6.931516054464737e-07
estimated O 0 1.1454545045808118e-07
to O 0 6.736846636101745e-09
contribute O 0 1.5969469302490324e-08
97 O 0 4.262641368768527e-07
% O 0 2.525745479431407e-08
of O 0 7.889828168572421e-08
the O 0 8.85268676142914e-08
population O 0 5.200534758387221e-08
variance O 0 1.2788674439434544e-06
. O 0 2.1578082396445097e-06

CONCLUSION O 0 0.0001991164608625695
Susceptibility O 0 0.0003864926111418754
to O 0 3.550230758264661e-06
AS B-Disease 0 0.05676406994462013
is O 0 7.623331299555502e-08
largely O 0 5.235897759803265e-08
genetically O 0 8.65589377951892e-09
determined O 0 2.6046393486467423e-08
, O 0 1.2767377377542743e-08
and O 0 6.8906111927447e-09
the O 0 9.12927546892206e-08
environmental O 0 4.724441566850146e-07
trigger O 0 2.0509251044131815e-06
for O 0 1.1304350522323148e-07
the O 0 3.4419933854223927e-06
disease O 0 0.01828131638467312
is O 0 1.4776861689824727e-06
probably O 0 3.0024477837287122e-06
ubiquitous O 0 1.2464801329770125e-05
. O 0 2.090506086460664e-06

HLA O 1 0.9973809123039246
- O 0 0.0002856554347090423
B27 O 0 9.521032916381955e-05
accounts O 0 2.2982931113801897e-07
for O 0 6.78523335295722e-08
a O 0 7.304696225673979e-08
minority O 0 1.5914311646270107e-08
of O 0 5.370634781343142e-08
the O 0 1.0090780477867156e-07
overall O 0 9.812548569243518e-07
genetic O 0 6.037975026629283e-07
susceptibility O 0 0.00034663802944123745
to O 0 4.2538185880403034e-06
AS B-Disease 1 0.9999992847442627
. O 0 1.1614916729740798e-05

Cell O 0 0.034545544534921646
cycle O 0 0.00038441611104644835
- O 0 3.5892466257791966e-05
dependent O 0 5.615419468085747e-06
colocalization O 0 2.0319188479334116e-05
of O 0 1.903798533930967e-06
BARD1 O 0 8.476220682496205e-05
and O 0 2.89194076685817e-07
BRCA1 O 0 1.1585516404011287e-06
proteins O 0 1.6057042273587285e-07
in O 0 1.1617530759622241e-07
discrete O 0 1.3352355381357484e-06
nuclear O 0 2.5358074708492495e-05
domains O 0 2.7182530175196007e-05
. O 0 5.083969426777912e-06

Germ O 1 0.9996423721313477
- O 0 0.00031203936669044197
line O 0 6.591577403014526e-06
mutations O 0 2.414717243937048e-07
of O 0 4.0471772422279173e-07
the O 0 3.9859403955233574e-07
BRCA1 O 0 5.364959633880062e-06
gene O 0 9.323387644144532e-07
predispose O 0 2.734813961069449e-06
women O 0 5.428813665275811e-08
to O 0 3.689532590556155e-08
early O 0 9.133939784078393e-06
- O 1 0.9847731590270996
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 0.9999910593032837
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 8.006371672308887e-07
compromising O 0 1.3526714610634372e-06
the O 0 3.1859011073720467e-07
genes O 0 1.9706807563579787e-07
presumptive O 0 4.826535132451681e-06
function O 0 4.333605829742737e-07
as O 0 2.876186044886708e-07
a O 0 2.980000317620579e-06
tumor B-Disease 1 0.9997995495796204
suppressor O 1 0.9998949766159058
. O 0 8.25759707367979e-06

Although O 0 6.143189693830209e-06
the O 0 1.4346229590955772e-06
biochemical O 0 1.559324846311938e-05
properties O 0 2.8799843221349875e-06
of O 0 1.6298472473863512e-06
BRCA1 O 0 1.1593005183385685e-05
polypeptides O 0 1.242292569259007e-06
are O 0 2.8176190269846302e-08
not O 0 9.120674882012736e-09
understood O 0 4.472448011938468e-08
, O 0 8.830927100689223e-09
their O 0 8.099665826932778e-09
expression O 0 1.4758184363472537e-07
pattern O 0 6.449009219977597e-07
and O 0 2.006473636129158e-07
subcellular O 0 5.775642057415098e-05
localization O 0 1.1985059245489538e-05
suggest O 0 1.0355505963843825e-07
a O 0 9.047300864040153e-08
role O 0 2.493030137884489e-07
in O 0 5.009592882743163e-07
cell O 0 6.836201646365225e-05
- O 0 1.4340908819576725e-05
cycle O 0 1.4544059922627639e-05
regulation O 0 3.5537198073143372e-06
. O 0 2.3326572318183025e-06

When O 0 8.188378706108779e-05
resting O 0 0.00012721797975245863
cells O 0 3.6833632748312084e-06
are O 0 1.1567030355763563e-07
induced O 0 2.3336920094152447e-06
to O 0 4.8407883923573536e-08
proliferate O 0 4.3659454718181223e-07
, O 0 3.551215144170783e-08
the O 0 5.4067001542534854e-08
steady O 0 1.0349833701184252e-06
- O 0 4.29784776656561e-08
state O 0 6.528953377937796e-09
levels O 0 3.1689737056694867e-08
of O 0 5.2504486092175284e-08
BRCA1 O 0 1.6804413860427303e-07
increase O 0 8.985785626691722e-08
in O 0 1.4046050011984335e-07
late O 0 7.294955821635085e-07
G1 O 0 2.5249469217669684e-06
and O 0 1.525085124853831e-08
reach O 0 3.6651311319246815e-08
a O 0 4.7214509635296054e-08
maximum O 0 3.039868659016065e-07
during O 0 1.0784088999571395e-06
S O 0 2.4353923436137848e-05
phase O 0 7.491914402635302e-06
. O 0 2.232214455943904e-06

Moreover O 0 0.00010666468006093055
, O 0 3.7931304177618586e-06
in O 0 3.653312205642578e-06
S O 0 0.00014028922305442393
phase O 0 1.2478050848585553e-05
cells O 0 1.4743527572136372e-06
, O 0 1.5393032981592114e-07
BRCA1 O 0 1.092062120733317e-06
polypeptides O 0 5.671346343660844e-07
are O 0 2.7694950333057022e-08
hyperphosphorylated O 0 1.2774607967003249e-06
and O 0 6.440361488557755e-08
accumulate O 0 1.0467405076042269e-07
into O 0 3.868433395837201e-08
discrete O 0 8.132112156999938e-07
subnuclear O 0 8.048038580454886e-06
foci O 0 1.2133841664763168e-05
termed O 0 4.226951205055229e-06
" O 0 1.4424289247472188e-06
BRCA1 O 0 5.136025265528588e-06
nuclear O 0 2.961165773740504e-05
dots O 0 3.8543341361219063e-05
. O 0 4.393178642203566e-06

" O 0 0.00027610737015493214
BRCA1 O 0 0.0009198831394314766
associates O 0 0.00014782478683628142
in O 0 1.8086827822116902e-06
vivo O 0 3.334329812787473e-05
with O 0 1.3885322402984457e-07
a O 0 2.109435399688664e-06
structurally O 0 1.6766740372986533e-05
related O 0 1.5943437574605923e-06
protein O 0 2.5724257284309715e-05
termed O 0 0.0003002891899086535
BARD1 O 0 0.08170279115438461
. O 0 1.2877973858849145e-05

Here O 0 3.181499050697312e-05
we O 0 5.627163091048715e-07
show O 0 2.9694962222492904e-07
that O 0 7.943416591160712e-08
the O 0 2.0268016953650658e-07
steady O 0 8.051432814681903e-06
- O 0 3.6966054040021845e-07
state O 0 3.938844628237348e-08
levels O 0 3.7274884334692615e-07
of O 0 5.750376317337214e-07
BARD1 O 0 0.00010319122520741075
, O 0 6.087582704594752e-08
unlike O 0 1.4757461030967534e-08
those O 0 5.067829267346724e-09
of O 0 1.4704741602145077e-07
BRCA1 O 0 1.0271963901686831e-06
, O 0 8.060355582983902e-08
remain O 0 6.332958690791202e-08
relatively O 0 2.281329258835285e-08
constant O 0 1.6275409109312022e-07
during O 0 5.522504125110572e-07
cell O 0 1.1511742741276976e-05
cycle O 0 7.836419172235765e-06
progression O 0 3.669702709885314e-05
. O 0 1.64742937158735e-06

However O 0 4.394172356114723e-05
, O 0 9.985103133658413e-06
immunostaining O 0 0.0001468679984100163
revealed O 0 9.979076821764465e-06
that O 0 8.226967338487157e-07
BARD1 O 0 4.775135312229395e-05
resides O 0 1.2278288750167121e-06
within O 0 9.647367704701537e-08
BRCA1 O 0 1.0691599072742974e-06
nuclear O 0 8.349804375029635e-06
dots O 0 4.084239662915934e-06
during O 0 3.5583491353463614e-06
S O 0 9.92315290204715e-06
phase O 0 8.337244139511313e-07
of O 0 2.2994352377736504e-07
the O 0 1.987679496551209e-07
cell O 0 1.1584609183046268e-06
cycle O 0 2.696027365800546e-07
, O 0 9.995191341261034e-09
but O 0 5.075180720126582e-09
not O 0 7.388768707983218e-09
during O 0 1.8939024926112324e-07
the O 0 5.38316101028613e-07
G1 O 0 5.0348855438642204e-05
phase O 0 7.792399628669955e-06
. O 0 1.7340452131975326e-06

Nevertheless O 0 0.00033160721068270504
, O 0 2.1957257558824494e-05
BARD1 O 0 0.00023161110584624112
polypeptides O 0 4.241176156938309e-06
are O 0 3.845437390737061e-08
found O 0 3.2996766208270856e-08
exclusively O 0 2.075728211536898e-08
in O 0 4.1078301649122295e-08
the O 0 1.052855651550999e-07
nuclear O 0 1.567854610584618e-06
fractions O 0 6.754463584002224e-07
of O 0 4.867582674705773e-07
both O 0 3.216837853869947e-07
G1 O 0 3.602153810788877e-05
- O 0 8.453624218418554e-07
and O 0 3.76359821530059e-07
S O 0 4.0395309042651206e-05
- O 0 3.76803313884011e-06
phase O 0 6.879594820929924e-06
cells O 0 5.448582669487223e-06
. O 0 2.2529040961671853e-06

Therefore O 0 1.592185435583815e-05
, O 0 2.0799229787371587e-06
progression O 0 2.5533448933856562e-05
to O 0 5.51561981865234e-07
S O 0 4.403141065267846e-05
phase O 0 5.443575446406612e-06
is O 0 1.5828737787160208e-07
accompanied O 0 3.75026246501875e-07
by O 0 4.7074323106244265e-08
the O 0 1.1410169520331692e-07
aggregation O 0 9.231567332790291e-07
of O 0 8.777260518399999e-07
nuclear O 0 1.3232259334472474e-05
BARD1 O 0 7.139476656448096e-05
polypeptides O 0 2.1071796254545916e-06
into O 0 4.311806094392523e-07
BRCA1 O 0 8.290785444842186e-06
nuclear O 0 5.725814844481647e-05
dots O 0 5.8574340073391795e-05
. O 0 9.455902727495413e-06

This O 0 2.7730749934562482e-05
cell O 0 0.00013251548807602376
cycle O 0 2.146487713616807e-05
- O 0 3.227421984774992e-06
dependent O 0 3.756207718197402e-07
colocalization O 0 3.0638414045824902e-06
of O 0 5.478775051415141e-07
BARD1 O 0 1.8346567230764776e-05
and O 0 1.231508264254444e-07
BRCA1 O 0 1.8424570953357033e-06
indicates O 0 1.3107566019243677e-06
a O 0 4.1351401591782633e-07
role O 0 3.969488204802474e-07
for O 0 3.290874701633584e-07
BARD1 O 0 7.456582534359768e-05
in O 0 1.3652282859766274e-06
BRCA1 O 0 4.573244950734079e-05
- O 0 7.654068758711219e-05
mediated O 0 0.0010177952935919166
tumor B-Disease 1 0.9999943971633911
suppression O 1 0.8900395631790161
. O 0 8.082613931037486e-06

Ethnic O 0 3.4238953503518132e-06
differences O 0 2.8718823159579188e-06
in O 0 3.819746325461892e-06
the O 0 6.4815362748049665e-06
HFE O 0 0.00039431845652870834
codon O 0 3.8768390368204564e-05
282 O 0 1.4000320334162097e-05
( O 0 2.311189291503979e-06
Cys O 0 0.003963233903050423
/ O 0 7.744093454675749e-05
Tyr O 0 7.244489097502083e-05
) O 0 9.881873666017782e-07
polymorphism O 0 7.788863513269462e-06
. O 0 3.155480726491078e-06

Recent O 0 9.923020115820691e-06
studies O 0 2.0481907085923012e-06
have O 0 1.519090631063591e-07
shown O 0 6.070620202081045e-07
that O 0 2.4655348624946782e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.0005322881042957306
HH B-Disease 1 1.0
) O 0 5.60315640996123e-07
is O 0 8.97078393791162e-08
likely O 0 4.344347814821958e-08
to O 0 1.0148934137532706e-08
be O 0 4.291785771215473e-08
caused O 0 1.4968650248192716e-06
by O 0 1.3435980861231656e-07
homozygosity O 0 5.349560979084345e-06
for O 0 8.029344655824389e-08
a O 0 7.217217898869421e-07
Cys282Tyr O 0 1.1113010259578004e-05
mutation O 0 2.3311663710501307e-07
in O 0 2.366332978454011e-07
the O 0 7.19258480330609e-07
HFE O 0 5.781141226179898e-05
gene O 0 1.0289503507010522e-06
located O 0 7.735799954389222e-06
4 O 0 8.080910447461065e-06
. O 0 6.020591627020622e-06

5 O 0 0.00014630984514951706
Mb O 0 0.001986338756978512
telomeric O 0 0.0005378248752094805
to O 0 2.6862162485485896e-05
HLA O 1 0.9919454455375671
- O 0 0.00023518517264164984
A O 0 7.475392339983955e-05
. O 0 4.6241862037277315e-06

Population O 0 1.4655408904218348e-06
studies O 0 1.7530537661514245e-06
of O 0 5.79598577132856e-07
this O 0 3.262901770995086e-08
polymorphism O 0 1.4708712114952505e-07
are O 0 8.42080982721427e-09
facilitated O 0 1.775814126858677e-07
by O 0 1.848654029856789e-08
the O 0 3.140932136602714e-08
fact O 0 1.4260816527666975e-08
that O 0 1.005435201761884e-08
the O 0 2.6798471708389116e-07
Cys282Tyr O 0 9.522696927888319e-06
mutation O 0 3.86157097409523e-07
creates O 0 5.407080720942758e-07
a O 0 2.1384489627962466e-06
Rsal O 0 4.256721877027303e-05
restriction O 0 1.3939887139713392e-05
site O 0 4.6805735109956e-06
. O 0 2.8387107704475056e-06

We O 0 4.1053854147321545e-06
have O 0 5.75603792185575e-07
studied O 0 2.886583615691052e-06
the O 0 1.76763069248409e-06
codon O 0 1.7675902199698612e-05
282 O 0 1.6149035218404606e-05
( O 0 2.6791851723828586e-06
Cys O 0 0.0019196869106963277
/ O 0 4.083907697349787e-05
Tyr O 0 1.407705985911889e-05
) O 0 5.595579821715546e-08
polymorphism O 0 1.0879419676257385e-07
in O 0 2.1004726846740596e-08
different O 0 2.395087905782134e-09
ethnic O 0 2.3557763739745496e-08
groups O 0 6.5873962284968e-08
. O 0 5.792294359707739e-07

In O 0 7.882230420364067e-06
agreement O 0 1.5074531347636366e-06
with O 0 1.6700344929176936e-07
previous O 0 1.736675017127709e-06
observations O 0 2.5219101189577486e-06
the O 0 2.5197293780365726e-06
Tyr O 0 1.059592432284262e-05
allele O 0 5.230926944932435e-07
appeared O 0 9.021107416629093e-07
to O 0 3.0808504192236796e-08
be O 0 5.825667059866646e-08
rare O 0 9.767456532472352e-08
or O 0 2.0975366510356253e-07
absent O 0 7.827053423170582e-07
in O 0 8.408679974536426e-08
Asiatic O 0 4.521347818808863e-06
( O 0 4.086986749030075e-08
Indian O 0 9.319958849118848e-08
, O 0 5.181169271395447e-08
Chinese O 0 3.5050129554292653e-07
) O 0 1.0372842496053636e-07
populations O 0 1.452097251330997e-07
. O 0 8.831046898194472e-07

The O 0 1.5617893950548023e-05
highest O 0 5.89803221373586e-06
allele O 0 7.441524871865113e-07
frequency O 0 1.6843799812704674e-06
( O 0 4.8054719314905014e-08
7 O 0 1.7009668340506323e-07
. O 0 5.683716164384123e-09
5 O 0 3.0026999553456335e-08
% O 0 1.2970710727699952e-08
) O 0 1.0273267569971267e-08
was O 0 3.163496842262248e-07
found O 0 3.623253164164453e-08
in O 0 2.407756767297542e-07
Swedes O 0 4.995489234715933e-06
. O 0 2.350696831854293e-06

Saamis O 0 0.0013649103930220008
( O 0 7.223646662168903e-06
2 O 0 2.9658922358066775e-06
% O 0 3.271308628427505e-07
) O 0 1.2298922058562312e-07
and O 0 1.9230115810842108e-07
Mordvinians O 0 6.7091145865560975e-06
( O 0 9.249053789517347e-08
1 O 0 1.472951538517009e-07
. O 0 1.015875294996249e-08
8 O 0 8.373756799073817e-08
% O 0 1.1415389522539954e-08
) O 0 8.531976014580778e-09
had O 0 6.656902229451589e-08
significantly O 0 9.450922533460471e-08
lower O 0 2.2256665488384897e-07
frequencies O 0 1.2244080949130876e-07
of O 0 6.344178018480306e-07
the O 0 2.1594880763586843e-06
Tyr O 0 4.667292523663491e-05
allele O 0 6.267878234211821e-06
. O 0 2.789279733406147e-06

Comparisons O 0 3.0769904697081074e-05
with O 0 8.27507733447419e-07
allele O 0 2.856163291653502e-06
frequencies O 0 9.709334563012817e-07
based O 0 1.4332348996504152e-07
on O 0 5.499563258126727e-07
prevalence O 0 1.1906703548447695e-05
estimates O 0 6.225595825526398e-07
of O 0 1.1210642014702898e-06
HH B-Disease 1 0.9996535778045654
showed O 0 2.5223430384357926e-06
some O 0 6.315564604619794e-08
disagreements O 0 1.0928611118288245e-06
with O 0 1.2208401756197418e-07
the O 0 1.0250591913063545e-06
RFLP O 0 8.613046702521387e-06
data O 0 2.53408217076867e-07
, O 0 7.842476890118633e-08
particularly O 0 1.1635592755965263e-07
in O 0 2.7718897399608977e-07
Finns O 0 3.878772986354306e-06
. O 0 2.113200707754004e-06

The O 0 7.88308898336254e-05
newly O 0 3.7590391002595425e-05
described O 0 1.6573601897107437e-05
HFE O 0 0.0003583978395909071
marker O 0 1.2457243428798392e-05
provides O 0 1.7599154489289504e-07
a O 0 2.4194611114580766e-07
new O 0 6.289827325645092e-08
approach O 0 7.978127314345329e-08
to O 0 1.621866196899191e-08
the O 0 6.064798441229868e-08
screening O 0 1.2204444033159234e-07
of O 0 1.2406894711602945e-06
HH B-Disease 1 0.99988853931427
as O 0 2.2074598859944672e-07
well O 0 1.2945130301034169e-08
as O 0 7.424084902396544e-09
studies O 0 1.2826689044231898e-08
of O 0 3.504083068150976e-08
the O 0 6.574442323881158e-08
relationship O 0 5.174650752337584e-08
between O 0 3.0795879979450547e-07
the O 0 4.357228590379236e-06
HFE O 1 0.8144935369491577
Tyr O 0 3.8705482438672334e-05
allele O 0 7.419091048177506e-07
and O 0 1.1874683281121179e-07
different O 0 1.0505006287075958e-07
disorders O 1 0.9998656511306763
including O 0 0.00016654047067277133
cancer B-Disease 1 0.9999998807907104

Autosomal B-Disease 1 0.999997615814209
dominant I-Disease 1 0.9999667406082153
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999361038208008
associated O 0 2.6571012767817592e-06
with O 0 6.796268792186311e-08
a O 0 6.759843813597399e-07
missense O 0 2.8217548333486775e-06
mutation O 0 4.271247746601148e-07
encoding O 0 5.227844894761802e-07
Gly23 O 0 5.850265370099805e-05
- O 0 1.008898743748432e-05
- O 0 1.1128790902148467e-05
> O 0 5.60803391636e-06
Val O 0 1.202872135763755e-05
in O 0 1.665099603087583e-06
neurophysin O 0 0.000242064765188843
II O 1 0.8383622169494629
. O 0 6.5451167756691575e-06

Autosomal B-Disease 1 0.9999833106994629
dominant I-Disease 1 0.9989238381385803
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.999996542930603
( O 0 1.02500043794862e-05
ADNDI B-Disease 1 0.9612534642219543
) O 0 3.7849608247597644e-07
is O 0 1.2696982309989835e-07
an O 0 9.898105872707674e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9999717473983765
by O 0 2.2142343368614092e-05
progressive O 1 0.9047699570655823
degeneration O 1 0.9999974966049194
of O 0 5.0030088459607214e-05
the O 0 8.200817319448106e-06
magnocellular O 0 4.683298902818933e-05
neurons O 0 2.0715021946671186e-06
of O 0 2.0212901290506124e-06
the O 0 2.509221530999639e-06
hypothalamus O 0 1.495695596531732e-05
leading O 0 3.8511075217684265e-06
to O 0 4.9634735432846355e-08
decreased O 0 1.4951821867725812e-05
ability O 0 1.0147621765099757e-07
to O 0 1.1092599550011073e-07
produce O 0 6.061479780328227e-07
the O 0 1.727209564705845e-05
hormone O 0 6.350807234412059e-05
arginine O 0 2.521964597690385e-05
vasopressin O 0 1.3285773093230091e-05
( O 0 1.8734821196630946e-06
AVP O 0 0.0002419678494334221
) O 0 6.572918778147141e-07
. O 0 1.8826882524081157e-06

Affected O 0 2.3649987269891426e-05
individuals O 0 2.3654574476950074e-07
are O 0 5.979205752737471e-08
not O 0 9.408494605622764e-08
symptomatic O 0 7.500970968976617e-05
at O 0 6.648288035648875e-06
birth O 0 1.275958311452996e-06
, O 0 4.6965446642843744e-08
but O 0 1.570576024789716e-08
usually O 0 6.83962468883692e-08
develop O 0 4.1164585695696587e-07
diabetes B-Disease 1 0.9983378648757935
insipidus I-Disease 0 0.002674900693818927
at O 0 2.2278281903709285e-05
1 O 0 1.8129256886822986e-06
- O 0 2.0968316221114947e-06
6 O 0 3.7946283555356786e-06
yr O 0 3.625253521022387e-05
of O 0 1.1999468370049726e-06
age O 0 6.410815331037156e-06
. O 0 2.7604828574112616e-06

The O 0 8.414971489401069e-06
genetic O 0 3.103509698121343e-06
locus O 0 2.3581071218359284e-05
of O 0 6.482648586825235e-06
the O 0 1.084523228200851e-05
disease O 0 0.003001613076776266
is O 0 9.297230008087354e-07
the O 0 3.4894183045253158e-06
AVP O 0 0.0018675801111385226
- O 0 1.059229725797195e-05
neurophysin O 0 4.077856647199951e-05
II O 0 0.02520003356039524
( O 0 3.623205202529789e-07
NPII O 0 1.8512831957195885e-05
) O 0 4.5206650867157805e-08
gene O 0 2.5965146477346934e-08
, O 0 2.2593873438836454e-08
and O 0 2.023923073579681e-08
mutations O 0 5.603526176400919e-08
that O 0 9.734054629007005e-08
cause O 0 3.6753733638761332e-06
ADNDI B-Disease 0 0.0013480038614943624
have O 0 7.230176635175667e-08
been O 0 1.1333970917348779e-07
found O 0 3.1689978641225025e-08
in O 0 4.136685305411447e-08
both O 0 3.5214494431556886e-08
the O 0 3.0753969326724473e-07
signal O 0 4.557169631880242e-06
peptide O 0 1.0030150860984577e-06
of O 0 1.447745944460621e-06
the O 0 5.974901796435006e-06
prepro O 0 0.00044115199125371873
- O 0 0.00013464644143823534
AVP O 0 0.42267245054244995
- O 0 1.288259318243945e-05
NPII O 0 5.548538683797233e-05
precursor O 0 1.996074843191309e-06
and O 0 7.011524161271154e-08
within O 0 2.9708274951190106e-07
NPII O 0 0.000168591650435701
itself O 0 1.2087908771718503e-06
. O 0 2.730068445089273e-06

An O 0 3.995472434326075e-05
affected O 0 1.1175405234098434e-05
girl O 0 1.3468297765939496e-05
who O 0 4.770017767441459e-07
presented O 0 9.422409448234248e-07
at O 0 1.769064169820922e-06
9 O 0 9.815815928959637e-07
months O 0 1.3511987617675913e-07
of O 0 1.9017538477328344e-07
age O 0 5.218644218984991e-07
and O 0 1.7954378961348993e-07
her O 0 1.2756979685946135e-06
similarly O 0 2.5657168407633435e-06
affected O 0 1.565911929901631e-06
younger O 0 1.7161181631308864e-06
brother O 0 3.4283127661183244e-06
and O 0 1.7380340011641238e-07
father O 0 6.257560016820207e-07
were O 0 1.1561901658296847e-07
all O 0 1.0950886419891503e-08
found O 0 2.3300412266280546e-08
to O 0 1.312440556233696e-08
have O 0 3.454985630924057e-08
a O 0 1.4509745938084961e-07
novel O 0 6.827535230513604e-07
missense O 0 2.2736546725354856e-06
mutation O 0 5.934463160883752e-07
( O 0 3.259648906350776e-07
G1758 O 0 8.897713087208103e-06
- O 0 1.985588824027218e-06
- O 0 2.95679569717322e-06
> O 0 2.015594191107084e-06
T O 0 1.1766592251660768e-06
) O 0 2.078485650258699e-08
encoding O 0 2.109389640736481e-08
the O 0 1.5563924193884304e-07
amino O 0 2.724110572671634e-07
acid O 0 1.9676591023198853e-07
substitution O 0 1.8138093764719088e-06
Gly23 O 0 1.2390847587084863e-05
- O 0 3.1002675768831978e-06
- O 0 3.8104176383058075e-06
> O 0 2.3951452021719888e-06
Val O 0 1.0864476280403323e-05
within O 0 1.852635705290595e-06
NPII O 0 0.0003277011273894459
. O 0 4.025308044219855e-06

The O 0 1.2410608178470284e-05
mutation O 0 3.681768703245325e-06
was O 0 9.881855476123746e-06
confirmed O 0 7.568925752821087e-07
by O 0 8.26660766506393e-08
restriction O 0 3.483074806354125e-06
endonuclease O 0 9.636634058551863e-05
analysis O 0 2.6803584205481457e-06
. O 0 3.4656293337320676e-06

A O 0 0.0010349793592467904
T1 O 0 0.014611344784498215
- O 0 7.52512933104299e-05
weighted O 0 2.8773198209819384e-05
magnetic O 0 1.1335120689182077e-05
resonance O 0 7.012245532678207e-06
imaging O 0 2.428323386993725e-05
of O 0 8.189727850549389e-06
the O 0 2.061134910036344e-05
fathers O 0 9.213743032887578e-05
pituitary O 1 0.9995262622833252
gland O 0 0.25726205110549927
demonstrates O 0 8.024114322324749e-06
an O 0 2.870688604161842e-06
attenuated O 0 0.04276501387357712
posterior O 1 0.9998040795326233
pituitary O 1 0.9999998807907104
bright O 0 0.024195155128836632
spot O 0 0.00012496518320403993
. O 0 6.8689228100993205e-06

This O 0 6.212296739249723e-06
mutation O 0 4.269245891919127e-06
may O 0 1.944441919476958e-06
be O 0 9.03800554397094e-08
valuable O 0 2.0775291886820924e-07
for O 0 6.48017390858513e-08
developing O 0 3.349364590121695e-07
models O 0 2.3621616662694578e-07
of O 0 1.491231273575977e-06
dominantly B-Disease 0 0.019861916080117226
inherited I-Disease 1 0.992043673992157
neurodegeneration I-Disease 1 1.0
, O 0 4.907416268906672e-07
as O 0 9.91408342088107e-08
the O 0 4.184569490917056e-08
early O 0 7.363110654523553e-08
age O 0 7.34096801124906e-08
of O 0 4.2348492002020066e-07
onset O 0 0.4547578990459442
of O 0 1.984888149308972e-05
symptoms O 1 0.9058018326759338
suggests O 0 3.0749333745916374e-07
that O 0 1.9684112118056873e-08
this O 0 1.6852359507879555e-08
mutation O 0 7.295422932429574e-08
may O 0 1.5398435948554834e-07
be O 0 2.3685812422513663e-08
particularly O 0 3.212719335010661e-08
deleterious O 0 4.372028854504606e-07
to O 0 1.197537642383395e-07
the O 0 2.6281795726390556e-06
magnocellular O 0 0.0003341386909596622
neuron O 0 0.0001221030979650095
. O 0 1.0993600199071807e-06
. O 0 4.270875251677353e-06

Frequent O 0 9.402136493008584e-05
inactivation O 0 0.10301708430051804
of O 0 0.0003806338645517826
PTEN O 1 0.9999985694885254
/ O 0 0.08356684446334839
MMAC1 O 1 0.6345523595809937
in O 0 3.378395149411517e-06
primary O 1 0.9994738698005676
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.577492629527114e-05

Sporadic B-Disease 1 0.9999955892562866
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 8.456280193058774e-05
the O 0 1.120024421652488e-06
most O 0 7.104641497335251e-08
common O 0 1.183474083177316e-07
male B-Disease 0 8.133059168358159e-07
cancer I-Disease 0 1.0583250514173415e-05
in O 0 2.9775355869787745e-07
the O 0 4.102208777112537e-07
Western O 0 4.5497816358874843e-07
world O 0 1.7928714157733339e-07
, O 0 1.0722049026412606e-08
yet O 0 6.215656433994354e-09
many O 0 1.081570499827933e-09
of O 0 2.702848789226664e-08
the O 0 5.3665079491338474e-08
major O 0 9.753550500590791e-08
genetic O 0 2.2732544735504234e-08
events O 0 4.3674024396977984e-08
involved O 0 4.4522256104073676e-08
in O 0 4.48273063113902e-08
the O 0 1.7591051459930895e-07
progression O 0 5.253952167549869e-06
of O 0 1.7342523506158614e-07
this O 0 7.838259818981896e-08
often O 0 1.6158057292159356e-07
fatal O 0 0.00692828930914402
cancer B-Disease 0 0.00030860977130942047
remain O 0 5.793852437818714e-07
to O 0 3.7792180052065305e-08
be O 0 5.049779474575189e-07
elucidated O 0 9.713976760394871e-05
. O 0 2.6615393835527357e-06

Numerous O 0 3.2336458389181644e-05
cytogenetic O 0 0.002818910637870431
and O 0 3.57114504367928e-06
allelotype O 0 8.177407289622352e-05
studies O 0 1.4191726904755342e-06
have O 0 6.148519560156274e-08
reported O 0 4.602943306508678e-07
frequent O 0 2.8356001280371856e-07
loss O 0 6.8723952608706895e-06
of O 0 7.784557055856567e-06
heterozygosity O 0 0.16134986281394958
on O 0 5.465126014314592e-05
chromosomal O 1 0.999879002571106
arm O 1 0.9919244647026062
10q O 0 0.1085294634103775
in O 0 4.384130079415627e-06
sporadic B-Disease 1 0.9999955892562866
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.7557391149457544e-05

Deletion O 0 0.00010496610775589943
mapping O 0 1.6606289136689156e-05
studies O 0 3.493747044558404e-06
have O 0 5.275866215015412e-07
unambiguously O 0 2.7365983896743273e-06
identified O 0 3.536234203238564e-07
a O 0 4.06877546765827e-07
region O 0 3.6156046689939103e-07
of O 0 1.4085663906371337e-06
chromosome O 0 4.84614101878833e-05
10q23 O 0 2.5414145056856796e-05
to O 0 7.722363193352066e-08
be O 0 5.0647205540599316e-08
the O 0 4.296322941854669e-08
minimal O 0 4.853010295846616e-07
area O 0 4.874830210610526e-07
of O 0 1.1908927035619854e-06
loss O 0 7.705912867095321e-05
. O 0 5.675697593687801e-06

A O 0 9.083842451218516e-05
new O 0 6.188432053022552e-06
tumor B-Disease 0 0.006458166986703873
suppressor O 0 0.14621411263942719
gene O 0 2.5959036520362133e-06
, O 0 8.353607654498774e-07
PTEN O 0 0.0006996381562203169
/ O 0 1.4070510587771423e-05
MMAC1 O 0 0.00010928242409136146
, O 0 2.7362960963728256e-07
was O 0 3.0285625598480692e-06
isolated O 0 5.748555622631102e-07
recently O 0 5.653466814692365e-07
at O 0 3.897465887803264e-07
this O 0 7.495368770094046e-09
region O 0 1.8440442062228612e-08
of O 0 1.243641207793189e-07
chromosome O 0 2.45523751800647e-05
10q23 O 0 3.0208149837562814e-05
and O 0 8.595453238058326e-08
found O 0 3.331816600393722e-08
to O 0 8.269064544208504e-09
be O 0 1.9112732729809068e-08
inactivated O 0 8.270343414551462e-07
by O 0 1.7058590984220245e-08
mutation O 0 1.8348028874015654e-08
in O 0 7.2442013276941e-08
three O 0 4.834688752453076e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9094550609588623
lines O 0 1.261916713701794e-05
. O 0 2.212862909800606e-06

We O 0 1.1908077794942074e-05
screened O 0 6.0376889450708404e-05
80 O 0 0.00011933087807847187
prostate B-Disease 1 0.9999920129776001
tumors I-Disease 1 1.0
by O 0 1.7199733974848641e-06
microsatellite O 0 1.4850711522740312e-05
analysis O 0 2.1462403765326599e-07
and O 0 9.350120677709128e-08
found O 0 2.4214463678617903e-07
chromosome O 0 1.2719921869575046e-05
10q23 O 0 1.9011107724509202e-05
to O 0 1.5113108986497537e-07
be O 0 1.0935841032733151e-07
deleted O 0 4.447451544820069e-07
in O 0 1.07763021617302e-07
23 O 0 2.3337586299021496e-06
cases O 0 6.295275625234353e-07
. O 0 3.668170393211767e-06

We O 0 4.299301053833915e-06
then O 0 6.816722475377901e-07
proceeded O 0 9.074328204405901e-07
with O 0 1.8073908591986765e-08
sequence O 0 8.789090344407668e-08
analysis O 0 5.1226038522145245e-08
of O 0 3.136074724352511e-07
the O 0 1.2310484862609883e-06
entire O 0 1.1403808457544073e-05
PTEN O 0 0.011147404089570045
/ O 0 2.7231955755269155e-05
MMAC1 O 0 5.950236663920805e-05
coding O 0 1.5799494121893076e-06
region O 0 4.7552063620059926e-07
and O 0 1.4905188550073944e-07
tested O 0 1.6886006903860107e-07
for O 0 2.9413047997195463e-08
homozygous O 0 2.2214231876205304e-07
deletion O 0 3.3294918466708623e-07
with O 0 3.487174637939461e-08
new O 0 1.5294101274321292e-07
intragenic O 0 4.782749329024227e-06
markers O 0 3.5393148323237256e-07
in O 0 3.039108875668717e-08
these O 0 7.829948245330343e-09
23 O 0 5.726395215788216e-07
cases O 0 2.8172427946060452e-08
with O 0 1.2598520982010086e-07
10q23 O 0 0.0005251162219792604
loss O 0 0.0001467642723582685
of O 0 6.78791111567989e-05
heterozygosity O 0 0.03907326981425285
. O 0 1.3775461411569268e-05

The O 0 8.31286706670653e-06
identification O 0 2.475682777003385e-06
of O 0 3.93581422031275e-06
the O 0 2.6488885396247497e-06
second O 0 4.865067239734344e-06
mutational O 0 4.1958210204029456e-05
event O 0 1.7450955738240737e-06
in O 0 3.422500469696388e-07
10 O 0 1.7853045619631303e-07
( O 0 4.073414316962953e-08
43 O 0 6.635414706579468e-07
% O 0 2.674730410490156e-07
) O 0 9.255385862161347e-07
tumors B-Disease 1 0.9999998807907104
establishes O 0 0.0001040736970026046
PTEN O 1 0.9999572038650513
/ O 0 8.053141209529713e-05
MMAC1 O 0 0.0002050344628514722
as O 0 2.3279895344785473e-07
a O 0 1.098995596748864e-07
main O 0 7.397950980703172e-07
inactivation O 0 1.6175144992303103e-05
target O 0 2.462554959947738e-07
of O 0 2.4971942025331373e-07
10q O 0 1.0340646440454293e-05
loss O 0 1.8442221971781692e-06
in O 0 7.791988991812104e-07
sporadic B-Disease 1 0.9997919201850891
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.944156105717411e-06
. O 0 3.0978203540144023e-06

Risk O 0 7.943843229440972e-05
reversals O 0 6.469379150075838e-05
in O 0 5.456613507703878e-07
predictive O 0 7.33435854272102e-06
testing O 0 3.023584440597915e-06
for O 0 1.4114027180767152e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 8.683711712365039e-06

The O 0 1.0440778169140685e-05
first O 0 2.1308596842573024e-06
predictive O 0 4.846775027544936e-06
testing O 0 1.2213705531394226e-06
for O 0 2.3757015696901362e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9997896552085876
( O 0 1.8384326949671959e-07
HD B-Disease 0 3.831947196886176e-06
) O 0 1.7300211041515468e-08
was O 0 2.102192695474514e-07
based O 0 1.522893278149695e-08
on O 0 7.73309309920478e-08
analysis O 0 4.455334590147686e-08
of O 0 3.111405249001109e-07
linked O 0 2.324438810319407e-06
polymorphic O 0 7.375704171863617e-07
DNA O 0 2.495458772955317e-07
markers O 0 4.445907961780904e-07
to O 0 3.0808152473582595e-08
estimate O 0 1.732919798769217e-07
the O 0 8.39611544733998e-08
likelihood O 0 2.6233840344502823e-07
of O 0 6.514464416795818e-07
inheriting O 0 2.431467009955668e-06
the O 0 3.981521956575307e-07
mutation O 0 5.131924467605131e-07
for O 0 4.975084380021144e-07
HD B-Disease 0 6.241333176149055e-05
. O 0 4.255457952240249e-06

Limits O 0 1.1788734809670132e-05
to O 0 5.11089751853433e-07
accuracy O 0 1.523932837699249e-06
included O 0 3.8256706602624035e-07
recombination O 0 2.4136213028214115e-07
between O 0 1.92563774703558e-07
the O 0 1.643077212065691e-07
DNA O 0 1.7820097752974107e-07
markers O 0 7.776266102155205e-07
and O 0 2.2217199102669838e-07
the O 0 4.1396461369913595e-07
mutation O 0 3.1191149219012004e-07
, O 0 1.407751142323832e-07
pedigree O 0 9.538516678730957e-07
structure O 0 1.0124188065674389e-06
, O 0 9.036970993747673e-08
and O 0 3.228488409945385e-08
whether O 0 1.6844294847828678e-08
DNA O 0 5.8418901716095206e-08
samples O 0 5.354984722316658e-08
were O 0 3.322095381008694e-07
available O 0 9.354472751965659e-08
from O 0 2.931510323378461e-07
family O 0 3.9361191284115193e-07
members O 0 7.350523105742468e-07
. O 0 3.0345529467012966e-06

With O 0 2.988694859595853e-06
direct O 0 2.2270899080467643e-06
tests O 0 2.7289885906611744e-07
for O 0 9.771649445156072e-08
the O 0 2.662397662334115e-07
HD B-Disease 0 2.280756234540604e-06
mutation O 0 8.756427405387512e-08
, O 0 2.8418634556715006e-08
we O 0 9.412206125603007e-09
have O 0 1.3045565516733859e-08
assessed O 0 6.623403692174179e-08
the O 0 4.0424627201218755e-08
accuracy O 0 2.4591471969870327e-07
of O 0 2.262734568603264e-07
results O 0 1.26995487903514e-07
obtained O 0 1.9996997480120626e-07
by O 0 1.6170589844932692e-07
linkage O 0 2.0102343114558607e-06
approaches O 0 4.112750389140274e-07
when O 0 6.56277805433092e-08
requested O 0 9.465987460544056e-08
to O 0 4.984734403024049e-08
do O 0 2.4142471133359322e-08
so O 0 1.7497129078947182e-08
by O 0 3.516522895097296e-08
the O 0 1.0687016782640057e-07
test O 0 1.4820680860339053e-07
individuals O 0 1.823618021035145e-07
. O 0 2.2585702481592307e-06

For O 0 9.796665835892782e-06
six O 0 5.672520160260319e-07
such O 0 5.343822451209235e-08
individuals O 0 1.5567731992405243e-08
, O 0 2.6394971541776613e-08
there O 0 2.6417737331030366e-08
was O 0 4.764407890434086e-07
significant O 0 6.126079199475498e-08
disparity O 0 5.633434625451628e-07
between O 0 2.0408872103416797e-07
the O 0 6.207093292687205e-07
tests O 0 9.173609214485623e-07
. O 0 3.3531787266838364e-06

Three O 0 1.543711914564483e-05
went O 0 9.697419045551214e-06
from O 0 4.64190804905229e-07
a O 0 3.6017183902004035e-07
decreased O 0 6.010701326886192e-06
risk O 0 1.2733833898437297e-07
to O 0 1.3082967598165851e-08
an O 0 4.413687193505211e-08
increased O 0 5.786905603599735e-07
risk O 0 2.954784008579736e-07
, O 0 1.7407552732606746e-08
while O 0 7.2407724260870054e-09
in O 0 1.02107362565107e-08
another O 0 1.3759296813020683e-08
three O 0 1.8371421717233716e-08
the O 0 2.779715089218371e-07
risk O 0 1.431022383258096e-06
was O 0 2.8495431251940317e-05
decreased O 0 0.0004146784485783428
. O 0 4.318408628023462e-06

Knowledge O 0 2.2359099602908827e-05
of O 0 4.083857675141189e-06
the O 0 9.844943633652292e-07
potential O 0 4.690300556831062e-07
reasons O 0 2.0889387997158337e-07
for O 0 2.9789404720759194e-08
these O 0 3.964544692536265e-09
changes O 0 9.926246491431812e-09
in O 0 4.5314905605664535e-08
results O 0 6.331787716362669e-08
and O 0 1.5046776269400652e-08
impact O 0 1.1024177126728318e-07
of O 0 1.4437816275858495e-07
these O 0 1.7427751686227566e-08
risk O 0 2.104270606650971e-07
reversals O 0 5.2053655963391066e-06
on O 0 1.0557135965427733e-06
both O 0 8.862991762725869e-08
patients O 0 8.916317284501929e-08
and O 0 1.0145318185550423e-07
the O 0 3.762345670565992e-07
counseling O 0 3.159836126087612e-07
team O 0 5.310160844373968e-08
can O 0 6.805450869507013e-09
assist O 0 6.300188459817946e-08
in O 0 9.244978826927763e-08
the O 0 2.09413087759458e-07
development O 0 3.1689771162746183e-07
of O 0 2.2030874902156938e-07
strategies O 0 1.685513240090586e-07
for O 0 5.8850478268368533e-08
the O 0 2.1017436324655137e-07
prevention O 0 1.3866360859537963e-06
and O 0 6.73406148621325e-08
, O 0 3.595811293166662e-08
where O 0 2.2373622954319217e-08
necessary O 0 5.515315137927246e-08
, O 0 4.907584738589321e-08
management O 0 3.000759249971452e-07
of O 0 1.4418580462915997e-07
a O 0 8.124468990899913e-07
risk O 0 2.2345032846260438e-07
reversal O 0 6.543117478940985e-07
in O 0 1.1703362723380906e-08
any O 0 3.13900772042075e-09
predictive O 0 1.0055505583750346e-07
testing O 0 2.939083998398928e-08
program O 0 2.0035460579492792e-07
. O 0 1.508655458337671e-07
. O 0 9.145368267127196e-07

A O 0 7.59615286369808e-05
novel O 0 7.1820545599621255e-06
common O 0 8.652379506202124e-07
missense O 0 1.4515059774566907e-05
mutation O 0 2.3724344373476924e-06
G301C O 0 3.5221208236180246e-05
in O 0 1.0534738521528197e-06
the O 0 1.5322497119996115e-06
N O 0 1.6990168660413474e-05
- O 0 5.8997197811549995e-06
acetylgalactosamine O 0 2.0437852072063833e-05
- O 0 3.2633613500365755e-06
6 O 0 9.750601748237386e-06
- O 0 6.097534878790611e-06
sulfate O 0 6.141174708318431e-06
sulfatase O 0 3.257919161114842e-05
gene O 0 6.828024083915807e-07
in O 0 9.072649618246942e-07
mucopolysaccharidosis B-Disease 0 0.0001364135678159073
IVA I-Disease 0 0.01091286726295948
. O 0 9.720130947243888e-06

Mucopolysaccharidosis B-Disease 0 0.279569149017334
IVA I-Disease 1 0.9999101161956787
( O 0 0.00021810850012116134
MPS B-Disease 1 0.9999978542327881
IVA I-Disease 1 1.0
) O 0 2.415598146399134e-06
is O 0 2.0304872805354535e-07
an O 0 4.5862009301345097e-07
autosomal B-Disease 1 0.9812567830085754
recessive I-Disease 1 0.9999994039535522
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9999953508377075
by O 0 2.7616940769803477e-06
a O 0 0.00011044296115869656
genetic B-Disease 1 0.9999841451644897
defect I-Disease 1 0.9999949932098389
in O 0 7.5662806011678185e-06
N O 0 5.0552462198538706e-05
- O 0 6.58432054478908e-06
acetylgalactosamine O 0 7.889932749094442e-05
- O 0 5.127812983118929e-06
6 O 0 2.0542707716231234e-05
- O 0 1.7202086382894777e-05
sulfate O 0 2.525887975934893e-05
sulfatase O 0 0.00025486352387815714
( O 0 1.0044269629361224e-06
GALNS O 0 0.00016538587806280702
) O 0 1.2493452459239052e-06
. O 0 1.8703295836530742e-06

In O 0 6.491099156846758e-06
previous O 0 3.819571247731801e-06
studies O 0 1.8334914102524635e-06
, O 0 2.2402322485959303e-07
we O 0 2.552692812685109e-08
have O 0 2.17657287748807e-08
found O 0 2.8713399657931404e-08
two O 0 1.3499707129938088e-08
common O 0 2.7232630372964195e-08
mutations O 0 1.1519660603198645e-07
in O 0 2.4036086188061745e-07
Caucasians O 0 9.0978801381425e-07
and O 0 2.390259226103808e-07
Japanese O 0 1.9788345525739715e-05
, O 0 5.662877242684772e-07
respectively O 0 5.516636974789435e-06
. O 0 2.200266408181051e-06

To O 0 1.0735209798440337e-05
characterize O 0 1.812096706999e-05
the O 0 2.664526164153358e-06
mutational O 0 0.0001075479231076315
spectrum O 0 1.0576092108749435e-06
in O 0 3.035412632357293e-08
various O 0 4.581512058621229e-09
ethnic O 0 8.517975658151045e-09
groups O 0 7.244087996127746e-09
, O 0 1.1685206580125396e-08
mutations O 0 1.9002412088298115e-08
in O 0 1.0548737350291049e-07
the O 0 4.6427666688941827e-07
GALNS O 0 2.627382127684541e-05
gene O 0 1.6810376735065802e-07
in O 0 6.839194384156144e-07
Colombian O 0 2.8666327125392854e-05
MPS B-Disease 1 0.9911389946937561
IVA I-Disease 1 1.0
patients O 0 5.243633154350391e-07
were O 0 2.2315218473067944e-07
investigated O 0 2.698193100059143e-07
, O 0 1.4531771341808053e-08
and O 0 1.0120112747813437e-08
genetic O 0 3.125990488683783e-08
backgrounds O 0 1.3280683219818457e-08
were O 0 2.8544015151510393e-08
extensively O 0 2.7507745414823148e-08
analyzed O 0 2.642963004007015e-08
to O 0 8.626622083340862e-09
identify O 0 1.0148798246234492e-08
racial O 0 7.986607641896626e-08
origin O 0 9.546290868911456e-08
, O 0 5.0867839718193864e-08
based O 0 9.903348541229207e-08
on O 0 8.492151550854032e-07
mitochondrial O 0 5.4700535656593274e-06
DNA O 0 9.64015384852246e-07
( O 0 3.810959299244132e-07
mtDNA O 0 8.655301257931569e-07
) O 0 2.5120559143942955e-07
lineages O 0 2.193915634052246e-06
. O 0 1.82871883680491e-06

Three O 0 3.972611921199132e-06
novel O 0 4.279330823919736e-06
missense O 0 6.775857855245704e-06
mutations O 0 8.292741995319375e-07
never O 0 8.64848516357597e-07
identified O 0 2.4359201233892236e-07
previously O 0 1.452568199056259e-07
in O 0 2.8222661541121852e-08
other O 0 2.987975422641398e-09
populations O 0 8.763707981529478e-09
and O 0 2.8776010907449745e-08
found O 0 6.025043575164091e-08
in O 0 9.778585763342562e-08
16 O 0 5.561626039707335e-07
out O 0 7.172747729100593e-08
of O 0 1.1131347719128826e-06
19 O 0 3.2649106287863106e-05
Colombian O 0 5.582734593190253e-05
MPS B-Disease 0 0.16270332038402557
IVA I-Disease 1 0.999572217464447
unrelated O 0 1.461019564885646e-06
alleles O 0 1.4741334553036722e-07
account O 0 1.2664160919939604e-07
for O 0 2.1818314621668833e-07
84 O 0 1.5148277270782273e-05
. O 0 4.164721758570522e-06

2 O 0 2.6221907319268212e-05
% O 0 8.614932767159189e-07
of O 0 8.188706601686135e-07
the O 0 3.3486907113911e-07
alleles O 0 1.9770641301875003e-07
in O 0 1.377634504251546e-07
this O 0 9.794395339213224e-08
study O 0 6.337097033792816e-07
. O 0 1.678162107054959e-06

The O 0 7.82253046054393e-05
G301C O 0 0.0003317349764984101
and O 0 2.5295551040471764e-06
S162F O 0 6.0327853134367615e-05
mutations O 0 1.4622879689341062e-06
account O 0 8.968472684500739e-07
for O 0 8.941758551372914e-07
68 O 0 5.582239100476727e-05
. O 0 9.045884326042142e-06

4 O 0 5.828425855725072e-05
% O 0 3.4235949897265527e-06
and O 0 1.7968441170523874e-06
10 O 0 7.466657280019717e-06
. O 0 5.4974257182038855e-06

5 O 0 2.4023873265832663e-05
% O 0 9.216982448378985e-07
of O 0 9.761960200194153e-07
mutations O 0 4.6203285819501616e-07
, O 0 3.0982940302237694e-07
respectively O 0 8.318897357639798e-07
, O 0 5.597330599016459e-08
whereas O 0 8.60381845768643e-08
the O 0 1.3492234529621783e-07
remaining O 0 4.0136833945325634e-07
F69V O 0 1.893204535008408e-05
is O 0 5.4875396671150156e-08
limited O 0 3.910168189236174e-08
to O 0 4.1442191900387115e-08
a O 0 5.169230234969291e-07
single O 0 1.2345391269263928e-06
allele O 0 4.923757842334453e-06
. O 0 2.1631508388963994e-06

The O 0 3.6999688745709136e-05
skewed O 0 4.5907931053079665e-05
prevalence O 0 6.974874122533947e-05
of O 0 6.598199888685485e-06
G301C O 0 4.1595150833018124e-05
in O 0 3.6015566706737445e-07
only O 0 1.2688848016750853e-07
Colombian O 0 5.38421090823249e-06
patients O 0 2.642159984134196e-07
and O 0 1.9176019350197748e-07
haplotype O 0 3.2578543596173404e-06
analysis O 0 1.749964155806083e-07
by O 0 5.3139910249910827e-08
restriction O 0 1.3264283893477113e-07
fragment O 0 1.830032800853587e-07
length O 0 4.966077682411196e-08
polymorphisms O 0 2.1782389580948802e-07
in O 0 1.0476373546453033e-07
the O 0 4.1636715764070686e-07
GALNS O 0 2.1448382540256716e-05
gene O 0 1.4082452537422796e-07
suggest O 0 7.068067020554736e-08
that O 0 4.1775038539526577e-08
G301C O 0 7.626648311997997e-06
originated O 0 5.103747184875829e-07
from O 0 1.2910466296034429e-07
a O 0 4.0287739011546364e-07
common O 0 7.157358936638047e-07
ancestor O 0 2.6856374461203814e-05
. O 0 4.714971510111354e-06

Investigation O 0 7.866913074394688e-05
of O 0 4.590419393935008e-06
the O 0 1.0178146112593822e-06
genetic O 0 6.271678216762666e-07
background O 0 6.653728519268043e-07
by O 0 2.3969360540831985e-07
means O 0 1.1240023667369314e-07
of O 0 3.5566012002163916e-07
mtDNA O 0 2.576235260676185e-07
lineages O 0 8.524659023123604e-08
indicate O 0 4.91123657297976e-08
that O 0 1.4453130248170964e-08
all O 0 1.0211087086986481e-08
our O 0 6.047032741207659e-08
patients O 0 5.769614119799371e-08
are O 0 5.450630613523799e-09
probably O 0 7.601595086725865e-08
of O 0 2.838708894614683e-07
native O 0 9.190807759296149e-07
American O 0 1.4325968550110701e-05
descent O 0 0.00027797691291198134

Low O 0 4.902973523712717e-05
frequency O 0 4.516029548540246e-06
of O 0 1.3966588312541717e-06
BRCA1 O 0 9.544554814056028e-06
germline O 0 6.4203109104710165e-06
mutations O 0 8.610959412180819e-08
in O 0 9.18739218036535e-08
45 O 0 1.3983487860969035e-06
German O 1 0.9874000549316406
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.1735455650050426e-06
. O 0 5.312376288202358e-06

In O 0 2.856138735296554e-06
this O 0 8.612389024165168e-08
study O 0 9.593658489848167e-08
we O 0 2.1904332569988583e-08
investigated O 0 3.812395164004556e-07
45 O 0 2.4577502699685283e-06
German O 1 0.9917491674423218
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.2314574955071294e-08
for O 0 5.028623561997847e-08
germline O 0 2.7545054308575345e-06
mutations O 0 1.1173397496122561e-07
in O 0 1.840936221242373e-07
the O 0 1.0256096629746025e-06
BRCA1 O 0 2.528828554204665e-05
gene O 0 8.74214219948044e-06
. O 0 6.73846898280317e-06

We O 0 6.454999038396636e-06
identified O 0 3.470670208116644e-06
four O 0 6.358533823913604e-07
germline O 0 9.291067726735491e-06
mutations O 0 3.4298392392884125e-07
in O 0 1.6927106116781943e-07
three O 0 6.258974849515653e-07
breast B-Disease 1 0.9973758459091187
cancer I-Disease 1 0.933131217956543
families O 0 6.595367096906557e-08
and O 0 9.18523710424779e-08
in O 0 5.400026452662132e-07
one O 0 1.349709873466054e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 2.535216253818362e-06
. O 0 3.233375167610575e-08
among O 0 7.610209351582853e-09
these O 0 4.303497114221955e-09
were O 0 9.906220554967149e-08
one O 0 4.4420637834718946e-08
frameshift O 0 1.1149631973239593e-06
mutation O 0 6.92641535238181e-08
, O 0 6.55751080103073e-08
one O 0 5.774832345650793e-08
nonsense O 0 1.2397007367326296e-06
mutation O 0 8.782303240195688e-08
, O 0 3.371630796777936e-08
one O 0 2.2826915468954212e-08
novel O 0 8.819182539809844e-08
splice O 0 3.621063626724208e-07
site O 0 1.7610689440061833e-07
mutation O 0 8.127323525286556e-08
, O 0 4.0620015795411746e-08
and O 0 4.434969369526698e-08
one O 0 2.3853334596424247e-07
missense O 0 1.4580446077161469e-05
mutation O 0 9.178314940072596e-06
. O 0 9.657843293098267e-06

The O 0 1.5216297470033169e-05
missense O 0 4.594721758621745e-05
mutation O 0 4.993860329705058e-06
was O 0 2.78363331744913e-05
also O 0 4.900181806988257e-07
found O 0 2.1720076404108113e-07
in O 0 4.6725364200028707e-07
2 O 0 7.558072866231669e-06
. O 0 4.731746685138205e-06

8 O 0 4.439290569280274e-05
% O 0 8.68735469339299e-07
of O 0 5.428067879620357e-07
the O 0 4.390203400816972e-07
general O 0 4.65973812424636e-07
population O 0 2.3585368325029776e-08
, O 0 2.348835614895961e-08
suggesting O 0 1.1096577878788594e-07
that O 0 9.066247308453512e-09
it O 0 1.2930546411382693e-08
is O 0 8.676427398768283e-08
not O 0 1.5186489576990425e-07
disease O 0 0.0012545627541840076
associated O 0 5.3442781791090965e-06
. O 0 4.470700787351234e-06

The O 0 1.1608714885369409e-05
average O 0 2.5905346774379723e-06
age O 0 9.75423517957097e-07
of O 0 6.8955700953665655e-06
disease O 1 0.9989396929740906
onset O 1 0.99983811378479
in O 0 7.87358942488936e-07
those O 0 6.180323453008896e-08
families O 0 5.305453498749557e-08
harbouring O 0 1.9403742044232786e-05
causative O 0 6.698322977172211e-06
mutations O 0 6.542618393723387e-07
was O 0 1.0616842700983398e-05
between O 0 1.2491307188611245e-06
32 O 0 1.6670821423758753e-05
. O 0 3.859111529891379e-06

3 O 0 0.0001102035166695714
and O 0 7.5459738582139835e-06
37 O 0 5.659164526150562e-05
. O 0 1.0105578439834062e-05

4 O 0 7.927263504825532e-05
years O 0 3.4228048662043875e-06
, O 0 3.843102547307353e-07
whereas O 0 2.851197393738403e-07
the O 0 2.557303560024593e-07
family O 0 2.067549758066889e-07
harbouring O 0 1.8030814317171462e-05
the O 0 2.0233525788171391e-07
missense O 0 2.0895574834867148e-06
mutation O 0 2.6063594305014703e-07
had O 0 8.481711120111868e-07
an O 0 1.775803895043282e-07
average O 0 4.00972766101404e-07
age O 0 2.0447525628242147e-07
of O 0 1.8397462326902314e-06
onset O 0 0.09441499412059784
of O 0 3.561298944987357e-05
51 O 0 0.0001151114993263036
. O 0 7.82862935011508e-06

2 O 0 0.00034788635093718767
years O 0 8.453634654870257e-05
. O 0 2.3326670998358168e-05

These O 0 2.4538367142667994e-06
findings O 0 1.4982446145950234e-06
show O 0 5.852172648701526e-07
that O 0 9.124924105208265e-08
BRCA1 O 0 1.9179617538611637e-06
is O 0 1.6803548419375147e-07
implicated O 0 7.239614774334768e-07
in O 0 2.463277581910006e-08
a O 0 2.3847961827527797e-08
small O 0 1.0238077940982748e-08
fraction O 0 3.2162386531808806e-08
of O 0 2.8817921702284366e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0003320483065181e-07
suggesting O 0 3.4706462770373037e-07
the O 0 5.8200914310191365e-08
involvement O 0 4.2717363157862565e-07
of O 0 3.815286504504911e-07
another O 0 4.4670221654996567e-07
susceptibility O 0 1.838979915191885e-05
gene O 0 5.159137799637392e-06
( O 0 4.187243121123174e-06
s O 0 0.00022353738313540816
) O 0 1.1336494026181754e-05

Paternal O 1 0.9853515625
transmission O 1 0.9999039173126221
of O 1 0.9999960660934448
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00023954750213306397

We O 0 9.59386943577556e-06
report O 0 4.632246145774843e-06
a O 0 7.820837595318153e-07
rare O 0 7.465137628059892e-07
case O 0 1.005274157250824e-06
of O 0 1.3182532711653039e-05
paternally O 1 0.9996945858001709
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00011120404815301299
DM B-Disease 1 1.0
) O 0 3.645265906015993e-06
. O 0 1.9873887140420265e-06

The O 0 3.0484081435133703e-05
proband O 0 0.0002011481556110084
is O 0 7.861314088586369e-07
a O 0 6.299504207163409e-07
23 O 0 3.115103936579544e-06
year O 0 8.710059660188563e-07
old O 0 1.8336317225475796e-05
, O 0 1.5184233234322164e-05
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.0038408429827541113
who O 0 5.178992068977095e-05
suffers O 1 0.9999998807907104
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.0002981525321956724

He O 0 1.577541661390569e-05
presented O 0 1.2136295481468551e-05
with O 0 2.8698400456050877e-06
respiratory O 1 1.0
and O 0 7.580999408673961e-06
feeding O 0 0.00036419578827917576
difficulties O 0 0.0001227190368808806
at O 0 0.0012839901028200984
birth O 0 0.00019178446382284164
. O 0 4.71088605991099e-06

His O 0 9.716024214867502e-05
two O 0 1.587864062457811e-05
sibs O 1 0.9998561143875122
suffer O 0 0.0011556289391592145
from O 0 1.2805596270482056e-05
childhood O 0 0.487930566072464
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 6.42392406007275e-05

Their O 0 1.5750430975458585e-05
late O 0 5.8086727221962065e-05
father O 0 1.0247696991427802e-05
had O 0 1.43033059885056e-06
the O 0 2.817861570747482e-07
adult O 0 2.5171280526592454e-07
type O 0 2.0409390799613902e-06
of O 0 0.0004771785461343825
DM B-Disease 1 1.0
, O 0 1.1383816627130727e-06
with O 0 1.2671239346673246e-07
onset O 0 0.21671676635742188
around O 0 1.3391237416726653e-06
30 O 0 1.6752007923059864e-06
years O 0 8.429465196968522e-07
. O 0 1.4503286820399808e-06

Only O 0 2.3596112441737205e-06
six O 0 3.706259690261504e-07
other O 0 1.4932670211464938e-08
cases O 0 2.8777108695976494e-08
of O 0 6.035430146766885e-07
paternal O 0 0.21278871595859528
transmission O 1 0.998939573764801
of O 1 0.9998887777328491
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 3.5110190310660983e-06
been O 0 2.8212546112627024e-06
reported O 0 3.1509969176113373e-06
recently O 0 2.499722540960647e-06
. O 0 1.8359918385613128e-06

We O 0 2.260061137349112e-06
review O 0 8.123299721773947e-07
the O 0 1.45519976513242e-07
sex O 0 7.675344448898613e-08
related O 0 2.3104325919121038e-07
effects O 0 2.2614710815105354e-06
on O 0 2.7481792130856775e-06
transmission O 0 0.0008437192300334573
of O 0 0.045878902077674866
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00018505466869100928

Decreased O 0 0.0035611754283308983
fertility O 0 6.725771527271718e-05
of O 0 1.0957342055917252e-06
males O 0 7.269254354014265e-08
with O 0 4.022803423708865e-08
adult O 0 2.801107712002704e-06
onset O 1 0.9999979734420776
DM B-Disease 1 1.0
and O 0 4.1120501919067465e-06
contraction O 0 8.647012145956978e-05
of O 0 1.4888155419612303e-07
the O 0 7.29414324496247e-08
repeat O 0 5.0826812980631075e-08
upon O 0 4.179544177418393e-08
male O 0 1.1496590701653986e-07
transmission O 0 3.112509148195386e-07
contribute O 0 1.2412152194940518e-08
to O 0 1.1160016022415675e-08
the O 0 4.735438707825779e-08
almost O 0 1.0062681354838787e-07
absent O 0 2.3516625446973194e-07
occurrence O 0 9.910623788300654e-08
of O 0 2.0715641824153863e-07
paternal O 0 2.7581447284319438e-05
transmission O 0 0.00014599908899981529
of O 0 0.13429468870162964
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 8.93209726200439e-05

Also O 0 3.261941310483962e-05
the O 0 3.2921882393566193e-06
fathers O 0 1.7395774420947419e-06
of O 0 1.0254962035105564e-06
the O 0 1.4891451201037853e-06
reported O 0 2.283121648360975e-05
congenitally O 0 0.0005062777199782431
affected O 0 5.747158411395503e-07
children O 0 1.335255461754059e-07
showed O 0 1.1947010989388218e-06
, O 0 6.882233805072246e-08
on O 0 5.452233722280653e-07
average O 0 4.431769298207655e-07
, O 0 1.776037663603347e-07
shorter O 0 9.65662366070319e-07
CTG O 0 2.2349911887431517e-05
repeat O 0 3.305973734768486e-07
lengths O 0 3.896187763530179e-07
and O 0 3.029923689723546e-08
hence O 0 1.3954964117601776e-07
less O 0 1.0099638103611142e-07
severe O 0 0.0002783070376608521
clinical O 0 0.12710943818092346
symptoms O 0 0.01994241774082184
than O 0 7.899554788082241e-08
the O 0 2.567415435805742e-07
mothers O 0 1.5905578720776248e-07
of O 0 2.474872644597781e-07
children O 0 1.142525434261188e-06
with O 0 1.2175270057923626e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00033620884642004967

We O 0 7.471600838471204e-06
conclude O 0 6.301838766376022e-06
that O 0 3.883967281126388e-07
paternal O 0 7.586618448840454e-05
transmission O 0 0.0022962670773267746
of O 0 0.48397889733314514
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 6.482648586825235e-06
rare O 0 1.7805352570121613e-07
and O 0 3.617977029080066e-08
preferentially O 0 6.166334998169987e-08
occurs O 0 2.2570441515767925e-08
with O 0 1.3529660947142474e-08
onset O 0 0.00017655716510489583
of O 0 2.361599945288617e-05
DM B-Disease 1 1.0
past O 0 8.552587473786843e-07
30 O 0 3.115080744464649e-07
years O 0 4.425573152389006e-08
in O 0 4.9372911092859795e-08
the O 0 2.3486256850446807e-07
father O 0 2.756284175120527e-06
. O 0 3.856139301205985e-07
. O 0 2.166195827157935e-06

The O 0 0.00010556255438132212
RB1 O 0 0.0030148050282150507
gene O 0 3.597400336730061e-06
mutation O 0 9.907370213113609e-07
in O 0 3.5667065390043717e-07
a O 0 1.3272664318719762e-06
child O 0 4.613082182913786e-06
with O 0 6.031993052602047e-06
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.00016495058662258089

The O 0 7.10630338289775e-05
RB1 O 0 0.0009145160438492894
gene O 0 2.351912144149537e-06
mutation O 0 1.3918321428718627e-06
was O 0 5.837640401296085e-06
investigated O 0 7.575735594400612e-07
in O 0 2.435135115774756e-07
a O 0 1.1385466223146068e-06
child O 0 6.001124802423874e-06
with O 0 1.355101403532899e-06
ectopic B-Disease 1 0.9999973773956299
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.9894322156906128
using O 0 1.1830870505491475e-07
DNA O 0 1.3274457444367727e-07
obtained O 0 2.841352113591711e-07
from O 0 2.1138426120614895e-07
both O 0 5.7216904991719275e-08
the O 0 1.1892901738974615e-06
pineal B-Disease 0 0.12619175016880035
and I-Disease 0 2.1038824797869893e-06
retinal I-Disease 1 0.9999983310699463
tumours I-Disease 1 1.0
of O 0 0.0005598595598712564
the O 0 2.7827711164718494e-05
patient O 0 0.00013576913625001907
. O 0 1.3315478099684697e-05

A O 0 0.00028706772718578577
nonsense O 0 6.785580626456067e-05
mutation O 0 2.2069239093980286e-06
in O 0 8.236654593929416e-07
exon O 0 1.6797345097074867e-06
17 O 0 2.0754987417603843e-06
( O 0 2.6897970428763074e-07
codon O 0 2.066600700345589e-06
556 O 0 8.991646609501913e-07
) O 0 1.9997143496652825e-08
of O 0 1.2709871555216523e-07
the O 0 3.494082818633615e-07
RB1 O 0 2.492224666639231e-05
gene O 0 9.272051215702959e-08
was O 0 1.1875333711941494e-06
found O 0 5.3868852489813435e-08
to O 0 2.347962180238028e-08
be O 0 3.115704316769552e-08
present O 0 1.1188367921022291e-07
homozygously O 0 4.032166543765925e-06
in O 0 8.391152306330696e-08
both O 0 5.416289283743936e-08
the O 0 8.368932640223647e-07
retinal B-Disease 0 0.0023431815207004547
and I-Disease 0 1.2955252941537765e-06
the I-Disease 0 0.00010104472312377766
pineal I-Disease 1 0.9999988079071045
tumours I-Disease 1 1.0
. O 0 4.2354997276561335e-05

The O 0 8.05456602392951e-06
same O 0 5.869040364814282e-07
mutation O 0 5.443754957923375e-07
was O 0 2.475514975230908e-06
present O 0 8.510200899536358e-08
heterozygously O 0 2.305362386323395e-06
in O 0 1.243119385208047e-07
the O 0 1.8874617069286614e-07
DNA O 0 1.6174246297850914e-07
from O 0 2.1986377873872698e-07
the O 0 3.214871924228646e-07
constitutional O 0 9.430904697182996e-07
cells O 0 3.224611475616257e-07
of O 0 7.109296689122857e-07
the O 0 6.363422926369822e-07
patient O 0 6.335006901281304e-07
, O 0 3.850626129064949e-08
proving O 0 1.4861443276004138e-07
it O 0 4.5732702069756215e-09
to O 0 1.4200369768957444e-08
be O 0 4.761332306202348e-08
of O 0 8.196777230295993e-07
germline O 0 2.4066663172561675e-05
origin O 0 1.9110054836346535e-06
. O 0 2.4160242446669145e-06

The O 0 9.659621355240233e-06
initial O 0 2.436799150018487e-06
mutation O 0 5.838915626554808e-07
was O 0 1.0743738130258862e-06
shown O 0 6.212695780050126e-08
to O 0 1.8005643198648613e-08
have O 0 2.9070708507106247e-08
occurred O 0 1.000746806312236e-06
in O 0 2.0377871123855584e-07
the O 0 1.6927313026826596e-06
paternally O 0 3.2850362913450226e-05
derived O 0 9.27271776163252e-06
RB1 O 0 0.0006214022869244218
allele O 0 7.747531526547391e-06
. O 0 3.4642714581423206e-06

The O 0 1.5224006347125396e-05
mutation O 0 1.4546880038324161e-06
is O 0 2.550916917698487e-07
in O 0 1.7321036693829228e-07
an O 0 9.30699073364849e-08
area O 0 2.220749735215577e-07
of O 0 4.7442037498512946e-07
the O 0 4.692327593147638e-07
gene O 0 9.853118143610118e-08
that O 0 7.313408900699869e-08
encodes O 0 2.57697251981881e-07
the O 0 3.6873697695227747e-07
protein O 0 3.945846174246981e-07
- O 0 6.820734483881097e-07
binding O 0 1.7428524756724073e-07
region O 0 4.128874877551425e-07
known O 0 4.997414748686424e-07
as O 0 1.64239565947355e-07
the O 0 1.9431131192959583e-07
pocket O 0 1.0135372576769441e-06
region O 0 1.2770669854944572e-07
and O 0 7.99227635184252e-08
has O 0 8.429218212313572e-08
been O 0 8.344993318587512e-08
detected O 0 1.5087979932104645e-07
in O 0 3.646117008315741e-08
other O 0 1.2368384538774535e-08
cases O 0 6.196010104986271e-08
of O 0 2.193650061599328e-06
retinoblastoma B-Disease 0 0.362880140542984
. O 0 1.4866491255816072e-06
. O 0 3.227175739084487e-06

Low O 0 0.00013530450814869255
levels O 0 2.7316339128447e-06
of O 0 1.1268373327766312e-06
beta O 0 6.08448863204103e-06
hexosaminidase O 0 9.741929716255981e-06
A O 0 9.703372825242695e-07
in O 0 7.020543790758893e-08
healthy O 0 1.0280505335913404e-07
individuals O 0 6.723342771408625e-09
with O 0 3.7175762912511345e-08
apparent O 1 0.9295139908790588
deficiency O 1 0.9999998807907104
of O 0 0.0005258083110675216
this O 0 3.7477634577953722e-06
enzyme O 0 1.245399016625015e-05
. O 0 3.07965160573076e-06

Appreciable O 0 0.0010339387226849794
beta O 0 0.00015672959852963686
hexosaminidase O 0 0.00029312705737538636
A O 0 3.322395059512928e-05
( O 0 8.113041189972137e-07
hex O 0 6.980645594012458e-06
A O 0 1.0182029654970393e-06
) O 0 2.5536472492149187e-08
activity O 0 1.1648182862700196e-07
has O 0 1.8234922904980522e-08
been O 0 7.406154622913164e-08
detected O 0 9.190773084810644e-07
in O 0 1.747460373735521e-06
cultured O 1 0.9718884229660034
skin O 1 0.9999853372573853
fibroblasts O 1 0.9999959468841553
and O 0 0.0007770079537294805
melanoma B-Disease 1 1.0
tissue O 1 0.9985633492469788
from O 0 1.3694324252355727e-06
healthy O 0 8.84525945821224e-08
individuals O 0 2.9010263080664345e-09
previously O 0 6.985867173625593e-08
reported O 0 2.5581670115570887e-07
as O 0 1.5578640955027367e-07
having O 0 8.110117164505937e-07
deficiency B-Disease 0 0.2921295762062073
of I-Disease 0 4.4705943764711265e-06
hex I-Disease 0 4.202644413453527e-05
A I-Disease 0 1.365458729196689e-06
activity O 0 5.009707706449262e-07
indistinguishable O 0 1.6902971822219115e-07
from O 0 2.294643586253642e-08
that O 0 6.659858886592929e-09
of O 0 1.0402025907296775e-07
patients O 0 2.3535315563094628e-07
with O 0 6.069385563023388e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999979734420776
( O 0 3.492437826935202e-06
TSD B-Disease 0 0.011521603912115097
) O 0 1.4073982583795441e-06
. O 0 1.3745691376243485e-06

Identification O 0 1.7476289940532297e-05
and O 0 3.6306598758528708e-06
quantitation O 0 0.00010689020564313978
of O 0 1.042383610183606e-05
hex O 0 5.902730117668398e-05
A O 0 3.3838155104604084e-06
, O 0 9.107692022780611e-08
amounting O 0 1.0924828757197247e-06
to O 0 1.872784025636065e-07
3 O 0 4.9561031119083054e-06
. O 0 4.3592986003204715e-06

5 O 0 6.325935100903735e-05
% O 0 8.248483027273323e-06
- O 0 3.357033710926771e-05
6 O 0 3.936750363209285e-05
. O 0 5.624852747132536e-06

9 O 0 3.078199733863585e-05
% O 0 5.945725547462644e-07
of O 0 7.490775715268683e-07
total O 0 2.030322093560244e-06
beta O 0 3.3865210298245074e-06
hexosaminidase O 0 1.0217874660156667e-05
activity O 0 7.706860287726158e-07
, O 0 3.968087369798923e-08
has O 0 2.0264918632051376e-08
been O 0 7.756078446163883e-08
obtained O 0 2.911413901074411e-07
by O 0 5.688392548108823e-07
cellulose O 0 1.965284172911197e-05
acetate O 0 7.860528967285063e-06
gel O 0 3.594718464228208e-06
electrophoresis O 0 4.112356691621244e-06
, O 0 4.697086524174665e-07
DEAE O 0 4.850773621001281e-05
- O 0 4.115549472771818e-06
cellulose O 0 4.876578259427333e-06
ion O 0 8.31967918202281e-06
- O 0 2.868460796889849e-06
exchange O 0 4.25183134211693e-06
chromatography O 0 1.0839442438737024e-05
, O 0 3.4234210488648387e-07
radial O 0 1.7887290596263483e-05
immunodiffusion O 0 2.162200507882517e-05
, O 0 5.784565928479424e-07
and O 0 1.1643845709841116e-06
radioimmunoassay O 0 0.00034433527616783977
. O 0 9.297157703258563e-06

Previous O 0 3.7153098674025387e-05
family O 0 1.020403828988492e-06
studies O 0 1.530181862108293e-06
suggested O 0 5.343414954950276e-07
that O 0 3.333074971578753e-08
these O 0 1.344923195034653e-08
individuals O 0 2.5021543947900682e-08
may O 0 7.126518539735116e-07
be O 0 2.3938520143929054e-07
compound O 0 6.034375473973341e-06
heterozygotes O 0 6.971199013605656e-07
for O 0 4.142417608932192e-08
the O 0 1.1401304789160349e-07
common O 0 8.176284893579577e-08
mutant O 0 1.4027432371221948e-06
TSD B-Disease 0 2.9541000913013704e-05
gene O 0 2.106093575093837e-07
and O 0 7.266648083259497e-08
a O 0 2.3607609023201803e-07
rare O 0 1.7120660800173937e-07
( O 0 9.148711654916042e-08
allelic O 0 1.144332486546773e-06
) O 0 1.4829319638920424e-07
mutant O 0 4.5741198846371844e-06
gene O 0 3.684083367261337e-06
. O 0 2.9728103072557133e-06

Thus O 0 1.5634705050615594e-05
, O 0 1.2330106073932257e-06
the O 0 6.007779802530422e-07
postulated O 0 2.9566122066171374e-06
rate O 0 1.1778852240240667e-06
mutant O 0 2.496758497727569e-07
gene O 0 9.02914862876969e-08
appears O 0 7.772368348923919e-08
to O 0 1.1416304346312245e-08
code O 0 1.5798086394624988e-08
for O 0 1.4442410822823604e-08
the O 0 7.728787920768809e-08
expression O 0 7.249398237263449e-08
of O 0 1.433158161034953e-07
low O 0 7.466426268365467e-07
amounts O 0 8.345503488271788e-08
of O 0 2.387514541624114e-06
hex O 0 8.338130282936618e-05
A O 0 1.8416967577650212e-05
. O 0 2.8849158297816757e-06

Heterozygotes O 0 0.00037705013528466225
for O 0 2.1678658868040657e-06
the O 0 8.991406730274321e-07
rare O 0 4.793374728251365e-07
mutant O 0 3.3399912808818044e-06
may O 0 9.240022791345837e-07
be O 0 1.0167402564320582e-07
indistinguishable O 0 2.6078365067405684e-07
from O 0 7.567295767785254e-08
heterozygotes O 0 5.128039788360184e-07
for O 0 6.98433595403003e-08
the O 0 6.612522156501655e-07
common O 0 1.681858407209802e-06
TSD B-Disease 0 0.0003599359770305455
mutant O 0 1.791139402484987e-05
. O 0 3.9826945794629864e-06

However O 0 8.441430509265047e-06
, O 0 5.101358624415298e-07
direct O 0 9.18005071071093e-07
visualization O 0 1.0339186701457947e-05
and O 0 3.733579205800197e-07
quantitation O 0 2.8133983505540527e-05
of O 0 4.056140369357308e-06
hex O 0 2.539023626013659e-05
A O 0 1.8982652818522183e-06
by O 0 5.16112734771923e-08
the O 0 4.41149872187907e-08
methods O 0 1.5871410141699016e-07
described O 0 1.078873879123421e-06
may O 0 5.198452299737255e-07
prevent O 0 4.2081089191015053e-07
false O 0 2.886255970224738e-06
- O 0 1.1176652151334565e-05
positive O 0 8.27414623927325e-07
prenatal O 0 0.0016045657685026526
diagnosis O 0 0.00028056546580046415
of O 0 1.1333261682011653e-05
TSD B-Disease 0 0.0024826189037412405
in O 0 4.5286131467037194e-07
fetuses O 0 1.7487340073785163e-06
having O 0 2.1769845659491693e-07
the O 0 2.0716609583359968e-07
incomplete O 0 1.7219166466020397e-06
hex B-Disease 0 2.8598036806215532e-05
A I-Disease 0 2.3553066057502292e-05
deficiency I-Disease 0 0.12369562685489655
of O 0 1.7360274569000467e-06
the O 0 4.799811108568974e-07
type O 0 1.950310434040148e-06
described O 0 5.893562047276646e-07
in O 0 1.897668369110761e-07
the O 0 7.456272328454361e-07
four O 0 9.06019863577967e-07
healthy O 0 5.1184906624257565e-06
individuals O 0 2.075556039926596e-06

The O 0 8.83174070622772e-05
tumor B-Disease 1 0.9144519567489624
suppressor O 1 0.9844762682914734
gene O 0 1.390095076203579e-05
Smad4 O 0 0.00061124557396397
/ O 0 3.9104244933696464e-05
Dpc4 O 0 3.484329499769956e-05
is O 0 6.939665553318264e-08
required O 0 2.5311180706921732e-08
for O 0 2.990736547303641e-08
gastrulation O 0 1.7023476175381802e-06
and O 0 8.709289289754452e-08
later O 0 3.24072289004107e-07
for O 0 1.092081234332909e-07
anterior O 0 4.865302253165282e-05
development O 0 1.5170392089203233e-06
of O 0 2.050150669674622e-06
the O 0 3.8574999052798375e-06
mouse O 0 1.2133818927395623e-05
embryo O 0 1.7818951164372265e-05
. O 0 4.389694368001074e-06

Mutations O 0 3.4521643101470545e-05
in O 0 6.626399226661306e-06
the O 0 7.281233592948411e-06
SMAD4 O 0 0.04515965282917023
/ O 0 0.00023752950073685497
DPC4 O 0 0.04109270125627518
tumor B-Disease 1 0.9534212350845337
suppressor O 0 0.2725788652896881
gene O 0 5.744916506955633e-07
, O 0 1.3597652070984623e-07
a O 0 5.709997594749439e-07
key O 0 3.842702881229343e-06
signal O 0 1.1048759915865958e-05
transducer O 0 1.3007252164243255e-05
in O 0 5.373005933506647e-07
most O 0 2.7954158099419146e-07
TGFbeta O 0 6.410913920262828e-05
- O 0 2.63696688307391e-06
related O 0 8.958966191130457e-07
pathways O 0 2.3039688130666036e-06
, O 0 2.414896371760733e-08
are O 0 2.013606836825943e-09
involved O 0 5.690528048774013e-09
in O 0 3.083290067706912e-08
50 O 0 1.8438548465837812e-07
% O 0 3.166653925745777e-07
of O 0 2.1456811737152748e-05
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999997615814209
. O 0 6.363174179568887e-05

Homozygous O 0 0.0008528745966032147
Smad4 O 0 0.0011501038679853082
mutant O 0 0.0001417557505192235
mice O 0 4.981124948244542e-05
die O 0 1.223416347784223e-05
before O 0 6.463768045250617e-07
day O 0 1.2194675491628004e-06
7 O 0 4.5969381972099654e-06
. O 0 1.4607282992074033e-06

5 O 0 0.00010842070332728326
of O 0 5.783965389127843e-05
embryogenesis O 0 0.0009635334718041122
. O 0 7.669265323784202e-05

Mutant O 0 4.916823309031315e-05
embryos O 0 6.084175311116269e-06
have O 0 4.1337008838127076e-07
reduced O 0 6.293067258411611e-07
size O 0 1.5639895423191774e-07
, O 0 9.688710633781739e-08
fail O 0 1.7864815049506433e-07
to O 0 1.1524440424182103e-07
gastrulate O 0 9.882920494419523e-06
or O 0 3.160420760650595e-07
express O 0 2.610531169011665e-07
a O 0 7.830547588127956e-07
mesodermal O 0 1.7808044503908604e-05
marker O 0 7.987177014001645e-06
, O 0 5.152628901328171e-08
and O 0 4.422433974582418e-08
show O 0 7.003050654930121e-07
abnormal O 0 0.025554191321134567
visceral O 0 0.005284460727125406
endoderm O 0 0.0057841413654387
development O 0 1.9391753085074015e-05
. O 0 2.7466439860290848e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 0.9999998807907104
of O 0 4.30506952397991e-05
the O 0 3.163331712130457e-05
Smad4 O 0 0.31186413764953613
- O 0 0.00027688819682225585
deficient O 0 3.934645064873621e-05
embryos O 0 5.876265163351491e-07
results O 0 2.991478709191142e-07
from O 0 8.723188216208655e-08
reduced O 0 3.438623252804973e-07
cell O 0 4.1527760004100855e-06
proliferation O 0 4.175061349087628e-06
rather O 0 2.1117244841661886e-08
than O 0 1.7102538052427008e-08
increased O 0 1.2876225810032338e-06
apoptosis O 0 7.18155424692668e-05
. O 0 1.4232576859285473e-06

Aggregation O 0 0.0003754962235689163
of O 0 3.319943425594829e-05
mutant O 0 0.00010226298036286607
Smad4 O 0 0.0010052979923784733
ES O 0 0.07405068725347519
cells O 0 2.79995924756804e-06
with O 0 1.811363716797132e-07
wild O 0 1.188189344247803e-06
- O 0 3.942162948078476e-06
type O 0 2.6730574518296635e-06
tetraploid O 0 2.002226756303571e-05
morulae O 0 5.4988708143355325e-05
rescues O 0 1.1349735359544866e-05
the O 0 4.2134442992392e-06
gastrulation B-Disease 0 0.0002794972388073802
defect I-Disease 0 5.8972378610633314e-05
. O 0 4.792703293787781e-06

These O 0 3.818369350483408e-06
results O 0 3.71670853382966e-06
indicate O 0 2.1789714992337395e-06
that O 0 2.208342095855187e-07
Smad4 O 0 1.8914555766968988e-05
is O 0 1.0591317334274208e-07
initially O 0 1.136299800919005e-07
required O 0 1.9223875824536663e-08
for O 0 1.8512119837055252e-08
the O 0 7.384009848010464e-08
differentiation O 0 3.6665440461547405e-07
of O 0 1.1824998864540248e-06
the O 0 8.453221198578831e-07
visceral O 0 7.56656845624093e-06
endoderm O 0 1.3465536540024914e-05
and O 0 1.0801736038956733e-07
that O 0 4.381587004331777e-08
the O 0 6.464267130468215e-07
gastrulation B-Disease 0 3.013753484992776e-05
defect I-Disease 0 3.68150199392403e-06
in O 0 2.354433945583878e-07
the O 0 4.899924306300818e-07
epiblast O 0 1.7220107110915706e-05
is O 0 8.798515693797526e-08
secondary O 0 2.1334990378818475e-06
and O 0 1.968526248674607e-07
non O 0 3.2179319532588124e-05
- O 0 2.7757525458582677e-05
cell O 0 9.352828783448786e-05
autonomous O 0 2.1619551262119785e-05
. O 0 4.068991984240711e-06

Rescued O 0 0.0005880236276425421
embryos O 0 3.3102758607128635e-05
show O 0 6.259763904381543e-05
severe O 1 0.9481349587440491
anterior O 1 0.9979773163795471
truncations O 0 0.23471558094024658
, O 0 1.1303999372103135e-06
indicating O 0 2.292405270054587e-06
a O 0 1.9184139432582015e-07
second O 0 3.336122063046787e-07
important O 0 5.501604150026651e-08
role O 0 7.428691333188908e-07
for O 0 6.728540711264941e-07
Smad4 O 0 0.0006537124281749129
in O 0 3.783639385801507e-06
anterior O 1 0.756473183631897
patterning O 0 0.17507071793079376
during O 0 0.0004264740564394742
embryogenesis O 0 0.0003604331286624074
. O 0 8.855657142703421e-06

Prevalence O 0 0.0013918477343395352
of O 0 4.8978603444993496e-05
p16 O 0 0.00030682553187943995
and O 0 4.054798409924842e-06
CDK4 O 0 0.0007558174547739327
germline O 0 2.9576209271908738e-05
mutations O 0 1.206042156809417e-06
in O 0 1.2593887959155836e-06
48 O 0 5.967641845927574e-05
melanoma B-Disease 1 0.9999997615814209
- O 0 0.10570963472127914
prone O 0 2.7375604986445978e-05
families O 0 3.549745741793231e-08
in O 0 2.69190110202544e-07
France O 0 6.348485385387903e-06
. O 0 5.502398380485829e-06

The O 0 2.6747386073111556e-05
French O 0 0.00017704369383864105
Familial B-Disease 1 0.9952288866043091
Melanoma I-Disease 1 1.0
Study O 0 0.00028045554063282907
Group O 0 1.5148363672778942e-05
. O 0 4.5300012061488815e-06

Germline O 0 0.0007027219980955124
mutations O 0 1.3376162314671092e-05
in O 0 2.8457202461140696e-06
the O 0 2.2466883820015937e-06
p16 O 0 1.3593620678875595e-05
and O 0 3.821542975401826e-07
CDK4 O 0 2.811547528835945e-05
genes O 0 1.700253164926835e-07
have O 0 4.972570266659204e-08
been O 0 1.1235372454621029e-07
reported O 0 1.482950295894625e-07
in O 0 2.0813338608149934e-08
a O 0 1.7290652465362655e-07
subset O 0 6.838254762442375e-07
of O 0 2.1454147827171255e-06
melanoma B-Disease 1 0.9999858140945435
pedigrees O 0 3.893077973771142e-06
, O 0 4.6869246261849185e-08
but O 0 3.687462335477676e-09
their O 0 1.106936764472266e-08
prevalence O 0 2.082832907035481e-06
is O 0 5.4871836852044e-08
not O 0 3.010567795058705e-08
well O 0 2.503919063201465e-07
known O 0 5.840357971464982e-06
. O 0 3.870149612339446e-06

We O 0 3.7867907849431504e-06
searched O 0 2.248924147352227e-06
for O 0 1.199047261479791e-07
such O 0 1.0993750976240335e-07
germline O 0 4.305702077544993e-06
mutations O 0 3.230718448321568e-07
in O 0 8.064304779509257e-07
48 O 0 4.6028339966142084e-06
French O 0 0.0011481352848932147
melanoma B-Disease 1 0.9999998807907104
- O 0 0.00013347268395591527
prone O 0 3.905416633642744e-06
families O 0 1.6461788376886943e-08
selected O 0 4.46864518721668e-08
according O 0 2.132053467107653e-08
to O 0 1.5097889161097555e-08
two O 0 4.2844085612614435e-08
major O 0 5.62934189929365e-07
criteria O 0 1.2204444033159234e-07
families O 0 1.641810776220609e-08
with O 0 3.004229398584357e-08
at O 0 2.4289547582156956e-06
least O 0 3.3961054413111924e-08
three O 0 3.7546026732115934e-08
affected O 0 7.531685497497165e-08
members O 0 3.2277370110023185e-08
( O 0 4.702774702991519e-08
n O 0 3.4241395496792393e-07
= O 0 5.264748779154615e-07
20 O 0 2.571492814240628e-07
) O 0 3.2596297216969106e-08
or O 0 2.3303433849264366e-08
families O 0 4.7297405991741925e-09
with O 0 1.000846960863555e-08
two O 0 5.3983740144758485e-08
affected O 0 1.2708768792890623e-07
members O 0 3.833222450566609e-08
, O 0 2.4919049934624127e-08
one O 0 1.5990682555866442e-08
of O 0 7.725957829052277e-08
them O 0 1.4579105922507551e-08
affected O 0 1.4066719700167596e-07
before O 0 1.6885491049833945e-07
the O 0 1.2284689887565037e-07
age O 0 6.947730923911877e-08
of O 0 3.0145790219648916e-07
50 O 0 1.323563765254221e-07
( O 0 2.791993836126494e-08
n O 0 2.3662177284222707e-07
= O 0 2.6439320777171815e-07
28 O 0 4.3929426851718745e-07
) O 0 2.478996385946175e-08
, O 0 1.152578743557342e-08
and O 0 1.0788925308702346e-08
one O 0 1.629152102111675e-08
additional O 0 7.616384323227976e-08
minor O 0 7.541513241449138e-06
criterion O 0 0.00021867529721930623
. O 0 5.347806563804625e-06

Sixteen O 0 3.467817441560328e-05
different O 0 7.127966341613501e-07
p16 O 0 7.426962110912427e-05
germline O 0 2.2296051611192524e-05
mutations O 0 8.779026643424004e-07
were O 0 6.020047180754773e-07
found O 0 5.913346257102603e-08
in O 0 7.838932702952661e-08
21 O 0 7.194409477051522e-07
families O 0 2.408024712963197e-08
, O 0 5.6501146872278696e-08
while O 0 4.708635259476068e-08
one O 0 6.526266815853887e-08
germline O 0 2.656706101333839e-06
mutation O 0 2.652078592291218e-07
, O 0 1.6260763402442535e-07
Arg24His O 0 6.545017185999313e-06
, O 0 1.0410222728296503e-07
was O 0 1.2827212003685418e-06
detected O 0 9.237811582352151e-07
in O 0 3.732468485395657e-07
the O 0 4.980134235665901e-06
CDK4 O 0 0.003749270923435688
gene O 0 1.7507500160718337e-05
. O 0 1.1438641195127275e-05

The O 0 1.141671327786753e-05
frequency O 0 8.285664080176502e-06
of O 0 3.2755403935880167e-06
p16 O 0 9.228758244717028e-06
gene O 0 2.9588051120299497e-07
mutation O 0 9.805030742882082e-08
in O 0 1.2867198506683053e-07
our O 0 4.561189825835754e-08
sample O 0 3.177798646447627e-08
( O 0 2.5616623489099766e-08
44 O 0 7.21023525329656e-08
% O 0 2.7128839619194878e-08
) O 0 1.36241284920402e-08
is O 0 9.194593530992279e-09
among O 0 2.74539524447448e-09
the O 0 2.615442085129871e-08
highest O 0 4.893181539955549e-07
rates O 0 1.4095162725880073e-07
yet O 0 8.656950711838363e-09
reported O 0 1.5900997141216067e-07
and O 0 3.3046649861034894e-08
the O 0 2.634498343923042e-07
CDK4 O 0 2.5927001843228936e-05
mutation O 0 7.899087961504847e-08
is O 0 3.88304854936905e-08
the O 0 3.726243846813304e-08
second O 0 9.901063435791002e-08
mutation O 0 4.094610162042045e-08
detected O 0 1.3834578282967414e-07
in O 0 4.7121211821377074e-08
this O 0 2.181394087585886e-08
gene O 0 1.0295295851392439e-06
worldwide O 0 2.957991455332376e-06
. O 0 4.07642983191181e-06

In O 0 4.063000960741192e-05
summary O 0 0.00010687013127608225
, O 0 6.62260674744175e-07
our O 0 1.795126394199542e-07
results O 0 2.508417367153015e-07
show O 0 1.0218611379286813e-07
frequent O 0 1.6180139539301308e-07
involvement O 0 1.5724126569693908e-06
of O 0 1.0173449709327542e-06
the O 0 1.129400061472552e-06
p16 O 0 1.5230191820592154e-05
gene O 0 2.656954336544004e-07
in O 0 1.9650244098556868e-07
familial B-Disease 0 2.805227086355444e-05
melanoma I-Disease 1 0.9999911785125732
and O 0 8.676491347614501e-07
confirm O 0 5.490329044732789e-07
the O 0 5.849282160852454e-07
role O 0 5.538030904972402e-07
of O 0 1.1139514981550747e-06
the O 0 1.4704926343256375e-06
CDK4 O 0 0.0035276918206363916
gene O 0 9.071144404515508e-07
as O 0 6.1687768493357e-07
a O 0 3.842017576971557e-06
melanoma B-Disease 1 0.9999457597732544
- O 0 6.471724191214889e-05
predisposing O 0 3.953605119022541e-05
gene O 0 1.893845933409466e-06
. O 0 5.566613481278182e-07
. O 0 2.3494551442126976e-06

Progression O 0 0.00424719974398613
of O 0 4.287239062250592e-05
somatic O 0 0.00031299813417717814
CTG O 0 0.0004890867858193815
repeat O 0 2.025272806349676e-06
length O 0 3.960065839692106e-07
heterogeneity O 0 1.2823456927435473e-06
in O 0 1.6429267191142571e-07
the O 0 2.705072290609678e-07
blood O 0 1.3961288232167135e-06
cells O 0 9.41507732932223e-06
of O 0 0.4727950990200043
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0001594984787516296
. O 0 5.200820396566996e-06

The O 0 9.575534932082519e-06
genetic O 0 4.690135938290041e-06
basis O 0 9.486711860517971e-06
of O 0 0.0003134741564281285
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.0655979824368842e-05
DM B-Disease 1 1.0
) O 0 4.504264836668881e-07
is O 0 6.148906095404527e-08
the O 0 3.958819050353668e-08
expansion O 0 2.1187551624279877e-07
of O 0 2.3879124455561396e-07
an O 0 5.374783995648613e-07
unstable O 0 1.5013117263151798e-05
CTG O 0 4.5518463593907654e-05
repeat O 0 5.802378950647835e-07
in O 0 1.2401071103340655e-07
the O 0 2.569899208992865e-07
34 O 0 7.944853450680966e-07
UTR O 0 2.9298234949237667e-05
of O 0 3.499853164612432e-06
the O 0 1.5269255527528003e-05
DM B-Disease 1 0.9999997615814209
protein O 0 5.153718575456878e-06
kinase O 0 5.231024260865524e-06
gene O 0 4.4386086983649875e-07
on O 0 1.9799765595962526e-06
chromosome O 0 4.987246938981116e-05
19 O 0 3.355855733389035e-05
. O 0 3.905680841853609e-06

One O 0 1.5245725990098435e-05
of O 0 4.2221081457682885e-06
the O 0 2.314431867489475e-06
principal O 0 8.333146979566664e-06
features O 0 2.889663619498606e-07
of O 0 1.819894578147796e-06
the O 0 1.7237916836165823e-05
DM B-Disease 1 1.0
mutation O 0 1.146817908193043e-06
is O 0 2.2152416079279647e-07
an O 0 2.0398987032876903e-07
extraordinarily O 0 1.5102848465176066e-06
high O 0 2.247744760097703e-06
level O 0 2.311265632215509e-07
of O 0 3.9310322108576656e-07
somatic O 0 1.1982190699200146e-05
mosaicism O 0 0.000406461680540815
, O 0 7.633501297732437e-08
due O 0 3.199499190031929e-07
to O 0 3.124237935026031e-08
an O 0 1.228016799359466e-07
extremely O 0 1.5691453825183999e-07
high O 0 4.776823629981664e-07
degree O 0 1.09161737782415e-06
of O 0 1.201070972456364e-06
somatic O 0 1.4515709153783973e-05
instability O 0 1.1359220479789656e-05
both O 0 5.668118419066559e-08
within O 0 6.373699790174214e-08
and O 0 3.289176575549391e-08
between O 0 2.5891861810123373e-07
different O 0 1.2371668844934902e-07
tissues O 0 3.3407653972972184e-05
. O 0 8.271895239886362e-06

This O 0 2.191529347328469e-05
instability O 0 7.556150376331061e-05
appears O 0 1.7787883734854404e-06
to O 0 1.0161974017819375e-07
be O 0 6.646486383488082e-08
biased O 0 2.1640762781771627e-07
towards O 0 1.3616546823413955e-07
further O 0 3.8608781949278637e-08
expansion O 0 2.516813708552945e-07
and O 0 1.7077276481813897e-08
continuous O 0 2.0747314977143105e-07
throughout O 0 3.426882955182009e-08
the O 0 8.726616584908697e-08
life O 0 6.887736248017973e-08
of O 0 1.674244316518525e-07
an O 0 1.2100623791866383e-07
individual O 0 9.239846221476e-09
, O 0 2.0735676287131355e-08
features O 0 1.077555822348586e-08
that O 0 9.15116959987472e-09
could O 0 2.0096136310598922e-08
be O 0 2.237699270324356e-08
associated O 0 4.548332199760807e-08
with O 0 8.474254187262886e-09
the O 0 4.908745268039638e-07
progressive O 0 5.4608490245300345e-06
nature O 0 2.8135170282439503e-07
of O 0 1.431976784260769e-06
the O 0 8.31583201943431e-06
disease O 0 0.022986475378274918
. O 0 4.232759692968102e-06

Although O 0 4.205784534860868e-06
increasing O 0 3.026157628482906e-06
measured O 0 2.1032644781371346e-06
allele O 0 2.270832624162722e-07
size O 0 5.9117901685112884e-08
between O 0 2.2463873960987257e-07
patients O 0 1.1386494946918901e-07
clearly O 0 5.3313918613184796e-08
correlates O 0 1.433929384120347e-07
with O 0 4.570087863697836e-09
an O 0 2.3909993984716493e-08
increased O 0 1.87425627018456e-07
severity O 0 1.55462555539998e-06
of O 0 3.932189883926185e-06
symptoms O 0 0.0014192179078236222
and O 0 4.855857014263165e-07
an O 0 3.938229440336727e-07
earlier O 0 2.9098680442984914e-07
age O 0 1.5749368742490333e-07
of O 0 6.109172545620822e-07
onset O 0 0.00035000653588213027
, O 0 4.0782655474913554e-08
this O 0 7.657559031315486e-09
correlation O 0 1.261308000266581e-07
is O 0 2.5220003863068996e-08
not O 0 8.01761768087772e-09
precise O 0 5.961918958519163e-08
and O 0 4.9593097628530813e-08
measured O 0 4.249899632213783e-07
allele O 0 9.553157553909841e-08
length O 0 1.0304023589924327e-07
cannot O 0 2.436804713568108e-08
be O 0 1.1813435563112762e-08
used O 0 9.978105453001263e-09
as O 0 8.832341968911805e-09
an O 0 1.0581863385539236e-08
accurate O 0 1.0658679627795209e-07
predictor O 0 5.320468062564032e-06
of O 0 8.967035682871938e-07
age O 0 2.0445470454433234e-06
of O 0 1.5292325770133175e-05
onset O 1 0.9997546076774597
. O 0 1.6494606825290248e-05

In O 0 5.809460617456352e-06
order O 0 7.254446927618119e-07
to O 0 7.475668439838046e-08
further O 0 2.2569673774341936e-07
characterize O 0 4.376738615974318e-07
the O 0 6.662313012384402e-07
dynamics O 0 2.044609345830395e-06
of O 0 1.9080998754361644e-05
DM B-Disease 1 1.0
CTG O 0 0.00047349176020361483
repeat O 0 2.4624237084935885e-06
somatic O 0 3.63467870556633e-06
instability O 0 2.9845250537618995e-06
, O 0 3.4392979131325774e-08
we O 0 3.311819041229569e-09
have O 0 3.483131116865934e-09
studied O 0 5.43876339520466e-08
repeat O 0 2.7437527805318496e-08
length O 0 6.331787716362669e-08
changes O 0 1.4754337307465448e-08
over O 0 2.908607221741022e-08
time O 0 3.658475122847449e-08
in O 0 2.7814385816782305e-07
111 O 0 0.1385577917098999
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.0519524096253008e-07
with O 0 6.5672458582355375e-09
varying O 0 5.787468637663551e-08
clinical O 0 6.604104783036746e-06
severity O 0 1.2932718163938262e-05
and O 0 7.179495469245012e-07
CTG O 0 2.88629798887996e-05
repeat O 0 1.8314959504550643e-07
size O 0 2.0237338915762848e-08
over O 0 3.525939007431589e-08
time O 0 1.5762900318350148e-08
intervals O 0 4.9833086990247466e-08
of O 0 1.3568920564921427e-07
1 O 0 3.7121708373888396e-07
- O 0 4.520595950907591e-07
7 O 0 1.5859727682254743e-06
years O 0 5.561668103837292e-07
. O 0 1.2369254136501695e-06

We O 0 4.8616257117828354e-06
have O 0 2.35178376328804e-07
found O 0 2.0537990508273651e-07
a O 0 2.1137137196092226e-07
direct O 0 5.668075004905404e-07
progression O 0 1.1401850315451156e-05
of O 0 3.323819441902742e-07
the O 0 6.873470681512117e-08
size O 0 1.937280380559514e-08
heterogeneity O 0 2.524137698856066e-07
over O 0 7.781327582279118e-08
time O 0 3.976663975890915e-08
related O 0 4.7692214621974927e-08
to O 0 3.222920241796601e-08
initial O 0 8.516742013853218e-07
CTG O 0 1.1732142411347013e-05
repeat O 0 1.0860987487149032e-07
size O 0 4.559267807735523e-08
and O 0 2.8420911846183117e-08
the O 0 7.400181800676364e-08
time O 0 2.216308203628614e-08
interval O 0 1.1615635742145969e-07
and O 0 1.9589950994713945e-08
always O 0 4.8690033338516514e-08
biased O 0 3.5898978012482985e-07
towards O 0 2.035023527469093e-07
further O 0 1.9895645664291806e-07
expansion O 0 5.367395715438761e-06
. O 0 2.2348685888573527e-06

Attempts O 0 1.3779204891761765e-05
to O 0 4.4542218802234856e-07
mathematically O 0 5.006354513170663e-07
model O 0 4.397167572278704e-07
the O 0 1.146348367342398e-07
dynamics O 0 2.424006311230187e-07
have O 0 2.1736854094456248e-08
proved O 0 1.2920345682232437e-07
only O 0 1.8181994576593752e-08
partially O 0 2.421811302610877e-07
successful O 0 4.981018619787392e-08
suggesting O 0 5.2454634413834356e-08
that O 0 1.9768080505855323e-09
individual O 0 1.7346393210715405e-09
specific O 0 3.4446403507359946e-09
genetic O 0 8.737358569987919e-08
and O 0 6.19310412730556e-07
/ O 0 6.189731357153505e-05
or O 0 3.818016693912796e-07
environmental O 0 6.967782724132121e-07
factors O 0 9.87503625538011e-08
also O 0 5.195587604589491e-08
play O 0 2.2927842735498416e-08
a O 0 9.647808951740444e-08
role O 0 3.2117583259605453e-07
in O 0 3.84194805747029e-07
somatic O 0 2.3496488211094402e-05
mosaicism O 0 0.0009324129787273705
. O 0 7.728535820206162e-07
. O 0 1.6489635754624032e-06

Aspartylglucosaminuria B-Disease 1 0.9996811151504517
among O 0 1.1047115549445152e-05
Palestinian O 0 0.0001622853014850989
Arabs O 0 6.954485434107482e-05
. O 0 1.2567081284942105e-05

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.0017132716020569205
AGU B-Disease 1 1.0
) O 0 2.68301278083527e-06
is O 0 4.149155472532584e-07
a O 0 4.4104140783929324e-07
rare O 0 1.782274466677336e-06
disorder B-Disease 1 0.7896155118942261
of I-Disease 0 0.03162108734250069
glycoprotein I-Disease 1 0.9999997615814209
metabolism I-Disease 1 0.9990641474723816
caused O 0 0.0018048612400889397
by O 0 5.11283303694654e-07
the O 0 2.9885782169003505e-06
deficiency B-Disease 1 0.9983381032943726
of I-Disease 0 4.437639654497616e-05
the I-Disease 0 4.224391159368679e-05
lysosomal I-Disease 1 0.9936107993125916
enzyme I-Disease 0 1.9517226974130608e-05
aspartylglucosaminidase I-Disease 0 0.0002691597619559616
( O 0 2.395483306827373e-06
AGA O 0 0.03626606613397598
) O 0 1.6309620605170494e-06
. O 0 2.7027974738302873e-06

AGU B-Disease 1 1.0
is O 0 0.00012728979345411062
inherited O 0 0.0017435147892683744
as O 0 6.083299012971111e-06
an O 0 1.5376291457869229e-06
autosomal O 0 0.0019433792913332582
recessive O 0 0.002837566891685128
trait O 0 7.851927875890397e-06
and O 0 4.7089858412618923e-07
occurs O 0 1.3575184709679888e-07
with O 0 1.1432211621809074e-08
a O 0 1.832378160315784e-07
high O 0 2.547309577494161e-06
frequency O 0 2.639341687427077e-07
in O 0 4.1336097211797096e-08
Finland O 0 9.499049014038974e-08
because O 0 4.009306309171734e-08
of O 0 3.6334267861093394e-07
a O 0 2.9282289233378833e-06
founder O 0 5.6378772569587454e-05
effect O 0 6.437613592424896e-06
. O 0 4.419374818098731e-06

While O 0 3.496162025840022e-05
very O 0 2.1154187379579525e-06
few O 0 5.035083177062916e-07
patients O 0 6.133445253908576e-07
with O 0 6.894326816109242e-07
AGU B-Disease 1 0.9999998807907104
have O 0 1.5837419198305724e-07
been O 0 3.470540264061128e-07
reported O 0 4.1786358906392707e-07
from O 0 9.22635905453717e-08
non O 0 7.048813586152392e-07
- O 0 3.526830880673515e-07
Finnish O 0 1.508789182480541e-06
origin O 0 8.290687247836104e-08
, O 0 1.1259806598218347e-07
we O 0 1.0769418423706156e-07
diagnosed O 0 8.317371248267591e-05
the O 0 8.371950457330968e-07
disorder O 0 3.350739279994741e-05
in O 0 4.6691374677720887e-07
8 O 0 2.21919026444084e-06
patients O 0 7.309267147093124e-08
originating O 0 8.416220964591048e-08
from O 0 9.4242281534207e-08
3 O 0 1.5829884603135724e-07
unrelated O 0 5.850230522241873e-08
families O 0 6.2080971474642865e-09
, O 0 1.3359670703039228e-08
all O 0 1.2343920552382315e-08
Palestinian O 0 1.0161892305404763e-06
Arabs O 0 1.8781570076953358e-07
from O 0 6.4800381949226e-08
the O 0 5.386392132322726e-08
region O 0 1.0185142684804305e-07
of O 0 9.576141337674926e-07
Jerusalem O 0 0.00019452153355814517
. O 0 4.7627222556911875e-06

The O 0 1.9565477487049066e-05
clinical O 0 0.19425329566001892
diagnosis O 1 0.9999382495880127
of O 1 0.9877827763557434
AGU B-Disease 1 1.0
is O 0 2.0653437786677387e-06
often O 0 5.180931950121703e-08
difficult O 0 1.7771382587739026e-08
, O 0 9.475937368108589e-09
in O 0 2.0864613148319222e-08
particular O 0 1.908002467132519e-08
early O 0 1.3877644278181833e-07
in O 0 7.824576897519364e-08
the O 0 1.4045889429326053e-07
course O 0 3.7521766671488876e-07
of O 0 7.151116392378754e-07
the O 0 3.8160251278895885e-06
disease O 0 0.0005233021220192313
, O 0 1.2549536165806785e-07
and O 0 6.445645794883603e-08
most O 0 1.8421353331632417e-08
of O 0 2.181827341019016e-07
the O 0 9.146091883849294e-07
patients O 0 4.5447424668054737e-07
are O 0 6.211985237314366e-08
diagnosed O 0 0.010324692353606224
after O 0 1.0968938113364857e-06
the O 0 2.954541855615389e-07
age O 0 2.060125581238026e-07
of O 0 6.087885253691638e-07
5 O 0 2.7723231141862925e-06
years O 0 2.1057030608062632e-06
. O 0 3.875071797665441e-06

However O 0 9.037821655510925e-06
, O 0 1.0519719353396795e-06
since O 0 4.735809397971025e-07
these O 0 2.733551340838858e-08
patients O 0 1.425846960501076e-07
excrete O 0 3.21896436616953e-07
early O 0 1.4417150850931648e-07
large O 0 4.519043983464144e-08
amounts O 0 2.9954467350989944e-08
of O 0 5.638594302581623e-07
aspartylglucosamine O 0 8.920601430872921e-06
in O 0 1.6526696811069996e-07
urine O 0 2.030665484653582e-07
, O 0 3.492606381882979e-08
biochemical O 0 1.058196289704938e-06
screening O 0 1.9282197172287852e-07
is O 0 4.7491788279785396e-08
easy O 0 2.697662360162667e-08
by O 0 6.305490529712188e-08
urine O 0 9.58028863351501e-07
chromatography O 0 2.9975390134495683e-05
. O 0 8.125624049171165e-07
. O 0 2.107410637108842e-06

Detection O 0 0.00017791587742976844
of O 0 1.4610342077503446e-05
heterozygous O 0 1.133444038714515e-05
carriers O 0 2.582202569101355e-06
of O 0 5.277031505102059e-06
the O 0 1.89273869182216e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999282360076904
telangiectasia I-Disease 1 1.0
( O 0 1.3304524145496543e-05
ATM O 0 0.008494936861097813
) O 0 1.2981308827875182e-07
gene O 0 1.4297944517238648e-07
by O 0 3.43932498481081e-07
G2 O 0 0.0027625742368400097
phase O 0 5.8590580920281354e-06
chromosomal O 0 5.8777786762220785e-05
radiosensitivity O 0 5.956122913630679e-05
of O 0 1.0806618774950039e-05
peripheral O 1 0.840692937374115
blood O 0 0.000787088181823492
lymphocytes O 0 0.01591484248638153
. O 0 1.1891010217368603e-05

In O 0 0.000367626897059381
ataxia B-Disease 1 1.0
- I-Disease 1 0.999994158744812
telangiectasia I-Disease 1 1.0
( O 0 0.08452499657869339
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
) O 0 1.1301570168598118e-07
patients O 0 1.5520118523681958e-08
, O 0 4.448310164661962e-09
mutations O 0 8.720322242083967e-09
in O 0 1.724380993550767e-08
a O 0 3.977627116569238e-08
single O 0 3.160824491033054e-08
gene O 0 4.5846437757290914e-08
, O 0 4.577601231403605e-08
ATM O 0 2.5913355784723535e-05
, O 0 2.9553016034356006e-08
result O 0 9.271450096548506e-08
in O 0 3.3187640724463563e-07
an O 0 0.00034222277463413775
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.4543200450134464e-05
embraces O 0 1.242642156285001e-06
a O 0 2.0050407556482241e-07
variety O 0 2.1561611163178895e-08
of O 0 4.711784526989504e-07
clinical O 0 9.460493856749963e-06
features O 0 2.707555211145518e-07
and O 0 1.874279575986293e-07
manifests O 0 5.77530556711281e-07
extreme O 0 4.175156846031314e-06
radiosensitivity O 0 7.123033719835803e-05
and O 0 3.173238383169519e-07
a O 0 1.4709034985571634e-06
strong O 0 1.5013026768428972e-06
pre O 0 0.00013173474872019142
- O 0 1.5661566067137755e-05
disposition O 0 4.189943501842208e-05
to O 0 1.171188046100724e-06
malignancy B-Disease 1 0.7433940768241882
. O 0 5.7856309467752e-06

Heterozygotes O 0 0.00017828609270509332
for O 0 1.938269178936025e-06
the O 0 1.066394133886206e-06
ATM O 0 1.6305486497003585e-05
gene O 0 2.0528591448965017e-07
have O 0 2.801681553421531e-08
no O 0 4.904665118488083e-08
clinical O 0 1.7818580317907617e-06
expression O 0 1.4727310144735384e-06
of O 0 1.5446468751179054e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999978542327881
T I-Disease 1 1.0
but O 0 1.865253267396838e-07
may O 0 4.3541118088796793e-07
be O 0 1.53179072981402e-07
cancer B-Disease 0 6.483941433543805e-06
prone O 0 3.4446884455974214e-07
with O 0 1.5593229818477994e-08
a O 0 2.4983114599308465e-07
moderate O 0 3.1622298024558404e-07
increase O 0 9.241999521236721e-08
in O 0 9.815602908247456e-08
in O 0 5.91638070090994e-07
vitro O 0 8.238654845627025e-05
radiosensitivity O 0 0.0003992755082435906
. O 0 5.537573997571599e-06

We O 0 6.273182862059912e-06
performed O 0 1.1260916835453827e-05
a O 0 4.287116553314263e-06
blind O 0 2.0195608158246614e-05
chromosomal O 0 3.4730768675217405e-05
analysis O 0 1.7876963056551176e-06
on O 0 1.285321377508808e-05
G2 O 0 0.01308159064501524
- O 0 1.990541250052047e-06
phase O 0 2.4280375328089576e-06
lymphocytes O 0 1.0358088502471219e-06
from O 0 7.066570617553225e-08
7 O 0 4.797660153599281e-07
unrelated O 0 7.432418556163611e-07
A B-Disease 1 0.9325671792030334
- I-Disease 0 0.4669792950153351
T I-Disease 1 0.9999929666519165
patients O 0 2.775333882709674e-07
, O 0 5.2944550077427266e-08
13 O 0 4.3663325755005644e-07
obligate O 0 1.0650636568243499e-06
A B-Disease 1 0.9761787056922913
- I-Disease 0 0.005702380556613207
T I-Disease 1 0.999674916267395
heterozygotes O 0 1.382563823426608e-06
( O 0 5.72414684540945e-08
parents O 0 9.547161283762762e-09
of O 0 6.792381412878967e-08
the O 0 1.9454752475667192e-07
patients O 0 6.222301607294867e-08
) O 0 2.1633617564020824e-08
, O 0 2.156950884568687e-08
and O 0 3.743319254567723e-08
14 O 0 4.839274083678902e-07
normal O 0 3.6238412803868414e-07
controls O 0 3.273845834428357e-07
following O 0 3.7755725657007133e-07
X O 0 3.5971052056993358e-06
- O 0 4.211128157294297e-07
irradiation O 0 7.349765951403242e-07
with O 0 3.583213725733003e-08
1 O 0 8.656043632981891e-07
Gy O 0 5.407099251897307e-06
in O 0 4.2825455182082806e-08
order O 0 2.3030183982086783e-08
to O 0 8.929434969218164e-09
evaluate O 0 2.793373532483656e-08
this O 0 2.5827633365338443e-08
cytogenetic O 0 3.5172720345144626e-06
method O 0 8.743043622416735e-08
as O 0 5.14315381394681e-08
a O 0 3.503120638015389e-08
tool O 0 1.1874185901206147e-07
for O 0 1.3132143372729388e-08
detection O 0 5.150546371623932e-07
of O 0 1.6420194697275292e-06
ATM O 0 0.0005957771209068596
carriers O 0 5.998092092340812e-06
. O 0 2.727453193074325e-06

Both O 0 0.00012773858907166868
A B-Disease 1 0.9999839067459106
- I-Disease 1 0.9999252557754517
T I-Disease 1 0.9999978542327881
homozygotes O 0 3.16847326757852e-05
and O 0 4.002796458735247e-07
heterozygotes O 0 1.6043694586187485e-06
showed O 0 2.356084820576143e-07
significantly O 0 8.874748402831756e-08
increased O 0 1.0979124454024713e-07
levels O 0 1.0856575727302697e-07
of O 0 3.746441166185832e-07
radiation O 0 0.0016157005447894335
- O 0 1.1774712220358197e-05
induced O 0 5.824547406518832e-05
chromatid O 0 3.656906119431369e-05
damage O 0 5.962196610198589e-06
relative O 0 9.387948693984072e-07
to O 0 2.586342340293868e-08
that O 0 3.297065731544535e-08
of O 0 6.612099809899519e-07
normal O 0 5.799806785944384e-06
controls O 0 1.126519146055216e-05
. O 0 3.831428330158815e-06

These O 0 6.239532012841664e-06
results O 0 5.6855355978768785e-06
show O 0 2.6871866793953814e-06
that O 0 6.191190777826705e-07
the O 0 2.8423191906767897e-06
G2 O 0 0.0012275207554921508
- O 0 3.2357368127122754e-06
phase O 0 4.11611472372897e-06
chromosomal O 0 1.642484676267486e-05
radiosensitivity O 0 2.9046739655314013e-05
assay O 0 3.5663904327520868e-06
can O 0 1.2840936314262308e-08
be O 0 2.0788581522879213e-08
used O 0 1.6369671840266165e-08
for O 0 1.9377239368623123e-08
the O 0 1.5874239522872813e-07
detection O 0 1.4349117236633901e-06
of O 0 2.5693194402265362e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999957084655762
T I-Disease 1 0.9999997615814209
heterozygotes O 0 0.00010146338172489777
. O 0 2.4359417238883907e-06

In O 0 1.3554382348957006e-05
combination O 0 2.9014042866037926e-06
with O 0 1.4761620548142673e-07
molecular O 0 9.543825399305206e-06
genetic O 0 6.467394086939748e-07
analyses O 0 6.63536468437087e-07
, O 0 6.675313102277869e-08
this O 0 2.5490241029046956e-08
test O 0 4.238444617499226e-08
may O 0 4.739441550327683e-08
be O 0 5.107888334521249e-09
of O 0 2.79898948463142e-08
value O 0 2.1423911533702267e-08
in O 0 1.3857746949952343e-08
studies O 0 3.222268674107909e-08
of O 0 5.235708044892817e-08
familial B-Disease 0 3.477351810943219e-07
and I-Disease 0 3.332694120672386e-07
sporadic I-Disease 0 5.686240183422342e-05
cancers I-Disease 0 0.06357330828905106
aimed O 0 5.908548246225109e-06
at O 0 1.929700147229596e-06
determination O 0 7.462191575768884e-08
of O 0 1.3336087079096615e-07
the O 0 6.820579301347607e-08
potential O 0 9.525574284907634e-08
involvement O 0 5.851402420375962e-07
of O 0 6.584091920558421e-07
ATM O 0 4.672289651352912e-05
mutations O 0 3.911702037839859e-07
in O 0 7.655225431335566e-07
tumor B-Disease 1 0.9999934434890747
risk O 0 4.396883923618589e-06
or O 0 2.662458484792296e-07
development O 0 1.4009249298396753e-06
. O 0 2.0478378814914322e-07
. O 0 1.0569416417638422e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 0.999993085861206
telangiectasia I-Disease 1 1.0
: O 0 5.262020749796648e-06
identification O 0 2.659433562257618e-07
and O 0 1.9331911005338043e-07
detection O 0 7.095281489455374e-06
of O 0 2.4382854462601244e-05
founder O 0 0.0011042850092053413
- O 0 1.3306834034665371e-06
effect O 0 2.7163849836142617e-07
mutations O 0 4.651515084219682e-08
in O 0 5.616612241965413e-08
the O 0 1.3874216620024526e-07
ATM O 0 6.898319043102674e-06
gene O 0 1.1606091021576503e-07
in O 0 9.199965234074625e-08
ethnic O 0 9.275624535121096e-08
populations O 0 6.310928597486054e-07
. O 0 2.1272596768540097e-06

To O 0 3.2257664770440897e-06
facilitate O 0 4.09699578085565e-06
the O 0 6.675504096165241e-07
evaluation O 0 1.5872498124736012e-06
of O 0 1.7850589983936516e-06
ATM O 0 0.0005162021843716502
heterozygotes O 0 4.3715549509215634e-06
for O 0 1.5045546319925052e-07
susceptibility O 0 6.972170012886636e-06
to O 0 1.2454012221496669e-07
other O 0 1.2705666563306295e-07
diseases O 0 0.23471921682357788
, O 0 5.585598827906324e-08
such O 0 2.2719540027082985e-08
as O 0 1.5416171663673595e-06
breast B-Disease 0 0.4918875992298126
cancer I-Disease 0 0.3971581757068634
, O 0 1.8780710320243088e-07
we O 0 1.2946586913642477e-08
have O 0 1.2041588171030071e-08
attempted O 0 1.279810390997227e-07
to O 0 1.8811105562122066e-08
define O 0 5.238284828124051e-08
the O 0 7.024991077742015e-08
most O 0 1.0398728100824428e-08
common O 0 7.549329161804508e-09
mutations O 0 1.2227972412404142e-08
and O 0 1.3903708406814985e-08
their O 0 9.476695872479013e-09
frequencies O 0 5.470411110763962e-07
in O 0 1.3590785101769143e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9998539686203003
telangiectasia I-Disease 1 1.0
( O 0 0.001318161259405315
A B-Disease 1 1.0
- I-Disease 1 0.9998167157173157
T I-Disease 1 0.9999978542327881
) O 0 1.573752257399974e-07
homozygotes O 0 5.27189342847123e-07
from O 0 7.219703235250563e-08
10 O 0 5.732330166097199e-08
ethnic O 0 2.2356218210006773e-08
populations O 0 2.0566214686823514e-07
. O 0 7.055411970213754e-07

Both O 0 2.8355830181681085e-06
genomic O 0 1.0570924132480286e-05
mutations O 0 1.3388287243287778e-06
and O 0 3.487477897579083e-07
their O 0 9.349479057618737e-08
effects O 0 1.63242953021836e-06
on O 0 2.139146772606182e-06
cDNA O 0 6.833549377915915e-06
were O 0 1.327948893958819e-06
characterized O 0 4.6047921387071256e-06
. O 0 2.6864640858548228e-06

Protein O 0 0.00018876162357628345
- O 0 3.992326310253702e-05
truncation O 0 8.367067493963987e-05
testing O 0 1.324483378084551e-06
of O 0 8.459705895802472e-07
the O 0 2.240155367871921e-07
entire O 0 2.245661221422779e-07
ATM O 0 2.2376582364813657e-06
cDNA O 0 6.351406227622647e-07
detected O 0 1.542639296303605e-07
92 O 0 6.631493079112261e-07
( O 0 2.334008719628855e-08
66 O 0 1.5818731924355234e-07
% O 0 2.2505101782144266e-08
) O 0 1.3854814184810493e-08
truncating O 0 1.9771979964389175e-07
mutations O 0 2.5528388292173076e-08
in O 0 3.8213674002918196e-08
140 O 0 2.8472626922848576e-07
mutant O 0 3.989366916812287e-07
alleles O 0 5.664724653797748e-07
screened O 0 4.120544872421306e-06
. O 0 2.2789015474700136e-06

The O 0 7.385602657450363e-05
haplotyping O 0 0.00036570345400832593
of O 0 6.234613010747125e-06
patients O 0 9.228274961969873e-07
with O 0 3.675519621992862e-08
identical O 0 1.3689931677163258e-07
mutations O 0 2.4700861445126066e-07
indicates O 0 1.7815895034800633e-06
that O 0 1.4286517746597838e-08
almost O 0 2.2145883349367068e-08
all O 0 3.221400479702652e-09
of O 0 1.6099692246029917e-08
these O 0 1.8166420590048915e-09
represent O 0 9.727443739393493e-09
common O 0 3.462585240754379e-08
ancestry O 0 6.435805488536062e-08
and O 0 6.520555473343848e-08
that O 0 4.5358831357589224e-08
very O 0 4.154737709427536e-08
few O 0 5.957827298175289e-08
spontaneously O 0 1.917846930155065e-07
recurring O 0 6.551374553964706e-06
ATM O 0 3.120051042060368e-05
mutations O 0 9.778376579561154e-07
exist O 0 1.4317801060315105e-06
. O 0 2.2641427221969934e-06

Assays O 0 4.947055276716128e-05
requiring O 0 1.3441225519272848e-06
minimal O 0 1.7880713585327612e-06
amounts O 0 1.5572994982449018e-07
of O 0 1.5950206488923868e-07
genomic O 0 3.906188510427455e-07
DNA O 0 1.0742810019337412e-07
were O 0 5.2374460324244865e-08
designed O 0 4.050242452535713e-08
to O 0 5.573240979828142e-09
allow O 0 6.024696741491198e-09
rapid O 0 4.4793546294386033e-07
screening O 0 9.082798158033256e-08
for O 0 1.760190038169185e-08
common O 0 3.329110143113212e-08
ethnic O 0 2.8680394947855348e-08
mutations O 0 9.424674658475851e-07
. O 0 1.9679962406371487e-06

These O 0 2.1277792257023975e-06
rapid O 0 1.4859197108307853e-05
assays O 0 2.2984208953857888e-06
detected O 0 1.8262527419210528e-06
mutations O 0 3.1426702662429307e-07
in O 0 2.033399795209334e-07
76 O 0 1.0801031748997048e-06
% O 0 6.630646254279782e-08
of O 0 2.3722937214643025e-07
Costa O 0 1.1116613904960104e-06
Rican O 0 5.691036221833201e-06
patients O 0 1.8959227077175456e-07
( O 0 5.7155716604029294e-08
3 O 0 1.5573411360492173e-07
) O 0 1.1991599713212509e-08
, O 0 8.516172655959053e-09
50 O 0 2.1398713911935374e-08
% O 0 9.639050446708097e-09
of O 0 8.809632134898493e-08
Norwegian O 0 3.485237584754941e-06
patients O 0 6.309364408707552e-08
( O 0 1.2619259415203032e-08
1 O 0 8.943449358866928e-08
) O 0 8.43955838547572e-09
, O 0 6.45620046313411e-09
25 O 0 3.942242088328385e-08
% O 0 1.350153500112583e-08
of O 0 1.2874883736913034e-07
Polish O 0 5.738790605391841e-06
patients O 0 2.1024611385200842e-07
( O 0 6.722871148667764e-08
4 O 0 2.7029861371374864e-07
) O 0 1.4956043514757766e-08
, O 0 1.54326240675573e-08
and O 0 1.3648003616140159e-08
14 O 0 1.2597884335718845e-07
% O 0 2.1374361836024036e-08
of O 0 1.3450134872527997e-07
Italian O 0 1.5971958191585145e-06
patients O 0 1.1577746761304297e-07
( O 0 3.3412220545869786e-08
1 O 0 1.292677893616201e-07
) O 0 1.6961291038342097e-08
, O 0 1.1291998447404694e-08
as O 0 1.8781276978074857e-08
well O 0 8.39883451675405e-09
as O 0 1.6513581613253336e-08
in O 0 3.416649008158856e-08
patients O 0 2.8801817819612552e-08
of O 0 4.6365985895135964e-07
Amish O 0 1.7850483345682733e-05
/ O 0 1.2584542673721444e-05
Mennonite O 0 8.681889994477388e-06
and O 0 1.4117158286808262e-07
Irish O 0 1.608249704077025e-06
English O 0 1.6679970258337562e-06
backgrounds O 0 5.299476697473438e-07
. O 0 1.3404334140432184e-06

Additional O 0 3.4129609502997482e-06
mutations O 0 3.2537525385123445e-06
were O 0 1.73892885868554e-06
observed O 0 6.521420345961815e-07
in O 0 1.8120202582849743e-07
Japanese O 0 1.1980258705079905e-06
, O 0 4.709255208013019e-08
Utah O 0 6.156541303425911e-07
Mormon O 0 3.631182039498526e-07
, O 0 4.318867752317601e-08
and O 0 9.633907183115298e-08
African O 0 9.247886509911041e-07
American O 0 4.936574896419188e-06
patients O 0 1.7918814592121635e-06
. O 0 4.5205283640825655e-06

These O 0 8.435472409473732e-07
assays O 0 2.4460725853714393e-06
should O 0 1.1625166962403455e-07
facilitate O 0 3.7081156278873095e-07
screening O 0 5.650011871694005e-07
for O 0 8.472195531794569e-07
A B-Disease 1 0.9994152784347534
- I-Disease 1 0.9383335113525391
T I-Disease 1 0.9999659061431885
heterozygotes O 0 1.0948087947326712e-06
in O 0 3.486735522528761e-08
the O 0 2.8659997042268515e-08
populations O 0 1.1973225078065752e-08
studied O 0 2.9003123813708953e-07
. O 0 1.9659316308207053e-07
. O 0 1.7641950762481429e-06

The O 0 0.00014888602891005576
von B-Disease 1 0.7069655060768127
Hippel I-Disease 1 0.9999910593032837
- I-Disease 1 0.9992057681083679
Lindau I-Disease 1 0.9999336004257202
tumor I-Disease 1 0.9999973773956299
suppressor O 1 0.998839795589447
gene O 0 4.1563836816749244e-07
is O 0 2.6622293702871502e-08
required O 0 1.1891882145675936e-08
for O 0 2.9021347103252992e-08
cell O 0 2.385377456448623e-06
cycle O 0 8.738547307984845e-07
exit O 0 8.154510169333662e-07
upon O 0 3.531243066845491e-07
serum O 0 1.2953305486007594e-05
withdrawal O 0 5.2229646826162934e-05
. O 0 6.669320555374725e-06

The O 0 3.0289755159174092e-05
inactivation O 0 0.000768365862313658
of O 0 3.1101855711312965e-05
the O 0 1.7044649212039076e-05
von B-Disease 1 0.8825764060020447
Hippel I-Disease 1 0.9999984502792358
- I-Disease 1 0.9999598264694214
Lindau I-Disease 1 0.9999964237213135
( I-Disease 0 4.9111386033473536e-05
VHL I-Disease 1 0.9940134882926941
) I-Disease 0 2.125231958416407e-06
tumor I-Disease 1 0.9993333220481873
suppressor O 1 0.9999672174453735
gene O 0 1.056619112205226e-06
predisposes O 0 1.6074951645350666e-06
affected O 0 7.5428708612435e-08
individuals O 0 4.725106084180197e-09
to O 0 1.3149412225743617e-08
the O 0 9.345821467832138e-07
human O 1 0.9970759153366089
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 5.45083821634762e-06
is O 0 3.8177472561073955e-07
associated O 0 2.1762518542800535e-07
with O 0 1.0078125001200533e-07
sporadic B-Disease 1 0.99997878074646
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.0001479507191106677
RCC B-Disease 1 0.9999992847442627
) O 0 7.447900429724541e-07
and O 0 1.5111940001588664e-06
brain B-Disease 1 0.9999233484268188
hemangioblastomas I-Disease 1 0.999332845211029
. O 0 2.273422978760209e-05

VHL O 1 0.8589975237846375
- O 0 0.0011657419381663203
negative O 0 0.00011449187877587974
786 O 0 0.002471501473337412
- O 0 0.00011095609079347923
0 O 0 2.0505558495642617e-05
RCC B-Disease 0 0.06604362279176712
cells O 0 1.8849985963242943e-06
are O 0 7.271513879913982e-08
tumorigenic O 0 4.636369794752682e-06
in O 0 2.0624648300326953e-07
nude O 0 5.670990503858775e-06
mice O 0 3.463240147993929e-07
which O 0 3.429864747772626e-08
is O 0 3.35830705466833e-08
suppressed O 0 1.5328619440424518e-07
by O 0 1.7518233974556097e-08
the O 0 9.302696213353556e-08
reintroduction O 0 4.080598955624737e-06
of O 0 5.0652556637942325e-06
VHL B-Disease 0 0.0005208306829445064
. O 0 8.435210474999622e-06

Remarkably O 0 0.0004064083914272487
, O 0 2.1691396341338987e-06
this O 0 1.1878625372219176e-07
occurs O 0 8.488041203236207e-08
without O 0 2.9076643315306683e-08
affecting O 0 1.484116012306913e-07
the O 0 1.9217355884393328e-07
growth O 0 7.39965855700575e-07
rate O 0 1.6350800535747112e-07
and O 0 2.1017310558590907e-08
cell O 0 2.192219653807115e-06
cycle O 0 8.048277777561452e-07
profile O 0 5.713816619845602e-08
of O 0 4.561094613109162e-08
these O 0 1.5324506108527203e-08
cells O 0 3.2782668313302565e-07
in O 0 2.9151897251722403e-07
culture O 0 1.100703912015888e-06
. O 0 1.1303310429866542e-06

The O 0 0.000139918367494829
786 O 0 0.0006197952898219228
- O 0 1.9618762962636538e-05
0 O 0 5.4519609875569586e-06
cell O 0 1.9004655769094825e-05
line O 0 2.4705577743588947e-06
, O 0 4.213128335095462e-08
like O 0 1.0776195047412784e-08
many O 0 7.830710302414445e-09
cancer B-Disease 0 1.1172794529556995e-06
cells O 0 2.7364578158994846e-07
, O 0 4.844510925750001e-08
fails O 0 3.240091928091715e-08
to O 0 2.0060635819163508e-08
exit O 0 6.476281555478636e-07
the O 0 1.7017164566368592e-07
cell O 0 2.9580280624941224e-06
cycle O 0 9.283709232477122e-07
upon O 0 2.6916060846815526e-07
serum O 0 1.2200772289361339e-05
withdrawal O 0 2.9047572752460837e-05
. O 0 4.5581823542306665e-06

Here O 0 2.6526031433604658e-05
, O 0 1.1744798484869534e-06
it O 0 5.5426600198416054e-08
is O 0 4.1432627995163784e-08
shown O 0 2.6522146256979795e-08
that O 0 1.2227880041848493e-08
reintroduction O 0 3.7489357396225387e-07
of O 0 2.0244623044618493e-07
the O 0 3.9228982018357783e-07
wild O 0 3.6133434377916274e-07
- O 0 2.856937044271035e-06
type O 0 4.951435585098807e-06
VHL B-Disease 0 0.00019827907090075314
gene O 0 3.866520046358346e-07
restores O 0 1.5427907555931597e-06
the O 0 2.2499722263091826e-07
ability O 0 6.784677708537856e-08
of O 0 6.5070585151261184e-06
VHL O 1 0.9623490571975708
- O 0 0.0009273479226976633
negative O 0 6.729806045768782e-05
RCC B-Disease 1 0.9999812841415405
cancer I-Disease 0 5.963948296994204e-06
cells O 0 2.246346610945693e-07
to O 0 2.9354424668781576e-08
exit O 0 6.104384624450176e-07
the O 0 3.3710077218529477e-07
cell O 0 2.9041282232356025e-06
cycle O 0 7.091629754540918e-07
and O 0 7.944856150743362e-08
enter O 0 1.0526995311010978e-06
G0 O 0 0.00010934778401860967
/ O 0 1.0377673788752872e-05
quiescence O 0 9.784844223759137e-06
in O 0 7.303650022549846e-07
low O 0 1.808785236789845e-05
serum O 0 6.0007409047102556e-05
. O 0 5.891555701964535e-06

Both O 0 0.00011626939522102475
VHL O 0 0.4217863082885742
- O 0 0.00013928618864156306
positive O 0 6.359240614983719e-06
and O 0 1.9337346657266608e-06
VHL O 1 0.6731339693069458
- O 0 4.6190034481696784e-05
negative O 0 9.397011126566213e-06
RCC B-Disease 0 0.03500370308756828
cells O 0 7.31572413315007e-07
exit O 0 1.2409095688781235e-06
the O 0 1.570599152955765e-07
cell O 0 3.0236478778533638e-06
cycle O 0 1.0739414619820309e-06
by O 0 1.6473919117743208e-07
contact O 0 1.06388506537769e-06
inhibition O 0 0.00010420419130241498
. O 0 4.1483503991912585e-06

The O 0 0.00013107627455610782
cyclin O 0 0.00021459246636368334
- O 0 4.059674029122107e-05
dependent O 0 9.256548764824402e-06
kinase O 0 1.6257634342764504e-05
inhibitor O 0 1.392317335557891e-05
, O 0 1.9379960747301084e-07
p27 O 0 4.466550763027044e-06
, O 0 6.872238600408309e-08
accumulates O 0 1.4581449647721456e-07
upon O 0 1.2642922797567735e-07
serum O 0 1.5318199757530238e-06
withdrawal O 0 1.7138480643552612e-06
, O 0 6.578280675739734e-08
only O 0 1.8836166404412324e-08
in O 0 7.916070643432249e-08
the O 0 9.626890573599667e-08
presence O 0 1.7406631513949833e-07
of O 0 2.2209858343558153e-06
VHL B-Disease 0 0.0001597758091520518
, O 0 8.519832306319586e-08
as O 0 4.9657366218980314e-08
a O 0 3.765978107139745e-08
result O 0 2.9703448589657455e-08
of O 0 1.3447299807012314e-07
the O 0 2.9427954473248974e-07
stabilization O 0 4.253875431459164e-06
of O 0 1.2453090221242746e-06
the O 0 2.238170281998464e-06
protein O 0 9.300678357249126e-06
. O 0 6.8300832936074585e-06

We O 0 6.927194590389263e-06
propose O 0 2.302870598214213e-06
that O 0 2.1228913738013944e-07
the O 0 5.328967063178425e-07
loss O 0 2.2272004116530297e-06
of O 0 1.883205527519749e-06
wild O 0 3.811122724073357e-06
- O 0 5.525610686163418e-05
type O 0 7.198633102234453e-05
VHL B-Disease 0 0.11620158702135086
gene O 0 2.8351024639050593e-07
results O 0 1.9145063845371624e-07
in O 0 7.948038671656832e-08
a O 0 2.150348024088089e-07
specific O 0 1.1055277582272538e-07
cellular O 0 0.0006731462781317532
defect O 0 1.7239755834452808e-05
in O 0 5.134969569553505e-07
serum O 0 2.4907016268116422e-05
- O 0 2.435370333842002e-06
dependent O 0 3.286026242221851e-07
growth O 0 1.026864424602536e-06
control O 0 1.1944831612709095e-07
, O 0 1.842149366382273e-08
which O 0 1.4254561975235447e-08
may O 0 9.768201891802164e-08
initiate O 0 1.5144690905799507e-06
tumor B-Disease 0 0.23573556542396545
formation O 0 3.116747393505648e-05
. O 0 5.90285935686552e-06

This O 0 2.0165143723716028e-05
is O 0 3.5271341403131373e-06
corrected O 0 1.0000770089391153e-05
by O 0 3.2247746162283875e-07
the O 0 1.8200996976247552e-07
reintroduction O 0 1.2354706768746837e-06
of O 0 5.668042604156653e-07
wild O 0 1.238956087945553e-06
- O 0 1.1882099897775333e-05
type O 0 6.629661220358685e-05
VHL B-Disease 1 0.8942436575889587
, O 0 4.007153165730415e-06
implicating O 0 0.005721090827137232
VHL B-Disease 0 0.015718692913651466
as O 0 6.350952048705949e-07
the O 0 3.5171544254808396e-07
first O 0 6.009613002788683e-07
tumor B-Disease 0 0.0033183912746608257
suppressor O 0 0.006364326924085617
involved O 0 1.2596395038144692e-07
in O 0 7.870679041843687e-08
the O 0 1.346882356756396e-07
regulation O 0 1.950515553517107e-07
of O 0 6.228767119864642e-07
cell O 0 7.666544661333319e-06
cycle O 0 1.30675516629708e-06
exit O 0 3.925173359675682e-07
, O 0 1.2662079384995195e-08
which O 0 1.023848739123423e-08
is O 0 8.246666460820506e-09
consistent O 0 5.014324244712043e-08
with O 0 6.948285058427928e-09
its O 0 9.453609806087115e-08
gatekeeper O 0 3.4663858968997374e-05
function O 0 2.5426686534046894e-07
in O 0 2.067044988507405e-07
the O 0 1.4690756415802753e-06
kidney O 1 0.5040163993835449
. O 0 4.845873604608641e-07
. O 0 1.9038093341805506e-06

Piebaldism B-Disease 1 0.9999998807907104
with O 0 0.00010508488776395097
deafness B-Disease 1 1.0
: O 0 5.41432382306084e-06
molecular O 0 6.952728199394187e-06
evidence O 0 4.2960775203937374e-07
for O 0 2.0778739440174832e-07
an O 0 1.4641216239397181e-06
expanded O 0 0.0004051069845445454
syndrome O 1 1.0
. O 0 3.37382844008971e-05

In O 0 1.787402288755402e-05
a O 0 5.22646678291494e-06
South O 0 3.812631348409923e-06
African O 0 7.890818665146071e-07
girl O 0 6.822022555752483e-07
of O 0 5.639573714688595e-07
Xhosa O 0 0.00010332730016671121
stock O 0 6.653882792306831e-06
with O 0 7.441781235684175e-08
severe O 1 0.9979839324951172
piebaldism B-Disease 1 0.9999032020568848
and O 0 7.181191904237494e-06
profound O 1 0.9999992847442627
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 2.0145007511018775e-06
identified O 0 2.2732898230515275e-07
a O 0 9.974132098022892e-08
novel O 0 1.049363191896191e-07
missense O 0 6.398017262654321e-07
substitution O 0 1.2599725778272841e-06
at O 0 1.1628043239397812e-06
a O 0 1.4931509895177442e-07
highly O 0 1.4057883390705683e-07
conserved O 0 2.098018683227565e-07
residue O 0 1.1289865824437584e-06
in O 0 2.476426175235247e-07
the O 0 5.574677857111965e-07
intracellular O 0 4.200016519462224e-06
kinase O 0 4.707199423137354e-06
domain O 0 1.4580018614651635e-06
of O 0 2.6666054964152863e-06
the O 0 1.0029615623352583e-05
KIT O 0 6.720135570503771e-05
proto O 0 0.0007027216488495469
- O 0 7.193143392214552e-05
oncogene O 0 0.0012885064352303743
, O 0 2.456812808304676e-06
R796G O 0 0.00016806744679342955
. O 0 7.172423920565052e-06

Though O 0 3.110719262622297e-05
auditory B-Disease 0 0.0009684519027359784
anomalies I-Disease 0 0.0014537706738337874
have O 0 5.868894845661998e-07
been O 0 3.3115745168288413e-07
observed O 0 3.7397444430098403e-07
in O 0 2.412712376553827e-07
mice O 0 7.84888641192083e-07
with O 0 1.356322911760799e-07
dominant O 0 2.5581477984815137e-06
white O 0 1.243288238583773e-06
spotting O 0 1.1868441106344108e-05
( O 0 1.0148671663046116e-06
W O 0 0.014403825625777245
) O 0 9.104896037115395e-08
due O 0 9.868199413176626e-07
to O 0 9.069122341998082e-08
KIT O 0 6.644725999649381e-06
mutations O 0 1.0572854307611124e-06
, O 0 5.541208338399883e-06
deafness B-Disease 1 1.0
is O 0 6.878000817778229e-07
not O 0 3.6936093295025785e-08
typical O 0 3.155653303110739e-07
in O 0 2.6351918336331437e-07
human O 0 3.647721086963429e-06
piebaldism B-Disease 0 0.00029936537612229586
. O 0 4.535413154371781e-06

Thus O 0 8.378520760743413e-06
, O 0 4.041253021114244e-07
the O 0 2.1339518241347832e-07
occurrence O 0 2.4572159418312367e-06
of O 0 3.263933103880845e-05
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 0.010181655175983906
this O 0 6.225767492651357e-07
patient O 0 1.6378780856030062e-06
extends O 0 7.030700430732395e-07
considerably O 0 1.930313544562523e-07
the O 0 5.650017698144438e-08
phenotypic O 0 1.5213785786727385e-07
range O 0 2.294725192086844e-07
of O 0 7.271672757269698e-07
piebaldism B-Disease 0 1.587437145644799e-05
due O 0 2.8954448225704255e-06
to O 0 8.92834961518929e-08
KIT O 0 1.5976254417182645e-06
gene O 0 1.7896989845667122e-07
mutation O 0 1.28821056932793e-07
in O 0 1.0944479811314523e-07
humans O 0 5.183165541211565e-08
and O 0 7.064966922598614e-08
tightens O 0 1.650788703955186e-06
the O 0 1.2803998572508135e-07
clinical O 0 5.973694783278916e-07
similarity O 0 2.8152615527687885e-07
between O 0 5.070264137430058e-07
piebaldism B-Disease 0 1.511064783699112e-05
and O 0 4.327410607629645e-08
the O 0 3.381510182975944e-08
various O 0 9.357860264458395e-09
forms O 0 1.866283412255143e-07
of O 1 0.6576162576675415
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.2584374417201616e-05
. O 0 4.700811132352101e-06

Cycloheximide O 0 0.0020450055599212646
facilitates O 0 5.455201244330965e-05
the O 0 2.8060778731742175e-06
identification O 0 7.366938348241092e-07
of O 0 1.5669218100811122e-06
aberrant O 0 2.0456063793972135e-05
transcripts O 0 1.3656170267495327e-05
resulting O 0 4.043561148137087e-06
from O 0 7.523170779677457e-07
a O 0 6.106690761953359e-07
novel O 0 4.6599780034739524e-07
splice O 0 3.060760263906559e-06
- O 0 1.505397221990279e-06
site O 0 2.055566596936842e-07
mutation O 0 7.583811623135261e-08
in O 0 6.549223030560825e-08
COL17A1 O 0 2.1614356228383258e-05
in O 0 9.460283223461374e-08
a O 0 8.710267707101593e-07
patient O 0 3.2232787816610653e-06
with O 0 1.6360891095246188e-06
generalized O 1 0.9993532299995422
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999997615814209
bullosa I-Disease 1 0.9998329877853394
. O 0 2.3134951334213838e-05

Patients O 0 0.0006577065796591341
with O 0 2.0831881556659937e-05
generalized O 1 0.9999618530273438
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9996819496154785
often O 0 3.127135812519555e-07
show O 0 2.9438032811412995e-07
decreased O 0 4.093824827577919e-06
expression O 0 3.4170147955592256e-07
of O 0 6.446359179790306e-07
type O 0 6.960278369660955e-06
XVII O 1 0.9973984956741333
collagen O 0 6.278152432059869e-05
, O 0 3.843604474695894e-07
a O 0 3.219115001229511e-07
transmembrane O 0 5.235346179688349e-06
hemidesmosomal O 0 1.2167677596153226e-05
protein O 0 1.5508244359807577e-06
encoded O 0 9.830157523538219e-07
by O 0 1.8524112874729326e-06
COL17A1 O 0 0.0005013828631490469
. O 0 5.640828476316528e-06

This O 0 1.977678039111197e-05
report O 0 5.197780865273671e-06
documents O 0 9.773017382030957e-07
a O 0 1.4803463272983208e-06
novel O 0 2.4491491785738617e-06
splice O 0 1.762217652867548e-05
- O 0 2.9214061214588583e-06
site O 0 2.1747767675606156e-07
mutation O 0 5.9053771650496856e-08
in O 0 6.951336217753123e-08
COL17A1 O 0 1.5912657545413822e-05
in O 0 4.7093987376456425e-08
a O 0 4.220833886847686e-07
patient O 0 1.911402705445653e-06
with O 0 1.2946052265760954e-06
generalized O 1 0.9999955892562866
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999995231628418
bullosa I-Disease 1 0.908655047416687
, O 0 1.7788819661745947e-07
and O 0 2.89309838308327e-08
applies O 0 3.2915114189790984e-08
a O 0 3.18445465552486e-08
new O 0 2.878556060181836e-08
methodology O 0 9.782987575590596e-08
to O 0 1.3961320100008834e-08
define O 0 5.5261086373548096e-08
and O 0 6.662224194542432e-08
characterize O 0 5.173851604922675e-07
the O 0 4.761868410696479e-07
resulting O 0 6.294171726040076e-07
mRNA O 0 4.413027909322409e-06
splice O 0 7.148980330384802e-06
variants O 0 2.5496890430076746e-06
. O 0 2.5145081963273697e-06

Mutational O 0 0.009559696540236473
analysis O 0 3.0475101084448397e-05
of O 0 1.827954110922292e-05
COL17A1 O 0 0.0018091669771820307
identified O 0 8.111703209578991e-06
a O 0 3.864116024487885e-06
maternally O 0 1.2106517715437803e-05
inherited O 0 3.947909135604277e-05
G O 0 5.958094698144123e-05
- O 0 2.788253141261521e-06
to O 0 2.980708586619585e-07
- O 0 6.928608399903169e-06
T O 0 2.2098909539636225e-05
transversion O 0 5.32596095581539e-06
at O 0 1.225417804562312e-06
the O 0 9.891380159388063e-08
- O 0 9.379074583648617e-08
1 O 0 1.5439771061664942e-07
position O 0 2.699685808238428e-07
of O 0 5.93609343013668e-07
exon O 0 3.4740710361802485e-06
32 O 0 6.743290214217268e-06
. O 0 3.1162567211140413e-06

This O 0 1.4624339200963732e-05
acceptor O 0 6.3326547206088435e-06
splice O 0 3.059195296373218e-05
- O 0 6.547264547407394e-06
site O 0 1.3948339301350643e-06
mutation O 0 2.7043446948482597e-07
led O 0 5.697241931557073e-07
to O 0 2.6981409106952015e-08
the O 0 1.278731787124343e-07
formation O 0 6.414788344955014e-07
of O 0 1.0006800721384934e-06
aberrant O 0 1.56810820044484e-05
transcripts O 0 5.5907216847117525e-06
present O 0 6.111433208388917e-07
at O 0 9.486114322498906e-06
extremely O 0 2.1923908661847236e-06
low O 0 1.538041396997869e-05
levels O 0 2.9262469070090447e-06
. O 0 1.9978992895630654e-06

Based O 0 1.1756007552321535e-05
on O 0 4.683386578108184e-06
our O 0 4.835260938307329e-07
recent O 0 2.512887533612229e-07
finding O 0 1.4813389270784683e-07
that O 0 2.495489752618596e-07
cycloheximide O 0 6.969235982978716e-05
stabilized O 0 0.00019797909772023559
mutant O 0 6.244062205951195e-06
COL17A1 O 0 7.014623406575993e-05
transcripts O 0 3.907316568074748e-06
in O 0 2.5309330453637813e-07
keratinocytes O 0 1.6061711676229606e-06
homozygous O 0 2.511186778519914e-07
for O 0 8.488316183274947e-08
a O 0 2.6095005978277186e-07
frameshift O 0 2.0085269625269575e-06
mutation O 0 1.4348019305998605e-07
, O 0 1.1558120149857132e-07
the O 0 2.644985954702861e-07
effects O 0 1.9827430151053704e-06
of O 0 2.0364809643069748e-06
the O 0 1.6629444417048944e-06
splice O 0 4.351049938122742e-06
- O 0 1.7082118120015366e-06
site O 0 3.7144369002817257e-07
mutation O 0 6.46827018613294e-08
on O 0 3.7329456858969934e-07
splicing O 0 1.397442019879236e-07
of O 0 4.432343985172338e-07
COL17A1 O 0 9.443159797228873e-06
transcripts O 0 5.320065952219011e-07
were O 0 1.0378857950854581e-07
determined O 0 6.027998011859381e-08
using O 0 4.6581117629784785e-08
reverse O 0 1.3361628816710436e-06
transcriptase O 0 9.245696674042847e-06
polymerase O 0 8.276235348603223e-06
chain O 0 9.126383133661875e-07
reaction O 0 2.2008362066117115e-07
of O 0 2.546347559473361e-07
total O 0 9.163204595097341e-07
RNA O 0 2.8334582111710915e-06
from O 0 4.406781215493538e-07
keratinocytes O 0 2.5133815597655484e-06
incubated O 0 2.3602078726980835e-06
for O 0 3.396417014300823e-07
2 O 0 4.3762729546870105e-06
. O 0 2.7795397272711853e-06

5 O 0 6.989163375692442e-05
h O 0 3.661942173494026e-05
in O 0 8.007050951164274e-07
the O 0 5.27547911133297e-07
presence O 0 5.486445502356219e-07
or O 0 2.9523559419430967e-07
absence O 0 1.1598339142437908e-06
of O 0 1.545080408504873e-06
10 O 0 2.6988643639924703e-06
microg O 0 4.80786147818435e-05
cycloheximide O 0 6.217908958205953e-05
per O 0 1.3008442692807876e-05
ml O 0 3.5298777220305055e-05
. O 0 3.5267371458758134e-06

Using O 0 1.1421101589803584e-05
this O 0 9.60532702265482e-07
approach O 0 2.5630145046307007e-06
, O 0 3.3985813274739485e-07
an O 0 3.01307267136508e-07
abnormally O 0 1.1039490345865488e-05
spliced O 0 1.8648029254109133e-06
transcript O 0 1.1158738743688446e-05
was O 0 5.42470661457628e-06
identified O 0 8.645486815339609e-08
that O 0 1.973207730543436e-08
contains O 0 5.64108013634268e-08
an O 0 8.730195588668721e-08
extra O 0 6.158472132256065e-08
264 O 0 1.2379899771985947e-06
bases O 0 4.5131608317205973e-07
upstream O 0 1.95371535482991e-06
from O 0 1.6445255823782645e-07
exon O 0 2.2645912167718052e-07
32 O 0 2.7603277885646094e-07
, O 0 2.6307215961196562e-08
resulting O 0 1.3939427390141645e-07
in O 0 1.698821989748467e-07
a O 0 1.0836565706995316e-06
premature O 0 8.803417586022988e-06
termination O 0 7.13636472937651e-06
codon O 0 7.2060543061525095e-06
27 O 0 6.759374173270771e-06
bp O 0 4.632179752661614e-06
downstream O 0 5.109473022457678e-06
from O 0 5.568599590333179e-07
the O 0 1.6533142570551718e-06
cryptic O 0 1.839306059991941e-05
splice O 0 2.0512032278929837e-05
site O 0 2.360424514336046e-05
. O 0 7.760250809951685e-06

Three O 0 1.1629602340690326e-05
other O 0 3.7954501408421493e-07
splice O 0 5.853953553014435e-06
variants O 0 8.487035074722371e-07
, O 0 2.671487493444147e-07
including O 0 1.4928632197097613e-07
one O 0 8.99566359180426e-08
derived O 0 1.248643144435846e-07
from O 0 1.742322268682983e-07
the O 0 1.4457809527357313e-07
skipping O 0 1.3069902138340694e-07
of O 0 1.0298816732756677e-07
exon O 0 3.1110167242331954e-07
32 O 0 3.093841201007308e-07
, O 0 4.0611187301919927e-08
were O 0 1.9088930969246576e-07
also O 0 1.9877288082170708e-07
identified O 0 1.4712289839735604e-06
. O 0 2.29896022574394e-06

These O 0 2.0448435407161014e-06
results O 0 1.7085443460018723e-06
indicate O 0 1.2513090723587084e-06
the O 0 3.57461345856791e-07
usefulness O 0 9.625364327803254e-07
of O 0 7.184892751865846e-07
cycloheximide O 0 2.0255263734725304e-05
treatment O 0 1.2946064771313104e-06
in O 0 1.618946185999448e-07
evaluating O 0 2.775985308289819e-07
the O 0 7.90396882166533e-07
abnormal O 0 1.6318834241246805e-05
processing O 0 2.465932311679353e-06
of O 0 1.3481947007676354e-06
mRNA O 0 2.315425035703811e-06
due O 0 1.3916517218603985e-06
to O 0 1.2360511902897997e-07
splice O 0 1.741003075039771e-06
- O 0 8.315962531924015e-07
site O 0 2.2724140080754296e-07
mutations O 0 2.8827098930150896e-08
, O 0 7.099263399368283e-08
because O 0 7.026491743999941e-08
( O 0 1.0922062188001291e-07
i O 0 2.1003270944675023e-07
) O 0 7.377013133691435e-08
aberrant O 0 1.8900982468039729e-06
splicing O 0 3.812624242982565e-07
often O 0 3.7231323801734106e-08
generates O 0 1.5424744503889087e-07
a O 0 3.7974993460920814e-07
premature O 0 3.755731086130254e-06
termination O 0 2.2659378373646177e-06
codon O 0 1.6376391158701153e-06
, O 0 4.8901302562853743e-08
( O 0 2.0027679070722115e-08
ii O 0 1.0464266324561322e-06
) O 0 2.869336235278297e-08
transcripts O 0 3.4859050401792047e-07
with O 0 6.237737437686519e-08
premature O 0 1.7954489521798678e-05
termination O 0 4.8801698540046345e-06
codons O 0 9.700709142634878e-07
can O 0 1.672092686533233e-08
occur O 0 5.2307967735032435e-08
at O 0 1.4421799505726085e-06
low O 0 1.4047539025341393e-06
or O 0 1.3556750388943328e-07
undetectable O 0 3.091339522143244e-06
levels O 0 2.0219619045747095e-07
due O 0 4.627339933449548e-07
to O 0 5.487121157443653e-08
nonsense O 0 2.2094236555858515e-06
- O 0 2.603050859306677e-07
mediated O 0 5.270752012620505e-07
mRNA O 0 3.3458081816206686e-07
decay O 0 1.648202641035823e-07
, O 0 1.8243619948066225e-08
and O 0 2.104535035130084e-08
( O 0 2.8467569634926804e-08
iii O 0 1.2794945405403269e-06
) O 0 2.992916492416953e-08
the O 0 3.364654332926875e-08
levels O 0 7.047417227568076e-08
of O 0 4.702487288454904e-08
these O 0 6.439683453152156e-09
transcripts O 0 2.625824606639071e-07
can O 0 1.0205207345848066e-08
be O 0 5.620384868620931e-08
increased O 0 4.603940055858402e-07
by O 0 7.003117161730188e-07
cycloheximide O 0 3.585394370020367e-05
. O 0 2.638073738125968e-06

A O 0 9.592516289558262e-05
deletion O 0 3.027231286978349e-05
mutation O 0 2.8350582397251856e-06
in O 0 7.899763545538008e-07
COL17A1 O 0 4.779536902788095e-05
in O 0 6.779321637395697e-08
five O 0 5.423184035180384e-08
Austrian O 0 9.00529084901791e-06
families O 0 4.938364384088345e-08
with O 0 5.726188305743563e-07
generalized O 1 0.9999805688858032
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9993372559547424
represents O 0 1.5002578948042355e-06
propagation O 0 6.9037291723361704e-06
of O 0 8.174536674232513e-07
an O 0 7.098450396370026e-07
ancestral O 0 1.5398216419271193e-05
allele O 0 1.6954480088315904e-05
. O 0 4.486974830797408e-06

Patients O 0 0.0003055682172998786
with O 0 9.066681741387583e-06
generalized O 1 0.99992835521698
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999462366104126
, O 0 6.628179676226864e-07
a O 0 2.2267875010584248e-07
usually O 0 3.246042368232338e-08
nonlethal O 0 1.0631873692545923e-06
form O 0 1.5073668180320965e-07
of O 0 5.1052011258434504e-06
junctional B-Disease 1 0.9999035596847534
epidermolysis I-Disease 1 0.9999138116836548
bullosa I-Disease 0 0.36172881722450256
, O 0 3.493506426366366e-07
have O 0 7.830131210084801e-08
generalized O 0 1.1035343959520105e-05
blistering B-Disease 0 0.07182910293340683
, O 0 1.313707707595313e-05
nail B-Disease 1 0.9999988079071045
dystrophy I-Disease 1 0.9999992847442627
, O 0 1.6029241578507936e-06
patchy B-Disease 1 0.945033609867096
alopecia I-Disease 1 1.0
, O 0 6.613218829443213e-06
and O 0 2.0557641619234346e-05
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.009535310789942741

Skin B-Disease 1 0.9998437166213989
fragility I-Disease 1 0.9729048013687134
in O 0 2.8040233246429125e-06
most O 0 1.0451365994867956e-07
cases O 0 6.0864451256748e-08
is O 0 3.8773645627543374e-08
due O 0 2.0495669161846308e-07
to O 0 7.671768997852269e-09
mutations O 0 2.3108064794996608e-08
in O 0 8.913205817862035e-08
the O 0 7.929943990347965e-08
gene O 0 1.8098062071203458e-07
encoding O 0 6.34667173926573e-07
type O 0 6.0646307247225195e-05
XVII O 1 0.9999525547027588
collagen O 0 0.24562416970729828
( O 0 1.3945153114036657e-05
COL17A1 O 0 0.0018091617384925485
) O 0 1.8503473029340967e-06
. O 0 1.5386236782433116e-06

Recently O 0 0.00015224642993416637
, O 0 2.7101743853563676e-06
we O 0 1.727418634800415e-07
reported O 0 7.954147918098897e-07
five O 0 1.2283530281820276e-07
Austrian O 0 1.0294539606547914e-05
families O 0 8.197678624810578e-08
with O 0 9.86552663562179e-07
generalized O 1 0.999871015548706
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999349117279053
who O 0 1.3343980072022532e-06
share O 0 1.9306412468722556e-07
the O 0 2.1780978443075583e-07
same O 0 5.235937692305015e-07
COL17A1 O 0 0.00024861213751137257
mutation O 0 6.317351108009461e-06
. O 0 3.7232571230561007e-06

Affected O 0 2.303913606738206e-05
individuals O 0 5.492523200700816e-07
in O 0 4.23142552108402e-07
three O 0 8.157125819252542e-08
families O 0 1.6360338861431956e-08
are O 0 1.1073253425308849e-08
homozygous O 0 1.3498797102329263e-07
for O 0 1.0884130574595474e-07
4003delTC O 0 2.074008762065205e-06
, O 0 7.134135415753917e-08
whereas O 0 3.9983550692568315e-08
those O 0 5.043711670538187e-09
in O 0 2.935823317784525e-08
two O 0 4.255804597619317e-08
others O 0 1.2157362050402298e-07
are O 0 1.2082209366326424e-07
compound O 0 3.066018325625919e-05
heterozygotes O 0 1.725923539197538e-05
. O 0 4.657028512156103e-06

To O 0 3.4253712328791153e-06
determine O 0 4.77319872516091e-07
if O 0 1.6181697048978094e-07
the O 0 1.656342902833785e-07
occurrence O 0 9.238929692401143e-07
of O 0 9.762546824276797e-07
4003delTC O 0 1.855094978964189e-06
in O 0 6.475453773191475e-08
these O 0 9.366967645974e-09
unrelated O 0 1.9219793045976985e-07
families O 0 1.980114738842076e-08
signifies O 0 1.3096121165290242e-06
propagation O 0 1.3768952840109705e-06
of O 0 3.1473851436203404e-07
an O 0 2.2063085225454415e-07
ancestral O 0 1.1021480759154656e-06
allele O 0 6.096827291912632e-07
or O 0 1.6130468338815263e-07
a O 0 5.212551172917301e-07
mutational O 0 3.2013973395805806e-05
hot O 0 1.2160578990005888e-05
spot O 0 2.066043180093402e-06
, O 0 5.9529767781896226e-08
haplotypes O 0 3.51627221562012e-07
were O 0 8.426388831139775e-08
determined O 0 5.2102151926192164e-08
for O 0 2.55523069370156e-08
polymorphisms O 0 2.0652085197525594e-07
both O 0 6.173149103005926e-08
within O 0 2.3166742835201148e-07
and O 0 1.2895321788164438e-06
flanking O 0 0.01838955096900463
COL17A1 O 1 0.9066245555877686
. O 0 1.528996290289797e-05

Five O 0 0.00011319312761770561
intragenic O 0 0.00025759940035641193
polymorphisms O 0 3.42071070917882e-05
were O 0 4.606232778314734e-06
chosen O 0 8.3269458173163e-07
based O 0 2.944777861557668e-07
on O 0 1.3619824130728375e-06
their O 0 8.065027259362978e-07
informativeness O 0 0.000675869348924607
. O 0 9.247884008800611e-06

One O 0 7.871512025303673e-06
of O 0 1.948481212821207e-06
these O 0 7.982830396713325e-08
, O 0 7.820040792694272e-08
not O 0 2.1789073656464097e-08
previously O 0 2.815623929564026e-07
reported O 0 4.2628892060747603e-07
, O 0 8.963976938503038e-08
was O 0 2.8242532152944477e-06
2988 O 0 4.899437954009045e-06
A O 0 3.3105686725320993e-06
or O 0 2.425213381229696e-07
C O 0 5.252559731161455e-06
that O 0 3.349306609834457e-08
introduces O 0 1.5546403631105932e-07
a O 0 1.1537009214634963e-07
new O 0 6.436469135451262e-08
restriction O 0 3.5450639757073077e-07
site O 0 5.878036404283193e-07
for O 0 3.296613897418865e-07
Eco0109 O 0 5.272175985737704e-05
I O 0 4.248971526976675e-05
. O 0 6.6292122937738895e-06

All O 0 5.119584329804638e-06
the O 0 3.306839062133804e-06
4003delTC O 0 8.457014700979926e-06
alleles O 0 7.838108331270632e-07
showed O 0 7.865626798775338e-07
the O 0 1.6003168923361955e-07
same O 0 5.912680478559196e-08
haplotype O 0 6.903669031999016e-07
for O 0 1.8480653452002116e-08
these O 0 8.250662375530737e-09
five O 0 1.5806833175702195e-07
polymorphic O 0 2.9027935397607507e-06
markers O 0 1.5224601156660356e-05
. O 0 4.463016921363305e-06

Fourteen O 0 0.00011922668636543676
microsatellite O 0 0.00014225039922166616
polymorphisms O 0 1.3160099115339108e-05
were O 0 1.7211269778272253e-06
selected O 0 2.5062365693884203e-07
based O 0 8.31206321549871e-08
on O 0 2.3275632088370912e-07
their O 0 6.183283574046072e-08
high O 0 1.495766900916351e-05
heterozygosity O 0 1.7456401110393927e-05
and O 0 1.4432696104904608e-07
their O 0 8.611370105882088e-08
location O 0 1.7597858459339477e-06
within O 0 1.9411252196732676e-06
10q23 O 0 0.0002696384908631444
- O 0 8.025841816561297e-05
q25 O 0 0.00033935756073333323
near O 0 0.0003570000408217311
COL17A1 O 0 0.0013542977394536138
. O 0 1.2554264685604721e-05

Three O 0 8.745302693569101e-06
families O 0 3.583849945698603e-07
shared O 0 8.587937259108003e-07
microsatellite O 0 1.3380819837038871e-05
polymorphisms O 0 7.87567114457488e-06
covering O 0 2.440141724946443e-05
at O 0 1.431385589967249e-05
most O 0 1.3975899548768211e-07
19 O 0 1.339685809398361e-06
cM O 0 4.286945113562979e-06
, O 0 1.6284042203551508e-07
whereas O 0 7.735778240203217e-08
the O 0 5.3830230939411194e-08
others O 0 2.131715959308167e-08
shared O 0 3.068096177116786e-08
smaller O 0 3.3463756210494466e-08
regions O 0 3.893623912176736e-08
consistent O 0 3.8637739407931804e-07
with O 0 6.342061453779024e-08
cross O 0 9.32690056743013e-07
- O 0 3.584875400974852e-07
over O 0 2.8194254042546163e-08
events O 0 1.9340239632015255e-08
during O 0 4.228682470852618e-08
passage O 0 2.6909612316217135e-08
of O 0 1.1802084642908994e-08
this O 0 3.3976714775008077e-09
mutation O 0 1.7239798921764304e-08
through O 0 3.358518441132219e-08
several O 0 5.483459375454913e-08
generations O 0 7.108557724677667e-07
. O 0 2.381524836891913e-06

These O 0 7.452159024978755e-06
results O 0 7.705480129516218e-06
indicate O 0 2.2750277821614873e-06
that O 0 1.9256579264492757e-07
4003delTC O 0 4.425811312103178e-06
occurs O 0 2.697467493817385e-07
on O 0 5.392250272961974e-07
a O 0 2.6450237555764033e-07
single O 0 2.41186796756665e-07
ancestral O 0 2.812572120092227e-06
allele O 0 3.3291123600065475e-06
. O 0 4.7612144271624857e-07
. O 0 1.48955405165907e-06

The O 0 5.024663551012054e-05
haptoglobin O 0 0.0012521243188530207
- O 0 4.273890590411611e-05
gene O 0 2.8075260161131155e-06
deletion O 0 8.954491022450384e-06
responsible O 0 3.1261447475117166e-06
for O 0 1.94706944967038e-06
anhaptoglobinemia B-Disease 0 0.0006554651190526783
. O 0 6.950593615329126e-06

We O 0 8.530832928954624e-06
have O 0 3.401220567411656e-07
found O 0 3.3395664900126576e-07
an O 0 1.9881325385995297e-07
allelic O 0 1.8691902141654282e-06
deletion O 0 2.520929001548211e-06
of O 0 6.513397693197476e-06
the O 0 4.691827143687988e-06
haptoglobin O 0 6.231033330550417e-05
( O 0 5.185593749956752e-07
Hp O 0 4.534544132184237e-06
) O 0 5.061967911501597e-08
gene O 0 5.6664759995328495e-08
from O 0 1.1132447497175235e-07
an O 0 8.666503248377921e-08
individual O 0 4.443300838374853e-08
with O 0 6.926368314452702e-07
anhaptoglobinemia B-Disease 0 0.0755789577960968
. O 0 1.4144505257718265e-05

The O 0 0.00010070583812193945
Hp O 0 0.00020903628319501877
gene O 0 2.8888005090266233e-06
cluster O 0 6.007440788380336e-06
consists O 0 4.1704271325215814e-07
of O 0 5.58899785119138e-07
coding O 0 4.297470752590016e-07
regions O 0 8.197912393370643e-08
of O 0 9.500766964265495e-07
the O 0 1.1379778470654855e-06
alpha O 0 4.053097200085176e-06
chain O 0 5.423017341854575e-07
and O 0 7.392295486852163e-08
beta O 0 5.767671495959803e-07
chain O 0 4.1037273490474035e-07
of O 0 2.7702012062036374e-07
the O 0 4.396303836529114e-07
haptoglobin O 0 4.438804808160057e-06
gene O 0 1.856771660868617e-07
( O 0 1.0810145312234454e-07
Hp O 0 1.2613010085260612e-06
) O 0 1.5490838833898124e-08
and O 0 1.1376265263152163e-08
of O 0 1.7231752735824557e-07
the O 0 6.545851078954001e-07
alpha O 0 1.4212001815394615e-06
chain O 0 3.1493249252889655e-07
and O 0 9.688008617558808e-08
beta O 0 5.31362616129627e-07
chain O 0 4.771259796143568e-07
of O 0 2.7179009975952795e-07
the O 0 4.079320206074044e-07
haptoglobin O 0 7.594444923597621e-06
- O 0 7.13542760877317e-07
related O 0 2.5076494125642057e-07
gene O 0 3.2517718295821396e-07
( O 0 2.35559298289445e-07
Hpr O 0 3.079810085182544e-06
) O 0 9.649870236216884e-08
, O 0 5.7715734413932296e-08
in O 0 1.0869774058619441e-07
tandem O 0 4.24270547227934e-06
from O 0 2.944637458313082e-07
the O 0 4.976071750206756e-07
5 O 0 2.28237513510976e-06
side O 0 3.66480662705726e-06
. O 0 3.263473445258569e-06

Southern O 0 0.00010376689169788733
blot O 0 0.00017271641991101205
and O 0 4.42561713498435e-06
PCR O 0 1.2732871255138889e-05
analyses O 0 1.194967694573279e-06
have O 0 1.5534236297298776e-07
indicated O 0 5.331158376975509e-07
that O 0 4.896084604411044e-08
the O 0 1.5165416300533252e-07
individual O 0 1.0896256341652588e-08
with O 0 5.565171079524589e-08
anhaptoglobinemia B-Disease 0 1.0087457667395938e-05
was O 0 5.228610007179668e-06
homozygous O 0 1.080256097907295e-07
for O 0 3.2022093421346653e-08
the O 0 1.341399809007271e-07
gene O 0 7.784281308431673e-08
deletion O 0 3.521597875533189e-07
and O 0 9.830966263280061e-08
that O 0 4.56386182179358e-08
the O 0 1.0858045840222985e-07
gene O 0 6.718166645214296e-08
deletion O 0 6.503507847810397e-07
was O 0 8.156025614880491e-06
included O 0 4.808704261449748e-07
at O 0 1.9300332496641204e-06
least O 0 4.2830606616917066e-08
from O 0 1.4686173699374194e-07
the O 0 3.2979406228150765e-07
promoter O 0 4.035171059513232e-06
region O 0 3.2783856340756756e-07
of O 0 2.4212993139371974e-06
Hp O 0 8.771212378633209e-06
to O 0 2.0022376645556506e-07
Hpr O 0 9.323644007963594e-06
alpha O 0 2.897395006584702e-06
but O 0 2.3693354833653757e-08
not O 0 1.772412616674046e-08
to O 0 7.458577755414808e-08
Hpr O 0 4.624323082680348e-06
beta O 0 4.403640105010709e-06
( O 0 5.604791795121855e-07
Hpdel O 0 3.010361069755163e-05
) O 0 6.461512498390221e-07
. O 0 1.1160153690070729e-06

In O 0 1.8017715774476528e-05
addition O 0 1.2203156529722037e-06
, O 0 4.517256115832424e-07
we O 0 1.1138266131638375e-07
found O 0 1.4676511739253328e-07
seven O 0 9.238510045861403e-08
individuals O 0 7.855677885970636e-09
with O 0 4.6600753478287515e-08
hypohaptoglobinemia B-Disease 0 1.3958991075924132e-05
in O 0 5.374517968448345e-07
three O 0 1.48916484477013e-07
families O 0 2.4197376546908345e-08
, O 0 5.1529038813669104e-08
and O 0 3.693376626756617e-08
the O 0 1.8988215799708996e-07
genotypes O 0 3.9091622738851584e-07
of O 0 1.129023075918667e-06
six O 0 2.661798248482228e-07
of O 0 3.088758830926963e-07
the O 0 1.3473500359850732e-07
seven O 0 4.409445963915459e-08
individuals O 0 3.0722346888722996e-09
were O 0 7.810992741497103e-08
found O 0 5.733959795861665e-08
to O 0 7.801136803209374e-08
be O 0 1.6210796047744225e-06
Hp2 O 0 0.003565463935956359
/ O 0 0.00039405800634995103
Hpdel O 0 0.000525476410984993
. O 0 6.101188319007633e-06

The O 0 1.957314816536382e-05
phenotypes O 0 7.234532859001774e-06
and O 0 3.976027471708221e-07
genotypes O 0 1.4255834912546561e-06
in O 0 1.932029931595025e-07
one O 0 3.996060371491694e-08
of O 0 1.0332342981200782e-07
these O 0 8.619879032778499e-09
three O 0 4.911835915777374e-08
families O 0 2.3249715042084063e-08
showed O 0 1.1370860875103972e-06
the O 0 6.419684268621495e-07
father O 0 2.4535488591936883e-06
to O 0 2.2274947752976004e-07
be O 0 5.236447009338008e-07
hypohaptoglobinemic B-Disease 0 1.0970058610837441e-05
( O 0 2.7414887426857604e-07
Hp2 O 0 1.0439912330184598e-05
) O 0 1.0332244926303247e-07
and O 0 2.1504197889044008e-07
Hp2 O 0 5.563373269978911e-05
/ O 0 1.199321195599623e-05
Hpdel O 0 1.7981221390073188e-05
, O 0 1.2251253167505638e-07
the O 0 3.1714591841591755e-07
mother O 0 3.006723545695422e-07
to O 0 3.67464352279967e-08
be O 0 1.5030273914362624e-07
Hp2 O 0 4.238528163114097e-06
- O 0 5.134361913405883e-07
1 O 0 4.71528608159133e-07
and O 0 1.1290753576531642e-07
Hp1 O 0 1.5726340279798023e-05
/ O 0 3.8443263292720076e-06
Hp2 O 0 6.533617124659941e-06
, O 0 5.576497486003973e-08
one O 0 1.7902806348502054e-08
of O 0 1.582218800422197e-07
the O 0 2.2564637447430869e-07
two O 0 5.855377338548351e-08
children O 0 6.702296673211094e-08
to O 0 1.1543414046855105e-07
be O 0 4.176818890755385e-07
hypohaptoglobinemic B-Disease 0 1.123948095482774e-05
( O 0 2.1108914438627835e-07
Hp2 O 0 3.9949427446117625e-06
) O 0 5.01523302887108e-08
and O 0 1.0225766544635917e-07
Hp2 O 0 2.05293526960304e-05
/ O 0 7.99178633315023e-06
Hpdel O 0 1.4352744983625598e-05
, O 0 9.623365571087561e-08
and O 0 4.378637896707005e-08
the O 0 9.566523573312224e-08
other O 0 1.4932556524627216e-08
child O 0 1.7486894421381294e-07
to O 0 5.8025896976232616e-08
be O 0 3.014027072367753e-07
Hp1 O 0 1.907408659462817e-05
and O 0 7.606386702718737e-07
Hp1 O 0 0.0014664652990177274
/ O 0 5.532882278203033e-05
Hpdel O 0 4.279168206267059e-05
, O 0 1.3628681472255266e-07
showing O 0 6.250123192330648e-07
an O 0 2.0148415558196575e-07
anomalous O 0 1.1165806427015923e-05
inheritance O 0 2.7608145956037333e-06
of O 0 2.6589706976665184e-05
Hp O 0 7.325574551941827e-05
phenotypes O 0 9.100847933041223e-07
in O 0 2.2595689586069057e-07
the O 0 5.194319783186074e-07
child O 0 1.7021268376993248e-06
with O 0 1.0869343896047212e-06
Hp1 O 0 0.02485191822052002
. O 0 1.0887201824516524e-05

The O 0 0.00014778970216866583
Hp2 O 0 0.0031923784408718348
/ O 0 0.00022383297618944198
Hpdel O 0 0.00018230591376777738
individuals O 0 2.7669642577166087e-07
had O 0 1.9184703887731303e-06
an O 0 5.906030651203764e-07
extremely O 0 2.0682728063547984e-06
low O 0 2.871252490876941e-06
level O 0 1.3238923202152364e-06
of O 0 2.8864844807685586e-06
Hp O 0 9.456669431529008e-06
( O 0 6.974644151114262e-08
mean O 0 2.218685750676741e-07
+ O 0 2.508699594727659e-07
/ O 0 3.0228414971134043e-07
- O 0 2.0240435105733923e-07
SD O 0 1.5564755813102238e-06
= O 0 1.6078050180112768e-07
0 O 0 1.042972002096576e-07
. O 0 1.6954304626892736e-08
049 O 0 6.792678277633968e-07
+ O 0 1.465314198867418e-07
/ O 0 1.584881061944543e-07
- O 0 6.336994573530319e-08
0 O 0 3.3843107871689426e-08
. O 0 9.717688875809927e-09
043 O 0 8.987489081846434e-07
mg O 0 9.769139523996273e-07
/ O 0 3.0495291980514594e-07
ml O 0 1.826235518365138e-07
; O 0 9.744230311525826e-09
n O 0 1.1359986018533164e-07
= O 0 1.589220488540377e-07
6 O 0 2.6164553901253385e-07
) O 0 1.5408916809178663e-08
, O 0 1.0826958884990745e-08
compared O 0 3.29845590840705e-08
with O 0 6.42018349594764e-09
the O 0 6.768274829482834e-08
level O 0 2.53038024311536e-07
( O 0 2.0287115987116522e-08
1 O 0 7.740825935798057e-08
. O 0 1.1110148356863192e-08
64 O 0 8.27364274869069e-08
+ O 0 1.0393517158036047e-07
/ O 0 1.337800910050646e-07
- O 0 6.915868056012187e-08
1 O 0 9.067358774927925e-08
. O 0 1.3165749379595582e-08
07 O 0 1.1562578947632574e-06
mg O 0 1.2691136817011284e-06
/ O 0 3.7009439779467357e-07
ml O 0 3.015053380295285e-07
) O 0 7.557152237325226e-09
obtained O 0 5.730876040388466e-08
from O 0 8.488850511412238e-08
52 O 0 1.6053688796091592e-06
healthy O 0 2.654219315445516e-07
volunteers O 0 1.8954003166982147e-07
having O 0 3.243768560423632e-07
phenotype O 0 1.930057123900042e-06
Hp2 O 0 6.0171996665303595e-06
, O 0 4.88558100641967e-08
whereas O 0 4.9156223980162395e-08
the O 0 9.500733710865461e-08
serum O 0 2.3525535652879626e-06
Hp O 0 4.632462605513865e-06
level O 0 4.080787050497747e-07
of O 0 2.6887556714427774e-07
an O 0 5.6263161241076887e-08
individual O 0 1.100847679680328e-08
with O 0 1.4410071003112535e-07
Hp1 O 0 0.0012488443171605468
/ O 0 7.205040310509503e-05
Hpdel O 0 0.00010830041719600558
was O 0 3.263901817263104e-05
0 O 0 2.5891984023473924e-06
. O 0 1.2901952004540362e-06

50 O 0 0.00010921658395091072
mg O 0 0.00016192562179639935
/ O 0 2.147245322703384e-05
ml O 0 5.6265371313202195e-06
, O 0 1.2353170575352124e-07
which O 0 5.4910263003193904e-08
was O 0 7.169355171754432e-07
approximately O 0 5.81146188949333e-08
half O 0 4.904244121917145e-08
the O 0 1.5134050102005858e-07
level O 0 4.974182843398012e-07
of O 0 1.3548624338000081e-06
Hp O 0 6.900437711010454e-06
in O 0 2.7395651613915106e-07
control O 0 2.1363393898354843e-06
sera O 0 2.972871152451262e-05
from O 0 4.7493870170001173e-07
the O 0 4.160654611951031e-07
Hp1 O 0 4.655714292312041e-06
phenotype O 0 6.66050880226976e-07
( O 0 4.669310982308161e-08
1 O 0 1.0455832466504944e-07
. O 0 1.0129189043084352e-08
26 O 0 2.953212288048235e-07
+ O 0 1.0518198934050815e-07
/ O 0 1.53835230776167e-07
- O 0 5.052004325989401e-08
0 O 0 3.4542871674148046e-08
. O 0 4.858573543486955e-09
33 O 0 1.0073704004298634e-07
mg O 0 5.475985744851641e-07
/ O 0 1.9444422605374712e-07
ml O 0 1.8534014145643596e-07
; O 0 9.02076191522383e-09
n O 0 1.215491494122034e-07
= O 0 2.1648297376941628e-07
9 O 0 2.9886044217164454e-07
) O 0 1.3901162887464125e-08
, O 0 1.513092584559672e-08
showing O 0 1.3952568167496793e-07
a O 0 4.1506993397888436e-07
gene O 0 9.42549206683907e-07
- O 0 5.765703463112004e-06
dosage O 0 1.1731952326954342e-05
effect O 0 4.160966454946902e-06
. O 0 2.1106145595695125e-06

The O 0 5.4544940212508664e-05
other O 0 1.041049586092413e-06
allele O 0 3.5997823033540044e-06
( O 0 7.047779035929125e-07
Hp2 O 0 1.6445552319055423e-05
) O 0 9.209375662067032e-08
of O 0 2.5356970922985056e-07
individuals O 0 1.5618173421216852e-08
with O 0 1.28787874587033e-07
Hp2 O 0 0.012386076152324677
/ O 0 0.00014951058255974203
Hpdel O 0 0.00013232066703494638
was O 0 7.373857897619018e-06
found O 0 5.722607454572426e-08
to O 0 2.0016720725379855e-08
have O 0 1.5108287954035404e-08
, O 0 2.1125179827663487e-08
in O 0 1.954986217356236e-08
all O 0 8.102477799809549e-09
exons O 0 2.580848388333834e-07
, O 0 2.0716068860338055e-08
no O 0 2.4230997652807673e-08
mutation O 0 5.560385574199245e-08
, O 0 3.7338782732376785e-08
by O 0 3.4795604619830556e-08
DNA O 0 4.759026523970533e-07
sequencing O 0 8.578125743952114e-06
. O 0 4.579645974445157e-06

On O 0 4.209029793855734e-05
the O 0 9.605483910490875e-07
basis O 0 4.229521266552183e-07
of O 0 5.476131832438114e-07
the O 0 2.100282898709338e-07
present O 0 1.2895281997771235e-07
study O 0 1.3118066988226929e-07
, O 0 6.150442999341976e-08
the O 0 1.3010011912228947e-07
mechanism O 0 6.46671537651855e-07
of O 0 5.370500844037451e-07
anhaptoglobinemia B-Disease 0 9.911652341543231e-06
and O 0 1.2819992889490095e-07
the O 0 3.913940531674598e-07
mechanism O 0 1.1395155752325081e-06
of O 0 8.263673976216523e-07
anomalous O 0 4.782974792760797e-05
inheritance O 0 2.4095811568258796e-06
of O 0 2.4746965209487826e-05
Hp O 0 4.1492661694064736e-05
phenotypes O 0 1.180901790576172e-06
were O 0 5.863518026671954e-07
well O 0 4.059090201735671e-07
explained O 0 2.7642131499305833e-06
. O 0 3.2355301300412975e-06

However O 0 1.6513933587702923e-05
, O 0 1.5380325066871592e-06
the O 0 9.196033374792023e-07
mechanism O 0 4.455310772755183e-06
of O 0 6.399441190296784e-06
hypohaptoglobinemia B-Disease 0 0.0026192697696387768
remains O 0 0.00010576791100902483
unknown O 0 0.00011701425682986155

ATM O 0 0.0018149249954149127
mutations O 0 1.9958633856731467e-05
and O 0 4.269425062375376e-06
phenotypes O 0 4.0891416574595496e-05
in O 0 2.0903366021229886e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
families O 0 2.1457256025314564e-06
in O 0 1.6061866290328908e-06
the O 0 1.390366378473118e-06
British O 0 5.7851675592246465e-06
Isles O 0 3.4250906537636183e-06
: O 0 2.6700606170493302e-08
expression O 0 2.7117977197121945e-08
of O 0 3.835936013274477e-08
mutant O 0 4.19249460037463e-07
ATM O 0 1.1102798453066498e-05
and O 0 5.2828447394404066e-08
the O 0 2.3729067777367163e-07
risk O 0 3.852977670248947e-07
of O 0 5.096766017231857e-06
leukemia B-Disease 1 1.0
, O 0 0.19838285446166992
lymphoma B-Disease 1 1.0
, O 0 0.00021065035252831876
and O 0 4.652069037547335e-05
breast B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.2393247238360345e-05

We O 0 1.6659012544550933e-05
report O 0 8.768903171585407e-06
the O 0 7.910272756816994e-07
spectrum O 0 3.966301846958231e-07
of O 0 3.574037350517756e-07
59 O 0 3.2216162253462244e-06
ATM O 0 1.5461606380995363e-05
mutations O 0 4.3145334416294645e-07
observed O 0 1.3947181969342637e-06
in O 0 1.4281048379416461e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9998462200164795
telangiectasia I-Disease 1 1.0
( O 0 0.00015765753050800413
A B-Disease 1 1.0
- I-Disease 1 0.9999885559082031
T I-Disease 1 1.0
) O 0 1.307429045027675e-07
patients O 0 2.726110892581346e-08
in O 0 5.5496524709042205e-08
the O 0 6.89835815137485e-07
British O 0 1.0546295925450977e-05
Isles O 0 1.0647322596923914e-05
. O 0 3.5090840810880763e-06

Of O 0 4.508636993705295e-05
51 O 0 3.107191150775179e-05
ATM O 0 9.888663771562278e-05
mutations O 0 1.632030944165308e-06
identified O 0 6.421864213734807e-07
in O 0 2.0052588922681025e-07
families O 0 2.7054586126951108e-08
native O 0 5.201626152029348e-08
to O 0 4.118625085425265e-08
the O 0 4.3956669060207787e-07
British O 0 1.9651945422083372e-06
Isles O 0 1.3697183476324426e-06
, O 0 5.91446287501185e-08
11 O 0 3.074364656185935e-07
were O 0 2.3058584019963746e-07
founder O 0 1.8675455066841096e-06
mutations O 0 3.5415222754409115e-08
, O 0 5.0872010604052775e-08
and O 0 4.3622161882694854e-08
2 O 0 2.540550099183747e-07
of O 0 1.7904895344145189e-07
these O 0 2.6493426119600372e-08
11 O 0 7.882289878580195e-07
conferred O 0 3.8604403016506694e-06
a O 0 1.0876136684601079e-06
milder O 0 1.985251856240211e-06
clinical O 0 2.65483686234802e-06
phenotype O 0 6.465389787990716e-07
with O 0 1.7211149838658457e-08
respect O 0 7.824547765267198e-08
to O 0 1.7196292390053713e-07
both O 0 1.435965828022745e-06
cerebellar B-Disease 1 0.9999972581863403
degeneration I-Disease 1 1.0
and O 0 1.0008537174144294e-05
cellular O 0 0.0012689668219536543
features O 0 3.917285994248232e-06
. O 0 4.803603133041179e-06

We O 0 3.0045419407542795e-05
report O 0 1.077616798283998e-05
, O 0 5.979690627100354e-07
in O 0 2.3841170104788034e-07
two O 0 1.977677044351367e-07
A B-Disease 1 0.998625636100769
- I-Disease 1 0.7930864691734314
T I-Disease 1 0.9999909400939941
families O 0 1.0924603799367105e-07
, O 0 6.845028366342376e-08
an O 0 1.0324384902560269e-07
ATM O 0 5.327759481588146e-06
mutation O 0 2.013030382386205e-07
( O 0 1.1959946277784184e-07
7271T O 0 3.7484498989215354e-06
- O 0 7.591335702272772e-07
- O 0 1.2000795095445937e-06
> O 0 1.4185299050950562e-06
G O 0 3.376974518687348e-06
) O 0 3.688350602715218e-08
that O 0 1.0742067679814227e-08
may O 0 1.1227466956142962e-07
be O 0 1.8075839491871193e-08
associated O 0 2.462685522175434e-08
with O 0 3.6666185643241533e-09
an O 0 1.5305898770634485e-08
increased O 0 5.050000595474557e-07
risk O 0 2.496529987183749e-07
of O 0 2.3284010239876807e-06
breast B-Disease 1 0.9375907182693481
cancer I-Disease 0 0.01075458899140358
in O 0 3.2030590091380873e-07
both O 0 8.359203462759979e-08
homozygotes O 0 1.7115645505327848e-06
and O 0 1.9072263057751115e-07
heterozygotes O 0 8.902516697162355e-07
( O 0 5.8291458771009275e-08
relative O 0 4.1522312699271424e-07
risk O 0 1.486249203708212e-07
12 O 0 2.40386782479618e-07
. O 0 1.1257096588224158e-08
7 O 0 2.7476920649860404e-07
; O 0 6.173549138566159e-08
P O 0 9.707968274597079e-06
= O 0 5.707743753191608e-07
. O 0 4.770040362700456e-08
0025 O 0 2.1942232706351206e-06
) O 0 9.564786296323291e-09
, O 0 3.1111657694538053e-09
although O 0 1.8785639710472424e-09
there O 0 6.652977724286302e-09
is O 0 1.4812506776706869e-08
a O 0 1.5879054160450323e-07
less O 0 2.1400066430032894e-07
severe O 1 0.9346228241920471
A B-Disease 1 1.0
- I-Disease 1 0.9999979734420776
T I-Disease 1 0.9999996423721313
phenotype O 0 3.969261115344125e-07
in O 0 6.6866134851295556e-09
terms O 0 5.431514349396593e-09
of O 0 2.1149169526779588e-08
the O 0 3.3305330049415716e-08
degree O 0 5.124156359670451e-06
of O 0 4.184911449556239e-05
cerebellar B-Disease 1 0.9999988079071045
degeneration I-Disease 1 1.0
. O 0 3.153701618430205e-05

This O 0 1.5546656868536957e-05
mutation O 0 6.62277943774825e-06
( O 0 1.9775254713749746e-06
7271T O 0 2.6413250452606007e-05
- O 0 4.364831511338707e-06
- O 0 4.28942348662531e-06
> O 0 3.1736060464027105e-06
G O 0 3.4665813473111484e-06
) O 0 4.6024645428133226e-08
also O 0 4.410791731856989e-08
allows O 0 8.261339168313953e-09
expression O 0 7.036040727825821e-08
of O 0 2.207634537398917e-07
full O 0 1.6423345527982747e-07
- O 0 2.0883074114408373e-07
length O 0 8.728247280487267e-08
ATM O 0 3.6576630009221844e-06
protein O 0 2.674408960956498e-07
at O 0 2.8294977028053836e-07
a O 0 3.1915995180042955e-08
level O 0 1.1713215997133375e-07
comparable O 0 3.115722080337946e-08
with O 0 4.6108974416370074e-09
that O 0 1.649393865932325e-08
in O 0 2.409118735613447e-07
unaffected O 0 7.6227433964959346e-06
individuals O 0 2.0805289580039243e-07
. O 0 1.9153242192260223e-06

In O 0 1.0170919267693534e-05
addition O 0 8.043075467867311e-07
, O 0 2.300975268099137e-07
we O 0 2.064215465225061e-08
have O 0 1.1631593466177037e-08
studied O 0 3.3781589081627317e-07
18 O 0 3.2746470424172003e-06
A B-Disease 1 0.999977707862854
- I-Disease 1 0.9999724626541138
T I-Disease 1 1.0
patients O 0 3.592661528273311e-07
, O 0 3.550483640424318e-08
in O 0 3.631998879427556e-08
15 O 0 1.9787580640695523e-07
families O 0 1.5753013116182046e-08
, O 0 3.352905153519714e-08
who O 0 8.29919954981051e-08
developed O 0 1.7233048765774583e-06
leukemia B-Disease 1 1.0
, O 0 0.0005393837345764041
lymphoma B-Disease 1 1.0
, O 0 0.00021452968940138817
preleukemic O 1 0.9999450445175171
T O 1 0.9955571293830872
- O 0 2.1589119569398463e-05
cell O 0 0.00018568479572422802
proliferation O 0 0.012407281436026096
, O 0 6.085453492232773e-07
or O 0 3.1648738513467833e-05
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 7.51393599784933e-07
mostly O 0 9.149828628096657e-08
in O 0 1.9335729462000018e-07
childhood O 0 1.3481379937729798e-05
. O 0 3.251165708206827e-06

A O 0 0.0001427987590432167
wide O 0 7.875822120695375e-06
variety O 0 5.982349193800474e-07
of O 0 2.7627372674032813e-06
ATM O 0 5.608501669485122e-05
mutation O 0 2.5588892071937153e-07
types O 0 7.471235363709638e-08
, O 0 4.654461704944879e-08
including O 0 3.50548674532547e-08
missense O 0 1.2028913261019625e-06
mutations O 0 2.457093728480686e-07
and O 0 4.440043994691223e-07
in O 0 2.039267656073207e-06
- O 0 5.9766457525256556e-06
frame O 0 6.955128810659517e-06
deletions O 0 6.489908059847949e-07
, O 0 5.51612551191738e-08
were O 0 9.394274513851997e-08
seen O 0 1.3178443225569936e-07
in O 0 5.2575835240986635e-08
these O 0 6.562815713095915e-08
patients O 0 1.4260511989050428e-06
. O 0 2.108454054905451e-06

We O 0 1.0131158887816127e-05
also O 0 1.3058643162366934e-06
show O 0 2.889586312448955e-07
that O 0 3.452212382626385e-08
25 O 0 1.9218933289266715e-07
% O 0 4.146702181628825e-08
of O 0 2.429551670957153e-07
all O 0 1.825880389105805e-07
A B-Disease 1 0.9999592304229736
- I-Disease 1 0.9938327074050903
T I-Disease 1 0.9999994039535522
patients O 0 3.3180361924678436e-07
carried O 0 7.926395255708485e-07
in O 0 6.798641152272467e-07
- O 0 1.8304253899259493e-06
frame O 0 2.1363332507462474e-06
deletions O 0 4.3560928020269785e-07
or O 0 5.437498273863639e-08
missense O 0 5.295737537380774e-07
mutations O 0 5.9430728782672304e-08
, O 0 2.42546729367632e-08
many O 0 1.474085520314361e-09
of O 0 2.9520057509557773e-08
which O 0 3.022898198423718e-08
were O 0 1.3993198422213027e-07
also O 0 6.857533918491754e-08
associated O 0 3.072505805334913e-08
with O 0 1.6369453348374918e-08
expression O 0 4.13982775171462e-07
of O 0 1.355163476546295e-06
mutant O 0 9.726722964842338e-06
ATM O 0 0.0003592025605030358
protein O 0 2.682166450540535e-05
. O 0 6.05270406595082e-06

The O 0 6.0112273786216974e-05
DMPK O 0 0.005118340719491243
gene O 0 1.9731076463358477e-05
of O 0 3.260032463003881e-05
severely O 1 0.9999988079071045
affected O 1 0.999970555305481
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 9.115574357565492e-05
is O 0 1.7004330175041105e-06
hypermethylated O 0 5.269572284305468e-05
proximal O 0 3.8553745980607346e-05
to O 0 4.5315942998058745e-08
the O 0 1.1977111569194676e-07
largely O 0 2.2383657949376357e-07
expanded O 0 2.3926979793031933e-06
CTG O 0 6.701289385091513e-05
repeat O 0 5.030359716329258e-06
. O 0 2.98837016998732e-06

Using O 0 2.1067469788249582e-05
methylation O 0 7.780511805322021e-05
- O 0 3.231176742701791e-05
sensitive O 0 1.0364025001763366e-05
restriction O 0 2.619032102302299e-06
enzymes O 0 2.988005860515841e-07
, O 0 9.793686217562936e-08
we O 0 3.1977901215896054e-08
characterized O 0 2.073408182923231e-07
the O 0 1.6139222225319827e-07
methylation O 0 6.478641125795548e-07
pattern O 0 8.520739811501699e-07
on O 0 8.20747800389654e-07
the O 0 3.0703679954058316e-07
5 O 0 5.308394293024321e-07
side O 0 2.781820569452975e-07
of O 0 9.744965154823149e-07
the O 0 1.0041100040325546e-06
CTG O 0 2.6178478947258554e-05
repeat O 0 1.9210685309190012e-07
in O 0 5.772200495357538e-08
the O 0 8.915807114817653e-08
DMPK O 0 3.4128404422517633e-06
gene O 0 2.6573793832085357e-08
of O 0 1.1983841829987796e-07
normal O 0 2.3442262886419485e-07
individuals O 0 6.551581943625706e-09
and O 0 4.424112987067019e-08
of O 0 2.923022520917584e-06
patients O 0 9.74074919213308e-06
affected O 0 1.2067764146195259e-05
with O 0 0.000231400306802243
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 2.715413813803025e-07
showing O 0 4.085662510533439e-07
expansions O 0 5.569719974118925e-07
of O 0 4.0126232647708093e-07
the O 0 9.017640536512772e-07
repetitive O 0 6.316092367342208e-06
sequence O 0 2.324130491615506e-06
. O 0 2.907187536038691e-06

The O 0 1.4923843082215171e-05
gene O 0 2.748960241660825e-06
segment O 0 2.6260199774696957e-06
analyzed O 0 4.4812776422986644e-07
corresponds O 0 9.942040151145193e-07
to O 0 2.363518234460571e-07
the O 0 1.3633481330543873e-06
genomic O 0 1.631192753848154e-05
SacI O 0 0.00037026795325800776
- O 0 7.323106729018036e-06
HindIII O 0 1.249412616743939e-05
fragment O 0 1.6908903717194335e-06
carrying O 0 6.956880156394618e-07
exons O 0 1.7926267901202664e-06
11 O 0 3.635600705820252e-06
- O 0 6.163735179143259e-06
15 O 0 7.033899237285368e-06
. O 0 4.045756213599816e-06

There O 0 2.476495319569949e-05
is O 0 3.612934051488992e-06
constitutive O 0 1.538356809760444e-05
methylation O 0 4.566492407320766e-06
in O 0 5.946718033555953e-07
intron O 0 1.68169444805244e-05
12 O 0 2.869303671104717e-06
at O 0 1.8469819451638614e-06
restriction O 0 3.8223632259359874e-07
sites O 0 8.016061769922089e-08
of O 0 5.781653840131185e-07
SacII O 0 9.207369657815434e-06
and O 0 4.0340910345548764e-07
HhaI O 0 1.3925829080108088e-05
, O 0 1.708585273263452e-07
localized O 0 6.553003117915068e-07
1 O 0 3.3391589226994256e-07
, O 0 5.25130978701327e-08
159 O 0 4.1340047118865186e-07
- O 0 2.1458268406604475e-07
1 O 0 3.117731921520317e-07
, O 0 8.489449498938484e-08
232 O 0 6.246315820135351e-07
bp O 0 1.0909710681517026e-06
upstream O 0 8.911724762583617e-07
of O 0 5.699285452465119e-07
the O 0 9.496718007540039e-07
CTG O 0 1.556976894789841e-05
repeat O 0 4.554973997983325e-07
, O 0 6.867232826834879e-08
whereas O 0 4.7510361866898165e-08
most O 0 1.1973064317771787e-08
, O 0 1.6067298602706614e-08
if O 0 4.923577101578758e-09
not O 0 5.715492523705734e-09
all O 0 9.276115875422875e-09
, O 0 2.425383982540552e-08
of O 0 1.2584172282004147e-07
the O 0 1.2004269933640899e-07
other O 0 1.0940614636467672e-08
sites O 0 4.5595808018106254e-08
of O 0 6.096379365772009e-07
SacII O 0 2.6246174456900917e-05
, O 0 4.368602617432771e-07
HhaI O 0 1.4226053281163331e-05
, O 0 1.9131741169076122e-07
and O 0 2.039891029426144e-07
HpaII O 0 8.125934073177632e-06
in O 0 1.6457258311675105e-07
this O 0 2.693898437655662e-08
region O 0 5.9545556041484815e-08
are O 0 1.4114580615398609e-08
unmethylated O 0 4.2557482515803713e-07
, O 0 1.905754842823626e-08
in O 0 2.2270077337793737e-08
normal O 0 1.1813507683200442e-07
individuals O 0 4.479241866306438e-09
and O 0 1.729315002307885e-08
most O 0 2.013938171785412e-08
of O 0 5.205601496527379e-07
the O 0 3.094218072874355e-06
patients O 0 2.3352970401901985e-06
. O 0 3.2378607102145907e-06

In O 0 7.932384505693335e-06
a O 0 1.6602126606812817e-06
number O 0 3.539219903814228e-07
of O 0 1.5750390502944356e-06
young O 0 1.4504310001939302e-06
and O 0 6.051567993381468e-07
severely O 0 0.2744407057762146
affected O 0 1.0200710676144809e-06
patients O 0 1.544348151583108e-07
, O 0 4.603255021606856e-08
however O 0 3.26262785677045e-08
, O 0 1.4142822912788233e-08
complete O 0 7.542856650388785e-08
methylation O 0 3.5388353580856347e-07
of O 0 1.2229784829287382e-07
these O 0 8.933541018052438e-09
restriction O 0 1.9771188419781538e-07
sites O 0 3.783790347711147e-08
was O 0 5.544636678678216e-07
found O 0 4.383401019936173e-08
in O 0 7.933831369655309e-08
the O 0 5.574253236773075e-07
mutated O 0 4.438779342308408e-06
allele O 0 1.2368650459393393e-05
. O 0 4.91520995637984e-06

In O 0 4.977774551662151e-06
most O 0 1.610450652833606e-07
of O 0 1.6752665032981895e-07
these O 0 2.9409459756379874e-08
patients O 0 1.0620285451068412e-07
, O 0 3.7775027550424056e-08
the O 0 1.7841728094936116e-07
onset O 0 0.016596680507063866
of O 0 5.47950412510545e-06
the O 0 0.0004325143527239561
disease O 1 0.9999994039535522
was O 1 0.9999992847442627
congenital O 1 1.0
. O 0 5.6596290960442275e-05

Preliminary O 0 6.849651254015043e-05
in O 0 1.7207188648171723e-05
vivo O 0 0.00032568411552347243
footprinting O 0 0.0002112865768140182
data O 0 1.564547574162134e-06
gave O 0 3.014369269749295e-07
evidence O 0 2.0438459102933848e-07
for O 0 1.4307956064385507e-07
protein O 0 1.3197185353419627e-06
- O 0 2.566524472058518e-06
DNA O 0 6.201223641255638e-07
contact O 0 3.098819831848232e-07
in O 0 3.715244929480832e-07
normal O 0 1.3942845953351934e-06
genes O 0 2.771361096165492e-07
at O 0 3.476646497801994e-06
an O 0 2.811041497352562e-07
Sp1 O 0 3.076950861213845e-06
consensus O 0 1.5103181283393496e-07
binding O 0 1.7500376259249606e-07
site O 0 3.2429210250484175e-07
upstream O 0 7.750087434033048e-07
of O 0 2.493508191037108e-07
the O 0 6.652294359810185e-07
CTG O 0 1.1976833775406703e-05
repeat O 0 2.806013981171418e-07
and O 0 4.2366909980273704e-08
for O 0 2.2005586686191236e-08
a O 0 3.159642858463485e-08
significant O 0 2.0999641137109393e-08
reduction O 0 2.7051626716456667e-07
of O 0 1.0499858404955376e-07
this O 0 1.4849395491012274e-08
interaction O 0 2.6413351505993887e-08
in O 0 6.753136716497465e-08
cells O 0 8.018508879104047e-08
with O 0 3.5850458601771606e-08
a O 0 1.6706268297639326e-06
hypermethylated O 0 0.00014610798098146915
DMPK O 0 0.0010328576900064945
gene O 0 1.7036436474882066e-06
. O 0 2.519375925658096e-07
. O 0 1.0464086699357722e-06

The O 0 0.0004927790141664445
hemochromatosis B-Disease 1 1.0
gene O 0 3.561906851246022e-05
product O 0 3.5191208098694915e-06
complexes O 0 2.1842477053723997e-06
with O 0 7.342858765468918e-08
the O 0 6.575251063623e-07
transferrin O 0 1.2754918316204567e-05
receptor O 0 3.4327229059272213e-06
and O 0 1.673197260743109e-07
lowers O 0 3.9694650695309974e-06
its O 0 1.3151260702670697e-07
affinity O 0 5.49219919321331e-07
for O 0 2.8384948791426723e-07
ligand O 0 2.4878956537577324e-05
binding O 0 9.357484486827161e-06
. O 0 5.397742825152818e-06

We O 0 7.4818967732426245e-06
recently O 0 4.333057859184919e-06
reported O 0 1.047339083015686e-06
the O 0 1.5881690273999993e-07
positional O 0 2.2174426703713834e-06
cloning O 0 5.442187216431194e-07
of O 0 1.8749589969502267e-07
a O 0 5.56179543309554e-07
candidate O 0 1.169735810435668e-06
gene O 0 4.669049303629436e-06
for O 0 2.415611015749164e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999806880950928
HFE O 1 0.9999964237213135
. O 0 2.4132028556778096e-05

The O 0 2.25440689973766e-05
gene O 0 3.556676574589801e-06
product O 0 1.3364407323024352e-06
, O 0 2.180496210257843e-07
a O 0 6.075948704165057e-07
member O 0 4.5092247091815807e-07
of O 0 5.313615929480875e-07
the O 0 1.1073865380240022e-06
major O 0 1.4986710084485821e-05
histocompatibility O 0 0.0013068919070065022
complex O 0 4.289856951800175e-05
class O 0 2.2943563635635655e-06
I O 0 5.491672709467821e-06
- O 0 1.0027387133959564e-06
like O 0 6.157861065503312e-08
family O 0 5.957145532420327e-08
, O 0 3.928610681214195e-08
was O 0 6.363951570165227e-07
found O 0 3.696682071563373e-08
to O 0 2.5300561645735797e-08
have O 0 4.017742227802046e-08
a O 0 4.6461198621727817e-07
mutation O 0 6.775248948542867e-07
, O 0 6.353017738547351e-07
Cys O 0 5.7267599913757294e-05
- O 0 2.8465235573094105e-06
282 O 0 1.3182255315768998e-05
- O 0 5.411422080214834e-06
- O 0 4.02501291318913e-06
> O 0 2.925672106357524e-06
Tyr O 0 4.596464805217693e-06
( O 0 1.0233961944550174e-07
C282Y O 0 1.5335053831222467e-06
) O 0 1.1867456350955763e-08
, O 0 5.596601404533885e-09
in O 0 8.811039897693718e-09
85 O 0 8.765635328700228e-08
% O 0 2.369633911314395e-08
of O 0 3.9048475741765287e-07
patient O 0 7.610939519508975e-06
chromosomes O 0 4.037412873003632e-05
. O 0 1.2099108971597161e-05

This O 0 3.0587789296987467e-06
mutation O 0 3.0508458621625323e-06
eliminates O 0 3.017264816662646e-06
the O 0 5.32430931343697e-07
ability O 0 2.1234218650079129e-07
of O 0 2.3161605895438697e-06
HFE O 0 0.00029117095982655883
to O 0 5.615074769593775e-07
associate O 0 7.978300345712341e-06
with O 0 6.584996299352497e-07
beta2 O 0 0.00037923234049230814
- O 0 5.554425297304988e-05
microglobulin O 0 0.00028850245871581137
( O 0 5.675696002072073e-07
beta2m O 0 9.330004104413092e-06
) O 0 9.08210537886589e-08
and O 0 8.92334384161586e-08
prevents O 0 8.85027020558482e-07
cell O 0 0.00013917652540840209
- O 0 1.1218320651096292e-05
surface O 0 1.2425732165866066e-05
expression O 0 1.2583630450535566e-05
. O 0 2.2502756564790616e-06

A O 0 0.00010858479799935594
second O 0 8.254526619566604e-06
mutation O 0 4.886368287770892e-07
that O 0 7.862681172809971e-08
has O 0 1.104273863461458e-07
no O 0 9.800151445915617e-08
effect O 0 7.823844043741701e-07
on O 0 4.069790975336218e-06
beta2m O 0 2.973622758872807e-05
association O 0 5.502175213223381e-07
, O 0 8.956303787499564e-08
H63D O 0 7.269375601026695e-06
, O 0 7.27649478449166e-08
was O 0 1.0945852864097105e-06
found O 0 2.8773046167884786e-08
in O 0 2.641425922433882e-08
eight O 0 5.147451886955423e-08
out O 0 2.927201414593128e-08
of O 0 3.159998982482648e-07
nine O 0 6.171784434627625e-07
patients O 0 1.5584376455990423e-07
heterozygous O 0 3.376477479832829e-07
for O 0 1.7897298221214442e-07
the O 0 2.380078285568743e-06
C282Y O 0 0.00014299905160441995
mutant O 0 2.6551975679467432e-05
. O 0 7.495616046071518e-06

In O 0 2.9476954296114855e-05
this O 0 1.3591421748060384e-06
report O 0 1.243731730937725e-06
, O 0 8.558057373875272e-08
we O 0 2.1598159705149556e-08
demonstrate O 0 1.6236667477187439e-07
in O 0 3.8117372014312423e-07
cultured O 0 9.780553227756172e-06
293 O 0 1.6204077837755904e-05
cells O 0 3.1612364637112478e-06
overexpressing O 0 1.738766695780214e-05
wild O 0 1.4689243243992678e-06
- O 0 2.2249691937759053e-06
type O 0 4.73544787382707e-07
or O 0 2.1430619767670578e-07
mutant O 0 1.6113107221826795e-06
HFE O 0 2.401778328930959e-05
proteins O 0 7.046973138358226e-08
that O 0 1.8496381315458166e-08
both O 0 3.3184726078161475e-08
the O 0 2.0966226088603435e-07
wild O 0 5.105626996737556e-07
- O 0 1.5911357422737638e-06
type O 0 2.0520403722912306e-06
and O 0 2.4644582481414545e-06
H63D O 1 0.9859078526496887
HFE O 0 0.0036198757588863373
proteins O 0 4.890307536697946e-07
form O 0 1.9191972455701034e-07
stable O 0 1.9014396457350813e-06
complexes O 0 6.075114242776181e-07
with O 0 2.317754344005607e-08
the O 0 3.498827823023021e-07
transferrin O 0 8.904027708922513e-06
receptor O 0 5.434591002995148e-06
( O 0 7.492268991882156e-07
TfR O 0 0.0015890335198491812
) O 0 1.0332378224120475e-06
. O 0 2.0288316591177136e-06

The O 0 3.929687591153197e-05
C282Y O 0 0.00014756988093722612
mutation O 0 3.7674403756682295e-06
nearly O 0 1.4294060974862077e-06
completely O 0 9.069785846804734e-07
prevents O 0 2.4217212057919824e-07
the O 0 3.9114294736464217e-07
association O 0 1.4976788520471018e-07
of O 0 1.1104983599352636e-07
the O 0 2.131494909463072e-07
mutant O 0 3.242121692892397e-06
HFE O 0 0.0002094373048748821
protein O 0 1.0845238875845098e-06
with O 0 2.1999716182108386e-07
the O 0 1.0269808626617305e-05
TfR O 1 0.9980220794677734
. O 0 7.1824388214736246e-06

Studies O 0 0.00011505663132993504
on O 0 3.852250301861204e-05
cell O 0 0.000125317441415973
- O 0 7.889984772191383e-06
associated O 0 1.0641956578183454e-06
transferrin O 0 8.537424946553074e-06
at O 0 1.9026005020350567e-06
37 O 0 6.999578090471914e-07
degrees O 0 3.6139297208137577e-06
C O 0 8.727647582418285e-06
suggest O 0 1.1413369804813556e-07
that O 0 4.536731168514052e-08
the O 0 5.984220479149371e-07
overexpressed O 0 1.3149159713066183e-05
wild O 0 8.017741492949426e-07
- O 0 3.2367124731536023e-06
type O 0 2.125041646650061e-06
HFE O 0 6.597660103579983e-05
protein O 0 4.779438995683449e-07
decreases O 0 4.5662997649742465e-07
the O 0 8.754039271252623e-08
affinity O 0 1.0742768807858738e-07
of O 0 4.78583388030529e-07
the O 0 1.4452613186222152e-06
TfR O 0 0.0023346429225057364
for O 0 1.3022266784901149e-06
transferrin O 0 0.00010992308671120554
. O 0 3.8079620026110206e-06

The O 0 0.00010844055213965476
overexpressed O 0 0.0006514128181152046
H63D O 0 0.0010632514022290707
protein O 0 7.559370715171099e-06
does O 0 6.315926270872296e-08
not O 0 1.2757980449862316e-08
have O 0 7.302101590056509e-09
this O 0 7.226051312869686e-09
effect O 0 7.408061719615944e-08
, O 0 1.3059033854290192e-08
providing O 0 1.3833240330995977e-08
the O 0 1.9783856330946037e-08
first O 0 3.572949580643581e-08
direct O 0 3.112390345449967e-08
evidence O 0 4.376283513352064e-08
for O 0 2.5431093675365446e-08
a O 0 2.4939123477452085e-07
functional O 0 8.750106417210191e-07
consequence O 0 2.6036243525595637e-06
of O 0 1.5014744576546946e-06
the O 0 3.799592832365306e-06
H63D O 0 0.0007355759735219181
mutation O 0 7.064103556331247e-06
. O 0 4.916194484394509e-06

Addition O 0 1.4847908460069448e-05
of O 0 1.652833270782139e-05
soluble O 0 3.9644633943680674e-05
wild O 0 9.34802937990753e-06
- O 0 4.144259219174273e-05
type O 0 6.740751268807799e-05
HFE O 1 0.998258650302887
/ O 0 0.00022072921274229884
beta2m O 0 3.452599048614502e-05
heterodimers O 0 3.964467396144755e-06
to O 0 1.639930502506104e-07
cultured O 0 3.254596776969265e-06
cells O 0 5.068407631370064e-07
also O 0 8.366923509584012e-08
decreased O 0 1.961670704986318e-06
the O 0 9.377053089565379e-08
apparent O 0 4.307852066176565e-07
affinity O 0 2.7837074867420597e-07
of O 0 1.101244606616092e-06
the O 0 1.0362376769990078e-06
TfR O 0 0.00011860596714541316
for O 0 9.046041782312386e-08
its O 0 1.1597715143807363e-07
ligand O 0 2.282636387462844e-06
under O 0 6.140620598671376e-07
steady O 0 8.263852578238584e-06
- O 0 2.2441220437485754e-07
state O 0 1.6467565089328673e-08
conditions O 0 1.304991172901282e-07
, O 0 3.536290904548878e-08
both O 0 1.02611457108992e-08
in O 0 5.618273135610252e-08
293 O 0 1.0229878171230666e-06
cells O 0 4.4138684529571037e-07
and O 0 1.737543442459355e-07
in O 0 1.5104102430996136e-06
HeLa O 0 0.00039667217060923576
cells O 0 1.262073237739969e-05
. O 0 3.400776904527447e-06

Furthermore O 0 3.114899664069526e-05
, O 0 1.2356887282294338e-06
at O 0 2.269300694024423e-06
4 O 0 1.0807697208292666e-06
degrees O 0 5.703484021069016e-06
C O 0 9.25642507354496e-06
, O 0 1.3388500974542694e-07
the O 0 4.789399667970429e-07
added O 0 1.0999430060110171e-06
soluble O 0 1.1484727338029188e-06
complex O 0 1.6073388451331994e-06
of O 0 5.3470057537197135e-06
HFE O 0 0.3357631266117096
/ O 0 3.502512845443562e-05
beta2m O 0 4.243124203640036e-05
inhibited O 0 3.4873189633799484e-06
binding O 0 3.6332883723844134e-07
of O 0 1.1207156376258354e-06
transferrin O 0 1.070692997018341e-05
to O 0 3.1171433079180133e-07
HeLa O 0 6.900078733451664e-05
cell O 0 1.2598123248608317e-05
TfR O 0 0.00019412243273109198
in O 0 1.520917294328683e-07
a O 0 3.7298639199434547e-07
concentration O 0 1.525346397102112e-05
- O 0 4.483894826989854e-06
dependent O 0 1.069365907824249e-06
manner O 0 2.1721373286709422e-06
. O 0 2.121985744452104e-06

Scatchard O 0 0.0005789169226773083
plots O 0 2.2575262846658006e-05
of O 0 1.515153826403548e-06
these O 0 7.209327890222994e-08
data O 0 3.059693085560866e-07
indicate O 0 3.3130845622508787e-07
that O 0 7.190075024254838e-08
the O 0 3.6096443523092603e-07
added O 0 6.294879995039082e-07
heterodimer O 0 2.697487843761337e-06
substantially O 0 2.875124778256577e-07
reduced O 0 1.1971333435667475e-07
the O 0 4.2895269558584914e-08
affinity O 0 1.909257179022461e-07
of O 0 1.0153503353649285e-06
TfR O 0 0.0019045677036046982
for O 0 2.2369774796970887e-06
transferrin O 0 0.0002279509062645957
. O 0 6.90461138219689e-06

These O 0 2.0771003619302064e-06
results O 0 1.3773142200079747e-06
establish O 0 7.096676881701569e-07
a O 0 8.015279604478565e-07
molecular O 0 3.714908416441176e-06
link O 0 2.947836264866055e-06
between O 0 1.2212657338750432e-06
HFE O 0 0.0001983271213248372
and O 0 4.0201533124673006e-07
a O 0 8.962384754340746e-07
key O 0 1.3767036080025719e-06
protein O 0 2.5301798700638756e-07
involved O 0 1.703637195760166e-07
in O 0 5.282522010929824e-07
iron O 0 7.143911352613941e-05
transport O 0 1.863178113126196e-06
, O 0 9.788158195078722e-08
the O 0 2.3350425237822492e-07
TfR O 0 0.00015392419300042093
, O 0 3.6987628959650465e-08
and O 0 2.6025734456425198e-08
raise O 0 5.298475613813025e-08
the O 0 6.73753035584923e-08
possibility O 0 4.130315289785358e-08
that O 0 1.552571404772607e-08
alterations O 0 3.5684246313394397e-07
in O 0 5.75080463249833e-08
this O 0 1.8753285146999588e-08
regulatory O 0 2.0572451830958016e-07
mechanism O 0 4.460445097720367e-07
may O 0 7.009251135059458e-08
play O 0 2.3315170238902283e-08
a O 0 4.6761023497765564e-08
role O 0 1.46226682318229e-07
in O 0 1.6699308957868197e-07
the O 0 1.1217111932637636e-06
pathogenesis O 1 0.9995601773262024
of O 1 0.8435434699058533
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 4.675560921896249e-05
. O 0 1.1867286957567558e-05

Genomic O 0 0.00022622442338615656
organization O 0 1.4062113223189954e-05
of O 0 4.742760665976675e-06
the O 0 4.765448011312401e-06
UBE3A O 0 0.007143079768866301
/ O 0 6.593157741008326e-05
E6 O 0 0.0018643307266756892
- O 0 1.95632383110933e-05
AP O 0 8.138822522596456e-06
gene O 0 2.1307225495093007e-07
and O 0 2.2818650791123218e-07
related O 0 5.379356480261777e-06
pseudogenes O 0 7.988572178874165e-05
. O 0 5.700172550859861e-06

The O 0 0.00011538116814335808
UBE3A O 0 0.0009655994945205748
gene O 0 7.876692507124972e-06
encodes O 0 1.7296490113949403e-05
the O 0 5.065753157396102e-06
E6 O 0 0.00036473380168899894
- O 0 5.400809823186137e-05
AP O 0 6.920823216205463e-05
ubiquitin O 0 1.4376510989677627e-05
- O 0 1.8057459101328277e-06
protein O 0 4.8416842446386e-07
ligase O 0 4.261929973381484e-07
and O 0 3.5646515073040064e-08
has O 0 4.134413700285222e-08
recently O 0 7.176593186386526e-08
been O 0 2.55915217906022e-08
shown O 0 1.0854355636524815e-08
to O 0 7.267115798015311e-09
be O 0 3.0897716385425156e-08
mutated O 0 1.014150257105939e-06
in O 0 0.001042392454110086
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.5303650498390198
who O 0 6.3659031184215564e-06
lack O 0 0.00016558502102270722
15q11 O 1 0.8285319805145264
- O 0 0.00012770548346452415
q13 O 0 0.00013477372704073787
deletions O 0 8.271864317066502e-06
or O 0 8.664360962029605e-07
chromosome O 0 0.00014335100422613323
15 O 0 2.7872381906490773e-05
paternal O 1 0.9628056883811951
uniparental B-Disease 1 0.9999982118606567
disomy I-Disease 1 0.8989222049713135
. O 0 9.733375918585807e-06

Previous O 0 0.0001399263710482046
UBE3A O 0 0.0016129889991134405
cDNA O 0 4.3365660530980676e-05
analysis O 0 1.2291737903069588e-06
has O 0 2.026971941404554e-07
shown O 0 1.6606686870090925e-07
a O 0 4.0401280898549885e-07
coding O 0 3.80290686052831e-07
region O 0 9.94076287952339e-08
of O 0 3.730354762865318e-07
approximately O 0 1.1070148957514903e-06
2 O 0 4.4969733608013485e-06
. O 0 2.652589500939939e-06

6 O 0 0.0002528013428673148
kb O 0 0.00038177092210389674
and O 0 4.271575562597718e-06
a O 0 3.7898760183452396e-06
3 O 0 2.6508444079809124e-06
- O 0 1.9271899418527028e-06
untranslated O 0 2.1124162230989896e-05
region O 0 7.807223028066801e-07
( O 0 1.2311265606967936e-07
UTR O 0 7.254181127791526e-06
) O 0 3.800397152531332e-08
of O 0 4.607291259617341e-07
< O 0 1.9889719169441378e-06
50 O 0 6.14084342487331e-07
bp O 0 6.633782732023974e-07
, O 0 4.191550928567267e-08
whereas O 0 3.320384678318078e-08
Northern O 0 6.048255585255902e-08
analysis O 0 3.157016337240748e-08
has O 0 1.799060811435993e-08
indicated O 0 5.984408346648706e-08
mRNA O 0 1.3238427243322803e-07
sizes O 0 2.244517283145342e-08
of O 0 2.0922064436490473e-07
5 O 0 1.257130293197406e-06
- O 0 3.6666665437223855e-06
8 O 0 1.4716734767716844e-05
kb O 0 0.00010391898831585422
. O 0 3.6345122680359054e-06

We O 0 3.2456237022415735e-06
have O 0 2.600852440082235e-07
analyzed O 0 3.5648088214657037e-07
additional O 0 1.6827347337766696e-07
cDNA O 0 4.754635028803023e-06
clones O 0 7.781169415466138e-07
and O 0 3.513117263764798e-08
provide O 0 1.6422241344571376e-08
evidence O 0 7.944689173200459e-08
for O 0 4.589928437326307e-08
an O 0 1.4682363769225049e-07
additional O 0 4.488069293984154e-07
0 O 0 7.858984645281453e-06
. O 0 4.684619852923788e-06

5 O 0 0.00010549875878496096
kb O 0 0.00022697995882481337
of O 0 1.5971920220181346e-05
5 O 0 6.625337846344337e-06
- O 0 2.9392017495410983e-06
UTR O 0 3.881651718984358e-05
and O 0 3.494932627745584e-07
> O 0 7.860865025577368e-07
2 O 0 7.1259205469687e-07
kb O 0 6.1563446251966525e-06
of O 0 2.9710079161304748e-06
3 O 0 1.3974655303172767e-05
- O 0 6.966000364627689e-05
UTR O 0 0.0014754398725926876
. O 0 5.6422377383569255e-06

We O 0 3.936719167541014e-06
have O 0 2.212632068676612e-07
established O 0 4.5846394414184033e-07
the O 0 2.0584170101756172e-07
genomic O 0 1.1889295592482085e-06
organization O 0 3.0726059208063816e-07
of O 0 8.865940230862179e-07
UBE3A O 0 0.00013460383343044668
and O 0 2.3396232506911474e-07
the O 0 4.3697775709006237e-07
sequence O 0 4.53970443459184e-07
of O 0 3.0455785235972144e-06
intron O 0 0.00028025638312101364
- O 0 5.014128328184597e-05
exon O 0 1.3760126421402674e-05
borders O 0 2.5602980713301804e-06
. O 0 3.3471849292254774e-06

We O 0 1.5255296602845192e-05
have O 0 1.3219545280662715e-06
also O 0 4.623184679530823e-07
mapped O 0 1.3424239568848861e-06
two O 0 1.678370438185084e-07
highly O 0 6.330809583232622e-07
homologous O 0 8.175082371053577e-07
processed O 0 1.4091616549194441e-06
pseudogenes O 0 5.058202987129334e-06
, O 0 4.889664069196442e-07
UBE3AP1 O 0 2.0891049643978477e-05
and O 0 4.500164152432262e-07
UBE3AP2 O 0 1.7478172594564967e-05
, O 0 7.38413632461743e-08
to O 0 1.3622724281958654e-08
chromosomes O 0 1.0461018717933257e-07
2 O 0 2.849620557299204e-07
and O 0 5.622561616291932e-08
21 O 0 7.026504817986279e-07
, O 0 1.7721827560990278e-08
respectively O 0 8.648719074244582e-08
, O 0 5.8520468471101594e-09
and O 0 7.296310222670854e-09
determined O 0 2.6991241242058095e-08
their O 0 2.4656467090267142e-08
genomic O 0 3.251017005823087e-06
organization O 0 2.5887070478347596e-06
. O 0 2.56574844570423e-06

These O 0 1.9474928194540553e-06
results O 0 1.4164927506499225e-06
will O 0 2.8118638084606573e-08
form O 0 4.954400001366821e-09
the O 0 9.016943636197539e-09
basis O 0 1.2607229926686614e-08
for O 0 5.823042492636432e-09
studies O 0 3.478140442325639e-08
of O 0 1.1077313644136666e-07
mutation O 0 1.598001801994542e-07
and O 0 1.1330016036481538e-07
imprinting O 0 1.400269684381783e-05
of O 0 2.9441805963870138e-05
UBE3A O 1 0.825222373008728
. O 0 6.904005658725509e-06

Mutation O 0 0.00016090688586700708
spectrum O 0 5.276370939100161e-05
and O 0 2.596842250568443e-06
genotype O 0 2.2219297534320503e-05
- O 0 1.9838927983073518e-05
phenotype O 0 5.4516490308742505e-06
analyses O 0 4.727677662685892e-07
in O 0 6.972375672376074e-07
Cowden B-Disease 1 0.9998376369476318
disease I-Disease 0 0.3393496870994568
and O 0 4.669347617891617e-06
Bannayan B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 8.436735470240819e-07
two O 0 5.797090807391214e-07
hamartoma B-Disease 1 0.9998587369918823
syndromes I-Disease 1 0.9992859959602356
with O 0 3.6060700949747115e-06
germline O 1 0.9998599290847778
PTEN O 1 0.9999980926513672
mutation O 0 3.700078377733007e-05
. O 0 4.705332230514614e-06

The O 0 0.0005739203770644963
tumour B-Disease 1 1.0
suppressor O 1 0.9999912977218628
gene O 0 6.643952656304464e-05
PTEN O 0 0.028007332235574722
, O 0 2.1051216947398643e-07
which O 0 5.538031189189496e-08
maps O 0 6.824052434240002e-07
to O 0 4.7123913304858434e-07
10q23 O 0 0.0005184314795769751
. O 0 1.2060032531735487e-05

3 O 0 2.5536297471262515e-05
and O 0 1.1593496083150967e-06
encodes O 0 4.884918780589942e-06
a O 0 3.5358063996682176e-06
403 O 0 5.1601018640212715e-06
amino O 0 1.3166223880034522e-06
acid O 0 5.131845455252915e-07
dual O 0 2.3837515072955284e-06
specificity O 0 5.961696842859965e-06
phosphatase O 0 0.0003525498614180833
( O 0 1.011818426377431e-06
protein O 0 4.907668426312739e-06
tyrosine O 0 8.768292900640517e-06
phosphatase O 0 2.769198181340471e-05
; O 0 1.5454723722996278e-07
PTPase O 0 5.7549914345145226e-06
) O 0 4.669845310445453e-08
, O 0 2.147419131404149e-08
was O 0 1.3770724649475596e-07
shown O 0 2.415509214870326e-08
recently O 0 6.904242866312416e-08
to O 0 5.828998173029731e-09
play O 0 1.5266216735199123e-08
a O 0 6.125927143330046e-08
broad O 0 3.84196653158142e-07
role O 0 4.5979419383002096e-07
in O 0 5.643673262056836e-07
human O 0 8.36359140521381e-06
malignancy B-Disease 0 0.43396902084350586
. O 0 9.78555362962652e-06

Somatic O 0 0.14310580492019653
PTEN O 1 0.8246580958366394
deletions O 0 5.2910334488842636e-05
and O 0 5.605074875347782e-07
mutations O 0 2.2042895864160528e-07
were O 0 7.747946284553109e-08
observed O 0 3.388625202660478e-08
in O 0 2.3040771068849608e-08
sporadic B-Disease 0 1.911784966068808e-05
breast I-Disease 1 0.9998922348022461
, I-Disease 0 6.691226008115336e-05
brain I-Disease 1 0.9999977350234985
, I-Disease 0 1.4909987839928363e-05
prostate I-Disease 1 1.0
and I-Disease 0 0.12433468550443649
kidney I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
cell O 1 0.7889086008071899
lines O 0 8.768617476562213e-07
and O 0 3.580166918482064e-08
in O 0 5.39272448918382e-08
several O 0 9.549204804670808e-08
primary O 0 0.0018384999129921198
tumours B-Disease 1 1.0
such O 0 1.1620614941421081e-06
as O 0 0.0010530599392950535
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999990463256836
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999996423721313
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.0008325144299305975

In O 0 9.54769529926125e-06
addition O 0 1.6830987306093448e-06
, O 0 1.3766853044216987e-06
PTEN O 0 0.004742219112813473
was O 0 6.885252787469653e-06
identified O 0 2.8760544523720455e-07
as O 0 7.554576342272412e-08
the O 0 9.117495380905893e-08
susceptibility O 0 3.8599687286478e-06
gene O 0 6.195537594066991e-07
for O 0 2.926674653735972e-07
two O 0 6.517710062325932e-06
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.999994158744812
( O 0 1.2397775890349294e-06
CD B-Disease 0 1.4555257621395867e-05
; O 0 3.3327066262245353e-07
MIM O 0 0.0005031360196880996
158350 O 0 9.174552360491361e-06
) O 0 1.1231728791472051e-07
and O 0 3.035888198610337e-07
Bannayan B-Disease 0 6.953152478672564e-05
- I-Disease 0 3.140589615213685e-05
Zonana I-Disease 0 0.00030114877154119313
( I-Disease 0 6.363829925248865e-07
BZS I-Disease 0 7.174872007453814e-05
) I-Disease 0 2.1127341653937037e-07
or I-Disease 0 2.7711629968507623e-07
Ruvalcaba I-Disease 0 4.332949538365938e-05
- I-Disease 0 2.1470526917255484e-05
Riley I-Disease 0 1.9107879779767245e-05
- I-Disease 0 0.0007869078544899821
Smith I-Disease 0 0.0024549481458961964
syndrome I-Disease 1 0.9999986886978149
( O 0 7.225120498333126e-06
MIM O 1 0.9988471269607544
153480 O 0 0.00017985694285016507
) O 0 1.91025469575834e-06
. O 0 1.5652669844712364e-06

Constitutive O 0 0.0009999298490583897
DNA O 0 2.243195012852084e-05
from O 0 3.0814408091828227e-06
37 O 0 7.223653028631816e-06
CD B-Disease 0 5.962219347566133e-06
families O 0 6.695166376857742e-08
and O 0 1.5709078127201792e-07
seven O 0 2.631520317208924e-07
BZS B-Disease 0 4.730500950245187e-05
families O 0 2.4614363880459678e-08
was O 0 7.820151495252503e-07
screened O 0 8.367687769350596e-07
for O 0 3.8491432974296913e-07
germline O 0 0.00015405604790430516
PTEN O 0 0.0036833039484918118
mutations O 0 7.425231160596013e-06
. O 0 4.5956321628182195e-06

PTEN O 0 0.003080180613324046
mutations O 0 1.4157109944790136e-05
were O 0 5.458927262225188e-06
identified O 0 4.868079486186616e-07
in O 0 1.9376855675545812e-07
30 O 0 4.106303208573081e-07
of O 0 4.6779757667536614e-07
37 O 0 1.0604087492538383e-06
( O 0 7.222650566518496e-08
81 O 0 5.408911647464265e-07
% O 0 6.298842691876416e-08
) O 0 3.8439342375795604e-08
CD B-Disease 0 5.654351298289839e-07
families O 0 5.660174995369971e-09
, O 0 1.2287498130092445e-08
including O 0 3.752726840389187e-08
missense O 0 9.306846777690225e-07
and O 0 4.6825908839309704e-07
nonsense O 0 1.3803577530779876e-05
point O 0 1.4273327906266786e-06
mutations O 0 3.6640265932419425e-08
, O 0 4.066218650677911e-08
deletions O 0 2.1836071084635478e-07
, O 0 6.604379620966938e-08
insertions O 0 4.3620252654363867e-07
, O 0 1.1060043902944017e-07
a O 0 4.0387257627116924e-07
deletion O 0 1.121222521760501e-05
/ O 0 2.902896267187316e-05
insertion O 0 6.8118947638140526e-06
and O 0 5.498938548953447e-07
splice O 0 1.820646684791427e-05
site O 0 3.5658054002851713e-06
mutations O 0 3.2636912692396436e-06
. O 0 3.439620968492818e-06

These O 0 1.2141863408032805e-06
mutations O 0 1.3624851362692425e-06
were O 0 5.834584726471803e-07
scattered O 0 4.281079952761502e-07
over O 0 2.639905574142176e-07
the O 0 1.8899186216003727e-07
entire O 0 2.063472237523456e-07
length O 0 1.998212724174664e-07
of O 0 1.913857886393089e-06
PTEN O 0 0.00013508264964912087
, O 0 5.9430046661645974e-08
with O 0 7.97016852516208e-09
the O 0 7.493955678228303e-08
exception O 0 3.8577571359610374e-08
of O 0 1.3406517496150627e-07
the O 0 2.2637577501427586e-07
first O 0 4.4064870508009335e-07
, O 0 1.737762147513422e-07
fourth O 0 3.995281986135524e-06
and O 0 2.38818785192052e-07
last O 0 4.852222900808556e-06
exons O 0 1.825337494665291e-05
. O 0 6.7205896812083665e-06

A O 0 0.0003761235566344112
hot O 0 0.00012551080726552755
spot O 0 2.0092349586775526e-05
for O 0 1.8106778725268668e-06
PTEN O 0 0.00013426451187115163
mutation O 0 6.036052013769222e-07
in O 0 4.6693156718902173e-07
CD B-Disease 0 2.4905093596316874e-06
was O 0 2.543775053709396e-06
identified O 0 8.062707479439268e-08
in O 0 1.0223719471014192e-07
exon O 0 2.5071855702663015e-07
5 O 0 2.0046221038683143e-07
that O 0 3.177253304897931e-08
contains O 0 9.052082816651819e-08
the O 0 7.685245009270147e-07
PTPase O 0 2.2571517547476105e-05
core O 0 3.649224026958109e-06
motif O 0 5.754029643867398e-07
, O 0 2.2478332084574504e-08
with O 0 6.508934724536175e-09
13 O 0 1.422100268655413e-07
of O 0 3.46117332128415e-07
30 O 0 3.622148199156072e-07
( O 0 4.3791725801156645e-08
43 O 0 2.3916339841889567e-07
% O 0 4.675620601801711e-08
) O 0 2.8158462228589087e-08
CD B-Disease 0 2.978237034767517e-07
mutations O 0 2.9556455061197084e-08
identified O 0 8.351203462098056e-08
in O 0 1.1498937624310201e-07
this O 0 3.1891232765701716e-07
exon O 0 4.826176336791832e-06
. O 0 1.8820168179445318e-06

Seven O 0 3.1513027352048084e-05
of O 0 9.206500180880539e-06
30 O 0 2.221176600869512e-06
( O 0 1.1117700182694534e-07
23 O 0 6.681051445411867e-07
% O 0 5.211954601236357e-08
) O 0 1.9632743430975097e-08
were O 0 5.6914974067012736e-08
within O 0 2.432045320688303e-08
the O 0 1.5350856585882866e-07
core O 0 1.4381599839907722e-06
motif O 0 5.993238687551639e-07
, O 0 3.992091279769738e-08
the O 0 1.0500239966404479e-07
majority O 0 1.8257928502407594e-08
( O 0 3.822424332611263e-08
five O 0 3.789698510558992e-08
of O 0 2.691059535209206e-07
seven O 0 2.444649567223678e-07
) O 0 1.9497431225090622e-08
of O 0 4.5436937767817653e-08
which O 0 1.4753971377956532e-08
were O 0 5.696764660001463e-08
missense O 0 3.835903612525726e-07
mutations O 0 7.928627354658602e-08
, O 0 8.240161264438939e-08
possibly O 0 1.257572534996143e-07
pointing O 0 4.3040498098889657e-07
to O 0 1.2788142100816913e-08
the O 0 4.55765949425313e-08
functional O 0 9.016619628710032e-08
significance O 0 1.0376086834185116e-07
of O 0 7.090724238878465e-07
this O 0 2.6842874945032236e-07
region O 0 1.6065098407125333e-06
. O 0 2.4378939542657463e-06

Germline O 0 0.002419584197923541
PTEN O 0 0.0019919227343052626
mutations O 0 4.090187758265529e-06
were O 0 1.533952854515519e-06
identified O 0 2.4026644496188965e-07
in O 0 8.751335656143056e-08
four O 0 5.0994902522916163e-08
of O 0 2.743070979249751e-07
seven O 0 2.4175099611056794e-07
( O 0 1.449442237344556e-07
57 O 0 1.7491978496764204e-06
% O 0 3.4566670592539595e-07
) O 0 6.564436603184731e-07
BZS B-Disease 0 0.0002559407730586827
families O 0 3.1086528906598687e-07
studied O 0 1.08365065898397e-05
. O 0 4.53379152531852e-06

Interestingly O 0 0.00010362669854657724
, O 0 1.378667889184726e-06
none O 0 2.0066897832293762e-07
of O 0 7.839994253799887e-08
these O 0 4.121428531789206e-09
mutations O 0 5.0287965791540046e-08
was O 0 2.3971333575900644e-06
observed O 0 1.48063278970767e-07
in O 0 1.2736698806747881e-07
the O 0 8.206491770579305e-07
PTPase O 0 0.0001284783793380484
core O 0 5.7431065215496346e-05
motif O 0 3.628961349022575e-05
. O 0 4.940399321640143e-06

It O 0 6.269444838835625e-06
is O 0 1.1909971817658516e-06
also O 0 2.3410426308601018e-07
worthy O 0 5.240563609731907e-07
of O 0 1.152578533947235e-06
note O 0 5.952965125288756e-07
that O 0 4.1915992454732987e-08
a O 0 3.90495927149459e-07
single O 0 3.704573998675187e-07
nonsense O 0 3.6558285501087084e-06
point O 0 1.6197845980059355e-06
mutation O 0 1.2158695028574584e-07
, O 0 1.6381579825974768e-07
R233X O 0 2.1803350591653725e-06
, O 0 6.112726680385094e-08
was O 0 3.6979028550376825e-07
observed O 0 7.216027597678476e-08
in O 0 3.466021425424515e-08
the O 0 8.764164505237204e-08
germline O 0 1.4603285762859741e-06
DNA O 0 1.612566933317794e-07
from O 0 1.4578390050701273e-07
two O 0 4.7913410128330725e-08
unrelated O 0 6.172307962515333e-07
CD B-Disease 0 3.3223564059881028e-06
families O 0 3.231870593367603e-08
and O 0 2.2912854547030292e-07
one O 0 2.7700873488356592e-06
BZS B-Disease 0 0.0566633865237236
family O 0 2.4494713670719648e-06
. O 0 3.514372338031535e-06

Genotype O 0 0.0012339965905994177
- O 0 0.00012725399574264884
phenotype O 0 1.3745175238000229e-05
studies O 0 1.223417598339438e-06
were O 0 1.6367478394840873e-07
not O 0 1.901996427022823e-08
performed O 0 1.9960147312758636e-07
on O 0 2.6737663461062766e-07
this O 0 3.658614389223658e-08
small O 0 5.8871357566658844e-08
group O 0 1.220423513359492e-07
of O 0 2.09568020181905e-06
BZS B-Disease 0 0.0014804932288825512
families O 0 8.876168635651993e-07
. O 0 4.328288014221471e-06

However O 0 2.4874872906366363e-05
, O 0 5.792410775029566e-06
genotype O 0 2.8126149118179455e-05
- O 0 1.6414342098869383e-05
phenotype O 0 8.445247658528388e-06
analysis O 0 5.383905659073207e-07
inthe O 0 5.523080290004145e-06
group O 0 1.2085170908449072e-07
of O 0 2.6722725010586146e-07
CD B-Disease 0 1.0670910342014395e-06
families O 0 1.0677600137398713e-08
revealed O 0 1.477595787946484e-07
two O 0 1.395753912447617e-08
possible O 0 2.4362517336840028e-08
associations O 0 5.460050189753929e-08
worthy O 0 1.829537268349668e-07
of O 0 5.319934075487254e-07
follow O 0 1.7779561289898993e-07
- O 0 3.224706972559943e-07
up O 0 1.0800170713309853e-07
in O 0 1.0811238837504789e-07
independent O 0 3.4915277069558215e-07
analyses O 0 2.3419922854373e-06
. O 0 4.39522773376666e-06

The O 0 2.3482150936615653e-05
first O 0 5.940527444181498e-06
was O 0 1.6351517842849717e-05
an O 0 1.0150502021133434e-06
association O 0 4.5626430278389307e-07
noted O 0 1.3942165821845265e-07
in O 0 5.01966397337128e-08
the O 0 1.8141366808777093e-07
group O 0 5.661430790837585e-08
of O 0 3.219344932858803e-07
CD B-Disease 0 1.0291340004187077e-05
families O 0 3.263212988713349e-08
with O 0 1.7688145135252853e-06
breast B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0001135168713517487

A O 0 3.9116926927817985e-05
correlation O 0 1.5615212760167196e-05
was O 0 6.5474641814944334e-06
observed O 0 6.381253001563891e-07
between O 0 2.1452171949931653e-07
the O 0 2.886655749989586e-07
presence O 0 1.2223470093886135e-06
/ O 0 4.338545295468066e-06
absence O 0 8.126507395900262e-07
of O 0 6.263441036935546e-07
a O 0 1.7577143580638221e-06
PTEN O 0 0.0006520395400002599
mutation O 0 4.827557020803397e-08
and O 0 4.115593910114512e-08
the O 0 1.2669573834500625e-07
type O 0 8.879072765921592e-07
of O 0 7.662495590921026e-06
breast O 1 0.9997053742408752
involvement O 1 0.7715992331504822
( O 0 2.0294979549362324e-05
unaffected O 0 0.0005091933417133987
versus O 0 4.834808351006359e-05
benign O 0 0.06777370721101761
versus O 0 2.5804161850828677e-05
malignant O 1 0.8911438584327698
) O 0 1.222087121277582e-06
. O 0 9.921212722474593e-07

Specifically O 0 1.5796564184711315e-05
and O 0 1.649723230912059e-06
more O 0 1.4818249383097282e-07
directly O 0 2.4923502905949135e-07
, O 0 6.569453603333386e-08
an O 0 1.3203879234424676e-07
association O 0 3.5220043059780437e-07
was O 0 6.129591270109813e-07
also O 0 3.2563363561166625e-08
observed O 0 4.140648357520149e-08
between O 0 2.0259818711565458e-08
the O 0 2.299458756738204e-08
presence O 0 3.1448763593289186e-08
of O 0 2.1311674913704337e-07
a O 0 5.625040557788452e-06
PTEN O 1 0.9998075366020203
mutation O 0 1.3591235074272845e-05
and O 0 0.00037274285568855703
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 7.334801921388134e-05

Secondly O 0 0.0003299802483525127
, O 0 4.869709300692193e-06
there O 0 5.54053485757322e-07
appeared O 0 1.8784305666486034e-06
to O 0 9.755856922311068e-08
be O 0 1.5527008656590624e-07
an O 0 3.2515640668862034e-07
interdependent O 0 3.847950665658573e-06
association O 0 2.571578647803108e-07
between O 0 1.5649580120680184e-07
mutations O 0 2.0374859843741433e-07
upstream O 0 3.0905612220522016e-06
and O 0 1.0637922542855449e-07
within O 0 1.5004351894276624e-07
the O 0 6.459281962634122e-07
PTPase O 0 2.0100284018553793e-05
core O 0 3.5960626973974286e-06
motif O 0 1.5500156678172061e-06
, O 0 8.086208680424534e-08
the O 0 2.372845813169988e-07
core O 0 1.1192609008503496e-06
motif O 0 3.6066231245968083e-07
containing O 0 6.727142221052418e-08
the O 0 3.939475945458071e-08
majority O 0 4.5956292105131524e-09
of O 0 1.2983723252091295e-07
missense O 0 7.726509352323774e-07
mutations O 0 6.242819949875411e-08
, O 0 7.433638415932364e-08
and O 0 2.8533401419394977e-08
the O 0 1.0076855971874465e-07
involvement O 0 2.577422151261999e-07
of O 0 4.3175668906769715e-07
all O 0 5.076006104332009e-08
major O 0 1.096549749490805e-05
organ O 1 0.9999287128448486
systems O 0 0.0016919239424169064
( O 0 1.051895765158406e-06
central O 0 0.00012881707516498864
nervous O 0 0.0004498685011640191
system O 0 2.316905010957271e-06
, O 0 7.204145049399813e-07
thyroid O 1 0.9999973773956299
, O 0 1.672313010203652e-05
breast O 1 0.9999983310699463
, O 0 0.019137578085064888
skin O 1 0.9999998807907104
and O 1 0.9999958276748657
gastrointestinal O 1 1.0
tract O 1 1.0
) O 0 0.004318651277571917
. O 0 2.2853959308122285e-05

However O 0 9.41453890845878e-06
, O 0 4.788421961166023e-07
these O 0 1.870484744870282e-08
observations O 0 2.6467674274499586e-07
would O 0 7.365751031329637e-08
need O 0 5.198511843218512e-08
to O 0 2.9042555027558592e-08
be O 0 5.7295100219789674e-08
confirmed O 0 1.681111427842552e-07
by O 0 3.150315563971162e-08
studying O 0 5.417838622179261e-08
a O 0 4.7723883511707754e-08
larger O 0 2.5354859545245745e-08
number O 0 3.4455879927008937e-08
of O 0 6.893071144986607e-07
CD B-Disease 0 1.4740357983100694e-05
families O 0 6.063092428121308e-07
. O 0 4.613504643202759e-06

Molecular O 1 0.8995656371116638
defects O 1 0.9930747747421265
leading O 0 3.4339973353780806e-05
to O 0 2.3941419158290955e-07
human O 0 1.2491461802710546e-06
complement B-Disease 0 2.5622895918786526e-05
component I-Disease 1 0.9997438788414001
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 9.784935173229314e-07
an O 0 7.002302595537913e-07
African O 0 1.860012730503513e-06
- O 0 6.612790002691327e-06
American O 0 2.771490699160495e-06
family O 0 7.807877864252077e-07
. O 0 2.7012154077965533e-06

Complement B-Disease 0 0.0012690863804891706
component I-Disease 1 0.9982784986495972
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 7.63235948397778e-06
C6D B-Disease 0 0.0009398077963851392
) O 0 3.855076329273288e-07
was O 0 7.388076937786536e-06
diagnosed O 0 1.0500842108740471e-05
in O 0 1.8819240210632415e-07
a O 0 8.177452741620073e-07
16 O 0 2.372205926803872e-06
- O 0 1.3390688309300458e-06
year O 0 9.444505053579633e-07
- O 0 9.8352779787092e-07
old O 0 2.0503346149780555e-06
African O 0 6.999725314926764e-07
- O 0 1.0701882047214895e-06
American O 0 6.08879133778828e-07
male O 0 1.1989950507995673e-06
with O 0 3.3216119845747016e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 3.108859891653992e-05

The O 0 6.260981172090396e-05
patients O 0 1.2981204235984478e-05
father O 0 1.0951598596875556e-05
and O 0 5.89682315421669e-07
two O 0 4.6170072209861246e-07
brothers O 0 2.4577955628046766e-05
also O 0 7.328125661842932e-07
had O 0 4.613359124050476e-06
C6D B-Disease 0 0.005960554350167513
, O 0 8.162542286527241e-08
but O 0 7.1310304328164875e-09
gave O 0 1.456148623901754e-08
no O 0 1.7805717789087794e-08
history O 0 1.0193674171432576e-07
of O 0 5.406552645581542e-06
meningitis B-Disease 1 1.0
or O 0 3.661784603536944e-06
other O 0 1.1312412198094535e-06
neisserial B-Disease 1 0.9375771880149841
infection I-Disease 1 0.9639209508895874
. O 0 9.687352758191992e-06

By O 0 1.8650021957000718e-05
using O 0 2.1818595996592194e-06
exon O 0 6.115051746746758e-06
- O 0 2.4544990537833655e-06
specific O 0 2.913472201271361e-07
polymerase O 0 4.064105814904906e-05
chain O 0 1.1446214557508938e-05
reaction O 0 2.195847628172487e-06
( O 0 2.5395718239451526e-07
PCR O 0 1.9429237454460235e-06
) O 0 8.337595147622778e-08
/ O 0 5.773972588940524e-07
single O 0 2.2853714654047508e-07
- O 0 7.128109018594841e-07
strand O 0 8.8353766614091e-07
conformation O 0 1.3630631201522192e-07
polymorphism O 0 7.566876547571155e-08
as O 0 1.7706286215002365e-08
a O 0 1.7007323549478315e-08
screening O 0 1.9711501764163586e-08
step O 0 4.679421294895292e-08
and O 0 9.933651234916852e-09
nucleotide O 0 7.715620853332439e-08
sequencing O 0 7.150741510031366e-08
of O 0 1.0463453747888707e-07
target O 0 1.8336001517127443e-07
exons O 0 1.3480028826506896e-07
, O 0 1.7493391624157084e-08
we O 0 6.042188971377982e-09
determined O 0 2.5677232784460102e-08
that O 0 1.739915411747006e-08
the O 0 2.2702219837356097e-07
proband O 0 8.37637981021544e-06
was O 0 4.384180101624224e-06
a O 0 5.269967573440226e-07
compound O 0 2.9389325391093735e-06
heterozygote O 0 8.376630376005778e-07
for O 0 4.812351406258131e-08
two O 0 2.9481807928277703e-07
C6 O 0 0.012836859561502934
gene O 0 8.410967893723864e-06
mutations O 0 1.0335045772080775e-05
. O 0 1.0078976629301906e-05

The O 0 3.373748404555954e-05
first O 0 5.8465329857426696e-06
, O 0 5.365852189243014e-07
1195delC O 0 2.3169668565969914e-06
located O 0 9.059783678821987e-07
in O 0 1.0120850646444524e-07
exon O 0 4.1674454109852377e-07
7 O 0 1.067774064722471e-06
, O 0 5.854885642975205e-08
is O 0 3.4311142371734604e-08
a O 0 7.47867758832399e-08
novel O 0 1.2321966380568483e-07
mutation O 0 4.797650632326622e-08
, O 0 4.114557938805774e-08
while O 0 2.770393159323703e-08
the O 0 8.692362030160439e-08
second O 0 3.8174997030182567e-07
, O 0 4.6592493418984304e-08
1936delG O 0 1.9956777919105662e-07
in O 0 5.62567237238909e-08
exon O 0 1.414059056514816e-07
12 O 0 1.88234224651751e-07
, O 0 2.1033953245819248e-08
has O 0 2.147226751958442e-08
been O 0 7.508478461204504e-08
described O 0 1.0893081281437844e-07
before O 0 1.25110091175884e-07
to O 0 5.449427931125683e-08
cause O 0 2.921863142546499e-06
C6D B-Disease 0 0.00035866806865669787
in O 0 3.4689719541347586e-07
an O 0 2.6080030579578306e-07
unrelated O 0 8.939815074882063e-07
African O 0 1.2770223065672326e-06
- O 0 4.3320624172338285e-06
American O 0 1.0255001825498766e-06
individual O 0 2.4673221332705e-07
. O 0 2.240887170046335e-06

Both O 0 2.6584875740809366e-06
mutations O 0 3.1247766401065746e-06
result O 0 1.381712309012073e-06
in O 0 1.1133545285701985e-06
premature O 0 2.7624879294307902e-05
termination O 0 1.6115003745653667e-05
codons O 0 5.521963885257719e-06
and O 0 1.6877535244930186e-06
C6 O 0 0.0020862342789769173
null O 0 7.861776248319075e-05
alleles O 0 1.0918560292338952e-05
. O 0 6.376238161465153e-06

Allele O 0 0.00032093803747557104
- O 0 3.976580046582967e-05
specific O 0 9.153073392553779e-07
PCR O 0 1.7705728168948554e-05
indicated O 0 1.0619540944389882e-06
that O 0 7.444705829584564e-08
the O 0 2.8370499194352305e-07
probands O 0 1.2202598554722499e-05
two O 0 2.9772942866657104e-07
brothers O 0 1.5733210602775216e-05
also O 0 3.5674548826136743e-07
inherited O 0 3.0906437586963875e-06
the O 0 7.687957577218185e-07
1195delC O 0 2.8313027087278897e-06
mutation O 0 1.2552216333006072e-07
from O 0 7.228659626434819e-08
their O 0 1.7502269855640407e-08
heterozygous O 0 1.674611667112913e-07
mother O 0 3.1060332617016684e-07
and O 0 8.264983364369982e-08
the O 0 2.15889400578817e-07
1936delG O 0 1.0114971473740297e-06
mutation O 0 8.826586395116465e-08
from O 0 5.971945427063474e-08
their O 0 4.936367759000859e-08
homozygous O 0 2.0845300241489895e-06
father O 0 1.0436886441311799e-05
. O 0 5.834930334458477e-07
. O 0 2.092197519232286e-06

PAX6 O 0 0.04762918874621391
mutations O 0 0.00023666345805395395
reviewed O 0 0.0002519615227356553
. O 0 4.5182609028415754e-05

Mutations O 0 3.533488415996544e-05
in O 0 5.52057417735341e-06
PAX6 O 0 0.0005567711777985096
are O 0 7.979785721090593e-08
responsible O 0 1.2256651871211943e-07
for O 0 5.574625561166613e-08
human O 0 1.7742003137755091e-06
aniridia B-Disease 1 0.9999991655349731
and O 0 3.5218263860770094e-07
have O 0 9.104756770739186e-08
also O 0 1.0137890171790787e-07
been O 0 1.2026202966808341e-07
found O 0 4.7938641500877566e-08
in O 0 9.852930560327877e-08
patients O 0 3.786484228385234e-07
with O 0 1.0028917358795297e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 4.915486442769179e-06
with O 0 0.03768761456012726
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 3.878414645441808e-05
with O 0 5.704070531464822e-07
autosomal B-Disease 1 0.9998288154602051
dominant I-Disease 1 0.9997718930244446
keratitis I-Disease 1 1.0
, O 0 1.0196158655162435e-06
and O 0 4.1398908479095553e-07
with O 0 3.7297822927939706e-06
isolated B-Disease 1 0.9999833106994629
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.004972662776708603

No O 0 3.5628039768198505e-05
locus O 0 5.393254468799569e-05
other O 0 2.912266552357323e-07
than O 0 1.7982620192924514e-07
chromosome O 0 1.748704380588606e-05
11p13 O 0 7.123834802769125e-05
has O 0 7.524692478000361e-07
been O 0 1.1432317705839523e-06
implicated O 0 4.917441856377991e-06
in O 0 1.2532794926300994e-06
aniridia B-Disease 1 0.9999474287033081
, O 0 3.613467356444744e-07
and O 0 2.651805459663592e-07
PAX6 O 0 0.0004909930867142975
is O 0 2.1662567917246633e-07
clearly O 0 1.1047941939068551e-07
the O 0 1.56686354557678e-07
major O 0 4.044692332172417e-07
, O 0 3.492213096478736e-08
if O 0 6.7303482786940094e-09
not O 0 8.417485375389333e-09
only O 0 2.239736218712096e-08
, O 0 1.1542424260824191e-07
gene O 0 9.58697000896791e-07
responsible O 0 6.321702585410094e-06
. O 0 7.796548743499443e-06

Twenty O 0 8.509173494530842e-05
- O 0 1.5353785784100182e-05
eight O 0 9.370631346428127e-07
percent O 0 5.894427772545896e-07
of O 0 2.0638735520606133e-07
identified O 0 8.324151394845103e-07
PAX6 O 0 4.585393617162481e-05
mutations O 0 5.534155320674472e-07
are O 0 1.7578925337602413e-07
C O 0 2.4678573026903905e-05
- O 0 1.0426680091768503e-05
T O 0 1.6527355910511687e-05
changes O 0 9.997102523584545e-08
at O 0 2.146714450645959e-06
CpG O 0 4.659876594814705e-06
dinucleotides O 0 1.67087046065717e-06
, O 0 3.54697071713872e-08
20 O 0 5.792814405936042e-08
% O 0 8.379153371151915e-09
are O 0 3.1699995961531613e-09
splicing O 0 6.640137684144065e-08
errors O 0 1.1045451628888259e-06
, O 0 6.49828137966324e-08
and O 0 2.818081235034242e-08
more O 0 4.369574924112385e-09
than O 0 5.549237069857327e-09
30 O 0 6.656382112169013e-08
% O 0 1.655855719207011e-08
are O 0 4.725178026632193e-09
deletion O 0 2.8535910701066314e-07
or O 0 1.3181548297325207e-07
insertion O 0 1.944942596310284e-06
events O 0 8.538643783140287e-07
. O 0 1.6409894669777714e-06

There O 0 8.010718374862336e-06
is O 0 8.830448336993868e-07
a O 0 1.6105548183986684e-06
noticeably O 0 7.796191312081646e-06
elevated O 0 3.5157339880242944e-05
level O 0 9.644475085224258e-07
of O 0 3.215681374513224e-07
mutation O 0 1.0532252048278679e-07
in O 0 1.4063112985240878e-07
the O 0 2.139133243872493e-07
paired O 0 1.9789543159731693e-07
domain O 0 2.0408833734109066e-07
compared O 0 1.547061856399523e-07
with O 0 1.1174223324417198e-08
the O 0 9.642106135743234e-08
rest O 0 7.736723262041778e-08
of O 0 2.9330874440347543e-07
the O 0 1.2468765362427803e-06
gene O 0 3.5009948078368325e-06
. O 0 3.576042445274652e-06

Increased O 0 2.8651240427279845e-05
mutation O 0 3.0016146865818882e-06
in O 0 9.043072282111098e-07
the O 0 7.999304898476112e-07
homeodomain O 0 6.260070676944451e-06
is O 0 1.8140865165605646e-07
accounted O 0 8.386462582166132e-07
for O 0 5.872220754099544e-08
by O 0 1.0055985200096984e-07
the O 0 1.0197596793659613e-06
hypermutable O 0 3.338491660542786e-05
CpG O 0 3.4734046494122595e-05
dinucleotide O 0 1.8810493202181533e-05
in O 0 1.6866240457602544e-06
codon O 0 8.886128853191622e-06
240 O 0 4.2458909774723e-06
. O 0 1.8317035710424534e-06

Very O 0 3.822530288744019e-06
nearly O 0 6.975182031965232e-07
all O 0 2.253938191643101e-08
mutations O 0 6.248335182590381e-08
appear O 0 1.1340036820683963e-07
to O 0 1.6714901462933085e-08
cause O 0 3.6786835266866547e-07
loss O 0 2.066315119009232e-06
of O 0 1.043741576722823e-06
function O 0 4.6845653400851006e-07
of O 0 6.726577339577489e-07
the O 0 3.304381834823289e-07
mutant O 0 3.709770908244536e-07
allele O 0 1.630017010256779e-07
, O 0 2.2625181728130883e-08
and O 0 1.6917704570573733e-08
more O 0 1.991111719945593e-09
than O 0 5.090071475422064e-09
80 O 0 5.586003837265707e-08
% O 0 2.596504522500709e-08
of O 0 2.42788871673838e-07
exonic O 0 4.3029353946621995e-06
substitutions O 0 2.090018824674189e-07
result O 0 1.2512178670931462e-07
in O 0 3.039196485588036e-07
nonsense O 0 1.362097555102082e-05
codons O 0 1.1151589205837809e-05
. O 0 3.2385864869866055e-06

In O 0 8.436923963017762e-06
a O 0 2.4382286483159987e-06
gene O 0 2.894365991323866e-07
with O 0 2.4299682266359923e-08
such O 0 8.86972344460446e-08
extraordinarily O 0 4.615132638718933e-06
high O 0 7.34899515464349e-07
sequence O 0 3.784772317771967e-08
conservation O 0 3.229257927728213e-08
throughout O 0 4.9948396529941874e-09
evolution O 0 3.6749941756397675e-08
, O 0 8.309998911215644e-09
there O 0 1.1849475178848934e-08
are O 0 9.79095560182941e-09
presumed O 0 1.3421629319054773e-06
undiscovered O 0 5.647158104693517e-06
missense O 0 1.3953234656582936e-06
mutations O 0 1.0574281361641624e-07
, O 0 3.7085253978830224e-08
these O 0 3.48354300960807e-09
are O 0 4.112343354734094e-09
hypothesized O 0 7.457297357404968e-08
to O 0 9.21330833847378e-09
exist O 0 4.027678102147547e-08
in O 0 1.561176219411209e-07
as O 0 8.545299010620511e-07
- O 0 2.2611175154452212e-06
yet O 0 1.8586354144645156e-07
unidentified O 0 2.5245087726943893e-06
phenotypes O 0 1.7318158143098117e-06
. O 0 2.9087885877743247e-07
. O 0 1.0665467016224284e-06

Genetic O 0 3.413873855606653e-05
heterogeneity O 0 2.997782030433882e-05
and O 0 1.983930815185886e-06
penetrance O 0 7.463753718184307e-05
analysis O 0 6.435965360651608e-07
of O 0 4.344940407463582e-07
the O 0 5.431215868156869e-07
BRCA1 O 0 4.663268555304967e-06
and O 0 3.2404383887296717e-07
BRCA2 O 0 6.784936886106152e-06
genes O 0 8.560935498280742e-07
in O 0 6.1142527556512505e-06
breast B-Disease 1 0.9999948740005493
cancer I-Disease 1 0.9999133348464966
families O 0 1.2536369240478962e-06
. O 0 7.702217772020958e-06

The O 0 0.0010205800645053387
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9904362559318542
Consortium O 0 0.00014548101171385497
. O 0 1.1629258551693056e-05

The O 0 3.4654974570003105e-06
contribution O 0 1.7129281104644178e-06
of O 0 8.976361414170242e-07
BRCA1 O 0 7.426477168337442e-06
and O 0 5.80453729526198e-07
BRCA2 O 0 5.710296318284236e-05
to O 0 2.1261057554511353e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.9997381567955017
assessed O 0 1.5296711808332475e-06
by O 0 3.237806112110775e-08
linkage O 0 5.516703254215827e-07
and O 0 3.363204115203189e-08
mutation O 0 6.370053284854293e-08
analysis O 0 3.661657999032286e-08
in O 0 3.9519459704706605e-08
237 O 0 3.394865757400112e-07
families O 0 1.336609312119208e-08
, O 0 2.2094832630159544e-08
each O 0 3.461679165539522e-09
with O 0 1.3145976751616217e-08
at O 0 1.180369281428284e-06
least O 0 1.2799977966437837e-08
four O 0 1.4577633322687689e-08
cases O 0 1.9668387807314502e-08
of O 0 2.9246064059407217e-06
breast B-Disease 1 0.9999880790710449
cancer I-Disease 1 0.6791748404502869
, O 0 5.085561483042511e-08
collected O 0 2.4153063549192666e-08
by O 0 4.7189299579031285e-08
the O 0 3.3922326565516414e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.3275408446788788
Consortium O 0 2.8915323127876036e-05
. O 0 2.7530741135706194e-06

Families O 0 1.3900428257329622e-06
were O 0 4.651320182347263e-07
included O 0 1.8010663893619494e-07
without O 0 4.372862605350747e-08
regard O 0 1.4691691774260107e-07
to O 0 2.256622266827435e-08
the O 0 1.845269110845038e-07
occurrence O 0 2.893446435336955e-06
of O 0 5.2857183618471026e-05
ovarian B-Disease 1 1.0
or I-Disease 0 5.14026905875653e-05
other I-Disease 0 2.575257667558617e-06
cancers I-Disease 1 0.9999879598617554
. O 0 4.246500611770898e-05

Overall O 0 0.0013471940765157342
, O 0 2.6560917831375264e-05
disease O 0 0.0005240775644779205
was O 0 3.709178781718947e-05
linked O 0 1.6438621059933212e-06
to O 0 5.694146665291555e-08
BRCA1 O 0 8.951262771006441e-07
in O 0 1.3465175641158567e-07
an O 0 1.0258605698254541e-07
estimated O 0 9.628616481904828e-08
52 O 0 2.2857200576709147e-07
% O 0 4.4838937895974595e-08
of O 0 3.1535503808299836e-07
families O 0 3.334219300654695e-08
, O 0 4.370169293110848e-08
to O 0 3.3552083777976804e-08
BRCA2 O 0 2.861090422356938e-07
in O 0 1.6334901431491744e-07
32 O 0 3.18386611297683e-07
% O 0 3.967594963683041e-08
of O 0 2.2374310049144697e-07
families O 0 2.620195438396422e-08
, O 0 3.498152878478322e-08
and O 0 2.7415975267786052e-08
to O 0 3.263032510858466e-08
neither O 0 6.362439819440624e-08
gene O 0 6.4104703767498e-08
in O 0 6.162419907695948e-08
16 O 0 3.496259353141795e-07
% O 0 2.9457178030156683e-08
( O 0 1.7685426456637288e-08
95 O 0 8.611156232518624e-08
% O 0 2.300454582382372e-08
confidence O 0 3.1506644404544204e-07
interval O 0 1.0870329560930259e-06
[ O 0 4.15897261518694e-07
CI O 0 8.068022725638002e-05
] O 0 2.2829425461168285e-07
6 O 0 2.0529766686649964e-07
% O 0 2.265255893973972e-08
- O 0 7.328642936954566e-08
28 O 0 2.0841970638230123e-07
% O 0 2.9786964006461858e-08
) O 0 2.0994875171709282e-08
, O 0 4.0034372261743556e-08
suggesting O 0 1.7084320802496222e-07
other O 0 2.483089822646889e-08
predisposition O 0 1.902073563542217e-05
genes O 0 3.826097326964373e-06
. O 0 3.933390416932525e-06

The O 0 3.2191539503401145e-05
majority O 0 9.490054821981175e-07
( O 0 6.709996114295791e-07
81 O 0 3.2045059015217703e-06
% O 0 1.6012327819225902e-07
) O 0 4.779931117582237e-08
of O 0 3.5206375059715356e-07
the O 0 1.175567194877658e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0173745579322713e-07
were O 0 3.544496109952888e-07
due O 0 6.296957053564256e-07
to O 0 6.309183220309933e-08
BRCA1 O 0 1.0918621455857647e-06
, O 0 1.2573447349950584e-07
with O 0 2.8670164908817242e-08
most O 0 2.4810445253820035e-08
others O 0 4.0476010099155246e-08
( O 0 1.7818832631633086e-08
14 O 0 1.2609832822363387e-07
% O 0 4.0836440007296915e-08
) O 0 2.8944450392032195e-08
due O 0 7.399855803669197e-07
to O 0 4.828744977203314e-07
BRCA2 O 0 7.853998249629512e-05
. O 0 9.798646715353243e-06

Conversely O 0 0.00010252270294586197
, O 0 1.1474107850517612e-06
the O 0 2.512329331239016e-07
majority O 0 2.369941398683295e-08
of O 0 2.6717424361777375e-07
families O 0 3.399254921987449e-08
with O 0 1.0491010726809691e-07
male B-Disease 0 1.8074300896842033e-05
and I-Disease 0 5.846789008501219e-06
female I-Disease 1 0.7739033699035645
breast I-Disease 1 0.9999916553497314
cancer I-Disease 1 0.996575653553009
were O 0 3.6409194308362203e-06
due O 0 6.5566241573833395e-06
to O 0 1.9954494234752929e-07
BRCA2 O 0 3.2055786505225115e-06
( O 0 2.1855070997389703e-07
76 O 0 6.831665814388543e-06
% O 0 3.9009876218187856e-07
) O 0 4.545800038613379e-07
. O 0 2.2189658466231776e-06

The O 0 2.73233417829033e-05
largest O 0 7.850339898141101e-06
proportion O 0 1.884049652289832e-06
( O 0 2.601951507585909e-07
67 O 0 1.1583770174183883e-06
% O 0 1.4967336880999937e-07
) O 0 5.406668890373112e-08
of O 0 4.5990339003765257e-07
families O 0 4.875704107121237e-08
due O 0 6.023194600857096e-07
to O 0 3.294507422424431e-08
other O 0 1.3831762402105596e-08
genes O 0 9.736245232261354e-08
was O 0 4.164062374911737e-06
found O 0 3.6624683730224206e-08
in O 0 3.1638887065810195e-08
families O 0 4.966700384301248e-09
with O 0 1.1190390836191e-08
four O 0 7.140084079537701e-08
or O 0 3.940242265798588e-08
five O 0 2.1693944418643696e-08
cases O 0 3.018559979750535e-08
of O 0 2.648441295605153e-06
female O 1 0.5665715336799622
breast B-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9996850490570068
only O 0 1.133008481701836e-06
. O 0 2.2222823190531926e-06

These O 0 2.9918035124865128e-06
estimates O 0 1.574059979247977e-06
were O 0 3.457184618582687e-07
not O 0 5.630116106658534e-08
substantially O 0 3.640099919266504e-07
affected O 0 4.671769815445259e-08
either O 0 2.542148891393481e-08
by O 0 3.01887084219743e-08
changing O 0 2.911610152978028e-08
the O 0 4.24068460347371e-08
assumed O 0 2.1114692572155036e-07
penetrance O 0 1.26367172015307e-06
model O 0 6.60400232277425e-08
for O 0 2.097314144577922e-08
BRCA1 O 0 4.720879189790139e-07
or O 0 3.8824115478064414e-08
by O 0 2.0955067014938322e-08
including O 0 3.778180257540953e-08
or O 0 1.1900123553232334e-07
excluding O 0 4.357727448223159e-06
BRCA1 O 0 1.2936737221025396e-05
mutation O 0 2.802328253892483e-06
data O 0 3.6144365367363207e-06
. O 0 3.3176547731272876e-06

Among O 0 5.7565939641790465e-06
those O 0 2.1096718683111249e-07
families O 0 9.451157012563272e-08
with O 0 1.5484833681966848e-07
disease O 0 0.0008972889045253396
due O 0 1.3533549463318195e-05
to O 0 9.504431375262357e-08
BRCA1 O 0 7.352443844865775e-07
that O 0 7.866147200275009e-08
were O 0 2.3313243957545637e-07
tested O 0 7.208173258277384e-08
by O 0 4.5478728338821384e-08
one O 0 2.071164395545111e-08
of O 0 7.479847141667051e-08
the O 0 8.89184477159688e-08
standard O 0 4.364213523899707e-08
screening O 0 2.4275777832372114e-08
methods O 0 2.0444904436089928e-08
, O 0 1.0546923334686653e-08
mutations O 0 2.1032027675005338e-08
were O 0 7.596334228310297e-08
detected O 0 3.1065604844116024e-07
in O 0 9.399974487678264e-08
the O 0 2.2820478307039593e-07
coding O 0 2.5276932547058095e-07
sequence O 0 1.9664905437366542e-07
or O 0 8.757997704833542e-08
splice O 0 5.07168067542807e-07
sites O 0 7.100116761193931e-08
in O 0 6.419059417339668e-08
an O 0 6.12264514643357e-08
estimated O 0 8.13171183722261e-08
63 O 0 1.817069801290927e-07
% O 0 2.6747194681320252e-08
( O 0 1.1285065326660515e-08
95 O 0 8.635119996824869e-08
% O 0 4.6578449541812006e-08
CI O 0 5.829527071909979e-05
51 O 0 4.776769060299557e-07
% O 0 1.1196501503718537e-07
- O 0 7.451211558873183e-07
77 O 0 1.978723048523534e-06
% O 0 3.753443422738201e-07
) O 0 5.213853455643402e-07
. O 0 2.520102043490624e-06

The O 0 9.701739145384636e-06
estimated O 0 1.175154238808318e-06
sensitivity O 0 8.871970749169122e-07
was O 0 1.099357859857264e-06
identical O 0 3.818322014126352e-08
for O 0 1.5165570133035544e-08
direct O 0 1.3174195601095562e-07
sequencing O 0 4.984578367839276e-07
and O 0 9.671484946238706e-08
other O 0 5.7533611652615946e-08
techniques O 0 2.0302002212702064e-06
. O 0 2.147936811525142e-06

The O 0 1.4626402844442055e-05
penetrance O 0 8.211069507524371e-05
of O 0 6.332038537948392e-06
BRCA2 O 0 2.619296355987899e-05
was O 0 1.2515139133029152e-05
estimated O 0 3.3274412203354586e-07
by O 0 8.634329873302704e-08
maximizing O 0 6.781435786251677e-07
the O 0 1.0231400437987759e-06
LOD O 0 0.00021506195480469614
score O 0 6.147980116111285e-07
in O 0 3.286380376721354e-07
BRCA2 O 0 6.775728706998052e-06
- O 0 3.0395233352464857e-06
mutation O 0 1.253432202474869e-07
families O 0 6.1165379428018696e-09
, O 0 5.950623993555837e-09
over O 0 9.725866334520106e-09
all O 0 1.1302427438408813e-08
possible O 0 2.240334850966974e-07
penetrance O 0 6.469107756856829e-05
functions O 0 2.8480606033554068e-06
. O 0 4.1579669414204545e-06

The O 0 1.0719394595071208e-05
estimated O 0 2.696366436794051e-06
cumulative O 0 1.1186654774064664e-05
risk O 0 3.294528369224281e-06
of O 0 2.778977886919165e-06
breast B-Disease 0 0.057086408138275146
cancer I-Disease 0 0.006433084141463041
reached O 0 1.033348871715134e-05
28 O 0 1.0917507324847975e-06
% O 0 5.865817342964874e-08
( O 0 1.898071566586168e-08
95 O 0 1.0267454086942962e-07
% O 0 5.7000903552761883e-08
CI O 0 6.961452163523063e-05
9 O 0 1.396136781295354e-06
% O 0 7.003504975955366e-08
- O 0 6.974191535391583e-08
44 O 0 1.1638067576313915e-07
% O 0 2.470872395576862e-08
) O 0 1.0041894427104125e-08
by O 0 1.3028581768992353e-08
age O 0 4.7553786686194144e-08
50 O 0 8.055452127564422e-08
years O 0 6.172172106744256e-08
and O 0 2.9523775424422638e-08
84 O 0 3.3583140179871407e-07
% O 0 2.381623431801927e-08
( O 0 1.4652870916620486e-08
95 O 0 8.528757433623468e-08
% O 0 4.156743216299219e-08
CI O 0 2.278893043694552e-05
43 O 0 3.6896102528771735e-07
% O 0 3.529269676505464e-08
- O 0 4.955310117793488e-08
95 O 0 5.706040795416811e-08
% O 0 1.7290380682766227e-08
) O 0 1.084326495259802e-08
by O 0 1.8923058675568427e-08
age O 0 1.6595936358498875e-07
70 O 0 8.255733519035857e-07
years O 0 9.259835564989771e-07
. O 0 1.8969876691699028e-06

The O 0 8.103467553155497e-05
corresponding O 1 0.6713261008262634
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 8.97601930773817e-05
were O 0 3.2189011562877567e-06
0 O 0 2.4511539322702447e-06
. O 0 1.4128230532151065e-06

4 O 0 2.9704906410188414e-05
% O 0 1.2738136092593777e-06
( O 0 3.4255961622875475e-07
95 O 0 1.074066403816687e-06
% O 0 2.0734833583446743e-07
CI O 0 5.21372894581873e-05
0 O 0 2.5552435545250773e-07
% O 0 3.903275569427933e-08
- O 0 7.58845573045619e-08
1 O 0 9.380130450153956e-08
% O 0 1.4254290192639019e-08
) O 0 4.232957095950951e-09
by O 0 6.071254166073459e-09
age O 0 2.6509196615620567e-08
50 O 0 4.5273264248635314e-08
years O 0 3.845019236337066e-08
and O 0 2.5416641236120086e-08
27 O 0 3.4446884455974214e-07
% O 0 2.0913063281113864e-08
( O 0 8.156530562075659e-09
95 O 0 8.67521947611749e-08
% O 0 5.4691287942887357e-08
CI O 0 1.549291300761979e-05
0 O 0 8.089201486427555e-08
% O 0 1.8173535565324528e-08
- O 0 3.684665728087566e-08
47 O 0 1.0944271622292945e-07
% O 0 1.3654382513550445e-08
) O 0 9.595246375226907e-09
by O 0 1.9818752861056055e-08
age O 0 1.8900159659551719e-07
70 O 0 7.778870099173218e-07
years O 0 1.0136841410712805e-06
. O 0 1.7597556052351138e-06

The O 0 1.220307603944093e-05
lifetime O 0 1.1063583770010155e-05
risk O 0 6.526355264213635e-06
of O 0 9.107759069593158e-06
breast B-Disease 1 0.9981892704963684
cancer I-Disease 1 0.9167728424072266
appears O 0 8.47611545395921e-07
similar O 0 3.7222022797323007e-08
to O 0 4.2682344769673364e-08
the O 0 2.5618928134463204e-07
risk O 0 1.429345957149053e-07
in O 0 8.023496178566347e-08
BRCA1 O 0 4.473625949685811e-07
carriers O 0 4.521751506558758e-08
, O 0 1.9090252934006458e-08
but O 0 5.150405435472294e-09
there O 0 1.4032254469498184e-08
was O 0 7.764824090372713e-07
some O 0 7.278185165660034e-09
suggestion O 0 1.9265176831595454e-07
of O 0 3.5113060903313453e-07
a O 0 1.2838092970923753e-06
lower O 0 5.777912065241253e-06
risk O 0 2.234650366972346e-07
in O 0 1.124626365367476e-07
BRCA2 O 0 7.388749168057984e-07
carriers O 0 1.09902074996171e-07
< O 0 1.5188371662588906e-06
50 O 0 1.9663778516587627e-07
years O 0 9.028529035504107e-08
of O 0 6.039230697751918e-07
age O 0 3.132142865069909e-06
. O 0 2.2997364794719033e-06

Eye B-Disease 1 0.9999992847442627
movement I-Disease 1 0.9910707473754883
abnormalities I-Disease 1 0.9999924898147583
correlate O 0 9.983494237530977e-06
with O 0 1.6540305125545274e-07
genotype O 0 1.7525273506180383e-05
in O 0 1.6293469116135384e-06
autosomal O 1 0.9657151103019714
dominant O 1 0.6468701362609863
cerebellar B-Disease 1 0.9999998807907104
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 0.9999971389770508
. O 0 5.8285593695472926e-05

We O 0 2.4299704818986356e-05
compared O 0 3.250204099458642e-05
horizontal O 0 0.00023175973910838366
eye O 0 0.0002886276342906058
movements O 0 2.446283724566456e-05
( O 0 3.737519307378534e-07
visually O 0 2.37755060084055e-07
guided O 0 8.922184520088194e-07
saccades O 0 4.439405984157929e-06
, O 0 2.0961567770427791e-07
antisaccades O 0 1.458229917261633e-06
, O 0 4.437474032670252e-08
and O 0 5.491696342119212e-08
smooth O 0 8.80823563420563e-07
pursuit O 0 2.7885137114935787e-06
) O 0 3.549136096125949e-08
in O 0 2.870135418220343e-08
control O 0 1.2986409103632468e-07
subjects O 0 1.949150600921712e-07
( O 0 5.8751108866772483e-08
n O 0 2.2572214675165014e-07
= O 0 3.5074606330454117e-07
14 O 0 2.46278489157703e-07
) O 0 2.255452002941638e-08
and O 0 2.302447299484811e-08
patients O 0 2.891763450918461e-08
with O 0 7.198882379100269e-09
three O 0 4.1299369257785656e-08
forms O 0 8.878372170784132e-08
of O 0 7.191252734628506e-06
autosomal O 0 0.0021708968561142683
dominant O 0 5.995438186801039e-05
cerebellar B-Disease 0 0.3044584095478058
ataxias I-Disease 0 0.0011509538162499666
type I-Disease 0 1.2222967598063406e-05
I I-Disease 0 1.5594052456435747e-05
spinocerebellar B-Disease 0 0.00034088705433532596
ataxias I-Disease 0 2.0904242774122395e-05
1 I-Disease 0 7.39823349249491e-07
and I-Disease 0 1.2017306971756625e-07
2 I-Disease 0 3.669510419967992e-07
( O 0 1.4672230008727638e-07
SCA1 B-Disease 0 3.945088792534079e-06
, O 0 8.152164099328729e-08
n O 0 3.096745899711095e-07
= O 0 3.149955603021226e-07
11 O 0 2.617269103666331e-07
; O 0 3.640418810846313e-08
SCA2 B-Disease 0 2.4559319626860088e-06
, O 0 5.7983189805099755e-08
n O 0 2.5207964426954277e-07
= O 0 3.3411146205253317e-07
10 O 0 1.4020942273873516e-07
) O 0 3.714507101904019e-08
and O 0 1.639928797203538e-07
SCA3 B-Disease 1 0.9999814033508301
/ O 0 1.0879936780838761e-05
Machado B-Disease 0 6.520289844047511e-06
- I-Disease 0 6.504234988824464e-06
Joseph I-Disease 0 0.00024584485800005496
disease I-Disease 0 2.2499349142890424e-05
( O 0 4.2632672148101847e-07
MJD B-Disease 1 0.9431295990943909
) O 0 9.771184039664149e-08
( O 0 5.3925806042798285e-08
n O 0 8.255277066382405e-07
= O 0 1.3896677728553186e-06
16 O 0 2.338002332180622e-06
) O 0 6.54650079923158e-07
. O 0 1.3211529221734963e-06

In O 0 4.767059726873413e-05
SCA1 B-Disease 0 0.0002906866720877588
, O 0 1.0248929811496055e-06
saccade O 0 1.523200626252219e-05
amplitude O 0 3.5463663152768277e-06
was O 0 1.6857893569977023e-06
significantly O 0 3.0829437491775025e-07
increased O 0 4.230461456700141e-07
, O 0 1.3338949145236256e-07
resulting O 0 1.0553452511885553e-06
in O 0 1.5894705711616552e-06
hypermetria B-Disease 0 0.0002063242718577385
. O 0 6.641279469477013e-06

The O 0 3.120607652817853e-05
smooth O 0 4.396850636112504e-05
pursuit O 0 3.260547964600846e-05
gain O 0 2.5651161195128225e-05
was O 0 8.284102659672499e-05
decreased O 0 0.000576987222302705
. O 0 6.8250042204454076e-06

In O 0 8.90712472028099e-05
SCA2 B-Disease 0 0.0010567775461822748
, O 0 2.384984099990106e-06
saccade O 0 7.967848068801686e-05
velocity O 0 4.1948365833377466e-05
was O 0 5.534228330361657e-05
markedly O 0 9.679625509306788e-05
decreased O 0 0.00010741550795501098
. O 0 5.6956728258228395e-06

The O 0 1.28843630591291e-05
percentage O 0 4.50803918283782e-06
of O 0 9.209636573359603e-07
errors O 0 7.4861932262138e-06
in O 0 8.337585768458666e-07
antisaccades O 0 2.448134546284564e-05
was O 0 1.2560783488879679e-06
greatly O 0 5.930186830482853e-08
increased O 0 7.802460544326095e-08
and O 0 1.6952137471548667e-08
was O 0 5.085494194645435e-07
significantly O 0 3.2626154222725745e-08
correlated O 0 6.459553247850636e-08
with O 0 9.149283997089697e-09
age O 0 1.6265057638520375e-06
at O 0 0.0010391765972599387
disease O 1 0.5109589099884033
onset O 1 0.9837130308151245
. O 0 5.4080792324384674e-06

In O 0 6.758523340977263e-06
addition O 0 4.752681093123101e-07
, O 0 1.14800911887869e-07
a O 0 5.579444462000538e-08
correlation O 0 1.5093735328264302e-07
between O 0 1.0369953429290035e-07
smooth O 0 7.284951379915583e-07
pursuit O 0 1.3637734355143039e-06
gain O 0 4.701438172105554e-07
and O 0 3.8363751286851766e-08
the O 0 6.027560317534153e-08
number O 0 7.82959332923383e-08
of O 0 1.235197373716801e-06
trinucleotide O 0 9.472104284213856e-05
repeats O 0 5.421588411991252e-06
was O 0 2.3202206648420542e-05
found O 0 1.737536308610288e-06
. O 0 3.128011712760781e-06

In O 0 0.0006590456468984485
SCA3 B-Disease 1 1.0
, O 0 7.047201506793499e-05
gaze B-Disease 0 0.13762231171131134
- I-Disease 0 9.131269325735047e-05
evoked I-Disease 0 4.37408743891865e-05
nystagmus I-Disease 0 0.0004576357896439731
was O 0 4.397219072416192e-06
often O 0 1.222125778355121e-08
present O 0 1.859985943042375e-08
as O 0 4.3367972324404036e-08
was O 0 9.72166617430048e-07
saccade O 0 2.1106750409671804e-06
hypometria O 0 2.0682036847574636e-06
and O 0 8.815364793690605e-08
smooth O 0 1.475250087423774e-06
pursuit O 0 6.721973932144465e-06
gain O 0 6.841471986263059e-06
was O 0 5.444620182970539e-05
markedly O 0 3.345272853039205e-05
decreased O 0 7.573839684482664e-05
. O 0 2.9142381663405104e-06

Three O 0 1.7378482880303636e-05
major O 0 8.833237188810017e-06
criteria O 0 1.2322535667408374e-06
, O 0 3.62771743311896e-07
saccade O 0 8.822461495583411e-06
amplitude O 0 2.33519017456274e-06
, O 0 1.2594016141065367e-07
saccade O 0 2.6167351734329714e-06
velocity O 0 1.7015360072036856e-06
, O 0 1.0746744294465316e-07
and O 0 6.270589381074387e-08
presence O 0 4.7459911911573727e-07
of O 0 7.289688710443443e-06
gaze B-Disease 0 0.041596006602048874
- I-Disease 0 1.2437705663614906e-05
evoked I-Disease 0 6.47346860205289e-06
nystagmus I-Disease 0 7.792534233885817e-06
, O 0 4.702989997440454e-08
permitted O 0 4.978995349347315e-08
the O 0 1.404513909619709e-07
correct O 0 2.629398068165756e-07
assignment O 0 3.967701900364773e-07
of O 0 2.1215959122855566e-07
90 O 0 2.1020201756982715e-07
% O 0 6.467838176149598e-08
of O 0 2.4838911372171424e-07
the O 0 5.248315915196144e-07
SCA1 B-Disease 0 7.743705282337032e-06
, O 0 2.6259790786298254e-08
90 O 0 4.99722432323324e-08
% O 0 2.9021126835004907e-08
of O 0 2.2021106360625708e-07
the O 0 6.11647124060255e-07
SCA2 B-Disease 0 1.3952576409792528e-05
, O 0 4.977979273235178e-08
and O 0 3.0357544034131934e-08
93 O 0 5.218141723162262e-07
% O 0 3.16723358650961e-08
of O 0 1.7938975815923186e-07
the O 0 5.932222961746447e-07
patients O 0 2.6887633453043236e-07
with O 0 5.32351691617805e-07
SCA3 B-Disease 1 1.0
to O 0 1.2762050971559802e-07
their O 0 5.34365902638001e-08
genetically O 0 3.108623332082061e-07
confirmed O 0 2.3510576738772215e-06
patient O 0 1.5941583342282684e-06
group O 0 1.213085170093109e-07
and O 0 7.117756695151911e-08
, O 0 4.630059180499302e-08
therefore O 0 9.157877656207347e-08
, O 0 7.352893760526058e-08
may O 0 2.1190784593727585e-07
help O 0 7.74933539560152e-08
orient O 0 2.1092357201268896e-05
diagnoses O 0 8.177668860298581e-06
of O 0 1.2022081136819907e-05
SCA1 B-Disease 1 0.5397815108299255
, O 0 7.169655873440206e-07
SCA2 B-Disease 0 6.391234637703747e-05
, O 0 1.001851899218309e-07
and O 0 2.1736343569500605e-07
SCA3 B-Disease 1 0.9999984502792358
at O 0 1.1369191952326219e-06
early O 0 9.308730852808367e-08
clinical O 0 4.5342568455453147e-07
stages O 0 4.1508022263769817e-07
of O 0 8.009266707631468e-07
the O 0 5.8514638112683315e-06
diseases O 1 0.590221643447876
. O 0 4.64104033426338e-07
. O 0 3.2718314741941867e-06

Genetic O 0 9.011802831082605e-06
basis O 0 2.4743585527176037e-06
and O 0 5.901267741137417e-07
molecular O 0 2.170822335756384e-05
mechanism O 0 7.623401324963197e-05
for O 0 6.817276880610734e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.000279805448371917

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9999972581863403
causes O 0 3.621106952778064e-05
more O 0 1.1588969783815628e-07
than O 0 4.6658747976380255e-08
300 O 0 1.519487824452881e-07
, O 0 2.6942736042201432e-08
000 O 0 4.2104733211090206e-07
sudden O 0 8.801753210718744e-07
deaths O 0 1.4143206783501228e-07
each O 0 1.2516542469143133e-08
year O 0 7.040699046001464e-08
in O 0 5.08463990911423e-08
the O 0 4.734436629405536e-07
USA O 0 4.581646862789057e-06
alone O 0 1.0959672636090545e-06
. O 0 2.3175880414783023e-06

In O 0 1.1563832231331617e-05
approximately O 0 2.1528505840251455e-06
5 O 0 1.797673689907242e-06
- O 0 6.873233928672562e-07
12 O 0 1.779706764182265e-07
% O 0 1.360875323541677e-08
of O 0 2.7446217742976842e-08
these O 0 2.0373036591081473e-09
cases O 0 5.5855320368891626e-09
, O 0 9.272453915798451e-09
there O 0 7.554399772402576e-09
are O 0 4.392822994248036e-09
no O 0 6.132438556960551e-08
demonstrable O 0 0.04099172353744507
cardiac O 1 1.0
or O 0 4.4671896830550395e-06
non O 0 0.008865537121891975
- O 0 0.005272413603961468
cardiac O 1 0.9999994039535522
causes O 0 2.3871132270869566e-07
to O 0 7.641481225562075e-09
account O 0 7.0867334223123635e-09
for O 0 7.11417147414295e-09
the O 0 2.846159752323274e-08
episode O 0 8.041267562930443e-08
, O 0 1.215277745103549e-08
which O 0 6.579119027350089e-09
is O 0 1.1933281029996579e-08
therefore O 0 2.3867347209716172e-08
classified O 0 2.710727926569234e-07
as O 0 1.2536880603875034e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 4.010141856269911e-05
IVF B-Disease 1 1.0
) O 0 9.276814694203495e-07
. O 0 8.593155484959425e-07

A O 0 4.4859963963972405e-05
distinct O 0 1.001388341137499e-06
group O 0 1.1104534678452183e-06
of O 0 2.953520606752136e-06
IVF B-Disease 1 1.0
patients O 0 1.2266700650798157e-06
has O 0 1.3261463038816146e-07
been O 0 8.068460743970718e-08
found O 0 1.6781120493192248e-08
to O 0 7.618313091484197e-09
present O 0 3.370383439005309e-08
with O 0 3.960948902204109e-08
a O 0 2.650824171723798e-06
characteristic O 0 7.392945553874597e-05
electrocardiographic O 0 0.04263202100992203
pattern O 0 0.0004523538227658719
. O 0 1.2792682355211582e-05

Because O 0 7.993028702912852e-06
of O 0 2.5629562969697872e-06
the O 0 6.126862786004494e-07
small O 0 7.973761029234083e-08
size O 0 7.628421627714488e-08
of O 0 2.677481631963019e-07
most O 0 2.9001702372966065e-08
pedigrees O 0 1.775787126234718e-07
and O 0 4.2012519685385996e-08
the O 0 2.4398283926529984e-07
high O 0 2.397688695054967e-05
incidence O 0 0.00033583614276722074
of O 0 6.735931037837872e-06
sudden B-Disease 0 0.44763436913490295
death I-Disease 0 0.00018582418852020055
, O 0 5.473543041034645e-08
however O 0 2.4604835502373135e-08
, O 0 1.1098161500910919e-08
molecular O 0 1.6100192112844525e-07
genetic O 0 3.9413247776565186e-08
studies O 0 1.9575726639686764e-07
of O 0 1.7850402400654275e-06
IVF B-Disease 1 0.9999961853027344
have O 0 8.061169864959083e-08
not O 0 2.368585683143465e-08
yet O 0 6.178402855994136e-08
been O 0 3.4934629411509377e-07
done O 0 5.268088898446877e-07
. O 0 2.8042106805514777e-06

Because O 0 5.774871533503756e-05
IVF B-Disease 1 0.9999998807907104
causes O 0 0.0031892508268356323
cardiac O 1 1.0
rhythm O 0 0.2685833275318146
disturbance O 0 9.970511018764228e-05
, O 0 7.840696980565554e-08
we O 0 1.3763943762512554e-08
investigated O 0 1.1992347026534844e-07
whether O 0 4.282022914026129e-08
malfunction O 0 1.6817120922496542e-05
of O 0 1.3896753614517365e-07
ion O 0 1.2587030369104468e-06
channels O 0 1.633058701600021e-07
could O 0 1.504173070543402e-07
cause O 0 1.1116964060420287e-06
the O 0 4.734779679438361e-07
disorder O 0 5.18178012498538e-06
by O 0 3.502211853856352e-08
studying O 0 6.037617339416101e-08
mutations O 0 3.457016006791491e-08
in O 0 5.9138987040796565e-08
the O 0 3.3025798984454013e-07
cardiac O 0 0.06555339694023132
sodium O 0 3.9380970520142e-06
channel O 0 1.153152061306173e-05
gene O 0 1.5522966350545175e-05
SCN5A O 0 0.0009301449754275382
. O 0 1.0433821444166824e-05

We O 0 4.469141458685044e-06
have O 0 4.878913841821486e-07
now O 0 1.201504886694238e-07
identified O 0 2.4497512640664354e-07
a O 0 2.478595035881881e-07
missense O 0 2.6669565613701707e-06
mutation O 0 3.0802047490396944e-07
, O 0 2.221722041895191e-07
a O 0 5.749784008912684e-07
splice O 0 2.9474851999111706e-06
- O 0 2.55734312304412e-06
donor O 0 3.733885591827857e-07
mutation O 0 2.389431870142289e-07
, O 0 7.937767065868684e-08
and O 0 4.925646379660975e-08
a O 0 3.5683532928487693e-07
frameshift O 0 1.938143441293505e-06
mutation O 0 7.557689229997777e-08
in O 0 9.797814470857702e-08
the O 0 1.5002734699010034e-07
coding O 0 2.5507321765871893e-07
region O 0 1.5554915933080338e-07
of O 0 1.9842809706460685e-06
SCN5A O 0 0.00039088583434931934
in O 0 1.1644156074908096e-06
three O 0 1.8684611404751195e-06
IVF B-Disease 1 0.9999918937683105
families O 0 9.738555490912404e-07
. O 0 3.9418318920070305e-06

We O 0 5.385875283536734e-06
show O 0 8.302031915263797e-07
that O 0 6.500786042806794e-08
sodium O 0 1.6670142599650717e-07
channels O 0 5.747580900106186e-08
with O 0 1.4725520358638278e-08
the O 0 1.0335910616277033e-07
missense O 0 1.2822687267544097e-06
mutation O 0 2.1420565587959572e-07
recover O 0 4.358232956747088e-07
from O 0 2.0650037413361133e-07
inactivation O 0 2.9028353310422972e-05
more O 0 6.306642763576065e-09
rapidly O 0 2.9106217880325858e-08
than O 0 6.40090158654516e-09
normal O 0 4.1169524678252856e-08
and O 0 1.2284779415949743e-08
that O 0 6.3136833539090276e-09
the O 0 7.882547237159088e-08
frameshift O 0 9.97443407868559e-07
mutation O 0 5.291547466867996e-08
causes O 0 9.306103265771526e-08
the O 0 8.292379760632684e-08
sodium O 0 1.2473898891585122e-07
channel O 0 1.3619209937587584e-07
to O 0 5.4813678929122034e-08
be O 0 1.6436490568594309e-07
non O 0 4.2636634134396445e-06
- O 0 7.526532954216236e-06
functional O 0 8.240525858127512e-06
. O 0 2.5051112970686518e-06

Our O 0 3.781550549319945e-05
results O 0 4.5857032091589645e-06
indicate O 0 1.111088977268082e-06
that O 0 1.0944271622292945e-07
mutations O 0 2.634337477047666e-07
in O 0 4.7217750420713855e-07
cardiac O 0 0.34816819429397583
ion O 0 4.225766133458819e-06
- O 0 4.7466249952776707e-07
channel O 0 1.1744490535647856e-07
genes O 0 1.1788001685886229e-08
contribute O 0 1.9776161153117755e-08
to O 0 1.0586546750346315e-08
the O 0 5.448201534363761e-08
risk O 0 1.0381689463656585e-07
of O 0 3.230385630104138e-07
developing O 0 2.3309762582357507e-06
IVF B-Disease 1 0.9999845027923584
. O 0 3.7359728821684257e-07
. O 0 1.2959231980858021e-06

Molecular O 0 0.00022601161617785692
heterogeneity O 0 7.977092900546268e-05
in O 0 6.459272754000267e-06
mucopolysaccharidosis B-Disease 0 0.00010255516826873645
IVA I-Disease 0 0.0015018484555184841
in O 0 5.782988523606036e-07
Australia O 0 6.826982712482277e-08
and O 0 2.342835436763835e-08
Northern O 0 5.8393169410919654e-08
Ireland O 0 3.315093977107608e-08
: O 0 9.855576799111532e-09
nine O 0 2.1018832896402273e-08
novel O 0 3.491194178195656e-08
mutations O 0 2.8240268790113987e-08
including O 0 1.0757921131698822e-07
T312S O 0 2.0466091882553883e-05
, O 0 7.38603844752106e-08
a O 0 1.3545931665248645e-07
common O 0 8.678181728782874e-08
allele O 0 3.689096672587766e-07
that O 0 5.260733360046288e-08
confers O 0 6.204682904353831e-06
a O 0 9.579498509992845e-06
mild O 0 0.00030454303487204015
phenotype O 0 0.00031189658329822123
. O 0 8.59829924593214e-06

Mucopolysaccharidosis B-Disease 0 0.40732401609420776
IVA I-Disease 1 0.9997360110282898
( O 0 0.0004211037594359368
MPS B-Disease 1 0.9999905824661255
IVA I-Disease 1 1.0
) O 0 1.607406375114806e-06
is O 0 2.2782489850214915e-07
an O 0 7.27262374766724e-07
autosomal B-Disease 1 0.9195606112480164
recessive I-Disease 1 0.9999979734420776
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.999976396560669
by O 0 3.068089881708147e-06
a O 0 2.8032374757458456e-05
genetic B-Disease 1 0.999977707862854
defect I-Disease 1 0.9999988079071045
in O 0 1.5210683159239125e-05
N O 0 9.278176003135741e-05
- O 0 1.1462479960755445e-05
acetylgalactosamine O 0 0.0001545312552480027
- O 0 4.5796109588991385e-06
6 O 0 1.978817454073578e-05
- O 0 1.069284826371586e-05
sulfate O 0 1.4639996152254753e-05
sulfatase O 0 0.00021457468392327428
( O 0 1.923202034959104e-06
GALNS O 0 0.00018963837646879256
) O 0 1.157398628492956e-06
. O 0 2.0545410279737553e-06

Previous O 0 2.1765954443253577e-05
studies O 0 6.14166674495209e-06
of O 0 4.527694727585185e-06
patients O 0 1.68904182373808e-06
from O 0 9.503939395472116e-07
a O 0 1.6369349395972677e-06
British O 0 5.781053914688528e-06
- O 0 1.0705546173994662e-06
Irish O 0 1.3164851964120317e-07
population O 0 1.0379071824218045e-08
showed O 0 1.6233894939432503e-07
that O 0 2.556883416104938e-08
the O 0 2.195193218312852e-07
I113F O 0 6.84705901221605e-06
mutation O 0 1.6161972382633394e-07
is O 0 3.520079516761143e-08
the O 0 3.341757448538374e-08
most O 0 7.738490737096981e-09
common O 0 1.495627266479005e-08
single O 0 5.782183976066335e-08
mutation O 0 1.5801950326022052e-07
among O 0 3.6980367212890997e-07
MPS B-Disease 1 0.9999202489852905
IVA I-Disease 1 1.0
patients O 0 7.881056944825104e-07
and O 0 8.39163263322007e-08
produces O 0 2.3695983486504701e-07
a O 0 1.5060765008456656e-06
severe O 1 0.657940149307251
clinical O 0 0.04824741929769516
phenotype O 0 0.00039836493670009077
. O 0 9.08717902348144e-06

We O 0 6.118756118667079e-06
studied O 0 5.528592737391591e-06
mutations O 0 1.2278896974748932e-06
in O 0 5.953623940513353e-07
the O 0 5.956974291621009e-07
GALNS O 0 2.0582849174388684e-05
gene O 0 2.8795946604986966e-07
from O 0 4.807810114471067e-07
23 O 0 1.668725644776714e-06
additional O 0 9.225072403751255e-07
MPS B-Disease 0 0.40007802844047546
IVA I-Disease 1 0.9999995231628418
patients O 0 2.3314516965911025e-06
( O 0 1.6597647345406585e-07
15 O 0 3.6245464229978097e-07
from O 0 8.346808044734644e-08
Australia O 0 4.0848437521390224e-08
, O 0 2.143163690959682e-08
8 O 0 1.737695782821902e-07
from O 0 5.225212973414273e-08
Northern O 0 6.059779877887195e-08
Ireland O 0 3.3311430058802216e-08
) O 0 9.258440236692422e-09
, O 0 3.642486534616296e-09
with O 0 2.38957564846487e-09
various O 0 1.2448141184506767e-08
clinical O 0 1.5378171156044118e-05
phenotypes O 0 1.223870367539348e-05
( O 0 9.468042208027327e-07
severe O 0 0.024697525426745415
, O 0 1.2675096172642952e-07
16 O 0 4.0370892406826897e-07
cases O 0 2.9780656163325148e-08
; O 0 2.7603190844160963e-08
intermediate O 0 5.861835461473675e-07
, O 0 3.425562766778967e-08
4 O 0 4.224055203394528e-07
cases O 0 4.7743547781919915e-08
; O 0 5.3287180890038144e-08
mild O 0 2.9239927243907005e-06
, O 0 9.856464089352812e-08
3 O 0 5.915873089179513e-07
cases O 0 2.8655247774622694e-07
) O 0 7.073703613968974e-07
. O 0 3.0762523692828836e-06

We O 0 8.06890420790296e-06
found O 0 8.376399023291015e-07
two O 0 6.882653735829081e-08
common O 0 4.911948536800992e-08
mutations O 0 6.703523069973016e-08
that O 0 2.2112876862934172e-08
together O 0 1.4176581686342615e-08
accounted O 0 3.393943188712001e-07
for O 0 3.008885940403161e-08
32 O 0 1.735830892357626e-07
% O 0 1.8967938331115874e-08
of O 0 1.5505315786867868e-07
the O 0 3.150784664285311e-07
44 O 0 7.333620715144207e-07
unrelated O 0 2.206956679629002e-07
alleles O 0 8.307276289087895e-08
in O 0 6.433547383721816e-08
these O 0 5.557787829957306e-08
patients O 0 1.3126078783898265e-06
. O 0 3.0357398372871103e-06

One O 0 1.368281664326787e-05
is O 0 1.1097758942923974e-06
the O 0 6.340428626572248e-07
T312S O 0 2.0540748664643615e-05
mutation O 0 3.3758209383449866e-07
, O 0 1.2679230110279605e-07
a O 0 1.2383496539314365e-07
novel O 0 1.7579378663867828e-07
mutation O 0 8.674640383787846e-08
found O 0 6.571358568407959e-08
exclusively O 0 5.598301910936243e-08
in O 0 1.4024968209014332e-07
milder O 0 4.723414349427912e-06
patients O 0 1.891993861136143e-06
. O 0 2.6804784738487797e-06

The O 0 2.5584220566088334e-05
other O 0 6.002687769068871e-07
is O 0 2.1267373995215166e-07
the O 0 1.3299039380854083e-07
previously O 0 5.295859182297136e-07
described O 0 6.40507437310589e-07
I113F O 0 1.2042070011375472e-05
that O 0 1.0400695771295432e-07
produces O 0 1.2055005527145113e-06
a O 0 6.78567448630929e-06
severe O 1 0.7062968611717224
phenotype O 0 0.003496375633403659
. O 0 1.2983457963855471e-05

The O 0 6.582867354154587e-05
I113F O 0 0.00020554002549033612
and O 0 2.003258714466938e-06
T312S O 0 2.2561447622138076e-05
mutations O 0 3.2826903861860046e-07
accounted O 0 1.2933995776620577e-06
for O 0 1.076841229519232e-07
8 O 0 4.802714101970196e-07
( O 0 2.5973960759984038e-08
18 O 0 1.2079202349468687e-07
% O 0 2.360845918758514e-08
) O 0 8.258393080495807e-09
and O 0 3.885122623614734e-08
6 O 0 3.2623236734252714e-07
( O 0 2.2293578538779002e-08
14 O 0 1.8251787992085156e-07
% O 0 2.8089585768498182e-08
) O 0 1.374751867899704e-08
of O 0 9.973827985731987e-08
44 O 0 6.891572184031247e-07
unrelated O 0 1.6089262544483063e-07
alleles O 0 2.3275276817003032e-07
, O 0 1.8226096187845542e-07
respectively O 0 3.7273641737556318e-06
. O 0 1.7058416688087163e-06

The O 0 2.128709456883371e-05
relatively O 0 8.262765732069965e-06
high O 0 2.9430299036903307e-05
residual O 0 3.135056613245979e-05
GALNS O 0 0.000352026749169454
activity O 0 6.4535956880718e-06
seen O 0 1.008691015158547e-06
when O 0 1.0698580155121817e-07
the O 0 2.003007324447026e-07
T312S O 0 3.843989361485001e-06
mutant O 0 8.600452474638587e-07
cDNA O 0 4.664398147724569e-06
is O 0 1.8728894701780519e-07
overexpressed O 0 1.339366463071201e-06
in O 0 7.369292376324665e-08
mutant O 0 5.303116950017284e-07
cells O 0 2.4907058104872704e-07
provides O 0 2.3000200854994546e-08
an O 0 2.6084775228696344e-08
explanation O 0 7.505585841727225e-08
for O 0 2.9367082987619142e-08
the O 0 4.859530804424139e-07
mild O 0 5.365941615309566e-05
phenotype O 0 9.481736924499273e-06
in O 0 1.3651940378167637e-07
patients O 0 3.25143325596855e-08
with O 0 1.2782216174400673e-08
this O 0 1.5001661779479036e-07
mutation O 0 2.4545317955926294e-06
. O 0 3.6239694054529537e-06

The O 0 7.883576472522691e-06
distribution O 0 1.7013575188684626e-06
and O 0 4.573726357648411e-07
relative O 0 1.0409820561108063e-06
frequencies O 0 6.403639076779655e-07
of O 0 8.219321330216189e-07
the O 0 1.13404416879348e-06
I113F O 0 1.2212517503940035e-05
and O 0 2.562386214322032e-07
T312S O 0 1.0169328561460134e-05
mutations O 0 1.356727779011635e-07
in O 0 1.6174153927295265e-07
Australia O 0 4.969033895463326e-08
corresponded O 0 5.317478724009561e-08
to O 0 1.060267251773439e-08
those O 0 1.1537840016728751e-08
observed O 0 1.6381953571453778e-07
in O 0 5.292395144351758e-08
Northern O 0 1.0268785644029776e-07
Ireland O 0 1.2514608904723445e-08
and O 0 1.0005663853007718e-08
are O 0 4.0505185872063976e-09
unique O 0 4.5737409415380625e-09
to O 0 5.472412745177735e-09
these O 0 4.22268353617028e-09
two O 0 1.2473382327016225e-08
populations O 0 2.5540467518680998e-08
, O 0 3.74531907709752e-08
suggesting O 0 6.379367079034637e-08
that O 0 7.736129070678999e-09
both O 0 1.8205799534598555e-08
mutations O 0 5.586067786111926e-08
were O 0 2.6506222639000043e-07
probably O 0 1.3937699350208277e-07
introduced O 0 5.2856968579817476e-08
to O 0 1.221853107580273e-08
Australia O 0 3.857411101648722e-08
by O 0 2.3904888735160057e-08
Irish O 0 1.0327496369200162e-07
migrants O 0 9.688341151559143e-08
during O 0 2.5083119226110284e-07
the O 0 3.3628458595558186e-07
19th O 0 4.2412857510498725e-06
century O 0 5.894658443139633e-06
. O 0 2.693955821087002e-06

Haplotype O 0 0.00035725795896723866
analysis O 0 7.038227067823755e-06
using O 0 1.214997155329911e-06
6 O 0 4.532494585873792e-06
RFLPs O 0 5.781340405519586e-06
provides O 0 4.2103970088192e-08
additional O 0 4.006768250519599e-08
data O 0 1.916227034826079e-07
that O 0 2.4843592072443244e-08
the O 0 4.3786468495454756e-07
I113F O 0 1.2877557310275733e-05
mutation O 0 2.642761955939932e-07
originated O 0 4.5172430418460863e-07
from O 0 1.787427379440487e-07
a O 0 4.61826687114808e-07
common O 0 7.286897130143188e-07
ancestor O 0 1.9087186956312507e-05
. O 0 3.4087515814462677e-06

The O 0 2.3583364963997155e-05
other O 0 3.170763989146508e-07
9 O 0 2.0697527816082584e-06
novel O 0 2.5315483753729495e-07
mutations O 0 2.1022508178702992e-07
identified O 0 1.7569674071182817e-07
in O 0 4.831490585388565e-08
these O 0 1.1809335731527426e-08
23 O 0 6.753149364158162e-07
patients O 0 2.4743151527673035e-08
were O 0 5.4095160351153027e-08
each O 0 3.1724072258043634e-09
limited O 0 3.267017945063344e-08
to O 0 4.489747240654651e-08
a O 0 1.0173411055802717e-06
single O 0 2.1450136955536436e-06
family O 0 2.2425888346333522e-06
. O 0 3.54131702806626e-06

These O 0 1.396560264765867e-06
data O 0 8.584014494772418e-07
provide O 0 5.732603369779099e-08
further O 0 4.6838682266070464e-08
evidence O 0 5.2006537742954606e-08
for O 0 3.8621671194505325e-08
extensive O 0 5.255894279798667e-07
allelic O 0 4.9770669647841714e-06
heterogeneity O 0 9.383488759340253e-06
in O 0 5.43098576599732e-06
MPS B-Disease 1 0.7706694006919861
IVA I-Disease 1 0.999997615814209
in O 0 9.321663014816295e-07
British O 0 4.832015292777214e-06
- O 0 2.0673833205364645e-06
Irish O 0 3.871039950809063e-07
patients O 0 2.2990157333424577e-08
and O 0 9.053494842703458e-09
provide O 0 7.606697494111359e-09
evidence O 0 9.42187341479439e-08
for O 0 4.834652500562697e-08
their O 0 4.120244057048694e-08
transmission O 0 2.4404944269917905e-06
to O 0 5.8284790327434166e-08
Australia O 0 1.9595843525621603e-07
by O 0 8.778468441050791e-08
British O 0 1.616371150703344e-06
- O 0 9.837116294875159e-07
Irish O 0 2.1190056997966167e-07
migrants O 0 1.6702747984709276e-07
. O 0 9.246583942967845e-08
. O 0 5.947330237177084e-07

Identification O 0 1.044906548486324e-05
of O 0 5.415221949078841e-06
constitutional O 0 2.7194508220418356e-05
WT1 O 0 0.004067933186888695
mutations O 0 1.0668579761841102e-06
, O 0 1.2837439555823948e-07
in O 0 8.097877213231186e-08
patients O 0 9.668551115282753e-08
with O 0 6.311470457376345e-08
isolated O 0 0.0001294261746807024
diffuse B-Disease 1 0.9999896287918091
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.3086617773060425e-07
and O 0 2.5756104804486313e-08
analysis O 0 5.260191215938903e-08
of O 0 6.329311759145639e-07
genotype O 0 9.977336048905272e-06
/ O 0 1.7023481632350013e-05
phenotype O 0 9.898492407955928e-07
correlations O 0 4.437042662175372e-07
by O 0 4.007777221204378e-08
use O 0 8.355868885701057e-09
of O 0 1.2705872620699665e-07
a O 0 4.6157833821780514e-07
computerized O 0 3.895087047567358e-06
mutation O 0 2.8523716082418105e-06
database O 0 3.2354746508644894e-06
. O 0 4.927722784486832e-06

Constitutional O 0 5.967254764982499e-05
mutations O 0 5.43469468539115e-06
of O 0 5.792985575681087e-06
the O 0 2.1118025870237034e-06
WT1 O 0 3.1715448130853474e-05
gene O 0 3.3343661698381766e-07
, O 0 7.807418000993493e-08
encoding O 0 2.3337979371262918e-07
a O 0 3.7365182379289763e-06
zinc O 0 0.18949684500694275
- O 0 6.617641338380054e-05
finger O 0 3.283614569227211e-05
transcription O 0 1.1675419045786839e-05
factor O 0 5.103416924612247e-07
involved O 0 1.0237690872827443e-07
in O 0 5.655558652506443e-07
renal O 1 0.9999998807907104
and O 0 1.3755749250776717e-06
gonadal O 1 0.9999934434890747
development O 0 4.219033598928945e-06
, O 0 4.553983856681043e-08
are O 0 3.344102550428829e-09
found O 0 1.956970940852898e-08
in O 0 3.606725940130673e-08
most O 0 4.714188861498769e-08
patients O 0 9.88666499779356e-08
with O 0 3.6219304888618353e-07
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.3316977098584175e-05
DDS B-Disease 1 1.0
) O 0 3.5877963000530144e-07
, O 0 1.278230712387085e-07
or O 0 1.4982446145950234e-06
diffuse B-Disease 1 0.9690360426902771
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 4.966662163496949e-05
DMS B-Disease 1 0.9999994039535522
) O 0 1.540197587246439e-07
associated O 0 2.2486594275505922e-07
with O 0 1.024708780050787e-07
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.3166941243980546e-05
/ O 0 0.2867313623428345
or O 0 7.161009853007272e-05
Wilms B-Disease 1 1.0
tumor I-Disease 1 1.0
( O 0 1.5233270460157655e-05
WT B-Disease 1 0.9999990463256836
) O 0 1.3952982271803194e-06
. O 0 1.273320549444179e-06

Most O 0 1.0524814570089802e-05
mutations O 0 1.5078763681231067e-05
in O 0 2.6437694032210857e-05
DDS B-Disease 1 1.0
patients O 0 1.6609710655757226e-05
lie O 0 8.377193807973526e-06
in O 0 4.5520991420744394e-07
exon O 0 9.894283721223474e-07
8 O 0 9.224140171681938e-07
or O 0 1.2953829298112396e-07
exon O 0 5.007299819226319e-07
9 O 0 1.0237861260975478e-06
, O 0 5.501929223328261e-08
encoding O 0 1.733060202013803e-07
zinc O 0 2.4011736968532205e-05
finger O 0 1.4552162610925734e-05
2 O 0 3.402119773454615e-06
or O 0 1.3374557283896138e-06
zinc O 0 0.0004922504303976893
finger O 0 1.2924457223562058e-05
3 O 0 9.178807545140444e-07
, O 0 5.66525422129871e-08
respectively O 0 1.1711517089452173e-07
, O 0 1.2695232420867342e-08
with O 0 1.8534379364609777e-08
a O 0 6.237606271497498e-07
hot O 0 7.4079584919672925e-06
spot O 0 3.241778586016153e-06
( O 0 1.4473452836227807e-07
R394W O 0 2.724089426919818e-06
) O 0 6.782206440902883e-08
in O 0 1.373148563743598e-07
exon O 0 1.8391814364804304e-06
9 O 0 8.213403816625942e-06
. O 0 2.1806802124046953e-06

We O 0 3.3381825232936535e-06
analyzed O 0 1.192238073599583e-06
a O 0 5.151341611053795e-07
series O 0 3.0492356017930433e-07
of O 0 6.012037943037285e-07
24 O 0 2.177675014536362e-06
patients O 0 8.512700588880762e-08
, O 0 7.467644991265843e-08
10 O 0 1.0236128389351506e-07
with O 0 7.174827487688162e-08
isolated B-Disease 0 1.257416806765832e-05
DMS I-Disease 1 0.9989339709281921
( O 0 8.618696369921963e-07
IDMS B-Disease 0 4.894601079286076e-05
) O 0 8.301954323997052e-08
, O 0 3.1882407824923575e-08
10 O 0 7.433950344193363e-08
with O 0 1.2304083440994873e-07
DDS B-Disease 1 1.0
, O 0 2.393416025370243e-07
and O 0 8.768929404823211e-08
4 O 0 1.7204213236254873e-06
with O 0 3.6320375329523813e-07
urogenital B-Disease 1 0.9999998807907104
abnormalities I-Disease 1 0.9999998807907104
and O 0 0.009636237286031246
/ O 1 0.9999717473983765
or O 0 0.03115815296769142
WT B-Disease 1 1.0
. O 0 1.2039544344588649e-05

We O 0 5.96228419453837e-05
report O 0 4.1523297113599256e-05
WT1 O 0 0.00023473148758057505
heterozygous O 0 2.4385030883422587e-06
mutations O 0 7.030110964478808e-07
in O 0 5.040156452196243e-07
16 O 0 1.6777141809143359e-06
patients O 0 1.4450931473675155e-07
, O 0 4.456889968196265e-08
4 O 0 3.779232997658255e-07
of O 0 4.408530003274791e-07
whom O 0 3.851838812352071e-07
presented O 0 1.7153753333332133e-06
with O 0 2.5415924937988166e-06
IDMS B-Disease 1 0.9967578053474426
. O 0 2.627251888043247e-05

One O 0 2.826899435603991e-05
male O 0 6.036102149664657e-06
and O 0 7.040926561785454e-07
two O 0 5.495882078321301e-07
female O 0 7.583205297123641e-05
IDMS B-Disease 1 0.9999978542327881
patients O 0 3.6288806768425275e-06
with O 0 1.2592926168508711e-06
WT1 O 1 0.9999862909317017
mutations O 0 0.0002392133610555902
underwent O 1 0.9999732971191406
normal O 0 0.002407096093520522
puberty O 0 0.011472424492239952
. O 0 6.51532354822848e-06

Two O 0 9.246648914995603e-06
mutations O 0 2.4562303224229254e-05
associated O 0 8.00247198640136e-06
with O 0 8.916519504964526e-07
IDMS B-Disease 1 0.6753506064414978
are O 0 2.6262947372401868e-08
different O 0 3.551843263949195e-09
from O 0 7.020543790758893e-08
those O 0 2.4648990404330107e-08
described O 0 1.0189664862991776e-06
in O 0 6.516336270578904e-06
DDS B-Disease 1 1.0
patients O 0 3.177451071678661e-05
. O 0 5.47521040061838e-06

No O 0 4.3051761167589575e-05
WT1 O 0 0.00033373344922438264
mutations O 0 1.800696963982773e-06
were O 0 1.0017168960985146e-06
detected O 0 1.4457812085311161e-06
in O 0 1.5796270247392385e-07
the O 0 2.0471426864787645e-07
six O 0 3.0506259918183787e-07
other O 0 1.590946112628444e-07
IDMS B-Disease 1 0.999924898147583
patients O 0 8.077404913819919e-07
, O 0 5.304805839045912e-08
suggesting O 0 1.0710115816436883e-07
genetic O 0 1.2925977443956072e-07
heterogeneity O 0 2.7769062853622017e-06
of O 0 4.555514351523016e-06
this O 0 6.751662112947088e-06
disease O 1 0.6681602001190186
. O 0 6.242609288165113e-06

We O 0 6.947704150661593e-06
analyzed O 0 6.6406714722688776e-06
genotype O 0 1.6391986719099805e-05
/ O 0 1.6971287550404668e-05
phenotype O 0 3.9658361856709234e-06
correlations O 0 2.658186076587299e-06
, O 0 2.142614334843529e-07
on O 0 2.2837241431261646e-07
the O 0 3.882056276438561e-08
basis O 0 6.517110762160883e-08
of O 0 1.3601648163330537e-07
the O 0 3.0157463015711983e-07
constitution O 0 1.9206913748348597e-07
of O 0 2.5882403065224935e-07
a O 0 1.0961920224872301e-06
WT1 O 0 1.705588510958478e-05
mutation O 0 2.1787147375107452e-07
database O 0 2.3365149104392913e-07
of O 0 8.247070013567281e-07
84 O 0 2.328542177565396e-05
germ O 0 0.298208087682724
- O 0 1.0099700375576504e-05
line O 0 1.4796208915868192e-06
mutations O 0 4.972655887058863e-08
, O 0 1.505777191823654e-08
to O 0 4.418705401576517e-09
compare O 0 5.986780848843409e-09
the O 0 1.9117033289717256e-08
distribution O 0 6.960331688787846e-08
and O 0 2.322608949612004e-08
type O 0 1.720647873071357e-07
of O 0 2.315263003538348e-07
mutations O 0 1.4649677382294612e-07
, O 0 3.245565949328011e-08
according O 0 1.0785139004099165e-08
to O 0 9.884021601180848e-09
the O 0 1.0852538423478109e-07
different O 0 5.3223086382558904e-08
symptoms O 0 0.0014382264344021678
. O 0 7.72827843320556e-06

This O 0 5.524049811356235e-06
demonstrated O 0 5.04140552948229e-06
( O 0 2.6198964064860775e-07
1 O 0 6.820714588684496e-07
) O 0 1.0764345859115565e-07
the O 0 2.1012505158068961e-07
association O 0 7.43417700732607e-08
between O 0 2.6206052439192717e-08
mutations O 0 3.450382379810435e-08
in O 0 8.093029180145095e-08
exons O 0 2.743290679063648e-07
8 O 0 6.064300919206289e-07
and O 0 1.095747137469516e-07
9 O 0 2.8015215320920106e-06
and O 0 5.899354391658562e-07
DMS B-Disease 0 0.24642615020275116
; O 0 5.0412332086580136e-08
( O 0 2.979327007324173e-08
2 O 0 1.6743753405989992e-07
) O 0 2.136315480072426e-08
among O 0 1.4177771845425013e-08
patients O 0 5.6191520769743875e-08
with O 0 1.4632377087764326e-07
DMS B-Disease 1 0.9995169639587402
, O 0 1.1037516145506743e-07
a O 0 1.4912824042312423e-07
higher O 0 1.1132637922628419e-07
frequency O 0 7.151696479468228e-08
of O 0 7.99309916033053e-08
exon O 0 2.076176315313205e-07
8 O 0 1.3999859049818042e-07
mutations O 0 3.055895803072417e-08
among O 0 2.085188377520808e-08
46 O 0 8.137263876051293e-07
, O 0 2.507465524104191e-07
XY O 1 0.7227359414100647
patients O 0 2.3012449901216314e-07
with O 0 6.767101012883359e-08
female O 0 2.5287133667006856e-06
phenotype O 0 2.0254155970178545e-06
than O 0 2.998161718892334e-08
among O 0 1.3611503923982582e-08
46 O 0 6.197925017659145e-07
, O 0 2.461192991631833e-07
XY O 0 0.00881852488964796
patients O 0 8.973625398311924e-08
with O 0 2.3785272418308523e-08
sexual O 0 8.573558716307161e-07
ambiguity O 0 8.987395631265827e-06
or O 0 1.0249780189042212e-06
male O 0 7.057188327053154e-07
phenotype O 0 6.160576049296651e-07
; O 0 2.0284563362338304e-08
and O 0 3.3397565601944734e-08
( O 0 2.0477999740364794e-08
3 O 0 6.668021512723499e-08
) O 0 4.5969703599269e-09
statistically O 0 1.028238383327107e-08
significant O 0 8.044946042673473e-09
evidence O 0 1.8765378584362225e-08
that O 0 5.973196159914096e-09
mutations O 0 1.9972480558294592e-08
in O 0 6.821008469160006e-08
exons O 0 1.8806142065841414e-07
8 O 0 4.1825430230346683e-07
and O 0 7.26878255363772e-08
9 O 0 1.2724003681796603e-06
preferentially O 0 2.528681761759799e-07
affect O 0 4.283730277165887e-07
amino O 0 3.523001907979051e-07
acids O 0 3.938228942956812e-08
with O 0 4.346964566082079e-09
different O 0 3.3025082668558525e-09
functions O 0 1.6239175693044672e-07
. O 0 1.6639646105431893e-07
. O 0 9.118153343479207e-07

The O 0 3.931602986995131e-05
185delAG O 0 5.502736530615948e-05
BRCA1 O 0 1.6166908608283848e-05
mutation O 0 2.058367272184114e-06
originated O 0 9.519151262793457e-07
before O 0 1.9391663386159053e-07
the O 0 6.756847170663605e-08
dispersion O 0 6.44211866074329e-07
of O 0 1.5099162453680037e-07
Jews O 0 1.4630256828240817e-07
in O 0 3.842379925345085e-08
the O 0 8.108386850835814e-08
diaspora O 0 9.235726849965431e-08
and O 0 4.80424375837174e-08
is O 0 2.2214672767972843e-08
not O 0 1.6010336167937567e-08
limited O 0 1.2773568869306473e-07
to O 0 3.47025576274973e-07
Ashkenazim O 0 4.1673843952594325e-05
. O 0 2.7032049274566816e-06

The O 0 2.135462091246154e-05
185delAG O 0 5.0900602218462154e-05
mutation O 0 1.3589321952167666e-06
in O 0 3.935300867397018e-07
BRCA1 O 0 3.308151235614787e-06
is O 0 1.156201179242089e-07
detected O 0 2.7986914119537687e-07
in O 0 4.625168870120433e-08
Ashkenazi O 0 4.2110556819352496e-07
Jews O 0 4.739279191312562e-08
both O 0 1.0686951767979735e-08
in O 0 1.0641332437444362e-07
familial B-Disease 0 0.20538407564163208
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.0134285680105677e-06
in O 0 1.3729302281717537e-06
the O 0 1.650129206609563e-06
general O 0 6.2682133830094244e-06
population O 0 1.5083892321854364e-06
. O 0 2.5023152829817263e-06

All O 0 5.6560725170129444e-06
tested O 0 3.021727934537921e-06
Ashkenazi O 0 4.827851626032498e-06
mutation O 0 4.731999183604785e-07
carriers O 0 1.704968468629886e-07
share O 0 5.386330315104715e-08
the O 0 5.751725851155243e-08
same O 0 3.382103486160304e-08
allelic O 0 1.1565887234610273e-06
pattern O 0 2.221990143880248e-06
at O 0 2.3517416138929548e-06
the O 0 9.318089269072516e-07
BRCA1 O 0 2.0460121959331445e-05
locus O 0 7.887712854426354e-05
. O 0 6.480485353677068e-06

Our O 0 1.546954081277363e-05
previous O 0 4.042238742840709e-06
study O 0 1.1105456678706105e-06
showed O 0 1.9972878817497985e-06
that O 0 1.2657025649787101e-07
this O 0 1.1023441004454071e-07
Ashkenazi O 0 2.6829438866116107e-06
mutation O 0 3.7002698149990465e-07
also O 0 2.6153878707191325e-07
occurs O 0 1.200799175649081e-07
in O 0 5.026130622809433e-08
Iraqi O 0 9.374001592732384e-07
Jews O 0 6.832870980133521e-08
with O 0 9.646517362682516e-09
a O 0 9.019027658041523e-08
similar O 0 1.0117974369450167e-07
allelic O 0 1.142432665801607e-05
pattern O 0 3.4541531931608915e-05
. O 0 6.8785716393904295e-06

We O 0 1.2743415936711244e-05
extended O 0 1.2190257621114142e-05
our O 0 1.8433958075547707e-06
analysis O 0 6.640403285018692e-07
to O 0 3.03083737662746e-07
other O 0 2.164068035881428e-07
non O 0 1.216148302773945e-05
- O 0 6.540381036757026e-06
Ashkenazi O 0 2.0992406462028157e-06
subsets O 0 9.103947604671703e-07
354 O 0 2.1357709556468762e-06
of O 0 3.288004393198207e-07
Moroccan O 0 9.694699656392913e-06
origin O 0 1.5451186641257664e-07
, O 0 6.123567430904586e-08
200 O 0 1.734726993163349e-07
Yemenites O 0 1.314993482992577e-06
and O 0 1.3006786048208596e-07
150 O 0 6.038942501618294e-07
Iranian O 0 6.526119250338525e-06
Jews O 0 3.17220792567241e-06
. O 0 3.277583800809225e-06

Heteroduplex O 0 0.001555230817757547
analysis O 0 1.5455651009688154e-05
complemented O 0 6.642672815360129e-06
by O 0 2.0288923963107663e-07
direct O 0 3.1781868869984464e-07
DNA O 0 5.002546004106989e-07
sequencing O 0 1.8347595869272482e-06
of O 0 2.3764471279719146e-06
abnormally O 0 2.4165741706383415e-05
migrating O 0 1.392300674751823e-07
bands O 0 2.1291259599820478e-07
were O 0 2.6931698471344134e-07
employed O 0 1.974794486159226e-06
. O 0 1.3558666296376032e-06

Four O 0 1.9494847947498783e-05
of O 0 1.5172710845945403e-05
Moroccan O 0 9.285982378059998e-05
origin O 0 6.899535947013646e-07
( O 0 1.0783066528574636e-07
1 O 0 2.1256120419366198e-07
. O 0 1.398653548534412e-08
1 O 0 7.776282728855222e-08
% O 0 2.481650440699923e-08
) O 0 1.3492910788670542e-08
and O 0 1.4722318475435259e-08
none O 0 3.433241602124326e-08
of O 0 5.639950018121453e-07
the O 0 1.7935706182470312e-06
Yemenites O 0 3.762822643693653e-06
or O 0 1.3906617368775187e-07
Iranians O 0 6.621028205699986e-07
was O 0 6.47352749183483e-07
a O 0 6.860425827426297e-08
carrier O 0 1.3079304039820272e-07
of O 0 1.5226093807996222e-07
the O 0 4.874927981290966e-07
185delAG O 0 1.0954533536278177e-05
mutation O 0 3.6133437788521405e-06
. O 0 3.044054210477043e-06

BRCA1 O 0 0.00020059941743966192
allelic O 0 6.719378870911896e-05
patterns O 0 8.045307367865462e-06
were O 0 1.9072402892561513e-06
determined O 0 2.2020412870915607e-07
for O 0 4.9965574788757294e-08
four O 0 3.548154836607864e-08
of O 0 7.691802039744289e-08
these O 0 7.277547009465479e-09
individuals O 0 5.647256440255433e-09
and O 0 4.211007365029218e-08
for O 0 9.233013997800299e-08
12 O 0 1.0158190661968547e-06
additional O 0 6.883906280563679e-07
non O 0 2.9042419555480592e-05
- O 0 7.894545888120774e-06
Ashkenazi O 0 2.836226485669613e-06
185delAG O 0 1.2497848729253747e-06
mutation O 0 8.034093212927473e-08
carriers O 0 8.305739385150446e-08
who O 0 1.0521932125584499e-07
had O 0 6.974922598601552e-06
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00011364673991920426

Six O 0 0.00015417275426443666
non O 0 0.0009001592989079654
- O 0 0.00022645315038971603
Ashkenazi O 0 2.9931197786936536e-05
individuals O 0 9.428471514638659e-08
shared O 0 5.724014613406325e-07
the O 0 8.852480846144317e-07
common O 0 3.828327805877052e-07
Ashkenazi O 0 3.787917648878647e-06
haplotype O 0 5.219727427174803e-06
, O 0 9.426385361166467e-08
four O 0 8.227910797131699e-08
had O 0 5.432915486380807e-07
a O 0 2.951472026779811e-07
closely O 0 1.0185181764654772e-07
related O 0 3.2625445101075456e-07
pattern O 0 3.713448904818506e-06
, O 0 1.250814705144876e-07
and O 0 6.310868627679156e-08
the O 0 3.528351726345136e-07
rest O 0 1.1034463653913917e-07
( O 0 4.5504759071945955e-08
n O 0 3.814006390712166e-07
= O 0 6.610176228605269e-07
6 O 0 5.008971584175015e-07
) O 0 1.6210496056601187e-08
displayed O 0 6.491926285434602e-08
a O 0 2.6013129428292814e-08
distinct O 0 2.2153150425197055e-08
BRCA1 O 0 2.9458665267156903e-06
allelic O 0 6.363353804772487e-06
pattern O 0 1.356052507617278e-05
. O 0 2.1932901290711015e-06

We O 0 6.265272531891242e-06
conclude O 0 4.996389634470688e-06
that O 0 2.1847193920621066e-07
the O 0 5.912263532081852e-07
185delAG O 0 4.010429620393552e-06
BRCA1 O 0 4.259672550688265e-06
mutation O 0 3.742570129361411e-07
occurs O 0 1.713000301606371e-07
in O 0 1.1815558309535845e-07
some O 0 4.061653058329284e-08
non O 0 2.4122598460962763e-06
- O 0 1.7144168396043824e-06
Ashkenazi O 0 8.275566187876393e-07
populations O 0 3.394589853655816e-08
at O 0 3.6381840118338005e-07
rates O 0 9.575559545282886e-08
comparable O 0 6.581694123042325e-08
with O 0 1.414757111461995e-08
that O 0 6.77707205909428e-08
of O 0 3.950412519770907e-06
Ashkenazim O 0 7.682659634156153e-05
. O 0 4.183594683127012e-06

The O 0 6.979474164836574e-06
majority O 0 2.5101928713411326e-07
of O 0 7.077117629705754e-07
Jewish O 0 2.022848320848425e-06
185delAG O 0 7.818182893970516e-06
mutation O 0 3.8685965364493313e-07
carriers O 0 2.1546486550505506e-07
have O 0 3.971797468693694e-08
a O 0 7.571323834554278e-08
common O 0 7.334712393003429e-08
allelic O 0 9.582975053490372e-07
pattern O 0 1.3845271951140603e-06
, O 0 7.594653084197489e-08
supporting O 0 2.4509665763616795e-07
the O 0 5.898656354474952e-07
founder O 0 9.471200428379234e-06
effect O 0 5.092249466542853e-07
notion O 0 2.4708563728381705e-07
, O 0 4.1806206496630693e-08
but O 0 7.4376065306580585e-09
dating O 0 5.578688799801057e-08
the O 0 5.6415103699691826e-08
mutations O 0 2.4510732998805906e-08
origin O 0 4.3842874219990335e-08
to O 0 4.327484859345532e-08
an O 0 1.2601584842286684e-07
earlier O 0 2.4598929826424865e-07
date O 0 3.734736537808203e-07
than O 0 9.631482100758149e-08
currently O 0 6.301456778601278e-07
estimated O 0 2.2244578303798335e-06
. O 0 3.290085260232445e-06

However O 0 1.1011134120053612e-05
, O 0 5.443676514005347e-07
the O 0 1.6251539136646898e-07
different O 0 9.489140140317431e-09
allelic O 0 9.567140750732506e-07
pattern O 0 3.1096838029043283e-06
at O 0 3.1928041153150843e-06
the O 0 2.555635774115217e-07
BRCA1 O 0 1.3460929721986759e-06
locus O 0 1.8772882413031766e-06
even O 0 1.6223612675503318e-08
in O 0 1.612243316628792e-08
some O 0 3.2776705793935434e-09
Jewish O 0 7.547648550598751e-08
mutation O 0 6.015375220158603e-08
carriers O 0 7.448654315567182e-08
, O 0 1.616375300272921e-08
might O 0 1.5719246349021887e-08
suggest O 0 2.0898069053032486e-08
that O 0 8.269505968883095e-09
the O 0 3.752655430844243e-08
mutation O 0 5.4861061471456196e-08
arose O 0 1.9202005319129967e-07
independently O 0 8.833272602259967e-08
. O 0 3.1809494771550817e-07
. O 0 1.442603661416797e-06

Crystal O 0 0.0024389647878706455
structure O 0 9.030121873365715e-05
of O 0 2.798165223794058e-05
the O 0 9.0751753305085e-05
hemochromatosis B-Disease 1 1.0
protein O 0 0.0003604570229072124
HFE O 1 0.6698706746101379
and O 0 8.871928685039165e-07
characterization O 0 5.1834408623108175e-06
of O 0 1.0261458101012977e-06
its O 0 3.0920301696824026e-07
interaction O 0 6.922762736394361e-07
with O 0 1.0197325082117459e-06
transferrin O 0 0.00018306121637579054
receptor O 0 8.982096915133297e-05
. O 0 9.44471776165301e-06

HFE O 1 0.9729741811752319
is O 0 3.9245605876203626e-05
an O 0 9.337062692793552e-06
MHC O 0 7.457812171196565e-05
- O 0 8.421369784628041e-06
related O 0 7.991724828571023e-07
protein O 0 4.805133357876912e-07
that O 0 3.7377255068804516e-08
is O 0 3.585285313079112e-08
mutated O 0 1.0354438018111978e-07
in O 0 2.0321823512858828e-07
the O 0 7.4993558882852085e-06
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.013452786952257156

HFE O 0 0.007891962304711342
binds O 0 7.878662290750071e-05
to O 0 6.405290605471237e-06
transferrin O 0 0.00012982245243620127
receptor O 0 2.4184091671486385e-05
( O 0 1.4918385886630858e-06
TfR O 0 0.00022228046145755798
) O 0 1.0621278079270269e-07
and O 0 4.4300154655729784e-08
reduces O 0 1.869204737658947e-07
its O 0 7.392888079493787e-08
affinity O 0 4.924415861751186e-07
for O 0 5.008923835703172e-07
iron O 0 0.0010375541169196367
- O 0 8.14046052255435e-06
loaded O 0 1.3104565823596204e-06
transferrin O 0 1.1082676792284474e-05
, O 0 2.529883147417422e-07
implicating O 0 6.234172178665176e-05
HFE O 1 0.8749579787254333
in O 0 2.6341307602706365e-05
iron O 1 0.9999946355819702
metabolism O 0 0.18472760915756226
. O 0 5.559023975365562e-06

The O 0 0.0001763713953550905
2 O 0 0.0001608101010788232
. O 0 3.0266364774433896e-05

6 O 0 0.000491021666675806
A O 0 0.00014869235747028142
crystal O 0 0.00015278377395588905
structure O 0 1.3936245522927493e-05
of O 0 9.010067515191622e-06
HFE O 0 0.05603413283824921
reveals O 0 1.7375480183545733e-06
the O 0 3.801974912676087e-07
locations O 0 2.1050112763987272e-07
of O 0 6.973380550334696e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 2.356892082389095e-06
and O 0 1.593653678355622e-06
a O 0 5.6276103350683115e-06
patch O 0 3.073547486565076e-05
of O 0 1.505906129750656e-05
histidines O 0 9.707929712021723e-05
that O 0 9.362559438841345e-08
could O 0 3.350054100792477e-08
be O 0 2.3708997431981516e-08
involved O 0 4.7446064854739234e-08
in O 0 3.349454118506401e-07
pH O 0 4.680981146520935e-05
- O 0 7.736404768365901e-06
dependent O 0 1.2857499314122833e-06
interactions O 0 1.8176206140196882e-06
. O 0 2.1636130895785755e-06

We O 0 1.2393044926284347e-05
also O 0 1.2740468946503825e-06
demonstrate O 0 1.0167165100938291e-06
that O 0 7.275356210811879e-07
soluble O 0 3.191603173036128e-05
TfR O 1 0.5002391934394836
and O 0 1.7027631429300527e-06
HFE O 0 0.00017058805678971112
bind O 0 7.999304898476112e-07
tightly O 0 2.2287683805188863e-06
at O 0 2.7950686671829317e-06
the O 0 3.2976041097754205e-07
basic O 0 5.68454254334938e-07
pH O 0 2.9735813313891413e-06
of O 0 1.1718517498593428e-06
the O 0 7.166826208049315e-07
cell O 0 3.879771611536853e-06
surface O 0 1.5843521623537526e-06
, O 0 1.9304019360788516e-07
but O 0 3.783025448456101e-08
not O 0 4.7281918824637614e-08
at O 0 2.2406861717172433e-06
the O 0 9.151380027105915e-07
acidic O 0 6.3441939346375875e-06
pH O 0 2.1150166503502987e-05
of O 0 1.4319111869554035e-05
intracellular O 0 0.000218808141653426
vesicles O 0 0.00023426399275194854
. O 0 7.84888743510237e-06

TfR O 1 0.9890986680984497
HFE O 0 0.02426992356777191
stoichiometry O 0 0.0003934849810320884
( O 0 6.830695383541752e-06
2 O 0 4.3243599066045135e-06
1 O 0 2.0161439806543058e-06
) O 0 2.7032825755668455e-07
differs O 0 1.6630016830276872e-07
from O 0 3.7475774661288597e-07
TfR O 0 5.810174479847774e-05
transferrin O 0 5.441188022814458e-06
stoichiometry O 0 1.4798706615692936e-06
( O 0 8.44110701336831e-08
2 O 0 1.3679543542366446e-07
2 O 0 1.6593611462667468e-07
) O 0 2.3458984088620127e-08
, O 0 1.2869575627405538e-08
implying O 0 8.380068550195574e-08
a O 0 2.38079671532887e-08
different O 0 1.060424414944805e-09
mode O 0 3.303757267758556e-08
of O 0 2.2635626706346557e-08
binding O 0 9.333869854799559e-08
for O 0 1.20674357617645e-07
HFE O 0 3.919361552107148e-05
and O 0 1.8505261323298328e-07
transferrin O 0 8.399521902902052e-06
to O 0 2.5753729460120667e-07
TfR O 0 0.0007785462075844407
, O 0 1.1778341502122203e-07
consistent O 0 1.784785439440384e-07
with O 0 2.4087690064789058e-08
our O 0 1.7349620407003385e-07
demonstration O 0 3.5528996704670135e-06
that O 0 1.8894067466135311e-07
HFE O 0 7.613738853251562e-05
, O 0 3.0134694384287286e-07
transferrin O 0 8.12060352473054e-06
, O 0 1.4473273779458395e-07
and O 0 1.6778840006281825e-07
TfR O 0 0.000972630106844008
form O 0 4.6039573931011546e-07
a O 0 3.7770887502119876e-06
ternary O 0 5.351872823666781e-05
complex O 0 2.7870095436810516e-05
. O 0 5.47287118024542e-06

Identification O 0 7.087342964950949e-06
of O 0 1.6246468703684513e-06
three O 0 1.351245089153963e-07
novel O 0 1.89840690723031e-07
mutations O 0 8.909211857144328e-08
and O 0 7.068619822803157e-08
a O 0 2.277360522384697e-07
high O 0 1.3690054174730903e-06
frequency O 0 3.806977986187121e-07
of O 0 2.007518702384914e-07
the O 0 3.2799587756926485e-07
Arg778Leu O 0 6.4692162595747504e-06
mutation O 0 1.082805738406023e-07
in O 0 2.162013430506704e-07
Korean O 0 1.5469866411876865e-05
patients O 0 4.1424974028814177e-07
with O 0 8.265187148026598e-07
Wilson B-Disease 0 0.4312816262245178
disease I-Disease 1 0.8344521522521973
. O 0 1.1318561519146897e-05

Four O 0 4.682244616560638e-05
mutations O 0 1.2681733096542303e-05
- O 0 4.422068013809621e-05
- O 0 3.810473936027847e-05
R778L O 0 6.296739593381062e-05
, O 0 7.718533652223414e-07
A874V O 0 1.3392934306466486e-05
, O 0 3.53342613834684e-07
L1083F O 0 4.645128228730755e-06
, O 0 1.4686972349409189e-07
and O 0 1.1109305830814264e-07
2304delC O 0 1.8095815903507173e-06
- O 0 7.537340138696891e-07
- O 0 4.5215443833512836e-07
in O 0 1.4370971257449128e-07
the O 0 6.244046062420239e-07
copper O 0 6.242356903385371e-05
- O 0 1.361857698611857e-06
transporting O 0 2.9034029012109386e-06
enzyme O 0 8.966171662905253e-07
, O 0 2.9641088872267574e-07
P O 0 2.010864409385249e-05
- O 0 1.2434779819159303e-06
type O 0 2.5916021968441783e-06
ATPase O 0 4.345831257523969e-05
( O 0 1.6292025861730508e-07
ATP7B O 0 4.5542892621597275e-06
) O 0 1.1503999530759756e-08
, O 0 5.43466427416206e-09
were O 0 1.548646721971636e-08
identified O 0 3.610297838463339e-08
in O 0 2.070173792390051e-07
Korean O 0 0.0001070084108505398
Patients O 0 1.4018364709045272e-06
with O 0 1.3057559726803447e-06
Wilson B-Disease 1 0.9375805258750916
disease I-Disease 1 0.9811413288116455
. O 0 7.8202265285654e-06

Arg778Leu O 0 0.0029439625795930624
, O 0 7.171801826189039e-06
the O 0 1.019823912429274e-06
most O 0 7.462875117880685e-08
frequently O 0 8.96250682558275e-08
reported O 0 2.3858839881540916e-07
mutation O 0 7.352669229021558e-08
of O 0 4.147379399910278e-07
this O 0 6.456522783082619e-08
enzyme O 0 1.3835699519404443e-07
, O 0 4.339635495398397e-08
was O 0 8.182336159734405e-07
found O 0 3.638460910337926e-08
in O 0 2.2811942557154907e-08
six O 0 4.533201902745532e-08
of O 0 2.601807409519097e-07
eight O 0 5.079784273220866e-07
unrelated O 0 1.189680347124522e-06
patients O 0 1.1667394517189678e-07
studied O 0 7.410887405967514e-07
, O 0 7.192544160261605e-08
an O 0 3.705880757820523e-08
allele O 0 6.686769182806529e-08
frequency O 0 3.8431502957791963e-07
of O 0 1.666160642344039e-06
37 O 0 2.237520311609842e-05
. O 0 6.527824552904349e-06

5 O 0 1.3886245142202824e-05
% O 0 5.65702578114724e-07
, O 0 1.2143421201926685e-07
which O 0 5.311234829719069e-08
is O 0 3.661777014940526e-08
considerably O 0 7.911980048902478e-08
higher O 0 7.43985140161385e-08
than O 0 2.3926132186602445e-09
those O 0 2.611991067880126e-09
in O 0 3.610573173773446e-08
other O 0 3.303114937125429e-08
Asian O 0 6.862472332613834e-07
populations O 0 1.1891830808963277e-07
. O 0 7.896396709838882e-07

The O 0 2.2057598471292295e-05
novel O 0 7.5320831456338055e-06
single O 0 1.1154567118865089e-06
nucleotide O 0 2.5030526558111887e-06
deletion O 0 3.4021329611277906e-06
, O 0 3.0388341087927984e-07
2304delC O 0 1.9420510852796724e-06
, O 0 1.1739383865005948e-07
was O 0 1.1051899946323829e-06
found O 0 8.877474755308867e-08
in O 0 1.4593760511161236e-07
one O 0 6.693161935800163e-07
patient O 0 2.2601070668315515e-05
. O 0 1.2702477761195041e-05

Since O 0 3.3145028282888234e-05
a O 0 5.658554528054083e-06
mutation O 0 1.333306499873288e-06
at O 0 2.9077477847749833e-06
cDNA O 0 5.359467650123406e-06
nucleotide O 0 6.036550985299982e-06
2302 O 0 3.703226684592664e-05
( O 0 3.6231327271707414e-07
2302insC O 0 2.097915739796008e-06
) O 0 6.904163996068746e-08
had O 0 3.6645931800194376e-07
been O 0 1.597010026443968e-07
previously O 0 3.0787538207732723e-07
described O 0 2.1897361079936672e-07
, O 0 1.991336873174987e-08
this O 0 1.2557887174580173e-08
region O 0 4.9195055140671684e-08
of O 0 3.4231078416269156e-07
the O 0 1.64603022767551e-06
ATP7B O 0 0.0030995099805295467
gene O 0 1.112278596338001e-06
may O 0 8.710400152267539e-07
be O 0 1.607251647328667e-07
susceptible O 0 6.255144171518623e-07
to O 0 1.0220678348105139e-07
gene O 0 4.88477917315322e-06
rearrangements O 0 0.20685699582099915
causing O 1 0.9996211528778076
Wilson B-Disease 1 0.994890570640564
disease I-Disease 1 0.9974707365036011
. O 0 1.4915135579940397e-05

Disruption O 0 0.0008087827009148896
of O 0 1.1962325515924022e-05
splicing O 0 5.010881523048738e-06
regulated O 0 1.8254430642627995e-06
by O 0 5.385271606428432e-07
a O 0 1.6424048681074055e-06
CUG O 0 0.00011021403770428151
- O 0 2.9767932119284524e-06
binding O 0 1.3699809642275795e-06
protein O 0 9.12185714696534e-06
in O 0 2.097309334203601e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.5060669284139294e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00022743856243323535
DM B-Disease 1 1.0
) O 0 1.454009748158569e-06
is O 0 1.9623428215709282e-07
caused O 0 9.924515325110406e-07
by O 0 8.216446900632945e-08
a O 0 2.1776905612114206e-07
CTG O 0 5.327170129021397e-06
expansion O 0 3.380176281098102e-07
in O 0 3.430531947401505e-08
the O 0 5.179035156288592e-08
3 O 0 1.914057321528162e-07
untranslated O 0 2.0021243472001515e-06
region O 0 2.6284200771442556e-07
of O 0 2.4933656277426053e-06
the O 0 3.424921669648029e-05
DM B-Disease 1 1.0
gene O 0 2.391214729868807e-05
. O 0 7.983377145137638e-06

One O 0 2.457814298395533e-05
model O 0 1.0898129403358325e-05
of O 0 2.898638922488317e-05
DM B-Disease 1 1.0
pathogenesis O 1 0.9946852922439575
suggests O 0 1.5173908423093962e-06
that O 0 1.2139160787683068e-07
RNAs O 0 2.544529479564517e-06
from O 0 1.7829752607667615e-07
the O 0 3.928865410784965e-08
expanded O 0 5.98390670347726e-08
allele O 0 5.425201266007207e-08
create O 0 1.8499203946475973e-08
a O 0 2.3625625544809736e-07
gain O 0 6.627737434428127e-07
- O 0 5.984146014270664e-07
of O 0 1.6136065141836298e-06
- O 0 9.323734388999583e-07
function O 0 9.8477450194423e-08
mutation O 0 2.2326601012423453e-08
by O 0 3.455789610029569e-08
the O 0 6.858789447505842e-08
inappropriate O 0 1.4650026969320606e-07
binding O 0 4.5592159381158126e-08
of O 0 1.5386751783807995e-07
proteins O 0 8.017010344474329e-08
to O 0 1.4199130760061962e-07
the O 0 3.0831515687168576e-06
CUG O 0 0.0007370905368588865
repeats O 0 3.0063503800192848e-05
. O 0 7.928633749543224e-06

Data O 0 7.720556459389627e-05
presented O 0 1.708694799162913e-05
here O 0 1.8734322111413348e-06
indicate O 0 1.0023017011917545e-06
that O 0 1.2501122625963035e-07
the O 0 5.686266604243428e-07
conserved O 0 2.5141966943920124e-06
heterogeneous O 0 4.949108642904321e-06
nuclear O 0 3.4164724638685584e-05
ribonucleoprotein O 0 8.86017587617971e-05
, O 0 9.030162004819431e-07
CUG O 0 2.4065744582912885e-05
- O 0 1.007834271149477e-06
binding O 0 6.529123766085831e-07
protein O 0 9.491511718806578e-07
( O 0 4.174473531293188e-07
CUG O 0 2.918106474680826e-05
- O 0 3.138248530376586e-06
BP O 0 6.230761300685117e-06
) O 0 5.2456233134989816e-08
, O 0 3.6766206079619224e-08
may O 0 7.306981331112183e-08
mediate O 0 2.7922129675062024e-07
the O 0 5.400628424467868e-07
trans O 0 2.0311140360718127e-06
- O 0 1.4744821328349644e-06
dominant O 0 2.0961788038675877e-07
effect O 0 1.3342612703581835e-07
of O 0 3.414070306462236e-07
the O 0 6.94168363679637e-07
RNA O 0 7.505623671022477e-06
. O 0 1.933056182679138e-06

CUG O 0 0.11225538700819016
- O 0 0.0006375818629749119
BP O 0 0.00022540774079971015
was O 0 1.0630428732838482e-05
found O 0 2.540496950587112e-07
to O 0 2.6702082323026843e-08
bind O 0 7.755870967685041e-08
to O 0 7.579068039831327e-08
the O 0 1.2395635167194996e-06
human O 0 3.0026829335838556e-05
cardiac O 1 1.0
troponin O 1 0.9999969005584717
T O 0 0.001170340576209128
( O 0 5.74681280340883e-07
cTNT O 0 2.800559968818561e-06
) O 0 4.9225558740317865e-08
pre O 0 1.1807510418293532e-06
- O 0 5.20158664585324e-07
messenger O 0 3.7076418379911047e-07
RNA O 0 9.632032771378363e-08
and O 0 1.8990853334344138e-08
regulate O 0 4.6402611530993454e-08
its O 0 6.365559812593347e-08
alternative O 0 6.553121920660487e-07
splicing O 0 3.6908422771375626e-06
. O 0 2.440161779304617e-06

Splicing O 0 7.603885023854673e-05
of O 0 1.394240007357439e-05
cTNT O 0 7.992609607754275e-05
was O 0 3.0173569030012004e-05
disrupted O 0 6.299861706793308e-05
in O 0 7.04935155226849e-06
DM B-Disease 1 1.0
striated O 0 0.0004391662951093167
muscle O 0 1.0277666660840623e-05
and O 0 3.105346024767641e-07
in O 0 2.0619359020201955e-07
normal O 0 5.626283154924749e-07
cells O 0 3.028626736067963e-07
expressing O 0 1.3803779097543156e-07
transcripts O 0 1.3884410918763024e-06
that O 0 1.6959390336523938e-07
contain O 0 1.9186679764970904e-06
CUG O 0 0.001165890833362937
repeats O 0 4.5946122554596514e-05
. O 0 1.0405044122308027e-05

Altered O 0 6.188161205500364e-05
expression O 0 8.463727681373712e-06
of O 0 1.832283601288509e-06
genes O 0 6.535577767863288e-07
regulated O 0 1.6975131984509062e-06
posttranscriptionally O 0 8.94366985448869e-06
by O 0 2.402297809567244e-07
CUG O 0 6.938414298929274e-05
- O 0 6.674741598544642e-06
BP O 0 4.076752247783588e-06
therefore O 0 7.963623005480258e-08
may O 0 9.610598539211423e-08
contribute O 0 1.1245813169580288e-07
to O 0 7.166033242356207e-07
DM B-Disease 1 1.0
pathogenesis O 1 0.9928860068321228
. O 0 1.7419314417566056e-06
. O 0 2.039744231296936e-06

Identification O 0 9.50002868194133e-06
of O 0 4.867359621130163e-06
a O 0 2.8188558189867763e-06
novel O 0 1.501382826063491e-06
nonsense O 0 2.2844983504910488e-06
mutation O 0 1.1138691746737095e-07
and O 0 6.030447252669546e-08
a O 0 2.502314941921213e-07
missense O 0 9.222943617714918e-07
substitution O 0 8.036864755922579e-07
in O 0 1.8085208353113558e-07
the O 0 4.4180251279613003e-07
vasopressin O 0 5.325940946931951e-06
- O 0 3.5492455481289653e-06
neurophysin O 0 9.077990398509428e-06
II O 0 0.00011320770863676444
gene O 0 9.911171616749925e-08
in O 0 3.5051392899276834e-08
two O 0 2.079024774559457e-08
Spanish O 0 5.57265821043984e-07
kindreds O 0 3.1961949389369693e-06
with O 0 2.204806719419139e-07
familial B-Disease 1 0.9969102740287781
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999977350234985
. O 0 3.0267001420725137e-05

Familial B-Disease 1 0.9999947547912598
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.0034790339414030313
FNDI B-Disease 1 1.0
) O 0 1.0555394283073838e-06
is O 0 5.76695136089711e-08
an O 0 1.7534975427224708e-07
autosomal B-Disease 1 0.7620524764060974
dominant I-Disease 1 0.99953293800354
disease I-Disease 1 1.0
caused O 1 0.9999991655349731
by O 0 0.014211044646799564
deficiency O 1 1.0
in O 0 3.955294960178435e-05
the O 0 5.7347329857293516e-05
antidiuretic O 0 0.21669524908065796
hormone O 0 4.869080657954328e-05
arginine O 0 8.561853064747993e-06
vasopressin O 0 4.450173037184868e-06
( O 0 3.397557293283171e-07
AVP O 0 1.7534637663629837e-05
) O 0 4.292211741585561e-08
encoded O 0 7.000780044563726e-08
by O 0 1.4679760340641224e-07
the O 0 1.3929621900388156e-06
AVP O 0 0.0005095424712635577
- O 0 9.111146937357262e-06
neurophysin O 0 6.182863580761477e-05
II O 1 0.9688032865524292
( O 0 1.943527877301676e-06
AVP O 0 0.003508487716317177
- O 0 4.315254955145065e-06
NPII O 0 2.955275158456061e-05
) O 0 1.552449049313509e-07
gene O 0 3.891285871304717e-07
on O 0 6.339990250125993e-06
chromosome O 0 0.0044340877793729305
20p13 O 0 0.009361425414681435
. O 0 1.0055953680421226e-05

In O 0 1.1281339538982138e-05
this O 0 2.2862805337808823e-07
study O 0 2.788971471545665e-07
, O 0 7.749364527853686e-08
we O 0 1.3656491937297233e-08
analyzed O 0 7.616166186608098e-08
two O 0 2.3769626267267085e-08
families O 0 1.5431830036050087e-08
with O 0 7.916765554227823e-08
FNDI B-Disease 1 0.9997735619544983
using O 0 7.003330892985105e-08
direct O 0 2.6993049573320604e-07
automated O 0 3.827604814432561e-06
fluorescent O 0 1.2177789585621213e-06
, O 0 5.367071054251937e-08
solid O 0 2.491974839813338e-07
phase O 0 7.570759521513537e-07
, O 0 3.7840575117797925e-08
single O 0 9.792639588113161e-08
- O 0 2.903309166413237e-07
stranded O 0 2.247321617687703e-07
DNA O 0 4.827465005519116e-08
sequencing O 0 3.563544339613145e-07
of O 0 2.599290155558265e-06
PCR O 0 4.265958705218509e-05
- O 0 2.372290146013256e-05
amplified O 0 0.00014103429566603154
AVP O 0 0.004552200902253389
- O 0 1.751718627929222e-05
NPII O 0 0.00010720246791606769
DNA O 0 5.317668637871975e-06
. O 0 5.1160354814783204e-06

In O 0 1.4713732525706291e-05
one O 0 1.0576403610684793e-06
of O 0 6.764725526409165e-07
the O 0 4.5827206918147567e-07
families O 0 3.912264290306666e-08
, O 0 3.689813965479516e-08
affected O 0 5.503807898321611e-08
individuals O 0 1.0258582427979945e-08
presented O 0 3.712304987857351e-07
a O 0 4.1092724245572754e-07
novel O 0 5.343679845282168e-07
nonsense O 0 1.323773631156655e-06
mutation O 0 6.723448109369201e-08
in O 0 8.465583078987038e-08
exon O 0 1.2943777960572334e-07
3 O 0 1.6210735509503138e-07
of O 0 2.0402625011683995e-07
the O 0 1.999489853687919e-07
gene O 0 6.058231605265973e-08
, O 0 2.963723666482565e-08
consisting O 0 6.307270439265267e-08
in O 0 1.4163993000693154e-07
a O 0 1.4005175899001188e-06
G O 0 1.9472405256237835e-05
to O 0 4.955367103320896e-07
T O 0 4.7628880565753207e-05
transition O 0 2.1142327568668406e-06
at O 0 2.925482249338529e-06
nucleotide O 0 9.589447245161864e-07
2101 O 0 6.249549187486991e-06
, O 0 2.6867965630117396e-08
which O 0 1.486225897906479e-08
produces O 0 1.72795004971249e-08
a O 0 4.0842127901896674e-08
stop O 0 4.784966378679201e-08
signal O 0 2.9102315579621063e-07
in O 0 1.3486328498402145e-07
codon O 0 1.4053864560992224e-06
82 O 0 1.6951092902672826e-06
( O 0 1.2804426319235063e-07
Glu O 0 2.5679257305455394e-05
) O 0 2.036330215560156e-07
of O 0 3.889897470799042e-06
NPII O 0 0.001270368928089738
. O 0 6.4683586060709786e-06

The O 0 0.00016375206178054214
premature O 0 0.00035765807842835784
termination O 0 3.8895967009011656e-05
eliminates O 0 5.7241304602939636e-06
part O 0 7.772855497023556e-07
of O 0 2.372619974266854e-06
the O 0 3.0965857149567455e-06
C O 0 3.2259638828691095e-05
- O 0 3.937154815503163e-06
terminal O 0 2.0286912331357598e-05
domain O 0 6.138067760730337e-07
of O 0 9.256639259547228e-07
NPII O 0 4.427562453201972e-05
, O 0 1.6298474747600267e-07
including O 0 1.0870272149077209e-07
a O 0 2.6014996024059656e-07
cysteine O 0 7.595450313147012e-08
residue O 0 2.5107817691605305e-07
in O 0 7.976118610031335e-08
position O 0 3.0539152362507593e-07
85 O 0 2.5132709424724453e-07
, O 0 1.5008911447011997e-08
which O 0 1.385793169106364e-08
could O 0 7.472529262031458e-09
be O 0 1.3960894662545797e-08
involved O 0 3.044911167648934e-08
in O 0 1.4990435204254027e-07
the O 0 8.33288765988982e-07
correct O 0 2.2422893835027935e-06
folding O 0 1.1811939657491166e-05
of O 0 4.626268491847441e-06
the O 0 1.0626891707943287e-05
prohormone O 0 0.003925854340195656
. O 0 6.0938614296901505e-06

In O 0 2.52575318882009e-05
the O 0 6.446312909247354e-06
second O 0 6.296384071902139e-06
family O 0 7.900743526079168e-07
, O 0 3.442964100486279e-07
a O 0 9.463673222853686e-07
G279A O 0 1.7096974261221476e-05
substitution O 0 6.365969966282137e-06
at O 0 4.264069957571337e-06
position O 0 8.942346880758123e-07
- O 0 1.8021076186869323e-07
1 O 0 1.4109903645476152e-07
of O 0 9.80916539106147e-08
the O 0 1.9251714888923743e-07
signal O 0 2.1202499738137703e-06
peptide O 0 4.462095830604085e-07
was O 0 4.93237735099683e-07
observed O 0 3.905733336750927e-08
in O 0 2.1772041947087928e-08
all O 0 1.5223648119899735e-08
affected O 0 1.5072704684371274e-07
individuals O 0 8.05499169587165e-08
. O 0 1.867513446995872e-06

This O 0 1.2528443221526686e-05
missense O 0 5.07017393829301e-05
mutation O 0 6.483217475761194e-06
, O 0 1.3216922525316477e-06
which O 0 9.707806611913838e-07
replaces O 0 3.2510321034351364e-05
Ala O 0 0.00011142334551550448
with O 0 3.2538815730731585e-07
Thr O 0 0.001828587963245809
, O 0 1.7626366854983644e-07
is O 0 2.4400044651429198e-08
frequent O 0 6.708409472366839e-08
among O 0 2.659595850218466e-07
FNDI B-Disease 1 1.0
patients O 0 5.043233386459178e-07
and O 0 1.2509613611655368e-07
is O 0 8.355313951824428e-08
thought O 0 1.9463358924554086e-08
to O 0 4.675315246061018e-09
reduce O 0 2.2200440596975568e-08
the O 0 1.0929667837444867e-07
efficiency O 0 1.9830520159302978e-07
of O 0 1.9720081922969257e-07
cleavage O 0 4.247855486028129e-06
by O 0 4.1772372583182005e-07
signal O 0 1.2321113899815828e-05
peptidases O 0 2.1339823433663696e-05
. O 0 5.668729272656492e-07
. O 0 2.6572583919914905e-06

Genetic O 0 7.19356830813922e-05
heterogeneity O 0 0.0003267128486186266
of O 0 0.00017302465857937932
Saethre B-Disease 1 0.9999957084655762
- I-Disease 1 0.9999977350234985
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.0997354138453375e-06
due O 0 5.029419298807625e-06
to O 0 3.1169500402938866e-07
TWIST O 0 1.9584853362175636e-05
and O 0 2.1113876300660195e-06
FGFR O 0 0.06565103679895401
mutations O 0 1.960286681423895e-05
. O 0 9.887511623674072e-06

Thirty O 0 0.0002948030596598983
- O 0 5.031621549278498e-05
two O 0 3.061642814827792e-07
unrelated O 0 3.4667302770685637e-06
patients O 0 2.5057991592802864e-07
with O 0 4.83343534085634e-08
features O 0 5.975284125270264e-07
of O 0 2.5859488232526928e-05
Saethre B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.5502779383023153e-07
a O 0 4.937201651955547e-07
common O 0 8.021993949114403e-07
autosomal B-Disease 0 0.02206427790224552
dominant I-Disease 0 0.07835966348648071
condition I-Disease 1 0.679541289806366
of O 1 0.8001097440719604
craniosynostosis B-Disease 1 1.0
and O 0 0.40918999910354614
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9991629123687744
, O 0 2.8469560220401036e-07
were O 0 1.180921600507645e-07
screened O 0 1.1693671808643558e-07
for O 0 2.791386854994471e-08
mutations O 0 1.4781045365452883e-07
in O 0 8.218576112994924e-07
TWIST O 0 1.1416082088544499e-05
, O 0 9.541755616737646e-07
FGFR2 O 0 0.0002932210045401007
, O 0 7.037677960397559e-07
and O 0 1.6723099633964011e-06
FGFR3 O 0 0.1358185112476349
. O 0 1.744194196362514e-05

Nine O 0 2.370293441344984e-05
novel O 0 4.055997123941779e-06
and O 0 6.969198125261755e-07
three O 0 5.474466320265492e-07
recurrent O 0 0.00017278724408242851
TWIST O 0 7.969388207129668e-06
mutations O 0 1.6905133293221297e-07
were O 0 1.5559665200726158e-07
found O 0 5.201209418714825e-08
in O 0 7.326337225777024e-08
12 O 0 6.726153856106976e-07
families O 0 2.0703573966329714e-07
. O 0 3.0337284897541394e-06

Seven O 0 2.073630821541883e-05
families O 0 4.69574302996989e-07
were O 0 6.257590143832203e-07
found O 0 9.991993010771694e-08
to O 0 4.684672560983927e-08
have O 0 1.2864916243415792e-07
the O 0 9.521883725938096e-07
FGFR3 O 0 0.00029710945091210306
P250R O 0 2.027122536674142e-05
mutation O 0 3.0211899115784036e-07
, O 0 6.258473206344206e-08
and O 0 4.543312215332662e-08
one O 0 4.2964543922607845e-08
individual O 0 2.6389633589474215e-08
was O 0 6.300739187281579e-06
found O 0 2.651881345627771e-07
to O 0 7.464853979399777e-08
have O 0 1.7819944275743183e-07
an O 0 2.176445832446916e-06
FGFR2 O 0 0.019393065944314003
VV269 O 0 0.0003518687153700739
- O 0 1.175706165668089e-05
270 O 0 7.152117177611217e-06
deletion O 0 2.6846180844586343e-05
. O 0 6.206434591149446e-06

To O 0 3.809668896792573e-06
date O 0 3.517520099194371e-06
, O 0 1.7239544547464902e-07
our O 0 6.29119512041143e-08
detection O 0 4.7310922468568606e-07
rate O 0 1.1992145800832077e-06
for O 0 6.695741205930972e-08
TWIST O 0 2.000122321987874e-06
or O 0 2.6172193656748277e-07
FGFR O 0 1.3127747479302343e-05
mutations O 0 5.2776677250676585e-08
is O 0 2.3781735691841277e-08
68 O 0 1.3654778285854263e-07
% O 0 1.9160035336085457e-08
in O 0 4.7571020900250005e-08
our O 0 6.340246727631893e-07
Saethre B-Disease 1 0.9967710375785828
- I-Disease 1 0.9999496936798096
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 3.379183510787698e-07
, O 0 3.5592780278648206e-08
including O 0 4.5889830602163784e-08
our O 0 6.401966601288223e-08
five O 0 1.3587658997948893e-07
patients O 0 5.789986090576349e-08
elsewhere O 0 1.6734287555664196e-07
reported O 0 4.939457198815944e-07
with O 0 1.770364264075397e-07
TWIST O 0 1.8087266653310508e-05
mutations O 0 3.2288628517562756e-06
. O 0 2.922476141975494e-06

More O 0 3.1670542739448138e-06
than O 0 4.6656879248985206e-07
35 O 0 6.222597903615679e-07
different O 0 3.065551723580029e-08
TWIST O 0 1.4442322253671591e-06
mutations O 0 1.0124538363243119e-07
are O 0 1.328704257730351e-08
now O 0 1.407189476054782e-08
known O 0 3.621664035335925e-08
in O 0 2.1045751807946544e-08
the O 0 1.898921055953906e-07
literature O 0 1.3733886135014473e-06
. O 0 1.7140114323410671e-06

The O 0 1.9638680896605365e-05
most O 0 2.8690413955700933e-07
common O 0 9.283093049816671e-08
phenotypic O 0 1.9699065489930945e-07
features O 0 1.5484729942727427e-07
, O 0 4.027916489235395e-08
present O 0 2.728972248178252e-08
in O 0 3.6940178915756405e-08
more O 0 6.067503388607065e-09
than O 0 1.3391330710987859e-08
a O 0 1.4996756192431349e-07
third O 0 7.374002279902925e-07
of O 0 3.75835440991068e-07
our O 0 3.567900535017543e-07
patients O 0 1.4970819961490633e-07
with O 0 8.940022411252357e-08
TWIST O 0 2.677139491424896e-06
mutations O 0 2.167381012441183e-07
, O 0 1.3147725042017555e-07
are O 0 5.1514103205363426e-08
coronal B-Disease 0 0.0005444365669973195
synostosis I-Disease 0 3.5067936551058665e-05
, O 0 4.898672614217503e-07
brachycephaly B-Disease 0 4.050694769830443e-05
, O 0 9.515130159343244e-07
low B-Disease 0 0.015618936158716679
frontal I-Disease 1 0.9999998807907104
hairline I-Disease 1 1.0
, O 0 7.15084170224145e-05
facial B-Disease 1 0.9999972581863403
asymmetry I-Disease 1 0.9999977350234985
, O 0 6.1027358242427e-06
ptosis B-Disease 1 0.99956876039505
, O 0 1.451115963391203e-06
hypertelorism B-Disease 0 0.0007676939130760729
, O 0 1.4949391697882675e-06
broad B-Disease 0 3.0831823096377775e-05
great I-Disease 0 0.000830319884698838
toes I-Disease 1 0.999680757522583
, O 0 2.9264310796861537e-06
and O 0 3.937267138098832e-06
clinodactyly B-Disease 0 0.44868528842926025
. O 0 2.4150720491888933e-05

Significant O 0 7.254008232848719e-05
intra O 0 0.0021463355515152216
- O 0 4.3710599129553884e-05
and O 0 5.353473397917696e-07
interfamilial O 0 9.506182323093526e-06
phenotypic O 0 4.62956876390308e-07
variability O 0 2.20084575630608e-06
is O 0 5.505466660338243e-08
present O 0 4.0255354605278626e-08
for O 0 5.809433289982735e-08
either O 0 1.2249465441982466e-07
TWIST O 0 3.390149686310906e-06
mutations O 0 7.886252433308982e-07
or O 0 2.2441870441980427e-06
FGFR O 0 0.0009909694781526923
mutations O 0 9.019214303407352e-06
. O 0 6.3638881329097785e-06

The O 0 4.73594036520808e-06
overlap O 0 1.0612808409860008e-06
in O 0 5.011953021494264e-07
clinical O 0 3.3628116398176644e-06
features O 0 2.400571190719347e-07
and O 0 1.770720530203107e-07
the O 0 3.577743825644575e-07
presence O 0 1.3152829581031256e-07
, O 0 7.185139594412249e-08
in O 0 4.291622346386248e-08
the O 0 1.0698131092112817e-07
same O 0 2.036380131187343e-08
genes O 0 2.65587960512903e-08
, O 0 3.499688006058932e-08
of O 0 1.1448472037045576e-07
mutations O 0 7.3190882687868e-08
for O 0 7.232480214725001e-08
more O 0 1.9972290488112776e-08
than O 0 5.581339124205442e-08
one O 0 1.754629863626178e-07
craniosynostotic B-Disease 0 1.5245086615323089e-05
condition I-Disease 0 4.47712636741926e-06
- O 0 9.762387662703986e-07
such O 0 7.092010179121644e-08
as O 0 6.618465135943552e-07
Saethre B-Disease 0 1.0785451195260976e-05
- I-Disease 0 1.648100351303583e-06
Chotzen I-Disease 0 7.287464086402906e-06
, I-Disease 0 1.840493979443636e-07
Crouzon I-Disease 0 1.0217388080491219e-05
, I-Disease 0 2.0171775361177424e-07
and I-Disease 0 7.802756840646907e-07
Pfeiffer I-Disease 1 0.9003945589065552
syndromes I-Disease 1 0.9469835758209229
- O 0 4.212969997752225e-06
support O 0 3.0161606900946936e-07
the O 0 2.3273345561847236e-07
hypothesis O 0 1.249100449740581e-07
that O 0 2.2503513719129842e-08
TWIST O 0 4.715627994755778e-07
and O 0 8.936118689462091e-08
FGFRs O 0 4.496389919950161e-06
are O 0 2.439376345364508e-08
components O 0 1.3263613141134556e-07
of O 0 1.4555675420524494e-07
the O 0 1.234762265767131e-07
same O 0 5.6653302493714364e-08
molecular O 0 1.5228605434458586e-06
pathway O 0 1.5472966197194182e-06
involved O 0 5.1158572489384824e-08
in O 0 3.53832163568768e-08
the O 0 1.2189136100460018e-07
modulation O 0 3.3246099064854207e-06
of O 0 5.929513008595677e-06
craniofacial O 1 0.9999996423721313
and O 0 2.3989605324459262e-05
limb O 1 0.9999998807907104
development O 0 2.048737951554358e-05
in O 0 4.186724993360258e-07
humans O 0 1.0550186146929263e-07
. O 0 1.2993940856631525e-07
. O 0 7.282304750333424e-07

Mutation O 0 3.557908348739147e-05
analysis O 0 6.341714197333204e-06
of O 0 1.3174890227674041e-05
UBE3A O 1 0.9999971389770508
in O 1 0.9716793894767761
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9984733462333679
. O 0 4.59308794233948e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.1278759241104126
AS B-Disease 1 0.9999998807907104
) O 0 8.556128250347683e-07
is O 0 1.8958378689148958e-07
caused O 0 2.520392854421516e-06
by O 0 4.4422927203413565e-07
chromosome O 0 0.10041451454162598
15q11 O 1 0.9970398545265198
- O 0 0.1997356116771698
q13 O 0 0.0040774233639240265
deletions O 0 7.637354428879917e-06
of O 0 5.425167273642728e-06
maternal O 0 0.0001841118501033634
origin O 0 6.43897408281191e-07
, O 0 3.150349243696837e-07
by O 0 3.9653224348512595e-07
paternal O 0 0.002003823406994343
uniparental B-Disease 1 0.9999046325683594
disomy I-Disease 1 0.8424438238143921
( O 0 3.7779248032165924e-06
UPD B-Disease 1 0.9999929666519165
) O 0 1.3820508115713892e-07
15 O 0 2.9920494171165046e-07
, O 0 2.5069553544199152e-08
by O 0 5.390420554363118e-08
imprinting O 0 0.0006263174582272768
defects O 1 0.8144732117652893
, O 0 6.480297543021152e-08
and O 0 2.176066615788841e-08
by O 0 3.266126924472701e-08
mutations O 0 8.093877568171592e-08
in O 0 3.203171843324526e-07
the O 0 6.123431830928894e-06
UBE3A O 0 0.360321581363678
gene O 0 1.2391886230034288e-05
. O 0 5.599525593424914e-06

UBE3A O 0 0.04215298965573311
encodes O 0 0.001013597589917481
a O 0 0.000190454360563308
ubiquitin O 0 0.000547723553609103
- O 0 3.317279333714396e-05
protein O 0 5.249344667390687e-06
ligase O 0 2.2752360564481933e-06
and O 0 2.4044800284173107e-07
shows O 0 2.495249646017328e-06
brain O 0 0.1297801434993744
- O 0 2.1116025891387835e-05
specific O 0 5.607213893199514e-07
imprinting O 0 0.0008191929082386196
. O 0 6.617040980927413e-06

Here O 0 4.907519178232178e-05
we O 0 1.9275703380117193e-06
describe O 0 1.9102528767689364e-06
UBE3A O 0 0.00020671103266067803
coding O 0 6.2351009546546265e-06
- O 0 2.076803184536402e-06
region O 0 1.8214959141005238e-07
mutations O 0 1.559997429012583e-07
detected O 0 9.123990025727835e-07
by O 0 1.0409071649064572e-07
SSCP O 0 8.037056431930978e-06
analysis O 0 4.490997795869589e-08
in O 0 7.241327892870686e-08
13 O 0 1.5334805993916234e-06
AS B-Disease 0 0.061541471630334854
individuals O 0 4.608438075592858e-08
or O 0 3.219001030174695e-07
families O 0 2.428689924727223e-07
. O 0 3.334771463414654e-06

Two O 0 8.502901437168475e-06
identical O 0 3.656853778011282e-06
de O 0 4.536051710601896e-05
novo O 0 2.9033086320850998e-05
5 O 0 5.606547347269952e-06
- O 0 3.672822685985011e-06
bp O 0 3.1525451049674302e-06
duplications O 0 1.737301090543042e-06
in O 0 3.56306856019728e-07
exon O 0 1.3274905086291255e-06
16 O 0 2.0403610960784135e-06
were O 0 1.1820691270258976e-06
found O 0 1.3268904694996309e-06
. O 0 2.9475779683707515e-06

Among O 0 1.0428002497064881e-05
the O 0 1.6424360183009412e-06
other O 0 5.997640784016767e-08
11 O 0 1.7823191456045606e-07
unique O 0 1.641438096555703e-08
mutations O 0 6.484043524324079e-08
, O 0 9.44252676049473e-08
8 O 0 3.7366569927144155e-07
were O 0 1.4282599636317173e-07
small O 0 7.086681819146179e-08
deletions O 0 6.223031618901587e-07
or O 0 1.9620058822056308e-07
insertions O 0 2.294732666996424e-06
predicted O 0 4.497067948250333e-06
to O 0 1.2502171387041017e-07
cause O 0 2.027394430115237e-06
frameshifts O 0 7.32789976609638e-06
, O 0 1.0243648063124056e-07
1 O 0 3.7112292261554103e-07
was O 0 7.346416737163963e-07
a O 0 5.5718302860441327e-08
mutation O 0 2.200222759540793e-08
to O 0 2.5469246267562085e-08
a O 0 2.2285932743670855e-07
stop O 0 2.243328083295637e-07
codon O 0 5.195994390305714e-07
, O 0 2.8301903043370658e-08
1 O 0 7.497988008253742e-08
was O 0 2.679009014627809e-07
a O 0 3.710039209181559e-08
missense O 0 9.381346899317577e-08
mutation O 0 1.6978413341917076e-08
, O 0 1.8525472711417024e-08
and O 0 1.929043236259531e-08
1 O 0 3.474365257716272e-07
was O 0 3.9857345655036625e-06
predicted O 0 8.800779482953658e-07
to O 0 3.6824317817263363e-08
cause O 0 6.79938693792792e-07
insertion O 0 2.7185565159015823e-06
of O 0 7.969357284309808e-06
an O 0 5.555558345804457e-06
isoleucine O 0 8.45954564283602e-05
in O 0 6.803648489039915e-07
the O 0 1.2725993201456731e-06
hect O 0 1.1315053598082159e-05
domain O 0 1.1561299970708205e-06
of O 0 1.3831071328240796e-06
the O 0 2.119704049619031e-06
UBE3A O 0 7.214790093712509e-05
protein O 0 3.629544380601146e-07
, O 0 3.088564071163091e-08
which O 0 1.3198864223795681e-08
functions O 0 7.828965919998154e-08
in O 0 1.6948945358308265e-07
E2 O 0 2.3112193957786076e-05
binding O 0 5.191051286601578e-07
and O 0 6.695651677546266e-07
ubiquitin O 0 1.883418735815212e-05
transfer O 0 7.8520324677811e-06
. O 0 8.727414751774631e-06

Eight O 0 1.699172571534291e-05
of O 0 2.1698681393900188e-06
the O 0 3.5358465311219334e-07
cases O 0 6.963757215316946e-08
were O 0 1.946659438090137e-07
familial O 0 8.842997658575769e-07
, O 0 1.8197231099748024e-07
and O 0 5.4415131955920515e-08
five O 0 9.700100633835973e-08
were O 0 6.476479370576271e-07
sporadic O 0 2.5264469513786025e-05
. O 0 7.1945592026168015e-06

In O 0 7.711051694059279e-06
two O 0 3.82475121796233e-07
familial O 0 6.083467269490939e-06
cases O 0 8.792507628641033e-07
and O 0 5.319847673490585e-07
one O 0 2.743382196968014e-07
sporadic O 0 4.644836280931486e-06
case O 0 2.1071575702080736e-06
, O 0 1.939693419217292e-07
mosaicism O 0 9.181221685139462e-06
for O 0 1.161971283636376e-07
UBE3A O 0 1.3452572602545843e-05
mutations O 0 7.853854100403623e-08
was O 0 2.4912194476200966e-06
detected O 0 3.151343719309807e-07
in O 0 1.1270486055536821e-07
the O 0 1.8514315058837383e-07
mother O 0 3.6469870678956795e-07
of O 0 8.598582326158066e-07
three O 0 8.01680869244592e-07
AS B-Disease 1 0.9999915361404419
sons O 0 1.0886818017752375e-05
, O 0 1.0421766205581662e-07
in O 0 9.538518952467712e-08
the O 0 3.6976064166083233e-07
maternal O 0 7.877701136749238e-05
grandfather O 0 9.385458542965353e-05
of O 0 1.3371622117119841e-05
two O 0 9.151851259048271e-07
AS B-Disease 1 0.9999028444290161
first O 0 2.9421967155940365e-06
cousins O 0 1.8389076785751968e-06
, O 0 1.1493872165146968e-07
and O 0 7.869463303222801e-08
in O 0 2.3066368726176734e-07
the O 0 6.053542165318504e-07
mother O 0 1.6195713214983698e-06
of O 0 1.1509438081702683e-05
an O 0 0.00024179463798645884
AS B-Disease 1 1.0
daughter O 1 0.9906914830207825
. O 0 3.721771645359695e-05

The O 0 1.1261959116382059e-05
frequencies O 0 1.5497761296501267e-06
with O 0 1.1436326730063229e-07
which O 0 6.813544928263582e-08
we O 0 2.4305474966013207e-08
detected O 0 1.029469203217559e-07
mutations O 0 4.432128264397761e-08
were O 0 3.2616702583254664e-07
5 O 0 2.653829369592131e-07
( O 0 1.77193939521203e-08
14 O 0 1.4782102653043694e-07
% O 0 2.246937391703341e-08
) O 0 9.926757194023139e-09
of O 0 1.2155611273101385e-07
35 O 0 1.1050723713879052e-07
in O 0 2.8744194580099247e-08
sporadic O 0 3.59984341002928e-07
cases O 0 4.2573880421059584e-08
and O 0 4.7778438982959415e-08
8 O 0 3.9000985907478025e-07
( O 0 1.1964687018917175e-08
80 O 0 3.355156863449338e-08
% O 0 8.279417151868529e-09
) O 0 4.443027723510795e-09
of O 0 3.848262153383075e-08
10 O 0 5.284164927843449e-08
in O 0 4.0111114429919326e-08
familial O 0 1.2264760016478249e-06
cases O 0 3.97807184526755e-07
. O 0 3.791644473949418e-07
. O 0 1.7050169844878837e-06

The O 0 0.0005702325724996626
hemochromatosis B-Disease 1 0.9999996423721313
845 O 0 0.20345808565616608
G O 0 0.0006910957745276392
- O 0 1.834495742514264e-05
- O 0 6.777551334380405e-06
> O 0 1.7626814496907173e-06
A O 0 1.0430470638311817e-06
and O 0 9.339640172356667e-08
187 O 0 8.535720326108276e-07
C O 0 2.6106433779204963e-06
- O 0 4.6742835024815577e-07
- O 0 8.570640375182847e-07
> O 0 1.417692828908912e-06
G O 0 3.790620667132316e-06
mutations O 0 9.738027983985376e-08
: O 0 4.0963442415886675e-08
prevalence O 0 8.286954766845156e-07
in O 0 9.575961712471326e-08
non O 0 2.9115492452547187e-06
- O 0 3.965590167354094e-06
Caucasian O 0 2.153355580958305e-06
populations O 0 4.2620882823030115e-07
. O 0 8.127925639200839e-07

Hemochromatosis B-Disease 1 0.999997615814209
, O 0 4.278694905224256e-05
the O 0 0.00019901833729818463
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 0.9999974966049194
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9996929168701172
, O 0 4.5424201289279154e-07
leads O 0 6.039276740921196e-07
, O 0 9.31391710423668e-08
if O 0 5.759136101346485e-08
untreated O 0 3.533198469085619e-05
, O 0 1.1556787171684846e-07
to O 0 3.4806166127054894e-07
progressive O 1 0.9907127022743225
iron B-Disease 1 1.0
overload I-Disease 1 0.9999980926513672
and O 0 3.299535092082806e-05
premature B-Disease 1 0.9994958639144897
death I-Disease 1 0.6636644601821899
. O 0 8.975712262326851e-06

The O 0 0.0004125481063965708
hemochromatosis B-Disease 1 1.0
gene O 0 3.8961752579780295e-05
, O 0 2.363762177992612e-06
HFE O 0 0.0009768422460183501
, O 0 4.965168614035065e-07
recently O 0 5.13675217916898e-07
has O 0 9.248048371546247e-08
been O 0 1.1275720623871166e-07
identified O 0 8.539778661997843e-08
, O 0 4.304714096292628e-08
and O 0 6.499112004121343e-08
characterization O 0 2.0201878214720637e-06
of O 0 1.7774859770725016e-06
this O 0 9.438475245815425e-08
gene O 0 1.1558583423720847e-07
has O 0 5.115183654424982e-08
shown O 0 3.9974779042495356e-08
that O 0 1.4594491837272017e-08
it O 0 4.237739492651826e-09
contains O 0 8.220409242198912e-09
two O 0 6.308964906054371e-09
mutations O 0 2.4944444732000193e-08
that O 0 4.040227352675174e-08
result O 0 3.255032936522184e-07
in O 0 3.45238078125476e-07
amino O 0 3.4946657478940324e-07
acid O 0 1.6661813617702137e-07
substitutions O 0 1.4250558422190807e-07
- O 0 7.781206932122586e-07
cDNA O 0 1.3575564707934973e-06
nucleotides O 0 4.653041401070368e-07
845 O 0 6.275941359490389e-06
G O 0 3.13919440486643e-06
- O 0 6.13284328210284e-07
- O 0 6.157932830319623e-07
> O 0 6.894385933264857e-07
A O 0 6.373869609888061e-07
( O 0 5.3773895558606455e-08
C282Y O 0 6.81099720623024e-07
) O 0 1.749873135281632e-08
and O 0 2.8509301586154834e-08
187 O 0 5.416381441136764e-07
C O 0 1.9610122308222344e-06
- O 0 6.153224489935383e-07
- O 0 1.9818771761492826e-06
> O 0 3.140937451462378e-06
G O 0 9.963111551769543e-06
( O 0 3.624954274528136e-07
H63D O 0 4.344323315308429e-05
) O 0 5.793852437818714e-07
. O 0 1.1179530474692e-06

Although O 0 0.0006926882197149098
hemochromatosis B-Disease 1 1.0
is O 0 4.241042915964499e-06
common O 0 3.1252275789483974e-07
in O 0 3.111589421678218e-07
Caucasians O 0 4.813458076569077e-07
, O 0 5.893314991567422e-08
affecting O 0 1.501215365351527e-07
> O 0 3.4999223430531856e-07
= O 0 3.7412925735225144e-07
1 O 0 5.980346600154007e-07
/ O 0 5.946303645032458e-07
300 O 0 5.509648204338191e-08
individuals O 0 3.10633918587655e-09
of O 0 6.846255473647034e-08
northern O 0 1.05362303770562e-07
European O 0 7.868217721807014e-08
origin O 0 2.88287491656547e-08
, O 0 1.1947993705518911e-08
it O 0 2.6647375417354624e-09
has O 0 5.799356106450659e-09
not O 0 3.304209572618788e-09
been O 0 1.660707660278149e-08
recognized O 0 1.6594475127362784e-08
in O 0 3.556468186616257e-08
other O 0 4.065365644123631e-08
populations O 0 3.583303112009162e-07
. O 0 1.6408987448812695e-06

The O 0 1.929312384163495e-05
present O 0 2.413967422398855e-06
study O 0 7.626834985785536e-07
used O 0 7.884710839789477e-07
PCR O 0 7.0707224040234e-06
and O 0 4.759012597332912e-07
restriction O 0 3.2814991755003575e-06
- O 0 6.25133907306008e-07
enzyme O 0 8.897274028640823e-08
digestion O 0 1.4501694067803328e-07
to O 0 1.1087666784703742e-08
analyze O 0 4.287433341687574e-08
the O 0 1.313365061150762e-07
frequency O 0 6.966965315768903e-07
of O 0 7.153087153710658e-07
the O 0 1.0604612725728657e-06
845 O 0 1.560009150125552e-05
G O 0 8.344231900991872e-06
- O 0 9.057373517862288e-07
- O 0 7.624216777912807e-07
> O 0 4.523985523974261e-07
A O 0 5.214858447288861e-07
and O 0 8.208755986061078e-08
187 O 0 1.6335040982085047e-06
C O 0 3.664289579319302e-06
- O 0 4.71758937692357e-07
- O 0 5.975278440928378e-07
> O 0 9.000603995445999e-07
G O 0 1.6381670775444945e-06
mutations O 0 5.4969259366544065e-08
in O 0 4.1661101590761973e-07
HLA O 0 1.4228711734176613e-05
- O 0 5.218087153480155e-07
typed O 0 2.8096610549255274e-07
samples O 0 5.502810651591972e-08
from O 0 1.3526077680126036e-07
non O 0 1.570620156599034e-06
- O 0 4.011264707060036e-07
Caucasian O 0 1.6498350419169583e-07
populations O 0 1.438484353855074e-08
, O 0 9.165073144856706e-09
comprising O 0 2.764629059015533e-08
Australian O 0 3.209106864687783e-07
Aboriginal O 0 1.6973159233657498e-07
, O 0 4.90423488486158e-08
Chinese O 0 2.0764178998433636e-07
, O 0 5.8821417070475945e-08
and O 0 2.202112767690778e-07
Pacific O 0 1.0314860446669627e-05
Islanders O 0 8.934053767006844e-06
. O 0 3.5852215205522953e-06

Results O 0 0.00012340799730736762
showed O 0 2.6655410692910664e-05
that O 0 1.2612492810148979e-06
the O 0 3.1306738037528703e-06
845 O 0 8.963471191236749e-05
G O 0 7.33657943783328e-05
- O 0 1.0173383088840637e-05
- O 0 5.699856956198346e-06
> O 0 1.8878915852837963e-06
A O 0 4.374280990759871e-07
mutation O 0 4.1256779326204196e-08
was O 0 5.189170337871474e-07
present O 0 1.7673793095696055e-08
in O 0 1.6032583260994215e-08
these O 0 5.162601013353196e-09
populations O 0 1.4968257744385483e-08
( O 0 6.4099787699944955e-09
allele O 0 1.414789529974314e-08
frequency O 0 3.5094071648700265e-08
0 O 0 2.0194615757418433e-08
. O 0 3.396932957144827e-09
32 O 0 4.24503845408708e-08
% O 0 1.2426268902743232e-08
) O 0 8.993463751494346e-09
, O 0 1.2719786113279952e-08
and O 0 2.621460204466075e-08
, O 0 2.759055739431915e-08
furthermore O 0 7.967771153971626e-08
, O 0 1.6755501874854417e-08
it O 0 9.160214808900946e-09
was O 0 1.1362341183485114e-06
always O 0 2.8180705768932057e-08
seen O 0 6.86143266648287e-08
in O 0 2.0052830507211183e-08
conjunction O 0 1.2833706364290265e-07
with O 0 6.700481236521227e-08
HLA O 0 0.0016943628434091806
haplotypes O 0 3.3231076486117672e-06
common O 0 2.3197785026241036e-07
in O 0 3.146208769067016e-07
Caucasians O 0 6.446223892453418e-07
, O 0 7.737121165973804e-08
suggesting O 0 2.836470684997039e-07
that O 0 5.812104220126457e-08
845 O 0 8.22489437268814e-06
G O 0 1.1053164598706644e-05
- O 0 2.295993454026757e-06
- O 0 2.292359567945823e-06
> O 0 1.3709505992665072e-06
A O 0 5.877161584066926e-07
may O 0 6.004268016113201e-08
have O 0 9.943774692544594e-09
been O 0 2.5182414375990447e-08
introduced O 0 1.5975500033960088e-08
into O 0 3.2782832004585316e-09
these O 0 1.9417631946794245e-09
populations O 0 1.384395620362966e-08
by O 0 5.144389803035665e-08
Caucasian O 0 2.289910071340273e-06
admixture O 0 2.0329187464085408e-05
. O 0 1.0768185347842518e-05

187 O 0 0.0003291213361080736
C O 0 0.0003149735275655985
- O 0 1.6009294995456003e-05
- O 0 1.8413877114653587e-05
> O 0 6.4376499722129665e-06
G O 0 1.0157987162529025e-05
was O 0 1.368323978567787e-06
present O 0 9.096633135641241e-08
at O 0 3.8209526564969565e-07
an O 0 3.787097213603374e-08
allele O 0 5.667567393174977e-08
frequency O 0 1.983401887173386e-07
of O 0 8.204417554225074e-07
2 O 0 3.3798003187257564e-06
. O 0 1.9099049950455083e-06

68 O 0 4.053561860928312e-05
% O 0 7.569633453385904e-07
in O 0 2.396456011410919e-07
the O 0 8.113553917610261e-08
two O 0 1.8549160429870426e-08
populations O 0 2.3901696621919655e-08
analyzed O 0 2.1933810501195694e-07
( O 0 9.125341904336892e-08
Australian O 0 1.0980795650539221e-06
Aboriginal O 0 5.02236446209281e-07
and O 0 1.997012475385418e-07
Chinese O 0 1.873893211268296e-06
) O 0 5.146029025127064e-07
. O 0 1.3024105101067107e-06

In O 0 2.6852967494050972e-05
the O 0 3.334307166369399e-06
Australian O 0 4.827143129659817e-06
Aboriginal O 0 8.503676554028061e-07
samples O 0 2.910606156092399e-07
, O 0 2.451076284160081e-07
187 O 0 1.8422392713546287e-06
C O 0 6.055359790479997e-06
- O 0 7.357936055996106e-07
- O 0 1.4262470813264372e-06
> O 0 1.9913234154955717e-06
G O 0 4.332309799792711e-06
was O 0 8.867470455697912e-07
found O 0 3.969055839547764e-08
to O 0 2.2157713885917474e-08
be O 0 1.1023946200339196e-07
associated O 0 3.062653490815137e-07
with O 0 2.5348558096993656e-07
HLA O 1 0.9081496000289917
haplotypes O 0 4.804656782653183e-06
common O 0 1.2124743875574495e-07
in O 0 1.619687424181393e-07
Caucasians O 0 3.929158367554919e-07
, O 0 1.964866491732664e-08
suggesting O 0 5.531507341061115e-08
that O 0 7.491252063118736e-09
it O 0 8.04344235660892e-09
was O 0 4.7080027343326947e-07
introduced O 0 6.78929907849124e-08
by O 0 6.26277270043829e-08
recent O 0 3.1907356401461584e-07
admixture O 0 6.613919140363578e-06
. O 0 6.113255949458107e-06

In O 0 3.4627220884431154e-05
the O 0 4.762177013617475e-06
Chinese O 0 2.6351367523602676e-06
samples O 0 2.207318630098598e-07
analyzed O 0 3.419150118588732e-07
, O 0 1.7947668595752475e-07
187 O 0 2.0834706901950995e-06
C O 0 3.7467020774784032e-06
- O 0 6.441799200729292e-07
- O 0 9.016359854285838e-07
> O 0 1.3657427189173177e-06
G O 0 3.99044256482739e-06
was O 0 1.0051686558654183e-06
present O 0 6.287392295689642e-08
in O 0 1.0233473801690707e-07
association O 0 8.011415530972954e-08
with O 0 1.0927100113633514e-08
a O 0 1.5822941179521877e-07
wide O 0 4.235988342315977e-07
variety O 0 6.850644496125824e-08
of O 0 3.3788687687774654e-06
HLA O 0 0.00926897767931223
haplotypes O 0 1.165717776530073e-06
, O 0 3.488544919605374e-08
showing O 0 1.0350075285714411e-07
this O 0 4.698199607133802e-09
mutation O 0 9.440902282165098e-09
to O 0 1.0399858751952706e-08
be O 0 2.3275804394984334e-08
widespread O 0 3.065350426822988e-07
and O 0 1.8649704713880055e-07
likely O 0 2.643977268235176e-07
to O 0 6.627283255511429e-08
predate O 0 2.032532620432903e-06
the O 0 3.3611527783250494e-07
more O 0 2.8657265005449517e-08
genetically O 0 1.014106203456322e-07
restricted O 0 5.265622462502506e-07
845 O 0 1.4739880498382263e-05
G O 0 2.2894404537510127e-05
- O 0 3.5881973872164963e-06
- O 0 3.580069005693076e-06
> O 0 2.2449939933721907e-06
A O 0 1.8769659391182358e-06
mutation O 0 1.7432593040211941e-06
. O 0 1.9170911400578916e-06

Genotype O 0 0.006918913219124079
- O 0 0.0008100133272819221
phenotype O 0 6.95121634635143e-05
correlations O 0 6.459934957092628e-05
in O 0 2.3491580577683635e-05
attenuated B-Disease 1 0.9957866072654724
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.0002025216381298378

Germ O 1 0.999747097492218
- O 0 0.00046620567445643246
line O 0 1.1107055797765497e-05
mutations O 0 3.929904153210373e-07
of O 0 1.0942867447738536e-06
the O 0 3.098617980867857e-06
tumor B-Disease 1 0.999915599822998
suppressor O 1 0.9999943971633911
APC O 0 4.564413029584102e-05
are O 0 4.396261488182063e-08
implicated O 0 1.170648602055735e-06
in O 0 5.465280423777585e-07
attenuated B-Disease 1 0.9552051424980164
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.7278473377227783
AAPC B-Disease 1 1.0
) O 0 1.8374757360106742e-07
, O 0 2.2002900834650063e-08
a O 0 6.076562186763113e-08
variant O 0 3.462355095962266e-07
of O 0 6.573102382390061e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.7671214938163757
FAP B-Disease 1 0.9999514818191528
) O 0 9.278007382818032e-06
. O 0 4.950330549036153e-06

AAPC B-Disease 1 0.9999662637710571
is O 0 3.6810174606216606e-06
recognized O 0 5.944590952822182e-07
by O 0 1.181179527520726e-07
the O 0 2.3071386578976671e-07
occurrence O 0 3.905264520653873e-07
of O 0 9.385871635458898e-07
< O 0 1.875525231298525e-05
100 O 0 2.549696318965289e-06
colonic B-Disease 0 0.004907575435936451
adenomas I-Disease 0 0.0002857679210137576
and O 0 5.04169470616489e-08
a O 0 1.7717846390041814e-07
later O 0 6.293570891102718e-07
onset O 0 0.14268964529037476
of O 0 0.03956584259867668
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.521457531656779e-07
age O 0 2.496391857675917e-07
> O 0 3.666921486455976e-07
40 O 0 3.405524466870702e-07
years O 0 2.243366452603368e-07
) O 0 3.398250782993273e-07
. O 0 2.054468495771289e-06

The O 0 1.0475236194906756e-05
aim O 0 2.5837591692834394e-06
of O 0 7.61944136229431e-07
this O 0 7.025312953601315e-08
study O 0 1.2636894552997546e-07
was O 0 1.144989596468804e-06
to O 0 7.907363652748245e-08
assess O 0 1.021698835756979e-06
genotype O 0 1.2456865079002455e-05
- O 0 5.038665040046908e-05
phenotype O 0 2.0046436475240625e-05
correlations O 0 1.573964982526377e-05
in O 0 4.219881157041527e-05
AAPC B-Disease 1 0.9999996423721313
families O 0 1.1767288015107624e-06
. O 0 3.946639026253251e-06

By O 0 3.294071211712435e-05
protein O 0 1.712734047032427e-05
- O 0 1.0560172995610628e-05
truncation O 0 8.27810144983232e-05
test O 0 1.6832768778840546e-06
( O 0 4.976645868737251e-07
PTT O 0 1.3726075849262998e-05
) O 0 1.052773370702198e-07
assay O 0 1.0811006632138742e-06
, O 0 4.8355193627003246e-08
the O 0 9.241541221172156e-08
entire O 0 1.1084139828199113e-07
coding O 0 2.7335886443324853e-07
region O 0 2.0245047949174477e-07
of O 0 1.1217582596145803e-06
the O 0 1.5279173339877161e-06
APC B-Disease 0 4.084356532985112e-06
gene O 0 1.4973291229125607e-07
was O 0 1.1756294497899944e-06
screened O 0 1.8704886883824656e-07
in O 0 4.1017230500983715e-08
affected O 0 5.2057750110634515e-08
individuals O 0 1.644462166439098e-08
from O 0 7.508062367378443e-07
11 O 0 0.00011985156015725806
AAPC B-Disease 1 0.9999998807907104
kindreds O 0 1.2647986295633018e-05
, O 0 6.812648223331053e-08
and O 0 2.74045799386613e-08
their O 0 1.1010745204487193e-08
phenotypic O 0 3.6603461239792523e-07
differences O 0 2.2587502712667629e-07
were O 0 2.4734031285333913e-06
examined O 0 1.3407427104539238e-05
. O 0 6.26115752311307e-06

Five O 0 3.678725261124782e-05
novel O 0 4.3626023398246616e-05
germ O 0 0.3175603747367859
- O 0 6.275327177718282e-05
line O 0 7.1884551289258525e-06
APC B-Disease 0 2.4728631160542136e-06
mutations O 0 7.560890225022376e-08
were O 0 2.0097597541735013e-07
identified O 0 2.1675214156857692e-07
in O 0 3.0245541893236805e-07
seven O 0 2.388291250099428e-06
kindreds O 0 0.00011440415255492553
. O 0 8.920737855078187e-06

Mutations O 0 2.610961746540852e-05
were O 0 9.275875527237076e-06
located O 0 1.5132260386963026e-06
in O 0 1.3394887332651706e-07
three O 0 3.378969992695602e-08
different O 0 2.062998216700862e-09
regions O 0 3.6294089511557104e-08
of O 0 7.485213018298964e-07
the O 0 1.2037589840474539e-06
APC B-Disease 0 1.9407254967518384e-06
gene O 0 1.2892871836811537e-07
( O 0 6.835477961431025e-08
1 O 0 2.394980072040198e-07
) O 0 2.9783155497398184e-08
at O 0 2.6897251359514485e-07
the O 0 6.490687809446172e-08
5 O 0 8.70669865093987e-08
end O 0 1.325624054970831e-07
spanning O 0 8.477184110233793e-08
exons O 0 1.0996938470952955e-07
4 O 0 2.2178480207912799e-07
and O 0 9.691557067981194e-08
5 O 0 3.3322552894787805e-07
, O 0 3.827384986720972e-08
( O 0 1.0102023217939404e-08
2 O 0 4.292342481448941e-08
) O 0 6.059234447519657e-09
within O 0 1.5553130339185373e-08
exon O 0 9.176726223358855e-08
9 O 0 2.899341779993847e-07
, O 0 2.1319923604323776e-08
and O 0 1.9971222897652297e-08
( O 0 1.902914448237425e-08
3 O 0 1.0354083457286833e-07
) O 0 2.0114695686856976e-08
at O 0 2.3394156301037583e-07
the O 0 5.371556355271423e-08
3 O 0 4.374406046281365e-07
distal O 0 3.1511351608060068e-06
end O 0 4.865030405198922e-07
of O 0 3.998744659838849e-07
the O 0 8.659875447847298e-07
gene O 0 1.6070936226242338e-06
. O 0 1.2543616776383715e-06

Variability O 0 7.467569957952946e-05
in O 0 1.4531239003190421e-06
the O 0 6.854735374872689e-07
number O 0 8.568875387027219e-07
of O 0 0.0006709327572025359
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 1 0.650847852230072
most O 0 6.363410420817672e-08
apparent O 0 4.912824920211278e-07
in O 0 5.9250762518558986e-08
individuals O 0 3.475240983874528e-09
with O 0 6.496730264871076e-09
mutations O 0 3.3814199440485027e-08
in O 0 1.6240120714883233e-07
region O 0 3.0385763238882646e-07
1 O 0 3.885915248247329e-06
, O 0 3.872575859986682e-07
and O 0 1.876493342933827e-06
upper O 1 0.9999954700469971
- O 1 0.9999836683273315
gastrointestinal O 1 0.9999998807907104
manifestations O 1 0.9999960660934448
were O 0 2.613353353808634e-05
more O 0 6.594184753794252e-08
severe O 0 0.0021770710591226816
in O 0 8.93356798314926e-07
them O 0 1.932627071710158e-07
. O 0 2.5945844299712917e-06

In O 0 5.257079919829266e-06
individuals O 0 8.087689451485858e-08
with O 0 5.834507277313605e-08
mutations O 0 1.5312417644963716e-07
in O 0 2.49685825792767e-07
either O 0 3.411342319736832e-08
region O 0 1.1054076054506368e-07
2 O 0 2.196466510895334e-07
or O 0 2.6756277193840106e-08
region O 0 5.301973615701172e-08
3 O 0 2.5259870994887024e-07
, O 0 2.8433001730832075e-08
the O 0 4.654364005318712e-08
average O 0 6.717282730051011e-08
number O 0 3.810878723697897e-08
of O 0 5.810917969029106e-07
adenomas B-Disease 0 4.4312117097433656e-05
tended O 0 2.3541846871921734e-07
to O 0 4.7087972632198216e-08
be O 0 7.679400226834332e-08
lower O 0 5.312982693794766e-07
than O 0 7.432161108766877e-09
those O 0 3.345608012850221e-09
in O 0 1.0862225785501778e-08
individuals O 0 9.322547178669538e-10
with O 0 2.724383829644239e-09
mutations O 0 2.0371260234242072e-08
in O 0 4.543277754009978e-08
region O 0 6.630102689086925e-08
1 O 0 1.916812095714704e-07
, O 0 1.1593785487207242e-08
although O 0 1.0927601046262225e-08
age O 0 7.382038802461466e-08
at O 0 1.2936943676322699e-06
diagnosis O 0 5.56751274416456e-06
was O 0 7.733874554105569e-06
similar O 0 4.84860606775328e-07
. O 0 1.9842070742015494e-06

In O 0 5.775465979240835e-05
all O 0 9.29501220525708e-06
AAPC B-Disease 1 0.9999915361404419
kindreds O 0 4.839739631279372e-05
, O 0 6.221506509973551e-07
a O 0 8.850826702655468e-07
predominance O 0 5.746743772760965e-05
of O 0 5.035797948949039e-05
right O 1 0.7869753837585449
- O 1 0.9999998807907104
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.10760784149169922
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999994039535522
sparing O 0 1.1198566426173784e-05
was O 0 8.867217729857657e-06
observed O 0 1.69016652762366e-06
. O 0 1.2153726629549055e-06

No O 0 0.0009033099631778896
desmoid B-Disease 1 0.9992263317108154
tumors I-Disease 1 1.0
were O 0 1.0345044756832067e-05
found O 0 4.3982581132695486e-07
in O 0 2.4190458702832984e-07
these O 0 1.900031492141352e-07
kindreds O 0 6.402873259503394e-05
. O 0 7.111065315257292e-06

Our O 0 2.7822854463011026e-05
data O 0 6.518654572573723e-06
suggest O 0 1.682666947999678e-06
that O 0 2.2783011388582963e-07
, O 0 3.709714633259864e-07
in O 0 1.7743594753483194e-06
AAPC B-Disease 1 0.9999951124191284
families O 0 8.999850820146094e-08
, O 0 6.183637424328481e-08
the O 0 7.102433130512509e-08
location O 0 3.5366693396099436e-07
of O 0 1.214239659930172e-06
the O 0 2.682910235307645e-06
APC B-Disease 0 4.4645759771810845e-05
mutation O 0 1.0112435120390728e-06
may O 0 1.3901634474677849e-06
partially O 0 2.977321400976507e-06
predict O 0 2.500356401924364e-07
specific O 0 1.1891047080325734e-07
phenotypic O 0 8.097666068351828e-06
expression O 0 1.6547606719541363e-05
. O 0 9.523514563625213e-06

This O 0 7.552647730335593e-06
should O 0 4.926369570057432e-07
help O 0 1.9243876181462838e-07
in O 0 2.0982429305149708e-07
the O 0 3.9382067029691825e-07
design O 0 7.805853101672255e-07
of O 0 4.916213356409571e-07
tailored O 0 8.335304073625593e-07
clinical O 0 0.00033230948611162603
- O 0 2.6293770133634098e-05
management O 0 2.0586655864462955e-06
protocols O 0 3.2476901878908393e-07
in O 0 2.984041813647309e-08
this O 0 1.1985242132084295e-08
subset O 0 2.0626616503705009e-07
of O 0 6.934306497896614e-07
FAP B-Disease 0 9.868900815490633e-05
patients O 0 5.628709232041729e-07
. O 0 2.0595402361323067e-07
. O 0 1.0855452501346008e-06

Wilms B-Disease 1 0.9893278479576111
' I-Disease 0 0.0005037719383835793
tumor I-Disease 0 0.0031078720930963755
1 O 0 1.122487083193846e-05
and O 0 1.4300142083811807e-06
Dax O 1 0.8669914603233337
- O 0 2.206599901910522e-06
1 O 0 6.458432153522153e-07
modulate O 0 9.092944992517005e-07
the O 0 4.079724931216333e-07
orphan O 0 2.7177477477380307e-06
nuclear O 0 2.8581334845512174e-06
receptor O 0 4.816740784008289e-06
SF O 0 0.018717968836426735
- O 0 7.038409535198298e-07
1 O 0 1.4145282989375119e-07
in O 0 2.3038092322735793e-08
sex O 0 6.392741624949849e-08
- O 0 1.474723916317089e-07
specific O 0 2.052069625335662e-08
gene O 0 5.96133929775533e-07
expression O 0 4.2908714021905325e-06
. O 0 1.9468095615593484e-06

Products O 0 5.4685562645317987e-05
of O 0 1.8801327314577065e-05
steroidogenic O 0 0.00023106054868549109
factor O 0 7.748174539301544e-06
1 O 0 2.127338802893064e-06
( O 0 4.0177656046580523e-07
SF O 0 0.00014412087330128998
- O 0 1.056810674526787e-06
1 O 0 4.0249832977679034e-07
) O 0 2.9660592204550085e-08
and O 0 1.0786707349552671e-07
Wilms B-Disease 0 0.0003733983321581036
tumor I-Disease 0 0.0035035230685025454
1 O 0 1.6254265347015462e-06
( O 0 1.4277301829679345e-07
WT1 O 0 3.2350028504879447e-06
) O 0 1.1507204078498035e-08
genes O 0 1.2343497779454538e-08
are O 0 3.3511386998696935e-09
essential O 0 2.4384087637940866e-08
for O 0 4.100018102803915e-08
mammalian O 0 1.8225867961518816e-06
gonadogenesis O 0 1.6443325421278132e-06
prior O 0 1.1664813115430661e-07
to O 0 3.752569455173216e-08
sexual O 0 5.989090254843177e-07
differentiation O 0 3.5510944144334644e-05
. O 0 5.24183587913285e-06

In O 0 1.1797506886068732e-05
males O 0 1.6254078900601598e-06
, O 0 1.7046706943801837e-06
SF O 0 0.0031493818387389183
- O 0 2.7452767881186446e-06
1 O 0 3.685625813432125e-07
participates O 0 3.169807882841269e-08
in O 0 1.414511530128948e-08
sexual O 0 1.721981846003473e-08
development O 0 1.2854124520345067e-07
by O 0 2.6040929412829428e-08
regulating O 0 1.9354416735950508e-07
expression O 0 1.4586900931590208e-07
of O 0 4.365533072814287e-07
the O 0 1.62897708833043e-06
polypeptide O 0 3.996737359557301e-05
hormone O 0 9.445654541195836e-06
Mullerian O 0 6.876287079649046e-05
inhibiting O 0 1.1165039722982328e-05
substance O 0 1.8567586721474072e-06
( O 0 1.1003700137734995e-06
MIS O 0 0.014137126505374908
) O 0 1.6066859416241641e-06
. O 0 1.369616484225844e-06

Here O 0 3.628653576015495e-05
, O 0 1.9332883312017657e-06
we O 0 2.1259769766857062e-07
show O 0 7.800925914125401e-07
that O 0 5.82578934427147e-07
WT1 O 0 0.00019386124040465802
- O 0 1.294811772822868e-05
KTS O 0 0.00026098769740201533
isoforms O 0 8.431378546447377e-07
associate O 0 1.2751797839882784e-06
and O 0 8.526252770479914e-08
synergize O 0 3.243176024625427e-06
with O 0 3.9771234128238575e-07
SF O 1 0.927953839302063
- O 0 2.714916263357736e-06
1 O 0 5.275584840092051e-07
to O 0 6.706554245283769e-08
promote O 0 1.6931089703575708e-06
MIS O 1 0.9791060090065002
expression O 0 2.4952021703938954e-05
. O 0 3.186501317031798e-06

In O 0 3.5679651773534715e-05
contrast O 0 1.2020968824799638e-05
, O 0 2.841110244844458e-06
WT1 O 0 0.0002478344540577382
missense O 0 1.6452439012937248e-05
mutations O 0 2.865139094865299e-06
, O 0 5.581168238677492e-07
associated O 0 8.115177365652926e-07
with O 0 3.146136862142157e-07
male B-Disease 0 8.617772255092859e-05
pseudohermaphroditism I-Disease 1 1.0
in O 0 0.00013153602776583284
Denys B-Disease 1 1.0
- I-Disease 1 0.9999978542327881
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 6.963809937587939e-07
fail O 0 1.5581834134081873e-07
to O 0 4.015451438021955e-08
synergize O 0 5.963857347524026e-06
with O 0 1.4015209899298497e-06
SF O 1 0.9999986886978149
- O 0 0.00014496478252112865
1 O 0 1.3484387636708561e-05
. O 0 2.0697368654509773e-06

Additionally O 0 2.2406014977605082e-05
, O 0 1.5143997416089405e-06
the O 0 1.2950805512446095e-06
X O 0 4.281445581000298e-05
- O 0 9.491081073065288e-06
linked O 0 7.556458513136022e-06
, O 0 2.0320271687523928e-07
candidate O 0 4.6241899553933763e-07
dosage O 0 1.226425501954509e-05
- O 0 3.180277644787566e-06
sensitive O 0 3.2382931749452837e-06
sex O 0 4.367253154669015e-07
- O 0 1.010017513181083e-06
reversal O 0 3.5918744742957642e-06
gene O 0 1.6056827689681086e-07
, O 0 2.445003985940275e-07
Dax O 0 0.000658603326883167
- O 0 4.4490764139482053e-07
1 O 0 4.338477026522014e-07
, O 0 7.82598021942249e-08
antagonizes O 0 7.503194865421392e-07
synergy O 0 6.407683486031601e-07
between O 0 5.284416602080455e-07
SF O 0 0.0001296077243750915
- O 0 4.882087978330674e-07
1 O 0 2.246153911755755e-07
and O 0 8.351616997970268e-08
WT1 O 0 6.05100103712175e-06
, O 0 2.4519149377510985e-08
most O 0 7.404653779019554e-09
likely O 0 1.293582574390939e-08
through O 0 9.243777299161593e-09
a O 0 4.6245336449146635e-08
direct O 0 8.802864215340378e-08
interaction O 0 1.1667105326296223e-07
with O 0 3.21300205996522e-07
SF O 1 0.992920458316803
- O 0 1.2769839486281853e-05
1 O 0 3.7805809824931202e-06
. O 0 1.6097286561489454e-06

We O 0 1.526991036371328e-05
propose O 0 8.352472832484636e-06
that O 0 2.2636547782894922e-06
WT1 O 0 0.00020356124150566757
and O 0 3.7356630855356343e-06
Dax O 1 0.880625307559967
- O 0 2.5875863229885e-06
1 O 0 3.760799529572978e-07
functionally O 0 2.090706630042405e-07
oppose O 0 6.381557682288985e-08
each O 0 8.101010529060204e-09
other O 0 7.163325044245994e-09
in O 0 1.388501686960808e-07
testis O 0 8.697005796420854e-06
development O 0 8.965599249677325e-07
by O 0 4.818431875719398e-07
modulating O 0 1.5449255442945287e-05
SF O 0 0.062153056263923645
- O 0 3.013991999978316e-06
1 O 0 1.948299086507177e-06
- O 0 1.5813211575732566e-06
mediated O 0 3.0811497708782554e-06
transactivation O 0 2.9419690690701827e-05
. O 0 1.5567664490845345e-07
. O 0 7.72638429680228e-07

A O 0 0.0001814696443034336
mouse O 0 1.7412621673429385e-05
model O 0 4.539311703410931e-06
for O 0 5.9043181863671634e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9999319314956665
centre O 0 0.0799066349864006
mutations O 0 4.690905370807741e-06
. O 0 2.395088358753128e-06

Imprinting O 0 0.0011295084841549397
in O 0 2.3650685761822388e-05
the O 0 1.5086400708241854e-05
15q11 O 0 0.00016124262765515596
- O 0 2.507714270905126e-05
q13 O 0 2.3081489416654222e-05
region O 0 4.7525861646136036e-07
involves O 0 2.0707108205897384e-07
an O 0 2.1094847113545256e-07
imprinting O 0 5.323331151885213e-06
centre O 0 2.2367501514963806e-05
( O 0 1.4394892389191227e-07
IC O 0 6.147819476609584e-06
) O 0 3.059126640891918e-08
, O 0 1.2933530690872885e-08
mapping O 0 8.607970869434212e-08
in O 0 2.135956655990867e-08
part O 0 6.2209252860157e-08
to O 0 6.713170819239167e-08
the O 0 5.568758751905989e-07
promoter O 0 7.057483799144393e-06
and O 0 1.3252170560917875e-07
first O 0 8.5088839796299e-07
exon O 0 1.6110063825180987e-06
of O 0 6.983468665566761e-06
SNRPN O 0 0.011141722090542316
. O 0 1.0135382581211161e-05

Deletion O 0 0.0001692274963716045
of O 0 8.828276804706547e-06
this O 0 8.356491889571771e-07
IC O 0 0.0002618328435346484
abolishes O 0 1.813808557926677e-05
local O 0 2.9658906441909494e-07
paternally O 0 1.2977313872397644e-06
derived O 0 6.184910716910963e-08
gene O 0 6.905586502625738e-08
expression O 0 1.5115817575406254e-07
and O 0 8.228349912542399e-08
results O 0 4.681322707256186e-07
in O 0 4.342229203757597e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999490976333618
PWS B-Disease 1 1.0
) O 0 1.608923776075244e-05
. O 0 8.859644367475994e-06

We O 0 3.5837720133713447e-06
have O 0 2.9279004820637056e-07
created O 0 2.1982999953706894e-07
two O 0 8.57374189422444e-08
deletion O 0 9.72536668086832e-07
mutations O 0 2.2370063845755794e-07
in O 0 2.6329360025556525e-07
mice O 0 8.393791404159856e-07
to O 0 2.1222962232059217e-07
understand O 0 5.009898131902446e-07
PWS B-Disease 1 1.0
and O 0 2.3683197980517434e-07
the O 0 3.2530653015783173e-07
mechanism O 0 6.615329084525001e-07
of O 0 8.141626040014671e-07
this O 0 1.1836439171020174e-06
IC O 0 0.00035818625474348664
. O 0 4.593879111780552e-06

Mice O 0 0.003072466468438506
harbouring O 0 0.015052353031933308
an O 0 2.370345282542985e-05
intragenic O 0 0.00036870542680844665
deletion O 0 4.5095570385456085e-05
in O 0 4.416202500578947e-06
Snrpn O 0 0.0001899047492770478
are O 0 3.4622723887878237e-07
phenotypically O 0 9.00632130651502e-06
normal O 0 1.0727633252827218e-06
, O 0 6.969617771801495e-08
suggesting O 0 8.468683176943159e-08
that O 0 5.9763074489183055e-09
mutations O 0 3.413978433286502e-08
of O 0 6.849859914836998e-07
SNRPN O 0 3.276588540757075e-05
are O 0 1.2483330813495286e-08
not O 0 1.0066785627316222e-08
sufficient O 0 2.458115488934709e-07
to O 0 1.1369050980647444e-06
induce O 0 0.002857304411008954
PWS B-Disease 1 1.0
. O 0 3.405971438041888e-05

Mice O 0 9.383595897816122e-05
with O 0 5.630512873722182e-07
a O 0 7.530686616519233e-07
larger O 0 1.8028862314167782e-07
deletion O 0 1.4272089856603998e-06
involving O 0 4.450604365047184e-07
both O 0 3.9443185073650966e-07
Snrpn O 0 4.446815000846982e-05
and O 0 4.3974989694106625e-07
the O 0 2.585953097877791e-06
putative O 0 0.003017646726220846
PWS O 1 1.0
- O 0 0.001649106852710247
IC O 0 0.021762480959296227
lack O 0 2.0616323581634788e-06
expression O 0 8.720923005967052e-07
of O 0 1.2304616348046693e-06
the O 0 7.88419924901973e-07
imprinted O 0 2.273017344123218e-06
genes O 0 6.033858994669572e-07
Zfp127 O 0 4.982041718903929e-05
( O 0 7.396434398287965e-07
mouse O 0 1.6515934930794174e-06
homologue O 0 4.74796479466022e-06
of O 0 8.851957886690798e-07
ZNF127 O 0 3.393295264686458e-05
) O 0 1.7893115966671758e-07
, O 0 2.414523692095827e-07
Ndn O 0 1.6415686332038604e-05
and O 0 1.9511702475938364e-07
Ipw O 0 2.6352312488597818e-05
, O 0 1.0422700569279186e-07
and O 0 3.662454517439073e-08
manifest O 0 3.6508740208773816e-07
several O 0 8.080534996679489e-08
phenotypes O 0 2.769537786662113e-06
common O 0 1.1213945754207089e-06
to O 0 9.864485036814585e-06
PWS B-Disease 1 1.0
infants O 1 0.9811018109321594
. O 0 1.1379387615306769e-05

These O 0 2.3127126951294485e-06
data O 0 1.0924266007350525e-06
demonstrate O 0 3.414363334286463e-07
that O 0 6.325353751890361e-08
both O 0 7.457212092276677e-08
the O 0 2.124274516290825e-07
position O 0 1.0079544381369487e-06
of O 0 9.148316735263506e-07
the O 0 1.2440578984751482e-06
IC O 0 3.304063284303993e-05
and O 0 1.022332938305226e-07
its O 0 1.6066708496964566e-07
role O 0 4.4998810722063354e-07
in O 0 1.2194067267046194e-07
the O 0 1.8878974117342295e-07
coordinate O 0 1.7446251376895816e-07
expression O 0 7.071437266858993e-07
of O 0 1.2394264103932073e-06
genes O 0 1.1166450519795035e-07
is O 0 6.03019358891288e-08
conserved O 0 5.817883064196394e-08
between O 0 6.385977968648149e-08
mouse O 0 2.1860054744138324e-07
and O 0 2.6842048583830547e-08
human O 0 6.692434340038744e-08
, O 0 1.8453460981504577e-08
and O 0 1.7261250206956902e-08
indicate O 0 1.5506218176142283e-07
that O 0 4.0286693092639325e-08
the O 0 2.5987941398852854e-07
mouse O 0 5.091030743642477e-07
is O 0 2.9115934552237377e-08
a O 0 4.411809939597333e-08
suitable O 0 6.797150575721389e-08
model O 0 1.1070934391455012e-07
system O 0 3.231716405593943e-08
in O 0 1.646257175025312e-08
which O 0 1.0814678930159971e-08
to O 0 8.240691684591184e-09
investigate O 0 2.8059007561864746e-08
the O 0 2.0615013340830046e-07
molecular O 0 1.684884523456276e-06
mechanisms O 0 6.212091534507636e-07
of O 0 8.359249363820709e-07
imprinting O 0 4.196384907118045e-06
in O 0 1.1351117024105406e-07
this O 0 2.020054878926203e-08
region O 0 2.684040900646778e-08
of O 0 1.1188794957206483e-07
the O 0 2.1606530253848177e-07
genome O 0 6.977078896852618e-07
. O 0 2.411477169061982e-07
. O 0 1.466681851525209e-06

Mutations O 0 1.8281771190231666e-05
of O 0 1.259479540749453e-05
the O 0 2.1858270429220283e-06
ATM O 0 7.828477100702003e-05
gene O 0 1.1052384252252523e-06
detected O 0 4.623027052730322e-06
in O 0 2.2040301246306626e-06
Japanese O 1 0.9529373049736023
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.6085442900657654
: O 0 1.4140644566396077e-07
possible O 0 7.673470747704414e-08
preponderance O 0 3.910253781214124e-06
of O 0 8.457624289803789e-07
the O 0 4.127835495637555e-07
two O 0 1.4425469885281927e-07
founder O 0 2.3209420760395005e-05
mutations O 0 1.8165063693231787e-06
4612del165 O 0 0.00012939298176206648
and O 0 6.434807801269926e-06
7883del5 O 0 0.0011405079858377576
. O 0 1.7985097656492144e-05

The O 0 5.7795979955699295e-05
ATM O 0 0.0008334152516908944
( O 0 7.776008715154603e-06
A O 1 0.999830961227417
- O 1 0.9599287509918213
T O 1 0.9999786615371704
, O 0 1.7939197505256743e-07
mutated O 0 1.0749757706207674e-07
) O 0 3.0897837177690235e-08
gene O 0 7.459730255732211e-08
on O 0 7.343782613133953e-07
human O 0 1.9694098227773793e-06
chromosome O 0 0.015735330060124397
11q22 O 0 0.018250174820423126
. O 0 7.179698968684534e-06

3 O 0 4.1162475099554285e-05
has O 0 8.098230068753764e-07
recently O 0 7.116969413800689e-07
been O 0 9.203370154864388e-08
identified O 0 5.4047720965400003e-08
as O 0 1.714352571013933e-08
the O 0 2.3111988767254843e-08
gene O 0 7.39328314125487e-08
responsible O 0 1.0585380039174197e-07
for O 0 4.241768536417112e-08
the O 0 8.151539532263996e-07
human O 0 0.0011744758812710643
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9998186230659485
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.373824362526648e-06
. O 0 3.901001491612988e-06

In O 0 5.908334060222842e-06
order O 0 6.370600544869376e-07
to O 0 1.1771873431598578e-07
define O 0 2.0700473157830857e-07
the O 0 3.334162670398655e-07
types O 0 1.770467150663535e-07
of O 0 1.7505797586636618e-05
disease O 1 0.9969993829727173
- O 0 2.7252219297224656e-05
causing O 0 2.5772453682293417e-06
ATM O 0 1.0445608495501801e-05
mutations O 0 7.998864504088488e-08
in O 0 2.0026654112825781e-07
Japanese O 0 3.1471045076614246e-05
A B-Disease 1 0.9999270439147949
- I-Disease 1 0.9691690802574158
T I-Disease 1 0.9999982118606567
patients O 0 1.2651244674088957e-07
as O 0 5.7586746038396086e-08
well O 0 1.4544415449790904e-08
as O 0 3.69429287161438e-08
to O 0 9.684827162459442e-09
look O 0 3.164986850379137e-08
for O 0 2.9666477274759018e-08
possible O 0 3.434880113672989e-07
mutational O 0 2.1733972971560434e-05
hotspots O 0 5.474844783748267e-06
, O 0 1.6026673677060899e-07
reverse O 0 8.622577070127591e-07
- O 0 9.035373977894778e-07
transcribed O 0 6.593027137569152e-07
RNA O 0 3.5451216717774514e-07
derived O 0 4.54851445397253e-08
from O 0 5.6375416335185946e-08
ten O 0 8.500013137791029e-08
patients O 0 2.002641963372298e-08
belonging O 0 8.149380903432757e-08
to O 0 1.9445732135636717e-08
eight O 0 3.103051824382419e-07
unrelated O 0 1.572271685290616e-06
Japanese O 0 0.00015199896006379277
A B-Disease 1 0.9999873638153076
- I-Disease 1 0.6288111209869385
T I-Disease 1 0.9841614961624146
families O 0 2.5660048308395744e-08
was O 0 2.919329631367873e-07
analyzed O 0 4.019321053760905e-08
for O 0 1.1008665090628256e-08
mutations O 0 3.275497562071905e-08
by O 0 2.8712303645761494e-08
the O 0 9.216614671458956e-08
restriction O 0 6.364776368172897e-07
endonuclease O 0 8.137426448229235e-06
fingerprinting O 0 1.7528464013594203e-06
method O 0 2.1496582576219225e-06
. O 0 3.080999704252463e-06

As O 0 1.4975937119743321e-05
has O 0 1.1599699973885436e-06
been O 0 8.287033779197372e-07
reported O 0 7.539662192357355e-07
by O 0 8.075050317302157e-08
others O 0 2.1394063409729824e-08
, O 0 1.177692166010047e-08
mutations O 0 2.4272257093116423e-08
that O 0 4.354551563778841e-08
lead O 0 2.634905342802085e-07
to O 0 1.1208167904896982e-07
exon O 0 3.3456915389251662e-06
skipping O 0 2.751467718553613e-06
or O 0 4.754272140417015e-07
premature O 0 4.569210432237014e-06
protein O 0 6.286132929744781e-07
truncation O 0 1.3873762327420991e-05
were O 0 2.6149064069613814e-07
also O 0 1.1071652750160865e-07
predominant O 0 2.2867472182497295e-07
in O 0 9.877241069489173e-08
our O 0 4.0459116235069814e-07
mutants O 0 4.733307832793798e-06
. O 0 2.12328927773342e-06

Six O 0 4.841715963266324e-06
different O 0 6.251995188222281e-08
mutations O 0 3.7246991269057617e-07
were O 0 5.690535544999875e-07
identified O 0 2.3372926705178543e-07
on O 0 8.722403777028376e-07
12 O 0 8.290132313959475e-07
of O 0 6.114814254942758e-07
the O 0 1.1988555570496828e-06
16 O 0 4.000905846623937e-06
alleles O 0 2.151298986063921e-06
examined O 0 1.043204974848777e-05
. O 0 5.5365176194754895e-06

Four O 0 1.6260239135590382e-05
were O 0 2.679346380318748e-06
deletions O 0 4.521864866546821e-06
involving O 0 3.115674417131231e-06
a O 0 2.0274351300031412e-06
loss O 0 9.475726983509958e-06
of O 0 4.2073088479810394e-06
a O 0 1.7018054450090858e-06
single O 0 7.649445592505799e-07
exon O 0 9.11981430817832e-07
exon O 0 6.592611612177279e-07
7 O 0 1.010647565635736e-06
, O 0 1.2005919813873334e-07
exon O 0 2.995743955125363e-07
16 O 0 5.349044158720062e-07
, O 0 1.3750762661857152e-07
exon O 0 4.950634320266545e-07
33 O 0 1.5010249398983433e-06
or O 0 5.832026204188878e-07
exon O 0 3.0402159154618857e-06
35 O 0 6.193131412146613e-06
. O 0 3.232856215618085e-06

The O 0 2.8542646759888157e-05
others O 0 1.6936501197051257e-06
were O 0 1.2437531040632166e-06
minute O 0 7.276230462593958e-07
deletions O 0 1.4993310060162912e-06
, O 0 1.8424697145746904e-07
4649delA O 0 1.1968827493546996e-06
in O 0 2.5886180310408236e-07
exon O 0 1.2165565976829384e-06
33 O 0 2.368153218412772e-06
and O 0 2.7736825813917676e-07
7883del5 O 0 1.8175920558860525e-05
in O 0 1.1164017905684887e-06
exon O 0 7.786427886458114e-06
55 O 0 1.30875068862224e-05
. O 0 4.546009677142138e-06

The O 0 3.483469117782079e-05
mutations O 0 1.8097067368216813e-05
4612del165 O 0 0.0002539250999689102
and O 0 3.0381263513845624e-06
7883del5 O 0 4.368951340438798e-05
were O 0 1.6884620208656997e-06
found O 0 2.6205535164081084e-07
in O 0 1.8155766667860007e-07
more O 0 1.4685355154142599e-08
than O 0 2.1235994296375793e-08
two O 0 3.658767866454582e-08
unrelated O 0 1.8782860422561498e-07
families O 0 1.1293333379569503e-08
; O 0 1.279780459384483e-08
44 O 0 1.6013520109936508e-07
% O 0 2.848283209289093e-08
( O 0 1.865500109943241e-08
7 O 0 2.5012150217662565e-07
of O 0 3.110841646503104e-07
16 O 0 7.108483259798959e-07
) O 0 3.501677880990428e-08
of O 0 1.1366195451500971e-07
the O 0 7.964215598121882e-08
mutant O 0 2.181107561227691e-07
alleles O 0 9.198912920282964e-08
had O 0 2.3526743575530418e-07
one O 0 3.6519633539455754e-08
of O 0 1.0960585683505997e-07
the O 0 2.1233367419881688e-07
two O 0 1.5237540651469317e-07
mutations O 0 2.0630484414141392e-06
. O 0 6.0193747231096495e-06

The O 0 2.7227386453887448e-05
4612del165 O 0 3.403367372811772e-05
mutations O 0 6.744923553014814e-07
in O 0 1.949464802919465e-07
three O 0 4.2730889049380494e-08
different O 0 2.4612660798339903e-09
families O 0 1.01590238443805e-08
were O 0 9.563056835304451e-08
all O 0 1.3957433431244226e-08
ascribed O 0 6.11540940553823e-07
to O 0 6.369494798263986e-08
the O 0 4.987911097487085e-07
same O 0 4.635342918390961e-07
T O 0 6.0815532378910575e-06
- O 0 6.411087838387175e-07
- O 0 9.672218084233464e-07
> O 0 5.195885250941501e-07
A O 0 4.315953106015513e-07
substitution O 0 4.1565380115571315e-07
at O 0 3.4773850643432525e-07
the O 0 8.121450889575499e-08
splice O 0 7.687825700486428e-07
donor O 0 3.022529995178047e-07
site O 0 6.625797368542408e-07
in O 0 6.213999199644604e-07
intron O 0 8.594523387728259e-05
33 O 0 5.240686368779279e-05
. O 0 1.1631675988610368e-05

Microsatellite O 0 0.0011376353213563561
genotyping O 0 0.00020866510749328882
around O 0 6.2246795096143615e-06
the O 0 1.5206010175461415e-06
ATM O 0 3.132139681838453e-05
locus O 0 7.521337920479709e-06
also O 0 3.656424496512045e-07
indicated O 0 2.3238614232923283e-07
that O 0 3.289251893079381e-08
a O 0 1.2575053176533402e-07
common O 0 7.312586092211859e-08
haplotype O 0 3.1152878818829777e-06
was O 0 1.0807223134179367e-06
shared O 0 2.8487612269145757e-08
by O 0 2.1436051156342728e-08
the O 0 4.5465718301329616e-08
mutant O 0 1.8491060416181426e-07
alleles O 0 5.311964201837327e-08
in O 0 8.790431138550048e-08
both O 0 1.97282830072254e-07
mutations O 0 2.8964666398678673e-06
. O 0 3.395883823031909e-06

This O 0 4.803273441211786e-06
suggests O 0 1.942825520018232e-06
that O 0 1.1267723465380186e-07
these O 0 3.29060121373459e-08
two O 0 1.1808123190348851e-07
founder O 0 7.912922228570096e-06
mutations O 0 3.6656697943726613e-07
may O 0 4.159273885306902e-07
be O 0 3.7419699339125145e-08
predominant O 0 1.8802843726462015e-07
among O 0 3.274410431686192e-08
Japanese O 0 3.0764399525651243e-06
ATM O 0 2.6811590942088515e-05
mutant O 0 6.258203484321712e-06
alleles O 0 3.822709004452918e-06
. O 0 1.8482363657312817e-06

W474C O 0 0.003879039315506816
amino O 0 0.0001649291953071952
acid O 0 1.034616980177816e-05
substitution O 0 2.8425577056623297e-06
affects O 0 1.389679482599604e-07
early O 0 1.238634297351382e-07
processing O 0 2.3980885544006014e-07
of O 0 3.5748624327425205e-07
the O 0 3.9260419271158753e-07
alpha O 0 8.125895192279131e-07
- O 0 1.0716102849528397e-07
subunit O 0 1.1896696605617763e-07
of O 0 2.3766891388277145e-07
beta O 0 1.268446908397891e-06
- O 0 8.664666779623076e-07
hexosaminidase O 0 2.9371228720265208e-06
A O 0 8.372572892767494e-07
and O 0 4.982871715242254e-08
is O 0 8.226671610600533e-08
associated O 0 2.1129093852323422e-07
with O 0 4.2722254534055537e-07
subacute O 1 0.999984860420227
G B-Disease 1 0.8961296677589417
( I-Disease 0 4.327833721617935e-06
M2 I-Disease 1 0.5259817838668823
) I-Disease 0 1.946182010215125e-06
gangliosidosis I-Disease 0 0.00014599881251342595
. O 0 4.376945071271621e-06

Mutations O 0 4.2816580389626324e-05
in O 0 6.403141014743596e-06
the O 0 4.285375325707719e-06
HEXA O 0 0.00011625431216089055
gene O 0 6.522315629808872e-07
, O 0 1.78962224595125e-07
encoding O 0 1.6455359741485154e-07
the O 0 2.778382111046085e-07
alpha O 0 6.426054142139037e-07
- O 0 1.0039330788913503e-07
subunit O 0 6.42262349970224e-08
of O 0 2.3913216296023165e-07
beta O 0 1.2548618997243466e-06
- O 0 5.699464509234531e-07
hexosaminidase O 0 2.7155012958246516e-06
A O 0 1.2033916618747753e-06
( O 0 8.155632258421974e-08
Hex O 0 1.2773048183589708e-06
A O 0 2.8992778311476286e-07
) O 0 1.2684703953880216e-08
, O 0 7.457821027401224e-09
that O 0 5.625744314841086e-09
abolish O 0 2.114925479190788e-07
Hex O 0 1.734688680699037e-06
A O 0 4.642448061531468e-07
enzyme O 0 1.6978064820705185e-07
activity O 0 1.8722247432378936e-06
cause O 0 0.0002782367228064686
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.8677161931991577
( O 0 5.665885964845074e-07
TSD B-Disease 0 5.8289933804189786e-05
) O 0 1.0141332751345544e-07
, O 0 5.427271432267844e-08
the O 0 3.0163820952111564e-07
fatal O 0 9.442542068427429e-05
infantile B-Disease 0 0.001877674600109458
form I-Disease 0 7.096244303284038e-07
of I-Disease 0 2.2073949367040768e-05
G I-Disease 0 9.495843551121652e-05
( I-Disease 0 3.95367720784634e-07
M2 I-Disease 0 0.0002795401378534734
) I-Disease 0 1.4461353714523284e-07
gangliosidosis I-Disease 0 3.2324121548299445e-06
, I-Disease 0 7.90397081118499e-08
Type I-Disease 0 1.1067688774346607e-06
1 I-Disease 0 4.871209512202768e-06
. O 0 2.2046733647584915e-06

Less O 0 0.00011472597543615848
severe O 1 0.954254150390625
, O 0 1.552342473587487e-05
subacute O 1 0.9990254640579224
( O 0 3.8157486415002495e-06
juvenile O 1 0.7891440987586975
- O 0 0.00014254299458116293
onset O 1 0.999247670173645
) O 0 7.459508424290107e-07
and O 0 1.653921458455443e-06
chronic O 1 0.9999994039535522
( O 0 1.0374183148087468e-06
adult O 0 1.1349453416187316e-05
- O 0 0.01208418607711792
onset O 1 0.9477218389511108
) O 0 5.588433538150639e-08
variants O 0 2.6198557989687288e-08
are O 0 4.196156755398306e-09
characterized O 0 3.018795879938807e-08
by O 0 1.3063169213012316e-08
a O 0 5.5266564658040807e-08
broad O 0 1.2351414113709325e-07
spectrum O 0 8.362999182054409e-08
of O 0 5.908914957331035e-08
clinical O 0 1.6414464880654123e-06
manifestations O 0 2.165473006243701e-06
and O 0 4.8684462683468155e-08
are O 0 5.711776385197709e-09
associated O 0 2.458213188560876e-08
with O 0 1.3489051653436945e-08
residual O 0 7.5365810516814236e-06
levels O 0 2.557796506152954e-06
of O 0 3.040746378246695e-06
Hex O 0 5.376144326874055e-05
A O 0 4.156214799877489e-06
enzyme O 0 1.2776398534697364e-06
activity O 0 4.646434717869852e-06
. O 0 1.0785159929582733e-06

We O 0 2.4854578441591002e-05
identified O 0 1.2671093827520963e-05
a O 0 9.692176718090195e-06
1422 O 0 0.00038616039091721177
G O 0 7.528551941504702e-05
- O 0 9.920219781633932e-06
- O 0 7.295739123946987e-06
> O 0 4.547197477222653e-06
C O 0 5.705458534066565e-06
( O 0 9.740109163658417e-08
amino O 0 2.0692303337455087e-07
acid O 0 9.695845903934242e-08
W474C O 0 1.1119434475403978e-06
) O 0 2.3361241829888968e-08
substitution O 0 8.979480980997323e-08
in O 0 2.8170816790407116e-08
the O 0 7.201027329983845e-08
first O 0 1.2152226247508224e-07
position O 0 2.3618304112460464e-07
of O 0 2.0540674938729353e-07
exon O 0 5.229320549915428e-07
13 O 0 7.818466656317469e-07
of O 0 1.198906943500333e-06
HEXA O 0 0.0008557636756449938
of O 0 2.2255951535044005e-06
a O 0 2.37652420764789e-06
non O 0 1.1551817806321196e-05
- O 0 5.65643449590425e-06
Jewish O 0 2.590116991996183e-06
proband O 0 3.0757229978917167e-05
who O 0 2.7308630023981095e-07
manifested O 0 1.2845538321926142e-06
a O 0 1.4316340184450382e-06
subacute O 0 7.924595411168411e-05
variant O 0 1.8978380467160605e-06
of O 0 1.4353770893649198e-05
G B-Disease 0 0.00043785874731838703
( I-Disease 0 9.349690230919805e-07
M2 I-Disease 0 0.004698922857642174
) I-Disease 0 2.368794639551197e-06
gangliosidosis I-Disease 0 8.020777022466063e-05
. O 0 3.0369444630196085e-06

On O 0 0.0001979968510568142
the O 0 1.2972614968020935e-05
second O 0 1.2087206414435059e-05
maternally O 0 2.1966892745695077e-05
inherited O 0 9.332086847280152e-06
allele O 0 1.140687686529418e-06
, O 0 1.0077951628773008e-07
we O 0 2.296946988167292e-08
identified O 0 1.299483329830764e-07
the O 0 3.9955884290066024e-07
common O 0 3.332857431814773e-06
infantile O 1 0.9999896287918091
disease O 1 0.9989890456199646
- O 0 4.258886110619642e-05
causing O 0 8.577729022363201e-05
4 O 0 1.3999012480780948e-05
- O 0 6.3469656197412405e-06
bp O 0 4.249362518748967e-06
insertion O 0 1.0178030152019346e-06
, O 0 2.925773401329934e-07
+ O 0 1.0226357289866428e-06
TATC O 0 1.8533854017732665e-05
1278 O 0 1.2483347745728679e-05
, O 0 1.0289332408319751e-07
in O 0 2.0721944338220055e-07
exon O 0 1.666178150117048e-06
11 O 0 5.294730726745911e-06
. O 0 2.429561845929129e-06

Pulse O 0 0.00284448079764843
- O 0 6.826267053838819e-05
chase O 0 7.459298103640322e-06
analysis O 0 4.73081684049248e-07
using O 0 6.180371201480739e-07
proband O 0 3.102099071838893e-05
fibroblasts O 0 2.1350753740989603e-05
revealed O 0 4.951010396325728e-06
that O 0 2.3285957695406978e-07
the O 0 1.44773900956352e-06
W474C O 0 7.11053598934086e-06
- O 0 6.657505196017155e-07
containing O 0 4.4413692990019626e-07
alpha O 0 2.180559476983035e-06
- O 0 3.12225154175394e-07
subunit O 0 5.184110136724485e-07
precursor O 0 9.942979204424773e-07
was O 0 1.5603961855958914e-06
normally O 0 9.762185726458483e-08
synthesized O 0 3.572561695364129e-07
, O 0 3.360511158234658e-08
but O 0 1.1155121271144708e-08
not O 0 1.2066487364847944e-08
phosphorylated O 0 2.908752492203348e-07
or O 0 6.658133600012661e-08
secreted O 0 3.1281498991120316e-07
, O 0 2.619730921082919e-08
and O 0 2.2052603299016482e-08
the O 0 1.596971799244784e-07
mature O 0 3.2291350748892e-07
lysosomal O 0 1.1515619917190634e-05
alpha O 0 1.6938132603172562e-06
- O 0 2.704886412630003e-07
subunit O 0 2.6923788709609653e-07
was O 0 1.1433887721068459e-06
not O 0 8.337261903079707e-08
detected O 0 5.010107543057529e-06
. O 0 2.2621138668910135e-06

When O 0 7.690284110140055e-05
the O 0 1.529616019979585e-05
W474C O 0 8.787242404650897e-05
- O 0 5.224602773523657e-06
containing O 0 1.4384945643541869e-06
alpha O 0 3.832572474493645e-06
- O 0 7.206893997135921e-07
subunit O 0 8.414742183049384e-07
was O 0 2.6507229904382257e-06
transiently O 0 2.919832695624791e-06
co O 0 1.2517064078565454e-06
- O 0 4.178795336429175e-07
expressed O 0 1.6083141929357225e-07
with O 0 3.316738528269525e-08
the O 0 2.4354068273169105e-07
beta O 0 4.1317264276585774e-07
- O 0 7.172898364160574e-08
subunit O 0 6.065885571615581e-08
to O 0 1.587550535475657e-08
produce O 0 4.954988597205556e-08
Hex O 0 3.6358471788844327e-06
A O 0 2.1103733160998672e-06
( O 0 1.0932337346503118e-07
alphabeta O 0 1.8639833569977782e-06
) O 0 6.966853050016653e-08
in O 0 3.532930747951468e-07
COS O 0 4.1758703446248546e-05
- O 0 1.0564660897216527e-06
7 O 0 1.6639280602248618e-06
cells O 0 1.6044749884258636e-07
, O 0 3.829174133329616e-08
the O 0 8.427448960901529e-08
mature O 0 6.678802577653187e-08
alpha O 0 2.77697523642928e-07
- O 0 3.488704436449552e-08
subunit O 0 4.538808440202047e-08
was O 0 2.1240860803573014e-07
present O 0 2.0012061341390108e-08
, O 0 8.486499503135292e-09
but O 0 4.305623857447927e-09
its O 0 1.650337999592466e-08
level O 0 2.444388655931107e-07
was O 0 1.3851399671693798e-06
much O 0 5.8036743411093994e-08
lower O 0 2.1902853575284098e-07
than O 0 5.44405409641513e-09
that O 0 7.278448954650685e-09
from O 0 3.135879467208724e-08
normal O 0 1.5234881800552103e-07
alpha O 0 5.66363326015562e-07
- O 0 7.975616256317153e-08
subunit O 0 1.2529469017863448e-07
transfections O 0 5.297586653796316e-07
, O 0 1.881017297478138e-08
although O 0 1.0618863122147104e-08
higher O 0 5.385960477610752e-08
than O 0 3.676296378429811e-09
in O 0 1.7254997430882213e-08
those O 0 1.2131263105175094e-08
cells O 0 2.6425934152030095e-07
transfected O 0 1.3046756066614762e-06
with O 0 2.638440221858218e-08
an O 0 1.899500716717739e-07
alpha O 0 2.12100644603197e-06
- O 0 5.708353114641795e-07
subunit O 0 8.04839316970174e-07
associated O 0 5.197421728553309e-07
with O 0 5.454085112432949e-07
infantile O 1 0.9982258677482605
TSD B-Disease 0 0.4432213306427002
. O 0 7.993654435267672e-06

Furthermore O 0 4.29700558015611e-05
, O 0 1.2197118621770642e-06
the O 0 6.837354931121808e-07
precursor O 0 2.097219521601801e-06
level O 0 1.1710260423569707e-06
of O 0 1.1044365919588017e-06
the O 0 1.535554133624828e-06
W474C O 0 1.6033938663895242e-05
alpha O 0 3.185589775966946e-06
- O 0 3.033474627045507e-07
subunit O 0 3.333205711442133e-07
was O 0 8.591925961809466e-07
found O 0 3.876979803862923e-08
to O 0 1.4523098279539681e-08
accumulate O 0 1.078259330711262e-07
in O 0 5.321679452663375e-08
comparison O 0 5.435268590758824e-08
to O 0 2.8685700925734636e-08
the O 0 2.738225077791867e-07
normal O 0 1.7220431800524238e-06
alpha O 0 4.2564074647089e-06
- O 0 6.519622957057436e-07
subunit O 0 7.116466917977959e-07
precursor O 0 4.088463811058318e-06
levels O 0 2.2195204110175837e-06
. O 0 1.3743097042606678e-06

We O 0 9.040139957505744e-06
conclude O 0 1.6548583516851068e-05
that O 0 7.30647855107236e-07
the O 0 1.9079643607256003e-06
1422 O 0 0.00027001716080121696
G O 0 4.565749622997828e-05
- O 0 5.019509899284458e-06
- O 0 2.86473186861258e-06
> O 0 1.0738441460489412e-06
C O 0 1.3755670806858689e-06
mutation O 0 1.7071089430942266e-08
is O 0 1.6528076685062842e-08
the O 0 2.3138232663200142e-08
cause O 0 1.231219357578084e-07
of O 0 1.4236677543522092e-06
Hex B-Disease 0 0.007244478911161423
A I-Disease 0 0.3366006910800934
enzyme I-Disease 1 0.9999991655349731
deficiency I-Disease 1 1.0
in O 0 1.1447154975030571e-06
the O 0 5.399895144364564e-06
proband O 0 0.0003567970998119563
. O 0 6.156832114356803e-06

The O 0 5.3838091844227165e-05
resulting O 0 4.0088078094413504e-05
W474C O 0 0.0002960527781397104
substitution O 0 2.1820196707267314e-05
clearly O 0 3.404703647902352e-06
interferes O 0 1.999254436668707e-06
with O 0 1.6768362343100307e-07
alpha O 0 2.4136613774317084e-06
- O 0 2.338581452931976e-07
subunit O 0 2.3253711844972713e-07
processing O 0 4.0988848581946513e-07
, O 0 4.290214405955339e-08
but O 0 1.0002954020649213e-08
because O 0 1.1726958959457079e-08
the O 0 5.798296953685167e-08
base O 0 4.5807107085238385e-07
substitution O 0 9.258157547265e-07
falls O 0 5.80084633838851e-06
at O 0 8.844481840242224e-07
the O 0 1.6028646143695369e-07
first O 0 3.0103097969913506e-07
position O 0 3.555017826784024e-07
of O 0 5.513705332305108e-07
exon O 0 6.227953690540744e-07
13 O 0 8.111076681416307e-07
, O 0 9.128213918074835e-08
aberrant O 0 1.7278978248214116e-06
splicing O 0 4.571620024762524e-07
may O 0 1.9571284326502791e-07
also O 0 3.11318579804265e-08
contribute O 0 2.6166494748736113e-08
to O 0 5.651386203453512e-08
Hex B-Disease 0 6.801601557526737e-05
A I-Disease 0 6.810078048147261e-05
deficiency I-Disease 0 0.23712946474552155
in O 0 3.849334575534158e-07
this O 0 1.7150762232631678e-07
proband O 0 1.895007153507322e-05
. O 0 3.8058200857449265e-07
. O 0 2.25944700105174e-06

Two O 0 2.861176881197025e-06
frequent O 0 6.427000698749907e-06
missense O 0 7.472812285413966e-05
mutations O 0 6.750670581823215e-05
in O 0 0.005036144517362118
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00016345658514183015

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.009621788747608662
an O 1 0.6746186017990112
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 1.0
by O 0 0.0009147257660515606
early O 1 0.9477897882461548
childhood O 1 0.9999998807907104
deafness B-Disease 1 1.0
and O 1 0.9999997615814209
goiter B-Disease 1 1.0
. O 0 0.10681456327438354

A O 0 3.888476931024343e-05
century O 0 2.993869884448941e-06
after O 0 3.2595931998002925e-07
its O 0 3.2785411718805335e-08
recognition O 0 2.534688974265009e-07
as O 0 8.93376409294433e-07
a O 0 1.4359495253302157e-05
syndrome O 1 0.9999964237213135
by O 0 1.8847829323931364e-06
Vaughan O 0 0.00012486297055147588
Pendred O 0 0.0003728620649781078
, O 0 2.2881300765220658e-07
the O 0 5.939576226410281e-07
disease O 0 9.472482815908734e-06
gene O 0 5.300447014633392e-07
( O 0 5.724560878661578e-07
PDS O 0 3.0110531952232122e-05
) O 0 1.0346127510274528e-07
was O 0 1.6711128409951925e-06
mapped O 0 4.97509404340235e-07
to O 0 3.1307644121625344e-07
chromosome O 0 0.027357563376426697
7q22 O 1 0.9975374937057495
- O 1 0.5656169056892395
q31 O 0 0.07646799832582474
. O 0 9.264815162168816e-06

1 O 0 4.142299803788774e-05
and O 0 1.226812855747994e-06
, O 0 3.7165202115829743e-07
recently O 0 4.346772470853466e-07
, O 0 2.039715241153317e-08
found O 0 2.8352905800943518e-08
to O 0 1.8637040355429235e-08
encode O 0 2.1901746549701784e-07
a O 0 3.935168479074491e-06
putative O 0 0.00012814058572985232
sulfate O 0 0.0003765763249248266
transporter O 0 0.002076273551210761
. O 0 1.0709370144468267e-05

We O 0 4.590690878103487e-06
performed O 0 1.7841263115769834e-06
mutation O 0 4.986428052689007e-07
analysis O 0 3.3988666814366297e-07
of O 0 5.475990860759339e-07
the O 0 2.5078027192648733e-06
PDS B-Disease 0 3.0150500606396236e-05
gene O 0 3.9488801917286764e-07
in O 0 3.3227007634195616e-07
patients O 0 1.635644508723999e-07
from O 0 3.4294924944333616e-07
14 O 0 3.691961865115445e-06
Pendred B-Disease 0 1.4319289221020881e-05
families O 0 3.436032613990392e-08
originating O 0 1.7496421378382365e-07
from O 0 5.104170597292068e-08
seven O 0 3.0498402026069016e-08
countries O 0 5.208175224424849e-09
and O 0 3.150219285430467e-08
identified O 0 1.601588621724659e-07
all O 0 1.1153169765520943e-07
mutations O 0 4.540905592875788e-06
. O 0 9.64682567428099e-06

The O 0 1.4525847291224636e-05
mutations O 0 9.952959771908354e-07
include O 0 5.654399615195871e-07
three O 0 1.8536169932303892e-07
single O 0 5.197728683015157e-07
base O 0 1.5357035181295942e-06
deletions O 0 1.8391674529993907e-06
, O 0 1.2304329288781446e-07
one O 0 4.786043561466613e-08
splice O 0 4.0769052134237427e-07
site O 0 9.413430746008089e-08
mutation O 0 2.1853919562886404e-08
and O 0 2.7610983721615412e-08
10 O 0 6.481818104475678e-07
missense O 0 9.629820851841941e-06
mutations O 0 5.264364517643116e-06
. O 0 6.181471690069884e-06

One O 0 1.9067067114519887e-05
missense O 0 4.407610686030239e-05
mutation O 0 8.418888683081605e-06
( O 0 1.921988314279588e-06
L236P O 0 2.5931105483323336e-05
) O 0 2.1983106535117258e-07
was O 0 1.3976222135170246e-06
found O 0 2.586431158135838e-08
in O 0 1.7901848892165617e-08
a O 0 2.8371569982255096e-08
homozygous O 0 3.445509477728592e-08
state O 0 3.033827056242444e-08
in O 0 8.335926082736478e-08
two O 0 5.695971694308355e-08
consanguineous O 0 3.068879777856637e-06
families O 0 1.2282951544762e-08
and O 0 3.8603037211260016e-08
in O 0 4.870656411526397e-08
a O 0 6.206430924748929e-08
heterozygous O 0 1.9461168676571106e-08
state O 0 6.650922479423116e-09
in O 0 2.2978232649961683e-08
five O 0 2.985436253766238e-08
additional O 0 1.6282487536045664e-07
non O 0 1.1177291526109912e-05
- O 0 2.8009715606458485e-05
consanguineous O 0 4.718421769212e-05
families O 0 3.668905037557124e-07
. O 0 2.3518896341556683e-06

Another O 0 7.094061584211886e-05
missense O 0 5.70427073398605e-05
mutation O 0 7.656863090232946e-06
( O 0 1.3455487533065025e-06
T416P O 0 2.198045331169851e-05
) O 0 2.561042720117257e-07
was O 0 2.363879502809141e-06
found O 0 3.627754807666861e-08
in O 0 2.6483169435209675e-08
a O 0 3.8073114438930133e-08
homozygous O 0 5.6244921609049925e-08
state O 0 3.5456924507570875e-08
in O 0 8.054284705849568e-08
one O 0 5.5002193022346546e-08
family O 0 2.952951838608442e-08
and O 0 2.689534817079675e-08
in O 0 4.742643255895018e-08
a O 0 1.0948258477583295e-07
heterozygous O 0 6.142459341162976e-08
state O 0 3.912324331167838e-08
in O 0 1.1622505979858033e-07
four O 0 1.8212351449164998e-07
families O 0 2.482597949438059e-07
. O 0 2.6537027224549092e-06

Pendred B-Disease 0 0.02221694216132164
patients O 0 1.695184619165957e-05
in O 0 3.4322645205975277e-06
three O 0 8.414148169322289e-07
non O 0 1.890970452222973e-05
- O 0 8.451725989289116e-06
consanguineous O 0 6.775295787520008e-06
families O 0 2.6659488838731704e-08
were O 0 5.123893842551297e-08
shown O 0 3.2883800571426036e-08
to O 0 3.0205008272332634e-08
be O 0 2.1488249046797137e-07
compound O 0 3.928809292119695e-06
heterozygotes O 0 1.1556713843674515e-06
for O 0 2.383014390261451e-07
L236P O 0 3.688107608468272e-05
and O 0 2.831399797287304e-06
T416P O 0 0.00022834245464764535
. O 0 3.865922280965606e-06

In O 0 1.362575676466804e-05
total O 0 5.672748557117302e-06
, O 0 6.641366212534194e-07
one O 0 1.6207442854465626e-07
or O 0 6.153224063609741e-08
both O 0 1.360013790474568e-08
of O 0 9.218513952191643e-08
these O 0 3.9237937343727936e-09
mutations O 0 2.5987986873587943e-08
were O 0 2.2413671274534863e-07
found O 0 3.9139809615562626e-08
in O 0 3.401278192427526e-08
nine O 0 9.499466102624865e-08
of O 0 2.9097458309479407e-07
the O 0 4.1655860627543007e-07
14 O 0 1.1584388630581088e-06
families O 0 7.569590820821759e-08
analyzed O 0 2.0464158296817914e-06
. O 0 3.6270016607886646e-06

The O 0 5.556654741667444e-06
identification O 0 3.990249410890101e-07
of O 0 4.3198031107749557e-07
two O 0 9.643264320402523e-08
frequent O 0 7.580411534036102e-07
PDS B-Disease 0 2.0001923985546455e-05
mutations O 0 5.37633297881257e-08
will O 0 1.0002420225418973e-08
facilitate O 0 6.338687796869635e-08
the O 0 1.420323343381824e-07
molecular O 0 5.689467798219994e-05
diagnosis O 1 0.9828586578369141
of O 1 0.999795138835907
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0003182133659720421

Insertional O 0 0.000934427313040942
mutation O 0 9.991847946366761e-06
by O 0 8.909311191018787e-07
transposable O 0 1.068781057256274e-05
element O 0 1.3664306379723712e-06
, O 0 2.1036507291682938e-07
L1 O 0 9.934420631907415e-06
, O 0 6.303698540932601e-08
in O 0 7.393197876126578e-08
the O 0 6.953854949642846e-07
DMD B-Disease 1 0.9999998807907104
gene O 0 6.897437287989305e-07
results O 0 9.023809184327547e-07
in O 0 2.965267185572884e-06
X B-Disease 1 0.999980092048645
- I-Disease 1 0.9999960660934448
linked I-Disease 1 0.9999953508377075
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
. O 0 0.00015625283413100988

X B-Disease 1 0.9980841875076294
- I-Disease 1 0.9996528625488281
linked I-Disease 1 0.9997264742851257
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
( O 0 3.18837228405755e-05
XLDCM B-Disease 1 0.996601939201355
) O 0 1.606384216756851e-07
is O 0 3.311087937163393e-08
a O 0 6.972076960209961e-08
clinical O 0 3.574528591343551e-06
phenotype O 0 3.4950398912769742e-06
of O 0 4.978135166311404e-06
dystrophinopathy B-Disease 0 0.004742368124425411
which O 0 1.464760970293355e-07
is O 0 5.3325919679991785e-08
characterized O 0 1.4129778946880833e-07
by O 0 4.6375891571415195e-08
preferential O 0 7.48389493310242e-06
myocardial B-Disease 1 1.0
involvement I-Disease 0 5.631454314425355e-06
without O 0 3.3189408554790134e-08
any O 0 1.3489565908741952e-08
overt O 0 1.7055260741472011e-06
clinical O 0 0.0006458492716774344
signs O 0 0.0009730059537105262
of O 1 0.6354056596755981
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.00012321372923906893

To O 0 3.4900672289950307e-06
date O 0 3.943305728171254e-06
, O 0 1.3521848529762792e-07
several O 0 2.826516443121818e-08
mutations O 0 1.460569336586559e-07
in O 0 7.490610869353986e-07
the O 0 9.233383025275543e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999996423721313
gene O 0 7.456247203663224e-06
, O 0 1.6930282527027884e-06
DMD O 1 0.9999998807907104
, O 0 1.0331496014259756e-07
have O 0 1.0278540685249027e-08
been O 0 3.361344269592337e-08
identified O 0 4.412432730305227e-08
in O 0 5.1479037921353665e-08
patients O 0 1.0586288112790498e-07
with O 0 8.421295660809847e-08
XLDCM B-Disease 1 0.9991831183433533
, O 0 2.8993525802434306e-07
but O 0 2.311309010849527e-08
a O 0 5.61821984490507e-08
pathogenic O 0 7.537865798212806e-08
correlation O 0 2.5970649630835396e-07
of O 0 2.3606145305166137e-07
these O 0 5.256039514733857e-08
cardiospecific O 0 1.283961501030717e-05
mutations O 0 5.356313295123982e-07
in O 0 1.5930944528008695e-06
DMD O 1 1.0
with O 0 2.7624844278761884e-07
the O 0 6.221569492481649e-06
XLDCM B-Disease 0 0.061402589082717896
phenotype O 0 7.1251988629228435e-06
has O 0 3.5738156611841987e-07
remained O 0 3.063479198317509e-06
to O 0 6.062531809902794e-08
be O 0 6.622139494538715e-07
elucidated O 0 6.59291836200282e-05
. O 0 2.499784613974043e-06

We O 0 3.089616438956e-05
report O 0 9.099632734432817e-06
here O 0 3.976835216690233e-07
the O 0 8.768160597583119e-08
identification O 0 1.0519443094381131e-07
of O 0 4.937102175972541e-07
a O 0 4.5805052195646567e-07
unique O 0 2.5508268208795926e-07
de O 0 1.4793155060033314e-05
novo O 0 1.2082227840437554e-05
L1 O 0 1.736486410663929e-05
insertion O 0 1.63339655046002e-06
in O 0 2.3336087906500325e-07
the O 0 3.372284140823467e-07
muscle O 0 3.805257620115299e-07
exon O 0 4.954611085850047e-07
1 O 0 5.005618959330604e-07
in O 0 6.211333243300032e-07
DMD O 1 0.9999995231628418
in O 0 6.329456709863734e-07
three O 0 6.282195386120293e-07
XLDCM B-Disease 0 0.00962788425385952
patients O 0 3.1807400091565796e-07
from O 0 2.624317403387977e-07
two O 0 9.205704998294095e-08
unrelated O 0 1.5489754332520533e-06
Japanese O 0 8.706765584065579e-06
families O 0 3.653148041848908e-07
. O 0 1.8222809785584104e-06

The O 0 5.1967130275443196e-05
insertion O 0 5.061236151959747e-05
was O 0 2.4395832951995544e-05
a O 0 2.45080786953622e-06
5 O 0 1.3212033991294447e-06
- O 0 6.04867182119051e-07
truncated O 0 1.2934759752170066e-06
form O 0 3.5481683369198436e-08
of O 0 3.20642101314661e-07
human O 0 3.217534185750992e-07
L1 O 0 8.337042345374357e-06
inversely O 0 4.042913133162074e-06
integrated O 0 1.0999534652000875e-06
in O 0 1.8679644142594043e-07
the O 0 2.1163943131341512e-07
5 O 0 3.6812383541473537e-07
- O 0 3.409007831578492e-07
untranslated O 0 3.1056620173330884e-06
region O 0 1.4650949253791623e-07
in O 0 1.8309685856365832e-07
the O 0 2.2938786514714593e-07
muscle O 0 2.496936986062792e-07
exon O 0 2.544332460274745e-07
1 O 0 2.6961583898810204e-07
, O 0 1.769629065506706e-08
which O 0 1.1281534817442207e-08
affected O 0 2.4453903790799814e-08
the O 0 5.2216265089555236e-08
transcription O 0 5.341061637409439e-07
or O 0 4.0964689418387934e-08
the O 0 1.4708403739405185e-07
stability O 0 5.526719064619101e-07
of O 0 1.1678108648993657e-06
the O 0 1.1027990467482596e-06
muscle O 0 5.88199497997266e-07
form O 0 4.244390794383435e-08
of O 0 5.889921226298611e-07
dystrophin O 0 1.8099319731845753e-06
transcripts O 0 1.1297705668766866e-06
but O 0 3.5736309911271746e-08
not O 0 1.4315758356531205e-08
that O 0 2.1627428736792353e-08
of O 0 4.965765469933103e-07
the O 0 3.0919024993636413e-06
brain O 0 0.10889767855405807
or O 0 2.8407744139258284e-06
Purkinje O 1 0.9254711270332336
cell O 0 3.01617164950585e-05
form O 0 1.2254606929218426e-07
, O 0 8.264164108595651e-08
probably O 0 7.910093557939035e-08
due O 0 9.881480877993454e-08
to O 0 8.562984099569348e-09
its O 0 2.3882236632744025e-08
unique O 0 2.0351258456230426e-08
site O 0 1.5900876348950987e-07
of O 0 4.735240111131134e-07
integration O 0 5.1127190090483055e-06
. O 0 3.3703695407893974e-06

We O 0 8.856299245962873e-06
speculate O 0 5.928342488914495e-06
that O 0 2.1466516386681178e-07
this O 0 8.897205105995454e-08
insertion O 0 4.5825325400983274e-07
of O 0 2.9763117481707013e-07
an O 0 2.3995158926481963e-07
L1 O 0 4.338615326560102e-06
sequence O 0 2.6138519615415134e-07
in O 0 8.598648264523945e-07
DMD O 1 1.0
is O 0 2.3347219268998742e-07
responsible O 0 1.075995257338036e-07
for O 0 1.919932657301615e-08
some O 0 3.360573597177563e-09
of O 0 4.8304858779602e-08
the O 0 3.4613901078728304e-08
population O 0 5.9428089116408955e-09
of O 0 1.0090126068007521e-07
Japanese O 0 5.928523478360148e-06
patients O 0 2.1645303149853135e-07
with O 0 3.888659705353348e-07
XLDCM B-Disease 0 0.19036626815795898
. O 0 1.3041581041761674e-06
. O 0 3.6605035802494967e-06

Severe O 1 0.9998751878738403
early O 0 0.15558673441410065
- O 1 0.9999996423721313
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.16417329013347626
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.001732274075038731
red O 1 0.9934359788894653
hair O 1 0.9996943473815918
pigmentation O 1 0.9999988079071045
caused O 1 0.9998810291290283
by O 0 7.073756933095865e-06
POMC O 1 0.6965740919113159
mutations O 0 1.3008092309974018e-06
in O 0 5.641553002533328e-07
humans O 0 6.38797530427837e-07
. O 0 1.6353308183170157e-06

Sequential O 0 0.0004715751565527171
cleavage O 0 0.00033726601395756006
of O 0 3.843832382699475e-05
the O 0 3.977544110966846e-06
precursor O 0 1.1145657481392846e-05
protein O 0 1.664194655859319e-06
pre O 0 1.971543133549858e-05
- O 0 1.0903900147241075e-05
pro O 0 4.30976870120503e-05
- O 0 4.0463346522301435e-06
opiomelanocortin O 0 1.126390361605445e-05
( O 0 3.0790653227086295e-07
POMC O 0 2.3663134925300255e-05
) O 0 7.829653014823634e-08
generates O 0 1.410769669973888e-07
the O 0 9.480185667598562e-07
melanocortin O 0 3.82165344490204e-05
peptides O 0 2.63229344454885e-06
adrenocorticotrophin O 0 2.1507416022359394e-05
( O 0 8.958470516517991e-07
ACTH O 0 3.437100167502649e-05
) O 0 2.2952221456762345e-07
, O 0 2.761143775842356e-07
melanocyte O 0 1.6843458070070483e-05
- O 0 3.0263076951086987e-06
stimulating O 0 3.1213276088237762e-06
hormones O 0 9.334028163721086e-07
( O 0 6.405117147778583e-08
MSH O 0 1.0489845863048686e-06
) O 0 1.256148074446628e-08
alpha O 0 1.0017678420126686e-07
, O 0 6.881863079399864e-09
beta O 0 5.165361827152992e-08
and O 0 1.6565380178690248e-08
gamma O 0 2.813871162743453e-07
as O 0 5.1222130537098565e-08
well O 0 2.7031218152728798e-08
as O 0 2.9888148844747775e-08
the O 0 1.2843783281368815e-07
opioid O 0 3.390208121345495e-06
- O 0 6.969935952838568e-07
receptor O 0 2.1605183064821176e-06
ligand O 0 1.2643547961488366e-05
beta O 0 9.05641536519397e-06
- O 0 1.7373511582263745e-05
endorphin O 0 0.00013563816901296377
. O 0 1.6245307961071376e-06

While O 0 4.172282842773711e-06
a O 0 8.750648703426123e-07
few O 0 8.287003794293923e-08
cases O 0 7.20528632314199e-08
of O 0 6.244591986614978e-06
isolated O 0 0.028827227652072906
ACTH B-Disease 1 0.9999990463256836
deficiency I-Disease 1 0.995245635509491
have O 0 1.591551779256406e-07
been O 0 4.073100683399389e-07
reported O 0 1.1042354799428722e-06
( O 0 4.4528374587571307e-07
OMIM O 0 0.00012670719297602773
201400 O 0 1.159679868578678e-05
) O 0 1.5438490663655102e-07
, O 0 9.020335056675322e-08
an O 0 6.16972442912811e-07
inherited O 1 0.7487665414810181
POMC O 1 0.9999995231628418
defect O 0 0.000841632834635675
has O 0 3.188645791851741e-07
not O 0 4.279344878455049e-08
been O 0 4.1249978721680236e-07
described O 0 7.770172487653326e-07
so O 0 1.5105327122455492e-07
far O 0 9.36077981350536e-07
. O 0 1.9926724235119764e-06

Recent O 0 2.3810840502846986e-05
studies O 0 4.66546589450445e-06
in O 0 1.1835265922854887e-06
animal O 0 6.379993919836124e-07
models O 0 3.596051953991264e-07
elucidated O 0 6.8967797233199235e-06
a O 0 5.724560878661578e-07
central O 0 9.127123234975443e-07
role O 0 3.0921421512175584e-07
of O 0 1.2210025488457177e-06
alpha O 0 6.896227660035947e-06
- O 0 3.1225245038513094e-06
MSH O 0 1.4448478395934217e-05
in O 0 9.86024346616432e-08
the O 0 1.1160318535985425e-07
regulation O 0 8.081212854449404e-08
of O 0 2.4171708901121747e-07
food O 0 3.8727011997252703e-07
intake O 0 8.522413281752961e-07
by O 0 7.143243863083626e-08
activation O 0 6.315589189398452e-07
of O 0 1.1801273558376124e-06
the O 0 1.6200132222365937e-06
brain O 0 1.8905197066487744e-05
melanocortin O 0 4.1713170503498986e-05
- O 0 1.1692116004269337e-06
4 O 0 1.4861317367831361e-06
- O 0 3.19281781457903e-07
receptor O 0 9.63710249379801e-07
( O 0 2.7247912726124923e-07
MC4 O 0 1.130772852775408e-05
- O 0 9.19729643555911e-07
R O 0 1.327751306234859e-06
; O 0 4.180748192084138e-08
refs O 0 4.779575419888715e-07
3 O 0 1.7857252032627002e-07
- O 0 7.925029876787448e-08
5 O 0 1.0508273362574982e-07
) O 0 8.450157018558002e-09
and O 0 1.1619198936330122e-08
the O 0 7.0905628035689e-08
linkage O 0 1.471863356528047e-06
of O 0 1.4938445929146837e-06
human O 0 4.414446721057175e-06
obesity B-Disease 1 0.9879419207572937
to O 0 4.1711899712026934e-08
chromosome O 0 1.0031920965047902e-06
2 O 0 4.16411609194256e-07
in O 0 7.685348890618116e-08
close O 0 2.6326799229536846e-07
proximity O 0 2.439616650917742e-07
to O 0 6.223013571116098e-08
the O 0 5.90802528677159e-07
POMC O 0 2.0298350136727095e-05
locus O 0 1.1638117030088324e-06
, O 0 5.278342030123895e-08
led O 0 1.83149765575763e-07
to O 0 9.976012904644449e-09
the O 0 5.3742823524771666e-08
proposal O 0 6.461463186724359e-08
of O 0 3.030565665085305e-07
an O 0 3.5293609812470095e-07
association O 0 2.0255843935501616e-07
of O 0 1.6993304825518862e-06
POMC O 1 0.5668202042579651
with O 0 5.043959845352219e-07
human O 0 0.013138658367097378
obesity B-Disease 1 1.0
. O 0 8.854914085532073e-06

The O 0 2.3027339921100065e-05
dual O 0 2.0680459783761762e-05
role O 0 7.892679604992736e-06
of O 0 8.571902981202584e-06
alpha O 0 7.342080061789602e-05
- O 0 1.666387470322661e-05
MSH O 0 7.6881937275175e-05
in O 0 1.5896358718237025e-07
regulating O 0 1.1179744205946918e-06
food O 0 7.768446153022524e-07
intake O 0 7.754621037747711e-06
and O 0 3.2040856012827135e-07
influencing O 0 7.496052148781018e-06
hair O 0 0.00010858199675567448
pigmentation O 0 0.0040133376605808735
predicts O 0 5.2727355068782344e-06
that O 0 1.696365181658166e-08
the O 0 6.547112718635617e-08
phenotype O 0 3.9539298768431763e-07
associated O 0 6.77088323186581e-08
with O 0 2.014898647928476e-08
a O 0 1.2571928209581529e-06
defect O 0 1.8972166799358092e-05
in O 0 9.67400865192758e-07
POMC O 0 0.010450824163854122
function O 0 4.235713504385785e-07
would O 0 7.859697603862514e-08
include O 0 6.399176299964893e-07
obesity B-Disease 1 0.9999995231628418
, O 0 1.253398664857741e-07
alteration O 0 1.1133802217955235e-05
in O 0 7.65602362662321e-06
pigmentation O 1 0.9999512434005737
and O 1 0.9668431878089905
ACTH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 2.3591686840518378e-05

The O 0 1.3017154742556158e-05
observation O 0 7.868271495681256e-05
of O 0 5.699911525880452e-06
these O 0 4.352442886101926e-07
symptoms O 0 5.6113691243808717e-05
in O 0 7.48511240544758e-07
two O 0 1.6741103081585607e-07
probands O 0 4.057127807755023e-05
prompted O 0 1.2801218645108747e-06
us O 0 7.868427331914063e-08
to O 0 7.476692154284592e-09
search O 0 2.2558779733117262e-08
for O 0 1.7898127424587074e-08
mutations O 0 8.665264061846756e-08
within O 0 2.2588299941617151e-07
their O 0 3.55775142679704e-07
POMC O 0 0.00153625151142478
genes O 0 6.092815510783112e-06
. O 0 7.306043698918074e-06

Patient O 0 0.0002205516502726823
1 O 0 2.001440225285478e-05
was O 0 1.1481834008009173e-05
found O 0 1.9912768323138152e-07
to O 0 4.363606009860632e-08
be O 0 2.2870109717132436e-07
a O 0 7.759568916299031e-07
compound O 0 5.780094397778157e-06
heterozygote O 0 1.2585362583195092e-06
for O 0 3.8599726082111374e-08
two O 0 2.3187359587950596e-08
mutations O 0 5.5095430440132986e-08
in O 0 2.2367504470821586e-07
exon O 0 7.355081379500916e-07
3 O 0 8.056940714595839e-07
( O 0 1.2296646900722408e-07
G7013T O 0 3.0248825169110205e-06
, O 0 1.7774507909962267e-07
C7133delta O 0 2.4313001176778926e-06
) O 0 2.5358826150068126e-08
which O 0 1.6176645800669576e-08
interfere O 0 5.493802390788005e-08
with O 0 1.4551631011272548e-08
appropriate O 0 1.2208832345095288e-07
synthesis O 0 2.1112084596097702e-06
of O 0 1.7739533859639778e-06
ACTH O 0 6.070446761441417e-05
and O 0 1.2982029602426337e-06
alpha O 0 5.555569441639818e-05
- O 0 5.152479570824653e-05
MSH O 0 0.0006008798372931778
. O 0 2.5057945549633587e-06

Patient O 0 0.0001290377404075116
2 O 0 1.4864837794448249e-05
was O 0 5.686478743882617e-06
homozygous O 0 4.5667701442653197e-07
for O 0 5.329734875658687e-08
a O 0 1.0104917436137839e-07
mutation O 0 6.035326549636011e-08
in O 0 1.2394035309171159e-07
exon O 0 3.3352981176903995e-07
2 O 0 4.6943057441239944e-07
( O 0 1.4423764582716103e-07
C3804A O 0 8.552419785701204e-06
) O 0 1.0227600455436914e-07
which O 0 4.453262079096021e-07
abolishes O 0 7.009140244917944e-05
POMC O 0 0.0010240920819342136
translation O 0 4.643488136935048e-05
. O 0 4.1111488826572895e-06

These O 0 1.0584506071609212e-06
findings O 0 9.800036195883877e-07
represent O 0 4.607207415574521e-08
the O 0 5.41993685487796e-08
first O 0 5.1924672561654006e-08
examples O 0 4.7769965760835476e-08
of O 0 5.145773798176378e-07
a O 0 8.894345228327438e-06
genetic B-Disease 1 0.9999222755432129
defect I-Disease 1 0.9999709129333496
within O 0 2.8686693553936493e-07
the O 0 1.193523644360539e-06
POMC O 0 0.00011743422510335222
gene O 0 1.1104200581257828e-07
and O 0 3.790696467831367e-08
define O 0 8.150733066258908e-08
a O 0 5.098328301755828e-07
new O 0 1.4200228406480164e-06
monogenic B-Disease 1 0.9999991655349731
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9583601951599121
resulting O 0 1.8196204791820492e-06
in O 0 2.686192885903438e-07
early O 0 1.4569187442248221e-05
- O 1 0.9861836433410645
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0009157629101537168
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.0003626082034315914
red O 1 0.8276374340057373
hair O 1 0.9308481216430664
pigmentation O 1 0.9972614049911499
. O 0 3.632876541814767e-06
. O 0 5.243451141723199e-06

A O 0 8.75093464856036e-05
European O 0 1.4290394574345555e-05
multicenter O 0 0.0005772490985691547
study O 0 9.759700333233923e-06
of O 0 0.00015150208491832018
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
: O 0 6.782289574402967e-07
classification O 0 4.179823349659273e-07
of O 0 1.940439204872746e-07
105 O 0 9.295191034652817e-07
mutations O 0 6.772123128939711e-08
and O 0 1.1648016595700028e-07
a O 0 8.092825964922667e-07
general O 0 1.48749575146212e-06
system O 0 2.3176312424766365e-07
for O 0 7.333509444151787e-08
genotype O 0 1.62680203175114e-06
- O 0 3.2824164009070955e-06
based O 0 4.308957670673408e-07
prediction O 0 1.8953756807604805e-05
of O 0 7.906223800091539e-06
metabolic O 1 0.9993700385093689
phenotype O 0 0.00012570808758027852
. O 0 4.696456016972661e-06

Phenylketonuria B-Disease 1 0.6688703894615173
( O 0 3.2310068490915e-05
PKU B-Disease 0 0.006889830343425274
) O 0 1.815624955270323e-06
and O 0 1.7696074792183936e-06
mild B-Disease 1 0.9999570846557617
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.07010938227176666
MHP B-Disease 1 1.0
) O 0 3.9434985410480294e-07
are O 0 2.817092514817432e-08
allelic B-Disease 0 0.00010034052684204653
disorders I-Disease 1 0.9996016621589661
caused O 0 0.002725940430536866
by O 0 1.1844372238556389e-07
mutations O 0 7.719859951293984e-08
in O 0 1.7445817945827002e-07
the O 0 3.040373428575549e-07
gene O 0 5.962726277175534e-07
encoding O 0 1.8856818542190013e-06
phenylalanine O 0 4.0763752622297034e-05
hydroxylase O 0 9.221530490322039e-05
( O 0 6.1009145611024e-06
PAH O 1 0.9999411106109619
) O 0 3.258699507568963e-06
. O 0 3.623071279434953e-06

Previous O 0 7.431784069922287e-06
studies O 0 2.474165285093477e-06
have O 0 2.3802093096492172e-07
suggested O 0 2.766207103377383e-07
that O 0 2.623080597174976e-08
the O 0 1.187552101100664e-07
highly O 0 6.15883664067951e-07
variable O 0 1.9203271222067997e-05
metabolic O 1 0.9958475828170776
phenotypes O 0 0.0001481785875512287
of O 1 0.9463266730308533
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.00012763802078552544
with O 0 2.2306090613710694e-05
PAH O 1 1.0
genotypes O 0 0.041543733328580856
. O 0 2.818406755977776e-05

We O 0 8.035937753447797e-06
identified O 0 2.102265852954588e-06
both O 0 1.3849019353529002e-07
causative O 0 6.51208665658487e-06
mutations O 0 7.366692216237425e-07
in O 0 6.282872391238925e-07
686 O 0 0.00019146178965456784
patients O 0 5.716148621104367e-07
from O 0 5.288041506901209e-07
seven O 0 4.6737082470826863e-07
European O 0 1.0959265637211502e-06
centers O 0 4.544076546153519e-06
. O 0 2.484502601873828e-06

On O 0 2.5476605514995754e-05
the O 0 5.988450766380993e-07
basis O 0 2.432593362300395e-07
of O 0 4.1620197066549736e-07
the O 0 1.2347504707577173e-07
phenotypic O 0 3.651079225619469e-07
characteristics O 0 3.710439955284528e-07
of O 0 3.0271505693235667e-06
297 O 0 3.309082967462018e-05
functionally O 0 1.4588513295166194e-05
hemizygous O 0 2.6246274501318112e-05
patients O 0 2.776842791263334e-07
, O 0 1.3070165039152926e-07
105 O 0 5.270887868391583e-07
of O 0 1.195791554664538e-07
the O 0 7.623170716897221e-08
mutations O 0 3.259294345525632e-08
were O 0 1.179058060074567e-07
assigned O 0 5.1253795874117714e-08
to O 0 1.5591682611670876e-08
one O 0 3.403757631303961e-08
of O 0 2.2056941872961033e-07
four O 0 2.4220932459684263e-07
arbitrary O 0 9.831876013777219e-06
phenotype O 0 2.8061020202585496e-05
categories O 0 5.982758921163622e-06
. O 0 2.445335667289328e-06

We O 0 4.391984930407489e-06
proposed O 0 1.332012743660016e-06
and O 0 2.155779128543145e-07
tested O 0 2.3619678302111424e-07
a O 0 9.508239173783295e-08
simple O 0 3.1640876585470323e-08
model O 0 5.8877649422584e-08
for O 0 1.004593652709218e-08
correlation O 0 1.8343801855280617e-07
between O 0 9.183941074297763e-08
genotype O 0 5.590682121692225e-07
and O 0 1.3670127430032153e-07
phenotypic O 0 3.000775905093178e-06
outcome O 0 7.085079232638236e-06
. O 0 5.271458121569594e-06

The O 0 2.5158584321616217e-05
observed O 0 1.3220175787864719e-05
phenotype O 0 1.935198270075489e-05
matched O 0 2.474292614351725e-06
the O 0 1.2102395885449369e-06
predicted O 0 2.5724791612447007e-06
phenotype O 0 5.061157253294368e-07
in O 0 9.110524246125351e-08
79 O 0 7.524455440943711e-07
% O 0 3.7593178348060974e-08
of O 0 2.2667302346235374e-07
the O 0 1.4622278854403703e-07
cases O 0 6.6998289582898e-08
, O 0 5.764641741734522e-08
and O 0 4.6597914860058154e-08
in O 0 6.411179498400088e-08
only O 0 1.9372876636225556e-08
5 O 0 1.6896363774776546e-07
of O 0 2.7822639481200895e-07
184 O 0 1.810161620596773e-06
patients O 0 1.9167919163010083e-07
was O 0 9.408426194568165e-06
the O 0 2.3711740482212917e-07
observed O 0 2.6947881792693806e-07
phenotype O 0 2.9984823868289823e-07
more O 0 4.6961030619740995e-09
than O 0 7.563338400018438e-09
one O 0 1.2638167845580028e-08
category O 0 5.7766833094774483e-08
away O 0 1.7809181684924624e-08
from O 0 5.44639355837262e-08
that O 0 5.1825725932985733e-08
expected O 0 9.529496765026124e-07
. O 0 1.5461137081729248e-06

Among O 0 7.287547759915469e-06
the O 0 1.371867483612732e-06
seven O 0 4.415607293140056e-07
contributing O 0 1.2271708555999794e-06
centers O 0 5.340673965292808e-07
, O 0 3.370178092154674e-08
the O 0 3.301817130818563e-08
proportion O 0 8.9398007219188e-08
of O 0 6.109288506195298e-07
patients O 0 1.5687504628658644e-07
for O 0 5.448450934864013e-08
whom O 0 8.05016853178131e-08
the O 0 1.4658915858944965e-07
observed O 0 2.523848934288253e-07
phenotype O 0 7.138762612157734e-07
did O 0 5.2249738757836894e-08
not O 0 1.8608128371511157e-08
match O 0 1.4436535877848655e-07
the O 0 3.9334699408755114e-07
predicted O 0 6.646321253356291e-07
phenotype O 0 2.0146993051639583e-07
was O 0 8.985766157820763e-07
4 O 0 2.192891770391725e-07
% O 0 2.3147412875346163e-08
- O 0 9.071060702581235e-08
23 O 0 5.07283232309419e-07
% O 0 8.758849645573719e-08
( O 0 8.613127278067623e-08
P O 0 1.5097699360921979e-05
< O 0 9.942021961251157e-07
. O 0 2.7136913161029952e-08
0001 O 0 2.3867130494181765e-06
) O 0 9.901267361556165e-09
, O 0 3.157273775755698e-09
suggesting O 0 5.994070129133888e-09
that O 0 7.035229065976978e-10
differences O 0 1.0169642905566434e-09
in O 0 5.072597009103674e-09
methods O 0 1.1845452618786112e-08
used O 0 1.805840277313564e-08
for O 0 2.6382689810589e-08
mutation O 0 3.3808530019996397e-07
detection O 0 4.5678470996790566e-06
or O 0 7.674259450141108e-07
phenotype O 0 1.570147833263036e-05
classification O 0 7.441851153089374e-07
may O 0 9.375533238653588e-08
account O 0 1.0049443055493157e-08
for O 0 9.02573571437415e-09
a O 0 3.202429255111383e-08
considerable O 0 8.36786568925163e-08
proportion O 0 4.744045156712673e-07
of O 0 4.2335914258728735e-06
genotype O 0 5.3197403758531436e-05
- O 0 0.00017791790014598519
phenotype O 0 6.498565198853612e-05
inconsistencies O 0 4.924945824313909e-05
. O 0 5.738418167311465e-06

Our O 0 1.3569760994869284e-05
data O 0 5.884850907023065e-06
indicate O 0 4.761069249070715e-06
that O 0 1.0280363085257704e-06
the O 0 2.049165777862072e-05
PAH O 1 0.9999978542327881
- O 0 1.710677497612778e-05
mutation O 0 4.6698636424480355e-07
genotype O 0 6.050887577657704e-07
is O 0 6.593215573502675e-08
the O 0 6.181667799864954e-08
main O 0 1.2713741170955473e-06
determinant O 0 3.508869895085809e-06
of O 0 1.6810132592581795e-06
metabolic O 1 0.9857478737831116
phenotype O 0 3.5063110317423707e-06
in O 0 1.5572223333037982e-07
most O 0 1.428685010296249e-07
patients O 0 2.193892669311026e-06
with O 0 5.393434184952639e-05
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00038668885827064514

In O 0 8.909769348974805e-06
the O 0 1.4666007928099134e-06
present O 0 3.0250907911977265e-07
study O 0 3.02869324286803e-07
, O 0 1.1589113313448252e-07
the O 0 1.366882429465477e-07
classification O 0 3.84597683478205e-07
of O 0 2.4912244498409564e-06
105 O 0 7.933933375170454e-05
PAH O 1 0.9977163076400757
mutations O 0 1.141360257861379e-06
may O 0 2.0320751445979113e-06
allow O 0 6.866813606620781e-08
the O 0 4.3877423649973935e-07
prediction O 0 6.1374635151878465e-06
of O 0 4.714836450148141e-07
the O 0 6.19775960331026e-07
biochemical O 0 6.743367521266919e-06
phenotype O 0 2.0019026578665944e-06
in O 0 2.6355337467975914e-07
> O 0 5.230846795711841e-07
10 O 0 8.943944607153753e-08
, O 0 3.147834704009256e-08
000 O 0 2.23832316237349e-07
genotypes O 0 1.3625886197132786e-07
, O 0 2.6634786820523004e-08
which O 0 1.9933168005081825e-08
may O 0 2.8606530477759406e-08
be O 0 6.268291219413413e-09
useful O 0 9.852438864754731e-09
for O 0 1.8401371093546004e-08
the O 0 4.7041831408023427e-07
management O 0 4.256967713445192e-06
of O 0 7.517121048294939e-06
hyperphenylalaninemia B-Disease 1 0.9999986886978149
in O 0 2.0272578694857657e-05
newborns O 0 8.644975605420768e-05
. O 0 1.169257939181989e-05

Somatic O 0 0.0014174975221976638
instability O 0 0.0004595502687152475
of O 0 2.0523988496279344e-05
the O 0 9.324578059022315e-06
CTG O 0 0.0003160645719617605
repeat O 0 9.38291805141489e-07
in O 0 2.5715664264680527e-07
mice O 0 8.327930345330969e-07
transgenic O 0 1.6273589835691382e-06
for O 0 3.647153903330036e-07
the O 0 5.9094825701322407e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 6.6416703248251e-07
is O 0 7.155994552476841e-08
age O 0 6.91056669666068e-08
dependent O 0 3.167463091813261e-08
but O 0 5.609661180017156e-09
not O 0 2.6167881195249265e-09
correlated O 0 7.11880261405895e-08
to O 0 1.3897981432364759e-08
the O 0 1.5874437053753354e-07
relative O 0 1.5972598248481518e-06
intertissue O 0 2.1803223717142828e-05
transcription O 0 1.721332773740869e-05
levels O 0 1.934309921125532e-06
and O 0 1.2913634463984636e-06
proliferative O 1 0.9926980137825012
capacities O 0 0.0001933561870828271
. O 0 1.2275605513423216e-05

A O 0 0.00040643030661158264
( O 0 1.4635527804784942e-05
CTG O 0 0.00016739861166570336
) O 0 7.516473488067277e-07
nexpansion O 0 7.053345598251326e-06
in O 0 3.6674461512120615e-07
the O 0 2.994321448568371e-07
3 O 0 7.836680424588849e-07
- O 0 7.512173851864645e-07
untranslated O 0 6.595381819352042e-06
region O 0 4.4890927597407426e-07
( O 0 9.986010240936594e-08
UTR O 0 1.974199403775856e-05
) O 0 9.725221161716036e-08
of O 0 1.001563191493915e-06
the O 0 4.983744929631939e-06
DM O 1 0.9999982118606567
protein O 0 2.035189936577808e-06
kinase O 0 3.969325007346924e-06
gene O 0 2.738546527325525e-07
( O 0 1.998125043201071e-07
DMPK O 0 1.8782422557706013e-05
) O 0 3.090762135116165e-08
is O 0 1.7411403874234566e-08
responsible O 0 1.05788807047702e-07
for O 0 7.975127687132044e-07
causing O 1 0.9906195402145386
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00010672135977074504
DM B-Disease 1 1.0
) O 0 3.276312099842471e-06
. O 0 3.845357241516467e-06

Major O 0 0.000831340323202312
instability O 0 0.0002731400600168854
, O 0 5.553416144721268e-07
with O 0 5.0393200723419795e-08
very O 0 1.652038683630508e-08
large O 0 4.2558536250680845e-08
expansions O 0 2.789902850963699e-07
between O 0 6.105153005364627e-08
generations O 0 2.4237470697130448e-08
and O 0 4.759280258781473e-08
high O 0 1.3262882703202195e-06
levels O 0 1.1451572845544433e-07
of O 0 4.0263230971504527e-07
somatic O 0 3.2238236599368975e-05
mosaicism O 0 0.0004951296141371131
, O 0 1.8618108299506275e-07
is O 0 4.9323212181207055e-08
observed O 0 1.64788843903807e-07
in O 0 2.5161679673146864e-07
patients O 0 1.3803518186250585e-06
. O 0 2.992853751493385e-06

There O 0 1.0328799362468999e-05
is O 0 1.1221937938898918e-06
a O 0 4.107340885184385e-07
good O 0 1.6980526140741858e-07
correlation O 0 5.048093498771777e-07
between O 0 2.787160724437854e-07
repeat O 0 2.8897352422063705e-07
size O 0 1.3513752605831542e-07
( O 0 5.659260438051206e-08
at O 0 2.2098504359746585e-07
least O 0 8.462382794505174e-09
in O 0 3.8166110272186415e-08
leucocytes O 0 2.236796035504085e-06
) O 0 2.103539920028652e-08
, O 0 1.561882889689059e-08
clinical O 0 8.784327860666963e-07
severity O 0 1.9257990970800165e-06
and O 0 1.6421371640262805e-07
age O 0 2.656407104950631e-06
of O 0 2.161347038054373e-05
onset O 1 0.9999434947967529
. O 0 1.3041496458754409e-05

The O 0 7.083745731506497e-05
trinucleotide O 0 0.0009946450591087341
repeat O 0 3.158556864946149e-05
instability O 0 4.545375122688711e-05
mechanisms O 0 4.722247922472889e-06
involved O 0 1.2106620488339104e-06
in O 0 4.822578375751618e-06
DM B-Disease 1 1.0
and O 0 8.807664357846079e-07
other O 0 9.671613554473879e-08
human O 0 2.0510409740381874e-05
genetic B-Disease 1 0.9999998807907104
diseases I-Disease 1 1.0
are O 0 5.437466370494803e-07
unknown O 0 1.1777744475693908e-05
. O 0 2.7715088890545303e-06

We O 0 4.976677701051813e-06
studied O 0 1.3180093446862884e-05
somatic O 0 4.264612289262004e-05
instability O 0 6.371662311721593e-05
by O 0 8.41838641463255e-07
measuring O 0 3.287822619313374e-05
the O 0 5.798888651042944e-06
CTG O 0 0.0001142153560067527
repeat O 0 7.86411931130715e-07
length O 0 4.526428369899804e-07
at O 0 4.5735257003798324e-07
several O 0 1.704584029482703e-08
ages O 0 3.0843310128148005e-08
in O 0 1.885859823858027e-08
various O 0 2.646802244044011e-08
tissues O 0 5.990792715238058e-07
of O 0 1.2665540225498262e-06
transgenic O 0 4.963619176123757e-06
mice O 0 9.43950738019339e-07
carrying O 0 1.0541129995544907e-06
a O 0 1.0261908300890354e-06
( O 0 4.088172715910332e-07
CTG O 0 1.8446462490828708e-05
) O 0 1.6495771149038774e-07
55expansion O 0 3.666673364932649e-06
surrounded O 0 1.2263917597010732e-06
by O 0 8.05826445571256e-08
45 O 0 3.2728843279983266e-07
kb O 0 3.5803011542157037e-06
of O 0 7.314405934266688e-07
the O 0 1.348112391497125e-06
human O 0 4.624826033250429e-06
DM B-Disease 1 0.9999998807907104
region O 0 6.198203550411563e-07
, O 0 8.136086648846685e-08
using O 0 4.620812887878856e-08
small O 0 4.426164252890885e-07
- O 0 5.769773906649789e-06
pool O 0 7.59051999921212e-06
PCR O 0 1.9633867850643583e-05
. O 0 1.713913434286951e-06

These O 0 2.5845183699857444e-06
mice O 0 4.328725026425673e-06
have O 0 7.765433451822901e-08
been O 0 1.4038965900908806e-07
shown O 0 5.284114124037842e-08
to O 0 1.4726138530818389e-08
reproduce O 0 2.00734575628303e-08
the O 0 1.3379936092405842e-07
intergenerational O 0 1.0388498594693374e-06
and O 0 1.2259270931735955e-07
somatic O 0 3.2994364573823987e-06
instability O 0 8.548578989575617e-06
of O 0 1.9388737655390287e-06
the O 0 1.3265818097352167e-06
55 O 0 5.32547892362345e-06
CTG O 0 4.983742837794125e-05
repeat O 0 5.432127636595396e-07
suggesting O 0 1.81583118319395e-07
that O 0 1.3139635157699558e-08
surrounding O 0 7.513305888551258e-08
sequences O 0 3.732624875851798e-08
and O 0 3.9101905713323504e-08
the O 0 1.240030087501509e-07
chromatin O 0 3.9472348589697503e-07
environment O 0 5.501005873043141e-08
are O 0 3.6842564554717683e-09
involved O 0 1.468031385343238e-08
in O 0 9.981821591509288e-08
instability O 0 1.5442154108313844e-05
mechanisms O 0 1.3444736396195367e-05
. O 0 4.352635187387932e-06

As O 0 8.409387191932183e-06
observed O 0 1.7323807242064504e-06
in O 0 2.8389280259943916e-07
some O 0 3.580440122163964e-08
of O 0 4.555947157314222e-07
the O 0 7.681486522415071e-07
tissues O 0 3.2972407097986434e-06
of O 0 0.0010371034732088447
DM B-Disease 1 1.0
patients O 0 1.3950481161373318e-06
, O 0 7.412655378402633e-08
there O 0 4.333589131988447e-08
is O 0 3.215686916746563e-08
a O 0 5.302762673409234e-08
tendency O 0 5.285162529844456e-08
for O 0 2.404986076953719e-08
repeat O 0 8.591191402729237e-08
length O 0 1.1849840575450798e-07
and O 0 4.61251836725296e-08
somatic O 0 1.8767940446196008e-06
mosaicism O 0 4.790733783011092e-06
to O 0 1.52591148605552e-08
increase O 0 3.860598241089974e-08
with O 0 1.3351391991989203e-08
the O 0 1.5257171526172897e-07
age O 0 2.302338231174872e-07
of O 0 1.2297178955122945e-06
the O 0 4.745846581499791e-06
mouse O 0 1.5457595509360544e-05
. O 0 1.9231545138609363e-06

Furthermore O 0 3.615934474510141e-05
, O 0 8.695801057001518e-07
we O 0 3.021065353436825e-08
observed O 0 1.0124036720071672e-07
no O 0 2.5268009906653788e-08
correlation O 0 1.4029249939540023e-07
between O 0 4.265768183131513e-08
the O 0 7.868367646324259e-08
somatic O 0 1.0955711786664324e-06
mutation O 0 3.7045668932478293e-07
rate O 0 3.120687779301079e-06
and O 0 3.130836034870299e-07
tissue O 0 0.0003632901643868536
proliferation O 1 0.9120904207229614
capacity O 0 5.340233838069253e-05
. O 0 5.026599865232129e-06

The O 0 1.4644185284851119e-05
somatic O 0 2.2067339159548283e-05
mutation O 0 1.3228398074716097e-06
rates O 0 1.1090036196037545e-06
in O 0 8.636372683668014e-08
different O 0 4.442722634223628e-09
tissues O 0 1.5584183188366296e-07
were O 0 1.661472026626143e-07
also O 0 3.0305766784977095e-08
not O 0 1.2642387581252024e-08
correlated O 0 2.1796104476834444e-07
to O 0 3.449467911309512e-08
the O 0 2.416315965092508e-07
relative O 0 1.6684631418684148e-06
inter O 0 7.518935035477625e-06
- O 0 3.1466336167795816e-06
tissue O 0 3.0683122531627305e-06
difference O 0 1.031017689001601e-07
in O 0 9.002837941807229e-08
transcriptional O 0 9.631249895392102e-07
levels O 0 1.7129593743447913e-07
of O 0 2.0237540354628436e-07
the O 0 1.6749854125919228e-07
three O 0 5.382016965427283e-08
genes O 0 1.5705631994933356e-07
( O 0 2.462679162817949e-07
DMAHP O 0 2.4415874577243812e-05
, O 0 2.0550648116568482e-07
DMPK O 0 8.348044502781704e-06
and O 0 1.1802044497244424e-07
59 O 0 1.2558256230477127e-06
) O 0 4.847782975048176e-08
surrounding O 0 5.35421918357315e-07
the O 0 1.058307361745392e-06
repeat O 0 2.5486219783488195e-06
. O 0 4.965585276295315e-07
. O 0 2.212423851233325e-06

A O 0 2.792958912323229e-05
novel O 0 2.388338998571271e-06
missense O 0 8.31330271466868e-06
mutation O 0 6.487754831141501e-07
in O 0 4.196322720417811e-07
patients O 0 2.541383992138435e-07
from O 0 2.778742214104568e-07
a O 0 1.1866763998114038e-06
retinoblastoma B-Disease 0 0.021761957556009293
pedigree O 0 3.167389422742417e-06
showing O 0 1.6834550251587643e-06
only O 0 1.4946496662560094e-07
mild O 0 5.337910806701984e-06
expression O 0 1.0340185099266819e-06
of O 0 1.4295096661953721e-06
the O 0 9.57499651121907e-06
tumor B-Disease 1 0.9999798536300659
phenotype O 0 0.00013201075489632785
. O 0 6.030290933267679e-06

We O 0 6.897345883771777e-06
have O 0 4.901424972558743e-07
used O 0 4.607198889061692e-07
single O 0 4.617152740138408e-07
strand O 0 2.457703430991387e-06
conformation O 0 3.51846921375909e-07
polymorphism O 0 1.8885673114255042e-07
analysis O 0 3.0124116534580025e-08
to O 0 9.122066657596406e-09
study O 0 4.127551278543251e-08
the O 0 1.0692031793269052e-07
27 O 0 9.450991456105839e-07
exons O 0 3.511744921524951e-07
of O 0 4.847976811106491e-07
the O 0 8.668451982885017e-07
RB1 O 0 2.7195701477467082e-05
gene O 0 4.282219023821199e-08
in O 0 3.011791349649684e-08
individuals O 0 7.953707026331358e-09
from O 0 6.949546360601744e-08
a O 0 3.258660683513881e-07
family O 0 1.4289480532170273e-07
showing O 0 2.196220521000214e-06
mild O 0 1.979668923013378e-05
expression O 0 2.1977521100779995e-06
of O 0 4.8240917749353684e-06
the O 0 5.404779585660435e-06
retinoblastoma B-Disease 0 0.18420365452766418
phenotype O 0 5.8419704146217555e-05
. O 0 4.0477048059983645e-06

In O 0 1.9867573428200558e-05
this O 0 7.881763508521544e-07
family O 0 2.3285468842004775e-07
affected O 0 1.3716211810788081e-07
individuals O 0 1.5213373671940644e-08
developed O 0 5.126406676936313e-07
unilateral B-Disease 0 0.0021062123123556376
tumors I-Disease 1 1.0
and O 0 1.9828337372018723e-06
, O 0 1.4668928827177297e-07
as O 0 4.581671930736775e-08
a O 0 3.319726005202028e-08
result O 0 3.114813296178909e-08
of O 0 3.425994634653762e-07
linkage O 0 1.1549404916877393e-05
analysis O 0 2.382160033675973e-07
, O 0 1.2751162614677014e-07
unaffected O 0 1.0027827102021547e-06
mutation O 0 6.285425513397058e-08
carriers O 0 4.5250988733869235e-08
were O 0 6.131222818339666e-08
also O 0 4.1593843036480393e-08
identified O 0 7.112003430620462e-08
within O 0 1.1602681837530326e-07
the O 0 1.509511662334262e-06
pedigree O 0 1.3345047591428738e-05
. O 0 3.8113589653221425e-06

A O 0 6.0119040426798165e-05
single O 0 3.620750021582353e-06
band O 0 2.4730989025556482e-06
shift O 0 9.738322432895075e-07
using O 0 1.5609185766152223e-07
SSCP O 0 4.230437843943946e-05
was O 0 3.4313220567128155e-06
identified O 0 8.438145471245662e-08
in O 0 5.884329823402368e-08
exon O 0 1.2708247254522576e-07
21 O 0 3.438603641825466e-07
which O 0 1.4849338647593413e-08
resulted O 0 8.778401650033629e-08
in O 0 3.744904475411204e-08
a O 0 1.452933844348081e-07
missense O 0 7.305754365916073e-07
mutation O 0 2.5535359782224987e-07
converting O 0 1.1055926734115928e-06
a O 0 1.4466749007624458e-06
cys O 0 2.6431895093992352e-05
- O 0 1.943177494467818e-06
- O 0 1.8009168343269266e-06
> O 0 8.805632205621805e-07
arg O 0 8.621623237559106e-07
at O 0 3.8740756735933246e-07
nucleotide O 0 2.1333129041067878e-07
position O 0 2.639304170770629e-07
28 O 0 8.181274893104273e-07
in O 0 1.5321663227041427e-07
the O 0 1.021448497340316e-06
exon O 0 7.803332664479967e-06
. O 0 3.055434945054003e-06

The O 0 2.1114052287884988e-05
mutation O 0 8.04418777988758e-06
destroyed O 0 3.096536238444969e-05
an O 0 2.371913979004603e-06
NdeI O 0 0.00013958202907815576
restriction O 0 1.572346081957221e-05
enzyme O 0 4.2070200834132265e-06
site O 0 3.897684564435622e-06
. O 0 2.2066797100706026e-06

Analysis O 0 2.4994722480187193e-05
of O 0 4.478258233575616e-06
all O 0 2.9788677124997776e-07
family O 0 1.684044690364317e-07
members O 0 2.490754980044585e-08
demonstrated O 0 1.4111316204434843e-07
that O 0 2.0848464288292234e-08
the O 0 1.1931408039345115e-07
missense O 0 2.7949301966145867e-06
mutation O 0 1.4856599364065914e-06
co O 0 4.927431291434914e-05
- O 0 5.817333203594899e-06
segregated O 0 8.111911711239372e-07
with O 0 5.101698619114359e-08
patients O 0 4.0858418515199446e-07
with O 0 1.0194787591899512e-06
tumors B-Disease 1 1.0
or O 0 0.0020889632869511843
who O 0 6.843173991910589e-07
, O 0 3.126538672404422e-08
as O 0 2.6235058570023284e-08
a O 0 3.9646526062142584e-08
result O 0 4.047662827133536e-08
of O 0 1.882004738718024e-07
linkage O 0 3.1134050004766323e-06
analysis O 0 1.1362792662339416e-07
had O 0 2.8068063784303376e-07
been O 0 1.5324000912642077e-07
predicted O 0 2.3683739414082083e-07
to O 0 7.583691896684286e-09
carry O 0 6.005264197028737e-08
the O 0 1.0190072998739197e-06
predisposing O 0 6.481896707555279e-05
mutation O 0 1.1340603123244364e-05
. O 0 5.8079540394828655e-06

These O 0 1.4218820751921157e-06
observations O 0 8.742908903514035e-06
point O 0 6.600087999686366e-06
to O 0 1.0052207244370948e-07
another O 0 1.3347373339911428e-07
region O 0 1.2391636516895232e-07
of O 0 7.628813136761892e-07
the O 0 1.6508407725268626e-06
RB1 O 0 4.4191845518071204e-05
gene O 0 1.2060186804774276e-07
where O 0 6.367927340988899e-08
mutations O 0 4.6153871835485916e-08
only O 0 2.376495800149314e-08
modify O 0 3.486602651037174e-08
the O 0 5.4358082479666336e-08
function O 0 7.674992730244412e-08
of O 0 1.1136970812231084e-07
the O 0 3.827881656093268e-08
gene O 0 2.4224114270054997e-08
and O 0 1.1360393514792122e-08
raise O 0 2.5542220782881486e-08
important O 0 1.81446484504022e-08
questions O 0 2.1102588121379995e-08
for O 0 1.0530841088041143e-08
genetic O 0 2.008280688414743e-07
counseling O 0 4.230622607792611e-07
in O 0 8.736042644841291e-08
families O 0 1.4528778180533664e-08
with O 0 1.1321263038155394e-08
these O 0 1.70475296101813e-08
distinctive O 0 8.066581926868821e-07
phenotypes O 0 4.813379746337887e-06
. O 0 4.5629477085640247e-07
. O 0 2.0648849385906942e-06

Maternal B-Disease 1 0.7644608020782471
disomy I-Disease 1 0.9962641596794128
and O 0 0.0023434623144567013
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.9950227737426758
with O 0 1.7601081481188885e-06
gamete O 0 0.12137091904878616
complementation O 1 0.9493815302848816
in O 0 4.830637863051379e-07
a O 0 4.052128588227788e-07
case O 0 1.543185135233216e-07
of O 0 5.465998924591986e-07
familial O 0 3.337017687954358e-06
translocation O 0 6.841152207925916e-05
( O 0 3.73657144336903e-07
3 O 0 5.929575763730099e-07
; O 0 3.3411456712428844e-08
15 O 0 3.442002594056248e-07
) O 0 6.779463745942849e-08
( O 0 4.522053131950088e-08
p25 O 0 3.5957677937403787e-06
; O 0 2.7210408148903298e-08
q11 O 0 2.346230758121237e-06
. O 0 3.9832379172821675e-08
2 O 0 5.753360028393217e-07
) O 0 3.371017385234154e-07
. O 0 8.019102892831143e-07

Maternal B-Disease 1 0.9823064208030701
uniparental I-Disease 1 0.9994131326675415
disomy I-Disease 1 0.9019671082496643
( I-Disease 0 6.508525257231668e-05
UPD I-Disease 1 0.9999237060546875
) I-Disease 0 7.883071475589531e-07
for I-Disease 0 1.543385224067606e-07
chromosome I-Disease 0 4.367562723928131e-06
15 I-Disease 0 9.255791724172013e-07
is O 0 7.887329900313489e-08
responsible O 0 8.442057009006021e-08
for O 0 2.5972278550057126e-08
an O 0 3.3658739795328074e-08
estimated O 0 3.8715409544920476e-08
30 O 0 5.9135494723250304e-08
% O 0 8.577925036945544e-09
of O 0 3.303946627397636e-08
cases O 0 5.311366280125185e-08
of O 0 6.593434227397665e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9993938207626343
PWS B-Disease 1 1.0
) O 0 9.145149306277744e-06
. O 0 3.7875058751524193e-06

We O 0 2.4888186089810915e-05
report O 0 7.749586075078696e-06
on O 0 2.1857040337636136e-06
an O 0 2.246168833153206e-07
unusual O 0 2.5277850568272697e-07
case O 0 5.210155791246507e-07
of O 0 1.8782801589622977e-06
maternal B-Disease 0 0.002016315935179591
disomy I-Disease 0 0.0018715307815000415
15 I-Disease 0 5.668271114700474e-06
in O 0 2.106801730406005e-06
PWS B-Disease 1 1.0
that O 0 1.5823469823317282e-07
is O 0 6.02368785962426e-08
most O 0 1.2580135155815242e-08
consistent O 0 1.392165245306387e-07
with O 0 3.012273808167265e-08
adjacent O 0 1.4032528952157008e-06
- O 0 6.427047196666535e-07
1 O 0 6.207827709658886e-07
segregation O 0 3.0660959282613476e-07
of O 0 3.918859761142812e-07
a O 0 6.247947794690845e-07
paternal O 0 9.078621587832458e-06
t O 0 1.6387656387450988e-06
( O 0 6.84649066329257e-08
3 O 0 1.5125812069527456e-07
; O 0 9.286276636544244e-09
15 O 0 1.2389024561798578e-07
) O 0 4.7479467468747316e-08
( O 0 6.496335913652729e-08
p25 O 0 2.864354883058695e-06
; O 0 2.9726347605674164e-08
q11 O 0 1.2246549658812e-06
. O 0 2.487612071888634e-08
2 O 0 8.826688002727678e-08
) O 0 8.546829910471843e-09
with O 0 8.95559981728411e-09
simultaneous O 0 1.3214780665293802e-06
maternal O 0 0.00011661003372864798
meiotic O 0 0.00031805079197511077
nondisjunction O 0 7.941086369100958e-05
for O 0 7.901692811174144e-07
chromosome O 0 4.993371112504974e-05
15 O 0 1.2980833162146155e-05
. O 0 3.1929077977110865e-06

The O 0 0.00010380846651969478
patient O 0 5.119126581121236e-05
( O 0 5.310420874593547e-06
J O 0 0.0001533938047941774
. O 0 3.92219504874447e-07
B O 0 2.794418378471164e-06
. O 0 2.93374107229738e-08
) O 0 1.2626386158842706e-08
, O 0 2.1461742605310974e-08
a O 0 1.0275564932271664e-07
17 O 0 9.812633834371809e-07
- O 0 1.3367159681365592e-06
year O 0 1.7504409015600686e-06
- O 0 2.8636256956815487e-06
old O 0 5.245776264928281e-06
white O 0 5.099665258967434e-07
male O 0 4.5723396624453017e-07
with O 0 3.1573961223330116e-07
PWS B-Disease 1 1.0
, O 0 6.949294402147643e-07
was O 0 3.175882966388599e-06
found O 0 2.759550277176004e-08
to O 0 1.1572575786544803e-08
have O 0 3.590746189274796e-08
47 O 0 8.075687674136134e-07
chromosomes O 0 5.978202466394578e-07
with O 0 2.0334985606496048e-07
a O 0 6.1778650888300035e-06
supernumerary O 1 0.8707756996154785
, O 0 6.505126748379553e-07
paternal O 0 2.0042956748511642e-05
der O 0 0.0001463346998207271
( O 0 8.25095014533872e-08
15 O 0 1.4025410166595975e-07
) O 0 1.3561852085786086e-08
consisting O 0 2.431553625115157e-08
of O 0 2.1632880020661105e-07
the O 0 9.193262826556747e-07
short O 0 3.5026846489927266e-06
arm O 0 1.4730944712937344e-05
and O 0 4.809231768376776e-07
the O 0 4.239146164763952e-06
proximal O 0 0.08986722677946091
long O 0 3.639274154920713e-06
arm O 0 4.094105861440767e-06
of O 0 7.796166414664185e-07
chromosome O 0 7.441095931426389e-06
15 O 0 1.5091417253643158e-06
, O 0 2.135403320835394e-07
and O 0 1.072379745892249e-06
distal O 1 0.8531825542449951
chromosome O 1 0.9999749660491943
arm O 1 0.9997041821479797
3p O 1 0.9997137188911438
. O 0 1.4363768059411086e-05

The O 0 9.217838669428602e-05
t O 0 3.126061710645445e-05
( O 0 4.799097155228083e-07
3 O 0 4.923560936731519e-07
; O 0 2.9303183879392236e-08
15 O 0 1.1968960222930036e-07
) O 0 2.980719671086263e-08
was O 0 1.9502382997416134e-07
present O 0 1.2995771569990211e-08
in O 0 1.4362390388100721e-08
the O 0 3.4103990742551105e-08
balanced O 0 1.9947353990801275e-08
state O 0 1.3285597511014657e-08
in O 0 5.381093615142163e-08
the O 0 4.077301696270297e-07
patients O 0 3.2038838071457576e-07
father O 0 3.867906343657523e-06
and O 0 6.448861427088559e-07
a O 0 1.0776856470329221e-05
sister O 0 0.00018925542826764286
. O 0 1.1387897757231258e-05

Fluorescent O 0 0.0002225154166808352
in O 0 2.66669712800649e-06
situ O 0 1.2678950952249579e-05
hybridization O 0 1.941390110005159e-06
analysis O 0 8.895082714843738e-07
demonstrated O 0 7.147441465349402e-07
that O 0 8.951811736324089e-08
the O 0 1.3348128504730994e-06
PWS B-Disease 1 0.9999992847442627
critical O 0 2.728283106989693e-06
region O 0 5.117291834721982e-07
resided O 0 2.3085942757461453e-06
on O 0 8.462408800369303e-07
the O 0 1.881891762423038e-07
derivative O 0 1.4400731060959515e-06
chromosome O 0 1.1385358220650232e-06
3 O 0 3.866848032885173e-07
and O 0 4.638438255710753e-08
that O 0 2.4890740135674605e-08
there O 0 3.579784646490225e-08
was O 0 1.2968652072231635e-06
no O 0 5.4575931329736704e-08
deletion O 0 6.548748956447525e-07
of O 0 2.139787511623581e-06
the O 0 6.115064024925232e-06
PWS B-Disease 1 1.0
region O 0 6.189349051055615e-07
on O 0 1.433576812814863e-06
the O 0 2.915996049068781e-07
normal O 0 6.60870171032002e-07
pair O 0 3.8892045495231287e-07
of O 0 1.396509674123081e-06
15s O 0 2.4927499907789752e-05
present O 0 6.620390422540368e-07
in O 0 5.446410796139389e-06
J O 0 0.00796585250645876
. O 0 9.390121704200283e-06

B O 0 0.007141239941120148
. O 0 0.0001274874375667423

Methylation O 0 0.000121888100693468
analysis O 0 9.29446287045721e-06
at O 0 7.738899512332864e-06
exon O 0 3.097134822382941e-06
alpha O 0 4.136853931413498e-06
of O 0 6.10653955845919e-07
the O 0 4.770395207742695e-07
small O 0 5.571999395215244e-07
nuclear O 0 1.774656993802637e-05
ribonucleoprotein O 0 6.905509508214891e-05
- O 0 2.1545922663790407e-06
associated O 0 1.040720007949858e-06
polypeptide O 0 4.771879048348637e-06
N O 0 2.488823383828276e-06
( O 0 8.748214241904861e-08
SNRPN O 0 3.817320703092264e-06
) O 0 2.276560806535599e-08
gene O 0 3.767242162666662e-08
showed O 0 2.1604490996196546e-07
a O 0 1.4409535253889771e-07
pattern O 0 3.704673190441099e-07
characteristic O 0 1.9231730163937755e-07
of O 0 2.432124972528982e-07
only O 0 3.005089155294627e-08
the O 0 1.327557299646287e-07
maternal O 0 6.196132289915113e-06
chromosome O 0 2.0528843378997408e-05
15 O 0 4.841563622903777e-06
in O 0 5.236874130787328e-06
J O 0 0.295215368270874
. O 0 5.264018000161741e-06

B O 0 0.014070359990000725
. O 0 0.00018273125169798732

Maternal B-Disease 0 0.0021426924504339695
disomy I-Disease 0 0.002022144617512822
was O 0 5.7523258874425665e-05
confirmed O 0 2.3904126464913134e-06
by O 0 4.391321510865964e-07
polymerase O 0 3.3182790502905846e-05
chain O 0 5.955087999609532e-06
reaction O 0 8.321071049977036e-07
analysis O 0 1.8253423661462875e-07
of O 0 5.81673987198883e-07
microsatellite O 0 5.803104158985661e-06
repeats O 0 3.0188937216735212e-06
at O 0 2.575594180598273e-06
the O 0 5.62713637464185e-07
gamma O 0 4.826999884244287e-06
- O 0 4.855361567024374e-06
aminobutyric O 0 1.7634853065828793e-05
acid O 0 5.790461159449478e-07
receptor O 0 1.534838247607695e-06
beta3 O 0 4.1958173824241385e-06
subunit O 0 8.391646701966238e-07
( O 0 3.378284532118414e-07
GABRB3 O 0 3.963284325436689e-05
) O 0 5.156419433660631e-07
locus O 0 1.950250953086652e-05
. O 0 2.498630919944844e-06

A O 0 0.0004969476722180843
niece O 0 0.00042488661711104214
( O 0 5.005685125070158e-06
B O 0 7.8658831625944e-06
. O 0 7.90449874443766e-08
B O 0 6.503576628347219e-07
. O 0 1.6830611571094778e-08
) O 0 6.377272487867458e-09
with O 0 7.890847975033921e-09
45 O 0 8.545301710682907e-08
chromosomes O 0 9.282402402277512e-08
and O 0 1.1451923143113163e-07
the O 0 2.9218421104815206e-07
derivative O 0 1.944560381161864e-06
3 O 0 4.012573526779306e-07
but O 0 3.8814786051943884e-08
without O 0 3.606278653478512e-08
the O 0 3.532132382133568e-07
der O 0 1.0991399904014543e-05
( O 0 3.026891093327322e-08
15 O 0 9.926306887564351e-08
) O 0 1.679450534197713e-08
demonstrated O 0 1.1371974295570908e-07
a O 0 9.678736745399874e-08
phenotype O 0 2.964929137760919e-07
consistent O 0 8.372271764756078e-08
with O 0 1.0215411627712001e-08
that O 0 1.759505252607596e-08
reported O 0 3.3143106747957063e-07
for O 0 8.274115970152707e-08
haploinsufficiency O 0 4.066834662808105e-06
of O 0 3.375206915734452e-06
distal O 0 0.0006785372388549149
3 O 0 4.874460501014255e-05
p O 0 0.00025462231133133173
. O 0 4.269001692591701e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999990463256836
associated O 0 0.00016781763406470418
with O 0 2.714535639825044e-06
unbalanced O 0 0.0004436933377292007
segregation O 0 7.815678145561833e-06
of O 0 3.2507255127711687e-06
non O 0 1.547420470160432e-05
- O 0 5.026096914662048e-06
Robertsonian O 0 1.5634346709703095e-05
translocations O 0 1.6786935930213076e-06
has O 0 1.9803589168532199e-07
been O 0 1.586824538435394e-07
reported O 0 3.435725375311449e-07
previously O 0 1.8117368938419531e-07
but O 0 1.2928475179307952e-08
has O 0 2.0881573803421816e-08
not O 0 7.229470355696321e-09
, O 0 1.3830232958866873e-08
to O 0 1.2299362417422799e-08
our O 0 4.116143514920623e-08
knowledge O 0 1.5198051528386713e-07
, O 0 6.660064855168457e-08
been O 0 6.661080931280594e-08
observed O 0 7.911195609722199e-08
in O 0 7.035691851342563e-08
a O 0 6.914692676218692e-07
case O 0 3.1830297757551307e-06
of O 0 8.011107274796814e-05
PWS B-Disease 1 1.0
. O 0 3.4929325920529664e-05

Furthermore O 0 7.114304025890306e-05
, O 0 2.3146280909713823e-06
our O 0 3.6745601050824916e-07
findings O 0 2.896400985719083e-07
are O 0 1.8897271303330854e-08
best O 0 4.902878814050382e-08
interpreted O 0 1.3875657600692648e-07
as O 0 4.192718350282121e-08
true O 0 1.9043817189867696e-07
gamete O 0 9.498533472651616e-06
complementation O 0 0.00011819612700492144
resulting O 0 2.3828240500733955e-06
in O 0 2.126089611920179e-06
maternal B-Disease 1 0.9690524339675903
UPD I-Disease 1 1.0
15 I-Disease 0 0.0002226474171038717
and O 0 0.00015754139167256653
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9984149932861328
- I-Disease 1 0.9996570348739624
Jampel I-Disease 1 0.9999983310699463
syndrome I-Disease 1 1.0
type I-Disease 0 0.00017978869436774403
2 I-Disease 0 2.543776463426184e-05
and O 0 3.6746619116456714e-06
Stuve B-Disease 1 0.9999784231185913
- I-Disease 1 0.9998624324798584
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 1.5197210245787574e-07
a O 0 1.6062863039678632e-07
case O 0 9.319354177250716e-08
for O 0 8.47469436848769e-08
" O 0 1.7071712363758706e-06
lumping O 0 1.9314086330268765e-06
" O 0 5.290182798489695e-06
. O 0 1.4783556707698153e-06

Recent O 0 8.46271086629713e-06
studies O 0 3.4395750390103785e-06
demonstrated O 0 1.9249471279181307e-06
the O 0 2.581776641363831e-07
existence O 0 2.567403214470687e-07
of O 0 4.2984791548406065e-07
a O 0 3.1266290534404106e-07
genetically O 0 5.2237179914982335e-08
distinct O 0 2.1736275002126604e-08
, O 0 4.291515764975884e-08
usually O 0 1.2751291578183555e-08
lethal O 0 1.589866229778636e-07
form O 0 2.1511290526632365e-08
of O 0 1.0242841881336062e-06
the O 0 5.893488832953153e-06
Schwartz B-Disease 0 0.009298264048993587
- I-Disease 0 0.21381931006908417
Jampel I-Disease 1 0.9999951124191284
syndrome I-Disease 1 1.0
( O 0 7.929207640700042e-06
SJS B-Disease 1 0.9999828338623047
) O 0 4.122272514450742e-07
of O 0 4.641696705220966e-06
myotonia B-Disease 1 0.9997257590293884
and O 0 5.33831916982308e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 0.9999998807907104
, O 0 9.90165631264972e-07
which O 0 1.6939847569119593e-07
we O 0 1.2849737629494484e-07
called O 0 2.0766485704371007e-06
SJS B-Disease 0 0.2644484043121338
type I-Disease 0 5.99334589423961e-06
2 I-Disease 0 1.4426917005039286e-05
. O 0 4.830817488254979e-06

This O 0 2.5040195396286435e-05
disorder O 1 0.500744104385376
is O 0 1.1478059604996815e-06
reminiscent O 0 2.5493461635051062e-06
of O 0 5.241823259893863e-07
another O 0 4.395352277697384e-07
rare O 0 1.1247437896599877e-06
condition O 0 7.552850001957268e-05
, O 0 4.279157508335629e-07
the O 0 4.4220055315236095e-06
Stuve B-Disease 1 0.9997115731239319
- I-Disease 1 0.999988317489624
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.744859582686331e-05
SWS B-Disease 1 0.9999744892120361
) O 0 2.0438439207737247e-07
, O 0 4.282692955825951e-08
which O 0 3.919778635008697e-08
comprises O 0 4.438879557255859e-07
campomelia B-Disease 0 0.00019883416825905442
at O 0 5.64619513170328e-05
birth O 0 2.0747582311742008e-05
with O 0 2.359069185331464e-06
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 2.4871789719327353e-05
contractures B-Disease 1 0.9997370839118958
, O 0 3.998088686785195e-07
and O 0 1.8053620465252607e-07
early B-Disease 0 9.953653716365807e-06
death I-Disease 0 0.019869498908519745
. O 0 8.10081746749347e-06

To O 0 7.318505595321767e-06
test O 0 1.657836151025549e-06
for O 0 1.9024540165446524e-07
possible O 0 4.4718257186104893e-07
nosologic O 0 2.5056964659597725e-05
identity O 0 1.4208069387677824e-07
between O 0 3.551771499132883e-07
these O 0 1.2330959009432263e-07
disorders O 0 0.004040249157696962
, O 0 9.720844218463753e-08
we O 0 1.1652267595252397e-08
reviewed O 0 8.507458204576324e-08
the O 0 5.09734121578731e-08
literature O 0 6.985880673937572e-08
and O 0 1.9294738251574017e-08
obtained O 0 1.9957788310875912e-07
a O 0 3.2966514140753134e-07
follow O 0 5.7891909932550334e-08
- O 0 2.579672297997604e-07
up O 0 7.469026996886896e-08
of O 0 1.2604445487340854e-07
the O 0 9.121443866888512e-08
only O 0 2.4243943741453222e-08
two O 0 2.5307848261491017e-08
surviving O 0 1.2187990705569973e-06
patients O 0 1.9612689072801004e-07
, O 0 8.080488811401665e-08
one O 0 5.096349298128189e-08
with O 0 7.244173616527405e-08
SJS B-Disease 0 0.0028012411203235388
type I-Disease 0 1.2178695669717854e-06
2 I-Disease 0 9.900891200231854e-07
at O 0 1.0175428997172276e-06
age O 0 3.4974590334968525e-08
10 O 0 4.147999277392955e-08
years O 0 3.9151160535766394e-08
and O 0 1.538058214123339e-08
another O 0 7.327329143436145e-08
with O 0 6.22236129288467e-08
SWS B-Disease 0 0.0016003447817638516
at O 0 1.8885469899032614e-06
age O 0 3.340279874919361e-07
7 O 0 2.4727121399337193e-06
years O 0 1.4659769931313349e-06
. O 0 1.7465124528825982e-06

Patients O 0 9.031448280438781e-05
reported O 0 1.4347557225846685e-05
as O 0 7.467658633686369e-07
having O 0 8.259773949248483e-07
either O 0 2.7491021228343016e-06
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 1.0147994544240646e-05
SWS B-Disease 1 0.9927535653114319
presented O 0 2.543580421843217e-07
a O 0 5.925472024159717e-08
combination O 0 4.812599030401543e-08
of O 0 4.1468217659712536e-07
a O 0 2.8192910122015746e-06
severe O 1 0.948247492313385
, O 0 3.818482582573779e-06
prenatal O 1 1.0
- O 1 1.0
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 6.663725798716769e-06
with O 0 5.203613454796141e-06
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9948118925094604
respiratory O 1 1.0
and O 0 2.352231604163535e-05
feeding O 0 0.00014267924416344613
difficulties O 0 1.5255819562298711e-05
, O 0 4.4418439415494504e-07
tendency O 0 7.866999567340827e-07
to O 0 1.4960829730625846e-07
hyperthermia B-Disease 0 0.3174823820590973
, O 0 1.0393200255975898e-07
and O 0 7.527420109454397e-08
frequent O 0 4.974078819941496e-07
death O 0 0.0023296833969652653
in O 0 2.7304984087095363e-06
infancy O 0 2.5628711227909662e-05
) O 0 3.950054505708067e-08
with O 0 1.776568758771191e-08
a O 0 6.424093612622528e-07
distinct O 0 1.778728915269312e-06
campomelic B-Disease 1 0.9999926090240479
- I-Disease 1 0.9999983310699463
metaphyseal I-Disease 1 0.9999998807907104
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 8.955977682489902e-05

The O 0 3.0512824196193833e-06
similarity O 0 1.0795810112540494e-06
of O 0 7.053305921544961e-07
the O 0 5.176536888029659e-07
clinical O 0 2.2180978703545406e-05
and O 0 5.123566779730027e-07
radiographic O 0 0.002182834781706333
findings O 0 3.60544095201476e-06
is O 0 1.6790829704405041e-07
so O 0 1.3116547847857873e-08
extensive O 0 1.8905838317095913e-07
that O 0 8.044121102557256e-08
these O 0 1.360500760938521e-07
disorders O 1 0.9390827417373657
appear O 0 6.283202083068318e-07
to O 0 5.554386106609854e-08
be O 0 1.534170905870269e-07
a O 0 7.071713525874657e-07
single O 0 9.551724815537455e-07
entity O 0 4.431715751707088e-06
. O 0 5.899561983824242e-06

The O 0 6.02869586145971e-05
follow O 0 6.265547654038528e-06
- O 0 4.402430931804702e-06
up O 0 2.973429502617364e-07
observation O 0 2.8984950404264964e-06
of O 0 2.3106419178020587e-07
an O 0 4.834080868931778e-08
identical O 0 2.137864285600699e-08
and O 0 1.2688865957954931e-08
unique O 0 1.8847559957180238e-08
pattern O 0 5.65455184187158e-06
of O 0 0.0005728735704906285
progressive O 1 0.9999939203262329
bone B-Disease 1 0.9999992847442627
dysplasia I-Disease 1 0.9999973773956299
in O 0 1.9653671188279986e-06
the O 0 1.0140361155208666e-06
two O 0 8.75410677281252e-08
patients O 0 8.203700474496145e-08
( O 0 6.074847647141723e-08
one O 0 8.035656406946146e-08
with O 0 1.0844716769042861e-07
SJS B-Disease 1 0.7787389159202576
type I-Disease 0 4.4033126869180705e-06
2 I-Disease 0 1.8135465325030964e-06
, O 0 8.230202297454525e-08
one O 0 4.29254711775684e-08
with O 0 1.2129220294809784e-07
SWS B-Disease 0 0.11559146642684937
) O 0 9.061790962050509e-08
surviving O 0 7.161251005527447e-07
beyond O 0 1.1944528068852378e-06
infancy O 0 2.5769036255951505e-06
adds O 0 3.291304295771624e-08
to O 0 5.557986071380583e-09
the O 0 2.0347881601878726e-08
evidence O 0 3.012193516838124e-08
in O 0 4.381712415124639e-08
favor O 0 1.1801672883393621e-07
of O 0 6.122867262092768e-07
identity O 0 1.8297812403034186e-06
. O 0 7.016332347120624e-06

The O 0 4.177806113148108e-05
hypothesis O 0 1.5819901818758808e-05
that O 0 1.5439889011759078e-06
SWS B-Disease 0 0.004601296037435532
and O 0 4.600183729053242e-06
SJS B-Disease 1 0.9892248511314392
type I-Disease 0 4.96859684062656e-06
2 I-Disease 0 3.2189318517339416e-06
are O 0 2.5539003800645332e-08
the O 0 1.1262986276960874e-07
same O 0 2.275285169162089e-07
disorder O 0 1.191568844660651e-05
should O 0 2.1600055077897196e-08
be O 0 2.4004949139566634e-08
testable O 0 3.0263257144724776e-07
by O 0 4.539310438644861e-08
molecular O 0 7.651342457393184e-07
methods O 0 2.7928467716265004e-07
. O 0 2.73931419769724e-07
. O 0 1.7750263623383944e-06

A O 0 8.715449075680226e-05
mouse O 0 9.984056305256672e-06
model O 0 7.501949426114152e-07
of O 0 1.6348006965927198e-06
severe O 1 0.9999983310699463
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.008595751598477364
defects O 1 0.9998781681060791
in O 0 6.875240160297835e-06
hemostasis O 1 0.9838517308235168
and O 0 6.069485971238464e-05
thrombosis B-Disease 1 1.0
. O 0 4.647550667868927e-05

von B-Disease 1 0.9256892204284668
Willebrand I-Disease 1 0.9999804496765137
factor I-Disease 0 0.0013108092825859785
( I-Disease 0 2.833287544490304e-05
vWf I-Disease 0 0.4950857162475586
) I-Disease 0 0.0003203975211363286
deficiency I-Disease 1 1.0
causes O 1 0.9900209903717041
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.0002190463274018839
humans O 0 1.6252931800408987e-06
. O 0 1.455692654417362e-06

We O 0 3.1831359592615627e-06
generated O 0 1.5590976545354351e-06
a O 0 9.475250521973066e-07
mouse O 0 4.3670945615303935e-07
model O 0 1.789741759239405e-07
for O 0 1.6830997040528928e-08
this O 0 2.9166683290782203e-08
disease O 0 2.61710198401488e-07
by O 0 4.34937170723515e-08
using O 0 6.57795453662402e-08
gene O 0 8.496793952872395e-07
targeting O 0 8.972494470071979e-06
. O 0 6.5250860643573105e-06

vWf B-Disease 0 0.01688452437520027
- I-Disease 0 0.026689033955335617
deficient I-Disease 0 0.007553590461611748
mice O 0 1.5736422938061878e-05
appeared O 0 5.557783424592344e-06
normal O 0 3.0947137474868214e-06
at O 0 1.2936117173012462e-06
birth O 0 1.912497253897527e-07
; O 0 7.117999079042647e-09
they O 0 3.72413189175802e-09
were O 0 3.813656590523351e-08
viable O 0 1.5464571845313912e-07
and O 0 1.1095202268052162e-07
fertile O 0 1.1388115126464982e-05
. O 0 4.4375860852596816e-06

Neither O 0 0.00021680000645574182
vWf O 0 0.001520290388725698
nor O 0 0.00013609575398731977
vWf O 0 0.0006104925414547324
propolypeptide O 0 0.0011053697671741247
( O 0 1.1058921700168867e-05
von B-Disease 0 0.0015533763216808438
Willebrand I-Disease 1 0.7261865735054016
antigen O 0 0.00016002249321900308
II O 1 0.7810875177383423
) O 0 2.3331948284521786e-07
were O 0 1.6302827532399533e-07
detectable O 0 8.613782824795635e-07
in O 0 9.365970754515729e-08
plasma O 0 3.862332960125059e-06
, O 0 1.5411335141379823e-07
platelets O 0 2.0198815491312416e-06
, O 0 3.9706770849079476e-07
or O 0 5.185682994124363e-07
endothelial O 0 7.018590986263007e-05
cells O 0 3.2961233387140965e-07
of O 0 3.2376644298892643e-07
the O 0 5.564479579334147e-07
homozygous O 0 2.4853154627635377e-06
mutant O 0 1.28056699395529e-05
mice O 0 1.5502031601499766e-05
. O 0 2.6911798158835154e-06

The O 0 2.8857117285951972e-05
mutant O 0 5.6619395763846114e-05
mice O 0 3.91682842746377e-05
exhibited O 0 0.000925527245271951
defects O 0 0.285342276096344
in O 0 8.675043545736116e-07
hemostasis O 0 4.726113911601715e-05
with O 0 8.362552250673616e-08
a O 0 1.0751291483757086e-06
highly O 0 7.333938810916152e-06
prolonged O 1 0.9964010715484619
bleeding O 1 0.999137282371521
time O 0 1.0227385871530714e-07
and O 0 4.683386123360833e-08
spontaneous O 0 1.8116830915460014e-06
bleeding O 0 0.00015547274961136281
events O 0 3.956992244980029e-08
in O 0 1.4088948674384483e-08
approximately O 0 3.4063294407360445e-08
10 O 0 6.401514696108279e-08
% O 0 7.301394333580902e-08
of O 0 9.693069387139985e-07
neonates O 0 5.227299698162824e-05
. O 0 7.187605206127046e-06

As O 0 1.5033047020551749e-05
in O 0 9.347443210572237e-07
the O 0 9.917013130689156e-07
human O 0 1.9913879896193976e-06
disease O 0 3.9770886360201985e-05
, O 0 1.1476631556206485e-07
the O 0 3.157028913847171e-07
factor O 0 6.268646188800631e-07
VIII O 0 0.00027292477898299694
level O 0 1.6042608876887243e-06
in O 0 8.777062276976721e-08
these O 0 1.3376116214658396e-08
mice O 0 4.0088553987516207e-07
was O 0 1.9295491711091017e-06
reduced O 0 2.5935872827176354e-07
strongly O 0 6.603372781910366e-08
as O 0 3.0652124394237035e-08
a O 0 4.211296555922672e-08
result O 0 2.1003925709806026e-08
of O 0 8.8212679827393e-08
the O 0 1.085601724071239e-07
lack O 0 2.2281705014393083e-07
of O 0 3.0535133532794134e-07
protection O 0 1.509782350694877e-06
provided O 0 5.040108135290211e-07
by O 0 1.6731315781726153e-06
vWf O 0 6.369926268234849e-05
. O 0 5.356575456971768e-06

Defective O 1 0.9986385703086853
thrombosis B-Disease 1 0.9999704360961914
in O 0 8.262970368377864e-06
mutant O 0 9.43601207836764e-06
mice O 0 3.320509676996153e-06
was O 0 2.6132736365980236e-06
also O 0 2.1971825248101595e-08
evident O 0 4.660751429241827e-08
in O 0 1.874892241460202e-08
an O 0 1.772628976937085e-08
in O 0 3.901117295868062e-08
vivo O 0 7.013930826360593e-06
model O 0 1.2126425872338586e-06
of O 0 4.3928317609243095e-05
vascular B-Disease 1 1.0
injury I-Disease 1 0.9999974966049194
. O 0 4.379313031677157e-05

In O 0 7.571650257887086e-06
this O 0 4.876717980550893e-07
model O 0 1.4968364894230035e-06
, O 0 2.0712421644475398e-07
the O 0 5.980409696348943e-07
exteriorized O 0 1.805509236874059e-05
mesentery O 0 5.7280209148302674e-05
was O 0 3.743020715774037e-05
superfused O 0 1.837710806285031e-05
with O 0 5.252351797935262e-07
ferric O 0 3.827456384897232e-05
chloride O 0 7.564043698948808e-06
and O 0 4.6594004743383266e-07
the O 0 1.3428810916593648e-06
accumulation O 0 1.5115720088942908e-05
of O 0 6.34814023214858e-06
fluorescently O 0 5.3110819862922654e-05
labeled O 0 2.027961272688117e-06
platelets O 0 1.8116278397428687e-06
was O 0 2.296068032592302e-06
observed O 0 3.6016669469063345e-07
by O 0 4.0698427028473816e-07
intravital O 0 2.663109808054287e-05
microscopy O 0 2.214006417489145e-05
. O 0 5.229078851698432e-06

We O 0 6.105681677581742e-06
conclude O 0 6.030187250871677e-06
that O 0 1.3592868697287486e-07
these O 0 7.42805355002929e-08
mice O 0 1.2250591225893004e-06
very O 0 1.1219118078997781e-07
closely O 0 3.404790618333209e-07
mimic O 0 4.877436003880575e-05
severe O 1 0.9929706454277039
human O 0 0.00977566558867693
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.5465797105207457e-06
will O 0 6.062670365736267e-08
be O 0 1.8131363077600327e-08
very O 0 3.970182405055311e-09
useful O 0 7.959140013724664e-09
for O 0 9.800072753307632e-09
investigating O 0 4.172065004581782e-08
the O 0 5.021665216986548e-08
role O 0 1.386534052016941e-07
of O 0 3.735402742677252e-07
vWf O 0 1.7059880974557018e-06
in O 0 1.288085229589342e-07
normal O 0 1.0139161759070703e-06
physiology O 0 1.240229084942257e-05
and O 0 1.6274167080609914e-07
in O 0 7.976511824381305e-07
disease O 0 0.0001362027251161635
models O 0 6.733329200869775e-07
. O 0 3.774449339744024e-07
. O 0 1.8644312831384013e-06

Oral O 0 0.00040233659092336893
contraceptives O 0 0.0010016891174018383
and O 0 1.9717722352652345e-06
the O 0 4.700569206761429e-06
risk O 0 3.849015411105938e-05
of O 0 0.11078574508428574
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00029964291024953127

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 0.9999880790710449
Study O 0 5.880470052943565e-05
Group O 0 1.4662939975096378e-05
. O 0 5.40304790774826e-06

BACKGROUND O 0 8.984187297755852e-05
Women O 0 1.8503773162592552e-06
with O 0 7.486212894036726e-08
mutations O 0 1.600286481107105e-07
in O 0 1.5100516748134396e-07
either O 0 5.887079979061127e-08
the O 0 2.0360621988402272e-07
BRCA1 O 0 1.2384575711621437e-06
or O 0 8.987174027197398e-08
the O 0 1.3067683823919651e-07
BRCA2 O 0 6.30065130735602e-07
gene O 0 8.11513274356912e-08
have O 0 1.4249832425150544e-08
a O 0 8.88619879901853e-08
high O 0 2.6918344246951165e-06
lifetime O 0 2.8091892545489827e-06
risk O 0 7.039193860691739e-06
of O 0 0.33680179715156555
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.5357021008385345e-05

Oral O 0 0.0012295100605115294
contraceptives O 0 0.014567544683814049
protect O 0 2.9266007913975045e-05
against O 0 0.2722245752811432
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.226775556366192e-06
general O 0 2.489127155058668e-06
, O 0 7.091171028150711e-08
but O 0 1.0973426611826653e-08
it O 0 4.05068867337377e-09
is O 0 1.2308373875669076e-08
not O 0 3.361240175081548e-09
known O 0 5.629353694303063e-08
whether O 0 6.7586363172722486e-09
they O 0 1.6411219050382897e-08
also O 0 1.3239248630725342e-07
protect O 0 2.0183013305086206e-07
against O 0 1.7876791389426216e-06
hereditary B-Disease 1 0.9967632293701172
forms I-Disease 0 5.745155067415908e-05
of I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.681400893488899e-05

METHODS O 0 0.00012987195805180818
We O 0 4.40162466475158e-06
enrolled O 0 1.0393223419669084e-05
207 O 0 1.3670503903995268e-05
women O 0 5.938182994214003e-07
with O 0 1.015009502225439e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.71166503202403e-06
161 O 0 6.897299499541987e-06
of O 0 3.613747139752377e-06
their O 0 2.8687404096672253e-07
sisters O 0 7.392234692815691e-06
as O 0 7.013055096649623e-07
controls O 0 6.905862619532854e-07
in O 0 1.7758445380877674e-07
a O 0 7.372658501481055e-07
case O 0 1.163374463430955e-06
- O 0 2.9903371796535794e-06
control O 0 2.697912123039714e-06
study O 0 2.7120565846416866e-06
. O 0 3.3894450552907074e-06

All O 0 1.9896190224244492e-06
the O 0 1.4788477074034745e-06
patients O 0 2.933940663751855e-07
carried O 0 3.444169465183222e-07
a O 0 2.2823874701316527e-07
pathogenic O 0 2.256037703318725e-07
mutation O 0 8.429233844253758e-08
in O 0 7.709926563848057e-08
either O 0 8.300544607209304e-08
BRCA1 O 0 7.899673732936208e-07
( O 0 5.998418828312424e-08
179 O 0 3.3377770591869194e-07
women O 0 4.790345187188905e-08
) O 0 3.533964942903367e-08
or O 0 1.0028709596099361e-07
BRCA2 O 0 1.1871744618474622e-06
( O 0 1.255135515521033e-07
28 O 0 5.100277121528052e-06
women O 0 5.684651114279404e-07
) O 0 8.212003308472049e-07
. O 0 1.5714052779003396e-06

The O 0 2.3265689378604293e-05
control O 0 5.109195171826286e-06
women O 0 2.0980948534088384e-07
were O 0 1.127317261762073e-07
enrolled O 0 1.3015683464345784e-07
regardless O 0 3.820995786441017e-08
of O 0 1.3367143480991217e-07
whether O 0 3.191526332102512e-08
or O 0 5.453898666019086e-08
not O 0 2.7731847040968205e-08
they O 0 2.2497461671378005e-08
had O 0 4.3237682234575914e-07
either O 0 2.5507708301120147e-07
mutation O 0 2.5989877485699253e-06
. O 0 3.7655581763829105e-06

Lifetime O 0 9.543529449729249e-05
histories O 0 8.292730854009278e-06
of O 0 8.9969234977616e-06
oral O 0 2.1857938918401487e-05
- O 0 1.4755773918295745e-05
contraceptive O 0 2.096673233609181e-05
use O 0 8.552851227250358e-08
were O 0 2.475368319210247e-07
obtained O 0 3.042571847799991e-07
by O 0 2.079596725934607e-07
interview O 0 1.0602044540064526e-06
or O 0 7.332026541462255e-08
by O 0 4.837401235135985e-08
written O 0 3.623826927423579e-08
questionnaire O 0 4.6658389152298696e-08
and O 0 4.661658081772657e-08
were O 0 2.2110836539468437e-07
compared O 0 1.5947772169511154e-07
between O 0 4.3253145065591525e-08
patients O 0 6.627308124507181e-08
and O 0 9.345949081307481e-08
control O 0 1.376904492644826e-06
women O 0 1.193243122088461e-07
, O 0 4.619464988309119e-08
after O 0 1.621778693561282e-07
adjustment O 0 5.181287860978046e-07
for O 0 1.7922554107485666e-08
year O 0 9.167629855255655e-08
of O 0 3.3566968227205507e-07
birth O 0 6.192576165631181e-06
and O 0 1.580422576807905e-06
parity O 0 4.745419937535189e-05
. O 0 5.039252300775843e-06

RESULTS O 0 0.00020429525466170162
The O 0 6.216688234417234e-06
adjusted O 0 1.190385410154704e-05
odds O 0 8.566108590457588e-06
ratio O 0 1.6975885955616832e-05
for O 0 9.21146147447871e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.8895234461524524e-06
with O 0 3.8483502606823095e-08
any O 0 3.403069470664377e-08
past O 0 9.20303619977858e-08
use O 0 1.4488541921764408e-08
of O 0 3.1280424650503846e-07
oral O 0 4.819065907213371e-06
contraceptives O 0 4.20223550463561e-05
was O 0 9.070736996363848e-05
0 O 0 3.486757123027928e-06
. O 0 1.9489123133098474e-06

5 O 0 4.586268187267706e-05
( O 0 1.4325503343570745e-06
95 O 0 4.075010565429693e-06
percent O 0 8.735506753509981e-07
confidence O 0 1.218917645928741e-06
interval O 0 8.38736582409183e-07
, O 0 3.519905078519514e-08
0 O 0 3.372042556293309e-08
. O 0 2.5091497768414683e-09
3 O 0 2.3516957270430794e-08
to O 0 9.333511741260736e-09
0 O 0 9.22562009009198e-08
. O 0 2.1020477802835558e-08
8 O 0 1.0724932053562952e-06
) O 0 3.900775595866435e-07
. O 0 1.2159359812358161e-06

The O 0 1.8236703908769414e-05
risk O 0 7.185261438280577e-06
decreased O 0 5.918958777328953e-06
with O 0 2.38352750869808e-08
increasing O 0 1.6757971366132551e-07
duration O 0 9.04643627563928e-07
of O 0 3.331607274503767e-07
use O 0 6.23542959488077e-08
( O 0 9.966887404289082e-08
P O 0 5.772536496806424e-06
for O 0 3.6915597689812785e-08
trend O 0 5.506663569576631e-07
, O 0 2.759339956526219e-08
< O 0 1.2309975261359796e-07
0 O 0 2.6525281526801336e-08
. O 0 8.696305009436855e-09
001 O 0 7.763832172713592e-07
) O 0 7.072001650954007e-09
; O 0 2.93125057559962e-09
use O 0 3.5453726621170745e-09
for O 0 1.971048746440829e-08
six O 0 4.2314656667485906e-08
or O 0 5.169609806898734e-08
more O 0 6.3547966888677365e-09
years O 0 9.866658245982762e-08
was O 0 7.618314725732489e-07
associated O 0 2.0976861137000924e-08
with O 0 3.8594034634797936e-09
a O 0 5.474858610909905e-08
60 O 0 9.853494020717335e-08
percent O 0 1.473264745754932e-07
reduction O 0 3.968420685396268e-07
in O 0 4.888050852969172e-07
risk O 0 4.558773525786819e-06
. O 0 2.6584141323837684e-06

Oral O 0 0.0017350980779156089
- O 0 0.0007396997534669936
contraceptive O 0 0.0005070433835498989
use O 0 8.87759085799189e-07
protected O 0 1.698292908258736e-05
against O 0 0.0005265806685201824
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 1.0949761986012163e-07
for O 0 2.8704308263627354e-08
carriers O 0 3.7259528795630104e-08
of O 0 1.7627071713377518e-07
the O 0 3.981757572546485e-07
BRCA1 O 0 1.5053196875669528e-06
mutation O 0 2.5008478132804157e-07
( O 0 1.1216251039058989e-07
odds O 0 6.02605553012836e-07
ratio O 0 3.7907295791228535e-07
, O 0 2.636468110495116e-08
0 O 0 5.052659446391772e-08
. O 0 5.31367394529525e-09
5 O 0 7.975144455940608e-08
; O 0 1.117590731070095e-08
95 O 0 1.721240465712981e-07
percent O 0 1.4033571460458916e-07
confidence O 0 3.7385461837402545e-07
interval O 0 3.6732427588503924e-07
, O 0 2.35779484825116e-08
0 O 0 3.53905065253457e-08
. O 0 4.1220498125937866e-09
3 O 0 3.5540949738788186e-08
to O 0 4.901511196919728e-09
0 O 0 5.961577898005999e-08
. O 0 1.1745136418994662e-08
9 O 0 2.3022110440251708e-07
) O 0 1.1745203032376139e-08
and O 0 8.762303771447932e-09
for O 0 1.0330978739148122e-08
carriers O 0 1.8104202581525897e-08
of O 0 1.6856513695984177e-07
the O 0 3.5184893931727856e-07
BRCA2 O 0 5.76334400648193e-07
mutation O 0 1.2779466374013282e-07
( O 0 5.615380871404341e-08
odds O 0 2.557576692652219e-07
ratio O 0 1.545941046288135e-07
, O 0 2.2202049976272065e-08
0 O 0 4.047331003675936e-08
. O 0 4.1340570966497125e-09
4 O 0 5.172973516209822e-08
; O 0 6.256549500704978e-09
95 O 0 1.0665736738246778e-07
percent O 0 9.539556344861921e-08
confidence O 0 2.2375824926257337e-07
interval O 0 1.755791600999146e-07
, O 0 1.4494180966551085e-08
0 O 0 1.482813871689359e-08
. O 0 1.8151492531259805e-09
2 O 0 2.02993870601631e-08
to O 0 5.264263691628912e-09
1 O 0 9.078242868554298e-08
. O 0 1.9756255298375436e-08
1 O 0 6.504059797407535e-07
) O 0 2.3161352658007672e-07
. O 0 6.567630066456331e-07

CONCLUSIONS O 0 0.0002808689314406365
Oral O 0 0.00011539196566445753
- O 0 3.397381806280464e-05
contraceptive O 0 4.399396857479587e-05
use O 0 1.4581476648345415e-07
may O 0 2.1719682763432502e-07
reduce O 0 5.172539019326905e-08
the O 0 1.6459392782053328e-07
risk O 0 1.883395839286095e-06
of O 0 0.0017457029316574335
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.0551817669911543e-06
women O 0 6.715425371339734e-08
with O 0 6.9780874412117555e-09
pathogenic O 0 7.334530494063074e-08
mutations O 0 3.401070713948684e-08
in O 0 6.736091506809316e-08
the O 0 5.6135166914828e-07
BRCA1 O 0 1.3108192433719523e-05
or O 0 6.591929377464112e-06
BRCA2 O 0 0.0003446983464527875
gene O 0 0.0002995949180331081

A O 0 0.001211857539601624
Japanese O 0 0.0002712039859034121
family O 0 5.107782271807082e-06
with O 0 1.4335753348859726e-06
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.1824571402030415e-06
a O 0 4.239134341332829e-06
codon O 0 5.928438440605532e-06
291 O 0 1.9510509901010664e-06
deletion O 0 9.912786254062667e-07
: O 0 3.3622868045313226e-08
a O 0 1.263590689859484e-07
clinical O 0 1.6099711501738057e-06
, O 0 9.119495558707058e-08
biochemical O 0 1.8984474081662484e-05
, O 0 1.389390575923244e-07
pathological O 0 0.003969076555222273
, O 0 2.9445163818309084e-07
and O 0 4.2066966443599085e-07
genetic O 0 1.1852765965159051e-05
report O 0 2.276052146044094e-05
. O 0 5.701128884538775e-06

We O 0 1.552958565298468e-05
report O 0 6.78423793942784e-06
a O 0 2.0634379325201735e-06
Japanese O 0 9.699426300358027e-06
family O 0 8.8914271145768e-07
with O 0 2.1189280232647434e-06
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.0005453327903524041
ALD B-Disease 1 1.0
) O 0 3.9232722315318824e-07
with O 0 1.1826798385072834e-07
a O 0 9.446828812542662e-07
three O 0 2.3395718073970784e-07
base O 0 3.173748382323538e-06
pair O 0 1.891773763418314e-06
deletion O 0 2.4784726520010736e-06
( O 0 2.3593653963871475e-07
delGAG O 0 3.3119138151960215e-06
291 O 0 2.089376039293711e-06
) O 0 7.826398018551117e-08
in O 0 2.1745071876466682e-07
the O 0 3.7018724015069893e-06
ALD B-Disease 1 1.0
gene O 0 2.0405210307217203e-05
. O 0 6.632956228713738e-06

A O 0 4.067672853125259e-05
variety O 0 7.024253250165202e-07
of O 0 8.002372169357841e-07
phenotypes O 0 2.9491579880414065e-06
were O 0 2.593582451027032e-07
observed O 0 1.754241765183906e-07
within O 0 5.7136642084287814e-08
this O 0 1.201692754193573e-07
family O 0 8.826601174405369e-07
. O 0 4.176566562819062e-06

While O 0 4.283103771740571e-05
the O 0 5.466501988848904e-06
proband O 0 4.5717883040197194e-05
( O 0 4.833315188079723e-07
patient O 0 5.736343382523046e-07
1 O 0 7.527082743763458e-07
) O 0 7.687504677278412e-08
was O 0 1.491308012191439e-06
classified O 0 7.08416791894706e-08
as O 0 6.940711472225303e-08
having O 0 4.547907295204823e-08
a O 0 1.0656524551677649e-07
rare O 0 8.986489064000125e-08
intermediate O 0 3.70169573216117e-06
type O 0 3.454297825555841e-07
of O 0 1.9269050426373724e-06
adult O 0 7.827135959814768e-06
cerebral O 1 0.8218803405761719
and O 0 7.103406460373662e-06
cerebello O 1 0.9992376565933228
- O 0 0.2123090922832489
brain O 0 0.11001616716384888
stem O 0 8.584795978094917e-06
forms O 0 2.2943051192214625e-07
, O 0 1.8692207959247753e-07
his O 0 8.601747936154425e-07
younger O 0 1.0672365533537231e-06
brother O 0 5.472417342389235e-06
( O 0 7.405250102010541e-08
patient O 0 3.56568619963582e-07
2 O 0 7.116616416169563e-07
) O 0 8.583051425148369e-08
and O 0 2.2034488722511014e-07
nephew O 0 0.0008420579833909869
( O 0 1.7469976398842846e-07
patient O 0 4.982610448678315e-07
3 O 0 6.160746011119045e-07
) O 0 7.02390607898451e-08
had O 0 1.1303084193059476e-06
a O 0 7.852968337829225e-06
childhood O 0 0.3730081021785736
ALD B-Disease 1 1.0
type O 0 0.0019079209305346012
. O 0 1.6737552869017236e-05

Another O 0 0.0002459728857502341
nephew O 0 0.0005539104458875954
( O 0 1.2647133189602755e-06
patient O 0 2.0958279947080882e-06
4 O 0 2.0647214569180505e-06
) O 0 4.6430415068243747e-08
of O 0 2.995989802911936e-07
patient O 0 1.7357974684273358e-06
1 O 0 1.9408143998589367e-06
was O 0 1.1014169103873428e-05
classified O 0 2.8335591650829883e-07
as O 0 1.378457170631009e-07
having O 0 3.4750576105579967e-07
an O 0 6.031822863405978e-07
adolescent O 0 3.347641177242622e-05
form O 0 2.124536877090577e-06
. O 0 7.63980278861709e-06

The O 0 2.9646071197930723e-05
tau O 0 3.617341644712724e-05
level O 0 7.148400982259773e-06
in O 0 9.696360621092026e-07
the O 0 1.4570914572686888e-06
cerebrospinal O 0 3.609291889006272e-05
fluid O 0 1.7312579075223766e-05
( O 0 1.358073177470942e-06
CSF O 0 0.00011108873877674341
) O 0 9.109204057722309e-08
in O 0 7.165049709101368e-08
patient O 0 2.26528655389302e-07
1 O 0 4.566256279758818e-07
was O 0 2.9699767765123397e-06
as O 0 9.736003647731195e-08
high O 0 7.142167532947497e-07
as O 0 1.3350576644199919e-08
that O 0 3.95857568946667e-09
of O 0 1.8982456140292925e-07
patients O 0 6.326728794192604e-07
with O 0 2.3010395580058685e-06
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999881982803345
( O 0 8.138808311741741e-07
AD B-Disease 0 2.3180447897175327e-05
) O 0 3.9081257341422315e-07
. O 0 7.582190164612257e-07

His O 0 0.00028976445901207626
brain O 0 0.018378600478172302
magnetic O 0 0.0002627817157190293
resonance O 0 5.5282194807659835e-05
image O 0 1.090879686671542e-05
( O 0 1.0006972388509894e-06
MRI O 0 0.00010949312127195299
) O 0 1.3565919232405577e-07
showed O 0 8.368965040972398e-07
abnormalities B-Disease 0 3.133819336653687e-05
in I-Disease 0 2.3004814408977836e-07
the I-Disease 0 6.129550911282422e-07
bilateral I-Disease 0 9.660021896706894e-05
cerebellar I-Disease 1 0.9999226331710815
hemispheres I-Disease 0 0.001826380961574614
and O 0 5.5699661061225925e-06
brain O 1 0.9086072444915771
stem O 0 0.00010168712469749153
, O 0 1.202538868483316e-07
but O 0 1.74049628043349e-08
not O 0 1.9172830434399657e-08
in O 0 1.635137749644855e-07
the O 0 1.2127154604968382e-06
cerebral O 0 0.04473751783370972
white O 0 9.75205011854996e-07
matter O 0 1.2183221542727551e-07
, O 0 3.4941919579978276e-08
where O 0 3.604380438559929e-08
marked O 0 2.622130921281496e-07
reductions O 0 3.101989705101005e-07
of O 0 5.27039503595006e-07
the O 0 1.9666306343424367e-06
cerebral O 0 0.0006786148878745735
blood O 0 2.270382992719533e-06
flow O 0 4.172720764472615e-06
and O 0 6.888812436045555e-07
oxygen O 0 5.452709956443869e-06
metabolism O 0 5.380567472457187e-06
were O 0 1.4064025322113594e-07
clearly O 0 2.6913202333389563e-08
demonstrated O 0 5.933196334240165e-08
by O 0 2.38052439982539e-08
positron O 0 1.0674605164240347e-06
emission O 0 1.031896545100608e-06
tomography O 0 3.0198382319213124e-06
( O 0 6.97620009759703e-07
PET O 0 4.0297445593751036e-06
) O 0 6.57069335829874e-07
. O 0 1.4532736258843215e-06

In O 0 1.4617507076764014e-05
patients O 0 1.719256715659867e-06
2 O 0 1.5113670315258787e-06
and O 0 2.809334205267078e-07
3 O 0 1.025636038320954e-06
, O 0 5.5022546519012394e-08
the O 0 4.7252886048454457e-08
autopsy O 0 2.018743316511973e-06
findings O 0 3.9112356375881063e-07
showed O 0 4.387313310871832e-06
massive O 0 0.04634004831314087
demyelination B-Disease 1 1.0
of I-Disease 0 0.0013754002284258604
the I-Disease 0 0.00013991023297421634
cerebral I-Disease 1 0.9984371066093445
white I-Disease 0 2.134268243025872e-06
matter I-Disease 0 1.1283347589596815e-07
with O 0 2.8944340257908152e-08
sparing O 0 4.177018126938492e-07
of O 0 1.679990873526549e-06
the O 0 1.64175817189971e-05
U O 1 0.9999946355819702
- O 0 0.00013464772200677544
fibers O 0 6.61791136735701e-06
, O 0 5.4436103624766474e-08
compatible O 0 8.979994703395278e-08
with O 0 1.2187899578464112e-08
the O 0 1.7622433290398476e-07
findings O 0 7.222464546430274e-07
of O 0 1.5698828065069392e-05
childhood O 1 0.9861548542976379
ALD B-Disease 1 1.0
. O 0 5.3492243750952184e-05

Oleic O 0 0.00504085561260581
and O 0 9.055179543793201e-05
erucic O 0 0.0021914553362876177
acids O 0 1.5544639609288424e-05
( O 0 1.83216479854309e-06
Lorenzos O 0 4.746972626890056e-05
Oil O 0 5.335101377568208e-06
) O 0 1.565354423860299e-08
were O 0 2.025394429949756e-08
administered O 0 1.015958606132017e-08
to O 0 9.330076267133336e-09
patients O 0 1.1856551296318685e-08
1 O 0 1.2575365815337136e-07
and O 0 3.242589485807912e-08
4 O 0 4.14301922546656e-07
, O 0 8.861940514748312e-09
but O 0 2.2112276454322455e-09
sufficient O 0 2.4714426061223094e-08
effectiveness O 0 2.8801412099710433e-07
was O 0 2.134573605871992e-06
not O 0 8.000222351256525e-08
obtained O 0 3.047350674023619e-06
. O 0 6.269020559557248e-06

The O 0 4.0022216126089916e-05
findings O 0 1.0083206689159852e-05
in O 0 1.2137209068896482e-06
this O 0 1.4950516913359024e-07
family O 0 9.936194089732453e-08
suggest O 0 1.0020831808787989e-07
that O 0 2.3236371049506488e-08
delGAG291 O 0 6.973679091970553e-07
is O 0 2.1216642664967367e-08
part O 0 3.3344104366506144e-08
of O 0 2.939457885986485e-07
the O 0 5.140956886862114e-07
cause O 0 2.4490789201081498e-06
of O 0 2.4716566258575767e-05
Japanese O 1 0.965039849281311
ALD B-Disease 1 1.0
with O 0 6.184764060890302e-07
phenotypic O 0 1.316770794801414e-05
variations O 0 2.4378459784202278e-05
. O 0 8.727181921130978e-06

Moreover O 0 6.694697367493063e-05
, O 0 2.1904033928876743e-06
although O 0 1.563096532208874e-07
the O 0 7.66331922363861e-08
scale O 0 4.445022057097958e-07
of O 0 2.527628168991214e-07
the O 0 1.5270389042143506e-07
study O 0 4.543745646401476e-08
is O 0 2.2120470788422608e-08
limited O 0 2.8573756694072472e-08
, O 0 1.2622364486958304e-08
there O 0 1.8038367244344045e-08
is O 0 2.7012561076844577e-08
a O 0 6.454417444956562e-08
possibility O 0 2.21942229927663e-07
that O 0 1.221508654225545e-07
PET O 0 3.3676096791168675e-06
can O 0 5.02898842569266e-08
detect O 0 1.285308599108248e-06
an O 0 4.226354576530866e-06
insidious B-Disease 0 0.16352227330207825
lesion I-Disease 1 0.999874472618103
which O 0 6.434136707866855e-07
is O 0 2.194667843014031e-07
undetectable O 0 1.3867842199033475e-06
by O 0 8.800630979521884e-08
computed O 0 4.076228776739299e-07
tomogram O 0 5.71039572605514e-06
( O 0 1.7962651099878713e-07
CT O 0 1.802675615181215e-05
) O 0 5.239144584834321e-08
or O 0 8.871516143926783e-08
MRI O 0 5.234297987044556e-06
analysis O 0 4.0673121759482456e-08
, O 0 1.6946511749438287e-08
and O 0 8.233967285775634e-09
that O 0 1.3174692448103542e-08
the O 0 9.262259226261449e-08
higher O 0 2.336468014618731e-07
level O 0 1.2061498466664489e-07
of O 0 1.3727833447774174e-07
tau O 0 8.406913707403874e-07
reflects O 0 2.35140404925005e-08
the O 0 2.3193551967892745e-08
process O 0 4.0520347965866677e-08
of O 0 6.639884304604493e-07
neuronal B-Disease 0 0.03664455935359001
degeneration I-Disease 1 0.9999980926513672
in O 0 5.386757038650103e-05
ALD B-Disease 1 1.0
. O 0 2.127356310666073e-05

Lorenzos O 0 0.005247857421636581
Oil O 0 0.0002538299304433167
should O 0 5.174019861442503e-07
be O 0 5.427902749488567e-08
given O 0 2.827799860938285e-08
in O 0 4.108833095983755e-08
the O 0 1.1237515451512081e-07
early O 0 3.7221386151031766e-07
stage O 0 1.2715852335531963e-06
. O 0 3.3563992474228144e-07
. O 0 1.5627820175723173e-06

Nonsense O 0 0.0003020101576112211
mutation O 0 4.8476990741619375e-06
in O 0 6.291710974437592e-07
exon O 0 1.0633393685566261e-06
4 O 0 7.350284931817441e-07
of O 0 2.1168263231174933e-07
human O 0 1.6774473010627844e-07
complement O 0 7.153360570555378e-07
C9 O 0 0.00013844958448316902
gene O 0 2.736014153015276e-07
is O 0 5.99040390625305e-08
the O 0 6.693545628877473e-08
major O 0 6.935496230653371e-07
cause O 0 8.926065220293822e-07
of O 0 4.147171694057761e-06
Japanese O 0 0.00022475425794254988
complement B-Disease 0 0.0016945726238191128
C9 I-Disease 1 0.9999986886978149
deficiency I-Disease 1 0.9999973773956299
. O 0 1.7223588656634092e-05

Deficiency B-Disease 1 0.9998693466186523
of I-Disease 0 6.021296576363966e-05
the I-Disease 0 1.4543714314640965e-05
ninth I-Disease 0 5.1797622290905565e-05
component I-Disease 0 3.4414911169733386e-06
of I-Disease 0 1.2763721315423027e-06
human I-Disease 0 9.962845979316626e-07
complement I-Disease 0 3.656477247204748e-06
( O 0 5.654701453750022e-07
C9 O 0 0.00017938388918992132
) O 0 1.079769944567488e-07
is O 0 3.273249049584592e-08
the O 0 5.929372548507672e-08
most O 0 3.71325334924677e-08
common O 0 8.495343877257255e-07
complement B-Disease 1 0.9999957084655762
deficiency I-Disease 1 1.0
in O 0 2.5672538868093397e-06
Japan O 0 1.0471094356034882e-06
but O 0 3.006017834650265e-08
is O 0 2.0599244976438058e-08
rare O 0 1.8509719978965222e-08
in O 0 5.266937819214945e-08
other O 0 2.4051420410842184e-08
countries O 0 1.5595438185300736e-07
. O 0 3.035487907254719e-06

We O 0 2.6888633328780998e-06
studied O 0 3.2556522455706727e-06
the O 0 3.5491032690515567e-07
molecular O 0 2.0451632281037746e-06
basis O 0 1.0285716598446015e-06
of O 0 1.1697419722622726e-05
C9 B-Disease 1 0.9999979734420776
deficiency I-Disease 1 0.999900221824646
in O 0 7.979783163136744e-07
four O 0 6.342684173432644e-07
Japanese O 0 0.00016105209942907095
C9 B-Disease 1 0.9999961853027344
- I-Disease 1 0.9776286482810974
deficient I-Disease 1 0.883727490901947
patients O 0 8.527226214027905e-07
who O 0 5.869465553587361e-07
had O 0 5.6462220527464524e-05
suffered O 1 0.9999998807907104
from O 1 0.7709129452705383
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.7449627193855122e-05

Direct O 0 2.7357655199011788e-05
sequencing O 0 2.1048090275144204e-05
of O 0 9.624129233998246e-06
amplified O 0 4.4405685912352055e-05
C9 O 0 8.555755630368367e-05
cDNA O 0 6.6193315433338284e-06
and O 0 2.712822890771349e-07
DNA O 0 9.515520105196629e-07
revealed O 0 3.819331141130533e-06
a O 0 1.4506399566016626e-06
nonsense O 0 1.0836392903001979e-05
substitution O 0 3.7922623050690163e-06
( O 0 4.819608534489817e-07
CGA O 0 5.462140507006552e-06
- O 0 1.1251428304603905e-06
- O 0 1.273915586352814e-06
> O 0 1.5524698255831026e-06
TGA O 0 3.3798712593124947e-06
) O 0 5.374959144432978e-08
at O 0 4.392565529087733e-07
codon O 0 4.773280579684069e-07
95 O 0 1.1944796085572307e-07
in O 0 2.8936502971532718e-08
exon O 0 8.914072679999663e-08
4 O 0 2.353185806214242e-07
in O 0 9.365935227378941e-08
the O 0 3.684996556785336e-07
four O 0 1.9335225260874722e-06
C9 B-Disease 0 0.4294915795326233
- I-Disease 0 0.0020306091755628586
deficient I-Disease 0 0.00018324702978134155
individuals O 0 2.8405636953721114e-07
. O 0 1.7434920209780103e-06

An O 0 5.141023939359002e-05
allele O 0 2.5640838430263102e-05
- O 0 8.41046312416438e-06
specific O 0 3.359720324169757e-07
polymerase O 0 4.337583595770411e-05
chain O 0 6.347111138893524e-06
reaction O 0 5.565945002672379e-07
system O 0 8.816373764375385e-08
designed O 0 1.2634147594781098e-07
to O 0 1.0265452488056326e-08
detect O 0 4.125323727066643e-08
exclusively O 0 1.8057438211371846e-08
only O 0 1.4880526144622763e-08
one O 0 1.2721677933313913e-08
of O 0 8.222670544455468e-08
the O 0 9.625899366483281e-08
normal O 0 1.6368539945688099e-07
and O 0 1.7564641296985428e-08
mutant O 0 1.4593760511161236e-07
alleles O 0 5.399228797386968e-08
indicated O 0 1.4914687085365586e-07
that O 0 1.5278539322594042e-08
all O 0 9.578953630295928e-09
the O 0 6.763668380926902e-08
four O 0 3.953552152324846e-08
patients O 0 1.880866662418157e-08
were O 0 4.7658570423436686e-08
homozygous O 0 5.832360017166138e-08
for O 0 3.858676933532479e-08
the O 0 1.0381175030715895e-07
mutation O 0 4.2558859547625616e-08
in O 0 9.70078488649051e-08
exon O 0 2.390582665157126e-07
4 O 0 2.303576991380396e-07
and O 0 4.166490796819744e-08
that O 0 3.573583029492511e-08
the O 0 2.3875159627095854e-07
parents O 0 5.418014836777729e-08
of O 0 5.994233447381703e-07
patient O 0 2.8976990051887697e-06
2 O 0 2.5371680294483667e-06
were O 0 2.8701190331048565e-06
heterozygous O 0 4.170242391410284e-06
. O 0 2.328709570065257e-06

The O 0 1.7331578419543803e-05
common O 0 1.0620482271406217e-06
mutation O 0 1.1048633723476087e-06
at O 0 2.5849471967376303e-06
codon O 0 1.0016988198913168e-06
95 O 0 1.2055333797889034e-07
in O 0 2.0085291652094384e-08
exon O 0 2.0828120739224687e-07
4 O 0 2.8340858193587337e-07
might O 0 3.970843209799568e-08
be O 0 3.6775322342919026e-08
responsible O 0 1.0306263931170179e-07
for O 0 7.86931266816282e-08
most O 0 2.984434672725911e-07
Japanese O 0 0.00044779153540730476
C9 B-Disease 1 0.9999964237213135
deficiency I-Disease 1 0.9999805688858032
. O 0 8.59711462908308e-07
. O 0 1.7907642586578731e-06

BRCA1 O 0 0.00013528218551073223
required O 0 2.561262817835086e-06
for O 0 1.7908138261191198e-06
transcription O 0 0.00010902720532612875
- O 0 4.7390796680701897e-05
coupled O 0 3.3496340620331466e-05
repair O 0 8.1559792306507e-06
of O 0 1.8670256167752086e-06
oxidative O 0 3.9713242586003616e-05
DNA O 0 5.0252770051884e-06
damage O 0 0.0001339316659141332
. O 0 8.986281500256155e-06

The O 0 0.00020942272385582328
breast B-Disease 1 0.999971866607666
and I-Disease 1 0.5826124548912048
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9068066477775574
gene O 0 4.83984649690683e-06
BRCA1 O 0 1.6369023796869442e-05
encodes O 0 1.2810334737878293e-05
a O 0 1.6873555068741553e-05
zinc O 0 0.2908172309398651
finger O 0 7.721366273472086e-05
protein O 0 1.8746974319583387e-06
of O 0 2.7237310860073194e-06
unknown O 0 8.83401298779063e-06
function O 0 3.1271645184460795e-06
. O 0 2.0615143512259237e-06

Association O 0 8.797940972726792e-05
of O 0 9.303996193921193e-06
the O 0 3.0353896818269277e-06
BRCA1 O 0 1.0036122148449067e-05
protein O 0 2.6673073989513796e-06
with O 0 1.5304182454656257e-07
the O 0 1.052742732099432e-06
DNA O 0 2.2433589492720785e-06
repair O 0 2.3178014089353383e-05
protein O 0 8.070997864706442e-06
Rad51 O 0 3.997050225734711e-05
and O 0 4.6768607830927067e-07
changes O 0 8.176861854281015e-08
in O 0 8.491328173931834e-08
the O 0 6.98157904821528e-08
phosphorylation O 0 4.631242802588531e-07
and O 0 8.88018405476032e-08
cellular O 0 3.65446226169297e-06
localization O 0 1.1453158549556974e-05
of O 0 4.346904916019412e-07
the O 0 3.220468727249681e-07
protein O 0 2.761636324066785e-07
after O 0 7.408414717247069e-07
exposure O 0 9.14989584543946e-07
to O 0 7.811245694711033e-08
DNA O 0 2.2541482849192107e-06
- O 0 1.6282598153338768e-05
damaging O 0 1.4448160982283298e-05
agents O 0 2.5061075348276063e-07
are O 0 1.0242921177905373e-08
consistent O 0 9.980146131738366e-08
with O 0 9.777611609251835e-09
a O 0 7.805690671602861e-08
role O 0 9.695994407366015e-08
for O 0 2.9500473175403386e-08
BRCA1 O 0 8.00686052571109e-07
in O 0 4.4088577055845235e-07
DNA O 0 3.981548161391402e-06
repair O 0 0.00015030574286356568
. O 0 1.4275711691880133e-05

Here O 0 3.302047116449103e-05
, O 0 8.056387628130324e-07
it O 0 7.792957035235304e-08
is O 0 1.0618664703088143e-07
shown O 0 1.4788024316203519e-07
that O 0 1.7409551844593807e-07
mouse O 0 2.2165061182022328e-06
embryonic O 0 5.880497610633029e-06
stem O 0 1.0148266483156476e-05
cells O 0 2.451462478347821e-06
deficient B-Disease 0 5.315873295330675e-06
in I-Disease 0 1.457221827649846e-07
BRCA1 I-Disease 0 1.0533583463256946e-06
are O 0 4.85326907551098e-08
defective O 0 8.212942930185818e-07
in O 0 7.453998307482834e-08
the O 0 8.410828655769365e-08
ability O 0 1.647186920195054e-08
to O 0 5.038320338712765e-08
carry O 0 1.2113649461298337e-07
out O 0 3.315385583846364e-07
transcription O 0 1.99962014448829e-05
- O 0 6.053038305253722e-06
coupled O 0 1.6651483747409657e-05
repair O 0 3.7069773952680407e-06
of O 0 1.2255078445377876e-06
oxidative O 0 5.524766493181232e-06
DNA O 0 4.2162878344242927e-07
damage O 0 4.7862536121101584e-06
, O 0 1.6947151948443206e-07
and O 0 7.469425611361658e-08
are O 0 4.0285154767616405e-08
hypersensitive O 0 6.526442575705005e-06
to O 0 1.5275703901806992e-07
ionizing O 0 5.691138721886091e-05
radiation O 0 0.00045228737872093916
and O 0 1.8573609850136563e-06
hydrogen O 0 9.342316843685694e-06
peroxide O 0 6.085701534175314e-05
. O 0 8.131236427288968e-06

These O 0 6.903505436639534e-06
results O 0 4.410693236422958e-06
suggest O 0 5.263443654257571e-07
that O 0 1.2191532050565002e-07
BRCA1 O 0 2.2519202502735425e-06
participates O 0 5.998625169922889e-07
, O 0 2.000153500603119e-07
directly O 0 1.9226081349188462e-07
or O 0 1.4429998884679662e-07
indirectly O 0 2.9287940606081975e-07
, O 0 6.325631574100044e-08
in O 0 1.54118652062607e-07
transcription O 0 3.9548311178805307e-05
- O 0 2.1018286133767106e-05
coupled O 0 3.387385368114337e-05
repair O 0 5.068308837508084e-06
of O 0 2.2787125999457203e-06
oxidative O 0 1.798926678020507e-05
DNA O 0 1.9340648123034043e-06
damage O 0 2.261478039145004e-05
. O 0 1.1694726254063426e-06
. O 0 1.9382987375138327e-06

Truncation O 0 0.0019682690035551786
mutations O 0 2.6930516469292343e-05
in O 0 2.7802554996014806e-06
the O 0 1.1723043371603126e-06
transactivation O 0 3.245713378419168e-05
region O 0 8.293888527077797e-07
of O 0 2.9538473427237477e-06
PAX6 O 0 0.0008552452200092375
result O 0 1.123003130487632e-06
in O 0 7.193435749286436e-07
dominant O 0 5.403388058766723e-06
- O 0 5.580621746048564e-06
negative O 0 9.99903477350017e-07
mutants O 0 4.228604211675702e-06
. O 0 1.8991452179761836e-06

PAX6 O 0 0.010320375673472881
is O 0 1.630446240596939e-05
a O 0 2.864513362510479e-06
transcription O 0 1.0245392331853509e-05
factor O 0 6.157051757327281e-07
with O 0 3.348904087374649e-08
two O 0 3.550355032189145e-08
DNA O 0 4.967229187968769e-07
- O 0 1.0604835551930591e-06
binding O 0 3.8540952118637506e-07
domains O 0 8.461722700303653e-07
( O 0 1.5380237528006546e-07
paired O 0 3.180891781084938e-07
box O 0 1.0988610483764205e-06
and O 0 8.24437407231926e-08
homeobox O 0 2.460306404827861e-06
) O 0 5.5064539594695816e-08
and O 0 2.4576468149462016e-07
a O 0 3.1675829177402193e-06
proline O 0 1.320127830695128e-05
- O 0 4.780843482876662e-06
serine O 0 7.04623244018876e-06
- O 0 2.644511823746143e-06
threonine O 0 6.305000624706736e-06
( O 0 4.27571450245523e-07
PST O 0 4.440356860868633e-05
) O 0 4.5843160023650853e-07
- O 0 2.7956873509538127e-06
rich O 0 9.015740829454444e-07
transactivation O 0 6.685803236905485e-05
domain O 0 1.0572033716016449e-05
. O 0 3.0959095056459773e-06

PAX6 O 1 0.9804667830467224
regulates O 0 0.0009927104692906141
eye O 0 0.0026742443442344666
development O 0 1.4969669791753404e-05
in O 0 4.4503920548777387e-07
animals O 0 6.757826298553482e-08
ranging O 0 7.948794973344775e-07
from O 0 2.2862911919219187e-07
jellyfish O 0 4.0648777144269843e-07
to O 0 5.0559179953779676e-08
Drosophila O 0 3.1574734293826623e-06
to O 0 2.1664551752564876e-07
humans O 0 7.252219234032964e-07
. O 0 1.4721441630172194e-06

Heterozygous O 0 5.163186870049685e-05
mutations O 0 6.623303761443822e-06
in O 0 7.603159701830009e-07
the O 0 8.111981628644571e-07
human O 0 1.0935941645584535e-06
PAX6 O 0 0.0004902583314105868
gene O 0 3.609203815813089e-07
result O 0 1.5273344899924268e-07
in O 0 3.3031273716233045e-08
various O 0 2.2507677499561396e-08
phenotypes O 0 1.459693635297299e-06
, O 0 1.0578416720363748e-07
including O 0 7.036670695015346e-07
aniridia B-Disease 1 1.0
, O 0 5.3903440857538953e-05
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 6.800833034503739e-07
autosomal B-Disease 0 0.0027091389056295156
dominant I-Disease 0 0.02790265716612339
keratitis I-Disease 1 0.9999998807907104
, O 0 1.5729615370219108e-06
and O 0 2.94412211587769e-06
familial B-Disease 1 0.9999997615814209
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.434061199426651

It O 0 3.866195129376138e-06
is O 0 7.658540539523528e-07
believed O 0 6.612477818634943e-07
that O 0 5.481723519551451e-08
the O 0 2.0566196212712384e-07
mutated O 0 5.500889983522939e-07
allele O 0 8.84556982327922e-07
of O 0 2.1363250652939314e-06
PAX6 O 0 0.002017655875533819
produces O 0 6.985760592215229e-07
an O 0 2.7615496378530224e-07
inactive O 0 1.7354728925056406e-06
protein O 0 6.101032568039955e-07
and O 0 3.791618894410931e-07
aniridia B-Disease 1 0.9999980926513672
is O 0 3.687380285555264e-07
caused O 0 1.8569871826912276e-06
due O 0 2.2592550976696657e-06
to O 0 1.0409647188680538e-07
genetic O 0 7.555896900157677e-06
haploinsufficiency O 0 0.08034784346818924
. O 0 1.4024826668901369e-05

However O 0 1.2431302820914425e-05
, O 0 7.806716553204751e-07
several O 0 1.172182066966343e-07
truncation O 0 6.471530468843412e-06
mutations O 0 3.0073084644755e-07
have O 0 7.352458908371773e-08
been O 0 2.0313704851560033e-07
found O 0 3.9993771849822224e-08
to O 0 1.0278187190237986e-08
occur O 0 5.5534112419763915e-08
in O 0 1.3575264290466293e-07
the O 0 1.3946277022114373e-06
C O 0 0.00011483631533337757
- O 0 5.5651394177402835e-06
terminal O 0 2.59652515524067e-05
half O 0 1.616177200958191e-07
of O 0 5.891482715014718e-07
PAX6 O 0 7.141030073398724e-05
in O 0 2.2803337174082117e-07
patients O 0 1.4598590780678933e-07
with O 0 1.97397994838866e-07
Aniridia B-Disease 1 0.9999912977218628
resulting O 0 1.2410280305630295e-06
in O 0 1.0681921480681922e-07
mutant O 0 3.9255402839444287e-07
proteins O 0 6.087513781949383e-08
that O 0 3.490674771455815e-08
retain O 0 8.228726500192352e-08
the O 0 3.772700551962771e-07
DNA O 0 8.659164905111538e-07
- O 0 7.659913308089017e-07
binding O 0 4.3810481997752504e-07
domains O 0 6.590845487153274e-07
but O 0 4.676244813595076e-08
have O 0 3.594590580746626e-08
lost O 0 7.380917850241531e-07
most O 0 3.0441213993981364e-08
of O 0 3.49163457258328e-07
the O 0 3.5459604532661615e-06
transactivation O 0 0.00021681511134374887
domain O 0 1.874981535365805e-05
. O 0 4.7339399316115305e-06

It O 0 2.617768586787861e-06
is O 0 3.5488730532051704e-07
not O 0 4.049655188964607e-08
clear O 0 1.3496442363702954e-07
whether O 0 3.993081065800652e-08
such O 0 4.892705263159769e-08
mutants O 0 1.6489746030856622e-06
really O 0 5.188378509046743e-07
behave O 0 1.3582359770225594e-07
as O 0 1.6481115494570986e-07
loss O 0 1.6255814898613608e-06
- O 0 6.903662779222941e-07
of O 0 6.825816853961442e-07
- O 0 1.0362840612287982e-06
function O 0 2.5635372935539635e-07
mutants O 0 4.422999779762904e-07
as O 0 2.107638721327021e-07
predicted O 0 1.1460940640972694e-06
by O 0 3.2326354926226486e-07
haploinsufficiency O 0 3.582571298466064e-05
. O 0 3.5156492685928242e-06

Contrary O 0 3.908552753273398e-05
to O 0 8.033247809180466e-07
this O 0 1.6548980852348905e-07
theory O 0 8.970790190687694e-07
, O 0 5.016514847966391e-08
our O 0 5.141839309885654e-08
data O 0 3.075854522194277e-07
showed O 0 5.759761734225322e-07
that O 0 5.206073083741103e-08
these O 0 2.1782508241585674e-08
mutants O 0 5.19398270171223e-07
are O 0 1.8871119777941203e-08
dominant O 0 3.1162872460299695e-07
- O 0 2.3624140510491998e-07
negative O 0 8.856503797005644e-08
in O 0 8.26165873490936e-08
transient O 0 4.413461738295155e-06
transfection O 0 4.686487500293879e-06
assays O 0 3.93925120079075e-07
when O 0 7.131794887982323e-08
they O 0 1.3781805918711143e-08
are O 0 1.453166031950559e-08
coexpressed O 0 1.493674972152803e-06
with O 0 1.0828016172581556e-07
wild O 0 3.7731213069491787e-06
- O 0 7.281974103534594e-05
type O 0 0.00010403162013972178
PAX6 O 1 0.9403589367866516
. O 0 1.2597066415764857e-05

We O 0 5.591659828496631e-06
found O 0 7.368504384430707e-07
that O 0 1.0606843403593302e-07
the O 0 3.155746810534765e-07
dominant O 0 1.6435986935903202e-06
- O 0 2.3413401777361287e-06
negative O 0 8.675224876242282e-07
effects O 0 4.2043648136314005e-06
result O 0 3.149547183056711e-07
from O 0 5.086366527962127e-08
the O 0 2.3637024781919536e-08
enhanced O 0 7.879331320737037e-08
DNA O 0 7.617299502271635e-08
binding O 0 8.107227245091053e-08
ability O 0 3.553566330083413e-08
of O 0 3.672626291972847e-07
these O 0 2.0901681807572459e-07
mutants O 0 6.727425898134243e-06
. O 0 3.862845005642157e-06

Kinetic O 0 0.00026863469975069165
studies O 0 1.1038206139346585e-05
of O 0 4.231533239362761e-06
binding O 0 3.5640648547996534e-06
and O 0 8.323008273691812e-07
dissociation O 0 1.1030009773094207e-05
revealed O 0 1.2695592204181594e-06
that O 0 4.9968619464380026e-08
various O 0 6.684460629458044e-08
truncation O 0 7.898311196186114e-06
mutants O 0 8.634146411168331e-07
have O 0 5.258947410879955e-08
3 O 0 4.07810290425914e-07
- O 0 3.5375768447920564e-07
5 O 0 1.0730967687777593e-06
- O 0 8.67900723733328e-07
fold O 0 3.320961354802421e-07
higher O 0 2.21297597136072e-07
affinity O 0 6.626473947335398e-08
to O 0 1.2486498057739936e-08
various O 0 1.3895197881197419e-08
DNA O 0 1.0694540719669021e-07
- O 0 8.833593057033795e-08
binding O 0 3.687414817932222e-08
sites O 0 3.172426943365281e-08
when O 0 1.8221294695308643e-08
compared O 0 3.601137166242552e-08
with O 0 1.1402028654572405e-08
the O 0 2.6339733949498623e-07
wild O 0 8.241872819780838e-07
- O 0 1.0640642358339392e-05
type O 0 1.2092717952327803e-05
PAX6 O 0 0.017951399087905884
. O 0 9.500935448158998e-06

These O 0 2.039950459220563e-06
results O 0 1.6026505136323976e-06
provide O 0 1.5902666916645103e-07
a O 0 3.727189721303148e-07
new O 0 1.6222008980548708e-07
insight O 0 2.6096648753082263e-07
into O 0 2.399423593146821e-08
the O 0 3.651852154007429e-08
role O 0 1.07663375104039e-07
of O 0 4.296483098187309e-07
mutant O 0 6.360053248499753e-06
PAX6 O 0 0.0011278796009719372
in O 0 4.796754637936829e-06
causing O 0 0.00013164269330445677
aniridia B-Disease 1 0.9999912977218628
. O 0 2.340846776860417e-06
. O 0 3.666176780825481e-06

Reversal O 0 0.020367899909615517
of O 0 0.0003274400078225881
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 0.0004433646681718528
excellent O 0 0.00024398890673182905
neuropsychologic O 0 0.006116420961916447
outcome O 0 3.3277312923019053e-06
in O 0 7.084357207531866e-07
very B-Disease 0 2.7109450684292824e-07
- I-Disease 0 2.56385283137206e-06
long I-Disease 0 3.137243083983776e-06
- I-Disease 0 1.360625265078852e-05
chain I-Disease 0 3.186560934409499e-05
acyl I-Disease 0 8.756052011449356e-06
- I-Disease 0 1.5142991287575569e-05
coenzyme I-Disease 0 6.7999390012118965e-06
A I-Disease 0 0.00011591315706027672
dehydrogenase I-Disease 0 0.0002548608463257551
deficiency I-Disease 1 0.9206308722496033
. O 0 3.7933909879939165e-06

Very B-Disease 0 5.7565288443583995e-05
- I-Disease 0 8.586356125306338e-05
long I-Disease 0 1.929209247464314e-05
- I-Disease 0 3.0358523872564547e-05
chain I-Disease 0 1.3288484296936076e-05
acyl I-Disease 0 3.6237554468243616e-06
- I-Disease 0 1.6589511915299227e-06
coenzyme I-Disease 0 9.972436600946821e-07
A I-Disease 0 1.9881772459484637e-06
dehydrogenase I-Disease 0 7.479889063688461e-07
( I-Disease 0 2.3739004006984032e-07
VLCAD I-Disease 0 0.0009063376346603036
) I-Disease 0 1.6238677744695451e-06
deficiency I-Disease 1 0.7070990800857544
is O 0 1.96292305076895e-07
a O 0 5.818609452035162e-07
disorder O 0 0.00033345705014653504
of O 0 4.812172846868634e-05
fatty O 0 2.114452036039438e-05
acid O 0 6.792568569835566e-07
beta O 0 4.4977488755648665e-07
oxidation O 0 2.2944341537822766e-07
that O 0 4.599305469810133e-08
reportedly O 0 7.330361881940917e-07
has O 0 6.348172831849297e-08
high O 0 1.4406692798729637e-06
rates O 0 2.324619430282837e-07
of O 0 2.805623466883844e-07
morbidity O 0 0.3321017026901245
and O 0 1.6442259038740303e-06
mortality O 0 0.0021920125000178814
. O 0 4.360666480351938e-06

We O 0 6.321220098470803e-06
describe O 0 2.1632458810927346e-06
the O 0 1.0004844170907745e-06
outcome O 0 8.031601055336068e-07
of O 0 5.810242100778851e-07
a O 0 4.522812275808974e-07
5 O 0 7.504139603042859e-07
- O 0 8.889714422366524e-07
year O 0 8.219956271204865e-07
- O 0 8.10493759217934e-07
old O 0 2.988375854329206e-06
girl O 0 2.64268669525336e-06
with O 0 2.12279928746284e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 6.417725444407552e-07
was O 0 4.424469352670712e-06
first O 0 1.9139477558383078e-07
seen O 0 2.4508076990059635e-07
at O 0 2.2242321051635372e-07
5 O 0 5.2320039856113e-08
months O 0 2.431414714010316e-08
of O 0 2.4384831931456574e-08
age O 0 2.4303534473801847e-07
with O 0 2.5161727990052896e-07
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999734163284302
hepatomegaly B-Disease 1 1.0
, O 1 0.9993622899055481
encephalopathy B-Disease 1 0.9999998807907104
, O 0 3.1880149435892235e-06
and O 0 1.5338799130404368e-05
hypotonia B-Disease 1 0.9954487681388855
. O 0 3.192385338479653e-05

Biochemical O 0 0.0038208733312785625
studies O 0 0.000474155240226537
indicated O 1 0.9984385371208191
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 1 0.5174764394760132
by O 0 6.030689405633893e-07
a O 0 9.69155280472478e-07
stable O 0 3.1294678137783194e-06
yet O 0 2.2306984703845956e-07
inactive O 0 5.703472652385244e-06
enzyme O 0 1.9017516024177894e-06
. O 0 9.890453611660632e-07

Molecular O 0 0.0002055255463346839
genetic O 0 1.1544768312887754e-05
analysis O 0 3.605035090004094e-06
of O 0 4.193728727841517e-06
her O 0 9.567355846229475e-06
VLCAD O 1 0.9414162635803223
gene O 0 5.6760227380436845e-06
revealed O 0 1.134337162511656e-05
a O 0 4.358142632554518e-06
T1372C O 0 6.3063416746445e-05
( O 0 6.906725502631161e-07
F458L O 0 9.572074304742273e-06
) O 0 9.093302111295998e-08
missense O 0 1.6072101516328985e-06
mutation O 0 3.0081343993515475e-07
and O 0 4.4074957372686185e-07
a O 0 7.1193435360328294e-06
1668 O 0 0.32327523827552795
ACAG O 0 0.00677206227555871
1669 O 0 0.0006320622051134706
splice O 0 1.792475813999772e-05
site O 0 5.334887646313291e-06
mutation O 0 4.190518666291609e-06
. O 0 5.008229891245719e-06

After O 0 8.500843978254125e-05
initial O 0 1.9373675968381576e-05
treatment O 0 1.9792592865996994e-05
with O 0 5.726865310862195e-07
intravenous O 0 4.2988740460714325e-05
glucose O 0 2.797741035465151e-05
and O 0 1.2588700428750599e-06
carnitine O 0 2.6285146304871887e-05
, O 0 1.3462377523865143e-07
the O 0 2.521962585433357e-07
patient O 0 7.457992978743277e-07
has O 0 2.653806632224587e-07
thrived O 0 1.409880837854871e-06
on O 0 8.014270633793785e-07
a O 0 7.029360062915657e-07
low O 0 4.37029621025431e-06
- O 0 1.694805291663215e-06
fat O 0 1.5353725757449865e-06
diet O 0 1.4844260931567987e-07
supplemented O 0 3.906507828332906e-08
with O 0 2.3189041797877508e-08
medium O 0 5.891336627428245e-07
- O 0 1.5992625321814558e-06
chain O 0 1.4442266547121108e-06
triglyceride O 0 5.674095518770628e-06
oil O 0 2.5127080789388856e-06
and O 0 1.3385577801727777e-07
carnitine O 0 1.2247483937244397e-05
and O 0 2.219455979002305e-07
avoidance O 0 1.7125250451499596e-05
of O 0 1.5937805073917843e-05
fasting O 0 9.368468454340473e-05
. O 0 3.494689963190467e-06

Her O 0 0.0013829157687723637
ventricular O 1 0.9999978542327881
hypertrophy O 1 0.9586557745933533
resolved O 0 5.401497219281737e-06
significantly O 0 3.1476852768719255e-07
over O 0 1.517576180276592e-07
1 O 0 2.8528648954306846e-07
year O 0 1.2689572770341329e-07
, O 0 2.060533610404036e-08
and O 0 5.8533672131488856e-08
cognitively O 0 1.4283759810496122e-06
, O 0 2.0285416013621216e-08
she O 0 3.431068407167004e-08
is O 0 1.977238817119087e-08
in O 0 3.0266601669382e-08
the O 0 6.837042576535168e-08
superior O 0 6.403407155630703e-07
range O 0 4.32844274200761e-07
for O 0 1.8525919642797817e-07
age O 0 3.8501784729305655e-06
. O 0 3.665932126750704e-06

Clinical O 0 0.00019653049821499735
recognition O 0 3.1631836463930085e-05
of O 1 0.9700259566307068
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.0417149951535976e-06
important O 0 8.047651078868512e-08
because O 0 1.6116590728643132e-08
it O 0 5.083435006270065e-09
is O 0 1.1897372864666522e-08
one O 0 8.833352715953424e-09
of O 0 7.428111103990886e-08
the O 0 1.8310103655494459e-07
few O 0 1.1291517409972585e-07
directly O 0 9.288012847719074e-07
treatable O 0 0.2508253753185272
causes O 0 4.8928381147561595e-05
of O 1 0.7500895261764526
cardiomyopathy B-Disease 1 1.0
in O 0 1.753748074406758e-05
children O 0 1.920938302646391e-06
. O 0 6.331256372504868e-07
. O 0 2.717068582569482e-06

Cloning O 0 4.113736213184893e-05
of O 0 5.145811428519664e-06
a O 0 1.958044776984025e-06
novel O 0 1.1884420700880582e-06
member O 0 2.966371539514512e-07
of O 0 9.792991022550268e-07
the O 0 1.7925275415109354e-06
low O 0 3.122870475635864e-05
- O 0 4.12366625823779e-06
density O 0 6.075298188079614e-06
lipoprotein O 0 0.0006959165330044925
receptor O 0 8.84147229953669e-05
family O 0 3.9076667235349305e-06
. O 0 3.763597760553239e-06

A O 0 0.0001058918351191096
gene O 0 6.583152753592003e-06
encoding O 0 1.9015049019799335e-06
a O 0 1.714412064757198e-06
novel O 0 1.2129340802857769e-06
transmembrane O 0 4.575913408189081e-06
protein O 0 1.4461866157944314e-06
was O 0 1.4813773532296182e-06
identified O 0 3.795891245772509e-08
by O 0 1.4182234053805587e-08
DNA O 0 3.120890923469233e-08
sequence O 0 3.358518441132219e-08
analysis O 0 2.824657308053702e-08
within O 0 4.454858526514727e-08
the O 0 4.875908530266315e-07
insulin B-Disease 0 0.0006024229805916548
- I-Disease 0 0.21912109851837158
dependent I-Disease 1 0.5804458260536194
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.5408586477860808e-06
IDDM B-Disease 0 0.0008336070459336042
) O 0 3.3342135452585353e-07
locus O 0 1.0756432857306208e-05
IDDM4 O 0 0.00011794360761996359
on O 0 1.0059713531518355e-05
chromosome O 0 0.0003285820712335408
11q13 O 0 0.0004606126749422401
. O 0 1.3683598808711395e-05

Based O 0 2.2213218471733853e-05
on O 0 5.967498509562574e-06
its O 0 7.070102014949953e-07
chromosomal O 0 7.764798647258431e-05
position O 0 6.851533271401422e-06
, O 0 8.315741695241741e-08
this O 0 1.6798157531638935e-08
gene O 0 3.9895791559274585e-08
is O 0 2.09697006425813e-08
a O 0 4.610125969861656e-08
candidate O 0 2.8745839486532532e-08
for O 0 1.736334986901511e-08
conferring O 0 2.020715783146443e-06
susceptibility O 0 0.00464641535654664
to O 0 1.293577497563092e-05
diabetes B-Disease 1 0.9999990463256836
. O 0 1.6571832020417787e-05

The O 0 6.312598998192698e-05
gene O 0 1.4823134733887855e-05
, O 0 2.6778698156704195e-06
termed O 0 2.292791941727046e-05
low O 0 1.7262509572901763e-05
- O 0 1.7443037449993426e-06
density O 0 8.224535577028291e-07
lipoprotein O 0 6.9052307480887976e-06
receptor O 0 2.341045274079079e-06
related O 0 4.4572729507308395e-07
protein O 0 7.979882070685562e-07
5 O 0 1.086116867554665e-06
( O 0 1.123860826623968e-07
LRP5 O 0 8.282915587187745e-06
) O 0 3.3894206552531614e-08
, O 0 2.8427310283518636e-08
encodes O 0 1.2646539460092754e-07
a O 0 3.333704796659731e-07
protein O 0 7.565504915874044e-07
of O 0 4.949915364704793e-06
1615 O 0 0.00035790877882391214
amino O 0 7.55211146952206e-07
acids O 0 9.003885992342475e-08
that O 0 6.186088530313327e-09
contains O 0 9.506694098604385e-09
conserved O 0 7.17458163990159e-08
modules O 0 1.258342763321707e-07
which O 0 8.529762673958885e-09
are O 0 3.384748037404961e-09
characteristic O 0 3.3357459017224755e-08
of O 0 2.3195326548375306e-07
the O 0 5.768864639321691e-07
low O 0 5.934740329394117e-06
- O 0 9.039528094945126e-07
density O 0 2.469784931236063e-06
lipoprotein O 0 0.00010514965106267482
( O 0 8.918067351260106e-07
LDL O 0 0.0010016522137448192
) O 0 6.966891987758572e-07
receptor O 0 9.219565072271507e-06
family O 0 1.8260699334859964e-06
. O 0 2.048436726909131e-06

These O 0 2.437647481201566e-06
modules O 0 1.0473917427589186e-05
include O 0 5.906030651203764e-07
a O 0 1.1720919701474486e-06
putative O 0 6.874347945995396e-06
signal O 0 5.533772764465539e-06
peptide O 0 4.448330059858563e-07
for O 0 4.828569899473223e-08
protein O 0 4.3468347143971187e-07
export O 0 1.7810663166528684e-06
, O 0 1.0672350470031233e-07
four O 0 1.7327165835467895e-07
epidermal O 0 6.974297320994083e-06
growth O 0 2.8690408271359047e-06
factor O 0 5.084010012978979e-07
( O 0 1.0794713745099216e-07
EGF O 0 5.203837190492777e-06
) O 0 7.842417204528829e-08
repeats O 0 1.7866960888568428e-07
with O 0 4.4982591873576894e-08
associated O 0 8.451867188341566e-07
spacer O 0 4.879545940639218e-06
domains O 0 1.2429372873157263e-06
, O 0 2.2233415108985355e-07
three O 0 1.8706599291817838e-07
LDL O 0 6.595741433557123e-05
- O 0 3.7543134112638654e-06
receptor O 0 4.2212027437926736e-06
( O 0 2.365486864164268e-07
LDLR O 0 2.1583458874374628e-05
) O 0 6.419929121648238e-08
repeats O 0 2.541997048410849e-07
, O 0 7.912478139360246e-08
a O 0 1.3535614584725408e-07
single O 0 1.0936362571101199e-07
transmembrane O 0 1.3653598216478713e-06
spanning O 0 9.511428515907028e-07
domain O 0 4.3213734102209855e-07
, O 0 6.731301027684822e-08
and O 0 1.0915543668943428e-07
a O 0 1.2090305290257675e-06
cytoplasmic O 0 1.0517579539737199e-05
domain O 0 9.627653525967617e-06
. O 0 3.7348008845583536e-06

The O 0 1.5339208403020166e-05
encoded O 0 2.2391864149540197e-06
protein O 0 2.629373057061457e-06
has O 0 1.5492057059418585e-07
a O 0 1.3249794506009493e-07
unique O 0 4.0454093408470726e-08
organization O 0 2.620031409605872e-07
of O 0 2.5277900022047106e-06
EGF O 0 0.0001758072612574324
and O 0 7.339749572565779e-07
LDLR O 0 0.00028379270224832
repeats O 0 1.48051003634464e-06
; O 0 6.051059386891211e-08
therefore O 0 7.375001587206498e-08
, O 0 7.515240696420733e-08
LRP5 O 0 2.6653631721273996e-05
likely O 0 1.051495033266292e-07
represents O 0 5.6039962004206245e-08
a O 0 4.841305667468987e-08
new O 0 1.914308711548074e-08
category O 0 1.1457668591674519e-07
of O 0 3.6535800518322503e-07
the O 0 3.0765575047553284e-06
LDLR O 0 0.002397232223302126
family O 0 4.387049102660967e-06
. O 0 5.321300250216154e-06

Both O 0 3.6735124012921005e-05
human O 0 1.7691820175969042e-05
and O 0 5.645563760481309e-06
mouse O 0 2.1906516849412583e-05
LRP5 O 0 0.0002340456412639469
cDNAs O 0 8.81114465300925e-06
have O 0 1.183462856602091e-07
been O 0 1.5219242754938023e-07
isolated O 0 3.141990134736261e-07
and O 0 6.028446364325646e-08
the O 0 1.7715278488594777e-07
encoded O 0 8.985323063370743e-08
mature O 0 3.505513390678061e-08
proteins O 0 1.1046083159271802e-08
are O 0 2.983692848346209e-09
95 O 0 3.149985161599034e-08
% O 0 7.1037846716137665e-09
identical O 0 8.79972006373464e-09
, O 0 1.1883084738428806e-08
indicating O 0 1.526376394167528e-07
a O 0 4.018056287691252e-08
high O 0 3.098305683124636e-07
degree O 0 5.062045147496974e-07
of O 0 4.1350850210619683e-07
evolutionary O 0 1.1251449905103073e-06
conservation O 0 3.1514159104517603e-07
. O 0 9.606952033891503e-08
. O 0 7.85900624578062e-07

The O 0 0.0002169371146010235
APC B-Disease 0 0.00047648136387579143
variants O 0 1.4049619494471699e-05
I1307K O 0 0.0002966933243442327
and O 0 2.560867187639815e-06
E1317Q O 0 0.0005579755525104702
are O 0 3.716818355314899e-07
associated O 0 4.122357040614588e-06
with O 0 0.00021523241593968123
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.56311647919938e-05
but O 0 2.7683014991453092e-08
not O 0 1.2941401728028268e-08
always O 0 7.872387186580454e-09
with O 0 1.504852598088746e-08
a O 0 4.6486462679240503e-07
family O 0 3.715407501658774e-07
history O 0 4.021705535706133e-06
. O 0 6.695448973914608e-06

Classical O 0 0.001961032161489129
familial B-Disease 1 0.9999994039535522
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.11147008836269379
FAP B-Disease 1 0.9998941421508789
) O 0 1.571288294144324e-06
is O 0 4.28871743451964e-07
a O 0 1.7555649947098573e-06
high O 1 0.7683247923851013
- O 1 0.869395911693573
penetrance O 1 0.999962329864502
autosomal B-Disease 1 0.998094379901886
dominant I-Disease 1 0.5603472590446472
disease I-Disease 0 0.07725217193365097
that O 0 5.980688655427002e-08
predisposes O 0 8.524868349013559e-07
to O 0 2.8534651974609915e-08
hundreds O 0 9.360737607266856e-08
or O 0 5.664649549430578e-08
thousands O 0 8.372607140927357e-08
of O 0 0.00023192510707303882
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.3237665295600891
carcinoma I-Disease 1 1.0
and O 0 7.681566671635665e-07
that O 0 6.182197864745831e-08
results O 0 1.0749553069899775e-07
from O 0 8.928689254616984e-08
truncating O 0 9.81424250312557e-07
mutations O 0 7.60000062882682e-08
in O 0 2.2979729408234562e-07
the O 0 1.9041399355046451e-06
APC B-Disease 0 3.659142385004088e-05
gene O 0 3.9777678466634825e-06
. O 0 4.320336756791221e-06

A O 0 9.594263246981427e-05
variant O 0 1.8551781977294013e-05
of O 0 1.1317158168822061e-05
FAP B-Disease 0 0.0011407732963562012
is O 0 4.082981831743382e-06
attenuated B-Disease 0 0.0004503125965129584
adenomatous I-Disease 1 0.9999896287918091
polyposis I-Disease 1 0.9999924898147583
coli I-Disease 1 0.9999871253967285
, O 0 2.01098032448499e-06
which O 0 2.010760624671093e-07
results O 0 7.057282118694275e-07
from O 0 9.132791660704243e-07
germ O 0 0.03268285468220711
- O 0 3.1191941616270924e-06
line O 0 9.589218734618044e-07
mutations O 0 3.2137368322082693e-08
in O 0 6.467023894174417e-08
the O 0 9.658524646738442e-08
5 O 0 1.1226845941791908e-07
and O 0 1.685515726990161e-08
3 O 0 1.856902684949091e-07
regions O 0 4.0045982530045876e-08
of O 0 7.191624717961531e-07
the O 0 8.806574442132842e-06
APC B-Disease 0 8.113179501378909e-05
gene O 0 4.122030986764003e-06
. O 0 3.427204546824214e-06

Attenuated B-Disease 1 0.999854326248169
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 0.041564252227544785
have O 0 1.430390625500877e-06
" O 0 5.168750703887781e-06
multiple O 0 6.61530020806822e-06
" O 1 0.9983510971069336
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 2.6818617016033386e-07
typically O 0 1.5865031954831466e-08
fewer O 0 5.014484827370325e-09
than O 0 9.528533517766391e-09
100 O 0 1.207841933137388e-07
) O 0 1.818733608160983e-08
without O 0 2.296784806787855e-08
the O 0 3.141492754821229e-07
florid O 0 1.0489492524357047e-05
phenotype O 0 1.473399720453017e-06
of O 0 1.5105226793821203e-06
classical O 0 1.0547653801040724e-05
FAP B-Disease 0 7.749900396447629e-05
. O 0 4.666952463594498e-06

Another O 0 5.0347414799034595e-05
group O 0 2.724216756178066e-06
of O 0 1.0195517461397685e-06
patients O 0 3.7352603499130055e-07
with O 0 9.467088801784485e-08
multiple O 0 5.286960004013963e-06
adenomas B-Disease 1 0.9999717473983765
has O 0 4.644467423986498e-07
no O 0 5.182691253935445e-08
mutations O 0 5.536130842642706e-08
in O 0 1.8120046263447875e-07
the O 0 4.584827877351927e-07
APC B-Disease 0 2.5361205189255998e-06
gene O 0 1.6900071386771742e-07
, O 0 5.079163400978359e-08
and O 0 3.456521469047402e-08
their O 0 4.396907371528869e-08
phenotype O 0 2.937313411166542e-06
probably O 0 2.912830154855328e-07
results O 0 8.196427359052905e-08
from O 0 2.6716449497143913e-08
variation O 0 9.86107124845148e-08
at O 0 7.533265602432948e-07
a O 0 1.2696425244485e-07
locus O 0 9.576634738550638e-07
, O 0 6.772394556264771e-08
or O 0 5.077807685438529e-08
loci O 0 4.798914119419351e-07
, O 0 3.5432517364597516e-08
elsewhere O 0 4.175106127490835e-08
in O 0 3.820223426487246e-08
the O 0 6.923033311068139e-07
genome O 0 6.076335466786986e-06
. O 0 3.754592853510985e-06

Recently O 0 0.00013490808487404138
, O 0 2.140799779226654e-06
however O 0 2.864945543024078e-07
, O 0 5.8227900723295534e-08
a O 0 1.566382366036123e-07
missense O 0 1.0337552112105186e-06
variant O 0 1.1713744925145875e-06
of O 0 9.291502465202939e-06
APC B-Disease 0 6.606694660149515e-05
( O 0 3.863685549276852e-07
I1307K O 0 1.0887243661272805e-05
) O 0 5.587837037523968e-08
was O 0 4.3064230226264044e-07
described O 0 4.7566665273279796e-08
that O 0 3.588759067696401e-09
confers O 0 1.384715773156131e-07
an O 0 7.952785097131709e-08
increased O 0 2.871022616091068e-06
risk O 0 1.0285373718943447e-05
of O 1 0.9662293195724487
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 6.728785592713393e-06
including O 0 7.034483360257582e-07
multiple O 0 4.522994913713774e-06
adenomas B-Disease 1 0.9968528151512146
, O 0 1.6739805914767203e-06
in O 0 3.689325467348681e-06
Ashkenazim O 0 0.0002084129664581269
. O 0 6.686285814794246e-06

We O 0 3.5365885651117424e-06
have O 0 2.0155871993665642e-07
studied O 0 7.300997140191612e-07
a O 0 2.3146736793933087e-07
set O 0 1.6419696180491883e-07
of O 0 2.805091128266213e-07
164 O 0 5.3673652473662514e-06
patients O 0 2.68288005145223e-07
with O 0 2.9970243531352025e-07
multiple O 1 0.9022584557533264
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.36103370785713196
/ I-Disease 1 0.9996078610420227
or I-Disease 0 5.1731574785662815e-05
carcinoma I-Disease 1 1.0
and O 0 2.216499979112996e-06
analyzed O 0 2.168695118598407e-06
codons O 0 5.2332347877381835e-06
1263 O 0 4.042293949169107e-05
- O 0 3.849000222544419e-06
1377 O 0 2.235532519989647e-05
( O 0 2.10966362601539e-07
exon O 0 7.032819553387526e-07
15G O 0 2.6988413992512506e-06
) O 0 2.98747551141787e-08
of O 0 2.168669084312569e-07
the O 0 3.1481778250963544e-07
APC B-Disease 0 2.5206356895068893e-06
gene O 0 2.0870690775609546e-07
for O 0 3.8567938531741675e-07
germ O 1 0.8380550742149353
- O 0 5.807420893688686e-05
line O 0 2.1196323359617963e-05
variants O 0 1.929000973177608e-06
. O 0 2.0058280369994463e-06

Three O 0 1.6442369087599218e-05
patients O 0 2.9895559237047564e-06
with O 0 3.329418802877626e-07
the O 0 2.9131044811947504e-06
I1307K O 0 3.141460911137983e-05
allele O 0 6.285077915890724e-07
were O 0 3.051871431125619e-07
detected O 0 3.2907556146710704e-07
, O 0 2.366553530919191e-08
each O 0 9.09531117088136e-09
of O 0 6.991132295297575e-07
Ashkenazi O 0 0.0002590214426163584
descent O 0 0.00028014311101287603
. O 0 7.529225058533484e-06

Four O 0 4.1045666876016185e-05
patients O 0 8.42749977891799e-06
had O 0 1.894013439596165e-05
a O 0 3.174522134941071e-05
germ O 1 0.9899481534957886
- O 0 6.174408918013796e-05
line O 0 2.1307203496689908e-05
E1317Q O 0 1.5303237887565047e-05
missense O 0 2.2560666366189253e-06
variant O 0 5.371996394387679e-07
of O 0 1.5077722537171212e-06
APC O 0 3.963662038586335e-06
that O 0 6.555209353109603e-08
was O 0 1.1020640613423893e-06
not O 0 2.140059152111462e-08
present O 0 7.033276716583714e-08
in O 0 1.4978232343310083e-07
controls O 0 5.660037345478486e-07
; O 0 4.62723406258192e-08
one O 0 3.524782599129139e-08
of O 0 7.011123415168186e-08
these O 0 9.974109538291032e-09
individuals O 0 1.2004529814646503e-08
had O 0 3.779852875140932e-07
an O 0 1.1778791275673939e-07
unusually O 0 3.5600729120233154e-07
large O 0 6.372265204390715e-08
number O 0 1.2544545313630806e-07
of O 0 2.552817932155449e-06
metaplastic B-Disease 0 0.00029729530797339976
polyps I-Disease 0 4.179295865469612e-05
of I-Disease 0 5.390196292864857e-06
the I-Disease 0 1.5439298294950277e-05
colorectum I-Disease 0 0.00042432561167515814
. O 0 1.0928228221018799e-05

There O 0 5.260179023025557e-06
is O 0 3.7939807384645974e-07
increasing O 0 1.8119372668934375e-07
evidence O 0 1.621215801606013e-07
that O 0 4.147516818875374e-08
there O 0 5.951625681177575e-08
exist O 0 2.78329082448181e-07
germ O 0 0.001832657610066235
- O 0 4.987482498108875e-06
line O 0 9.53902599576395e-07
variants O 0 3.424759142944822e-08
of O 0 2.0493597219228832e-07
the O 0 4.4680660948870354e-07
APC B-Disease 0 1.8190287391917082e-06
gene O 0 2.755563599521338e-08
that O 0 7.095294130010643e-09
predispose O 0 2.8980258548472193e-07
to O 0 2.297104551018947e-08
the O 0 1.0555761775776773e-07
development O 0 3.4403089443912904e-07
of O 0 2.671992206160212e-06
multiple O 1 0.9991455078125
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9997890591621399
carcinoma I-Disease 1 1.0
, O 0 2.317738108104095e-06
but O 0 2.3357008771540677e-08
without O 0 2.982289259989557e-08
the O 0 2.0283756896333216e-07
florid O 0 3.895220743288519e-06
phenotype O 0 5.055359224570566e-07
of O 0 3.7094102367518644e-07
classical O 0 2.459006964272703e-06
FAP B-Disease 0 7.27403585187858e-06
, O 0 2.8350958913847535e-08
and O 0 4.165797040656116e-09
possibly O 0 1.3878246107879022e-08
with O 0 3.444935670060545e-09
importance O 0 7.562056794085947e-07
for O 0 0.0006627854891121387
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 6.864487659186125e-05
in O 0 2.3116888314689277e-07
the O 0 1.5436312139627262e-07
general O 0 3.8658970424876316e-07
population O 0 4.5031779194459887e-08
. O 0 1.597716874357502e-07
. O 0 1.5226282812363934e-06

Genomic O 0 0.0002053422067547217
structure O 0 1.157389397121733e-05
of O 0 2.268586513309856e-06
the O 0 4.713910584541736e-06
human O 0 0.39744332432746887
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.16851139068603516
CLD B-Disease 1 0.9999817609786987
) O 0 1.7665757923168712e-06
gene O 0 4.651591098081553e-06
. O 0 4.263598839315819e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.014293155632913113
CLD B-Disease 1 0.9999383687973022
) O 0 5.048734124102339e-07
is O 0 5.8704515026875015e-08
caused O 0 3.250953284350544e-07
by O 0 1.2435136476085518e-08
mutations O 0 1.6374949396436023e-08
in O 0 3.8900761722970856e-08
a O 0 8.160097308973491e-08
gene O 0 5.704332295408676e-08
which O 0 6.646600070325803e-08
encodes O 0 1.969896402442828e-06
an O 0 5.121156846144004e-06
intestinal O 1 0.9999996423721313
anion O 0 0.3537614047527313
transporter O 0 0.09945807605981827
. O 0 9.75376406131545e-06

We O 0 3.060496601392515e-05
report O 0 5.333107765181921e-06
here O 0 2.4250238084277953e-07
the O 0 1.6127160051837564e-07
complete O 0 3.1345467732535326e-07
genomic O 0 1.3027334944126778e-06
organization O 0 5.637917297462991e-07
of O 0 8.053683018260926e-07
the O 0 1.995840875679278e-06
human O 0 5.052634151070379e-06
CLD B-Disease 0 0.0002237416774732992
gene O 0 4.461764149255032e-07
which O 0 8.187240041479527e-08
spans O 0 6.10969607350853e-07
approximately O 0 2.12005488720024e-07
39kb O 0 2.6497020826354856e-06
, O 0 6.188144396901407e-08
and O 0 7.945158841948796e-08
comprises O 0 4.7603157327102963e-07
21 O 0 6.968713023525197e-06
exons O 0 3.0194642022252083e-05
. O 0 9.79552623903146e-06

All O 0 1.9835975763271563e-05
exon O 0 9.847617911873385e-05
/ O 0 2.8361124350340106e-05
intron O 0 3.540584657457657e-05
boundaries O 0 7.44352689707739e-07
conform O 0 5.214420752963633e-07
to O 0 1.3642998908380832e-07
the O 0 1.2349123608146328e-06
GT O 0 3.979288521804847e-05
/ O 0 3.136157101835124e-05
AG O 0 0.00029336081934161484
rule O 0 4.772488864546176e-06
. O 0 3.7205811622698093e-06

An O 0 1.496620006946614e-05
analysis O 0 2.2535141397383995e-06
of O 0 1.525308221062005e-06
the O 0 1.5938923070279998e-06
putative O 0 1.6939722627284937e-05
promoter O 0 9.368189239467029e-06
region O 0 1.1044023295880834e-07
sequence O 0 1.2164377949375194e-07
shows O 0 2.6089207949553384e-07
a O 0 1.987411451409571e-06
putative O 0 0.00010587407450657338
TATA O 0 0.007695140782743692
box O 0 4.163871835771715e-06
and O 0 1.731315819597512e-07
predicts O 0 1.3492108337231912e-06
multiple O 0 1.884465348211961e-07
transcription O 0 9.2007858256693e-06
factor O 0 1.0667725973689812e-06
binding O 0 9.594881476004957e-07
sites O 0 2.366207127124653e-06
. O 0 2.7503031105879927e-06

The O 0 2.1202793504926376e-05
genomic O 0 2.3228863938129507e-05
structure O 0 7.18687897460768e-06
was O 0 8.018973858270328e-06
determined O 0 2.1692005702789174e-07
using O 0 4.7496769184363075e-08
DNA O 0 2.3018618833248183e-07
from O 0 1.4102477052801987e-07
several O 0 3.046932661732171e-08
sources O 0 4.7424709492815964e-08
including O 0 3.583706131848885e-08
multiple O 0 1.507389839616735e-07
large O 0 1.929004611156415e-06
- O 0 2.035926081589423e-05
insert O 0 1.2980110568605596e-06
libaries O 0 2.7597723146755015e-06
and O 0 3.639682688572066e-08
genomic O 0 4.959953798788774e-07
DNA O 0 3.394189036498574e-07
from O 0 5.375363230086805e-07
Finnish O 0 0.00017966651648748666
CLD B-Disease 1 0.8440097570419312
patients O 0 3.520661493894295e-06
and O 0 1.9791423255810514e-06
controls O 0 5.529147892957553e-05
. O 0 6.836906322860159e-06

Exon O 0 0.00034874698030762374
- O 0 2.0699773813248612e-05
specific O 0 2.2625425799560617e-07
primers O 0 3.059023811147199e-06
developed O 0 1.2288415973671363e-07
in O 0 1.8195317252889254e-08
this O 0 3.3523406273161527e-09
study O 0 5.0035739995735184e-09
will O 0 2.1758661539195145e-09
facilitate O 0 1.220837386739504e-08
mutation O 0 1.7088678916366007e-08
screening O 0 3.759016919957503e-08
studies O 0 5.781533474191747e-08
of O 0 1.9402281736802252e-07
patients O 0 1.8680213997868123e-07
with O 0 1.822699999820543e-07
the O 0 3.330218169139698e-05
disease O 1 0.9898093938827515
. O 0 7.89618025009986e-06

Genomic O 0 0.00012323888950049877
sequencing O 0 4.765173071064055e-05
of O 0 1.7692935216473415e-05
a O 0 2.5286066374974325e-05
BAC O 0 0.0019105231622233987
clone O 0 0.00011916848598048091
H O 1 0.9999935626983643
_ O 0 8.780809821473667e-07
RG364P16 O 0 1.2764361599693075e-05
revealed O 0 1.4772408576391172e-06
the O 0 3.1008005407784367e-07
presence O 0 2.1132642302745808e-07
of O 0 4.5361946376942797e-07
another O 0 3.169814419834438e-07
, O 0 4.211231896533718e-08
highly O 0 3.277197180295843e-08
homologous O 0 3.1692820812168065e-08
gene O 0 6.625374027180442e-08
3 O 0 4.2165288505202625e-07
of O 0 7.812898275005864e-07
the O 0 1.7266031591134379e-06
CLD B-Disease 0 0.00012587601668201387
gene O 0 2.2960738021993166e-07
, O 0 2.313518621122057e-08
with O 0 5.767410105050885e-09
a O 0 4.923786178778755e-08
similar O 0 1.9083882918380368e-08
genomic O 0 4.3639639102366345e-07
structure O 0 7.789611231601157e-07
, O 0 5.7102106154616195e-08
recently O 0 1.4038471363164717e-07
identified O 0 8.032699128079912e-08
as O 0 2.218123000830019e-07
the O 0 8.286486263386905e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.2263693861314096e-05
( O 0 2.067152763629565e-06
PDS B-Disease 0 0.00016898917965590954
) O 0 3.000633341798675e-07
. O 0 2.3816285477096244e-07
. O 0 1.3605297226604307e-06

The O 0 9.085150668397546e-05
APCI1307K O 0 0.0018936492269858718
allele O 0 1.565880302223377e-05
and O 0 1.2770771036230144e-06
cancer B-Disease 0 0.006207319442182779
risk O 0 1.7614951275390922e-06
in O 0 1.3893296113565157e-07
a O 0 3.1731445915283985e-07
community O 0 7.287050607374113e-08
- O 0 2.477734994954517e-07
based O 0 3.6414188997468955e-08
study O 0 3.285621374971015e-08
of O 0 4.556529518140451e-07
Ashkenazi O 0 5.760130989074241e-06
Jews O 0 3.3675964914436918e-06
. O 0 3.1808024232304888e-06

Mutations O 0 0.0001421486958861351
in O 0 2.7838432288262993e-05
APC O 0 0.00021687691332772374
are O 0 1.7157763920749858e-07
classically O 0 2.5409783120267093e-05
associated O 0 4.112714862003486e-07
with O 0 2.684440971734148e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9918016791343689
FAP B-Disease 1 0.9999982118606567
) O 0 3.5955852695224166e-07
, O 0 6.441356958930555e-08
a O 0 5.929530288995011e-07
highly O 0 0.00015130660904105753
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999600648880005
by O 0 3.814669980783947e-05
multiple O 0 0.01666705682873726
intestinal O 1 1.0
polyps B-Disease 1 0.9999995231628418
and O 0 2.354724301767419e-06
, O 0 1.5304648570690915e-07
without O 0 1.140254468623425e-07
surgical O 1 0.7648119330406189
intervention O 0 7.923704106360674e-05
, O 0 1.2770792068295123e-07
the O 0 1.4291209993189113e-07
development O 0 2.680885017980472e-06
of O 0 0.48036497831344604
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.0005893331253901124
CRC B-Disease 1 0.9999477863311768
) O 0 3.921098141290713e-06
. O 0 6.528559424623381e-06

APC B-Disease 0 0.0033586560748517513
is O 0 1.9803694158326834e-05
a O 0 3.739374369615689e-05
tumour O 1 1.0
- O 0 0.001610844861716032
suppressor O 1 0.9781343340873718
gene O 0 3.8455183926089376e-07
, O 0 7.02378528671943e-08
and O 0 9.28883139295067e-08
somatic O 0 4.139764860155992e-05
loss O 0 0.026716288179159164
occurs O 0 7.749379619781394e-06
in O 0 1.944048926816322e-05
tumours B-Disease 1 1.0
. O 0 2.9512335459003225e-05

The O 0 0.00011820402141893283
germline O 0 0.0011707948287948966
T O 0 0.0003706615825649351
- O 0 7.589709184685489e-06
to O 0 3.850641405733768e-07
- O 0 2.2235033156903228e-06
A O 0 2.5527765501465183e-06
transversion O 0 6.784418928873492e-06
responsible O 0 4.308049312840012e-07
for O 0 2.0571687286974338e-07
the O 0 1.6938649878284195e-06
APC O 0 1.2901354239147622e-05
I1307K O 0 6.480164302047342e-06
allele O 0 2.978185875690542e-07
converts O 0 1.587608693398579e-07
the O 0 1.3194174641739664e-07
wild O 0 1.0628147606439597e-07
- O 0 1.6198681862533704e-07
type O 0 4.601551495397871e-08
sequence O 0 4.654301832829333e-08
to O 0 4.166315648035379e-08
a O 0 2.965063458759687e-06
homopolymer O 0 0.0014079951215535402
tract O 1 0.9694269895553589
( O 0 9.348067351311329e-07
A8 O 0 0.005079933442175388
) O 0 3.324205621879628e-08
that O 0 8.500463444249817e-09
is O 0 4.148142096482843e-08
genetically O 0 2.8902118742735183e-07
unstable O 0 6.903057510498911e-06
and O 0 3.177690075517603e-07
prone O 0 4.18658419221174e-06
to O 0 2.3134133186886174e-07
somatic O 0 5.5283620895352215e-05
mutation O 0 1.3376966307987459e-05
. O 0 6.493229648185661e-06

The O 0 0.00012269671424292028
I1307K O 0 0.0005065086879767478
allele O 0 2.2258573153521866e-05
was O 0 1.8385624571237713e-05
found O 0 7.098030891938834e-07
in O 0 9.69787834037561e-07
6 O 0 2.894978752010502e-05
. O 0 8.276282642327715e-06

1 O 0 2.3703361875959672e-05
% O 0 1.7752463463693857e-06
of O 0 2.458505150571e-06
unselected O 0 0.0001242315338458866
Ashkenazi O 0 8.218645234592259e-06
Jews O 0 1.2844166121794842e-06
and O 0 3.4313310948164144e-07
higher O 0 1.7080521956813755e-06
proportions O 0 8.74109787218913e-07
of O 0 2.023600927714142e-06
Ashkenazim O 0 7.178330179158365e-06
with O 0 8.656756023128764e-08
family O 0 2.2169429314544686e-07
or O 0 1.9932356565277587e-07
personal O 0 1.1739803085220046e-06
histories O 0 7.803701578268374e-07
of O 0 0.00018935523985419422
CRC B-Disease 1 0.9112147092819214
( O 0 4.2938003730341734e-07
ref O 0 2.2041849661036395e-05
. O 0 9.586067051259306e-08
2 O 0 1.4078829053687514e-06
) O 0 4.7230452082658303e-07
. O 0 1.2076684470230248e-06

To O 0 6.97948735250975e-06
evaluate O 0 3.6960025227017468e-06
the O 0 1.167250843536749e-06
role O 0 1.7755730823409976e-06
of O 0 3.2623097467876505e-06
I1307K O 0 9.485843474976718e-05
in O 0 1.5869002254476072e-06
cancer B-Disease 0 4.5582321035908535e-05
, O 0 1.8510237964619591e-07
we O 0 4.644972406708803e-08
genotyped O 0 2.9729094421782065e-06
5 O 0 9.081028338187025e-07
, O 0 2.505806264707644e-07
081 O 0 1.4775869203731418e-05
Ashkenazi O 0 1.4412051996259834e-06
volunteers O 0 1.0035464725888232e-07
in O 0 8.525928052449672e-08
a O 0 3.4567528928164393e-07
community O 0 5.041218855694751e-07
survey O 0 4.396548774820985e-06
. O 0 2.5880749490170274e-06

Risk O 0 0.00016149757720995694
of O 0 1.456977133784676e-05
developing O 0 0.00012576360313687474
colorectal B-Disease 1 1.0
, I-Disease 0 4.7539080696878955e-05
breast I-Disease 0 0.41398298740386963
and I-Disease 0 1.5295413504645694e-06
other I-Disease 0 2.479342242622806e-07
cancers I-Disease 0 0.1428511142730713
were O 0 5.304581009113463e-06
compared O 0 1.515231815574225e-06
between O 0 4.780278004545835e-07
genotyped O 0 3.1267147278413177e-05
I1307K O 0 8.211829481297173e-06
carriers O 0 9.714301540952874e-08
and O 0 1.3226993189618952e-07
non O 0 9.097064435081847e-07
- O 0 2.2434734603393736e-07
carriers O 0 2.2408556787922862e-08
and O 0 1.7158443554876612e-08
their O 0 1.4367595113640164e-08
first O 0 4.871390615335258e-07
- O 0 1.7944962564797606e-06
degree O 0 3.5408280382398516e-05
relatives O 0 4.5958686314406805e-06
. O 0 3.626649004218052e-06

Sperm O 0 6.506762292701751e-05
DNA O 0 1.2470412912080064e-05
analysis O 0 1.9286974293208914e-06
in O 0 1.9689912278408883e-06
a O 0 1.3779691471427213e-05
Friedreich B-Disease 1 0.9993390440940857
ataxia I-Disease 1 0.9999991655349731
premutation O 1 0.9998055100440979
carrier O 0 2.0216244593029842e-05
suggests O 0 8.579905852457159e-07
both O 0 6.814558162204776e-08
meiotic O 0 3.7072989016451174e-06
and O 0 6.556447118555297e-08
mitotic O 0 1.909089178298018e-06
expansion O 0 8.405117455367872e-07
in O 0 2.1747477774169965e-07
the O 0 9.681964456831338e-07
FRDA B-Disease 0 0.00034567443071864545
gene O 0 1.075619729817845e-05
. O 0 6.08612526775687e-06

Friedreich B-Disease 1 0.9999935626983643
ataxia I-Disease 1 0.9999998807907104
is O 0 0.0001219335463247262
usually O 0 3.4977942959812935e-06
caused O 0 1.4294756510935258e-05
by O 0 1.504108553262995e-07
an O 0 7.52987645569192e-08
expansion O 0 7.671317803215061e-07
of O 0 4.2127626898036397e-07
a O 0 1.3271511534185265e-06
GAA O 0 3.2336486128770048e-06
trinucleotide O 0 2.906175723182969e-06
repeat O 0 2.591542624941212e-07
in O 0 1.883335158936461e-07
intron O 0 5.337972197594354e-06
1 O 0 9.970782457457972e-07
of O 0 1.1868721685459604e-06
the O 0 5.702684575226158e-06
FRDA B-Disease 0 0.002367153065279126
gene O 0 8.48030686029233e-06
. O 0 5.058029273641296e-06

Occasionally O 0 3.819245830527507e-05
, O 0 2.483574007783318e-06
a O 0 1.0095167226609192e-06
fully O 0 3.724478858657676e-07
expanded O 0 3.6706654782392434e-07
allele O 0 3.2839307095855474e-07
has O 0 8.33034690117529e-08
been O 0 9.272334011711791e-08
found O 0 4.041152124045766e-08
to O 0 1.67423408470313e-08
arise O 0 1.3705111712170037e-07
from O 0 3.276435052157467e-07
a O 0 4.459602962469944e-07
premutation O 0 5.935736226092558e-06
of O 0 1.1872367622345337e-06
100 O 0 1.7551329847265151e-06
or O 0 2.538983210342849e-07
less O 0 4.807003506357432e-07
triplet O 0 0.00015613561845384538
repeats O 0 2.505538759578485e-05
. O 0 5.997027983539738e-06

We O 0 1.1383316632418428e-05
have O 0 4.750365292238712e-07
examined O 0 6.340585514408303e-07
the O 0 1.538457894412204e-07
sperm O 0 3.01061419349935e-07
DNA O 0 3.025595844974305e-07
of O 0 1.7210252281074645e-06
a O 0 7.5358843787398655e-06
premutation O 0 0.00024009168555494398
carrier O 0 3.154562000418082e-05
. O 0 7.28802024241304e-06

This O 0 1.6510060959262773e-05
mans O 0 8.190886001102626e-05
leucocyte O 0 6.517902511404827e-05
DNA O 0 2.5307713258371223e-06
showed O 0 5.523659638129175e-06
one O 0 1.748230999965017e-07
normal O 0 7.582544867545948e-07
allele O 0 5.32430931343697e-07
and O 0 6.718256173599002e-08
one O 0 2.5246571055959066e-08
allele O 0 4.7960408977587576e-08
of O 0 7.778299959682045e-08
approximately O 0 2.560647089921986e-07
100 O 0 1.4424042547034333e-06
repeats O 0 5.3096005103725474e-06
. O 0 4.1080447772401385e-06

His O 0 6.755087088095024e-05
sperm O 0 1.1894298950210214e-05
showed O 0 4.934146090818103e-06
an O 0 2.4060258851932304e-07
expanded O 0 3.9392287476403e-07
allele O 0 4.0514214560971595e-07
in O 0 2.0411091838923312e-07
a O 0 9.501356430519081e-07
tight O 0 1.5990917745511979e-06
range O 0 3.413132958485221e-07
centering O 0 1.398842300659453e-06
on O 0 2.7250044354332204e-07
a O 0 8.099515014237113e-08
size O 0 2.919918706822955e-08
of O 0 2.757467711944628e-07
approximately O 0 1.657273401178827e-06
320 O 0 8.326585884788074e-06
trinucleotide O 0 5.7153956731781363e-05
repeats O 0 1.3986534213472623e-05
. O 0 4.876410457654856e-06

His O 0 0.00038627878529950976
affected O 0 9.210694406647235e-05
son O 0 0.00032253580866381526
has O 0 1.4298015003078035e-06
repeat O 0 1.0496449931451934e-06
sizes O 0 3.1880043138698966e-07
of O 0 2.371425580349751e-06
1040 O 0 1.3892427887185477e-05
and O 0 1.5748438499940676e-06
540 O 0 5.252118353382684e-05
. O 0 3.2185084819502663e-06

These O 0 1.8598086626298027e-06
data O 0 2.618158077893895e-06
suggest O 0 5.373667022467998e-07
that O 0 8.303538123755061e-08
expansion O 0 9.848569106907235e-07
occurs O 0 5.563758875837266e-08
in O 0 3.108219459591055e-08
two O 0 1.2166601059959703e-08
stages O 0 1.0763893953935622e-07
, O 0 2.77095342227085e-08
the O 0 3.638183443399612e-08
first O 0 5.1369866582717805e-08
during O 0 9.377983900549225e-08
meiosis O 0 9.646079490721604e-08
followed O 0 1.8831627812687657e-07
by O 0 3.8418377812377e-08
a O 0 1.512516263346697e-07
second O 0 1.1141246432089247e-06
mitotic O 0 1.4278638445830438e-05
expansion O 0 1.5215136954793707e-05
. O 0 3.5295397537993267e-06

We O 0 1.3459001820592675e-05
also O 0 1.7538213796797208e-06
show O 0 3.9274425489566056e-07
that O 0 4.9624041764673166e-08
in O 0 5.5020869638156e-08
all O 0 1.6252259982252326e-08
informative O 0 2.7083194709121017e-07
carrier O 0 6.387573421307025e-07
father O 0 6.282225513132289e-07
to O 0 5.664692537266092e-08
affected O 0 2.0023597357976541e-07
child O 0 4.296597921893408e-07
transmissions O 0 1.3048522760072956e-06
, O 0 4.5561034056618155e-08
with O 0 5.934732705270562e-09
the O 0 5.538686664863235e-08
notable O 0 6.708486210982301e-08
exception O 0 5.70081901685171e-08
of O 0 2.0397159516960528e-07
the O 0 3.875073275594332e-07
premutation O 0 4.553794042294612e-06
carrier O 0 3.0279278462330694e-07
, O 0 1.8306710813931204e-08
the O 0 2.681298383322428e-08
expansion O 0 1.9108802007394843e-07
size O 0 6.796839358003126e-08
decreases O 0 1.182016262646357e-06
. O 0 4.893844334219466e-07
. O 0 2.0740028503496433e-06

The O 0 4.125698978896253e-05
R496H O 0 0.00010148040746571496
mutation O 0 2.176167754441849e-06
of O 0 2.0822451460844604e-06
arylsulfatase O 0 0.0002741620410233736
A O 0 6.717603810102446e-06
does O 0 1.3155903388906154e-07
not O 0 2.642739502789482e-07
cause O 0 0.0022264334838837385
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 2.560223038017284e-05

Deficiency B-Disease 1 0.9999884366989136
of I-Disease 0 0.00022260198602452874
arylsulfatase I-Disease 0 0.0830288901925087
A I-Disease 0 0.00023903849069029093
( O 0 2.8685758479696233e-06
ARSA O 0 0.0004254090308677405
) O 0 3.281488432094193e-07
enzyme O 0 1.0791846989377518e-06
activity O 0 5.0780968194885645e-06
causes O 0 3.0350965971592814e-05
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 1.0
( O 0 2.3469949155696668e-05
MLD B-Disease 1 0.9999998807907104
) O 0 2.3144823444454232e-06
. O 0 2.313089908057009e-06

A O 0 5.193621473154053e-05
number O 0 1.6564233646931825e-06
of O 0 5.101249371364247e-06
ARSA O 0 0.0007508078124374151
gene O 0 1.2998494867133559e-06
mutations O 0 9.245504770660773e-07
responsible O 0 2.205981218139641e-06
for O 0 1.2165137377451174e-06
MLD B-Disease 1 1.0
have O 0 3.970324939928105e-07
been O 0 9.710889798952849e-07
identified O 0 1.8034742197414744e-06
. O 0 2.012116055993829e-06

Recently O 0 0.0001300920994253829
, O 0 4.8184683691943064e-06
the O 0 1.951136482603033e-06
R496H O 0 2.16185835597571e-05
mutation O 0 1.1805472013293183e-06
of O 0 3.5024543194595026e-06
ARSA O 0 0.00018931066733784974
was O 0 3.3007204365276266e-06
proposed O 0 1.1588218029601194e-07
to O 0 1.1735730609530037e-08
be O 0 4.1329077049567786e-08
a O 0 1.7351506187424093e-07
cause O 0 1.0117200872628018e-06
of O 0 2.1614170691464096e-05
MLD B-Disease 1 1.0
( O 0 3.0880815415912366e-07
Draghia O 0 9.053565918293316e-06
et O 0 1.1499114407342859e-05
al O 0 9.232182492269203e-06
. O 0 6.574856570296106e-08
, O 0 9.38718187626364e-08
1997 O 0 1.4609066738557885e-06
) O 0 3.752226405140391e-07
. O 0 1.189327576867072e-06

We O 0 6.8212557380320504e-06
have O 0 6.120799866948801e-07
investigated O 0 1.6266623106275802e-06
the O 0 5.281091830511286e-07
R496H O 0 8.166337465809193e-06
mutation O 0 1.3088849470932473e-07
and O 0 7.862786333134864e-08
found O 0 4.05963938021614e-08
this O 0 1.1832964830205128e-08
mutation O 0 8.938487638943116e-08
at O 0 1.0437635182825034e-06
a O 0 1.0016455576078442e-07
relatively O 0 1.9741563050956756e-08
high O 0 2.4264579678856535e-07
frequency O 0 9.273978918145076e-08
in O 0 4.004857956374508e-08
an O 0 8.053746824998598e-08
African O 0 7.299403392835302e-08
American O 0 5.004807235309272e-08
population O 0 6.531942542409297e-09
( O 0 1.2753188727288034e-08
f O 0 2.792101270188141e-07
= O 0 1.3486457817180053e-07
0 O 0 7.675285473851545e-08
. O 0 1.3080372340823487e-08
09 O 0 6.524474542857206e-07
, O 0 2.503023033284535e-08
n O 0 2.5587817731320683e-07
= O 0 6.550747571054671e-07
61 O 0 8.968848987933598e-07
subjects O 0 6.214988843566971e-07
) O 0 8.761763297115976e-07
. O 0 9.894755521600018e-07

The O 0 0.00015814461221452802
ARSA O 0 0.00196833279915154
enzyme O 0 6.894714715599548e-06
activity O 0 2.476790314176469e-06
in O 0 1.0106980141699751e-07
subjects O 0 1.0945920081439908e-07
with O 0 2.9070598372982204e-08
and O 0 1.060676169117869e-07
without O 0 5.8894723764524315e-08
the O 0 2.5127269509539474e-07
R496H O 0 2.849989641617867e-06
mutation O 0 8.258869854671502e-08
was O 0 8.822578365652589e-07
determined O 0 4.039241119357939e-08
and O 0 1.8163138548743518e-08
found O 0 5.4507687252680626e-08
to O 0 4.6226997341136666e-08
be O 0 4.7358903998429014e-07
normal O 0 7.615070444444427e-06
. O 0 4.122392510907957e-06

It O 0 4.704327238869155e-06
is O 0 4.664077550842194e-07
therefore O 0 1.6957949355855817e-07
concluded O 0 5.139407903698157e-07
that O 0 5.122721091765925e-08
the O 0 2.8026923359902867e-07
R496H O 0 5.116870397614548e-06
mutation O 0 2.1465308464030386e-07
of O 0 2.079815885736025e-06
ARSA O 0 0.0003190064453519881
does O 0 3.6268762215740935e-08
not O 0 2.1123932825162228e-08
negatively O 0 1.3711100166347023e-07
influence O 0 1.1785004261355425e-07
the O 0 1.1939478383737878e-07
activity O 0 3.11935593799717e-07
of O 0 3.801035575179412e-07
ARSA O 0 7.263290899572894e-05
and O 0 8.575425880508192e-08
is O 0 4.4749910443897534e-08
not O 0 3.887227961740791e-08
a O 0 5.949037813479663e-07
cause O 0 1.98161415028153e-05
of O 0 0.011829579249024391
MLD B-Disease 1 1.0

Down O 0 0.001205970416776836
- O 0 5.443747795652598e-05
regulation O 0 6.177717750688316e-06
of O 0 2.302404936926905e-06
transmembrane O 0 5.267230881145224e-05
carbonic O 0 9.920863521983847e-05
anhydrases O 0 0.000398939911974594
in O 0 3.57526441803202e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9103519320487976
lines O 0 2.776276005533873e-06
by O 0 1.693647107003926e-07
wild O 0 3.5252739394309174e-07
- O 0 2.323687340322067e-06
type O 0 4.896738118986832e-06
von B-Disease 1 0.9964427351951599
Hippel I-Disease 1 0.9999972581863403
- I-Disease 1 0.9267849922180176
Lindau I-Disease 1 0.9283314347267151
transgenes O 0 0.0003329322789795697
. O 0 6.662035502813524e-06

To O 0 5.740870619774796e-06
discover O 0 2.740563104453031e-06
genes O 0 8.384878356082481e-07
involved O 0 1.4639233540947316e-06
in O 0 1.8816219835571246e-06
von B-Disease 0 0.06960566341876984
Hippel I-Disease 1 0.9999170303344727
- I-Disease 0 0.2991641163825989
Lindau I-Disease 1 0.9159584045410156
( O 0 4.744081707031e-06
VHL B-Disease 0 0.0002540601999498904
) O 0 4.123696157876111e-07
- O 0 1.320994215348037e-06
mediated O 0 4.6657332859467715e-06
carcinogenesis O 0 0.0018976242281496525
, O 0 7.639269483661337e-08
we O 0 3.570177042888645e-08
used O 0 2.4395988020842196e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9969000816345215
lines O 0 1.0434437172079924e-05
stably O 0 4.4669439375866205e-05
transfected O 0 4.421752691996517e-06
with O 0 8.944967788693248e-08
wild O 0 1.2061331062795944e-06
- O 0 7.355975412792759e-06
type O 0 1.8171118426835164e-05
VHL O 0 0.3985421359539032
- O 0 3.171055141137913e-05
expressing O 0 3.5949515222455375e-06
transgenes O 0 4.057089245179668e-05
. O 0 4.71219391329214e-06

Large O 0 2.12364066101145e-05
- O 0 7.794139492034446e-06
scale O 0 4.696142241300549e-06
RNA O 0 4.06374874728499e-06
differential O 0 1.6345793483196758e-06
display O 0 2.3451563890830585e-07
technology O 0 4.865986511504161e-07
applied O 0 8.078454527549184e-08
to O 0 2.4699488676560577e-08
these O 0 2.6231708361024175e-08
cell O 0 1.8056476847050362e-06
lines O 0 2.3708959417945152e-07
identified O 0 5.4058855170069364e-08
several O 0 1.6190041307595493e-08
differentially O 0 5.399639917413879e-07
expressed O 0 7.742110597064311e-08
genes O 0 3.733023490326559e-08
, O 0 4.10971878750388e-08
including O 0 3.8644806465981674e-08
an O 0 1.7226494719579932e-07
alpha O 0 4.27094028054853e-06
carbonic O 0 7.035690032353159e-06
anhydrase O 0 2.099342418659944e-05
gene O 0 1.0825575600392767e-06
, O 0 4.970522127223376e-07
termed O 0 2.3590517230331898e-05
CA12 O 0 0.0008031983743421733
. O 0 8.790982974460348e-06

The O 0 3.167330942233093e-05
deduced O 0 2.367399247305002e-05
protein O 0 2.1094797375553753e-06
sequence O 0 7.266397687999415e-07
was O 0 5.093272648082348e-06
classified O 0 2.9748758834102773e-07
as O 0 3.0330869549288764e-07
a O 0 3.651740883015009e-07
one O 0 3.1250846177499625e-07
- O 0 3.128476919300738e-06
pass O 0 1.4913307495589834e-06
transmembrane O 0 2.564484930189792e-05
CA O 0 2.085333107970655e-06
possessing O 0 1.7675733943178784e-06
an O 0 9.185287694890576e-07
apparently O 0 1.7667695146883489e-06
intact O 0 5.431413114820316e-07
catalytic O 0 5.801250608783448e-07
domain O 0 3.1036822178975854e-07
in O 0 1.393222390788651e-07
the O 0 9.686674502518144e-07
extracellular O 0 5.7436758652329445e-05
CA O 0 1.482503012084635e-05
module O 0 9.789661999093369e-05
. O 0 3.7586262351396726e-06

Reintroduced O 0 0.00016570757725276053
wild O 0 4.3526084482437e-05
- O 0 8.711319242138416e-05
type O 0 5.8072328101843596e-05
VHL B-Disease 0 0.034861356019973755
strongly O 0 2.404125098109944e-06
inhibited O 0 2.4885339371394366e-06
the O 0 1.7464130053213012e-07
overexpression O 0 1.4854883829684695e-06
of O 0 2.4953922661552497e-07
the O 0 2.1570212993538007e-07
CA12 O 0 1.541796518722549e-05
gene O 0 1.099024942163851e-07
in O 0 1.009076129321329e-07
the O 0 1.0606777323118877e-06
parental O 0 0.0606563426554203
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999985694885254
lines O 0 0.00017592162475921214
. O 0 8.982152394310106e-06

Similar O 0 9.26451502891723e-06
results O 0 2.6568757220957195e-06
were O 0 8.340250019500672e-07
obtained O 0 9.632857427277486e-07
with O 0 3.8895532838978397e-07
CA9 O 0 0.00032091079629026353
, O 0 2.2084073236783297e-07
encoding O 0 2.7700664873009373e-07
another O 0 1.0010284086092724e-06
transmembrane O 0 2.3224656615639105e-05
CA O 0 1.8079516621583025e-06
with O 0 1.0936550864926176e-07
an O 0 1.0493847639736487e-06
intact O 0 7.038066087261541e-06
catalytic O 0 1.3668470273842104e-05
domain O 0 1.3120099538355134e-05
. O 0 3.6789608657272765e-06

Although O 0 4.952937160851434e-06
both O 0 7.575237077617203e-07
domains O 0 4.226403234497411e-06
of O 0 4.627773250831524e-06
the O 0 6.164305432321271e-06
VHL B-Disease 0 8.46523471409455e-05
protein O 0 9.801419764698949e-07
contribute O 0 2.5209092768818664e-07
to O 0 1.441189851902891e-07
regulation O 0 9.679896493253182e-07
of O 0 2.8330907753115753e-06
CA12 O 0 0.00020472444884944707
expression O 0 9.909014124787063e-07
, O 0 8.235855375460233e-08
the O 0 2.1166043495668418e-07
elongin O 0 2.2490485207526945e-06
binding O 0 1.8594366224533587e-07
domain O 0 6.105328225203266e-07
alone O 0 1.1423148293943086e-07
could O 0 5.2821491181020974e-08
effectively O 0 4.4735872961609857e-07
regulate O 0 3.397904492885573e-06
CA9 O 0 0.00040787571924738586
expression O 0 1.1005538908648305e-05
. O 0 5.1233009799034335e-06

We O 0 2.5505825760774314e-05
mapped O 0 6.303768896032125e-05
CA12 O 0 0.0011681331088766456
and O 0 1.1242739674344193e-05
CA9 O 0 0.0015636613825336099
loci O 0 9.167310963675845e-06
to O 0 4.4222068140697957e-07
chromosome O 0 6.498713628388941e-05
bands O 0 1.9731491192942485e-05
15q22 O 0 0.0003479949664324522
and O 0 1.0976211342494935e-05
17q21 O 0 0.0011339773191139102
. O 0 1.408390835422324e-05

2 O 0 7.254500087583438e-05
respectively O 0 1.2641932698898017e-05
, O 0 5.78692777253309e-07
regions O 0 4.0959309899335494e-07
prone O 0 3.507424480631016e-06
to O 0 1.0668076555475636e-07
amplification O 0 1.0266616300214082e-05
in O 0 4.6166994138729933e-07
some O 0 2.062913324607507e-07
human O 0 1.4215202099876478e-05
cancers B-Disease 1 0.9925393462181091
. O 0 1.3457576642394997e-05

Additional O 0 2.8414735879778164e-06
experiments O 0 3.030299012607429e-06
are O 0 1.1809598987611025e-07
needed O 0 9.109881915492224e-08
to O 0 2.5021925864621153e-08
define O 0 5.3448214742957134e-08
the O 0 2.9131052770026145e-07
role O 0 3.712474949679745e-07
of O 0 3.403443770366721e-06
CA O 0 2.0771080926351715e-06
IX O 0 0.00019330235954839736
and O 0 1.0451680054757162e-06
CA O 0 2.041044126599445e-06
XII O 0 0.000204849784495309
enzymes O 0 2.7307640948492917e-07
in O 0 1.23295251341915e-07
the O 0 1.5372904726973502e-07
regulation O 0 1.5491112037580024e-07
of O 0 3.610277872212464e-07
pH O 0 1.8136191783924005e-06
in O 0 8.85059208144412e-08
the O 0 1.8523675748838286e-07
extracellular O 0 2.181366426157183e-06
microenvironment O 0 3.3785368032113183e-06
and O 0 2.851115077362465e-08
its O 0 2.1314514597747802e-08
potential O 0 8.150718144861457e-08
impact O 0 3.2059375598691986e-07
on O 0 3.4616259654285386e-06
cancer B-Disease 1 0.590774655342102
cell O 0 0.03140756115317345
growth O 0 4.085750333615579e-05
. O 0 1.5237293382597272e-06

A O 0 5.1298877224326134e-05
gene O 0 5.4412707868323196e-06
encoding O 0 1.8114603790309047e-06
a O 0 1.1048401802327135e-06
transmembrane O 0 1.2000877177342772e-05
protein O 0 1.3851902167516528e-06
is O 0 7.595291151574202e-08
mutated O 0 1.3686042166227708e-07
in O 0 6.730273582888913e-08
patients O 0 6.921686122041137e-07
with O 0 6.676517841697205e-06
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999926090240479
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9999445676803589
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.0153184121008962e-05
. O 0 4.175300091446843e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.5140612125396729
WFS B-Disease 1 0.9999997615814209
; O 0 2.023676825047005e-05
OMIM O 1 0.9998629093170166
222300 O 0 0.0014208859065547585
) O 0 4.7050085072442016e-07
is O 0 1.2425918782810186e-07
an O 0 7.551758471890935e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 0.002434716559946537
by O 0 5.144329406903125e-06
young O 0 1.0622959962347522e-05
- O 0 0.07700207084417343
onset O 1 0.9999998807907104
non O 1 0.9999687671661377
- O 1 0.9995228052139282
immune O 1 0.9974091649055481
insulin B-Disease 1 0.9999270439147949
- I-Disease 1 0.9994344115257263
dependent I-Disease 1 0.9947549104690552
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.07859309017658234
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 0 5.382033123169094e-05

Linkage O 0 0.000717913790140301
to O 0 4.379216534289299e-06
markers O 0 1.1719918802555185e-05
on O 0 9.765510185388848e-06
chromosome O 0 0.0015801528934389353
4p O 1 0.9947633147239685
was O 0 4.1884570237016305e-05
confirmed O 0 1.2071307082806015e-06
in O 0 3.9590611322637415e-07
five O 0 8.133640676533105e-07
families O 0 5.101688884678879e-07
. O 0 3.500907951092813e-06

On O 0 1.2252997294126544e-05
the O 0 6.471194069490593e-07
basis O 0 5.218410024099285e-07
of O 0 1.6405356291215867e-06
meiotic O 0 0.0008114258525893092
recombinants O 1 0.6678433418273926
and O 0 1.9567081835702993e-05
disease O 1 0.9994742274284363
- O 0 2.759731069090776e-05
associated O 0 9.979324886444374e-07
haplotypes O 0 2.3955517463036813e-06
, O 0 1.5615111692568462e-07
the O 0 5.292274636303773e-07
WFS B-Disease 0 2.488156496838201e-05
gene O 0 1.2913704949824023e-07
was O 0 1.6605688415438635e-06
localized O 0 6.165818717818183e-07
to O 0 1.6286183779357088e-07
a O 0 8.171642548404634e-06
BAC O 0 0.0007073038723319769
/ O 0 3.54707044607494e-05
P1 O 0 0.00011302359780529514
contig O 0 1.0182021469518077e-05
of O 0 1.194800233861315e-06
less O 0 2.405266741334344e-07
than O 0 1.3234186724275787e-07
250 O 0 1.5580720855723484e-06
kb O 0 4.9500191380502656e-05
. O 0 6.283936727413675e-06

Mutations O 0 4.0939339669421315e-05
in O 0 4.12494864576729e-06
a O 0 3.8026380480005173e-06
novel O 0 2.6016584797616815e-06
gene O 0 1.6736996713007102e-06
( O 0 8.472511012769246e-07
WFS1 O 0 5.717237581848167e-05
) O 0 1.0790493831791537e-07
encoding O 0 1.274050163146967e-07
a O 0 4.5423072947414767e-07
putative O 0 2.3159839201980503e-06
transmembrane O 0 1.9084611722064437e-06
protein O 0 3.9664911355430377e-07
were O 0 1.2477039490477182e-07
found O 0 3.6988190288411715e-08
in O 0 2.1309434217187118e-08
all O 0 1.7312027367211158e-08
affected O 0 1.3640853069318837e-07
individuals O 0 2.0845241976985562e-08
in O 0 2.836984833720635e-07
six O 0 1.8638553456185036e-06
WFS B-Disease 0 0.0026360906194895506
families O 0 2.277168675846042e-08
, O 0 2.3288503570029206e-08
and O 0 6.0273634971963475e-09
these O 0 1.4297686368180962e-09
mutations O 0 2.5139703652143908e-08
were O 0 1.5914196183075546e-07
associated O 0 1.2330583842867782e-07
with O 0 7.131400536763977e-08
the O 0 3.014015055669006e-05
disease O 1 0.9997978806495667
phenotype O 0 0.0033637606538832188
. O 0 7.133724921004614e-06

WFS1 O 0 0.006982655264437199
appears O 0 1.1103857104899362e-05
to O 0 3.150574343635526e-07
function O 0 7.922072882138309e-07
in O 0 2.0204814177304797e-07
survival O 0 4.788956857737503e-07
of O 0 1.3289978824104764e-06
islet O 0 0.00011756396997952834
beta O 0 1.5998050002963282e-05
- O 0 3.112552803941071e-06
cells O 0 2.859584640191315e-07
and O 0 1.8403710555503494e-07
neurons O 0 3.524592102621682e-06
. O 0 1.8530921863657568e-07
. O 0 6.228196980373468e-07

Stable O 0 0.00024915600079111755
interaction O 0 4.221118160785409e-06
between O 0 1.8469644373908523e-06
the O 0 7.765809186821571e-07
products O 0 2.1685264073312283e-07
of O 0 2.0004874556889263e-07
the O 0 2.945929509223788e-07
BRCA1 O 0 2.0891150143143022e-06
and O 0 5.179020376999688e-07
BRCA2 O 0 4.1762446926441044e-05
tumor B-Disease 1 0.9997697472572327
suppressor O 1 0.9296262264251709
genes O 0 2.447108045089408e-07
in O 0 2.3481307209749502e-07
mitotic O 0 6.824132469773758e-06
and O 0 7.828815000721079e-07
meiotic O 0 0.0007593375630676746
cells O 0 6.760862015653402e-05
. O 0 8.337240615219343e-06

BRCA1 O 0 0.0006172253633849323
and O 0 6.515659151773434e-06
BRCA2 O 0 2.465932811901439e-05
account O 0 3.523267650962225e-07
for O 0 4.7691035121033565e-08
most O 0 7.691357772898755e-09
cases O 0 7.801475021551596e-09
of O 0 7.273359159398751e-08
familial O 0 9.323511221737135e-06
, O 0 1.257415760846925e-06
early O 0 2.2976379113970324e-05
onset O 1 0.9999961853027344
breast B-Disease 1 0.9994813799858093
and I-Disease 0 0.006476397160440683
/ I-Disease 1 1.0
or I-Disease 1 0.9999938011169434
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.417230219492922e-07
encode O 0 2.561755820806866e-07
products O 0 3.574477034362644e-07
that O 0 2.6291564481084606e-08
each O 0 1.2872766852467521e-08
interact O 0 3.467145504032487e-08
with O 0 1.83579587087479e-07
hRAD51 O 0 4.552042082650587e-05
. O 0 5.272650014376268e-06

Results O 0 6.777981616323814e-05
presented O 0 7.12924975232454e-06
here O 0 6.644685868195666e-07
show O 0 1.2722919962016022e-07
that O 0 3.558436034722945e-08
BRCA1 O 0 1.6093786143756006e-06
and O 0 3.182263128564955e-07
BRCA2 O 0 2.8668471259152284e-06
coexist O 0 1.2382315617287531e-07
in O 0 1.9800435779870895e-07
a O 0 6.858155074951355e-07
biochemical O 0 3.920400922652334e-05
complex O 0 6.994706382101867e-06
and O 0 6.72728333483974e-07
colocalize O 0 3.3964130125241354e-05
in O 0 8.199693297683552e-07
subnuclear O 0 2.2304388039628975e-05
foci O 0 8.842695024213754e-06
in O 0 2.1959722573683393e-07
somatic O 0 2.006582008107216e-06
cells O 0 6.06652236001537e-07
and O 0 6.342001057646485e-08
on O 0 3.579887390969816e-07
the O 0 7.501764542894307e-08
axial O 0 7.383593469967309e-07
elements O 0 1.533932447728148e-07
of O 0 1.8934883883048315e-06
developing O 0 6.08661275691702e-06
synaptonemal O 0 0.0002542618603911251
complexes O 0 5.742772191297263e-05
. O 0 5.284908183966763e-06

Like O 0 3.905489938915707e-05
BRCA1 O 0 0.00013282721920404583
and O 0 1.0751397894637194e-05
RAD51 O 0 0.0012183614308014512
, O 0 2.513985691621201e-06
BRCA2 O 0 1.4236788047128357e-05
relocates O 0 9.817409591050819e-06
to O 0 3.5989197044727916e-07
PCNA O 0 1.6881504052435048e-05
+ O 0 5.337344077815942e-07
replication O 0 2.8978541877222597e-07
sites O 0 3.678549731489511e-08
following O 0 1.838118777186537e-07
exposure O 0 5.675398710991431e-07
of O 0 1.3517699244403047e-06
S O 0 4.908268238068558e-05
phase O 0 2.46213721766253e-06
cells O 0 3.333940128413815e-07
to O 0 1.6677505243478663e-07
hydroxyurea O 0 1.5745219570817426e-05
or O 0 1.9931742372136796e-06
UV O 0 0.0007443070062436163
irradiation O 0 7.3837443778757e-05
. O 0 3.4951499401358888e-06

Thus O 0 1.7400439901393838e-05
, O 0 9.840213124334696e-07
BRCA1 O 0 4.319611434766557e-06
and O 0 2.744805840393383e-07
BRCA2 O 0 1.0180359595324262e-06
participate O 0 1.0872013689322557e-07
, O 0 6.83503458276391e-08
together O 0 2.8144931718543376e-08
, O 0 5.8112952672217943e-08
in O 0 9.294041802831998e-08
a O 0 5.874869657418458e-07
pathway O 0 5.143971520737978e-06
( O 0 1.1493423102137967e-07
s O 0 1.8506597143641557e-06
) O 0 2.5610663811903578e-08
associated O 0 6.095728366517505e-08
with O 0 2.327664638812621e-08
the O 0 2.8415715291885135e-07
activation O 0 1.4238850098990952e-06
of O 0 1.666192474658601e-06
double O 0 3.5682344332599314e-06
- O 0 2.365088221267797e-06
strand O 0 3.0437840905506164e-06
break O 0 6.266614036576357e-07
repair O 0 3.6033404740010155e-06
and O 0 4.722130881873454e-07
/ O 0 7.934760105854366e-06
or O 0 3.138872273211746e-07
homologous O 0 1.054070821737696e-06
recombination O 0 3.173539653289481e-06
. O 0 1.6061344467743766e-06

Dysfunction O 1 0.9958985447883606
of O 0 3.128187745460309e-05
this O 0 1.1732461189239984e-06
pathway O 0 2.612286880321335e-05
may O 0 2.6767614258460526e-07
be O 0 2.419137778986169e-08
a O 0 8.284538211000836e-08
general O 0 1.250979266842478e-07
phenomenon O 0 1.5911949446945073e-07
in O 0 1.7280028075106202e-08
the O 0 1.5349108650752896e-08
majority O 0 3.0371081205515793e-09
of O 0 7.620728581514413e-08
cases O 0 5.243963130396878e-08
of O 0 8.030267963476945e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9996613264083862
/ I-Disease 1 1.0
or I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.708658707386348e-06
. O 0 2.7358992156223394e-06

A O 0 0.00021082554303575307
novel O 0 1.3602932085632347e-05
Arg362Ser O 0 7.6166725193616e-05
mutation O 0 9.482210998612572e-07
in O 0 5.253403401184187e-07
the O 0 8.570575573685346e-07
sterol O 0 7.0590795075986534e-06
27 O 0 6.775910151191056e-06
- O 0 3.1654751637688605e-06
hydroxylase O 0 7.012994501565117e-06
gene O 0 2.974569781599712e-07
( O 0 2.491164536877477e-07
CYP27 O 0 2.499374568287749e-05
) O 0 8.540331464246265e-08
: O 0 3.3073511929160304e-08
its O 0 5.4503423996266065e-08
effects O 0 5.35107460564177e-07
on O 0 1.3752733138971962e-06
pre O 0 4.926566361973528e-06
- O 0 5.958554538665339e-07
mRNA O 0 4.6833324063300097e-07
splicing O 0 3.400571984002454e-07
and O 0 1.081569465100074e-07
enzyme O 0 1.1382883258193033e-06
activity O 0 5.271931058814516e-06
. O 0 2.9776679184578825e-06

A O 0 0.00019581989909056574
novel O 0 3.3634940336924046e-05
C O 0 5.904508725507185e-05
to O 0 4.033302616335277e-07
A O 0 1.831427653087303e-06
mutation O 0 1.3341023930024676e-07
in O 0 1.4415527971323172e-07
the O 0 2.6517497531131085e-07
sterol O 0 3.3387905205017887e-06
27 O 0 2.381601916567888e-06
- O 0 2.211246965089231e-06
hydroxylase O 0 2.3683294330112403e-06
gene O 0 2.202938134132637e-07
( O 0 1.2809043425932032e-07
CYP27 O 0 9.164828952634707e-06
) O 0 2.7373966204891076e-08
was O 0 4.0562656522524776e-07
identified O 0 2.6953889786796026e-08
by O 0 2.1425996976631723e-08
sequencing O 0 4.452642201613344e-07
amplified O 0 4.00358521801536e-06
CYP27 O 0 3.865192775265314e-05
gene O 0 2.6926406349048193e-07
products O 0 1.7834173604569514e-07
from O 0 1.0626283142300963e-07
a O 0 3.171271600876935e-07
patient O 0 8.542528462385235e-07
with O 0 8.600386536272708e-07
cerebrotendinous B-Disease 1 0.9999998807907104
xanthomatosis I-Disease 1 0.9999992847442627
( O 0 8.685550710652024e-06
CTX B-Disease 0 0.013294350355863571
) O 0 1.4527997791446978e-06
. O 0 1.4508087815556792e-06

The O 0 2.1749896404799074e-05
mutation O 0 7.161031135183293e-06
changed O 0 3.94383232560358e-06
the O 0 2.935201791842701e-06
adrenodoxin O 0 6.0952679632464424e-05
cofactor O 0 1.5236946637742221e-05
binding O 0 1.3005115988562466e-06
residue O 0 6.245241820579395e-06
362Arg O 0 2.312144033567165e-06
to O 0 2.572039932147163e-07
362Ser O 0 5.460593456518836e-06
( O 0 9.773342526386841e-07
CGT O 0 8.308231190312654e-05
362Arg O 0 4.14668920711847e-06
to O 0 3.6146599313724437e-07
AGT O 0 5.496517042047344e-05
362Ser O 0 8.451903340755962e-06
) O 0 1.3313075442056288e-07
, O 0 4.239585038590121e-08
and O 0 5.6341768583934027e-08
was O 0 4.720388915302465e-06
responsible O 0 1.0968989272441831e-06
for O 0 7.85905115208152e-07
deficiency O 1 0.9138574004173279
in O 0 1.0433972192913643e-06
the O 0 1.4274389741331106e-06
sterol O 0 1.5439651178894565e-05
27 O 0 7.888773325248621e-06
- O 0 2.8150516300229356e-06
hydroxylase O 0 3.6812632515648147e-06
activity O 0 8.959273714026494e-07
, O 0 3.219454924874299e-08
as O 0 2.3450843045225156e-08
confirmed O 0 2.5472793652170367e-08
by O 0 1.2760707157610796e-08
expression O 0 5.37397504274395e-08
of O 0 1.709674108951731e-07
mutant O 0 4.698197813013394e-07
cDNA O 0 1.968191327250679e-06
into O 0 6.362677140714368e-07
COS O 0 6.491428939625621e-05
- O 0 2.109805791405961e-06
1 O 0 1.8475404885975877e-06
cells O 0 3.4191702980024274e-06
. O 0 2.1013197510910686e-06

Quantitative O 0 0.0002389507571933791
analysis O 0 8.174448339559603e-06
showed O 0 3.8031348594813608e-06
that O 0 1.1942974253997818e-07
the O 0 1.672560756560415e-07
expression O 0 2.4048949853749946e-07
of O 0 8.054635145526845e-07
CYP27 O 0 2.0361590941320173e-05
gene O 0 1.3322956249339768e-07
mRNA O 0 4.210662325476733e-07
in O 0 9.055381156031217e-08
the O 0 1.5688462440266449e-07
patient O 0 8.00363864073006e-07
represented O 0 1.9256631276221015e-06
52 O 0 3.113390630460344e-05
. O 0 9.615248018235434e-06

5 O 0 1.7614413081901148e-05
% O 0 1.6321866951329866e-06
of O 0 2.32596403293428e-06
the O 0 3.5288969684188487e-06
normal O 0 1.1524199180712458e-05
level O 0 2.658207631611731e-05
. O 0 6.150001354399137e-06

As O 0 1.0100568033521995e-05
the O 0 1.0601963822409743e-06
mutation O 0 9.962911917682504e-07
occurred O 0 6.591131295863306e-06
at O 0 2.3005086404737085e-06
the O 0 3.2307463015968096e-07
penultimate O 0 2.310385070813936e-06
nucleotide O 0 2.874020026411017e-07
of O 0 6.501529696834041e-07
exon O 0 5.183309781386924e-07
6 O 0 1.9588514987844974e-06
( O 0 1.225845238650436e-07
- O 0 3.540273212365719e-07
2 O 0 4.4839921997663623e-07
position O 0 4.763871572777134e-07
of O 0 6.754604555680999e-07
exon O 0 8.629915555502521e-07
6 O 0 8.236411304096691e-07
- O 0 3.8892233078513527e-07
intron O 0 3.164856252624304e-06
6 O 0 1.083648271560378e-06
splice O 0 9.192613106279168e-07
site O 0 3.42299983913108e-07
) O 0 1.634477442280513e-08
of O 0 6.75849705089604e-08
the O 0 1.3078269489597005e-07
gene O 0 1.0792140869853029e-07
, O 0 7.078090646928104e-08
we O 0 1.5495183802727297e-08
hypothesized O 0 2.6241022510475887e-07
that O 0 1.9922980598607865e-08
the O 0 6.037098643218997e-08
mutation O 0 9.956151814094483e-08
may O 0 2.1592975940620818e-07
partially O 0 2.740066804562957e-07
affect O 0 3.443643237233118e-08
the O 0 8.137638474181585e-08
normal O 0 8.731094425229458e-08
splicing O 0 4.5334267895214e-08
efficiency O 0 9.297907155314533e-08
in O 0 2.1830423690971656e-08
exon O 0 1.249121908131201e-07
6 O 0 2.8311521305113274e-07
and O 0 2.573508872671937e-08
cause O 0 9.934792188914798e-08
alternative O 0 2.4586492841649488e-08
splicing O 0 5.417807713570255e-08
elsewhere O 0 2.2649706110655643e-08
, O 0 3.0128353145641995e-09
which O 0 3.124003722376756e-09
resulted O 0 3.187936670201452e-08
in O 0 3.3568724688848306e-08
decreased O 0 4.215678927721456e-06
transcript O 0 2.3799852897354867e-06
in O 0 2.3566938978092367e-07
the O 0 1.2280723922231118e-06
patient O 0 1.2403651453496423e-05
. O 0 6.8617855504271574e-06

Transfection O 0 0.0015472378581762314
of O 0 4.793916014023125e-05
constructed O 0 7.034524605842307e-05
minigenes O 0 6.586696690646932e-05
, O 0 4.6724025537514535e-07
with O 0 9.399023781497817e-08
or O 0 2.5716448703860806e-07
without O 0 8.822782149309205e-08
the O 0 2.531239431391441e-07
mutation O 0 1.7521666961783922e-07
, O 0 1.533629614414167e-07
into O 0 4.2555410573186236e-07
COS O 0 0.00011202186578884721
- O 0 1.6879564554983517e-06
1 O 0 9.401235843142786e-07
cells O 0 1.481377012169105e-07
confirmed O 0 1.0275957151861803e-07
that O 0 1.3257499986707444e-08
the O 0 6.592675561023498e-08
mutant O 0 6.753058983122173e-07
minigene O 0 7.565082796645584e-06
was O 0 3.3548803912708536e-06
responsible O 0 1.199584858113667e-07
for O 0 3.859155484065013e-08
a O 0 1.0077162926336314e-07
mRNA O 0 2.1673541539257712e-07
species O 0 9.009499812862032e-09
alternatively O 0 1.6979164740860142e-07
spliced O 0 7.191254098870559e-07
at O 0 2.3347449769062223e-06
an O 0 4.337451287028671e-07
activated O 0 3.536659733072156e-06
cryptic O 0 2.1207615645835176e-06
5 O 0 4.99833504363778e-07
splice O 0 9.291557034885045e-07
site O 0 1.2451511111066793e-06
88 O 0 1.6433542668892187e-06
bp O 0 1.1035975830964162e-06
upstream O 0 6.7330086039874e-07
from O 0 1.796330195702467e-07
the O 0 2.285386671019296e-07
3 O 0 3.5709027201846766e-07
end O 0 3.952983433919144e-07
of O 0 7.130828976187331e-07
exon O 0 4.034000994579401e-06
6 O 0 1.5394340152852237e-05
. O 0 4.1411567508475855e-06

Our O 0 1.7461747120250948e-05
data O 0 2.8593221941264346e-06
suggest O 0 1.039011294778902e-06
that O 0 1.3092159178995644e-07
the O 0 8.712892736184585e-07
C O 0 7.040314812911674e-06
to O 0 1.0210506218299997e-07
A O 0 1.826442598940048e-06
mutation O 0 3.1953095458447933e-07
at O 0 3.1666859285905957e-06
the O 0 4.0223358155344613e-07
penultimate O 0 2.0276613668102073e-06
nucleotide O 0 1.7035837629464368e-07
of O 0 2.3778997615409025e-07
exon O 0 3.5029211176151875e-07
6 O 0 6.745361247340043e-07
of O 0 5.072880640000221e-07
the O 0 7.366073759840219e-07
CYP27 O 0 1.5479694411624223e-05
gene O 0 9.596475791795456e-08
not O 0 3.019222205580263e-08
only O 0 3.6516848211931574e-08
causes O 0 6.704763677589654e-07
the O 0 2.6209211227978813e-06
deficiency B-Disease 0 0.011123613454401493
in I-Disease 0 4.5494172695725865e-07
the I-Disease 0 7.648949349459144e-07
sterol I-Disease 0 5.14005341756274e-06
27 I-Disease 0 3.914462467946578e-06
- I-Disease 0 1.1838133104902226e-06
hydroxylase I-Disease 0 2.2626791178481653e-06
activity I-Disease 0 3.4299375784030417e-07
, O 0 2.2572422153643856e-08
but O 0 7.260160916899849e-09
also O 0 3.520791480582375e-08
partially O 0 5.30340003024321e-07
leads O 0 1.4147470039915788e-07
to O 0 3.603198450718992e-08
alternative O 0 1.2496747103796224e-07
pre O 0 1.7393684856870095e-06
- O 0 2.225819315526678e-07
mRNA O 0 2.4578693569310417e-07
splicing O 0 4.194157909864771e-08
of O 0 1.382699394980591e-07
the O 0 3.147241045553528e-07
gene O 0 1.9047027990382048e-06
. O 0 1.678301373431168e-06

To O 0 5.18057458975818e-06
our O 0 1.0549376838753233e-06
knowledge O 0 9.192000334223849e-07
, O 0 1.5465427338767768e-07
this O 0 3.194047337728989e-08
is O 0 4.0851865890090266e-08
the O 0 8.959310804357301e-08
first O 0 2.1593757537630154e-07
report O 0 2.6300298827663937e-07
regarding O 0 3.024392754014116e-07
effects O 0 2.8839585866080597e-06
on O 0 3.276865072621149e-06
pre O 0 4.255165549693629e-06
- O 0 3.1220523055708327e-07
mRNA O 0 2.328295920506207e-07
splicing O 0 6.70718094397671e-08
of O 0 1.7286595266341465e-07
a O 0 1.443343791152074e-07
mutation O 0 1.0782243720086626e-07
at O 0 8.120952657009184e-07
the O 0 2.5420479232707294e-07
- O 0 4.1383515281268046e-07
2 O 0 3.1228680086314853e-07
position O 0 3.611255863233964e-07
of O 0 3.586592072224448e-07
a O 0 7.741016929685429e-07
5 O 0 1.8009649238592829e-06
splice O 0 8.747762876737397e-06
site O 0 5.993037575535709e-06
. O 0 2.236250111309346e-06

ATM O 0 0.003177137579768896
germline O 0 0.0005266615771688521
mutations O 0 1.207846071338281e-05
in O 0 5.657259407598758e-06
classical O 0 0.17776286602020264
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.003832346759736538
in O 0 1.3750568541581742e-06
the O 0 1.8929214320451138e-06
Dutch O 0 2.2421749235945754e-05
population O 0 5.480071081365168e-07
. O 0 1.2114231822124566e-06

Germline O 0 0.0015434154774993658
mutations O 0 1.580631396791432e-05
in O 0 1.6015550272641121e-06
the O 0 1.244662030330801e-06
ATM O 0 5.354981840355322e-05
gene O 0 3.7507666661440453e-07
are O 0 9.572907799793029e-09
responsible O 0 7.28955313888946e-08
for O 0 8.625704595033312e-08
the O 0 0.001890908693894744
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999995231628418
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.4003447732829954e-06
. O 0 3.007795612575137e-06

In O 0 1.223785147885792e-05
our O 0 1.1697826494128094e-06
study O 0 3.968133057696832e-07
, O 0 9.470086581586656e-08
we O 0 1.6094103827413164e-08
have O 0 1.607036281825458e-08
determined O 0 7.134148916065897e-08
the O 0 1.7446782862862165e-07
ATM O 0 2.4956830202427227e-06
mutation O 0 6.83490384290053e-08
spectrum O 0 1.1821678924661683e-07
in O 0 5.974725780788503e-08
19 O 0 7.98537143964495e-07
classical O 0 8.237242582254112e-06
A B-Disease 1 0.9999799728393555
- I-Disease 1 0.9993564486503601
T I-Disease 1 0.9999998807907104
patients O 0 1.0316411902522304e-07
, O 0 1.3972456081035034e-08
including O 0 1.2260364279370606e-08
some O 0 5.512724943201874e-09
immigrant O 0 3.351102151327723e-08
populations O 0 5.741649822255113e-09
, O 0 6.389691442620915e-09
as O 0 1.293197726681683e-08
well O 0 1.0539723760416564e-08
as O 0 2.0710182013772283e-08
12 O 0 8.492364855783308e-08
of O 0 1.1605880700926718e-07
Dutch O 0 8.260537356363784e-07
ethnic O 0 6.770586225002262e-08
origin O 0 1.0729843324952526e-06
. O 0 4.224613803671673e-06

Both O 0 1.2985958164790645e-05
the O 0 4.8434294512844644e-06
protein O 0 5.9537878769333474e-06
truncation O 0 4.603326669894159e-05
test O 0 1.6470947912239353e-06
( O 0 6.047829970157181e-07
PTT O 0 2.247344673378393e-05
) O 0 1.31287166027505e-07
and O 0 9.099392883626933e-08
the O 0 1.8149603420170024e-07
restriction O 0 6.377238150889752e-07
endonuclease O 0 5.7425513659836724e-06
fingerprinting O 0 1.3052929261903046e-06
( O 0 1.8060543993669853e-07
REF O 0 7.871436537243426e-06
) O 0 2.108006036394272e-08
method O 0 1.6628185051104083e-08
were O 0 3.9486081959694275e-08
used O 0 1.536923299738646e-08
and O 0 2.7549436509843872e-08
compared O 0 2.5161585881505744e-07
for O 0 1.1176312320060333e-08
their O 0 1.1371231956047723e-08
detection O 0 9.436888035452284e-07
efficiency O 0 3.91959986245638e-07
, O 0 3.6586005336403105e-08
identifying O 0 1.959503492798831e-08
76 O 0 3.190717450252123e-07
% O 0 3.042728025093311e-08
and O 0 2.1691544560553666e-08
60 O 0 6.499706728391175e-08
% O 0 1.4827827854446696e-08
of O 0 5.948334802496902e-08
the O 0 1.758637182547318e-07
mutations O 0 3.9663095208197774e-07
, O 0 4.061041920522257e-07
respectively O 0 5.017710464017e-06
. O 0 2.402926384093007e-06

Most O 0 6.910539923410397e-06
patients O 0 1.4161037142912392e-06
were O 0 5.465139452098811e-07
found O 0 2.247679589117979e-07
to O 0 1.3297442080784094e-07
be O 0 1.236880734722945e-06
compound O 0 0.00013019882317166775
heterozygote O 0 6.258701614569873e-05
. O 0 3.3853550576168345e-06

Seventeen O 0 5.8565572544466704e-05
mutations O 0 2.6090751816809643e-06
were O 0 6.477862939391343e-07
distinct O 0 5.5938727427928825e-08
, O 0 5.879953945964189e-08
of O 0 1.4907405443409516e-07
which O 0 5.896306021213604e-08
10 O 0 1.5173590384165436e-07
were O 0 1.623711654019644e-07
not O 0 1.1022137869076687e-07
reported O 0 3.273953780080774e-06
previously O 0 1.2193780094094109e-05
. O 0 5.3484795898839366e-06

Mutations O 0 3.142986315651797e-05
are O 0 6.108432444307255e-07
small O 0 3.8123189938232827e-07
deletions O 0 3.802815854214714e-06
or O 0 8.147047765305615e-07
point O 0 1.782011054274335e-06
mutations O 0 3.583955674457684e-07
frequently O 0 1.946499708083138e-07
affecting O 0 1.113537223318417e-06
splice O 0 9.02340434549842e-06
sites O 0 2.476974486853578e-06
. O 0 3.344549440953415e-06

Moreover O 0 7.727186311967671e-05
, O 0 6.078584647184471e-06
a O 0 6.593645593966357e-06
16 O 0 1.9231751139159314e-05
. O 0 6.012914582242956e-06

7 O 0 0.00028472335543483496
- O 0 4.0022216126089916e-05
kb O 0 5.215041892370209e-05
genomic O 0 5.968488949292805e-06
deletion O 0 3.7407360196084483e-06
of O 0 3.959800778829958e-06
the O 0 1.213072891914635e-06
3 O 0 8.358882723769057e-07
end O 0 5.35780486643489e-07
of O 0 2.7105338062938245e-07
the O 0 2.0174564951958018e-07
gene O 0 1.1223784923686253e-07
, O 0 6.058335344505394e-08
most O 0 1.898770385366788e-08
likely O 0 4.3146197725718594e-08
a O 0 3.7938139740845145e-08
result O 0 2.470721405245513e-08
of O 0 7.714002236980377e-08
recombination O 0 4.32153761664722e-08
between O 0 5.337954789297328e-08
two O 0 3.5138143061885785e-08
LINE O 0 2.370805987084168e-06
elements O 0 1.685873201040522e-07
, O 0 1.2320003861532314e-07
was O 0 3.823817678494379e-06
identified O 0 1.6816226207083673e-06
. O 0 2.858607786038192e-06

The O 0 1.595928188180551e-05
most O 0 4.562112394523865e-07
frequently O 0 1.952322605802692e-07
found O 0 1.0364634306370135e-07
mutation O 0 1.3862378978046763e-07
, O 0 7.321713013652698e-08
identified O 0 7.222705988851885e-08
in O 0 8.120521499677125e-08
three O 0 1.0759502089285888e-07
unrelated O 0 8.713175247976324e-07
Turkish O 0 2.5652432668721303e-05
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9991593360900879
T I-Disease 1 0.9999920129776001
individuals O 0 3.8807826285847113e-08
, O 0 7.507733101874692e-08
was O 0 1.3990584193379618e-06
previously O 0 1.9355672975507332e-07
described O 0 8.642782489687306e-08
to O 0 1.3695228950894034e-08
be O 0 3.41893091615475e-08
a O 0 2.7836304639095033e-07
Turkish O 0 6.6958450588572305e-06
A B-Disease 1 0.9999958276748657
- I-Disease 1 0.9999428987503052
T I-Disease 1 0.9999998807907104
founder O 0 0.0003201447252649814
mutation O 0 3.3668934520392213e-06
. O 0 2.221828935944359e-06

The O 0 1.3609861525765155e-05
presence O 0 2.3734619389870204e-06
of O 0 1.5407116507049068e-06
a O 0 3.0107803468126804e-06
founder O 0 1.8326107237953693e-05
mutation O 0 1.2388882453251426e-07
among O 0 2.3516957270430794e-08
relatively O 0 1.5995624380593654e-08
small O 0 2.043125002515467e-09
ethnic O 0 1.0797813754237495e-09
population O 0 1.7227397286490032e-09
groups O 0 1.0120301263683018e-09
in O 0 5.865456564890792e-09
Western O 0 8.013432761799777e-08
Europe O 0 6.218078141273509e-08
could O 0 1.3229007223003464e-08
indicate O 0 4.385926644090432e-08
a O 0 1.0261051386351028e-07
high O 0 5.994872935843887e-07
carrier O 0 8.540283147340233e-08
frequency O 0 1.2950593486493744e-07
in O 0 3.6889414190000025e-08
such O 0 4.428148159263401e-08
communities O 0 1.6951725001490558e-07
. O 0 1.0518294857320143e-06

In O 0 3.438430940150283e-05
patients O 0 2.7690573460859014e-06
of O 0 8.128809554364125e-07
Dutch O 0 1.6317897006956628e-06
ethnic O 0 4.243524998059911e-08
origin O 0 9.085033525479957e-08
, O 0 1.8933780765451047e-08
however O 0 9.330698880205546e-09
, O 0 5.75009950765093e-09
no O 0 1.3229865203356894e-08
significant O 0 9.391945354764175e-08
founder O 0 5.852524282090599e-06
effect O 0 5.401463454290933e-07
could O 0 1.5556948085304612e-07
be O 0 1.978314685402438e-07
identified O 0 1.5449890042873449e-06
. O 0 2.3217137368192198e-06

The O 0 6.06113735557301e-06
observed O 0 1.0204738600805285e-06
genetic O 0 7.025057584542083e-07
heterogeneity O 0 4.278849246475147e-06
including O 0 4.599262126703252e-07
the O 0 6.390114322130103e-07
relative O 0 4.257373802829534e-06
high O 0 9.446609510632697e-06
percentage O 0 4.971707880940812e-07
of O 0 1.0610419849399477e-06
splice O 0 7.284455932676792e-06
- O 0 1.4262986951507628e-06
site O 0 1.5814597986718582e-07
mutations O 0 4.26004405085223e-08
had O 0 3.7842457345504954e-07
no O 0 1.1575339442515542e-07
reflection O 0 1.6847687902554753e-06
on O 0 2.9524956062232377e-06
the O 0 2.381865442657727e-06
phenotype O 0 4.397324664751068e-05
. O 0 4.328593149693916e-06

All O 0 7.758460014883894e-06
patients O 0 2.0221461909386562e-06
manifested O 0 4.661405455408385e-06
classical O 0 2.9186852771090344e-05
A B-Disease 1 0.9998576641082764
- I-Disease 1 0.5727180242538452
T I-Disease 1 0.9882005453109741
and O 0 1.6311660999690503e-07
increased O 0 1.8428544308335404e-06
cellular O 0 1.531211455585435e-05
radioresistant O 0 2.2894470021128654e-05
DNA O 0 2.383512764936313e-06
synthesis O 0 2.5421151804039255e-05
. O 0 4.5796150516252965e-06

Determination O 0 2.9911252568126656e-05
of O 0 4.412720954860561e-06
the O 0 9.71557710727211e-07
genomic O 0 2.7950686671829317e-06
structure O 0 7.552550869149854e-07
of O 0 3.534922825565445e-07
the O 0 4.800214128408697e-07
COL4A4 O 0 0.00010532083979342133
gene O 0 1.167674525959228e-07
and O 0 1.7390460627098037e-08
of O 0 2.054304530929585e-07
novel O 0 2.3071636405802565e-06
mutations O 0 7.334809197345749e-05
causing O 1 0.6441173553466797
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0072496491484344006

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.0001985867420444265
a O 0 6.301977555267513e-05
progressive O 1 0.9495328664779663
hematuric B-Disease 1 0.9999872446060181
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.9958826303482056
by O 0 0.0001292559754801914
glomerular B-Disease 1 0.9999998807907104
basement I-Disease 1 0.9999642372131348
membrane I-Disease 0 0.43440112471580505
abnormalities I-Disease 1 0.998865008354187
and O 0 6.763344799765036e-07
associated O 0 2.5896454758367327e-07
with O 0 3.0839899523016356e-08
mutations O 0 1.5216150472951995e-07
in O 0 7.334004976655706e-07
either O 0 2.462423083215981e-07
the O 0 2.561575684012496e-06
COL4A3 O 0 0.00028824483160860837
or O 0 4.128851287532598e-07
the O 0 1.1670126696117222e-06
COL4A4 O 0 2.1140971512068063e-05
gene O 0 1.5143781695314829e-07
, O 0 4.155585742182666e-08
which O 0 1.8656175271303255e-08
encode O 0 4.807122166994304e-08
the O 0 6.981338174227858e-07
alpha3 O 0 1.7905791537486948e-05
and O 0 1.2067957868566737e-06
alpha4 O 0 0.0005008939187973738
type O 0 0.000306834583170712
IV O 1 1.0
collagen O 1 0.9995707869529724
chains O 0 5.63658686587587e-05
, O 0 1.2547852747957222e-06
respectively O 0 7.3372966653550975e-06
. O 0 2.136043804057408e-06

To O 0 6.165151717141271e-06
date O 0 3.3930996323761065e-06
, O 0 1.447073572080626e-07
mutation O 0 5.031866479043856e-08
screening O 0 1.3670948817434692e-07
in O 0 8.886622993031779e-08
the O 0 7.020249626066288e-08
two O 0 1.4820759730582722e-08
genes O 0 2.5706880180109692e-08
has O 0 5.9155571108249205e-08
been O 0 8.67058744802307e-08
hampered O 0 6.123135563029791e-07
by O 0 1.2054433007335774e-08
the O 0 2.70130264823365e-08
lack O 0 5.7261775765482525e-08
of O 0 4.010829002254468e-07
genomic O 0 4.660054401028901e-06
structure O 0 5.58099418412894e-06
information O 0 1.5828752566449111e-06
. O 0 5.517905265151057e-06

We O 0 4.0235983760794625e-05
report O 0 9.15034888748778e-06
here O 0 5.575959676207276e-07
the O 0 2.927559705767635e-07
complete O 0 8.077512916315754e-07
characterization O 0 1.8527116480981931e-06
of O 0 1.5852530168558587e-06
the O 0 4.1150804008793784e-07
48 O 0 4.304033041080402e-07
exons O 0 6.253628725971794e-07
of O 0 1.0779832564367098e-06
the O 0 1.0952285265375394e-06
COL4A4 O 0 2.910161310865078e-05
gene O 0 1.3437774271096714e-07
, O 0 2.4969386558382212e-08
a O 0 2.978361202110591e-08
comprehensive O 0 9.286421942533707e-08
gene O 0 9.322625516006156e-08
screen O 0 2.7684896508617385e-07
, O 0 3.831234351991952e-08
and O 0 1.720655440351493e-08
the O 0 4.3444305930506744e-08
subsequent O 0 9.689819080449524e-08
detection O 0 1.1678348954546891e-07
of O 0 1.175663797425841e-07
10 O 0 7.611011199060158e-08
novel O 0 7.467260587645796e-08
mutations O 0 4.4555047651329005e-08
in O 0 7.289845171953857e-08
eight O 0 1.4744848613190698e-06
patients O 0 1.755672383296769e-05
diagnosed O 1 0.9992819428443909
with O 0 6.6077718656742945e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.043193284422159195

Furthermore O 0 4.729368447442539e-05
, O 0 2.6369568786321906e-06
we O 0 2.107693006792033e-07
identified O 0 6.9628538312827e-07
a O 0 1.012339566841547e-06
glycine O 0 2.6766083465190604e-06
to O 0 3.1909974040900124e-07
alanine O 0 2.82625251202262e-06
substitution O 0 1.3750660627920297e-06
in O 0 1.949150600921712e-07
the O 0 4.566944085127034e-07
collagenous O 0 1.833350324886851e-05
domain O 0 4.6942966491769766e-07
that O 0 4.2571038250116544e-08
is O 0 9.475778028900095e-08
apparently O 0 4.183356736575661e-07
silent O 0 1.4191240325089893e-06
in O 0 7.886698227821398e-08
the O 0 1.281465102920265e-07
heterozygous O 0 8.466131617979045e-08
carriers O 0 7.634258736288757e-08
, O 0 6.182434475476839e-08
in O 0 2.988855385410716e-07
11 O 0 4.736974915431347e-06
. O 0 1.6072407333922456e-06

5 O 0 1.269646963919513e-05
% O 0 6.211286063262378e-07
of O 0 5.332388468559657e-07
all O 0 4.82844129123805e-08
control O 0 3.598772480017942e-07
individuals O 0 1.810831129489543e-08
, O 0 4.381444895784625e-08
and O 0 2.035758583929237e-08
in O 0 5.786751344771801e-08
one O 0 2.341955429585596e-08
control O 0 9.36979489551959e-08
individual O 0 1.1466365634760223e-08
homozygous O 0 2.451688771998306e-07
for O 0 1.3139113264060143e-07
this O 0 1.9666198625145626e-07
glycine O 0 8.039264685066883e-06
substitution O 0 7.87011504144175e-06
. O 0 1.984453092518379e-06

There O 0 6.830434813309694e-06
has O 0 1.3275296169013018e-06
been O 0 5.335430728337087e-07
no O 0 9.669750511420716e-08
previous O 0 1.8160025661018153e-07
finding O 0 7.338000784784526e-08
of O 0 2.726475543113338e-07
a O 0 6.917397286088089e-07
glycine O 0 9.963899856302305e-07
substitution O 0 5.15053102390084e-07
that O 0 1.6232339916655292e-08
is O 0 2.5289079275125914e-08
not O 0 5.6484417143565224e-09
associated O 0 2.7882155251290897e-08
with O 0 6.700989985120032e-09
any O 0 6.155442378030784e-08
obvious O 0 1.481863364460878e-06
phenotype O 0 2.8175386432849336e-06
in O 0 2.1675627692729904e-07
homozygous O 0 1.3689021898244391e-06
individuals O 0 1.720743085797949e-07
. O 0 2.2583269583265064e-06

Founder O 0 0.0016955012688413262
BRCA1 O 0 4.868931864621118e-05
and O 0 7.480802537429554e-07
BRCA2 O 0 3.7374838939285837e-06
mutations O 0 3.019441408014245e-07
in O 0 2.7632643195829587e-07
French O 0 1.580557545821648e-05
Canadian O 0 0.0019324935274198651
breast B-Disease 1 0.9999970197677612
and I-Disease 1 0.9990513920783997
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.534659521799767e-06
. O 0 4.718273430626141e-06

We O 0 4.151817847741768e-06
have O 0 2.998001775722514e-07
identified O 0 2.9192514716669393e-07
four O 0 4.782119944479746e-08
mutations O 0 1.0102142766754696e-07
in O 0 1.06711695480044e-07
each O 0 1.0529596750075143e-08
of O 0 4.237095083681197e-07
the O 0 6.6163715928269085e-06
breast B-Disease 1 0.9999967813491821
cancer I-Disease 1 0.9999997615814209
- O 0 0.027716368436813354
susceptibility O 0 6.371869676513597e-05
genes O 0 2.994772785314126e-07
, O 0 9.535190059750676e-08
BRCA1 O 0 7.734279847682046e-07
and O 0 8.49255883395017e-08
BRCA2 O 0 8.515102081219084e-07
, O 0 1.6816942505215593e-08
in O 0 1.8876592733363395e-08
French O 0 2.611034233268583e-06
Canadian O 0 3.36932425852865e-05
breast B-Disease 1 0.9991946816444397
cancer I-Disease 1 0.9997590184211731
and O 0 0.01165479701012373
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.404235139394586e-07
from O 0 3.541357727954164e-06
Quebec O 0 2.8738944820361212e-05
. O 0 7.265466592798475e-06

To O 0 7.383399406535318e-06
identify O 0 2.5073579763557063e-06
founder O 0 6.456030678236857e-05
effects O 0 6.562228918483015e-06
, O 0 1.4342766974095866e-07
we O 0 1.580113107024772e-08
examined O 0 7.16089658681085e-08
independently O 0 4.3683940020855516e-08
ascertained O 0 9.153570204034622e-07
French O 0 4.484647433855571e-06
Canadian O 0 1.2263390090083703e-05
cancer B-Disease 0 5.644121301884297e-06
families O 0 1.6576317207750435e-08
for O 0 1.5489540317048522e-08
the O 0 6.103429939230409e-08
distribution O 0 5.5313073232809984e-08
of O 0 1.4040546147953137e-07
these O 0 2.554348732530798e-08
eight O 0 5.658849886458484e-07
mutations O 0 3.0681892440043157e-06
. O 0 5.045378202339634e-06

Mutations O 0 2.6500751118874177e-05
were O 0 5.23701373822405e-06
found O 0 2.3445639385499817e-07
in O 0 1.1797126830970228e-07
41 O 0 1.1226069318581722e-06
of O 0 1.1306674423394725e-06
97 O 0 2.658073208294809e-05
families O 0 5.673521172866458e-07
. O 0 3.3357196116412524e-06

Six O 0 8.701742444827687e-06
of O 0 1.6365977444365853e-06
eight O 0 3.1889044294075575e-07
mutations O 0 1.9483216817661742e-07
were O 0 3.201764116056438e-07
observed O 0 4.326759039940953e-07
at O 0 1.4819538591837045e-06
least O 0 8.572580867394208e-08
twice O 0 8.969498708211177e-07
. O 0 1.4169061159918783e-06

The O 0 5.111184873385355e-05
BRCA1 O 0 0.00019111594883725047
C4446T O 0 0.00047566540888510644
mutation O 0 8.063772838795558e-06
was O 0 2.342712650715839e-05
the O 0 2.186518344160504e-07
most O 0 1.5278946108310265e-08
common O 0 1.8816345814798296e-08
mutation O 0 6.107715222469778e-08
found O 0 9.226236130643883e-08
, O 0 2.8191134759936176e-08
followed O 0 1.1096049234993188e-07
by O 0 6.076434999613411e-08
the O 0 6.135065859780298e-07
BRCA2 O 0 1.4152870789985172e-05
8765delAG O 0 5.7426786952419207e-05
mutation O 0 1.3679737094207667e-05
. O 0 6.468506398960017e-06

Together O 0 6.173977453727275e-06
, O 0 6.003712655910931e-07
these O 0 2.637750640133163e-08
mutations O 0 1.1636868890718688e-07
were O 0 2.82842108845216e-07
found O 0 6.721344902871351e-08
in O 0 6.157238630066786e-08
28 O 0 6.385344022419304e-07
of O 0 3.646583479621768e-07
41 O 0 1.4497022675641347e-06
families O 0 2.1088586876771842e-08
identified O 0 1.384068752940948e-07
to O 0 4.243006657134174e-08
have O 0 1.177123465367913e-07
a O 0 1.145742203334521e-06
mutation O 0 4.539389919955283e-06
. O 0 4.175881713308627e-06

The O 0 1.9473371139611118e-05
odds O 0 9.261706509278156e-06
of O 0 1.1615375115070492e-06
detection O 0 9.068878057405527e-07
of O 0 5.674597787219682e-07
any O 0 6.043885036888241e-08
of O 0 6.826389835623559e-07
the O 0 4.4564652057488274e-07
four O 0 2.774555980522564e-07
BRCA1 O 0 3.6031137824465986e-06
mutations O 0 2.5613896923459833e-06
was O 0 0.0001495917240390554
18 O 0 1.3910406778450124e-05
. O 0 7.945301149447914e-06

7x O 0 0.008492812514305115
greater O 0 1.9636994693428278e-05
if O 0 9.443829185329378e-07
one O 0 1.1692802104334987e-07
or O 0 4.771350958776566e-08
more O 0 3.2002660521612825e-09
cases O 0 2.7590452589265624e-08
of O 0 0.00025113028823398054
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 5.300571046973346e-06
also O 0 1.2337099519754702e-07
present O 0 7.294977422134252e-08
in O 0 3.0644588377981563e-07
the O 0 2.2092908693593927e-06
family O 0 1.568092329762294e-06
. O 0 5.3949693210597616e-06

The O 0 2.520613452361431e-05
odds O 0 8.344940397364553e-06
of O 0 1.1008938827217207e-06
detection O 0 1.0065481319543323e-06
of O 0 5.156389875082823e-07
any O 0 5.914755973890351e-08
of O 0 7.043424830044387e-07
the O 0 3.330768549858476e-07
four O 0 1.6736312602461112e-07
BRCA2 O 0 8.1425577036498e-07
mutations O 0 6.219880788194132e-07
was O 0 3.205698521924205e-05
5 O 0 5.965905074845068e-06
. O 0 2.254356786579592e-06

3x O 0 0.00040209005237556994
greater O 0 2.8953288619959494e-06
if O 0 2.191735433143549e-07
there O 0 7.240333843583358e-08
were O 0 1.371275999417776e-07
at O 0 1.4178453966451343e-07
least O 0 4.4763974749173485e-09
five O 0 6.872025615223265e-09
cases O 0 1.0908026482070454e-08
of O 0 1.2335516430539428e-06
breast B-Disease 1 0.9999697208404541
cancer I-Disease 1 0.9998918771743774
in O 0 2.6169400371145457e-06
the O 0 6.331320037133992e-06
family O 0 3.1579675123794004e-06
. O 0 4.0917752812674735e-06

Interestingly O 0 0.00010694374213926494
, O 0 1.3416880619843141e-06
the O 0 3.124143006516533e-07
presence O 0 4.289101696031139e-07
of O 0 1.178224465547828e-06
a O 0 9.70171095104888e-06
breast B-Disease 1 0.7788587808609009
cancer I-Disease 1 0.7352911829948425
case O 0 5.3542157729680184e-06
< O 0 8.93700143933529e-06
36 O 0 7.223517854981765e-07
years O 0 8.673416118654131e-08
of O 0 1.3801817999592458e-07
age O 0 3.250413840305555e-07
was O 0 1.518024760116532e-06
strongly O 0 1.1758364593106307e-07
predictive O 0 2.723263605730608e-07
of O 0 1.3148051891676005e-07
the O 0 7.817551050948168e-08
presence O 0 5.6311684204501944e-08
of O 0 1.8209574648153648e-07
any O 0 8.357226732869094e-08
of O 0 3.7235520267131506e-07
the O 0 3.592233213112195e-07
eight O 0 2.874217273074464e-07
mutations O 0 7.176640792749822e-07
screened O 0 1.0641901099006645e-05
. O 0 3.790259370362037e-06

Carriers O 0 2.0451050659175962e-05
of O 0 3.7457768939930247e-06
the O 0 7.76121908074856e-07
same O 0 2.057902719343474e-07
mutation O 0 2.2428488932746404e-07
, O 0 8.442234644689961e-08
from O 0 4.8521119566657944e-08
different O 0 2.8744233659949714e-09
families O 0 7.079383301800135e-09
, O 0 1.2757592315892907e-08
shared O 0 2.5302586692532714e-08
similar O 0 3.073385101970416e-08
haplotypes O 0 8.071506272244733e-07
, O 0 4.956122978683197e-08
indicating O 0 4.3697195906133857e-07
that O 0 2.191787196181849e-08
the O 0 5.460977092752728e-08
mutant O 0 1.7644327954258188e-07
alleles O 0 5.040819672785801e-08
were O 0 1.2267621229966608e-07
likely O 0 3.129677139668274e-08
to O 0 9.276292622928395e-09
be O 0 1.4816463611566633e-08
identical O 0 3.447073737561368e-08
by O 0 2.4548302945959222e-08
descent O 0 2.459728989379073e-07
for O 0 1.0893076662910062e-08
a O 0 4.415312204741895e-08
mutation O 0 3.1619698859230994e-08
in O 0 6.035326549636011e-08
the O 0 4.455666271496739e-07
founder O 0 1.2861245522799436e-05
population O 0 3.442064837599901e-07
. O 0 1.2788040066880058e-06

The O 0 7.903284313215408e-06
identification O 0 8.45538181692973e-07
of O 0 8.030169169614965e-07
common O 0 2.2677032518458873e-07
BRCA1 O 0 6.448427939176327e-06
and O 0 2.767705780115648e-07
BRCA2 O 0 1.0875762654904975e-06
mutations O 0 5.67411113649996e-08
will O 0 1.2860055242924773e-08
facilitate O 0 7.519685851775648e-08
carrier O 0 8.09461866424499e-08
detection O 0 1.0980255638060044e-07
in O 0 5.885250331516545e-08
French O 0 4.234390871715732e-06
Canadian O 0 5.331746433512308e-05
breast B-Disease 1 0.9900920987129211
cancer I-Disease 1 0.9909370541572571
and O 0 5.63319590582978e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.154656825354323e-06
. O 0 9.17622401175322e-06

Are O 0 3.120229666819796e-05
Dp71 O 0 0.001500096172094345
and O 0 1.8688086129259318e-05
Dp140 O 1 0.5819137692451477
brain O 0 0.023067569360136986
dystrophin O 0 4.236453241901472e-05
isoforms O 0 1.1654000218186411e-06
related O 0 4.0655640987097286e-07
to O 0 3.1835926961321093e-07
cognitive B-Disease 0 0.17921747267246246
impairment I-Disease 1 0.9999978542327881
in O 0 0.28492218255996704
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 0.00011030456516891718

Molecular O 0 0.00020751749980263412
study O 0 1.8472533156455029e-06
and O 0 2.1822103235535906e-07
neuropsychological O 0 3.707461701196735e-06
analysis O 0 7.012513947302068e-08
were O 0 6.234585470110687e-08
performed O 0 1.1269818855907943e-07
concurrently O 0 2.611679121855559e-07
on O 0 7.60013733724918e-07
49 O 0 2.489678081474267e-06
patients O 0 6.629513791267527e-07
with O 0 4.696043561125407e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
( O 0 3.4527474781498313e-06
DMD B-Disease 1 0.9999992847442627
) O 0 1.9102818882288375e-08
in O 0 5.408378633831035e-09
order O 0 3.4113731839369166e-09
to O 0 4.746477433315022e-09
find O 0 8.709783116955805e-09
a O 0 1.1609556338498805e-07
molecular O 0 1.0245227031191462e-06
explanation O 0 1.7378235384057916e-07
for O 0 7.169779792093323e-08
the O 0 7.545431230937538e-07
cognitive B-Disease 0 9.869869973044842e-05
impairment I-Disease 0 0.004852715414017439
observed O 0 8.934308652897016e-07
in O 0 6.931846314728318e-07
most O 0 2.7893488550034817e-06
DMD B-Disease 1 1.0
patients O 0 2.5280471163569018e-05
. O 0 6.894754278619075e-06

Complete O 0 4.2591178498696536e-05
analysis O 0 6.974064490350429e-06
of O 0 2.671834181455779e-06
the O 0 1.361082581752271e-06
dystrophin O 0 6.611446224269457e-06
gene O 0 5.51609332433145e-07
was O 0 4.77065941595356e-06
performed O 0 4.108778739464469e-07
to O 0 3.3017794720535676e-08
define O 0 7.181029815228612e-08
the O 0 3.7709594380430644e-07
localization O 0 3.6223282222636044e-06
of O 0 1.269039557882934e-07
deletions O 0 4.0934239109446935e-07
and O 0 6.329602086907471e-08
duplications O 0 4.617835145381832e-07
in O 0 5.10654665220045e-08
relation O 0 6.15723990904371e-07
to O 0 8.81144757158836e-08
the O 0 8.185996875909041e-07
different O 0 9.616885563445976e-07
DMD B-Disease 1 1.0
promoters O 0 0.0005404402036219835
. O 0 8.360338142665569e-06

Qualitative O 0 0.0002494717191439122
analysis O 0 1.7494798157713376e-05
of O 0 7.4028316703333985e-06
the O 0 4.106156666239258e-06
Dp71 O 0 4.569530938169919e-05
transcript O 0 7.900887794676237e-06
and O 0 2.01270978550383e-07
testing O 0 1.585916749036187e-07
for O 0 5.069659181344832e-08
the O 0 9.313703941415952e-08
specific O 0 1.822657758054902e-08
first O 0 3.4088387224073813e-07
exon O 0 4.0982007476486615e-07
of O 0 8.367113650820102e-07
Dp140 O 0 1.116222938435385e-05
were O 0 5.691279056918574e-07
also O 0 2.0219289353917702e-07
carried O 0 1.2003633855783846e-06
out O 0 1.6961699884632253e-06
. O 0 3.1894960557110608e-06

Neuropsychological O 0 0.0008699084282852709
analysis O 0 1.0101820407726336e-05
assessed O 0 1.093978153221542e-05
verbal O 0 2.3326982045546174e-05
and O 0 2.483152456989046e-06
visuospatial O 0 0.0003832581569440663
intelligence O 0 4.808048743143445e-06
, O 0 4.458420619357639e-07
verbal O 0 1.1960489246121142e-05
memory O 0 0.02237231470644474
, O 0 1.1658090670607635e-06
and O 0 5.362845172385278e-07
reading O 0 2.179599141527433e-05
skills O 0 1.1573099072847981e-05
. O 0 7.566799922642531e-06

Comparison O 0 3.3205134968739e-05
of O 0 7.480512522306526e-06
molecular O 0 2.3924945708131418e-05
and O 0 9.676795116320136e-07
psychometric O 0 4.26283513661474e-05
findings O 0 1.1633767371677095e-06
demonstrated O 0 4.992251660951297e-07
that O 0 3.7286685738990855e-08
deletions O 0 2.730795358729665e-07
and O 0 3.6625664279199555e-08
duplications O 0 5.721078650822164e-07
that O 0 3.523317104736634e-08
were O 0 8.400920847861926e-08
localized O 0 5.07549884787295e-07
in O 0 2.8036922117280483e-07
the O 0 7.834057669242611e-07
distal O 0 6.03091211814899e-06
part O 0 1.7524108386623993e-07
of O 0 6.679871944470506e-07
the O 0 4.7471772290919034e-07
gene O 0 2.6544924480731424e-07
seemed O 0 1.3719888158902904e-07
to O 0 9.742483264574275e-09
be O 0 2.5081797971893138e-08
preferentially O 0 1.1098801167008787e-07
associated O 0 1.7066587076897122e-07
with O 0 1.9479091406537918e-07
cognitive B-Disease 1 0.6836721301078796
impairment I-Disease 1 0.9999568462371826
. O 0 8.632272511022165e-06

Two O 0 2.0067036530235782e-05
altered O 0 2.5744724553078413e-05
Dp71 O 0 0.00014476143405772746
transcripts O 0 2.437599869153928e-05
and O 0 4.348360391759343e-07
two O 0 2.573170831965399e-07
deleted O 0 1.2417738162184833e-06
Dp140 O 0 2.7814912755275145e-06
DNA O 0 6.583276501714863e-08
sequences O 0 4.832154232303765e-08
were O 0 5.230477384543519e-08
found O 0 3.0419855079344416e-08
in O 0 4.141753962016992e-08
four O 0 1.2673778826410853e-07
patients O 0 1.0274579835822806e-06
with O 0 6.538665729749482e-06
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.0001448616967536509

These O 0 4.816070486413082e-06
findings O 0 4.108279426873196e-06
suggest O 0 4.93321465455665e-07
that O 0 4.10845686360517e-08
some O 0 1.2414211880695802e-08
sequences O 0 3.4784321201186685e-08
located O 0 3.911720511950989e-07
in O 0 9.378949528127123e-08
the O 0 1.6419930659594684e-07
distal O 0 9.246369359061646e-07
part O 0 5.483794041083456e-08
of O 0 2.2450102221682755e-07
the O 0 1.9549999308310362e-07
gene O 0 5.789654977661485e-08
and O 0 6.1087170877272e-08
, O 0 3.8477189434615866e-08
in O 0 5.691594751056073e-08
particular O 0 7.2995980815449e-08
, O 0 7.398841006533985e-08
some O 0 3.511650348286821e-08
DMD B-Disease 1 0.9999841451644897
isoforms O 0 2.1975559150178015e-07
expressed O 0 1.010399230949588e-07
in O 0 8.29538535640495e-08
the O 0 8.328025842274656e-07
brain O 0 0.00011587801418500021
may O 0 4.345359059243492e-07
be O 0 2.135826449034539e-08
related O 0 4.0375695675720635e-08
to O 0 1.73268936976001e-08
the O 0 5.835364049744385e-07
cognitive B-Disease 0 0.04075620323419571
impairment I-Disease 1 0.9995310306549072
associated O 0 7.699426532781217e-06
with O 0 3.121050895060762e-06
DMD B-Disease 1 1.0
. O 0 3.583416628316627e-06
. O 0 3.1284951091947732e-06

I1307K O 0 0.005383484996855259
APC O 0 0.00043091742554679513
and O 0 2.184332970500691e-06
hMLH1 O 0 8.472530680592172e-06
mutations O 0 5.224126766734116e-07
in O 0 2.845642086413136e-07
a O 0 8.417053436460264e-07
non O 0 1.2859025446232408e-05
- O 0 7.254595857375534e-06
Jewish O 0 7.054853199406352e-07
family O 0 5.099392907936817e-08
with O 0 6.157156207109438e-08
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00016218816745094955

We O 0 6.093413503549527e-06
describe O 0 2.9088014343869872e-06
a O 0 2.7480534754431574e-06
French O 0 5.654979031533003e-05
Canadian O 0 0.0001374492421746254
hereditary B-Disease 1 0.9999957084655762
non I-Disease 1 0.9999996423721313
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.009502232074737549
HNPCC B-Disease 1 0.9999977350234985
) O 0 4.5100978240952827e-07
kindred O 0 2.297456603628234e-06
which O 0 3.848834850828098e-08
carries O 0 1.77969653236687e-07
a O 0 1.2030665175188915e-07
novel O 0 3.5241782825323753e-07
truncating O 0 3.784971113418578e-06
mutation O 0 2.889977679387812e-07
in O 0 6.779457066841132e-07
hMLH1 O 0 2.826740274031181e-05
. O 0 3.3225496736122295e-06

Interestingly O 0 0.0002961524296551943
, O 0 1.1150334103149362e-05
the O 0 4.070742306794273e-06
I1307K O 0 8.57779523357749e-05
APC O 0 9.740992027218454e-06
polymorphism O 0 9.978772368413047e-07
, O 0 5.5908220275568965e-08
associated O 0 2.8282421737912955e-08
with O 0 4.363645000893257e-09
an O 0 9.18446616537949e-08
increased O 0 1.0109356480825227e-05
risk O 0 4.210547558614053e-05
of O 1 0.9994432330131531
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.612322080291051e-06
is O 0 1.0306617070909851e-07
also O 0 3.3384321085350166e-08
present O 0 5.510993261736985e-08
in O 0 2.0497566310950788e-07
this O 0 2.2552548273324646e-07
family O 0 1.6183671505132224e-06
. O 0 7.933769666124135e-06

The O 0 8.132815855788067e-05
I1307K O 0 0.00016921135829761624
polymorphism O 0 7.515078323194757e-06
has O 0 3.6723108109981695e-07
previously O 0 4.079145412561047e-07
only O 0 3.8886813769067885e-08
been O 0 1.2564073870180437e-07
identified O 0 8.831638353967719e-08
in O 0 5.614438336465355e-08
individuals O 0 1.7608817515224473e-08
of O 0 1.9235726540500764e-06
self O 0 6.994803698034957e-05
- O 0 0.000600703526288271
reported O 0 9.088357728614938e-06
Ashkenazi O 0 6.387685971276369e-06
Jewish O 0 1.808298179639678e-06
origins O 0 3.5362043036002433e-06
. O 0 2.463471446390031e-06

In O 0 1.1050529792555608e-05
addition O 0 1.1334008149788133e-06
, O 0 3.358563844813034e-07
in O 0 1.4792087199566595e-07
this O 0 7.007834312844352e-08
family O 0 5.678355208260655e-08
, O 0 3.063540887637828e-08
there O 0 2.8560680931377647e-08
appears O 0 1.3104575202760316e-07
to O 0 2.015759648088533e-08
be O 0 6.013333120336029e-08
no O 0 3.541386917049749e-08
relationship O 0 3.158256944857385e-08
between O 0 2.22937146077129e-07
the O 0 4.6543820531042e-07
I1307K O 0 3.0733258427062538e-06
polymorphism O 0 1.9506475723574113e-07
and O 0 5.249086498793076e-08
the O 0 1.2976765617622732e-07
presence O 0 1.5305860756598122e-07
or O 0 1.3959927969153796e-07
absence O 0 1.0149591389563284e-06
of O 0 2.7738308290281566e-06
cancer B-Disease 0 0.15555225312709808
. O 0 7.035926046228269e-07
. O 0 1.8782550341711612e-06

Identification O 0 7.113330411812058e-06
of O 0 2.993441512444406e-06
a O 0 1.6440455965494039e-06
novel O 0 6.237338538994663e-07
mutation O 0 2.134578807044818e-07
of O 0 5.960054636489076e-07
the O 0 8.54191796406667e-07
CPO O 0 0.0003114805440418422
gene O 0 1.2333970289546414e-07
in O 0 2.3044624697377003e-07
a O 0 1.889590180326195e-06
Japanese O 0 0.00018705488764680922
hereditary B-Disease 1 0.9999991655349731
coproporphyria I-Disease 1 0.9997174143791199
family O 0 3.122876296401955e-05
. O 0 1.3458103239827324e-05

Hereditary B-Disease 1 0.9999991655349731
coproporphyria I-Disease 1 0.9999850988388062
( O 0 0.0006496350397355855
HCP B-Disease 1 0.9999997615814209
) O 0 3.7430343127198284e-06
is O 0 3.4544424920568417e-07
an O 0 5.466698098643974e-07
autosomal B-Disease 1 0.9899435043334961
dominant I-Disease 1 0.9973695278167725
disease I-Disease 1 0.9999887943267822
characterized O 0 0.00010126677079824731
by O 0 1.3497797226591501e-06
a O 0 1.4940077562641818e-05
deficiency B-Disease 1 0.9998916387557983
of I-Disease 0 0.003003510180860758
coproporphyrinogen I-Disease 1 0.920244038105011
oxidase I-Disease 0 4.4117317884229124e-05
( O 0 2.6898354121840384e-07
CPO O 0 0.00020434374164324254
) O 0 3.8866641460799656e-08
caused O 0 2.661554674432409e-07
by O 0 1.6199804164784837e-08
a O 0 7.628101883483396e-08
mutation O 0 7.783791744486734e-08
in O 0 1.8363544995736447e-07
the O 0 2.9098946470185183e-06
CPO O 1 0.5036778450012207
gene O 0 6.9182283368718345e-06
. O 0 7.385850949503947e-06

Only O 0 3.3148969578178367e-06
11 O 0 3.695854275065358e-06
mutations O 0 2.9216747066129756e-07
of O 0 4.0596981421003875e-07
the O 0 1.6439486216768273e-07
gene O 0 1.4765520006676525e-07
have O 0 4.917291818173908e-08
been O 0 2.1894896917729056e-07
reported O 0 1.5017666328276391e-06
in O 0 1.898196387628559e-06
HCP B-Disease 1 0.9999958276748657
patients O 0 1.4955885490053333e-05
. O 0 9.7819520306075e-06

We O 0 9.144015166384634e-06
report O 0 3.527628905430902e-06
another O 0 2.209317244705744e-07
mutation O 0 2.1000765570988733e-07
in O 0 2.206931526416156e-07
a O 0 1.131456997427449e-06
Japanese O 0 1.9700357370311394e-05
family O 0 3.3662190617178567e-06
. O 0 4.467296548682498e-06

Polymerase O 1 0.9867948889732361
chain O 0 0.0013578144134953618
reaction O 0 5.0291364459553733e-05
- O 0 1.1823908607766498e-05
single O 0 4.205244295008015e-07
strand O 0 1.1785998594859848e-06
conformational O 0 1.363351742611485e-07
polymorphism O 0 8.289833886010456e-08
and O 0 1.3858830527624377e-08
direct O 0 6.268185614999311e-08
sequence O 0 7.042297056614188e-08
analyses O 0 2.4151663069460483e-07
demonstrated O 0 1.020685999719717e-06
a O 0 1.177293370346888e-06
C O 0 5.12077531311661e-06
to O 0 1.3730164027947467e-07
T O 0 1.372998326587549e-06
substitution O 0 1.59697648882684e-07
in O 0 4.559624144917507e-08
exon O 0 7.573244431569037e-08
1 O 0 8.544225948980966e-08
of O 0 2.1055834054095612e-07
the O 0 6.12918825027009e-07
CPO O 0 2.3562095520901494e-05
gene O 0 2.1758181389941456e-07
at O 0 7.906924679446092e-07
nucleotide O 0 6.242271979317593e-07
position O 0 5.855030735801847e-07
85 O 0 3.5279916232866526e-07
, O 0 3.828276007311615e-08
which O 0 4.18188079720494e-08
lies O 0 3.277382063515688e-07
in O 0 1.2045772734836646e-07
the O 0 3.109969384240685e-07
putative O 0 3.6512153656076407e-06
presequence O 0 9.907455932989251e-06
for O 0 2.085008219410156e-07
targeting O 0 2.097737706208136e-06
to O 0 5.400891609497194e-07
mitochondria O 0 3.678398934425786e-05
. O 0 7.638257557118777e-06

This O 0 3.9894230212667026e-06
mutation O 0 1.236342882293684e-06
changes O 0 2.971090680148336e-07
the O 0 3.843194065211719e-07
codon O 0 1.5105139254956157e-06
for O 0 4.674800280213276e-08
glutamine O 0 1.8089917830366176e-07
to O 0 2.3039145702341557e-08
a O 0 6.080040861888847e-07
termination O 0 5.076595698483288e-06
codon O 0 7.548327175754821e-06
at O 0 3.126091087324312e-06
amino O 0 6.292268608376617e-07
acid O 0 4.220696894208231e-07
position O 0 1.841508606048592e-06
29 O 0 1.45786671055248e-05
. O 0 3.5893608583137393e-06

MaeI O 0 0.0025289501063525677
restriction O 0 7.240263948915526e-05
analysis O 0 4.4199146032042336e-06
showed O 0 1.8170279645346454e-06
two O 0 6.099914884316604e-08
other O 0 2.5040545637011746e-08
carriers O 0 1.5325784374908835e-07
in O 0 2.0130859468281415e-07
the O 0 1.3627840189656126e-06
family O 0 1.9108560991298873e-06
. O 0 5.301364581100643e-06

The O 0 0.00021247567201498896
C O 0 0.002579674357548356
- O 0 0.0002535056264605373
T O 0 6.098360609030351e-05
mutation O 0 2.7472938768369204e-07
is O 0 6.82596663637014e-08
located O 0 1.592833314134623e-07
within O 0 3.193426323377935e-08
a O 0 1.4183578400661645e-07
recently O 0 2.60963275877657e-07
proposed O 0 1.8039646931811149e-07
putative O 0 9.9540602604975e-07
alternative O 0 1.427663391950773e-07
translation O 0 1.8602964928504662e-06
initiation O 0 1.0290299314874574e-06
codon O 0 2.5413646653760225e-06
( O 0 1.1521132137204404e-07
TIC O 0 3.122474026895361e-06
- O 0 2.6040663669846253e-07
1 O 0 2.409348667242739e-07
) O 0 2.8260799922463775e-08
, O 0 3.3296561952056436e-08
supporting O 0 2.697225625070132e-07
that O 0 1.8412366387110524e-07
TIC O 0 2.7605232389760204e-05
- O 0 1.1487202300486388e-06
1 O 0 5.588859153249359e-07
is O 0 5.775603639790461e-08
the O 0 3.701579203152505e-07
real O 0 3.2023581297835335e-06
TIC O 0 5.316241004038602e-05
rather O 0 1.72452828905989e-07
than O 0 2.19600366335726e-07
TIC O 0 1.96451619558502e-05
- O 0 1.4858568420095253e-06
2 O 0 8.800040518508467e-07
. O 0 2.0633738984088268e-07
. O 0 2.1450607619044604e-06

Human B-Disease 0 2.0254316041246057e-05
complement I-Disease 0 9.521068568574265e-05
factor I-Disease 1 0.9923446774482727
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.00012527417857199907
with O 0 0.0013283012667670846
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9421523809432983

This O 0 2.4672494873811956e-06
study O 0 8.411163889832096e-07
reports O 0 4.7043354811648896e-07
on O 0 5.967243055238214e-07
six O 0 1.1936870691897639e-07
cases O 0 7.79627242764036e-08
of O 0 6.474264864664292e-06
deficiency B-Disease 1 0.999987006187439
in I-Disease 0 9.557164730722434e-07
the I-Disease 0 5.702003704755043e-07
human I-Disease 0 2.860236349988554e-07
complement I-Disease 0 4.7069650577213906e-07
regulatory I-Disease 0 2.6017055461124983e-06
protein I-Disease 0 5.674279691447737e-06
Factor I-Disease 0 2.1851310521014966e-05
H I-Disease 1 0.9995386600494385
( O 0 3.1897681651571475e-07
FH O 0 1.6366182535421103e-05
) O 0 2.0380040766099228e-08
in O 0 8.602338397167841e-09
the O 0 1.291521467550183e-08
context O 0 3.1981929993207814e-08
of O 0 2.5959852223422786e-07
an O 0 3.468697104835883e-05
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.00010939857747871429

Five O 0 1.0280175956722815e-05
of O 0 1.0019385854320717e-06
the O 0 2.2147916922676814e-07
cases O 0 2.6878833381260847e-08
were O 0 4.4551903499723267e-08
observed O 0 8.901958636897689e-08
in O 0 3.6365463529364206e-08
children O 0 5.098138444736833e-08
presenting O 0 5.968518053123262e-07
with O 0 5.5014752433635294e-06
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999998807907104
HUS B-Disease 1 1.0
) O 0 0.00026852916926145554
. O 0 1.8521592210163362e-05

Two O 0 5.926866833760869e-06
of O 0 2.161626980523579e-06
the O 0 1.046539409799152e-06
children O 0 2.0638775310999335e-07
exhibited O 0 1.2684417924901936e-05
a O 0 3.3173762403748697e-06
homozygous O 0 3.611474676290527e-05
deficiency O 1 0.999908447265625
characterized O 0 4.768257895193528e-06
by O 0 2.412765240933368e-07
the O 0 2.084415626768532e-07
absence O 0 9.87819930742262e-07
of O 0 7.994141242306796e-07
the O 0 8.604702088632621e-07
150 O 0 3.612678369790956e-07
- O 0 1.784244290092829e-07
kD O 0 1.0145730584554258e-06
form O 0 1.8557159364718245e-08
of O 0 7.534306973866478e-07
Factor O 0 3.819411176664289e-06
H O 1 0.815912127494812
and O 0 1.6878439623724262e-07
the O 0 2.460270991377911e-07
presence O 0 1.5158836674800114e-07
, O 0 7.588730710494929e-08
upon O 0 1.830048574902321e-07
immunoblotting O 0 2.107089130731765e-06
, O 0 7.44780166428427e-08
of O 0 4.2511322817517794e-07
the O 0 5.641725238092477e-07
42 O 0 1.5058108147059102e-06
- O 0 1.4418238833968644e-06
kD O 0 2.1171394109842367e-05
Factor O 0 5.6204448810603935e-06
H O 0 0.003474228084087372
- O 0 5.265476943350222e-07
like O 0 4.9278074953917894e-08
protein O 0 1.6070079311703012e-07
1 O 0 5.7024499255931e-07
( O 0 8.866543055319198e-08
FHL O 0 3.7433769648487214e-06
- O 0 2.835916461663146e-07
1 O 0 3.603652771744237e-07
) O 0 2.355938200082619e-08
and O 0 2.0384396393069437e-08
other O 0 5.470964481446572e-08
FH O 0 3.018703864654526e-05
- O 0 1.7318158143098117e-06
related O 0 5.078204594610725e-07
protein O 0 1.2361425660856185e-06
( O 0 4.6310171342156536e-07
FHR O 0 4.127253487240523e-05
) O 0 2.7897164045498357e-07
bands O 0 1.6877601183296065e-06
. O 0 1.6593800182818086e-06

Southern O 0 5.506500747287646e-05
blot O 0 0.00015606626402586699
and O 0 3.900488536601188e-06
PCR O 0 1.2941105524078012e-05
analysis O 0 2.02553806616379e-07
of O 0 2.9870659545849776e-07
DNA O 0 5.837790695295553e-07
of O 0 1.4869029882902396e-06
one O 0 5.631135309158708e-07
patient O 0 1.6709311694285134e-06
with O 0 3.3172517532875645e-07
homozygous O 0 5.855412018718198e-05
deficiency O 1 0.9998507499694824
ruled O 0 1.859801614045864e-06
out O 0 5.7038100464978925e-08
the O 0 5.0689919817159534e-08
presence O 0 3.381626356713241e-08
of O 0 9.704060488502364e-08
a O 0 6.872827640336254e-08
large O 0 4.263596409259662e-08
deletion O 0 1.5619252735632472e-07
of O 0 2.2773951968702022e-07
the O 0 2.85671177380209e-07
FH O 0 2.82960736512905e-05
gene O 0 1.1315352566043657e-07
as O 0 1.4266670689266903e-07
the O 0 2.930894993369293e-07
underlying O 0 4.4924348912900314e-05
defect O 0 1.1378019735275302e-05
for O 0 8.72207124302804e-07
the O 0 0.00011215589620405808
deficiency O 1 0.9999991655349731
. O 0 2.1351730538299307e-05

The O 0 2.1136576833669096e-05
other O 0 3.435427231579524e-07
four O 0 2.534268332965439e-07
children O 0 8.849613664096978e-08
presented O 0 4.386751015772461e-07
with O 0 1.7162460608233232e-07
heterozygous O 0 1.973169855773449e-05
deficiency O 1 0.9998136162757874
and O 0 1.65280837904902e-07
exhibited O 0 5.1853076001862064e-05
a O 0 7.681113061153155e-07
normal O 0 1.3018653817198356e-06
immunoblotting O 0 4.664870175474789e-06
pattern O 0 4.068872669904522e-07
of O 0 1.766931774227487e-07
proteins O 0 1.0751685408649791e-07
of O 0 1.2783309557562461e-06
the O 0 5.825583230034681e-06
FH O 0 0.0014025424607098103
family O 0 4.249905941833276e-06
. O 0 4.859947694058064e-06

Factor B-Disease 1 0.9999830722808838
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
is O 0 3.863906385959126e-07
the O 0 2.3747925581574236e-07
only O 0 3.656738272184157e-07
complement B-Disease 1 0.9999983310699463
deficiency I-Disease 1 1.0
associated O 0 0.00010550711158430204
with O 0 1.3084886631986592e-05
HUS B-Disease 1 1.0
. O 0 8.500373951392248e-05

These O 0 2.033676537394058e-06
observations O 0 8.41318160382798e-06
suggest O 0 1.8394690641798661e-06
a O 0 1.2674699974013492e-06
role O 0 1.00527984159271e-06
for O 0 6.297323693615908e-07
FH O 0 0.0001801974867703393
and O 0 1.5913360584818292e-06
/ O 0 6.067871072445996e-05
or O 0 1.6784309764261707e-06
FH O 0 0.0015850441996008158
receptors O 0 1.1237229955440853e-06
in O 0 1.2847286257056112e-07
the O 0 8.114109277812531e-07
pathogenesis O 0 0.013382922857999802
of O 0 2.6054072804981843e-05
idiopathic O 1 1.0
HUS B-Disease 1 1.0
. O 0 8.672828698763624e-06
. O 0 3.5262160054116976e-06

Further O 0 2.912521040343563e-06
evidence O 0 5.88035732107528e-07
for O 0 8.229685022342892e-08
a O 0 3.111773310138233e-07
major O 0 1.3119446293785586e-06
ancient O 0 2.8518493309093174e-06
mutation O 0 0.001130746677517891
underlying O 1 0.9999974966049194
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.2588592426254763e-06
linkage O 0 1.7170255887322128e-05
disequilibrium O 0 1.5429468476213515e-05
studies O 0 4.031990954445064e-07
in O 0 1.0418884244245419e-07
the O 0 2.520041562092956e-07
Japanese O 0 1.91007256944431e-06
population O 0 2.3624950529210764e-07
. O 0 9.924467576638563e-07

The O 0 0.006596758496016264
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00010845358337974176
DM B-Disease 1 1.0
) O 0 9.117432000493864e-07
mutation O 0 1.185390374303097e-06
is O 0 3.6937578329343523e-07
an O 0 7.61251953917963e-07
unstable O 0 1.004782461677678e-05
( O 0 3.4879334975812526e-07
CTG O 0 1.9141398297506385e-05
) O 0 7.455675898881964e-08
n O 0 3.962090602271928e-07
repeat O 0 2.979410282932804e-07
, O 0 7.456557682417042e-08
present O 0 1.1277001021881006e-07
at O 0 5.426691132015549e-07
a O 0 1.2394413317906583e-07
copy O 0 1.6396521118622331e-07
number O 0 4.677137255271191e-08
of O 0 5.090413992547838e-07
5 O 0 1.281673235098424e-06
- O 0 1.016353962768335e-06
37 O 0 1.9305505247757537e-06
repeats O 0 6.177012892294442e-07
on O 0 7.612068770868063e-07
normal O 0 3.8712684613528836e-07
chromosomes O 0 1.6879180009254924e-07
but O 0 3.947463866893486e-08
amplified O 0 2.609164653222251e-07
to O 0 2.537643695177394e-08
50 O 0 2.0958870550202846e-07
- O 0 2.142745216815456e-07
3000 O 0 3.7391845353340614e-07
copies O 0 2.3428562201388559e-07
on O 0 7.689637641306035e-06
DM B-Disease 1 0.9999608993530273
chromosomes O 0 4.348202492110431e-05
. O 0 9.125616088567767e-06

Previous O 0 3.631897197919898e-05
findings O 0 5.805472937936429e-06
in O 0 5.87656757033983e-07
Caucasian O 0 2.355496917516575e-06
populations O 0 1.4726256836183893e-07
of O 0 9.627502777220798e-07
a O 0 2.2759220883017406e-05
DM B-Disease 1 1.0
founder O 0 0.00535778421908617
chromosome O 0 6.212889275047928e-06
raise O 0 1.3486200600709708e-07
a O 0 8.4952318957221e-08
question O 0 3.1519022059001145e-08
about O 0 1.534035654060517e-08
the O 0 3.6500971134501015e-08
molecular O 0 1.514921308398698e-07
events O 0 4.170259160218848e-08
involved O 0 4.0100097464801365e-08
in O 0 1.3444542901197565e-07
the O 0 4.2779086584232573e-07
expansion O 0 5.180130301596364e-06
mutation O 0 2.7721698643290438e-06
. O 0 2.539344222896034e-06

To O 0 7.088052370818332e-06
investigate O 0 4.66788696940057e-06
whether O 0 8.718129151930043e-07
a O 0 3.891058895533206e-06
founder O 0 2.8828126232838258e-05
chromosome O 0 1.1254056516918354e-05
for O 0 5.31564353423164e-07
the O 0 7.079601346049458e-06
DM B-Disease 1 1.0
mutation O 0 4.073461923326249e-07
exists O 0 4.4568643886577775e-08
in O 0 4.275118925534116e-08
the O 0 6.339146807476936e-08
Japanese O 0 3.4395611692161765e-07
population O 0 1.9710636678382798e-08
, O 0 1.8682383640111766e-08
we O 0 1.4810925819119802e-08
genotyped O 0 6.637433784817404e-07
families O 0 1.6168318239806467e-08
using O 0 3.6458107643966287e-08
polymorphic O 0 2.7767768528974557e-07
markers O 0 6.935621854609053e-07
near O 0 8.860768502927385e-06
the O 0 5.427048108685995e-07
( O 0 2.2645413366717548e-07
CTG O 0 1.2440338650776539e-05
) O 0 9.332517691973408e-08
n O 0 4.071508215020003e-07
repeat O 0 3.1348216111837246e-07
region O 0 3.7831276245015033e-07
and O 0 4.3703110463866324e-07
constructed O 0 6.489362567663193e-05
haplotypes O 0 3.272126559750177e-05
. O 0 5.56767690795823e-06

Six O 0 6.698246124869911e-06
different O 0 2.3341273447385902e-07
haplotypes O 0 1.273743782803649e-05
were O 0 1.1763921747842687e-06
found O 0 7.616106927343935e-07
and O 0 1.0671674317563884e-06
DM B-Disease 1 1.0
alleles O 0 7.855948638280097e-07
were O 0 4.941483098264143e-07
always O 0 2.2960102796787396e-07
haplotype O 0 8.607988092990126e-06
A O 0 7.586177616758505e-06
. O 0 2.608597469588858e-06

To O 0 1.576348950038664e-05
find O 0 6.062202260181948e-07
an O 0 4.885142743660253e-07
origin O 0 2.4235094997493434e-07
of O 0 1.1679545650622458e-06
the O 0 1.129234192376316e-06
( O 0 2.1704401831357245e-07
CTG O 0 1.581278229423333e-05
) O 0 8.201963197507212e-08
n O 0 2.3463667275791522e-07
repeat O 0 6.425429432965757e-08
mutation O 0 2.3272873406199324e-08
and O 0 2.4088700811830677e-08
to O 0 1.7702705079614134e-08
investigate O 0 7.325038353656055e-08
the O 0 2.6093638894053583e-07
mechanism O 0 4.5393019831863057e-07
of O 0 2.398060985342454e-07
the O 0 1.4714969154283608e-07
expansion O 0 5.924042056904e-07
mutation O 0 3.786736257893608e-08
in O 0 4.771569450667812e-08
the O 0 9.613092544213941e-08
Japanese O 0 3.387346509953204e-07
population O 0 8.396784600961382e-09
we O 0 6.089833526345956e-09
have O 0 1.1343526118423597e-08
studied O 0 4.525280132838816e-07
90 O 0 1.1915469713130733e-06
Japanese O 0 1.5201155292743351e-05
DM B-Disease 1 0.9999704360961914
families O 0 4.043095103156702e-08
comprising O 0 5.7742600034771385e-08
190 O 0 4.166308826825116e-07
affected O 0 6.835556121131958e-08
and O 0 5.2797116012470724e-08
130 O 0 1.0551549394222093e-06
unaffected O 0 4.002794867119519e-06
members O 0 2.563676844147267e-07
. O 0 1.5274961242539575e-06

The O 0 2.3098928068066016e-05
results O 0 4.110403551749187e-06
suggest O 0 3.5287925470584014e-07
that O 0 1.463137238033596e-07
a O 0 5.348472313926322e-07
few O 0 6.302616384346038e-08
common O 0 5.1487482721768174e-08
ancestral O 0 6.450663931900635e-07
mutations O 0 9.02957921766756e-08
in O 0 1.64549831538352e-07
both O 0 1.1164023305809678e-07
Caucasian O 0 1.4563619288310292e-06
and O 0 1.7402713581304852e-07
Japanese O 0 1.4803971453147824e-06
populations O 0 2.1264691341116304e-08
have O 0 8.653467276076299e-09
originated O 0 4.377068307803711e-08
by O 0 3.137040494038956e-08
expansion O 0 2.821233522354305e-07
of O 0 1.9783749394264305e-07
an O 0 9.676355716692342e-08
ancestral O 0 5.769767312813201e-07
n O 0 7.838332294340944e-07
= O 0 6.789997542000492e-07
5 O 0 3.8718076211807784e-07
repeat O 0 2.1086862034280784e-07
to O 0 9.557604840892964e-08
n O 0 1.7784558394851047e-06
= O 0 1.9462099771772046e-06
19 O 0 3.785758053709287e-06
- O 0 1.2210351769681438e-06
37 O 0 1.2931244555147714e-06
copies O 0 8.669510407344205e-07
. O 0 1.3602754052044475e-06

These O 0 1.4897926803314476e-06
data O 0 1.7443818478568573e-06
support O 0 9.90977923720493e-07
multistep O 0 9.440071153221652e-06
models O 0 9.453137295167835e-07
of O 0 1.1730089681805111e-06
triplet O 0 2.294043224537745e-05
repeat O 0 7.302389803953702e-07
expansion O 0 7.915615469755721e-07
that O 0 2.1042140474492044e-08
have O 0 1.2974570751111969e-08
been O 0 3.333914122549686e-08
proposed O 0 5.260091384684529e-08
for O 0 4.0272329471235935e-08
both O 0 6.086770554247778e-07
DM B-Disease 1 1.0
and O 0 6.518493137264159e-06
Friedreichs B-Disease 1 0.9261696934700012
ataxia I-Disease 1 0.999386191368103
. O 0 3.6185097087582108e-06
. O 0 4.970568625140004e-06

The O 0 8.640244232083205e-06
molecular O 0 1.3987854799779598e-05
basis O 0 1.0944477253360674e-05
of O 0 0.0004497407644521445
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.225809455718263e-06
the O 0 5.423152060757275e-07
western O 0 4.318802382385911e-07
Cape O 0 1.641640551497403e-06
, O 0 1.1587599146878347e-07
South O 0 5.531016427084978e-07
Africa O 0 1.3792820254820981e-06
. O 0 8.49455773277441e-07

Deficiency B-Disease 1 0.999757707118988
of I-Disease 0 4.5097633119439706e-05
the I-Disease 0 6.767546437913552e-06
sixth I-Disease 0 2.8572629162226804e-05
component I-Disease 0 1.3327662600204349e-06
of I-Disease 0 1.1092499789810972e-06
human I-Disease 0 8.040713623813645e-07
complement I-Disease 0 1.1275274118816014e-06
( O 0 6.479135663539637e-07
C6 O 0 0.00017103333084378392
) O 0 5.8299242766679527e-08
has O 0 3.018369909568719e-08
been O 0 3.337527942903762e-08
reported O 0 4.723108304460766e-08
in O 0 1.339914845743806e-08
a O 0 3.046700314257578e-08
number O 0 2.0373978060206355e-08
of O 0 2.2582591441278055e-07
families O 0 2.6379820994293368e-08
from O 0 1.8599935458496475e-07
the O 0 2.611001548302738e-07
western O 0 9.449856293031189e-07
Cape O 0 2.003388544835616e-06
, O 0 1.3674888066361746e-07
South O 0 6.078649334995134e-07
Africa O 0 1.0182457117480226e-06
. O 0 1.2630728178919526e-06

Meningococcal B-Disease 1 0.9999985694885254
disease I-Disease 1 0.8286416530609131
is O 0 1.1135541626572376e-06
endemic O 0 4.0593999983684625e-07
in O 0 9.610049289676681e-08
the O 0 1.2861617904036393e-07
Cape O 0 3.878607799379097e-07
and O 0 2.4155827560434773e-08
almost O 0 3.304085183231109e-08
all O 0 4.792426455679788e-09
pedigrees O 0 1.0063948252536647e-07
of O 0 3.4463644738025323e-07
total O 0 0.10535871982574463
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 4.636474955077574e-07
C6Q0 O 0 3.920755989383906e-05
) O 0 1.117386094762196e-08
have O 0 3.5819274213366725e-09
been O 0 2.489691297569152e-08
ascertained O 0 1.6050536544298666e-07
because O 0 1.907893221186896e-08
of O 0 1.0479836873855675e-06
recurrent O 1 0.9999921321868896
disease O 1 0.9999291896820068
. O 0 1.7044047126546502e-05

We O 0 2.757491301963455e-06
have O 0 2.495739579444489e-07
sequenced O 0 1.080092829397472e-06
the O 0 2.8719759370687825e-07
expressed O 0 1.978105217403936e-07
exons O 0 6.400940719686332e-07
of O 0 1.2935438462591264e-06
the O 0 1.1164422630827175e-06
C6 O 0 0.00015980809985194355
gene O 0 1.9300300380109547e-07
from O 0 1.0799944050177146e-07
selected O 0 3.617094179730884e-08
cases O 0 1.3730327985683743e-08
and O 0 3.325150288446821e-08
have O 0 2.546312849460719e-08
found O 0 6.884911840643326e-08
three O 0 2.5948912707463023e-07
molecular O 0 0.0016788312932476401
defects O 1 0.98643559217453
leading O 0 8.209942461689934e-05
to O 0 2.457902326113981e-07
total O 0 5.808490459457971e-05
deficiency O 1 0.9999665021896362
879delG O 0 3.038383692910429e-05
, O 0 2.1119505788647075e-07
which O 0 6.291867293839459e-08
is O 0 7.175539451509394e-08
the O 0 2.2530576870849472e-07
common O 0 4.17520993778453e-07
defect O 0 5.332914042810444e-06
in O 0 4.021292170364177e-07
the O 0 8.780298799138109e-07
Cape O 0 2.0885929643554846e-06
and O 0 9.765258823790646e-08
hitherto O 0 1.932960230988101e-06
unreported O 0 1.4100892258284148e-06
, O 0 7.358337228424716e-08
and O 0 6.016006892650694e-08
1195delC O 0 9.818427315622102e-07
and O 0 9.726333871640236e-08
1936delG O 0 5.488586225510517e-07
, O 0 2.4016763688905485e-08
which O 0 1.3203647952764186e-08
have O 0 2.0439406611671984e-08
been O 0 1.0493012325696327e-07
previously O 0 3.7404007002805884e-07
reported O 0 1.1411556215534802e-06
in O 0 8.445550747637753e-07
African O 0 5.382702056522248e-06
- O 0 1.1701257790264208e-05
Americans O 0 1.1227183449591394e-06
. O 0 2.179927378165303e-06

We O 0 1.1529739822435658e-05
also O 0 1.2783456213583122e-06
show O 0 4.663486095068947e-07
that O 0 8.95821656854423e-08
the O 0 4.041122281250864e-07
879delG O 0 8.034726306505036e-06
and O 0 1.8079171013596351e-06
1195delC O 0 0.00024730994482524693
defects O 0 0.4522205889225006
are O 0 8.44896845819676e-08
associated O 0 2.2898655060998863e-07
with O 0 7.68768089187688e-08
characteristic O 0 0.018150219693779945
C6 O 1 1.0
/ O 1 0.9739736318588257
C7 O 1 0.9713321328163147
region O 0 2.8320326350694813e-07
DNA O 0 3.7463695434780675e-07
marker O 0 3.377009988980717e-06
haplotypes O 0 8.560224955544982e-07
, O 0 1.7789625772479667e-08
although O 0 6.9689236603664995e-09
small O 0 1.3280860855502397e-08
variations O 0 1.4806172998760303e-07
were O 0 6.440282049879897e-07
observed O 0 1.7617672938285978e-06
. O 0 2.1627488422382157e-06

The O 0 6.455002585425973e-05
1936delG O 0 0.0002489527687430382
defect O 0 9.031740773934871e-05
was O 0 1.1224399713682942e-05
observed O 0 5.387911414800328e-07
only O 0 6.27212060066995e-08
once O 0 1.7728596901633864e-07
in O 0 1.0635164215955228e-07
the O 0 1.837573790908209e-07
Cape O 0 8.049368034335203e-07
, O 0 2.1653928428122526e-08
but O 0 6.027133458985645e-09
its O 0 6.284491149699534e-08
associated O 0 2.420319731299969e-07
haplotype O 0 2.554856564529473e-06
could O 0 2.094586193379655e-07
be O 0 4.834320179725182e-07
deduced O 0 1.2878047527919989e-05
. O 0 1.8301878981219488e-06

The O 0 2.7337155188433826e-05
data O 0 7.197860213636886e-06
from O 0 1.0708804438763764e-06
the O 0 2.83996797634245e-07
haplotypes O 0 1.3661465345649049e-06
indicate O 0 1.8441274107772188e-07
that O 0 2.148627764597677e-08
these O 0 1.348933409417441e-08
three O 0 1.9367895731647877e-07
molecular O 0 0.00022265547886490822
defects O 0 0.027214592322707176
account O 0 2.95260377924933e-07
for O 0 3.8063427609813516e-07
the O 0 3.841072611976415e-06
defects O 0 0.0017971417400985956
in O 0 1.986209099413827e-07
all O 0 3.323400221688644e-08
the O 0 3.663999166292342e-07
38 O 0 1.4672680208605016e-06
unrelated O 0 5.861555791852879e-07
C6Q0 O 0 2.1386007574619725e-05
individuals O 0 2.202986060240164e-08
we O 0 2.182834002439904e-08
have O 0 3.051038532930761e-08
studied O 0 6.460477379732765e-07
from O 0 4.803410433851241e-07
the O 0 1.1076538157794857e-06
Cape O 0 1.5390744010801427e-05
. O 0 2.255642812087899e-06

We O 0 6.878296062495792e-06
have O 0 5.936954039498232e-07
also O 0 3.7175058764660207e-07
observed O 0 8.81086577919632e-07
the O 0 7.413941602862906e-07
879delG O 0 4.893386176263448e-06
defect O 0 3.650212647698936e-06
in O 0 2.0881181228560308e-07
two O 0 4.866278686677106e-07
Dutch O 0 0.07866492867469788
C6 B-Disease 1 1.0
- I-Disease 1 0.9958075284957886
deficient I-Disease 1 0.9999898672103882
kindreds O 0 2.0692174075520597e-05
, O 0 9.48679073076164e-08
but O 0 1.924295389699182e-08
the O 0 1.1280485523457173e-07
879delG O 0 2.2919550701772096e-06
defect O 0 1.4823127685303916e-06
in O 0 1.6286976745050197e-07
the O 0 4.78385345559218e-07
Cape O 0 2.2631454612564994e-06
probably O 0 2.1339415923193883e-07
did O 0 3.2019894291579476e-08
not O 0 1.0605928579821011e-08
come O 0 1.658409587435017e-08
from O 0 6.837225186018259e-08
The O 0 1.878300253110865e-07
Netherlands O 0 9.45576118738245e-07
. O 0 4.2525553567429597e-07
. O 0 1.5287787391571328e-06

Complement B-Disease 1 0.9999624490737915
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.16615193898906e-06
seven O 0 1.041488530972856e-06
further O 0 1.298609163313813e-06
molecular O 0 0.08194379508495331
defects O 1 0.638247013092041
and O 0 3.816036269199685e-07
their O 0 2.779916314921138e-07
associated O 0 7.718334927631076e-06
marker O 0 0.00037293406785465777
haplotypes O 0 0.00014667974028270692
. O 0 6.5943499976128805e-06

Seven O 0 1.2888294804724865e-05
further O 0 2.048356691375375e-06
molecular O 0 2.4966420824057423e-05
bases O 0 1.602461634320207e-05
of O 0 0.17393946647644043
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.1635609098448185e-06
described O 0 4.505283868638799e-06
. O 0 1.1965208841502317e-06

All O 0 1.9713586425496032e-06
these O 0 3.0167186082508124e-07
new O 0 9.713410236145137e-07
molecular O 0 6.648108683293685e-05
defects O 0 0.00010431354166939855
involve O 0 8.468867349620268e-07
single O 0 2.371669779677177e-06
- O 0 2.776212340904749e-06
nucleotide O 0 1.2677105587499682e-06
events O 0 1.8867706330638612e-07
, O 0 7.105793287109918e-08
deletions O 0 2.5578376039447903e-07
and O 0 4.929706420853108e-08
substitutions O 0 7.741180496623201e-08
, O 0 3.5474581494554513e-08
some O 0 7.720945660594225e-09
of O 0 1.4788999180836981e-07
which O 0 1.2218278300224483e-07
alter O 0 4.028723878946039e-07
splice O 0 1.1076464261350338e-06
sites O 0 1.0456570009864663e-07
, O 0 5.033940198018172e-08
and O 0 1.6831069160616607e-07
others O 0 6.114173061178008e-07
codons O 0 1.675857129157521e-05
. O 0 4.732531579065835e-06

They O 0 2.3365466859104345e-06
are O 0 5.593862084651846e-08
distributed O 0 7.829787307400693e-08
along O 0 1.7084484227325447e-07
the O 0 3.6910603284923127e-07
C7 O 0 3.502118488540873e-05
gene O 0 1.4337625486859906e-07
, O 0 1.9674354589938048e-08
but O 0 5.485329079846224e-09
predominantly O 0 1.1177292869035682e-08
towards O 0 1.2565247686779912e-07
the O 0 1.842736736534789e-07
3 O 0 9.917239367496222e-07
end O 0 3.1069921533344314e-06
. O 0 2.0007232706120703e-06

All O 0 1.8822717038347037e-06
were O 0 9.069413522411196e-07
found O 0 2.531022289531393e-07
in O 0 2.570012043179304e-07
compound O 0 9.600093108019792e-06
heterozygous O 0 1.1697269428623258e-06
individuals O 0 2.4922837837948464e-07
. O 0 3.4444560697011184e-06

The O 0 0.00048330167192034423
C6 O 1 0.9999183416366577
/ O 0 0.2571617066860199
C7 O 1 0.9928763508796692
marker O 0 0.00022856463328935206
haplotypes O 0 3.173317600158043e-05
associated O 0 1.3941756833446561e-06
with O 0 3.549083089637861e-07
most O 0 5.637569302052725e-06
C7 B-Disease 1 1.0
defects I-Disease 1 0.9997696280479431
are O 0 1.2756891010212712e-07
tabulated O 0 2.5827198442129884e-06
. O 0 1.6995106477679656e-07
. O 0 7.966233965817082e-07

A O 0 0.00011152199294883758
genome O 0 1.528762913949322e-05
- O 0 3.4780359783326276e-06
wide O 0 4.937959374728962e-07
search O 0 1.1196138416380563e-07
for O 0 6.616610193077577e-08
chromosomal O 0 0.00011034379713237286
loci O 0 2.765136923699174e-05
linked O 0 1.313678967562737e-05
to O 0 1.473072330782088e-07
mental O 0 0.025965718552470207
health O 0 5.3295789257390425e-06
wellness O 0 7.695880776736885e-05
in O 0 1.8453694394793274e-07
relatives O 0 1.8624857034410525e-07
at O 0 7.467924660886638e-06
high O 0 0.0003007241466548294
risk O 0 4.959582838637289e-06
for O 0 4.252066446497338e-06
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 0.9999951124191284
among O 0 1.0472792837390443e-06
the O 0 1.6919823337957496e-06
Old O 0 1.0388447662990075e-05
Order O 0 1.8172272575611714e-06
Amish O 0 3.6390840250533074e-05
. O 0 5.6357093853875995e-06

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9996063113212585
BPAD B-Disease 1 1.0
; O 1 0.9698142409324646
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 1.823362140385143e-06
is O 0 8.115566174637934e-08
characterized O 0 8.368695603166998e-08
by O 0 1.3881291671680174e-08
episodes O 0 1.2611697286502022e-07
of O 0 4.67670543002896e-06
mania B-Disease 1 0.9966429471969604
and O 0 6.101333383412566e-06
/ O 1 0.9832567572593689
or O 0 6.048987415852025e-06
hypomania B-Disease 1 0.9989808201789856
interspersed O 0 4.469158739084378e-06
with O 0 9.986391802385697e-08
periods O 0 8.445537787338253e-06
of O 0 0.00011137045657960698
depression B-Disease 1 0.9999959468841553
. O 0 2.6006586267612875e-05

Compelling O 0 1.7198837667820044e-05
evidence O 0 1.769563596099033e-06
supports O 0 1.8915666544216947e-07
a O 0 9.985096482978406e-08
significant O 0 4.2257795485056704e-08
genetic O 0 1.1812358735596717e-07
component O 0 6.368693448166596e-07
in O 0 6.175539368769023e-08
the O 0 1.7613898251056526e-07
susceptibility O 0 7.133500275813276e-06
to O 0 8.408244980273594e-07
develop O 0 2.8674361601588316e-05
BPAD B-Disease 1 1.0
. O 0 4.224713484290987e-05

To O 0 3.117326741630677e-06
date O 0 2.807041482810746e-06
, O 0 1.3361561457259086e-07
however O 0 3.542657367461288e-08
, O 0 2.4583398428035252e-08
linkage O 0 6.615196070924867e-07
studies O 0 7.706913152105699e-08
have O 0 2.0149139245972947e-08
attempted O 0 2.0667728506396088e-07
only O 0 1.6923257462053698e-08
to O 0 1.9688542352014338e-08
identify O 0 5.850242246197013e-08
chromosomal O 0 2.5975925382226706e-05
loci O 0 5.142539521330036e-06
that O 0 8.967808184934256e-08
cause O 0 9.967321830117726e-07
or O 0 1.1883972916848506e-07
increase O 0 2.659255926573678e-07
the O 0 5.041367785452167e-07
risk O 0 1.0671113841453916e-06
of O 0 3.6637302400777116e-06
developing O 0 2.081218372040894e-05
BPAD B-Disease 1 1.0
. O 0 1.055715256370604e-05

To O 0 3.5125528938806383e-06
determine O 0 6.892269084346481e-07
whether O 0 2.5952476789825596e-07
there O 0 2.395064768734301e-07
could O 0 1.2335851806710707e-07
be O 0 9.300939751710757e-08
protective O 0 2.1541370642808033e-07
alleles O 0 3.0740238798898645e-08
that O 0 1.312230324401753e-08
prevent O 0 6.580037137382533e-08
or O 0 5.673278025142281e-08
reduce O 0 7.091874465459114e-08
the O 0 2.6391026608507673e-07
risk O 0 3.14160047309997e-07
of O 0 8.116987828543643e-07
developing O 0 2.3524032712884946e-06
BPAD B-Disease 1 0.9999998807907104
, O 0 2.422328115869732e-08
similar O 0 6.1074216795020675e-09
to O 0 3.4348250910198885e-09
what O 0 3.820250782382573e-09
is O 0 5.054169971430156e-09
observed O 0 1.751529410398689e-08
in O 0 2.124713560647251e-08
other O 0 7.169150961772175e-08
genetic B-Disease 1 0.9999996423721313
disorders I-Disease 1 1.0
, O 0 8.612353781245474e-07
we O 0 4.4259781617483895e-08
used O 0 2.81575296412484e-07
mental O 0 0.12624219059944153
health O 0 0.00026579812401905656
wellness O 1 0.6205418705940247
( O 0 4.6243005158430606e-07
absence O 0 2.158499910365208e-06
of O 0 9.385522616867092e-07
any O 0 5.330227850208757e-07
psychiatric B-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9996969699859619
) O 0 6.134907835075865e-07
as O 0 3.2466994071000954e-07
the O 0 2.6995778057425923e-07
phenotype O 0 5.834423859596427e-07
in O 0 1.4401030057342723e-07
our O 0 9.282084079131891e-08
genome O 0 5.162249863133184e-07
- O 0 1.1772551715694135e-06
wide O 0 1.6506013480466208e-06
linkage O 0 4.655802968045464e-06
scan O 0 1.2025541309412802e-06
of O 0 6.647969144069066e-07
several O 0 2.067137501171601e-07
large O 0 8.590074571657169e-07
multigeneration O 0 2.7872516511706635e-05
Old O 0 2.6470324883121066e-06
Order O 0 1.483901002075072e-07
Amish O 0 1.8703759678828646e-06
pedigrees O 0 6.101626013332861e-07
exhibiting O 0 4.573010983222048e-07
an O 0 9.116330090819247e-08
extremely O 0 4.627860619166313e-07
high O 0 1.6678199244779535e-05
incidence O 0 0.009865685366094112
of O 0 0.00010494050366105512
BPAD B-Disease 1 1.0
. O 0 1.9447777958703227e-05

We O 0 8.019982487894595e-06
have O 0 4.7642578238082933e-07
found O 0 2.41982121451656e-07
strong O 0 2.052966863175243e-07
evidence O 0 2.3112434632821532e-07
for O 0 1.6075091480161063e-07
a O 0 7.132311452551221e-07
locus O 0 8.280735528387595e-06
on O 0 5.439039796328871e-06
chromosome O 0 0.00016434898134320974
4p O 0 0.17943412065505981
at O 0 4.1880019125528634e-05
D4S2949 O 0 1.7514030332677066e-05
( O 0 1.3737432880134293e-07
maximum O 0 2.200652716055629e-06
GENEHUNTER O 0 2.3332189812208526e-05
- O 0 1.0275050499330973e-06
PLUS O 0 6.028412258274329e-07
nonparametric O 0 1.4933289094187785e-06
linkage O 0 8.178450912055268e-07
score O 0 1.2876026289632136e-07
= O 0 2.0547707890727906e-07
4 O 0 1.4198425901668088e-07
. O 0 2.405463206400782e-08
05 O 0 1.9927674657083116e-06
, O 0 7.891904374446312e-08
P O 0 1.3751238157055923e-06
= O 0 1.0674629891127552e-07
5 O 0 8.074372459532242e-08
. O 0 2.3720668096416375e-08
22 O 0 2.1379361214712844e-07
x O 0 4.658582781758014e-07
10 O 0 1.7316575906534126e-07
( O 0 2.368404850017214e-08
- O 0 9.070367923413869e-08
4 O 0 2.3828053485885903e-07
) O 0 1.765650736729185e-08
; O 0 1.585456566033372e-08
SIBPAL O 0 1.9816391159110935e-06
Pempirical O 0 1.0613111953716725e-06
value O 0 3.299822139979369e-07
< O 0 3.637982786131033e-07
3 O 0 2.5588380481167405e-07
x O 0 3.407811846045661e-07
10 O 0 1.563211355914973e-07
( O 0 5.8572982908344784e-08
- O 0 2.2333804849949956e-07
5 O 0 1.847096626761413e-07
) O 0 2.4819721389235383e-08
) O 0 2.082851047191525e-08
and O 0 2.6188114787828454e-08
suggestive O 0 3.6761409205610107e-07
evidence O 0 6.353951675919234e-08
for O 0 6.61122356859778e-08
a O 0 7.17323985099938e-07
locus O 0 8.160888683050871e-06
on O 0 8.053398232732434e-06
chromosome O 0 0.012684725224971771
4q O 1 0.9946590065956116
at O 0 4.8009518650360405e-05
D4S397 O 0 2.5649202143540606e-05
( O 0 2.361409343620835e-07
maximum O 0 1.2883374438388273e-06
GENEHUNTER O 0 2.6989086109097116e-05
- O 0 9.985208180296468e-07
PLUS O 0 5.23118615092244e-07
nonparametric O 0 1.728908046061406e-06
linkage O 0 1.3163812582206447e-06
score O 0 2.2152903511596378e-07
= O 0 3.0122856742309523e-07
3 O 0 9.424964275694947e-08
. O 0 1.5445463574792484e-08
29 O 0 4.793745347342337e-07
, O 0 8.611188917484469e-08
P O 0 1.886163886410941e-06
= O 0 1.9647545457246451e-07
2 O 0 1.5077176840350148e-07
. O 0 1.9425122843585996e-08
57 O 0 2.2400229227059754e-07
x O 0 2.6578007350508415e-07
10 O 0 1.1386744347419153e-07
( O 0 2.6082735971044713e-08
- O 0 1.1394141807841152e-07
3 O 0 1.203654136361365e-07
) O 0 2.277763933022925e-08
; O 0 2.8941361307488478e-08
SIBPAL O 0 2.1811024453199934e-06
Pempirical O 0 1.2922848782181973e-06
value O 0 1.6578252370891278e-07
< O 0 4.311370389586955e-07
1 O 0 1.827347091420961e-07
x O 0 1.8193361484009074e-07
10 O 0 7.362899623331032e-08
( O 0 2.1112008141699334e-08
- O 0 9.97535067881472e-08
3 O 0 1.0641981873504847e-07
) O 0 1.0290859719930268e-08
) O 0 3.727358421912186e-09
that O 0 2.6084858717467796e-09
are O 0 3.854702779193531e-09
linked O 0 3.596868225486105e-07
to O 0 8.007535257092968e-08
mental O 1 0.5283567905426025
health O 0 0.005000125151127577
wellness O 0 0.4525415301322937
. O 0 6.984733772696927e-06

These O 0 2.146247652490274e-06
findings O 0 2.575672624516301e-06
are O 0 8.066075452006771e-08
consistent O 0 3.213694697024039e-07
with O 0 1.7832906706871654e-08
the O 0 1.0896656732484189e-07
hypothesis O 0 6.792770079755428e-08
that O 0 3.2214988454626337e-09
certain O 0 8.480544266831203e-09
alleles O 0 4.573778866756584e-08
could O 0 2.9134044510215062e-08
prevent O 0 6.180123790500147e-08
or O 0 5.8941019176472764e-08
modify O 0 3.4734863874064104e-08
the O 0 1.2310890440403455e-07
clinical O 0 3.959577952628024e-06
manifestations O 0 7.256880780914798e-05
of O 0 9.082638280233368e-05
BPAD B-Disease 1 1.0
and O 0 4.375995956706902e-07
perhaps O 0 1.7859346712612023e-07
other O 0 8.0996379381304e-08
related O 0 5.746974056819454e-05
affective B-Disease 1 0.9999982118606567
disorders I-Disease 1 1.0
. O 0 7.771213131491095e-05

Segregation O 0 0.009327458217740059
distortion O 1 0.9996029734611511
in O 0 0.007044706493616104
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00014929189637769014

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.61000657081604
DM B-Disease 1 1.0
) O 0 6.9232187343004625e-06
is O 0 5.840597623318899e-07
an O 0 4.267933206847374e-07
autosomal B-Disease 0 0.00019715589587576687
dominant I-Disease 0 0.014693599194288254
disease I-Disease 1 0.9187222123146057
which O 0 4.3497868773556547e-07
, O 0 6.846725852938107e-08
in O 0 8.338167845067801e-08
the O 0 3.811417172983056e-07
typical O 0 5.716377700082376e-07
pedigree O 0 5.296389531395107e-07
, O 0 2.4240060625402293e-08
shows O 0 4.395322505956756e-08
a O 0 1.6927138801747788e-07
three O 0 1.0211889645006522e-07
generation O 0 1.981867626454914e-06
anticipation O 0 8.474389687762596e-06
cascade O 0 0.000296369893476367
. O 0 9.158537977782544e-06

This O 0 3.21205698128324e-06
results O 0 6.006885087117553e-06
in O 0 3.7915283428446855e-06
infertility B-Disease 1 0.9999996423721313
and O 1 0.998889148235321
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.2704366781690624e-05
CDM B-Disease 1 0.857090413570404
) O 0 2.8174577337836126e-08
with O 0 5.3219708640028784e-09
the O 0 9.336469730669705e-08
disappearance O 0 5.337462880561361e-06
of O 0 2.4647666577948257e-05
DM B-Disease 1 1.0
in O 0 2.6696895929489983e-06
that O 0 9.735240382724442e-07
pedigree O 0 3.457547791185789e-05
. O 0 4.78691117677954e-06

The O 0 1.228443670697743e-05
concept O 0 3.2843606732058106e-06
of O 0 1.695707396720536e-06
segregation O 0 6.769204901502235e-06
distortion O 0 2.4295000912388787e-05
, O 0 9.074728524183229e-08
where O 0 6.830747167896334e-08
there O 0 2.5393868341438974e-08
is O 0 2.1713400855105647e-08
preferential O 0 2.791717861327925e-07
transmission O 0 9.285604392061941e-07
of O 0 4.244710964940168e-07
the O 0 2.2851882874874718e-07
larger O 0 7.376774391332219e-08
allele O 0 2.0221816043886065e-07
at O 0 1.2971906926395604e-06
the O 0 6.239772005756095e-07
DM B-Disease 1 0.9999006986618042
locus O 0 2.5619908683438553e-06
, O 0 5.353595611268247e-08
has O 0 2.61124508682542e-08
been O 0 4.881947646140361e-08
put O 0 2.969534840246979e-08
forward O 0 4.4203595450653665e-08
to O 0 9.159656144674955e-09
explain O 0 6.500451377178251e-08
partially O 0 7.282721981027862e-07
the O 0 2.244939594220341e-07
maintenance O 0 2.907004727603635e-06
of O 0 5.458781743072905e-06
DM B-Disease 1 1.0
in O 0 5.448408728625509e-07
the O 0 4.943024691783648e-07
population O 0 4.0324675865122117e-07
. O 0 1.1481474757601973e-06

In O 0 1.5923493265290745e-05
a O 0 5.487018370331498e-06
survey O 0 4.385610282042762e-06
of O 0 4.914703367830953e-06
DM B-Disease 1 0.9999998807907104
in O 0 7.200786740213516e-07
Northern O 0 3.379409179160575e-07
Ireland O 0 1.0352523105439104e-07
, O 0 5.9277216024611334e-08
59 O 0 9.345955049866461e-07
pedigrees O 0 1.5935321471260977e-06
were O 0 2.0753541321028024e-06
ascertained O 0 3.153491343255155e-05
. O 0 5.686662916559726e-06

Sibships O 0 0.0009370292536914349
where O 0 4.269559667591238e-06
the O 0 7.141642868191411e-07
status O 0 2.980435738209053e-07
of O 0 5.556669293582672e-07
all O 0 7.159038517556837e-08
the O 0 2.993253929162165e-07
members O 0 3.551831539994055e-08
had O 0 1.6481304498938698e-07
been O 0 9.665343725373532e-08
identified O 0 4.4340730198655365e-08
were O 0 6.8861730539993e-08
examined O 0 1.115180765509649e-07
to O 0 2.116418151842936e-08
determine O 0 4.260019892399214e-08
the O 0 6.586679432984965e-07
transmission O 0 7.012472906353651e-06
of O 0 4.2315004975534976e-06
the O 0 1.1363792509655468e-05
DM B-Disease 1 1.0
expansion O 0 8.395332770305686e-06
from O 0 1.7827014175963996e-07
affected O 0 9.737043882296348e-08
parents O 0 2.3672487969861322e-08
to O 0 1.9136443540901382e-08
their O 0 1.1517298759144978e-07
offspring O 0 3.315298272354994e-06
. O 0 2.3534557840321213e-06

Where O 0 1.8218261175206862e-05
the O 0 5.588365183939459e-06
transmitting O 0 0.00020101373957004398
parent O 0 6.612751803913852e-06
was O 0 3.5538727388484403e-05
male O 0 3.3093817819462856e-06
, O 0 1.6800069033706677e-06
58 O 0 2.4624407160445116e-05
. O 0 5.879129275854211e-06

3 O 0 2.7470461645862088e-05
% O 0 1.1172846825502347e-06
of O 0 1.4202910278982017e-06
the O 0 5.891067189622845e-07
offspring O 0 1.243680287643656e-07
were O 0 3.071064895721065e-07
affected O 0 6.512165384719992e-08
, O 0 2.3977630547733497e-08
and O 0 2.465439763454924e-08
in O 0 4.880793369466119e-08
the O 0 1.669655489422439e-07
case O 0 1.308849988390648e-07
of O 0 3.738788620921696e-07
a O 0 7.297133493011643e-07
female O 0 1.9429330677667167e-06
transmitting O 0 0.00013982660311739892
parent O 0 1.7222467931787833e-06
, O 0 7.11070015313453e-07
68 O 0 2.1968611690681428e-05
. O 0 3.0520798190991627e-06

7 O 0 8.483303099637851e-05
% O 0 5.34178161615273e-06
were O 0 6.72800933898543e-06
affected O 0 1.381308538839221e-05
. O 0 9.568998393660877e-06

Studies O 0 9.059395961230621e-05
on O 0 1.720592445053626e-05
meiotic O 0 0.00016505173698533326
drive O 0 9.036313713295385e-06
in O 0 1.7554477835801663e-06
DM B-Disease 1 0.9999569654464722
have O 0 5.5981736579724384e-08
shown O 0 1.0819758955449288e-07
increased O 0 3.4639072055142606e-07
transmission O 0 4.922546850139042e-07
of O 0 1.302108358913756e-07
the O 0 8.399687345672646e-08
larger O 0 4.1850242382679426e-08
allele O 0 2.3443739394224394e-07
at O 0 1.7725903944665333e-06
the O 0 8.941468081502535e-07
DM B-Disease 1 0.9998925924301147
locus O 0 4.588476713252021e-06
in O 0 8.252364409599977e-07
non O 0 4.003122739959508e-05
- O 0 0.00026389220147393644
DM O 1 0.9999998807907104
heterozygotes O 0 2.1357229343266226e-05
for O 0 1.3740881286139484e-06
CTGn O 0 0.00025309843476861715
. O 0 5.511084509635111e-06

This O 0 1.4378609876075643e-06
study O 0 6.847978966106893e-07
provides O 0 1.4968378536650562e-07
further O 0 1.1495735918742866e-07
evidence O 0 2.844689674930123e-07
that O 0 1.5074660097980086e-07
the O 0 2.8187748739583185e-06
DM B-Disease 1 1.0
expansion O 0 1.0129178917850368e-05
tends O 0 7.309670877475583e-07
to O 0 7.959265246881841e-08
be O 0 3.0870569389662705e-07
transmitted O 0 4.0570653254690114e-06
preferentially O 0 4.881705990555929e-06
. O 0 2.6332452307542553e-06

Diagnosis O 1 0.9999586343765259
of O 0 0.26794376969337463
hemochromatosis B-Disease 1 1.0
. O 0 0.0008437358192168176

If O 0 0.00013046489038970321
untreated O 1 0.9987408518791199
, O 0 3.6632201954489574e-05
hemochromatosis B-Disease 1 1.0
can O 0 1.3737474091612967e-06
cause O 0 0.000842431967612356
serious O 0 0.05345262587070465
illness O 1 0.9714475274085999
and O 0 2.9880800411774544e-07
early B-Disease 0 1.98267866835522e-06
death I-Disease 0 2.1060439394204877e-05
, O 0 5.117252754871515e-08
but O 0 1.3954611688404839e-08
the O 0 2.5333235953439726e-07
disease O 0 7.984283001860604e-06
is O 0 9.440653769843266e-08
still O 0 4.546953391582065e-08
substantially O 0 1.0356093298469204e-06
under O 0 1.3386319551500492e-05
- O 0 0.09001947194337845
diagnosed O 1 0.6654214262962341
. O 0 5.924843662796775e-06

The O 0 2.273394784424454e-05
cornerstone O 0 5.378349669626914e-05
of O 0 8.958163562056143e-07
screening O 0 7.585111916341702e-07
and O 0 2.106254299860666e-07
case O 0 3.025835155767709e-07
detection O 0 1.1533767292348784e-06
is O 0 8.888572011755969e-08
the O 0 8.600503775824109e-08
measurement O 0 1.554477307763591e-06
of O 0 1.9360634269105503e-06
serum O 0 2.3287153453566134e-05
transferrin O 0 2.6116988010471687e-05
saturation O 0 9.53478320298018e-06
and O 0 2.994709973336285e-07
the O 0 1.115037662202667e-06
serum O 0 4.441500277607702e-05
ferritin O 0 0.0001872004650067538
level O 0 2.2269869077717885e-05
. O 0 4.979716322850436e-06

Once O 0 4.113367322133854e-05
the O 0 3.6807120977755403e-06
diagnosis O 0 8.415863703703508e-05
is O 0 5.131298053129285e-07
suspected O 0 5.903343662794214e-06
, O 0 2.004404109356983e-07
physicians O 0 2.509917749193846e-07
must O 0 4.7831782978846604e-08
use O 0 1.3814828037084226e-07
serum O 0 7.956806803122163e-05
ferritin O 0 0.0007921234937384725
levels O 0 7.88120087236166e-06
and O 0 2.302997927472461e-06
hepatic O 1 0.9999994039535522
iron O 1 0.9999504089355469
stores O 0 3.0024848456378095e-06
on O 0 6.709319222863996e-06
liver O 0 0.3422185778617859
biopsy O 0 0.00045552101801149547
specimens O 0 4.229981129810767e-07
to O 0 8.48200443215319e-08
assess O 0 2.9773113396913686e-07
patients O 0 1.0691848473243226e-07
for O 0 6.943306374296299e-08
the O 0 7.275509119608614e-07
presence O 0 2.287583129145787e-06
of O 0 5.665882781613618e-05
iron B-Disease 1 0.9999960660934448
overload I-Disease 1 0.9614765644073486
. O 0 6.209252660482889e-06

Liver O 1 0.9999905824661255
biopsy O 1 0.9991445541381836
is O 0 3.0285714274214115e-06
also O 0 1.1130897092925807e-07
used O 0 1.7183824141397963e-08
to O 0 5.92952753564191e-09
establish O 0 5.675821412864934e-08
the O 0 3.297770945209777e-07
presence O 0 5.109986318529991e-07
or O 0 2.8034622800987563e-07
absence O 0 2.143063056792016e-06
of O 0 3.2071534405986313e-06
cirrhosis B-Disease 1 0.9999995231628418
, O 0 9.217212948442466e-08
which O 0 2.0346250906300156e-08
can O 0 6.880642722251196e-09
affect O 0 6.169677249090455e-07
prognosis O 1 0.8192445039749146
and O 0 1.6882493127923226e-06
management O 0 5.44998147233855e-05
. O 0 3.470829142315779e-06

A O 0 0.00011203734902665019
DNA O 0 1.546467319712974e-05
- O 0 8.603294190834276e-06
based O 0 4.0675067225492967e-07
test O 0 1.4163548200940568e-07
for O 0 6.707001887207298e-08
the O 0 3.7582611867037485e-07
HFE O 0 1.8190503396908753e-05
gene O 0 7.850124461583619e-08
is O 0 1.9253011629416505e-08
commercially O 0 2.485373506999622e-08
available O 0 4.832123590148285e-09
, O 0 8.611678481429408e-09
but O 0 1.7003229935141917e-09
its O 0 4.068404280133109e-09
place O 0 2.051200986841195e-08
in O 0 3.910295021114507e-08
the O 0 3.402868742341525e-07
diagnosis O 0 0.00017480664246249944
of O 0 0.001748389913700521
hemochromatosis B-Disease 1 1.0
is O 0 3.992049187218072e-06
still O 0 5.851034075021744e-07
being O 0 8.560812716496002e-07
evaluated O 0 2.8474955797719304e-06
. O 0 2.2210408587852726e-06

Currently O 0 1.8080869267578237e-05
, O 0 5.808602168144716e-07
the O 0 1.767171085020891e-07
most O 0 2.4258836717194754e-08
useful O 0 4.47546923965092e-08
role O 0 1.4579015328308742e-07
for O 0 3.345009957911316e-08
this O 0 2.0274816492360515e-08
test O 0 3.0264061479101656e-08
is O 0 1.7206160052296582e-08
in O 0 2.4878113791260148e-08
the O 0 9.065421835430243e-08
detection O 0 1.1099865560026956e-06
of O 0 7.423781789839268e-05
hemochromatosis B-Disease 1 1.0
in O 0 6.4686792029533535e-06
the O 0 2.627260073495563e-06
family O 0 7.280924307906389e-08
members O 0 2.6271012032452745e-08
of O 0 2.1241874037514208e-07
patients O 0 6.534586560746902e-08
with O 0 2.533822751615844e-08
a O 0 1.1906292911589844e-06
proven O 0 5.990305908198934e-06
case O 0 4.444903254352539e-07
of O 0 2.6689972401072737e-06
the O 0 3.079876842093654e-05
disease O 1 0.5157784819602966
. O 0 1.2511738532339223e-05

It O 0 3.2740942970121978e-06
is O 0 8.222166911764361e-07
crucial O 0 1.967635853361571e-06
to O 0 1.4526556242344668e-06
diagnose O 1 0.9993065595626831
hemochromatosis B-Disease 1 1.0
before O 1 0.9949597120285034
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 7.837204066163395e-06
because O 0 5.772772624368372e-07
phlebotomy O 0 0.213809534907341
therapy O 0 1.4620810361520853e-05
can O 0 7.206880781041036e-08
avert O 0 2.7134250558447093e-05
serious O 1 0.9924448132514954
chronic O 1 1.0
disease O 1 0.9979608058929443
and O 0 1.4755637778307573e-07
can O 0 1.1195258053930957e-08
even O 0 1.2087818745953882e-08
lead O 0 4.5984457130998635e-08
to O 0 1.956023076843394e-08
normal O 0 8.375312745556585e-07
life O 0 5.752778520218271e-07
expectancy O 0 7.365796591329854e-06
. O 0 3.2587911391601665e-07
. O 0 1.067806692844897e-06

Prevalence O 0 0.0014734846772626042
of O 0 2.271047924295999e-05
the O 0 1.071902624971699e-05
I1307K O 0 0.00018510973313823342
APC B-Disease 0 1.6380112356273457e-05
gene O 0 1.5026533617401583e-07
variant O 0 8.899751691160418e-08
in O 0 1.5548087262118315e-08
Israeli O 0 1.3748389449119713e-07
Jews O 0 2.4079971794321864e-08
of O 0 1.3512432062157131e-08
differing O 0 3.3233988894210142e-09
ethnic O 0 4.738354597577654e-09
origin O 0 3.6990027041383655e-08
and O 0 6.71629578619104e-08
risk O 0 2.7119842798128957e-06
for O 0 1.6039582988014445e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.0351802454097196e-05

BACKGROUND O 0 0.0003101329202763736
& O 0 0.00010535137698752806
AIMS O 0 1.205423723149579e-05
Israeli O 0 8.511679880029988e-06
Jews O 0 9.168081760435598e-07
of O 0 6.325835784082301e-07
European O 0 3.694856900438026e-07
birth O 0 1.1002808832927258e-06
, O 0 1.0586207821461358e-07
i O 0 1.1898467278115277e-07
. O 0 3.0102636827678e-08
e O 0 1.3694071299141797e-07
. O 0 1.2451513597966368e-08
, O 0 2.1576420650148975e-08
Ashkenazim O 0 3.1213079410008504e-07
, O 0 8.887601765650288e-09
have O 0 5.417350124048426e-09
the O 0 9.041798421094427e-08
highest O 1 0.999828577041626
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9999563694000244
of O 0 4.587811417877674e-06
any O 0 1.6182175954781997e-07
Israeli O 0 1.1867558896483388e-05
ethnic O 0 4.605257117873407e-07
group O 0 3.336304644108168e-06
. O 0 3.086890956183197e-06

The O 0 0.00010996931814588606
I1307K O 0 0.0006991092232055962
APC B-Disease 0 9.7256364824716e-05
gene O 0 2.0959480480087223e-06
variant O 0 2.764033979474334e-06
was O 0 8.744126716919709e-06
found O 0 2.6002842901107215e-07
in O 0 6.18548369857308e-07
6 O 0 1.878697185020428e-05
. O 0 4.998234089725884e-06

1 O 0 1.8441853171680123e-05
% O 0 7.323528734559659e-07
of O 0 6.773802283532859e-07
American O 0 3.815672471318976e-07
Jews O 0 8.304947130000073e-08
, O 0 2.2198197058287406e-08
28 O 0 1.2098466584120615e-07
% O 0 1.35301760906259e-08
of O 0 5.689011928211585e-08
their O 0 2.4325379399670055e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 2.6535597498877905e-05
, O 0 1.2502516710810596e-07
but O 0 1.1401398047894418e-08
not O 0 1.2009086169939565e-08
in O 0 2.3473469923374068e-07
non O 0 5.887635325052543e-06
- O 0 4.9093446250481065e-06
Jews O 0 2.2946626359043876e-06
. O 0 2.666524324013153e-06

We O 0 9.486440831096843e-06
assessed O 0 9.267554560210556e-06
the O 0 1.1050761941078235e-06
I1307K O 0 2.2898902898305096e-05
prevalence O 0 3.0647736366518075e-06
in O 0 4.7641485423355334e-08
Israeli O 0 2.877376914511842e-07
Jews O 0 4.224039074074426e-08
of O 0 2.3676912874748268e-08
differing O 0 1.0149282303473228e-08
ethnic O 0 5.457621465865259e-09
origin O 0 2.8082727254741258e-08
and O 0 7.298484661077964e-08
risk O 0 6.9943730522936676e-06
for O 0 2.627820686029736e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.132186925038695e-05

METHODS O 0 3.946960350731388e-05
DNA O 0 7.804909728292841e-06
samples O 0 1.266956360268523e-06
from O 0 8.38853395634942e-07
500 O 0 4.061839433688874e-07
unrelated O 0 1.5579055911985051e-07
Jews O 0 2.1998248200816306e-07
of O 0 5.890718739465228e-07
European O 0 4.5451500341187057e-07
or O 0 1.9269494089257933e-07
non O 0 1.7620932339923456e-06
- O 0 2.98945394661132e-07
European O 0 7.483629360649502e-08
origin O 0 2.08544275182021e-08
, O 0 1.9006979101732213e-08
with O 0 7.08739555932425e-09
or O 0 4.856704194367012e-08
without O 0 4.26292139366069e-08
a O 0 3.701377977449738e-07
personal O 0 1.1044713801311445e-06
and O 0 4.073701347806491e-06
/ O 0 0.005130351986736059
or O 0 4.072009005540167e-07
family O 0 9.29631056578728e-08
history O 0 1.914882687970021e-07
of O 0 2.0903187305520987e-06
neoplasia B-Disease 0 0.006154925562441349
, O 0 1.4025155792296573e-07
were O 0 2.1448529707868147e-07
examined O 0 4.750329196667735e-07
for O 0 1.2127023296670814e-07
the O 0 7.170244202825415e-07
I1307K O 0 1.9442417396930978e-05
variant O 0 8.757736509323877e-07
by O 0 3.2465817412230535e-07
the O 0 4.957948362971365e-07
allele O 0 5.474440172292816e-07
- O 0 4.4328595549814054e-07
specific O 0 7.634404397549588e-08
oligonucleotide O 0 2.325635068700649e-05
( O 0 1.0811018000822514e-06
ASO O 0 0.00018540260498411953
) O 0 1.9866806155732775e-07
method O 0 7.252758678077953e-07
. O 0 1.9474371129035717e-06

RESULTS O 0 3.473947799648158e-05
In O 0 1.6489933614138863e-06
persons O 0 4.7492693511230755e-07
at O 0 1.3948738342151046e-06
average O 0 7.526903118559858e-07
risk O 0 1.4620342199123115e-06
for O 0 4.86242333863629e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.854973217836232e-06
I1307K O 0 0.00011899066885234788
was O 0 1.3342871170607395e-05
found O 0 1.5340523873419443e-07
in O 0 3.3612744232414116e-07
5 O 0 5.517242243513465e-06
. O 0 5.06817832501838e-06

0 O 0 1.1405939403630327e-05
% O 0 9.176392268273048e-07
of O 0 1.3083199519314803e-06
120 O 0 1.2507626934166183e-06
European O 0 1.1590002486627782e-06
and O 0 7.03425541814795e-07
1 O 0 8.221624739235267e-06
. O 0 3.2708580874896143e-06

6 O 0 4.99970446981024e-05
% O 0 2.3591207991557894e-06
of O 0 2.1600772015517578e-06
188 O 0 3.838325937977061e-06
non O 0 2.243594281026162e-06
- O 0 1.5092194871613174e-06
European O 0 2.143239754559545e-07
Jews O 0 2.4508216256435844e-07
( O 0 8.82725927908723e-08
P O 0 3.216789764337591e-06
= O 0 2.5721598717609595e-07
0 O 0 9.74508935769336e-08
. O 0 4.558711452773423e-08
08 O 0 3.1680119718657807e-06
) O 0 2.541531785027473e-07
. O 0 1.0744116707428475e-06

It O 0 5.536781372939004e-06
occurred O 0 2.0585754100466147e-05
in O 0 2.4477012630086392e-06
15 O 0 1.6417645383626223e-05
. O 0 5.351326308300486e-06

4 O 0 1.7796295651351102e-05
% O 0 8.911189297577948e-07
of O 0 1.1327481388434535e-06
52 O 0 2.681897512957221e-06
Ashkenazi O 0 9.813054475671379e-07
Israelis O 0 3.2881925449146365e-07
with O 0 4.251456076076465e-08
familial O 0 4.484204691834748e-05
cancer B-Disease 1 0.9992290735244751
( O 0 1.4088190027905512e-06
P O 0 5.604727630270645e-05
= O 0 5.148620516592928e-07
0 O 0 7.839845039825377e-08
. O 0 1.1339350791672587e-08
02 O 0 1.1171110827490338e-06
) O 0 1.3288182998394404e-08
and O 0 2.2263028753854996e-08
was O 0 5.569348218159575e-07
not O 0 1.2796047776930664e-08
detected O 0 1.4686817451092793e-07
in O 0 5.736530184208277e-08
51 O 0 6.312855020951247e-07
non O 0 1.4038565723240026e-06
- O 0 3.2462534704791324e-07
European O 0 2.2286819501005084e-08
Jews O 0 2.2013226796957497e-08
at O 0 4.064637266765203e-07
increased O 0 1.5018639487607288e-06
cancer B-Disease 0 0.00018096441635861993
risk O 0 4.476964477362344e-06
. O 0 2.039829951172578e-06

Colorectal B-Disease 1 0.9999043941497803
neoplasia I-Disease 1 0.99996018409729
occurred O 0 0.09429635852575302
personally O 0 2.447247607051395e-05
or O 0 1.6450446764793014e-06
in O 0 4.400943396376533e-07
the O 0 2.5803217340580886e-07
families O 0 1.6685754999912206e-08
of O 0 3.1810250789021666e-07
13 O 0 1.5387821576950955e-06
of O 0 2.8583351650013356e-06
20 O 0 6.096860488469247e-06
Ashkenazi O 0 1.1082814125984441e-05
I1307K O 0 2.005257374548819e-05
carriers O 0 1.747592506262663e-07
, O 0 6.103906713406104e-08
8 O 0 3.2162640195565473e-07
of O 0 1.7914339878188912e-07
whom O 0 1.5967189881394006e-07
also O 0 1.703148342357963e-07
had O 0 5.847832085237314e-07
a O 0 5.127520807945984e-07
personal O 0 1.8952191567223053e-06
or O 0 5.074854811937257e-07
family O 0 1.4635908485161053e-07
history O 0 7.547791938122828e-07
of O 0 2.8843529435107484e-05
noncolonic O 1 0.9893471002578735
neoplasia B-Disease 1 0.9999574422836304
. O 0 4.5892655180068687e-05

CONCLUSIONS O 0 0.0008566030883230269
The O 0 9.845552267506719e-05
I1307K O 0 0.001775697455741465
APC O 0 0.00020325675723142922
variant O 0 3.4692802728386596e-06
may O 0 2.444815265789657e-07
represent O 0 2.199820059445301e-08
a O 0 1.3076261495825747e-07
susceptibility O 0 3.5631810533232056e-06
gene O 0 1.063905415321642e-06
for O 0 2.056934590655146e-06
colorectal B-Disease 1 1.0
, I-Disease 0 8.521035852027126e-06
or I-Disease 0 5.662456032951013e-07
other I-Disease 0 5.50448007174964e-08
, I-Disease 0 3.3383690833943547e-07
cancers I-Disease 0 0.004465850535780191
in O 0 2.954197952931281e-07
Ashkenazi O 0 1.4107334891377832e-06
Jews O 0 1.2599494425558078e-07
, O 0 2.065649162830141e-08
and O 0 1.8643440569121594e-08
partially O 0 1.847961357270833e-06
explains O 0 1.1897331830823532e-07
the O 0 1.1414273615173443e-07
higher O 0 3.0963080916990293e-06
incidence O 0 0.0526076965034008
of O 1 0.6852186918258667
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.7927933388127713e-06
European O 0 1.3308127790878643e-06
Israelis O 0 3.266711928517907e-06
. O 0 1.916981545946328e-06

Systematic O 0 6.209915591171011e-05
analysis O 0 4.8722317842475604e-06
of O 0 9.524567758489866e-06
coproporphyrinogen O 0 0.09069208055734634
oxidase O 0 0.004071162082254887
gene O 0 8.066653390415013e-05
defects O 0 0.25083741545677185
in O 0 1.4595308357456815e-06
hereditary B-Disease 1 0.9999521970748901
coproporphyria I-Disease 1 0.9723208546638489
and O 0 3.435306780374958e-06
mutation O 0 1.9751749277929775e-05
update O 0 1.1375133908586577e-05
. O 0 3.7270799566613277e-06

Hereditary B-Disease 1 0.9999831914901733
coproporphyria I-Disease 1 0.9993996620178223
( O 0 6.754598143743351e-05
HC B-Disease 1 0.9999849796295166
) O 0 6.486439360742224e-06
is O 0 1.3912668919147109e-06
an O 0 2.6435020117787644e-05
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.0003944861236959696
autosomal O 1 0.9999877214431763
dominant O 1 0.6074787974357605
inheritance O 0 0.0017875238554552197
caused O 1 0.9588639736175537
by O 0 1.8812775124388281e-06
deficient B-Disease 0 3.1469695386476815e-05
activity I-Disease 0 9.99462031359144e-07
of I-Disease 0 1.6671986031724373e-06
coproporphyrinogen I-Disease 0 0.00022072438150644302
III I-Disease 1 0.9968910813331604
oxidase I-Disease 0 3.8279675209196284e-05
( O 0 1.5871651157794986e-06
CPO O 0 0.0066550844348967075
) O 0 7.524649277002027e-07
. O 0 1.9058093130297493e-06

Clinical O 0 0.12342476099729538
manifestations O 0 0.03052973933517933
of O 0 6.858449341962114e-05
the O 0 0.00011820131476270035
disease O 1 0.9180298447608948
are O 0 2.0600149142069313e-08
characterized O 0 5.173042723072285e-07
by O 0 2.072993083857e-07
acute O 1 0.9999998807907104
attacks O 0 0.03609384968876839
of O 1 0.9999672174453735
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 5.020774096919922e-06
precipitated O 0 0.0666404664516449
by O 0 1.5416743792684429e-07
drugs O 0 2.1513100989523082e-07
, O 0 7.434503146441784e-08
fasting O 0 5.661872819473501e-07
, O 0 1.722258531344778e-07
cyclical O 0 0.0005287860403768718
hormonal O 0 0.0005335764144547284
changes O 0 3.350412498548394e-07
, O 0 1.1623120599324466e-06
or O 0 1.891857937152963e-05
infectious B-Disease 1 0.9999998807907104
diseases I-Disease 1 0.9999996423721313
. O 0 2.150556792912539e-05

Skin O 1 0.9999977350234985
photosensitivity O 1 0.9999957084655762
may O 0 0.000217918524867855
also O 0 1.6880819657671964e-06
be O 0 2.9303251380952133e-07
present O 0 1.0920266504399478e-06
. O 0 2.3497912025050027e-06

The O 0 4.044982051709667e-05
seven O 0 3.802772198469029e-06
exons O 0 6.784205652365927e-06
, O 0 7.56475515117927e-07
the O 0 1.1954954288739827e-06
exon O 0 5.181948381505208e-06
/ O 0 4.298095973354066e-06
intron O 0 7.908275620138738e-06
boundaries O 0 2.1526358295886894e-07
and O 0 1.556177124939495e-07
part O 0 2.09949192253589e-07
of O 0 7.211156685116293e-07
3 O 0 5.008092216485238e-07
noncoding O 0 3.888407320573606e-07
sequence O 0 1.340232387292417e-07
of O 0 9.110921155297547e-07
the O 0 6.481001832980837e-07
CPO O 0 2.014776509895455e-05
gene O 0 4.8782617056986055e-08
were O 0 6.711941580306302e-08
systematically O 0 1.5589816371175402e-07
analyzed O 0 1.1472145189372895e-07
by O 0 4.852232393659506e-08
an O 0 1.2200685262087063e-07
exon O 0 5.016792670176073e-07
- O 0 1.079954813576478e-06
by O 0 6.053986680853995e-07
- O 0 2.440057187413913e-06
exon O 0 3.037179112652666e-06
denaturing O 0 2.1129080778337084e-05
gradient O 0 3.156415914418176e-05
gel O 0 5.474291356222238e-06
electrophoresis O 0 5.250000413070666e-06
( O 0 2.856978653653641e-07
DGGE O 0 1.5210987839964218e-05
) O 0 6.134403918167664e-08
strategy O 0 9.871703809949395e-08
followed O 0 8.557665154285132e-08
by O 0 1.3307255741779045e-08
direct O 0 6.677515784758725e-08
sequencing O 0 2.3785868563663826e-07
in O 0 7.185879979942911e-08
seven O 0 2.0159332336788793e-07
unrelated O 0 5.200396344662295e-07
heterozygous O 0 8.362351309187943e-07
HC B-Disease 0 0.00023561292618978769
patients O 0 2.9485801178452675e-07
from O 0 2.120960687079787e-07
France O 0 2.544580013363884e-07
, O 0 5.437155792265003e-08
Holland O 0 1.8032817195035022e-07
, O 0 2.453725755913183e-08
and O 0 3.897517686368701e-08
Czech O 0 1.4680140338896308e-06
Republic O 0 6.894596481288318e-06
. O 0 8.283879651571624e-06

Seven O 0 1.0603737791825552e-05
novel O 0 3.112496415269561e-06
mutations O 0 4.0910083498602035e-07
and O 0 1.2896462919798068e-07
two O 0 4.6458229263635076e-08
new O 0 1.4398573000562465e-07
polymorphisms O 0 1.2451558859538636e-06
were O 0 3.1965453217708273e-06
detected O 0 2.3304261048906483e-05
. O 0 4.809094662050484e-06

Among O 0 2.654284799064044e-06
these O 0 1.1794911358720128e-07
mutations O 0 2.913272112436971e-07
two O 0 1.3151699818081397e-07
are O 0 6.991959367042e-08
missense O 0 2.3463135221390985e-06
( O 0 3.4617076494214416e-07
G197W O 0 1.24398056868813e-05
, O 0 3.1642116482544225e-07
W427R O 0 6.249340458452934e-06
) O 0 7.084438635729384e-08
, O 0 3.752669641698958e-08
two O 0 1.830992424345368e-08
are O 0 2.8797039419714565e-08
nonsense O 0 6.776058398827445e-06
( O 0 5.426597908808617e-07
Q306X O 0 1.592798980709631e-05
, O 0 4.33621835327358e-07
Q385X O 0 4.06414392273291e-06
) O 0 6.172536615167701e-08
, O 0 2.5319678798041423e-08
two O 0 1.3918567631776568e-08
are O 0 1.3751610516976598e-08
small O 0 3.9708279331307494e-08
deletions O 0 5.399505766945367e-07
( O 0 6.83229018250131e-07
662de14bp O 0 1.3443838724924717e-05
; O 0 9.203826323300746e-08
1168del3bp O 0 3.628313152148621e-06
removing O 0 1.155475160885544e-06
a O 0 5.051426228419587e-07
glycine O 0 8.700404237060866e-07
at O 0 1.248010335075378e-06
position O 0 3.477915697658318e-07
390 O 0 3.843435933958972e-07
) O 0 1.5223356797378074e-08
, O 0 1.764765222844744e-08
and O 0 2.0722312754628547e-08
one O 0 5.5228838391485624e-08
is O 0 5.362712229839417e-08
a O 0 2.868012813905807e-07
splicing O 0 4.31815976753569e-07
mutation O 0 3.641009413968277e-07
( O 0 3.2027290330916003e-07
IVS1 O 0 4.864030779572204e-05
- O 0 2.615352968859952e-06
15c O 0 1.4699341591040138e-05
- O 0 9.240127951670729e-07
- O 0 9.611237601347966e-07
> O 0 5.560702902585035e-07
g O 0 5.031282057643693e-07
) O 0 2.2067961680249937e-08
which O 0 1.3261546527587598e-08
creates O 0 5.665275892852151e-08
a O 0 8.080904478902085e-08
new O 0 1.0207119061078629e-07
acceptor O 0 7.731050004622375e-07
splice O 0 6.683876108581899e-06
site O 0 5.5398818403773475e-06
. O 0 3.5657003536471166e-06

The O 0 2.073524046863895e-05
pathological O 0 5.103966759634204e-05
significance O 0 2.3056436475599185e-06
of O 0 2.5642270884418394e-06
the O 0 1.3957985629531322e-06
point O 0 1.9928888832509983e-06
mutations O 0 2.805142003126093e-07
G197W O 0 1.2527057151601184e-05
, O 0 2.7927990231546573e-07
W427R O 0 8.46347029437311e-06
, O 0 1.6033858685204905e-07
and O 0 1.211709275139583e-07
the O 0 5.329328018888191e-07
in O 0 8.154619308697875e-07
- O 0 5.778540526080178e-06
frame O 0 7.943513082864229e-06
deletion O 0 2.1698660930269398e-06
390delGly O 0 2.7633591344056185e-06
were O 0 1.8482842278899625e-07
assessed O 0 1.686127433231377e-07
by O 0 1.5062971314705464e-08
their O 0 5.626720867013546e-09
respective O 0 3.4863763431758343e-08
expression O 0 1.2076598920884862e-07
in O 0 4.6859593538783884e-08
a O 0 6.406632024891223e-08
prokaryotic O 0 6.297810273281357e-08
system O 0 8.861504596779923e-08
using O 0 3.4726387099226486e-08
site O 0 4.669627458042669e-07
- O 0 9.507746199233225e-07
directed O 0 1.2214660500831087e-06
mutagenesis O 0 1.682632864685729e-05
. O 0 4.323151642893208e-06

These O 0 5.9830165355379e-07
mutations O 0 1.0993600199071807e-06
resulted O 0 2.0037823560414836e-06
in O 0 3.10049898644138e-07
the O 0 4.3925069803663064e-07
absence O 0 2.2865451683173887e-06
or O 0 1.099874253895905e-07
a O 0 1.8187219552601164e-07
dramatic O 0 1.9784590676863445e-06
decrease O 0 1.0804681551235262e-05
of O 0 1.563154364703223e-05
CPO O 1 0.986275315284729
activity O 0 3.3895892556756735e-05
. O 0 4.010027623735368e-06

The O 0 2.979430246341508e-05
two O 0 6.732911970175337e-07
polymorphisms O 0 2.1453943190863356e-06
were O 0 8.254395424955874e-07
localized O 0 1.3671395890924032e-06
in O 0 1.652272629826257e-07
noncoding O 0 6.683275159957702e-07
part O 0 1.0297578256768247e-07
of O 0 3.3798505683080293e-07
the O 0 9.628873698375173e-08
gene O 0 4.171922185491894e-08
1 O 0 2.2454470638422208e-07
) O 0 4.3836600127633574e-08
a O 0 7.173650260483555e-07
C O 0 1.258102656720439e-05
/ O 0 3.0364899430423975e-06
G O 0 2.9698971957259346e-06
polymorphism O 0 1.3616286764772667e-07
in O 0 9.21517440133357e-08
the O 0 2.477621308116795e-07
promotor O 0 4.4807316044170875e-06
region O 0 2.0223687613452057e-07
, O 0 1.3310230428942305e-07
142 O 0 1.5119624094950268e-06
bp O 0 2.473547056069947e-06
upstream O 0 2.4857492917362833e-06
from O 0 2.2220822870622214e-07
the O 0 2.3671410076531174e-07
transcriptional O 0 2.338671265533776e-06
initiation O 0 1.1050740340579068e-06
site O 0 6.238391847546154e-07
( O 0 9.473012596572516e-08
- O 0 6.665439968855935e-07
142C O 0 9.490176125837024e-06
/ O 0 2.894249291784945e-06
G O 0 3.3315798191324575e-06
) O 0 4.670076947377311e-08
, O 0 2.187777603523955e-08
and O 0 2.076116167870623e-08
2 O 0 1.801598870088128e-07
) O 0 2.938198484514487e-08
a O 0 2.6347746029387054e-07
6 O 0 1.8288235423824517e-06
bp O 0 1.0093675655298284e-06
deletion O 0 2.591542624941212e-07
polymorphism O 0 9.934981903825246e-08
in O 0 4.6592582236826274e-08
the O 0 6.611349334662009e-08
3 O 0 1.491701908662435e-07
noncoding O 0 2.96776079267147e-07
part O 0 1.6524002433015994e-07
of O 0 5.792592787656758e-07
the O 0 1.5055206858960446e-06
CPO O 0 5.4766558605479077e-05
gene O 0 2.437489001749782e-07
, O 0 3.3047160741261905e-07
574 O 0 4.488601462071529e-06
bp O 0 2.575036660346086e-06
downstream O 0 1.6201028074647184e-06
of O 0 7.426226034112915e-07
the O 0 3.7176337741584575e-07
last O 0 5.246574801276438e-07
base O 0 6.068709694773133e-07
of O 0 4.942821760778315e-07
the O 0 4.715677732747281e-07
normal O 0 1.5496831338168704e-06
termination O 0 6.7123269218427595e-06
codon O 0 7.540110345871653e-06
( O 0 2.589877396985685e-07
+ O 0 1.3380272321228404e-06
574 O 0 1.1161590009578504e-05
delATTCTT O 0 2.3835560568841174e-05
) O 0 1.1361561291778344e-06
. O 0 1.917555664476822e-06

Five O 0 7.271503272932023e-05
intragenic O 0 0.0005032700719311833
dimorphisms O 0 0.0002734936715569347
are O 0 3.028300454843702e-07
now O 0 1.018001540842306e-07
well O 0 2.6515365902923804e-08
characterized O 0 1.3834683443292306e-07
and O 0 3.3872492366526785e-08
the O 0 1.1740447547481381e-07
high O 0 8.404268214690092e-07
degree O 0 5.311154041010013e-07
of O 0 4.036026552967087e-07
allelic O 0 1.896864660011488e-06
heterogeneity O 0 1.985554945349577e-06
in O 0 3.3485787298559444e-07
HC B-Disease 0 0.03378727287054062
is O 0 2.704631185679318e-07
demonstrated O 0 2.8663504281212226e-07
with O 0 1.2988411235426156e-08
seven O 0 1.6434524852115828e-08
new O 0 1.1332000227071148e-08
different O 0 8.669934214999842e-10
mutations O 0 1.4057274455581137e-08
making O 0 2.7698172644363694e-08
a O 0 6.28079988018726e-08
total O 0 1.7977973243432643e-07
of O 0 1.5776713553350419e-06
nineteen O 0 3.398678018129431e-05
CPO O 1 0.9901919364929199
gene B-Disease 0 9.051476808963344e-06
defects I-Disease 0 0.000591140182223171
reported O 0 3.4708818930084817e-06
so O 0 5.3037940261901895e-08
far O 0 1.496358237318418e-07
. O 0 1.1797666843449406e-07
. O 0 1.0789274256239878e-06

Coincidence O 0 0.00021632385323755443
of O 0 9.738771041156724e-06
two O 0 1.2065978580722003e-06
novel O 0 6.55676785754622e-06
arylsulfatase O 0 5.141897054272704e-05
A O 0 3.5915697935706703e-06
alleles O 0 2.320409038247817e-07
and O 0 5.562825222682477e-08
mutation O 0 3.3154739753626927e-07
459 O 0 8.449259439657908e-06
+ O 0 4.85410237160977e-06
1G O 0 0.00023417019110638648
> O 0 1.2905632047477411e-06
A O 0 2.6179480983046233e-07
within O 0 2.396725129472088e-08
a O 0 1.2186208664388687e-07
family O 0 5.816085391074921e-08
with O 0 1.6084031528862397e-07
metachromatic B-Disease 1 0.9999997615814209
leukodystrophy I-Disease 1 0.9999982118606567
: O 0 3.8964472537372785e-08
molecular O 0 1.818116714957796e-07
basis O 0 8.81620536574701e-08
of O 0 2.510396370780654e-07
phenotypic O 0 2.953948978756671e-06
heterogeneity O 0 2.7943282475462183e-05
. O 0 5.104178853798658e-06

In O 0 1.755029552441556e-05
a O 0 4.436257313500391e-06
family O 0 4.948146283823007e-07
with O 0 8.874241075318423e-08
three O 0 3.5976538015347614e-07
siblings O 0 5.38647327630315e-07
, O 0 7.236108956476528e-08
one O 0 3.632470324532733e-08
developed O 0 1.4615028476328007e-07
classical O 0 6.328645667963428e-06
late O 0 0.00023274072736967355
infantile O 1 0.9998691082000732
metachromatic B-Disease 1 0.9999995231628418
leukodystrophy I-Disease 1 0.9999964237213135
( O 0 1.5393927697004983e-06
MLD B-Disease 1 0.999993085861206
) O 0 1.5213234405564435e-07
, O 0 9.470953443724284e-08
fatal O 0 3.1114516332308995e-06
at O 0 1.395758658873092e-06
age O 0 2.495341959729558e-07
5 O 0 2.548689508330426e-07
years O 0 1.145463173202188e-07
, O 0 3.909608992103131e-08
with O 0 8.075543433960775e-08
deficient O 0 3.837521580862813e-05
arylsulfatase O 0 5.453220001072623e-05
A O 0 1.532122587377671e-05
( O 0 3.4366200907243183e-07
ARSA O 0 1.2786072147719096e-05
) O 0 3.875870646652402e-08
activity O 0 1.4843341489267914e-07
and O 0 4.679921516981267e-08
increased O 0 3.0869380225340137e-06
galactosylsulfatide O 0 6.453765672631562e-05
( O 0 3.724557245732285e-06
GS O 1 0.9999680519104004
) O 0 1.8974001250171568e-06
excretion O 0 3.460711377556436e-05
. O 0 2.9359352993196808e-06

The O 0 4.598644591169432e-05
two O 0 2.2742729015590157e-06
other O 0 2.830914525020489e-07
siblings O 0 1.2443807690942776e-06
, O 0 5.016859745410329e-07
apparently O 0 1.7098417401939514e-06
healthy O 0 3.899882869973226e-07
at O 0 1.168056996903033e-06
12 O 0 2.2378962682978454e-07
( O 0 2.3882737565372736e-08
1 O 0 3.0423399266510387e-07
/ O 0 5.46364901765628e-07
2 O 0 2.3056692555201153e-07
) O 0 1.5903507843972875e-08
and O 0 2.506405571978121e-08
15 O 0 1.0084892920758648e-07
years O 0 7.671641100159832e-08
, O 0 2.45818991828628e-08
respectively O 0 1.3242606655694544e-07
, O 0 2.1233969249578877e-08
and O 0 2.9007235724520797e-08
their O 0 5.223518684260853e-08
father O 0 4.622400865628151e-06
, O 0 3.208770351648127e-07
apparently O 0 8.129134698720009e-07
healthy O 0 1.0066866451552414e-07
as O 0 3.415580707155641e-08
well O 0 2.5797110225767028e-08
, O 0 2.0155443536395978e-08
presented O 0 3.6731586305904784e-07
ARSA O 0 0.00012181559577584267
and O 0 1.2712820307569928e-06
GS O 1 0.9998897314071655
values O 0 8.733643142022629e-08
within O 0 2.7600925989190728e-08
the O 0 7.651197364566542e-08
range O 0 4.114433238555648e-07
of O 0 6.871641744510271e-06
MLD B-Disease 1 1.0
patients O 0 1.5240580069075804e-05
. O 0 5.453608991956571e-06

Mutation O 0 8.811220141069498e-06
screening O 0 2.116807081620209e-06
and O 0 1.5374634187992342e-07
sequence O 0 2.1390721371972177e-07
analysis O 0 2.602013182695373e-07
disclosed O 0 6.697599133076437e-07
the O 0 2.417014286493213e-07
involvement O 0 5.484808411893027e-07
of O 0 3.2354296308767516e-07
three O 0 6.19739282115006e-08
different O 0 1.5681694165436966e-08
ARSA O 0 5.994900857331231e-05
mutations O 0 1.1866623594869452e-07
being O 0 1.3978166180095286e-07
the O 0 3.400532122554978e-08
molecular O 0 1.6809013914098614e-07
basis O 0 1.739352200047506e-07
of O 0 9.296219332100009e-07
intrafamilial O 0 4.06891449529212e-05
phenotypic O 0 8.177138624887448e-06
heterogeneity O 0 0.00010178374213865027
. O 0 1.2564624739752617e-05

The O 0 4.9009489885065705e-05
late O 0 0.00037880361196585
infantile O 1 0.9997040629386902
patient O 0 0.0003556514857336879
inherited O 0 0.030943794175982475
from O 0 1.7219448636751622e-05
his O 0 1.527371205156669e-05
mother O 0 7.054274192341836e-06
the O 0 1.8971251165567082e-06
frequent O 0 7.296598028005974e-07
0 O 0 1.0555717153692967e-06
- O 0 9.211893825522566e-07
type O 0 5.515798875421751e-07
mutation O 0 7.093821636772191e-07
459 O 0 1.2460950529202819e-05
+ O 0 2.4302660222019767e-06
1G O 0 6.828624464105815e-05
> O 0 9.84206167231605e-07
A O 0 9.130936859946814e-07
, O 0 3.8174697181148076e-08
and O 0 4.2112159093221635e-08
from O 0 1.6777352129793144e-07
his O 0 7.301205755538831e-07
father O 0 3.695805162351462e-06
a O 0 5.684900088454015e-07
novel O 0 4.602460421665455e-07
, O 0 5.581467021897879e-08
single O 0 1.7147083042345912e-07
basepair O 0 5.834601779497461e-06
microdeletion O 0 7.312170964723919e-06
of O 0 1.5575178622384556e-06
guanine O 0 2.0598085939127486e-06
at O 0 1.57921579102549e-06
nucleotide O 0 3.056100297271769e-07
7 O 0 3.397634884549916e-07
in O 0 7.101403554088392e-08
exon O 0 3.647404298590118e-07
1 O 0 5.573317594098626e-07
( O 0 1.7683578334981576e-07
7delG O 0 3.4853671877499437e-06
) O 0 5.378865921557008e-07
. O 0 1.3346499372346443e-06

The O 0 2.9228358471300453e-05
two O 0 3.8756520552851725e-06
clinically O 0 0.0057208845391869545
unaffected O 0 4.593166886479594e-05
siblings O 0 1.0651825732566067e-06
carried O 0 7.920403390926367e-07
the O 0 3.5306101153764757e-07
maternal O 0 1.1299557627353352e-05
mutation O 0 1.925209517139592e-06
459 O 0 3.902980824932456e-05
+ O 0 7.4775030043383595e-06
1G O 0 0.0001800552854547277
> O 0 4.61254558103974e-06
A O 0 1.423609433004458e-06
and O 0 1.081505445199582e-07
, O 0 7.894222875393098e-08
on O 0 2.4731596681704104e-07
their O 0 3.959188887847631e-08
paternal O 0 6.1632940742128994e-06
allele O 0 5.058527676737867e-07
, O 0 7.513879296539017e-08
a O 0 2.0185477467293822e-07
novel O 0 2.3861980480432976e-07
cytosine O 0 2.524320734664798e-07
to O 0 3.858080788177176e-08
thymidine O 0 1.9185454220860265e-06
transition O 0 1.9562005491025047e-06
at O 0 2.6544698812358547e-06
nucleotide O 0 1.8606284584166133e-06
2435 O 0 9.222713742929045e-06
in O 0 7.859652839670161e-08
exon O 0 1.6465939722820622e-07
8 O 0 4.1620992874413787e-07
, O 0 3.121426672691996e-08
resulting O 0 8.206689727785488e-08
in O 0 4.745158577179609e-08
substitution O 0 4.6541066467398196e-07
of O 0 7.832123287698778e-07
alanine O 0 2.7749656510422938e-06
464 O 0 3.705044036905747e-06
by O 0 9.094722486224782e-07
valine O 0 2.673948256415315e-05
( O 0 9.60449369813432e-07
A464V O 0 4.594546771841124e-05
) O 0 1.262924797629239e-06
. O 0 2.501064955140464e-06

The O 0 6.315032078418881e-05
fathers O 0 2.1982779799145646e-05
genotype O 0 9.557087651046459e-06
thus O 0 1.5506676618315396e-06
was O 0 4.2800904338946566e-05
7delG O 0 0.0001269071944989264
/ O 0 0.0003420461725909263
A464V O 0 0.0011175642721354961
. O 0 1.4400483451026957e-05

Mutation O 0 0.0002792908053379506
A464V O 0 0.00137815170455724
was O 0 4.741964221466333e-05
not O 0 2.1778609493594558e-07
found O 0 1.472353261533499e-07
in O 0 1.819029051830512e-07
18 O 0 2.938680381703307e-06
unrelated O 0 1.8492291928851046e-05
MLD B-Disease 1 1.0
patients O 0 1.902546046039788e-06
and O 0 5.689282147613994e-07
50 O 0 4.289255684852833e-06
controls O 0 1.4309065591078252e-05
. O 0 4.217331934341928e-06

A464V O 0 0.00407230481505394
, O 0 1.3728433259529993e-05
although O 0 1.9268866253696615e-06
clearly O 0 2.370299625908956e-06
modifying O 0 5.094268544780789e-06
ARSA O 0 0.0005630505620501935
and O 0 3.365686325196293e-06
GS O 1 1.0
levels O 0 1.872146185633028e-06
, O 0 7.032861049083294e-08
apparently O 0 1.9300613018913282e-07
bears O 0 1.0060340116524458e-07
little O 0 2.5285027405175242e-08
significance O 0 5.921958390331383e-08
for O 0 4.9535245238985226e-08
clinical O 0 9.45852752920473e-06
manifestation O 0 0.0006955989520065486
of O 0 0.0013231319608166814
MLD B-Disease 1 1.0
, O 0 3.155450485792244e-06
mimicking O 0 1.2562612027977593e-05
the O 0 1.9402648376853904e-06
frequent O 0 1.6950260032899678e-05
ARSA O 1 0.7909663915634155
pseudodeficiency O 0 0.00121384859085083
allele O 0 5.165324546396732e-05
. O 0 9.460422006668523e-06

Our O 0 2.6026931664091535e-05
results O 0 4.3319259930285625e-06
demonstrate O 0 9.498411941422091e-07
that O 0 5.0083215796803415e-08
in O 0 6.205353031418781e-08
certain O 0 4.6690082911027275e-08
genetic O 0 3.1888207558949944e-06
conditions O 0 0.0010550321312621236
MLD B-Disease 1 1.0
- O 0 0.0001010977357509546
like O 0 4.557424517770414e-07
ARSA O 0 0.00021523692703340203
and O 0 8.785752356743615e-07
GS O 1 0.9999942779541016
values O 0 3.431932427133688e-08
need O 0 8.918235039345745e-09
not O 0 3.74114783596724e-09
be O 0 5.358026911039815e-09
paralleled O 0 9.45885787473344e-08
by O 0 1.8764449549735218e-08
clinical O 0 1.0577973625913728e-05
disease O 0 9.81164430413628e-06
, O 0 2.6531807861829293e-08
a O 0 5.243163059276412e-08
finding O 0 1.656765569180152e-08
with O 0 2.408750354732092e-08
serious O 0 2.6621739834808977e-06
diagnostic O 0 2.0561739802360535e-05
and O 0 1.3854015605829773e-06
prognostic O 1 0.9148231148719788
implications O 0 3.45557346008718e-05
. O 0 6.493650289485231e-06

Moreover O 0 9.79546966846101e-05
, O 0 5.8562982303556055e-06
further O 0 4.923100732412422e-06
ARSA O 0 0.0003626139077823609
alleles O 0 2.9461107260431163e-06
functionally O 0 2.7068317649536766e-06
similar O 0 1.251001862101475e-07
to O 0 1.3464958215081424e-07
A464V O 0 5.376935860113008e-06
might O 0 5.3139707745231135e-08
exist O 0 2.2523909848359835e-08
which O 0 2.3747286803654788e-08
, O 0 1.2019719441980214e-08
together O 0 4.358147176475313e-09
with O 0 1.859641862722583e-08
0 O 0 8.772389605837816e-07
- O 0 1.5227734593281639e-06
type O 0 9.091375545722258e-07
mutations O 0 3.293615691291052e-07
, O 0 1.8229607690045668e-07
may O 0 6.974024699957226e-07
cause O 0 3.354285126988543e-06
pathological O 1 0.8604195713996887
ARSA O 1 0.7035902738571167
and O 0 2.5899960292008473e-06
GS O 1 1.0
levels O 0 2.9457748951244866e-07
, O 0 4.764836525339433e-09
but O 0 8.982933841217289e-10
not O 0 2.0754105101161713e-09
clinical O 0 3.6042712281414424e-07
outbreak O 0 2.1164498775760876e-06
of O 0 3.2821690183482133e-06
the O 0 4.861758498009294e-05
disease O 1 0.670323371887207
. O 0 1.1711221077348455e-06
. O 0 5.027213774155825e-06

Human O 1 0.885539710521698
MLH1 O 1 0.9999998807907104
deficiency O 1 1.0
predisposes O 0 0.002313382225111127
to O 0 7.950712642923463e-06
hematological B-Disease 1 0.9997475743293762
malignancy I-Disease 1 0.9999208450317383
and O 0 5.032591161580058e-06
neurofibromatosis B-Disease 1 0.9998292922973633
type I-Disease 0 0.0002532703219912946
1 I-Disease 0 0.0001302842574659735
. O 0 8.037953193706926e-06

Heterozygous O 0 0.0004262814181856811
germ O 1 0.9889488220214844
- O 0 6.938388105481863e-05
line O 0 3.441310809648712e-06
mutations O 0 8.842712873047276e-08
in O 0 5.2065097122522275e-08
the O 0 9.396389089033619e-08
DNA O 0 4.6997482172628224e-07
mismatch O 0 6.031347584212199e-05
repair O 0 1.1955892659898382e-05
genes O 0 8.278218501800438e-07
lead O 0 2.699227479752153e-06
to O 0 1.5148909824347356e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.126648415578529e-05

The O 0 8.654898556414992e-05
disease O 0 0.016217371448874474
susceptibility O 0 0.0002300434571225196
of O 0 3.7678425997000886e-06
individuals O 0 1.7091915083256026e-07
who O 0 4.901644388155546e-07
constitutionally O 0 4.359988906799117e-06
lack O 0 7.876143399698776e-07
both O 0 2.431633276955836e-07
wild O 0 1.177029503196536e-06
- O 0 3.3066212381527293e-06
type O 0 9.269182896787242e-07
alleles O 0 4.376575759579282e-07
is O 0 3.2908090474847995e-07
unknown O 0 3.892179847753141e-06
. O 0 1.4202882994140964e-06

We O 0 3.405632241992862e-06
have O 0 2.1481160672465194e-07
identified O 0 3.887591617512953e-07
three O 0 5.861288343567139e-08
offspring O 0 2.241753946918834e-07
in O 0 1.2172107233254792e-07
a O 0 9.796497579372954e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0001288695348193869
who O 0 1.2903564083899255e-06
developed O 0 3.449900304985931e-06
hematological B-Disease 1 0.5838161706924438
malignancy I-Disease 1 0.9955040812492371
at O 0 2.2918828108231537e-05
a O 0 2.9054808692308143e-07
very O 0 2.599933957014855e-08
early O 0 9.218091889806601e-08
age O 0 6.43254125520798e-08
, O 0 3.03138598667374e-08
and O 0 4.436458667100851e-08
at O 0 6.302952897385694e-07
least O 0 1.623658185678778e-08
two O 0 1.3363824713508166e-08
of O 0 1.3646629781760566e-07
them O 0 1.0901162639243012e-08
displayed O 0 1.5573217524433858e-06
signs O 0 2.0382333332236158e-06
of O 0 1.2826551483158255e-06
neurofibromatosis B-Disease 0 0.0022541540674865246
type I-Disease 0 1.346133831248153e-05
1 I-Disease 0 1.6753296222304925e-05
( O 0 1.1744842822736246e-06
NF1 B-Disease 0 0.00027290760772302747
) O 0 1.170666564576095e-06
. O 0 2.0817526547034504e-06

DNA O 0 7.439946330123348e-06
sequence O 0 2.9042944333923515e-06
analysis O 0 7.916295317045297e-07
and O 0 4.2482221829232003e-07
allele O 0 1.2350571978458902e-06
- O 0 7.670981290175405e-07
specific O 0 3.271869530863114e-08
amplification O 0 1.9358972167538013e-06
in O 0 1.3965188827569364e-07
two O 0 1.206609994142127e-07
siblings O 0 6.02873456045927e-07
revealed O 0 1.9298695406178012e-06
a O 0 1.3681309383173357e-06
homozygous O 0 3.0779222015553387e-06
MLH1 O 0 9.314220369560644e-05
mutation O 0 1.1605708323259023e-06
( O 0 5.889875751563522e-07
C676T O 0 2.2567643100046553e-05
- O 0 5.643830718327081e-06
- O 0 1.342344330623746e-05
> O 0 6.8801855377387255e-06
Arg226Stop O 0 3.292262044851668e-05
) O 0 6.771877565370232e-07
. O 0 1.4316734677777276e-06

Thus O 0 2.68908406724222e-05
, O 0 2.2064020868128864e-06
a O 0 2.0259913071640767e-06
homozygous O 0 9.852186849457212e-06
germ O 1 0.9987378716468811
- O 0 0.0020296182483434677
line O 0 3.635233952081762e-05
MLH1 O 0 9.126716759055853e-05
mutation O 0 3.829817671885394e-07
and O 0 1.681590902080643e-07
consequent O 0 0.4857858121395111
mismatch O 1 0.9999998807907104
repair O 1 0.9999992847442627
deficiency O 1 1.0
results O 0 3.1618001230526716e-06
in O 0 5.412766768131405e-07
a O 0 4.115619958611205e-06
mutator O 1 0.9709084033966064
phenotype O 0 2.1248093617032282e-05
characterized O 0 1.3278424830787117e-06
by O 0 3.7421347087729373e-07
leukemia B-Disease 1 0.9999951124191284
and O 0 8.869466546457261e-05
/ O 1 0.9999998807907104
or O 1 0.9993603825569153
lymphoma B-Disease 1 1.0
associated O 0 0.19820861518383026
with O 0 2.4614635094621917e-06
neurofibromatosis B-Disease 1 0.9999991655349731
type I-Disease 0 0.042726293206214905
1 I-Disease 0 0.00016771398077253252
. O 0 1.436665797882597e-06
. O 0 2.4031076009123353e-06

Missense O 0 0.000286980444798246
mutations O 0 2.065783155558165e-05
in O 0 3.9837359508965164e-06
the O 0 5.529270765691763e-07
most O 0 4.87692197737033e-08
ancient O 0 1.7525026407838595e-07
residues O 0 3.1035636993692606e-07
of O 0 6.032242367837171e-07
the O 0 2.718888254094054e-06
PAX6 O 0 0.014560873620212078
paired O 0 2.372950348217273e-06
domain O 0 1.1854219792439835e-06
underlie O 0 2.8586568987520877e-06
a O 0 3.5161212963430444e-07
spectrum O 0 1.4715574252477381e-06
of O 0 7.489463769161375e-06
human O 1 0.9997740387916565
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.0005704412469640374

Mutations O 0 2.2625868950854056e-05
of O 0 4.8599754336464684e-06
the O 0 2.526662228774512e-06
human O 0 6.521863269881578e-06
PAX6 O 1 0.6740878820419312
gene O 0 5.4942738643148914e-05
underlie O 1 0.9584499597549438
aniridia B-Disease 1 1.0
( O 0 0.0005073107895441353
congenital B-Disease 1 1.0
absence I-Disease 0 0.29573938250541687
of I-Disease 0 8.528369653504342e-05
the I-Disease 0 5.817249984829687e-06
iris I-Disease 0 0.0002632558753248304
) O 0 2.0081428431240056e-07
, O 0 6.323158885379598e-08
a O 0 2.232731048934511e-07
rare O 0 2.528619233999052e-06
dominant O 0 0.12659981846809387
malformation B-Disease 1 1.0
of I-Disease 1 0.9992710947990417
the I-Disease 1 0.9954755902290344
eye I-Disease 1 0.9999979734420776
. O 0 6.300475070020184e-05

The O 0 2.2868436644785106e-05
spectrum O 0 1.1201877896382939e-05
of O 0 7.11938491804176e-06
PAX6 O 0 0.0009871652582660317
mutations O 0 3.0835956295049982e-06
in O 0 5.605852493317798e-06
aniridia B-Disease 1 0.9999998807907104
patients O 0 3.031027290489874e-06
is O 0 1.4567716277724685e-07
highly O 0 9.596165284619929e-08
biased O 0 2.839913690877438e-07
, O 0 1.3025476697237082e-08
with O 0 5.339031439177688e-09
92 O 0 3.3596850812500634e-07
% O 0 1.8571959969904128e-08
of O 0 1.234798787663749e-07
all O 0 4.9550266112419195e-08
reported O 0 6.954637683520559e-07
mutations O 0 2.0537423495170515e-07
leading O 0 1.187337693409063e-05
to O 0 1.7728072521094873e-07
premature O 0 1.7036441931850277e-05
truncation O 0 3.592609937186353e-05
of O 0 3.776966423174599e-06
the O 0 1.7714141904434655e-06
protein O 0 9.418178024134249e-07
( O 0 1.2068700527834153e-07
nonsense O 0 1.2877280823886395e-06
, O 0 6.136534125289472e-08
splicing O 0 7.001581536769663e-08
, O 0 2.0956827384566168e-08
insertions O 0 1.372049069914283e-07
and O 0 8.813094609649852e-08
deletions O 0 5.629857469102717e-07
) O 0 6.183424972050489e-08
and O 0 6.374416727794596e-08
just O 0 9.177917092983989e-08
2 O 0 1.166495735560602e-07
% O 0 3.1873469197307713e-08
leading O 0 3.296104296168778e-07
to O 0 1.938385452149305e-08
substitution O 0 4.491057836730761e-07
of O 0 5.519534624909284e-07
one O 0 2.5861407948468695e-07
amino O 0 1.5957037646785466e-07
acid O 0 5.7143836329487385e-08
by O 0 4.4496786699710356e-08
another O 0 1.1986277570485981e-07
( O 0 7.603247809129243e-08
missense O 0 1.8636598042576225e-06
) O 0 5.304664796312863e-07
. O 0 1.6801334368210519e-06

The O 0 2.03334930120036e-05
extraordinary O 0 7.94286188465776e-06
conservation O 0 1.7943680177268106e-06
of O 0 1.4291634897745098e-06
the O 0 1.622530362510588e-06
PAX6 O 0 0.0001214889416587539
protein O 0 4.029760020785034e-06
at O 0 1.1340841410856228e-05
the O 0 1.8167177131545031e-06
amino O 0 2.061972509181942e-06
acid O 0 6.416630071726104e-07
level O 0 1.1195054412382888e-06
amongst O 0 3.154353578338487e-07
vertebrates O 0 1.4616410908274702e-06
predicts O 0 7.607744123561133e-07
that O 0 1.322315412721764e-08
pathological O 0 2.985920218634419e-06
missense O 0 1.632638259252417e-06
mutations O 0 1.5453676383003767e-07
should O 0 3.163454209698102e-08
in O 0 4.817264454004544e-08
fact O 0 2.2876255556525393e-08
be O 0 2.7483253006721498e-08
common O 0 1.6506779942915273e-08
even O 0 1.2330461984788599e-08
though O 0 8.739304391269798e-09
they O 0 3.96589117102053e-09
are O 0 4.976420164837236e-09
hardly O 0 5.2389445670542045e-08
ever O 0 9.969966896505866e-08
seen O 0 7.682592695346102e-07
in O 0 1.6788216044005821e-06
aniridia B-Disease 1 0.999998927116394
patients O 0 6.986199878156185e-06
. O 0 5.951210368948523e-06

This O 0 5.916983809584053e-06
indicates O 0 4.476917183637852e-06
that O 0 1.3237519169706502e-07
there O 0 1.5132029318465356e-07
is O 0 9.361809105712382e-08
a O 0 2.826787124377006e-07
heavy O 0 1.1936605005757883e-05
ascertainment O 0 0.0050044492818415165
bias O 0 2.0113295704504708e-06
in O 0 5.176536532758291e-08
the O 0 5.018017290581156e-08
selection O 0 6.238010996639787e-08
of O 0 1.5937798991672025e-07
patients O 0 7.526301004645575e-08
for O 0 9.799366296192602e-08
PAX6 O 0 0.00013227738963905722
mutation O 0 1.791068342527069e-07
analysis O 0 6.940260988130831e-08
and O 0 3.820004579324632e-08
that O 0 2.8540910079755122e-08
the O 0 4.5046039076623856e-07
missing O 0 3.474107643341995e-06
PAX6 O 0 0.0004590430180542171
missense O 0 1.2880971553386189e-05
mutations O 0 3.064814336539712e-06
frequently O 0 1.4216894896890153e-06
may O 0 1.311673258896917e-06
underlie O 0 1.217814951814944e-05
phenotypes O 0 1.0630616316120722e-06
distinct O 0 1.3028686396410194e-07
from O 0 2.611803665786283e-06
textbook O 0 0.0010428205132484436
aniridia B-Disease 1 0.9999346733093262
. O 0 9.872973350866232e-06

Here O 0 3.241920785512775e-05
we O 0 1.047866703629552e-06
present O 0 6.147511726339872e-07
four O 0 3.8219985754039953e-07
novel O 0 1.4907604963809717e-06
PAX6 O 0 7.528947026003152e-05
missense O 0 6.095889602875104e-06
mutations O 0 5.741669042436115e-07
, O 0 1.794660704490525e-07
two O 0 4.790555152567322e-08
in O 0 2.7223393317399314e-07
association O 0 4.6220296212595713e-07
with O 0 4.8235623495429536e-08
atypical O 0 0.006990933325141668
phenotypes O 0 0.0008459060918539762
ectopia B-Disease 0 0.44195839762687683
pupillae I-Disease 0 0.001598472474142909
( O 0 3.671354988910025e-07
displaced B-Disease 0 4.2252318621649465e-07
pupils I-Disease 0 9.31816089178028e-07
) O 0 1.9853605692787824e-07
and O 0 2.5342058052046923e-06
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9997385144233704
( O 0 1.0959286100842291e-06
searching B-Disease 0 7.322767601181113e-07
gaze I-Disease 0 2.7907039111596532e-05
) O 0 5.969371841274551e-08
, O 0 2.6375245099075073e-08
and O 0 2.665816545288635e-08
two O 0 2.6551502330107724e-08
in O 0 3.8649679368063516e-07
association O 0 7.119630254237563e-07
with O 0 6.950925524051854e-08
more O 0 3.1138276312958624e-07
recognizable O 0 8.46568655106239e-05
aniridia B-Disease 1 1.0
phenotypes O 0 0.0005502930725924671
. O 0 1.103791146306321e-05

Strikingly O 0 0.0002189358783653006
, O 0 2.2322569748212118e-06
all O 0 1.295288996061572e-07
four O 0 8.734792800169089e-08
mutations O 0 1.0028078634150006e-07
are O 0 1.9732000922090265e-08
located O 0 2.0853183002600417e-07
within O 0 4.454816249221949e-08
the O 0 3.4799063541868236e-07
PAX6 O 0 2.5064351575565524e-05
paired O 0 4.1972231201725663e-07
domain O 0 3.8153231685100764e-07
and O 0 1.003377931851901e-07
affect O 0 2.2791203946326277e-07
amino O 0 3.556224896783533e-07
acids O 0 5.1746901874594187e-08
which O 0 1.3753787442283283e-08
are O 0 2.3799600068485915e-09
highly O 0 1.4533573455821625e-08
conserved O 0 5.891325827178662e-08
in O 0 1.7463055002053807e-08
all O 0 1.556909801081474e-08
known O 0 3.6626786936722056e-07
paired O 0 6.758754125257838e-07
domain O 0 1.0714953759816126e-06
proteins O 0 1.8177785250372835e-06
. O 0 3.565873385014129e-06

Our O 0 2.1264027964207344e-05
results O 0 5.850225079484517e-06
support O 0 1.0371056760050124e-06
the O 0 3.605082383728586e-07
hypothesis O 0 2.7179450512448966e-07
that O 0 6.967079002606624e-08
the O 0 1.5865099101119995e-07
under O 0 3.3237179764000757e-07
- O 0 1.2964754603217443e-07
representation O 0 6.229307558669461e-08
of O 0 1.1664301524660914e-07
missense O 0 1.537995785838575e-06
mutations O 0 2.1829180241184076e-07
is O 0 9.56723482659072e-08
caused O 0 1.0172479960601777e-06
by O 0 6.868044977181853e-08
ascertainment O 0 3.9281621866393834e-05
bias O 0 7.1972647219809e-07
and O 0 1.5542573450488817e-08
suggest O 0 2.0678092127468517e-08
that O 0 5.785302903404954e-09
a O 0 3.243010127107482e-08
substantial O 0 1.6133851943322952e-07
burden O 0 8.532286415174895e-07
of O 0 6.927161393832648e-06
PAX6 B-Disease 1 0.9999897480010986
- I-Disease 0 0.0016600560629740357
related I-Disease 0 1.887824691948481e-05
disease I-Disease 0 0.00027103855973109603
remains O 0 6.363593456626404e-07
to O 0 2.0017903779034896e-08
be O 0 8.460417433298062e-08
uncovered O 0 6.136597676231759e-06
. O 0 3.1579867254549754e-07
. O 0 2.087366510750144e-06

The O 0 2.643293009896297e-05
chromosomal O 0 6.89080698066391e-05
order O 0 1.378301135446236e-06
of O 0 2.074720896416693e-06
genes O 0 1.0728737152021495e-06
controlling O 0 3.2946254577836953e-06
the O 0 2.6970710678142495e-06
major O 0 1.6522770238225348e-05
histocompatibility O 0 0.0005195123376324773
complex O 0 4.867285497311968e-06
, O 0 1.3796474718219542e-07
properdin O 0 2.8814238248742186e-06
factor O 0 6.907357033014705e-07
B O 0 3.111962314505945e-06
, O 0 4.425707800237433e-08
and O 0 1.1877288841333211e-07
deficiency B-Disease 0 0.015341768972575665
of I-Disease 0 2.05916035156406e-06
the I-Disease 0 1.5166486946327495e-06
second I-Disease 0 2.732498842306086e-06
component I-Disease 0 1.8061489299725508e-06
of I-Disease 0 1.7256039654967026e-06
complement I-Disease 0 1.3039022633165587e-05
. O 0 6.57366081213695e-06

The O 0 4.4664073357125744e-05
relationship O 0 2.937114231826854e-06
of O 0 3.688439164761803e-06
the O 0 9.885417284749565e-07
genes O 0 3.0338301826304814e-07
coding O 0 1.6567819329793565e-06
for O 0 5.259318527350842e-07
HLA O 0 2.662898987182416e-05
to O 0 1.0504867020699749e-07
those O 0 4.5489919386909605e-08
coding O 0 5.334107981980196e-07
for O 0 2.691872964533104e-07
properdin O 0 8.842407623887993e-06
Factor O 0 1.929797690536361e-06
B O 0 3.3921485282917274e-06
allotypes O 0 2.2624851681030123e-06
and O 0 1.2235105373292754e-07
for O 0 2.1890137702484935e-07
deficiency B-Disease 0 0.0002578126441221684
of I-Disease 0 2.7641233373287832e-06
the I-Disease 0 1.2732464256259846e-06
second I-Disease 0 2.079014620903763e-06
component I-Disease 0 1.0504751344342367e-06
of I-Disease 0 8.184568400793069e-07
complement I-Disease 0 1.091066906155902e-06
( O 0 3.2216422596320626e-07
C2 O 0 6.912069238751428e-06
) O 0 1.3024481937407018e-08
was O 0 1.0095862990056048e-07
studied O 0 4.0877427665009236e-08
in O 0 1.6026957538883835e-08
families O 0 5.578185913179823e-09
of O 0 2.6202610570180696e-07
patients O 0 2.230014388260315e-06
with O 0 3.788997128140181e-05
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.006712018977850676

Patients O 0 2.416122515569441e-05
were O 0 1.8795236655932968e-06
selected O 0 2.4278190835502755e-07
because O 0 2.0010345380683248e-08
they O 0 7.119139944222752e-09
were O 0 6.226243698392864e-08
heterozygous O 0 1.724918092804728e-07
or O 0 1.991692641922782e-07
homozygous O 0 9.527529073238838e-06
for O 0 0.0001315972622251138
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.4420121260627639e-05

12 O 0 5.3344312618719414e-05
families O 0 5.162633556210494e-07
with O 0 2.48737563879331e-07
15 O 0 2.643402694957331e-06
matings O 0 1.536494710308034e-05
informative O 0 1.5552053810097277e-05
for O 0 3.5598081012722105e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 5.476912974700099e-06
found O 0 2.7891626359632937e-06
. O 0 2.0190418581478298e-06

Of O 0 0.00010984387336065993
57 O 0 7.968350109877065e-05
informative O 0 1.2438856174412649e-05
meioses O 0 4.69462938781362e-05
, O 0 5.274578711578215e-07
two O 0 4.8328452351142914e-08
crossovers O 0 2.88676034188029e-07
were O 0 2.570257038314594e-07
noted O 0 5.25381437910255e-07
between O 0 9.514241128272261e-07
the O 0 0.00011118273687316105
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 6.837146315774589e-07
and O 0 3.9289784581342246e-07
the O 0 4.371505383460317e-06
HLA O 0 0.0030546681955456734
- O 0 7.899185220594518e-06
B O 0 9.046772902365774e-06
gene O 0 1.2419782535744162e-07
, O 0 3.5700885803180427e-08
with O 0 1.4548134252834188e-08
a O 0 2.18056271705791e-07
recombinant O 0 6.994960131123662e-07
fraction O 0 4.490775040721928e-07
of O 0 2.329300514247734e-06
0 O 0 5.019179752707714e-06
. O 0 2.189603492297465e-06

035 O 0 0.0886973962187767
. O 0 0.00042407610453665257

A O 0 0.000210701153264381
lod O 0 0.0007179000531323254
score O 0 3.875611582770944e-06
of O 0 1.2067358738931944e-06
13 O 0 1.3272043588585802e-06
was O 0 1.50834614487394e-06
calculated O 0 3.727986381818482e-07
for O 0 7.205341034932644e-08
linkage O 0 2.6053403416881338e-05
between O 0 0.00010381064930697903
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.4785882740397938e-06
HLA O 0 0.002605927875265479
- O 0 3.554556997187319e-06
B O 0 3.1635736377211288e-06
at O 0 1.5684841514485015e-07
a O 0 1.1700304725081878e-08
maximum O 0 3.8347433672925035e-08
likelihood O 0 6.617771219907809e-08
value O 0 4.0134072065711734e-08
of O 0 8.550518515448857e-08
the O 0 7.986302819062985e-08
recombinant O 0 2.6910132078228344e-07
fraction O 0 2.052285594800196e-07
of O 0 6.030959980307671e-07
0 O 0 2.5510582872811938e-06
. O 0 2.150982936655055e-06

04 O 0 0.048182614147663116
. O 0 0.0004309247888159007

18 O 0 7.558132347185165e-05
families O 0 6.963052783248713e-07
with O 0 1.8038510063433932e-07
21 O 0 2.2841672944196034e-06
informative O 0 3.7222096693767526e-07
matings O 0 1.0657902294042287e-06
for O 0 1.4679983451060252e-07
both O 0 2.1827806051533116e-07
properdin O 0 1.0771061170089524e-05
Factor O 0 4.569471911963774e-06
B O 0 8.035875907808077e-06
allotype O 0 6.371223207679577e-06
and O 0 7.837046496206312e-07
HLA O 0 0.001832960406318307
- O 0 1.3128009413776454e-05
B O 0 1.053504729497945e-05
were O 0 5.827233735544723e-07
found O 0 9.066992561201914e-07
. O 0 1.9257292933616554e-06

Of O 0 0.0001124117843573913
72 O 0 5.107735705678351e-05
informative O 0 6.85348140905262e-06
meioses O 0 3.9661008486291394e-05
, O 0 4.385776151138998e-07
three O 0 2.3402368753977498e-07
recombinants O 0 7.730851393716875e-06
were O 0 3.6836090089309437e-07
found O 0 1.3609900406663655e-07
, O 0 2.5556060379017254e-08
giving O 0 1.513297576138939e-08
a O 0 9.373476927976299e-08
recombinant O 0 4.93959362302121e-07
fraction O 0 2.351745393980309e-07
of O 0 1.3433204912871588e-06
0 O 0 4.321164851717185e-06
. O 0 1.54393740103842e-06

042 O 0 0.03482606261968613
. O 0 0.00047060337965376675

A O 0 0.0001772913383319974
lod O 0 0.0008407295099459589
score O 0 6.305313490884146e-06
of O 0 3.448061761446297e-06
16 O 0 6.997262062213849e-06
between O 0 2.3178554329206236e-06
HLA O 0 0.0004252132202964276
- O 0 7.011978141235886e-06
B O 0 4.650672963180114e-06
and O 0 1.1601144223050142e-07
Factor O 0 6.635528961851378e-07
B O 0 1.4395239986697561e-06
allotypes O 0 8.275613936348236e-07
was O 0 4.974344847141765e-07
calculated O 0 8.556261832382006e-08
at O 0 9.121060884353938e-08
a O 0 9.127427702537716e-09
maximum O 0 3.624123934287127e-08
likelihood O 0 5.295141747296839e-08
value O 0 4.9050392192384606e-08
of O 0 1.3970982593036751e-07
the O 0 1.3224835981873184e-07
recombinant O 0 3.785451383464533e-07
fraction O 0 2.563750172157597e-07
of O 0 1.0290642649124493e-06
0 O 0 3.0491473808069713e-06
. O 0 1.834833142311254e-06

04 O 0 0.0482608824968338
. O 0 0.0005394626059569418

A O 0 3.0783288821112365e-05
crossover O 0 7.889051630627364e-06
was O 0 5.4256743169389665e-06
shown O 0 1.8977118543261895e-07
to O 0 4.0188151473330436e-08
have O 0 1.7813801989063904e-08
occurred O 0 3.5127663977618795e-07
between O 0 5.02221126907898e-08
genes O 0 5.063339258981614e-08
for O 0 6.08901089549363e-08
Factor O 0 7.656977913939045e-07
B O 0 1.5883462083365885e-06
and O 0 2.177757210120035e-07
HLA O 0 3.364931762916967e-05
- O 0 3.974817445850931e-06
D O 0 3.327788590468117e-06
, O 0 6.519473316757285e-08
in O 0 8.58974971151838e-08
which O 0 1.747269209317892e-07
HLA O 0 4.636744415620342e-05
- O 0 9.107785444939509e-06
D O 0 1.6588974176556803e-05
segregared O 0 7.615447884745663e-06
with O 0 4.1900523228832753e-07
HLA O 0 0.1344374418258667
- O 0 8.003570656001102e-06
A O 0 4.894315225101309e-06
and O 0 5.027770271226473e-07
B O 0 3.814033334492706e-05
. O 0 1.830987457651645e-06

These O 0 1.0089921715916716e-06
studies O 0 1.8268154917677748e-06
suggest O 0 4.548757601696707e-07
that O 0 3.37304619790757e-08
the O 0 9.768183417691034e-08
genes O 0 7.501520826735941e-08
for O 0 1.7108452254888107e-07
Factor O 0 5.449829131976003e-06
B O 0 0.00010364743502577767
and O 0 1.970238736248575e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
are O 0 6.596146562287686e-08
located O 0 2.4651325247759814e-07
outside O 0 1.0026644048366506e-07
those O 0 5.774587030771272e-09
for O 0 4.2678109934968234e-08
HLA O 0 8.497624548908789e-06
, O 0 3.890862387834204e-08
that O 0 1.0039289399799145e-08
the O 0 6.935351137826729e-08
order O 0 8.212686708475303e-08
of O 0 1.1460788300610147e-06
genese O 0 2.7520727599039674e-05
is O 0 1.4916720374458237e-06
HLA O 0 1.8012218788499013e-05
- O 0 9.563291314407252e-07
A O 0 3.2399209430877818e-06
, O 0 1.350730940430367e-07
- O 0 4.246456057899195e-07
B O 0 1.3958771205579978e-06
, O 0 7.672226587374098e-08
- O 0 6.723646492901025e-07
D O 0 2.1862190351384925e-06
, O 0 8.955773722618687e-08
Factor O 0 1.434959585822071e-06
B O 0 1.3006359040446114e-05
allotype O 0 7.53911372157745e-05
, O 0 2.018923441937659e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 1.1196907223620656e-07
that O 0 1.9017932118003955e-08
the O 0 1.0010916895453192e-07
genes O 0 1.670031224421109e-07
coding O 0 5.246096407063305e-06
for O 0 1.6094179954961874e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 6.949612725293264e-07
Factor O 0 3.5065149859292433e-06
B O 0 3.344549440953415e-06
allotypes O 0 1.689740997790068e-06
are O 0 9.256356570119806e-09
approximately O 0 4.3880017841502195e-08
3 O 0 1.4259475733524596e-07
- O 0 1.9671357165407244e-07
- O 0 3.247882318646589e-07
5 O 0 4.452344910532702e-07
centimorgans O 0 1.6586775473115267e-06
from O 0 2.4137617060659977e-07
the O 0 5.277245236356976e-07
HLA O 0 7.313273272302467e-06
- O 0 5.368795541471627e-07
A O 0 8.652148721921549e-07
and O 0 1.5801904851286963e-07
HLA O 0 2.8277378078200854e-05
- O 0 2.3262391550815664e-06
B O 0 3.534926236170577e-06
loci O 0 1.919301553243713e-07
, O 0 1.8196356421640303e-08
and O 0 9.459251160137683e-09
that O 0 1.2965566398293049e-08
the O 0 5.655645551883026e-08
apparent O 0 1.029225245474663e-06
lack O 0 7.272692528204061e-07
of O 0 1.3101641798130004e-06
recombinants O 0 6.328760264295852e-06
between O 0 2.2172642388795794e-07
the O 0 4.989748276784667e-07
Factor O 0 1.465619220653025e-06
B O 0 1.0496156392036937e-05
gene O 0 2.6182131023233524e-06
and O 0 5.494619836099446e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.2018891766274464e-06
suggests O 0 1.8868318818476837e-07
that O 0 1.0096899316636154e-08
these O 0 3.920374691546158e-09
two O 0 1.2317861397548313e-08
genes O 0 8.69206360221142e-08
lie O 0 9.01740861536382e-07
in O 0 2.51175180210339e-07
close O 0 5.219614536144945e-07
proximity O 0 6.418582643163973e-07
to O 0 1.0860303945037231e-07
one O 0 5.999729069117166e-07
another O 0 2.2720766992279096e-06
. O 0 3.309930889372481e-06

Distribution O 0 2.831010897352826e-05
of O 0 1.0907756404776592e-05
emerin O 0 0.00010856036533368751
and O 0 1.7855732039606664e-06
lamins O 0 8.486022124998271e-05
in O 0 6.901365736666776e-07
the O 0 1.1685918934745132e-06
heart O 0 3.420652137720026e-05
and O 0 2.2023436940799002e-07
implications O 0 2.306519036210375e-06
for O 0 1.1766233001253568e-06
Emery B-Disease 1 0.9741120934486389
- I-Disease 1 0.999980092048645
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 4.4118580262875184e-05

Emerin O 0 0.002997164148837328
is O 0 1.350114143860992e-05
a O 0 6.022899924573721e-06
nuclear O 0 2.2154086764203385e-05
membrane O 0 1.5921732483548112e-05
protein O 0 1.8673781596589833e-06
which O 0 1.8514104738187598e-07
is O 0 2.111829644491081e-07
missing O 0 8.407346854255593e-07
or O 0 3.687316905143234e-07
defective O 0 2.683719685592223e-05
in O 0 3.8428347579611e-06
Emery B-Disease 1 0.9978017210960388
- I-Disease 1 0.9999979734420776
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.3329721190966666e-05
EDMD B-Disease 1 1.0
) O 0 2.383274249950773e-06
. O 0 2.302607072124374e-06

It O 0 9.678433343651704e-06
is O 0 1.7531557432448608e-06
one O 0 2.746541838405392e-07
member O 0 3.297755029052496e-07
of O 0 1.0838033404070302e-06
a O 0 2.806797738230671e-06
family O 0 6.335761781883775e-07
of O 0 2.50718803727068e-05
lamina O 1 0.9999672174453735
- O 0 0.0006329537718556821
associated O 0 1.7163866914415848e-06
proteins O 0 1.8937903689675295e-07
which O 0 1.0939116634745005e-07
includes O 0 2.455200842632621e-07
LAP1 O 0 0.0001323363248957321
, O 0 7.458804134330421e-07
LAP2 O 0 8.972740761237219e-05
and O 0 1.7431063952244585e-06
lamin O 0 7.744625327177346e-05
B O 0 3.211990770068951e-05
receptor O 0 1.4698696759296581e-05
( O 0 2.1761013613286195e-06
LBR O 0 8.534902008250356e-05
) O 0 1.3330725323612569e-06
. O 0 2.2295082544587785e-06

A O 0 0.00041636190144345164
panel O 0 3.082323746639304e-05
of O 0 6.318929990811739e-06
16 O 0 5.952833816991188e-06
monoclonal O 0 1.1509042451507412e-05
antibodies O 0 2.357895027671475e-06
( O 0 4.882236908088089e-07
mAbs O 0 1.7795518942875788e-06
) O 0 4.448499169029674e-08
has O 0 1.4862513886271245e-08
been O 0 2.9352747787925182e-08
mapped O 0 7.812482749613991e-08
to O 0 1.5294196131776516e-08
six O 0 3.5030538469982275e-08
specific O 0 1.3217960059819234e-08
sites O 0 5.261114566224023e-08
throughout O 0 5.276892522942944e-08
the O 0 2.2066535620979266e-07
emerin O 0 3.2485065730725182e-06
molecule O 0 3.6067814335183357e-07
using O 0 6.350679626621059e-08
phage O 0 4.991946980226203e-07
- O 0 1.3616599403576402e-07
displayed O 0 8.201728718404411e-08
peptide O 0 7.326295303755614e-08
libraries O 0 3.366008627381234e-08
and O 0 1.2991062448008961e-08
has O 0 1.9331462652871778e-08
been O 0 4.805930231555067e-08
used O 0 2.3438678553588943e-08
to O 0 3.99273112350329e-08
localize O 0 2.316233576493687e-06
emerin O 0 2.0844679966103286e-05
in O 0 5.214411089582427e-07
human O 0 1.4155339158605784e-06
and O 0 2.2433973754232284e-06
rabbit O 0 0.0003129238320980221
heart O 1 0.9575013518333435
. O 0 9.815387784328777e-06

Several O 0 2.254355240438599e-05
mAbs O 0 8.823263488011435e-05
against O 0 1.7004377923512948e-06
different O 0 1.2292893813992123e-07
emerin O 0 2.88954524876317e-05
epitopes O 0 1.1000523045368027e-05
did O 0 3.776116557219211e-07
not O 0 4.1501994729742364e-08
recognize O 0 9.46918277122677e-08
intercalated O 0 9.588820830686018e-06
discs O 0 2.9153056857467163e-06
in O 0 1.7011565489610803e-07
the O 0 6.57811767723615e-07
heart O 0 1.905216049635783e-05
, O 0 4.759244021101949e-08
though O 0 1.6556915838350506e-08
they O 0 3.928608549585988e-09
recognized O 0 3.7105632344491823e-08
cardiomyocyte O 0 2.0525883428490488e-06
nuclei O 0 1.369964024888759e-06
strongly O 0 3.0546317475455e-07
, O 0 8.732110501341594e-08
both O 0 8.487619851393902e-08
at O 0 2.993946964124916e-06
the O 0 3.755677653316525e-07
rim O 0 3.7164675177336903e-06
and O 0 4.71943408797415e-08
in O 0 2.6100232730641437e-07
intranuclear O 0 1.91493054444436e-05
spots O 0 1.840985419221397e-06
or O 0 7.802369736964465e-07
channels O 0 5.017490366299171e-06
. O 0 6.301982921286253e-06

A O 0 0.000431274704169482
polyclonal O 0 0.0009550542454235256
rabbit O 0 7.770545926177874e-05
antiserum O 0 6.856009713374078e-05
against O 0 6.307827334239846e-06
emerin O 0 3.066310819122009e-05
did O 0 2.4043171720222745e-07
recognize O 0 1.310733779291695e-07
both O 0 2.0511508580511872e-07
nuclear O 0 5.818043973704334e-06
membrane O 0 3.2264310902974103e-06
and O 0 2.5646403400969575e-07
intercalated O 0 1.2804277503164485e-05
discs O 0 1.968059905266273e-06
but O 0 1.889236855845411e-08
, O 0 1.292285389808967e-08
after O 0 2.794481979151442e-08
affinity O 0 4.348053295188947e-08
purification O 0 6.464994726229634e-07
against O 0 6.481156447080139e-07
a O 0 1.4580047036361066e-06
pure O 0 4.287443971406901e-06
- O 0 4.7029548113641795e-06
emerin O 0 1.5836008969927207e-05
band O 0 1.2565025144795072e-06
on O 0 5.525027404473803e-07
a O 0 2.3637504398266174e-07
western O 0 2.307387205746636e-07
blot O 0 2.3168411189544713e-06
, O 0 6.127633156438606e-08
it O 0 2.9957725189433404e-08
stained O 0 4.819286459678551e-06
only O 0 6.829939280805775e-08
the O 0 1.1687367305057705e-06
nuclear O 0 4.249555058777332e-05
membrane O 0 0.00011439302033977583
. O 0 9.766013135958929e-06

These O 0 1.549476223772217e-06
results O 0 2.878353370761033e-06
would O 0 2.423962541797664e-07
not O 0 8.577733012771205e-08
be O 0 1.2031834728531976e-07
expected O 0 2.9860916583857033e-07
if O 0 5.83034704959573e-08
immunostaining O 0 2.6020134100690484e-06
at O 0 8.16738292996888e-07
intercalated O 0 2.757827815003111e-06
discs O 0 7.180193506428623e-07
were O 0 2.282907587414229e-07
due O 0 4.0730265027377754e-07
to O 0 3.29006155652678e-08
a O 0 2.086209320850685e-07
product O 0 1.7117852735282213e-07
of O 0 4.6211923176997516e-07
the O 0 5.3518914455708e-07
emerin O 0 5.771887117589358e-06
gene O 0 7.988679584514102e-08
and O 0 5.3815654155187076e-08
, O 0 4.610776827007612e-08
therefore O 0 3.1952662737921855e-08
, O 0 1.2281405226133302e-08
cast O 0 3.455908270666441e-08
some O 0 6.471031266386262e-09
doubt O 0 4.56332216458577e-08
upon O 0 7.113414568493681e-08
the O 0 1.1973492064498714e-07
hypothesis O 0 5.968609002593439e-07
that O 0 2.8838766752414813e-07
cardiac B-Disease 1 1.0
defects I-Disease 1 0.9949086308479309
in O 0 1.2830018022214063e-05
EDMD B-Disease 1 1.0
are O 0 1.6502521305028495e-07
caused O 0 5.470022642839467e-06
by O 0 2.775937559817976e-07
absence O 0 3.033329221580061e-06
of O 0 5.797274297947297e-06
emerin O 0 0.00028800859581679106
from O 0 9.675257388153113e-06
intercalated O 0 0.0003437507839407772
discs O 0 0.00014465904678218067
. O 0 1.0996536730090156e-05

Although O 0 2.150712680304423e-05
emerin O 0 0.00028813903918489814
was O 0 1.8617785826791078e-05
abundant O 0 2.6688699108490255e-06
in O 0 4.3876002564502414e-07
the O 0 5.440806489787064e-07
membranes O 0 1.3552850077758194e-06
of O 0 2.9890543373767287e-06
cardiomyocyte O 0 3.460695006651804e-05
nuclei O 0 3.0155615604599006e-06
, O 0 1.918604226602838e-07
it O 0 4.285160315475878e-08
was O 0 1.9265557966718916e-06
absent O 0 5.913763629905588e-07
from O 0 6.907971084046949e-08
many O 0 1.1329794880055033e-08
non O 0 1.4695408481202321e-06
- O 0 3.325821353428182e-06
myocyte O 0 7.40972172934562e-05
cells O 0 3.277397695455875e-07
in O 0 2.210137068914264e-07
the O 0 1.909941374833579e-06
heart O 0 0.0009323041886091232
. O 0 6.67436597723281e-06

This O 0 6.637049864366418e-06
distribution O 0 2.3640780000278028e-06
of O 0 4.6161717364157084e-06
emerin O 0 4.14993119193241e-05
was O 0 4.996722964278888e-06
similar O 0 5.247204626357416e-08
to O 0 2.0959864954761542e-08
that O 0 1.5012261656011106e-08
of O 0 8.339470696228091e-07
lamin O 0 2.5327479306724854e-05
A O 0 2.323811486348859e-06
, O 0 6.184745870996267e-08
a O 0 1.1432238267161665e-07
candidate O 0 1.656418646689417e-07
gene O 0 1.21465490110495e-07
for O 0 6.813869646293824e-08
an O 0 1.984574993230126e-07
autosomal O 0 2.520010639273096e-06
form O 0 1.0411886250949465e-06
of O 1 0.5230085253715515
EDMD B-Disease 1 1.0
. O 0 5.593983951257542e-05

In O 0 4.385770080261864e-05
contrast O 0 2.9991428164066747e-05
, O 0 1.148358660429949e-05
lamin O 0 0.0010085164103657007
B1 O 1 0.999308705329895
was O 0 0.0001117144274758175
absent O 0 5.514586064236937e-06
from O 0 6.824924980719516e-07
cardiomyocyte O 0 7.696035027038306e-06
nuclei O 0 2.455327830830356e-06
, O 0 1.9268502171598811e-07
showing O 0 1.1521323131091776e-06
that O 0 4.251359086993034e-07
lamin O 0 0.00020511363982222974
B1 O 1 0.9183302521705627
is O 0 8.129121908950765e-08
not O 0 1.14846194776419e-08
essential O 0 8.81427126842027e-08
for O 0 9.286971902611185e-08
localization O 0 7.95474807091523e-06
of O 0 1.3375117760006106e-06
emerin O 0 1.2347767551545985e-05
to O 0 4.803868591807259e-07
the O 0 4.938048732583411e-06
nuclear O 0 0.000332851690473035
lamina O 1 0.9034674167633057
. O 0 2.3353693904937245e-05

Lamin O 1 0.9978644251823425
B1 O 1 0.9999346733093262
is O 0 9.014992429001722e-06
also O 0 1.7716641877996153e-06
almost O 0 1.4081392691878136e-06
completely O 0 5.042535121901892e-06
absent O 0 1.303362751059467e-05
from O 0 5.725304617953952e-06
skeletal O 1 0.9154481887817383
muscle O 0 0.00038201408460736275
nuclei O 0 0.00028954847948625684
. O 0 1.0905740964517463e-05

In O 0 9.723012044560164e-05
EDMD B-Disease 1 0.9999723434448242
, O 0 9.013384669742663e-07
the O 0 2.8339238156149804e-07
additional O 0 2.867493265057419e-07
absence O 0 6.313520316325594e-06
of O 0 2.3132435671868734e-05
lamin O 1 0.9609886407852173
B1 O 1 0.9999996423721313
from O 0 2.07819994102465e-05
heart O 1 0.9958925247192383
and O 0 1.8228220142191276e-05
skeletal O 1 0.9999992847442627
muscle O 0 0.0011173967504873872
nuclei O 0 1.2084601621609181e-05
which O 0 2.3460489728677203e-07
already O 0 1.853298954301863e-07
lack O 0 1.6566540352869197e-06
emerin O 0 3.8917860365472734e-05
may O 0 2.0117445842515735e-07
offer O 0 7.750529107397597e-09
an O 0 2.254595976580731e-08
alternative O 0 2.3254148828755206e-08
explanation O 0 4.521699636939047e-08
of O 0 1.8852023231374915e-07
why O 0 5.3914696707124676e-08
these O 0 1.9175866228238192e-08
tissues O 0 8.663411108500441e-07
are O 0 4.723774793546909e-08
particularly O 0 1.4590908392619895e-07
affected O 0 2.3829963424759626e-07
. O 0 2.416587960851757e-07
. O 0 1.1026843367289985e-06

Genetic O 0 2.5916617232724093e-05
mapping O 0 2.000276253966149e-05
of O 0 1.0006170668930281e-05
the O 0 1.6146417692652903e-05
copper B-Disease 0 0.004933277610689402
toxicosis I-Disease 0 0.0005735731683671474
locus O 0 1.2519795745902229e-05
in O 0 5.496154926731833e-07
Bedlington O 0 2.5655588615336455e-05
terriers O 0 3.1120512176130433e-06
to O 0 1.8867922335630283e-07
dog O 0 7.951433076414105e-07
chromosome O 0 2.9341381377889775e-06
10 O 0 3.7713803635597287e-07
, O 0 4.1114198268132895e-08
in O 0 6.52905498554901e-08
a O 0 1.416728991898708e-07
region O 0 1.4893011268668488e-07
syntenic O 0 4.277853804524057e-06
to O 0 8.176800037063003e-08
human O 0 1.0182311598327942e-06
chromosome O 0 6.92886023898609e-05
region O 0 2.12885770451976e-05
2p13 O 1 0.5005701184272766
- O 0 0.00036326510598883033
p16 O 0 0.0002120472490787506
. O 0 3.208909674867755e-06

Abnormal O 1 1.0
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999995231628418
accumulation I-Disease 0 0.023316828534007072
is O 0 2.4569342826907814e-07
recognized O 0 8.551840124937371e-08
as O 0 2.7690973070093605e-07
an O 0 2.7948290153290145e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.012980402447283268
man O 0 0.05733737349510193
, O 0 1.869698280643206e-06
mouse O 0 9.342948942503426e-06
, O 0 1.4873255622660508e-06
rat O 0 3.2864649256225675e-05
and O 0 2.2860785975353792e-06
dog O 0 3.823173392447643e-05
. O 0 8.579615496273618e-06

The O 0 3.573375943233259e-05
major O 0 3.247304994147271e-05
cause O 0 1.5117853763513267e-05
of O 0 0.00017068974557332695
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999997615814209
accumulation I-Disease 0 0.15260395407676697
in O 0 2.035252009591204e-06
man O 0 3.6473036288953153e-06
is O 0 7.059740170234363e-08
a O 0 1.6742474429065624e-07
dysfunctional O 0 1.0510192396395723e-06
ATP7B O 0 0.00010142468090634793
gene O 0 8.989160278360941e-07
, O 0 4.999631642021996e-07
causing O 0 1.965719275176525e-05
Wilson B-Disease 0 0.00021503549942281097
disease I-Disease 0 0.0004322184540797025
( O 0 1.7792802964322618e-06
WD B-Disease 0 0.0005475729703903198
) O 0 2.368681634834502e-06
. O 0 3.120628207398113e-06

Mutations O 0 4.843212082050741e-05
in O 0 5.81254744247417e-06
the O 0 2.7752357709687203e-06
ATP7B O 0 3.778338577831164e-05
genes O 0 2.2267450106028264e-07
have O 0 6.608538427599342e-08
also O 0 8.785234939523434e-08
been O 0 1.3601207626834366e-07
demonstrated O 0 7.193517603809596e-07
in O 0 6.193842523316562e-07
mouse O 0 5.937072273809463e-06
and O 0 2.8211818516865605e-06
rat O 0 0.0002376334450673312
. O 0 6.310438493528636e-06

The O 0 8.385350520256907e-05
ATP7B O 0 0.0008138038101606071
gene O 0 3.070677394134691e-06
has O 0 3.8617588415945647e-07
been O 0 1.963660736237216e-07
excluded O 0 1.1888224804579295e-07
in O 0 4.914506845921096e-08
the O 0 1.218460425889134e-07
much O 0 9.708799808549884e-08
rarer O 0 7.4621866588131525e-06
human O 0 0.00013605112326331437
copper B-Disease 1 1.0
overload I-Disease 1 0.999998927116394
disease O 1 0.9620993733406067
non B-Disease 0 0.0003198268241249025
- I-Disease 0 1.4532026398228481e-05
Indian I-Disease 0 1.0817401516760583e-06
childhood I-Disease 0 1.2898230124847032e-05
cirrhosis I-Disease 1 0.9999650716781616
, O 0 3.218460733478423e-07
indicating O 0 3.453415729381959e-06
genetic O 0 2.3576881176268216e-06
heterogeneity O 0 0.0001495994220022112
. O 0 1.1415439985285047e-05

By O 0 1.0077380466100294e-05
investigating O 0 7.127781373128528e-06
the O 0 2.4445569124509348e-06
common O 0 2.7196247174288146e-06
autosomal O 1 0.643425703048706
recessive O 1 0.9999874830245972
copper B-Disease 1 1.0
toxicosis I-Disease 1 0.9999948740005493
( O 0 6.239546337383217e-07
CT B-Disease 0 0.00019048414833378047
) O 0 2.953470179534179e-08
in O 0 4.9701142756930494e-08
Bedlington O 0 8.810506187728606e-06
terriers O 0 9.458836984777008e-07
, O 0 9.459358629726466e-09
we O 0 1.983754049916797e-09
have O 0 1.490503276357913e-09
identified O 0 7.139876689876701e-09
a O 0 8.783789695598898e-09
new O 0 1.3898459272354557e-08
locus O 0 3.2503797342542384e-07
involved O 0 9.202141626474258e-08
in O 0 2.9572411222034134e-06
progressive O 1 0.9999998807907104
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 5.973865700070746e-05

We O 0 6.144900908111595e-06
examined O 0 3.9891110645839944e-06
whether O 0 3.7430197608046e-07
the O 0 1.2855404065703624e-06
WD B-Disease 0 9.91449851426296e-05
gene O 0 5.849946319358423e-06
ATP7B O 0 0.0004730410873889923
was O 0 1.7795922758523375e-05
also O 0 2.037503463725443e-07
causative O 0 2.2487267870019423e-06
for O 0 3.31833376776558e-07
CT B-Disease 0 0.0008036906365305185
by O 0 4.1170238773702295e-07
investigating O 0 6.668720970992581e-07
the O 0 8.770064710006409e-07
chromosomal O 0 0.0009878817945718765
co O 0 0.015614231117069721
- O 0 6.587563984794542e-05
localization O 0 0.0006042991881258786
of O 0 4.0750651351117995e-06
ATP7B O 0 0.00041158590465784073
and O 0 5.514619942914578e-07
C04107 O 0 6.974908956181025e-06
, O 0 3.997592656901361e-08
using O 0 1.864194665301966e-08
fluorescence O 0 3.4570561524560617e-07
in O 0 2.210548188941175e-07
situ O 0 5.051131211075699e-06
hybridization O 0 1.0499493328097742e-06
( O 0 4.445836054856045e-07
FISH O 0 1.3618512184621068e-06
) O 0 2.878013560803083e-07
. O 0 9.161386742562172e-07

C04107 O 0 0.004206206649541855
is O 0 8.048016752582043e-06
an O 0 1.1775168786698487e-06
anonymous O 0 3.753196324396413e-06
microsatellite O 0 2.3236374545376748e-05
marker O 0 3.214132084394805e-05
closely O 0 9.555268434269237e-07
linked O 0 9.541560757497791e-06
to O 0 2.3373645490210038e-06
CT B-Disease 1 0.9581372141838074
. O 0 1.577200055180583e-05

However O 0 7.595740316901356e-05
, O 0 1.3615806892630644e-05
BAC O 0 0.00024038740957621485
clones O 0 8.734408766031265e-06
containing O 0 2.4971066068246728e-06
ATP7B O 0 6.788020982639864e-05
and O 0 5.416256954049459e-07
C04107 O 0 1.9123262973153032e-05
mapped O 0 1.074577653525921e-06
to O 0 1.5412392428970634e-07
the O 0 8.827324791127467e-07
canine O 0 7.955824912642129e-06
chromosome O 0 1.1405069926695433e-05
regions O 0 5.307938408805057e-07
CFA22q11 O 0 0.0001690945791779086
and O 0 5.848791033713496e-07
CFA10q26 O 0 5.012722613173537e-05
, O 0 9.294644343071923e-08
respectively O 0 2.0658133337292384e-07
, O 0 1.3137429810683443e-08
demonstrating O 0 1.206011717158617e-07
that O 0 3.7128639718275736e-08
WD B-Disease 0 6.6969305407837965e-06
cannot O 0 6.992506484948535e-08
be O 0 6.08240640076474e-08
homologous O 0 4.3889895096071996e-07
to O 0 5.88086777497665e-07
CT B-Disease 0 0.017509737983345985
. O 0 8.678645826876163e-06

The O 0 0.00019293995865155011
copper O 0 0.0004351744137238711
transport O 0 1.476745728723472e-05
genes O 0 4.37611879533506e-06
CTR1 O 0 0.00023912216420285404
and O 0 9.96327344182646e-07
CTR2 O 0 0.00010621159890433773
were O 0 5.273924443827127e-07
also O 0 9.565392389276894e-08
excluded O 0 1.5138843423301296e-07
as O 0 4.160534672337235e-08
candidate O 0 7.215298580831586e-08
genes O 0 3.473168419532158e-08
for O 0 7.855172157178458e-08
CT B-Disease 0 0.00022073659056331962
since O 0 1.8364104903412226e-07
they O 0 6.843589250848936e-09
both O 0 1.7332478563503173e-08
mapped O 0 3.03821678926397e-07
to O 0 1.3436287815693504e-07
canine O 0 2.1308442228473723e-05
chromosome O 0 0.00046007693163119256
region O 0 3.09519273287151e-05
CFA11q22 O 0 0.37680864334106445
. O 0 1.6255680748145096e-05

2 O 0 0.00031676076469011605
- O 0 0.00013563403626903892
22 O 0 0.00011649756197584793
. O 0 2.0746394511661492e-05

5 O 0 0.0004800152382813394
. O 0 0.00011363134399289265

A O 0 0.00018179940525442362
transcribed O 0 4.191869084024802e-05
sequence O 0 3.7524127947108354e-06
identified O 0 1.7527077034174e-06
from O 0 9.759093018146814e-07
the O 0 1.3149572168913437e-06
C04107 O 0 2.2056043235352263e-05
- O 0 2.4906423732318217e-06
containing O 0 5.859007501385349e-07
BAC O 0 1.2465657164284494e-05
was O 0 2.212884055552422e-06
found O 0 3.4016675698467225e-08
to O 0 1.3473006710285063e-08
be O 0 3.5229813732939874e-08
homologous O 0 3.347639676576364e-08
to O 0 1.7135810992385814e-08
a O 0 4.5853352048652596e-07
gene O 0 2.7212595909986703e-07
expressed O 0 2.5837888983915036e-07
from O 0 6.216038173079141e-07
human O 0 1.1339717502778512e-06
chromosome O 0 9.295019117416814e-05
2p13 O 0 0.0006799967959523201
- O 0 1.3625288374896627e-05
p16 O 0 4.963822902936954e-06
, O 0 2.5337746123454963e-08
a O 0 3.3971417678912985e-08
region O 0 2.8181888822587098e-08
devoid O 0 1.5749819226584805e-07
of O 0 5.224216081956001e-08
any O 0 4.818081933422036e-08
positional O 0 3.379990403118427e-06
candidate O 0 2.744185394476517e-06
genes O 0 1.9236440493841656e-06
. O 0 2.2340204850479495e-06

Molecular O 0 0.0002634436823427677
analysis O 0 8.412524039158598e-06
of O 0 3.81549762096256e-06
the O 0 3.017955350514967e-06
APC B-Disease 0 9.825614142755512e-06
gene O 0 2.5706344786158297e-07
in O 0 1.599994874368349e-07
205 O 0 1.079522348845785e-06
families O 0 5.047179030270854e-08
: O 0 7.797937939812982e-08
extended O 0 7.042484639896429e-07
genotype O 0 1.279922912544862e-06
- O 0 1.885356482489442e-06
phenotype O 0 4.976275818080467e-07
correlations O 0 2.9210951879576896e-07
in O 0 1.418924711060754e-07
FAP B-Disease 0 9.702632723929128e-07
and O 0 7.95775800810361e-09
evidence O 0 3.4826147299327204e-08
for O 0 1.2467959109585536e-08
the O 0 1.0850965281861136e-07
role O 0 5.83297719458642e-07
of O 0 8.537896974303294e-06
APC B-Disease 0 7.346576603595167e-05
amino O 0 1.5855463288971805e-06
acid O 0 3.2852273079697625e-07
changes O 0 2.0104806708332035e-07
in O 0 3.6205441574566066e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999911785125732
. O 0 4.603216802934185e-05

BACKGROUND O 0 0.00030367556610144675
/ O 0 0.00017180090071633458
AIMS O 0 7.46772548154695e-06
The O 0 6.150067974886042e-07
development O 0 1.7172346815641504e-06
of O 0 3.813531293417327e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.701438112737378e-07
a O 0 4.520319976109022e-07
variable O 0 5.803264571113687e-07
range O 0 1.917671283990785e-07
of O 0 8.966778750618687e-07
extracolonic O 0 9.951589163392782e-05
manifestations O 0 4.332746902946383e-05
in O 0 1.9986159713880625e-06
familial B-Disease 1 0.9999973773956299
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 1.0
( O 0 3.997042585979216e-05
FAP B-Disease 0 0.016022348776459694
) O 0 6.625425186257416e-08
is O 0 2.1046394849122407e-08
the O 0 2.5302201223098564e-08
result O 0 3.713869389798674e-08
of O 0 3.149279734770971e-07
the O 0 5.918898295931285e-07
dominant O 0 9.158617899629462e-07
inheritance O 0 1.5596197044942528e-06
of O 0 2.6415869797347113e-05
adenomatous B-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999996423721313
( O 0 2.368519562878646e-05
APC B-Disease 0 0.00014599587302654982
) O 0 4.2175383896392304e-07
gene O 0 1.2655699492825079e-06
mutations O 0 4.279257154848892e-06
. O 0 6.671050869044848e-06

In O 0 3.258373226344702e-06
this O 0 2.0698657010598254e-07
study O 0 1.3644664420553454e-07
, O 0 3.119641078797031e-08
direct O 0 4.58368205613624e-08
mutation O 0 7.8281303217409e-08
analysis O 0 7.953119052217517e-08
of O 0 3.1336139727500267e-07
the O 0 7.572940035061038e-07
APC B-Disease 0 2.8328583994152723e-06
gene O 0 1.6467572550027398e-07
was O 0 2.2182675820658915e-06
performed O 0 2.2213130534964876e-07
to O 0 3.879850041244026e-08
determine O 0 2.149288036434882e-07
genotype O 0 8.361294931091834e-06
- O 0 5.838319793838309e-06
phenotype O 0 1.6058619394243578e-06
correlations O 0 1.129249312725733e-06
for O 0 1.374447009538926e-07
nine O 0 5.472696784636355e-07
extracolonic O 0 4.729134161607362e-06
manifestations O 0 2.676863687156583e-06
and O 0 6.453297629605004e-08
to O 0 3.511194890393199e-08
investigate O 0 8.249439531482494e-08
the O 0 4.2901163510578044e-07
incidence O 0 0.00014038343215361238
of O 0 3.0532735308952397e-06
APC B-Disease 0 1.1140939022880048e-05
mutations O 0 1.3348747529562388e-07
in O 0 7.294893293874338e-07
non O 0 0.01599796675145626
- O 1 0.9999338388442993
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.684573908278253e-05

METHODS O 0 6.082012623664923e-05
The O 0 1.3045440937275998e-05
APC B-Disease 0 2.3357080863206647e-05
gene O 0 8.718046160538506e-07
was O 0 3.374061407157569e-06
analysed O 0 7.065384011184506e-07
in O 0 1.5630784844233858e-07
190 O 0 9.580205642123474e-07
unrelated O 0 7.69897781083273e-07
FAP B-Disease 0 5.676368800777709e-06
and O 0 1.650891192639392e-07
15 O 0 2.749518898781389e-06
non O 0 0.00047410413390025496
- O 1 0.9999282360076904
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 7.630016625626013e-06
using O 0 7.349780162257957e-07
denaturing O 0 3.62282371497713e-05
gradient O 0 6.736740760970861e-05
gel O 0 3.4335282634856412e-06
electrophoresis O 0 1.4863585420243908e-06
, O 0 1.0514047232845769e-07
the O 0 1.0435371677885996e-07
protein O 0 4.97283167533169e-07
truncation O 0 3.584988917282317e-06
test O 0 1.2799542048469448e-07
, O 0 3.003083648422944e-08
and O 0 3.028380746172843e-08
direct O 0 8.537218718629447e-07
sequencing O 0 1.1208653631911147e-05
. O 0 4.43392264060094e-06

RESULTS O 0 0.0004132305912207812
Chain O 0 6.163167563499883e-05
terminating O 0 5.3630874390364625e-06
signals O 0 1.5739789205326815e-06
were O 0 9.9759205340888e-08
only O 0 4.731815828051822e-09
identified O 0 3.4194002296317194e-08
in O 0 2.9152165126333784e-08
patients O 0 4.165187306170992e-08
belonging O 0 1.3273066201691108e-07
to O 0 3.257914116261418e-08
the O 0 6.33498814295308e-07
FAP B-Disease 0 1.2775930372299626e-05
group O 0 2.2478296557437716e-07
( O 0 8.120350969420542e-08
105 O 0 3.476096026133746e-06
patients O 0 5.369742552829848e-07
) O 0 8.912982707443007e-07
. O 0 3.5302905416756403e-06

Amino O 0 0.00016048749967012554
acid O 0 6.629673862335039e-06
changes O 0 3.0094457770246663e-07
were O 0 2.1279525697082136e-07
identified O 0 1.3318280878138467e-07
in O 0 5.405081182630056e-08
four O 0 1.1494124407818163e-07
patients O 0 7.772042209808205e-08
, O 0 4.5457483111022157e-08
three O 0 4.76516639480451e-08
of O 0 6.707206239298102e-07
whom O 0 2.3056692555201153e-07
belonged O 0 1.1372553672117647e-06
to O 0 9.373012233027112e-08
the O 0 1.9276658349554054e-06
non O 0 0.00017855352780316025
- O 0 0.00013755977852270007
FAP O 0 0.00014886175631545484
group O 0 3.9918558059071074e-07
of O 0 0.0006922401371411979
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0007150517776608467
. O 0 9.628956831875257e-06

Genotype O 0 0.004487276542931795
- O 0 0.00036373603506945074
phenotype O 0 2.402634891041089e-05
correlations O 0 4.293716301617678e-06
identified O 0 2.5875814912978967e-07
significant O 0 9.497689745785465e-08
differences O 0 5.197817998237042e-08
in O 0 1.1795575005635328e-07
the O 0 1.9454122934803308e-07
nature O 0 1.6081591525107797e-07
of O 0 2.776205008103716e-07
certain O 0 2.9411935997814e-07
extracolonic O 0 9.382933785673231e-05
manifestations O 0 5.651398896588944e-05
in O 0 2.2440735847339965e-06
FAP B-Disease 0 3.6882203858112916e-05
patients O 0 8.914617666277991e-08
belonging O 0 1.1347263750849379e-07
to O 0 2.1265096350475687e-08
three O 0 1.9706544662767556e-07
mutation O 0 2.375699295953382e-06
subgroups O 0 5.593941386905499e-05
. O 0 7.107003966666525e-06

CONCLUSIONS O 0 0.0006112025585025549
Extended O 0 0.00015286784037016332
genotype O 0 6.354672950692475e-05
- O 0 2.9815364541718736e-05
phenotype O 0 3.6137680581305176e-06
correlations O 0 1.2839708460887778e-06
made O 0 1.743161561762463e-07
in O 0 4.697512068219112e-08
this O 0 1.3406051380115969e-08
study O 0 3.4099045365110214e-08
may O 0 4.079385718114281e-08
have O 0 9.870757544661046e-09
the O 0 3.6602266106910974e-08
potential O 0 5.513821932368046e-08
to O 0 9.652167953788648e-09
determine O 0 1.2086780465381253e-08
the O 0 4.814793541640938e-08
most O 0 8.894724068397863e-09
appropriate O 0 1.2376125013702222e-08
surveillance O 0 7.353075375249318e-07
and O 0 1.256812396377427e-07
prophylactic O 1 0.9999291896820068
treatment O 0 0.05823769420385361
regimens O 0 3.87202908314066e-06
for O 0 2.4910400853173087e-08
those O 0 7.688087499957419e-09
patients O 0 1.3228452111491151e-08
with O 0 2.7746329678279835e-09
mutations O 0 1.3131297293966782e-07
associated O 0 1.5553358423403552e-07
with O 0 4.695210265026617e-08
life O 0 1.2875525499111973e-06
threatening O 0 2.5743032892933115e-05
conditions O 0 4.100153819308616e-05
. O 0 5.31652221980039e-06

This O 0 1.5594009710184764e-06
study O 0 5.585374651673192e-07
also O 0 1.3576739377185731e-07
provided O 0 8.805969997638385e-08
evidence O 0 2.0336440798018884e-07
for O 0 1.030331588935951e-07
the O 0 5.080423193248862e-07
pathological O 0 0.0003179358900524676
nature O 0 1.4321050230137189e-06
of O 0 5.108347068016883e-06
amino O 0 1.783214543138456e-06
acid O 0 2.1526605564758938e-07
changes O 0 3.5964969669066704e-08
in O 0 1.35248669153043e-07
APC O 0 2.674807092262199e-06
associated O 0 9.618704410740975e-08
with O 0 1.319564102431059e-08
both O 0 1.0125155824880494e-07
FAP B-Disease 0 1.4816577277088072e-05
and O 0 3.3500612062198343e-07
non O 1 0.9366436004638672
- O 1 0.9999982118606567
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.8347407603869215e-05
. O 0 4.790372258867137e-07
. O 0 2.735554744504043e-06

Inherited B-Disease 1 0.9999996423721313
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 0.03650997579097748
cancer B-Disease 1 0.9999992847442627
risk O 0 0.0002647671499289572
of O 0 2.4557619326515123e-05
the O 0 4.242104841978289e-05
APC O 0 0.000642786268144846
I1307K O 0 0.00025880319299176335
polymorphism O 0 3.513300544000231e-05
. O 0 5.404026978794718e-06

Germ O 1 0.999700665473938
- O 0 0.0009128688834607601
line O 0 2.1019990526838228e-05
and O 0 3.87054512884788e-07
somatic O 0 2.432652081552078e-06
truncating O 0 2.0819989003939554e-06
mutations O 0 1.5269908715254132e-07
of O 0 5.288414399728936e-07
the O 0 4.3168424213035905e-07
APC B-Disease 0 3.162171196890995e-06
gene O 0 5.0878707469337314e-08
are O 0 2.8110043182039135e-09
thought O 0 1.3622568850735206e-08
to O 0 2.1796804361429167e-08
initiate O 0 9.891010449791793e-06
colorectal B-Disease 1 1.0
tumor I-Disease 1 1.0
formation O 0 0.00015332757902797312
in O 0 1.4162348634272348e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9940409064292908
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 1.4926605217624456e-05
respectively O 0 1.6730467905290425e-05
. O 0 4.1483822315058205e-06

Recently O 0 0.00015557120786979795
, O 0 6.478823252109578e-06
an O 0 8.0742083810037e-06
isoleucine O 0 0.00023438732023350894
- O 0 2.8227506845723838e-05
- O 0 2.8066560844308697e-05
> O 0 1.1392645319574513e-05
lysine O 0 3.0075202630541753e-06
polymorphism O 0 2.792820055219636e-07
at O 0 1.2642913134186529e-06
codon O 0 1.8559621821623296e-06
1307 O 0 5.8064479162567295e-06
( O 0 1.0781523940295301e-07
I1307K O 0 9.836469416768523e-07
) O 0 2.646479124734924e-08
of O 0 1.1842305269738063e-07
the O 0 3.384259628091968e-07
APC B-Disease 0 1.5085963696037652e-06
gene O 0 9.955126500926781e-08
has O 0 6.117100070923698e-08
been O 0 8.012729324491374e-08
identified O 0 3.3281960298836566e-08
in O 0 4.4771084617423185e-08
6 O 0 3.1575709158460086e-07
% O 0 5.314903006592431e-08
- O 0 1.640773632516357e-07
7 O 0 4.4153125600132626e-07
% O 0 3.134432446927349e-08
of O 0 1.7244164496332814e-07
the O 0 4.6767803496550187e-07
Ashkenazi O 0 1.664042315496772e-06
Jewish O 0 8.664501365274191e-07
population O 0 3.3001933275045303e-07
. O 0 1.3213998499850277e-06

To O 0 7.177371571742697e-06
assess O 0 6.085301265557064e-06
the O 0 1.481535491620889e-06
risk O 0 1.2266818885109387e-06
of O 0 4.0526151678932365e-07
this O 0 1.252217032288172e-07
common O 0 3.2093026902657584e-07
APC B-Disease 0 4.253563020029105e-06
allelic O 0 1.1539092383827665e-06
variant O 0 1.2440899581633857e-06
in O 0 6.861851034045685e-07
colorectal O 1 1.0
carcinogenesis O 1 0.9963380098342896
, O 0 7.738995577710739e-08
we O 0 5.910592015823113e-09
have O 0 5.786671142260502e-09
analyzed O 0 2.989926883856242e-08
a O 0 6.153024401100993e-08
large O 0 1.0884296841595642e-07
cohort O 0 7.895238923083525e-06
of O 0 1.1299817970211734e-06
unselected O 0 0.00011443949915701523
Ashkenazi O 0 4.793608241016045e-06
Jewish O 0 1.3715797422264586e-06
subjects O 0 6.241384653549176e-07
with O 0 1.9605208478878922e-07
adenomatous B-Disease 0 0.013325786218047142
polyps I-Disease 0 0.06435492634773254
and O 0 2.9369473963924975e-07
. O 0 3.445611866936815e-07
or O 0 0.03672754392027855
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.3561680134444032e-06
for O 0 4.286542036879837e-07
the O 0 9.579664038028568e-06
APC O 0 0.00036549867945723236
I1307K O 0 0.00034007575595751405
polymorphism O 0 5.9862457419512793e-05
. O 0 1.107678053813288e-05

The O 0 0.00025265722069889307
APC O 0 0.0006098650046624243
I1307K O 0 0.00024672612198628485
allele O 0 1.4975851627241354e-05
was O 0 1.025981327984482e-05
identified O 0 7.288148253792315e-07
in O 0 1.4237448908716033e-07
48 O 0 4.866728886554483e-07
( O 0 2.5206922771303653e-08
10 O 0 3.7039161071561466e-08
. O 0 4.69989336338017e-09
1 O 0 5.0104329574196527e-08
% O 0 2.0632393571418106e-08
) O 0 1.77658900923916e-08
of O 0 3.585764432045835e-07
476 O 0 4.133850961807184e-05
patients O 0 2.981191300932551e-06
. O 0 3.2637783533573383e-06

Compared O 0 2.936128294095397e-05
with O 0 2.8487647796282545e-07
the O 0 3.825276735369698e-07
frequency O 0 4.061700167312665e-07
in O 0 1.9177841537043605e-08
two O 0 3.356089850470312e-09
separate O 0 3.0525677541248797e-09
population O 0 9.576998749594168e-09
control O 0 1.0381550907823112e-07
groups O 0 1.3416743271932319e-08
, O 0 5.9270995222959755e-08
the O 0 5.147447268427641e-07
APC O 0 2.2249872927204706e-05
I1307K O 0 1.2252016858838033e-05
allele O 0 3.603755658332375e-07
is O 0 5.045147943860684e-08
associated O 0 1.770041002657763e-08
with O 0 2.33266361782114e-09
an O 0 1.6999216256863292e-08
estimated O 0 6.10217298913085e-08
relative O 0 3.1527173405265785e-07
risk O 0 2.5602318487472076e-07
of O 0 2.3343463908531703e-06
1 O 0 1.8077817003359087e-05
. O 0 3.3356175208609784e-06

5 O 0 0.0002409907174296677
- O 0 0.00015933414397295564
1 O 0 4.288658237783238e-05
. O 0 1.073025578079978e-05

7 O 0 0.00014507568266708404
for O 0 1.6515759853064083e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9993483424186707
( O 0 1.5979088630047045e-06
both O 0 5.449770128507225e-07
P O 0 0.0002028985327342525
= O 0 2.374589257669868e-06
. O 0 1.1328319970971279e-07
01 O 0 1.9548821001080796e-05
) O 0 4.245553100190591e-07
. O 0 1.3767850077783805e-06

Furthermore O 0 5.572219015448354e-05
, O 0 3.7947113469272153e-06
compared O 0 2.525264790165238e-06
with O 0 1.5378095952200965e-07
noncarriers O 0 5.336721005733125e-05
, O 0 8.101598609755456e-07
APC O 0 9.374204637424555e-06
I1307K O 0 4.830338639294496e-06
carriers O 0 5.860092144871487e-08
had O 0 9.060616434908297e-08
increased O 0 2.557266896019428e-07
numbers O 0 7.675885882463263e-08
of O 0 1.0492026376596186e-06
adenomas B-Disease 1 0.9579535722732544
and O 0 7.200256277428707e-06
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999107122421265
per O 0 2.4558414224884473e-05
patient O 0 3.7382076243375195e-06
( O 0 3.3679424404908787e-07
P O 0 1.835062721511349e-05
= O 0 4.5467623976946925e-07
. O 0 3.0543574780494964e-08
03 O 0 1.634342424949864e-06
) O 0 2.4991209102154244e-08
, O 0 1.3025351464079904e-08
as O 0 2.5516509793988007e-08
well O 0 1.7444346411821243e-08
as O 0 5.028297778153501e-08
a O 0 1.8037650306723663e-07
younger O 0 2.0979666714993073e-07
age O 0 8.246841503023461e-07
at O 0 2.152803608623799e-05
diagnosis O 0 0.0001361567701678723
. O 0 4.578921107167844e-06

We O 0 1.0825557183125056e-05
conclude O 0 1.3371978639042936e-05
that O 0 7.675108690818888e-07
the O 0 3.1223726182361133e-06
APC O 0 3.607330290833488e-05
I1307K O 0 3.214975367882289e-05
variant O 0 2.4438459149678238e-06
leads O 0 1.5792534213687759e-06
to O 0 2.7777011268881324e-07
increased O 0 4.227457247907296e-05
adenoma B-Disease 1 1.0
formation O 0 8.207147402572446e-06
and O 0 4.128047805807e-07
directly O 0 1.1374718411616414e-07
contributes O 0 7.105359145498369e-08
to O 0 2.0003934508849852e-08
3 O 0 1.4200890063875704e-07
% O 0 2.236585672221736e-08
- O 0 7.011993119476756e-08
4 O 0 8.897968939436396e-08
% O 0 6.5452869790760815e-09
of O 0 2.2889173223461512e-08
all O 0 4.689902510790489e-08
Ashkenazi O 0 4.396796430228278e-05
Jewish O 1 0.8953086733818054
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.1301066226442344e-05

The O 0 6.7838500399375334e-06
estimated O 0 2.0980719455110375e-06
relative O 0 4.138290478294948e-06
risk O 0 5.321466005625552e-07
for O 0 8.251799243907953e-08
carriers O 0 1.7099773685913533e-07
may O 0 1.0914773440617864e-07
justify O 0 8.43809715433963e-08
specific O 0 7.406405266863203e-09
clinical O 0 4.1728014821273973e-07
screening O 0 1.6383296497224364e-07
for O 0 6.342170166817596e-08
the O 0 2.453330978369195e-07
360 O 0 5.73820386762236e-07
, O 0 2.8232246762627256e-08
000 O 0 3.47132157685337e-07
Americans O 0 2.204650506598682e-08
expected O 0 6.695268695011691e-08
to O 0 1.9996228672880534e-08
harbor O 0 1.5858186088735238e-06
this O 0 1.8539328294764346e-08
allele O 0 4.2930960120202144e-08
, O 0 1.175571462397329e-08
and O 0 8.321403122124593e-09
genetic O 0 3.05752259066594e-08
testing O 0 7.286230641057045e-08
in O 0 1.0103780567760623e-07
the O 0 1.9537212381237623e-07
setting O 0 2.916441133038461e-07
of O 0 6.189513896970311e-07
long O 0 1.5610601167281857e-06
- O 0 1.5755318827359588e-06
term O 0 9.328367696070927e-07
- O 0 1.291369216005478e-07
outcome O 0 2.2651478914781364e-08
studies O 0 5.021464133392328e-08
may O 0 2.5839064221599983e-08
impact O 0 1.0534060379541188e-07
significantly O 0 2.386560140621441e-07
on O 0 6.155508890515193e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 3.659267895272933e-05
in O 0 8.75547598866433e-08
this O 0 6.349262804405953e-08
population O 0 3.683721274683194e-07
. O 0 1.2914496210214566e-06

Localization O 0 0.0010610735043883324
of O 0 8.690522008691914e-06
human O 0 2.5792321594053647e-06
BRCA1 O 0 4.932762749376707e-06
and O 0 3.528674596964265e-07
its O 0 4.1219186641683336e-07
loss O 0 5.224353571975371e-06
in O 0 8.499281989315932e-07
high O 0 0.005301347002387047
- O 0 1.3183563169150148e-05
grade O 0 0.00011960701522184536
, O 0 9.089268360185088e-07
non B-Disease 0 0.0369630791246891
- I-Disease 1 0.9989935755729675
inherited I-Disease 1 0.9999971389770508
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.000172698637470603

Although O 0 8.615396836830769e-06
the O 0 1.543352937005693e-06
link O 0 2.000982703975751e-06
between O 0 8.279671419586521e-07
the O 0 2.058630343526602e-06
BRCA1 O 0 0.01252172701060772
tumour B-Disease 1 1.0
- O 1 0.9904174208641052
suppressor O 1 0.9999988079071045
gene O 0 2.1430385004350683e-06
and O 0 9.501664521849307e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 8.496883197040006e-07
established O 0 1.889134608745735e-07
, O 0 3.354638522523601e-08
the O 0 6.866420676487905e-08
role O 0 2.586525624792557e-07
, O 0 5.2825928520405796e-08
if O 0 6.014639009066514e-09
any O 0 8.043381072297962e-09
, O 0 3.339266285706799e-08
of O 0 3.030588686669944e-07
BRCA1 O 0 1.004709611152066e-05
in O 0 4.416771389514906e-06
non B-Disease 1 0.9950474500656128
- I-Disease 1 0.9976025223731995
familial I-Disease 1 0.9997944235801697
cancers I-Disease 1 1.0
is O 0 3.8226960896281525e-05
unclear O 0 5.487719590746565e-06
. O 0 2.2493682081403676e-06

BRCA1 O 0 0.0002272612473461777
mutations O 0 6.5590634221734945e-06
are O 0 6.474959945990122e-08
rare O 0 1.286180122406222e-07
in O 0 1.5663286490052997e-07
sporadic B-Disease 0 1.6269763364107348e-05
cancers I-Disease 1 0.9799829721450806
, O 0 1.8143337854326091e-07
but O 0 1.3352308592118334e-08
loss O 0 5.883016456209589e-07
of O 0 6.172890607558656e-07
BRCA1 O 0 2.9099669518473092e-06
resulting O 0 1.4017562079970958e-06
from O 0 3.412911553368758e-07
reduced O 0 6.405679187082569e-07
expression O 0 5.787766781395476e-07
or O 0 1.7352350312194176e-07
incorrect O 0 1.6154342574736802e-06
subcellular O 0 4.9475362175144255e-05
localization O 0 9.857863005890977e-06
is O 0 4.0193516070985424e-08
postulated O 0 1.472163546623051e-07
to O 0 5.098048205809391e-09
be O 0 8.44089420581895e-09
important O 0 8.516659377733049e-09
in O 0 5.959316240478074e-08
non B-Disease 0 1.7495915017207153e-05
- I-Disease 0 0.0012758480152115226
familial I-Disease 1 0.9969717264175415
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.0024024723097682

Epigenetic O 0 0.000990837230347097
loss O 0 0.0002659950696397573
, O 0 1.4562731394107686e-06
however O 0 1.3409074028913892e-07
, O 0 2.4090629935358265e-08
has O 0 1.6699509330919682e-08
not O 0 5.011969950174944e-09
received O 0 8.44721199655396e-08
general O 0 5.077856144453108e-07
acceptance O 0 1.1102374628535472e-06
due O 0 3.863895017275354e-06
to O 0 1.6674179903475306e-07
controversy O 0 9.785037491383264e-07
regarding O 0 9.95297796180239e-07
the O 0 2.2514821012009634e-06
subcellular O 0 4.8678452003514394e-05
localization O 0 1.566522587381769e-05
of O 0 1.3667902294400847e-06
BRCA1 O 0 1.2301014749027672e-06
proteins O 0 1.6043908601659496e-07
, O 0 5.9362072590829484e-08
reports O 0 1.1079045947326449e-07
of O 0 1.9882405410953652e-07
which O 0 1.0070553457808273e-07
have O 0 9.196298123015367e-08
ranged O 0 3.119396524198237e-06
from O 0 1.5301759503927315e-07
exclusively O 0 6.219988080147232e-08
nuclear O 0 1.150806951955019e-06
, O 0 4.783269247354838e-08
to O 0 2.165450752045217e-08
conditionally O 0 6.629545623582089e-07
nuclear O 0 2.611213631098508e-06
, O 0 1.3745139426646347e-07
to O 0 5.867775954015997e-08
the O 0 1.2230816537339706e-06
ER O 0 0.004713678266853094
/ O 0 5.367457197280601e-05
golgi O 0 0.0004816152504645288
, O 0 2.5450580665165035e-07
to O 0 1.2203594224047265e-07
cytoplasmic O 0 5.824777872476261e-06
invaginations O 0 2.383269566053059e-05
into O 0 6.242819949875411e-07
the O 0 1.7584520719537977e-06
nucleus O 0 1.728923416521866e-05
. O 0 4.681600785261253e-06

In O 0 1.045077897288138e-05
an O 0 1.0512377457416733e-06
attempt O 0 1.0600629138934892e-06
to O 0 1.1746283234970178e-07
resolve O 0 3.8581660533054674e-07
this O 0 8.475761603676801e-08
issue O 0 1.4895839228756813e-07
, O 0 3.98589037331476e-08
we O 0 1.8118019085022752e-08
have O 0 2.4204208415312678e-08
comprehensively O 0 6.764235536138585e-07
characterized O 0 9.202174169331556e-07
19 O 0 7.1733752520231064e-06
anti O 0 2.0105844669160433e-05
- O 0 1.5081912351888604e-05
BRCA1 O 0 1.4565047422365751e-05
antibodies O 0 6.338847924780566e-06
. O 0 5.642086762236431e-06

These O 0 8.19550950836856e-06
reagents O 0 5.1352613809285685e-05
detect O 0 1.1126244316983502e-05
a O 0 5.139131644682493e-06
220 O 0 4.542780970950844e-06
- O 0 1.3077873290967545e-06
kD O 0 5.446732757263817e-06
protein O 0 2.3459661235847307e-07
localized O 0 2.261949276771702e-07
in O 0 4.28319921752518e-08
discrete O 0 3.106951851350459e-07
nuclear O 0 2.532606231397949e-06
foci O 0 7.25051540939603e-06
in O 0 1.1701158086907526e-07
all O 0 2.9393197209515165e-08
epithelial O 0 1.4876070054015145e-05
cell O 0 9.62921512837056e-06
lines O 0 2.2994615278548736e-07
, O 0 1.5770959649330507e-08
including O 0 2.4225037975611485e-08
those O 0 1.7726154766251057e-08
derived O 0 4.1570612552277453e-07
from O 0 2.229278607046581e-06
breast B-Disease 0 0.0024538482539355755
malignancies I-Disease 0 0.02556035667657852
. O 0 1.2823803444916848e-05

Immunohistochemical O 0 0.014650733210146427
staining O 0 0.0010985949775204062
of O 0 5.8338759117759764e-05
human O 0 3.159084008075297e-05
breast O 0 0.0002366417902521789
specimens O 0 1.7019044662447413e-06
also O 0 6.582108085240179e-07
revealed O 0 4.464149242267013e-06
BRCA1 O 0 3.1345545721706e-05
nuclear O 0 9.461658919462934e-05
foci O 0 0.08412587642669678
in O 0 3.932632807845948e-06
benign O 1 0.9999845027923584
breast O 1 0.9580503106117249
, O 0 2.2777153390052263e-06
invasive B-Disease 1 0.9604749083518982
lobular I-Disease 1 1.0
cancers I-Disease 1 0.999998927116394
and O 0 0.00018544273916631937
low B-Disease 1 0.9998664855957031
- I-Disease 1 0.9897668957710266
grade I-Disease 1 0.9997240900993347
ductal I-Disease 1 0.9999998807907104
carcinomas I-Disease 1 1.0
. O 0 6.713774928357452e-05

Conversely O 0 8.042114495765418e-05
, O 0 2.089206645905506e-06
BRCA1 O 0 1.0274765372741967e-05
expression O 0 2.392100213910453e-06
was O 0 5.730242264689878e-06
reduced O 0 5.544943064705876e-07
or O 0 1.6821923054521903e-07
undetectable O 0 1.5340187928813975e-06
in O 0 6.412341235773056e-08
the O 0 7.78714763782773e-08
majority O 0 2.1013942586023404e-08
of O 0 8.885772899702715e-07
high O 0 0.0006360393017530441
- O 0 8.11946447356604e-05
grade O 0 0.0004013274156022817
, O 0 1.8721391370490892e-06
ductal B-Disease 1 0.9999456405639648
carcinomas I-Disease 1 1.0
, O 0 4.783182703249622e-07
suggesting O 0 4.1125267102870566e-07
that O 0 1.407041771983586e-08
absence O 0 3.8241824995566276e-07
of O 0 3.728448234596726e-07
BRCA1 O 0 2.7524047254701145e-06
may O 0 4.1563873764971504e-07
contribute O 0 4.7573564643244026e-08
to O 0 3.8490256315526494e-08
the O 0 3.0172049036991666e-07
pathogenesis O 0 1.5201909263851121e-05
of O 0 6.434713384351198e-08
a O 0 4.0627455177855154e-08
significant O 0 2.547284161380503e-08
percentage O 0 1.8945328861263988e-07
of O 0 3.4380525448796107e-07
sporadic B-Disease 0 0.07186317443847656
breast I-Disease 1 0.9999974966049194
cancers I-Disease 1 0.9999996423721313
. O 0 3.138473175567924e-06
. O 0 3.0811791020823875e-06

